,title,abstract,authors,link,ID,publication_date,update_date,subject,is_medRxiv
0,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has affected more than 15 million people and, as of 22 July 2019, caused deaths of more than 0.6 million individuals globally. With the excretion of SARS-CoV-2 in the stool of symptomatic and asymptomatic COVID-19 patients, its genome detection in the sewage water can be used as a powerful epidemiological tool to predict the number of positive cases in a population. This study was conducted to detect SARS-CoV-2 genome in sewage water during the lockdown. Sewage samples, from 28 pre-selected sites, were collected on alternate days from 13-25 July, 2020 from two selected areas [Johar Town (n = 05) and Township (n = 23)], where smart lockdown were implemented by the government authorities on 9th July, 2020. Genomic RNA was extracted and the SARS-CoV-2 was detected and quantified using commercially available kit through Real-Time PCR. Out of 28, sixteen samples were positive on day one while 19, 17, 23, 17, 05 and 09 samples were positive on day 3, 5, 7, 9, 11, and 13, respectively. These results indicate the decreasing viral copy load with the passage of time however few sites did not followed a clear pattern indicating the complexities in sewage water based surveillance i.e time of sampling. Hourly sampling from two sites for 24 hours also revealed the impact of time sampling time on detection of SARS-CoV-2 genome in sewage pipelines and lift/disposal stations. Results of current study indicate a possible role of sewage-based COVID-19 surveillance in monitoring and execution of smart lockdowns.","Yaqub, T.; Nawaz, M.; Shabbir, M. Z.; Ali, M. A.; Altaf, I.; Raza, S.; Shabbir, M. A. B.; Ashraf, M. A.; Aziz, S. Z.; Cheema, S. Q.; Shah, M. B.; Hassan, S.; Rafique, S.; Sardar, N.; Mehmood, A.; Aziz, M. W.; Fazal, S.; Khan, N.; Khan, M. T.; Attique, M. M.; Asif, A.; Anwar, M.; Awan, N. A.; Younis, M. U.; Bhatti, M. A.; Tahir, Z.; Mukhtar, N.; Sarwar, H.; Rana, M. S.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165126v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165126v1?rss=1,2020-08-04,2020-08-04,,True
1,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,"Introduction: COVID-19 affected worldwide, causing to date, around 500,000 deaths. In Mexico, by April 29, the general case fatality was 6.52%, with 11.1% confirmed case mortality and hospital recovery rate around 72%. Once hospitalized, the odds for recovery and hospital death rates depend mainly on the patients' comorbidities and age. In Mexico, triage guidelines use algorithms and risk estimation tools for severity assessment and decision-making. The study's objective is to analyze the underlying conditions of patients hospitalized for COVID-19 in Mexico concerning four severity outcomes. Materials and Methods: Retrospective cohort based on registries of all laboratory-confirmed patients with the COVID-19 infection that required hospitalization in Mexico. Independent variables were comorbidities and clinical manifestations. Dependent variables were four possible severity outcomes: (a) pneumonia, (b) mechanical ventilation (c) intensive care unit, and (d) death; all of them were coded as binary Results: We included 69,334 hospitalizations of laboratory-confirmed and hospitalized patients to June 30, 2020. Patients were 55.29 years, and 62.61% were male. Hospital mortality among patients aged<15 was 9.11%, 51.99% of those aged >65 died. Male gender and increasing age predicted every severity outcome. Diabetes and hypertension predicted every severity outcome significantly. Obesity did not predict mortality, but CKD, respiratory diseases, cardiopathies were significant predictors. Conclusion: Obesity increased the risk for pneumonia, mechanical ventilation, and intensive care admittance, but it was not a predictor of in-hospital death. Patients with respiratory diseases were less prone to develop pneumonia, to receive mechanical ventilation and intensive care unit assistance, but they were at higher risk of in-hospital death.","Carrillo, G.; Mendez Dominguez, N.; Santos Zaldivar, K. D.; Rochel Perez, A.; Azuela Morales, M.; Cuevas Koh, O.; Alvarez Baeza, A.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165480v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165480v1?rss=1,2020-08-04,2020-08-04,,True
2,Risk stratification as a tool to rationalize quarantine among health care workers exposed to COVID-19 cases - Evidence from a tertiary healthcare centre in India,"Background: Quarantine of healthcare workers (HCWs) exposed to COVID 19 confirmed cases is a well known strategy for limiting the transmission of infection. However, there is a need for evidence-based guidelines for the quarantine of HCWs in COVID 19. Methods: We describe our experience of contact tracing and risk stratification of 3853 HCWs who were exposed to confirmed COVID-19 cases in a tertiary health care institution in India. We developed an algorithm, on the basis of risk stratification, to rationalize quarantine among HCWs. Risk stratification was based on the duration of exposure, distance from the patient, and appropriateness of personal protection equipment (PPE) usage. Only high-risk contacts were quarantined for 14 days. They underwent testing for COVID 19 after five days of exposure, while low risk contacts continued their work with adherence to physical distancing, hand hygiene, and appropriate use of PPE. The low-risk contacts were encouraged to monitor for symptoms and report for COVID 19 screening if fever, cough, or shortness of breath occurred. We followed up all contacts for 14 days from the last exposure and observed for symptoms of COVID 19 and test positivity. Results and interpretation: Out of total 3853 contacts, 560 (14.5%) were categorized as high-risk contacts, and 40 of them were detected positive for COVID 19, with a test positivity rate of 7.1% (95% CI = 5.2, 9.6). Overall, 118 (3.1%) of all contacts tested positive. Our strategy prevented 3215 HCWs from being quarantined and saved 45,010 person-days of health workforce until June 8, 2020, in the institution. We conclude that exposure-based risk stratification and quarantine of HCWs is a viable strategy to prevent unnecessary quarantine, in a healthcare institution.","Kaur, R.; Kant, S.; Bairwa, M.; Kumar, A.; Dhakad, S.; Dwarakanathan, V.; Ahmad, A.; Pandey, P.; Kapil, A.; Lodha, R.; Wig, N.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166264v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166264v1?rss=1,2020-08-04,2020-08-04,,True
3,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,"As schools prepare for the start of the Fall 2020 semester, many are struggling to make decisions regarding whether or not to return to on-campus classes or whether to remain fully online. Unfortunately, there is no ""one-size-fits-all"" answer, and schools must balance their own risks against the costs of remote learning. We present a tool that integrates information about study body composition with predictions of COVID-19 infection rates in order to provide clarity and insight into the decisions facing colleges and universities nationwide. Our tool is freely available and currently hosted at the following location: https://bewicklab.shinyapps.io/covid-1/","Bewick, S.; Ludden, E.; Robertson, S.; Demers, J.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165761v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165761v1?rss=1,2020-08-04,2020-08-04,,True
4,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,"Importance: Current evidence suggests that transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is possible among symptom-free individuals but limited data are available on this topic in healthcare workers (HCW). The quality and acceptability of self-collected nasopharyngeal swabs (NPS) is unknown. Objective: To estimate the prevalence of SARS-CoV-2 infection and to assess the acceptability of self-collected NPS among HCW. Design: Cross-sectional convenience sample enrolled between April 20th and June 24th, 2020. We had >95% power to detect at least one positive test if the true underlying prevalence of SARS-CoV2 was > 1%. Setting: The metropolitan area surrounding Minneapolis and St. Paul, Minnesota. Participants: HCW free of self-reported upper respiratory symptoms were recruited. Exposures: Participants completed questionnaires regarding demographics, household characteristics, personal protective equipment (PPE) utilization and comorbidities. Outcomes: A participant self-collected nasopharyngeal swab (NPS) was obtained. SARS-CoV-2 infection was assessed via polymerase chain reaction. NPS discomfort was assessed on a scale of 1 (no discomfort) - 10 (extreme discomfort). NPS duration and depth into the nasopharynx, and willingness to perform future self-collections were assessed. Results: Among n=489 participants 80% were female and mean age+/-SD was 41+/-11. Participants reported being physicians (14%), nurse practitioners (8%), physicians assistants (4%), nurses (51%), medics (3%), or other which predominantly included laboratory technicians and administrative roles (22%). Exposure to a known/suspected COVID-19 case in the 14 days prior to enrollment was reported in 40% of participants. SARS-CoV-2 was not detected in any participant. The mean+/-SD discomfort level of the NPS was 4.5+/-2.0. 95% of participants reported that their self-swab was longer than or equal to the duration of patient swabs they had previously performed, and 89% reported the depth to be deeper than or equal to the depth of previous patient swabs. Over 95% of participants reported a willingness to repeat a self-collected NP swab in the future. Conclusions and Relevance: The point prevalence of SARS-CoV-2 infection was likely very low in symptom-free Minnesota healthcare workers from April 20th and June 24th, 2020. Self-collected NP swabs are well-tolerated and a viable alternative to provider-collected swabs to preserve PPE.","Demmer, R. T.; Ulrich, A.; Wiggen, T.; Strickland, A.; Naumchik, B.; Kulasingam, S.; Stovitz, S. D.; Marotz, C.; Belda-Ferre, P.; Humphrey, G.; De Hoff, P.; Laurent, L.; Kline, S.; Knight, R.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166066v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166066v1?rss=1,2020-08-04,2020-08-04,,True
5,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,"The first reported case of COVID-19 in the State of Oregon occurred in late February 2020, with subsequent outbreaks occurring in the populous Portland metro area but also with significant outbreaks in less-populous and rural areas. Here we report viral sequences from 188 patients across the hospitals and associated clinics in the Providence Health System in the State of Oregon dating back to the early days of the outbreak. We show a significant shift in dominant clade lineages over time in Oregon, with the rapid emergence and dominance of Spike D614G-positive variants. We also highlight significant diversity in SARS-CoV-2 sequences in Oregon, including a large number of rare mutations, indicative that these genomes could be utilized for outbreak tracing. Lastly, we show that SARS-CoV-2 genomic information may offer additional utility in combination with clinical covariates in the prediction of acute disease phenotypes.","Dowdell, A. K.; Matlock, K.; Robinson, F. L.; Weerasinghe, R.; Rattray, R.; Pukay, M.; Lathara, M.; Harlan, A.; Ward, T. R.; Campbell, M.; Urba, W. J.; Srinivasa, G.; Bifulco, C. B.; Piening, B. D.","https://www.medrxiv.org/content/10.1101/2020.07.30.20160069v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20160069v1?rss=1,2020-08-04,2020-08-04,,True
6,Analytical Model of COVID-19 for lifting non-pharmaceutical interventions,"In the present work, we outline a set of coarse-grain analytical models that can be used by decision-makers to bound the potential impact of the COVID-19 pandemic on specific communities with known or estimated social contact structure and to assess the effects of various non-pharmaceutical interventions on slowing the progression of disease spread. This work provides a multi-dimensional view of the problem by examining steady-state and dynamic disease spread using a network-based approach. In addition, Bayesian-based estimation procedures are used to provide a realistic assessment of the severity of outbreaks based on estimates of the average and instantaneous basic reproduction number R0.","Jacyna, G.; Thompson, J. R.; Koehler, M.; Slater, D. M.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166025v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166025v1?rss=1,2020-08-04,2020-08-04,,True
7,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19","The United States (US) public health interventions were rigorous and rapid, yet failed to arrest the spread of the Coronavirus Disease 2019 (COVID-19) pandemic as infections spread throughout the US. Many factors have contributed to the spread of COVID-19, and the success of public health interventions depends on the level of community adherence to preventative measures. Public health professionals must also understand regional demographic variation in health disparities and determinants to target interventions more effectively. In this study, a systematic evaluation of three significant interventions employed in the US, and their effectiveness in slowing the early spread of COVID-19 was conducted. Next, community-level compliance with a state-level stay at home orders was assessed to determine COVID-19 spread behavior. Finally, health disparities that may have contributed to the disproportionate acceleration of early COVID-19 spread between certain counties were characterized. The contribution of these factors for the disproportionate spread of the disease was analyzed using both univariate and multivariate statistical analyses. Results of this investigation show that delayed implementation of public health interventions, a low level of compliance with the stay at home orders, in conjunction with health disparities, significantly contributed to the early spread of the COVID-19 pandemic.","Jalali, A. M.; Khoury, S. G.; See, J.; Gulsvig, A. M.; Peterson, B. M.; Gunasekera, R. S.; Buzi, G.; Wilson, J.; Galbadage, T.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165654v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165654v1?rss=1,2020-08-04,2020-08-04,,True
8,Land Use Change and Coronavirus Emergence Risk,"Coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) causing coronaviruses are mostly discovered in Asian horseshoe bats. It is still unclear how ongoing land use changes may facilitate SARS-related coronavirus transmission to humans. Here we use a multivariate hotspot analysis of high-resolution land-use data to show that regions of China populated by horseshoe bats are hotspots of forest fragmentation, livestock and human density. We also identify areas susceptible to new hotspot emergence in response to moderate expansion of urbanization, livestock production, or forest disturbance, thereby highlighting regions vulnerable to SARS-CoV spillover under future land-use change. In China population growth and increasing meat consumption associated with urbanization and economic development have expanded the footprint of agriculture, leading to human encroachment in wildlife habitat and increased livestock density in areas adjacent to fragmented forests. The reduced distance between horseshoe-bats and humans elevates the risk for SARS-related coronavirus transmission to humans.","Rulli, M. C.; D'Odorico, P.; Galli, N.; Hayman, D.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166090v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166090v1?rss=1,2020-08-04,2020-08-04,,True
9,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,"While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about the mucosal immune response and its relationship to systemic antibody levels. Since SARS-CoV-2 initially replicates in the upper airway, the antibody response in the oral cavity is likely an important parameter that influences the course of infection. We developed enzyme linked immunosorbent assays to detect IgA and IgG antibodies to the SARS-CoV-2 spike protein (full length trimer) and its receptor binding domain (RBD) in serum (n=496) and saliva (n=90) of acute and convalescent patients with laboratory-diagnosed COVID-19 ranging from 3-115 days post-symptom onset (PSO), compared to negative controls. Anti-CoV-2 antibody responses were readily detected in serum and saliva, with peak IgG levels attained by 16-30 days PSO. Whereas anti-CoV-2 IgA antibodies rapidly decayed, IgG antibodies remained relatively stable up to 115 days PSO in both biofluids. Importantly, IgG responses in saliva and serum were correlated, suggesting that antibodies in the saliva may serve as a surrogate measure of systemic immunity.","Isho, B.; Abe, K. T.; Zuo, M.; Jamal, A. J.; Rathod, B.; Wang, J. H.; Li, Z.; Chao, G.; Rojas, O. L.; Bang, Y. M.; Pu, A.; Christie-Holmes, N.; Gervais, C.; Ceccarelli, D.; Samavarchi-Tehrani, P.; Guvenc, F.; Budylowski, P.; Li, A.; Paterson, A.; Feng Yun, Y.; Marin, L. G.; Caldwell, L.; Wrana, J. L.; Colwill, K.; Sicheri, F.; Mubareka, S.; Gray-Owen, S. D.; Drews, S. J.; Siqueira, W. L.; Barrios-Rodiles, M.; Ostrowski, M.; Rini, J. M.; Durocher, Y.; McGeer, A. J.; Gommerman, J. L.; Gingras, A.-C.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v1?rss=1,2020-08-04,2020-08-04,,True
10,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,"Objective To assess the association between the lockdowns due to COVID-19 and global online searches for toothache using Google Trends (GT). Methods We investigated GT online searches for the search terms toothache and tooth pain, within the past five years. The time frame for data gathering was considered as the initiation and end dates of national/regional lockdowns in each country. Relative search volumes (RSVs) for online Google Search queries in 2019 was considered as the control. We analysed data after normalising based on the Internet penetration rate. We used one-way ANOVA to identify statistical difference for RSVs between 2020 and 2016-2019 for each country. A linear regression model was used to assess whether there is a correlation between RSVs in 2020 and gross domestic production, COVID-19 deaths, dentists' density, YLDs of oral conditions, Internet access, lockdown duration, Education Index, and dental expenditure per capita. Results The results of worldwide RSVs for toothache and tooth pain also showed significantly higher values in 2020 compared to the previous four years. Of 23 included countries in our study, 16 showed significantly increased RSVs during the lockdown period compared to the same periods in the past four years. There was a statistically significant relationship between difference of RSVs means in 2020 and in 2016-2019 combined with percent of urban residency (B=-1.82; 95% CI: (-3.38, -0.26); p=0.026) and dental expenditure per capita (B=-0.42; 95% CI: (-0.80, -0.05); p=0.031) (R2=0.66). Conclusion Generally, the interest in toothache and tooth pain has significantly increased in 2020 compared to the last four years. This could implicitly reinforce the importance of dental care, as urgent medical care worldwide. Governments' expenditure on oral healthcare and the rate of urban residency, could be mentioned as important factors to direct general populations' online care-seeking behaviour with regard to dental pain.","Sofi-Mahmudi, A.; Shamsoddin, E.; Ghasemi, P.; Nasser, M.; Mesgarpour, B.","https://www.medrxiv.org/content/10.1101/2020.08.01.20157065v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20157065v1?rss=1,2020-08-04,2020-08-04,,True
11,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,"There are a number of recent studies detailing the transmission of SARS-CoV-2 (Covid-19) via both Droplet and Aerosol airborne particle routes of infection. Because of this, it is necessary to understand the release of different sized particles in activities such as playing brass instruments in order for an analysis of risk to take place for such activities. In this investigation, the quantity and size of particles released by brass instruments while they are played was analysed for 7 different types of brass instrument. This was contrasted with the same individuals breathing as a comparison for more general activities as well as the effect of a mitigating polycotton barrier over the end of their instruments. To investigate the particles released, the particles were size sorted and counted with a six-channel laser particle counter. Multiple measurements were made by each individual in each condition investigated. The mean concentration exiting across all instruments measured was found to be 1.21x107{+/-}1.03x106 Aerosol type particles/m3 and 1.43x104{+/-}9.01x102 Droplet type particles/m3 per minute. When breathing, the mean count was 1.61x107{+/-}1.33x106 Aerosol type particle/m3 and 5.45x103{+/-}1.20x103 Droplet type particles/m3. When playing with a barrier cover, the mean number of particles emitted fell to 2.60x106{+/-}2.11x105 Aerosol type particle/m3 and 5.20x103{+/-}8.02x102 Droplet type particles/m3. This barrier represented an average 78.5% reduction for the number of respiratory Aerosol type particles and 63.8% reduction for Droplet type particles compared to playing an instrument without the barrier covering. It was investigated what effect playing for a more extended period of time had on the release of particles with comparisons made to singing, breathing and covering the instruments' bell ends with a barrier cap. This showed that the mean number of Aerosol type particles produced while playing was 5.38x107{+/-}3.15x106 Aerosol type particles/m3 produced and showed a significant drop in Aerosol type particle production when playing with a barrier used, with a mean average of 2.28x106{+/-}8.01x104 Aerosol type particles/m3. Both breathing and singing showed consistent numbers of Aerosol type particles produced with means of 6.59x107{+/-}7.94x105 Aerosol type particles/m3 and 5.28x107{+/-}5.36x105 Aerosol type particles/m3 respectively. This showed a drop in mean Aerosol type particles/m3 of 95.7% when using a barrier cap compared to playing without a barrier. It is concluded that, while playing a brass instrument, the propagation of respiratory Aerosols does occur and, to a smaller extent, so do Droplet size particles, but at a lower level than when the subject was breathing without an instrument. Finally, it was shown that the use of a barrier cap on the bell end of the instrument offers a significant reduction in the production of respiratory Aerosols into the immediate surroundings, which offers a possible mitigation method for playing in groups from the release of Aerosol type particles, especially in hard to ventilate spaces.","Parker, A. S.; Crookston, K.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165837v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165837v1?rss=1,2020-08-04,2020-08-04,,True
12,A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae,"BACKGROUND: Seroreactivity against human endemic coronaviruses has been linked to disease severity after SARS-CoV-2 infection. Assays that are capable of concomitantly detecting antibodies against endemic coronaviridae such as OC43, 229E, NL63, and SARS-CoV-2 may help to elucidate this question. We set up a platform for serum-screening and developed a bead-based Western blot system, namely DigiWest, capable of running hundreds of assays using microgram amounts of protein prepared directly from different viruses. METHODS: The parallelized and miniaturised DigiWest assay was adapted for detecting antibodies using whole protein extract prepared from isolated SARS-CoV-2 virus particles. After characterisation and optimization of the newly established test, whole virus lysates of OC43, 229E, and NL63 were integrated into the system. RESULTS: The DigiWest-based immunoassay system for detection of SARS-CoV-2 specific antibodies shows a sensitivity of 87.2 % and diagnostic specificity of 100 %. Concordance analysis with the SARS-CoV-2 immunoassays available by Roche, Siemens, and Euroimmun indicates a comparable assay performance (Cohen's Kappa ranging from 0.8799-0.9429). In the multiplexed assay, antibodies against the endemic coronaviruses OC43, 229E, and NL63 were detected, displaying a high incidence of seroreactivity against these coronaviruses. CONCLUSION: The DigiWest-based immunoassay, which uses authentic antigens from isolated virus particles, is capable of detecting individual serum responses against SARS-CoV-2 with high specificity and sensitivity in one multiplexed assay. It shows high concordance with other commercially available serologic assays. The DigiWest approach enables a concomitant detection of antibodies against different endemic coronaviruses and will help to elucidate the role of these possibly cross-reactive antibodies.","Fink, S.; Ruoff, F.; Stahl, A.; Becker, M.; Kaiser, P.; Traenkle, B.; Junker, D.; Weise, F.; Ruetalo, N.; Hoerber, S.; Peter, A.; Nelde, A.; Walz, J.; Krause, G.; Schenke-Layland, K.; Joos, T.; Rothbauer, U.; Schneiderhan-Marra, N.; Schindler, M.; Templin, M. F.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165019v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165019v1?rss=1,2020-08-04,2020-08-04,,True
13,Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation,"Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there have been demands on the testing infrastructure that have strained testing capacity. As a simplification of method, we confirm the efficacy of RNA extraction-free RT-qPCR and saline as an alternative patient sample storage buffer. In addition, amongst potential reagent shortages, it has sometimes been difficult to obtain inactivated viral particles. We have therefore also characterized armored SARS-CoV-2 RNA from Asuragen as an alternative diagnostic standard to ATCC genomic SARS-CoV-2 RNA and heat inactivated virions and provide guidelines for its use in RT-qPCR.","Ragan, K. B.; Bhadra, S.; Choi, J. H.; Towers, D.; Sullivan, C. S.; Ellington, A. D.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166173v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166173v1?rss=1,2020-08-04,2020-08-04,,True
14,"Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India","Underreporting of COVID-19 cases and deaths is a hindrance to correctly modeling and monitoring the pandemic. This is primarily due to limited testing, lack of reporting infrastructure and a large number of asymptomatic infections. In addition, diagnostic tests (RT-PCR tests for detecting current infection) and serological antibody tests for IgG (to assess past infections) are imperfect. In particular, the diagnostic tests have a high false negative rate. Epidemiologic models with a latent compartment for unascertained infections like the Susceptible-Exposed-Infected-Removed (SEIR) models can provide predictions for unreported cases and deaths under certain assumptions. Typically, the number of unascertained cases is unobserved and thus we cannot validate these estimates for a real study except for simulation studies. Population-based seroprevalence studies can provide a rough estimate of the total number of infections and help us check epidemiologic model projections. In this paper, we develop a method to account for high false negative rates in RT-PCR in an extension to the classic SEIR model. We apply this method to Delhi, the national capital region of India, with a population of 19.8 million and a COVID-19 hotspot of the country, obtaining estimates of underreporting factor for cases at 34-53 times and that for deaths at 8-13 times. Based on a recently released serological survey for Delhi with an estimated 22.86% seroprevalence, we compute adjusted estimates of the true number of infections reported by the survey (after accounting for misclassification of the antibody test results) which is largely consistent with the model outputs, yielding an underreporting factor for cases from 30-42. Together with the model and the serosurvey, this implies approximately 96-98% cases in Delhi remained unreported and whereas only 109,140 cases were reported on July 10, the true number of infections varied somewhere between 4.4-4.6 million across different estimates. While repeated serological monitoring is resource intensive, model-based adjustments, run with the most up to date data, can provide a viable option to keep track of the unreported cases and deaths and gauge the true extent of transmission of this insidious virus.","Bhattacharyya, R.; Bhaduri, R.; Kundu, R.; Salvatore, M.; Mukherjee, B.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166249v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166249v1?rss=1,2020-08-04,2020-08-04,,True
15,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,"Introduction: One of the important measures to prevent spread of COVID-19 in community is use of face mask. Though the debate is going on regarding the airborne transmission of SARS-CoV-2 it makes reasonable point for universal use of face masks. A large variety of face masks are available in the market or people can make their own using household items. The efficacy of masks depends upon the type of cloth and number of layers of the cloth. Material and methods: We have created an innovative mask with two layers of cotton and an impervious layer. The impervious layer made from polypropylene coated with polyurethane was applied on the outer side in the middle half of the mask in front of mouth and nose. The efficacy of this test mask was measured against N95FFR (reference standard), triple layer surgical masks and single layer cotton mask. A manikin was used wearing these masks/respirator and aerosols/droplets of diluted red colored carbol fuchsin and fluorescent Auramine O were sprayed from distance of 1m and 2m. We also tested use of face shield. Both macroscopic and microscopic examination of the dissected masks and respirator was performed. Results: The N95FFR was able to block the aerosols/droplets by its front layer. One triple layer surgical mask showed microscopic presence of stain in its innermost layer while the other blocked it with middle layer. The single layer cotton mask was not able to protect as we observed stain on the face itself. The test mask blocked most of the stain on impervious layer and also on the front cotton layer on lateral sides, where impervious layer was absent. When fluorescent stain was used, ultraviolet examination demonstrated that the whole area covered by test mask was clean while the other non covered area was fluorescent. Conclusion: We believe that our innovation can be used in the community as well as in general areas of the hospital like, offices, labs, etc. and can be a better alternative to single use triple layer surgical masks. Further testing may be done by other organizations to rule out bias in our study.","Shahane-Kapse, P. L.; Shende, M. R.; Kar, S.; Deshmukh, P.; Bhandari, D.; Narang, R.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165563v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165563v1?rss=1,2020-08-04,2020-08-04,,True
16,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,"T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection. Here, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2. First, at the individual level, we deeply characterized 3 acutely infected and 58 recovered COVID-19 subjects by experimentally mapping their CD8 T-cell response through antigen stimulation to 545 Human Leukocyte Antigen (HLA) class I presented viral peptides (class II data in a forthcoming study). Then, at the population level, we performed T-cell repertoire sequencing on 1,015 samples (from 827 COVID-19 subjects) as well as 3,500 controls to identify shared ""public"" T-cell receptors (TCRs) associated with SARS-CoV-2 infection from both CD8 and CD4 T cells. Collectively, our data reveal that CD8 T-cell responses are often driven by a few immunodominant, HLA-restricted epitopes. As expected, the T-cell response to SARS-CoV-2 peaks about one to two weeks after infection and is detectable for several months after recovery. As an application of these data, we trained a classifier to diagnose SARS-CoV-2 infection based solely on TCR sequencing from blood samples, and observed, at 99.8% specificity, high early sensitivity soon after diagnosis (Day 3-7 = 83.8% [95% CI = 77.6-89.4]; Day 8-14 = 92.4 [87.6-96.6]) as well as lasting sensitivity after recovery (Day 29+/convalescent = 96.7% [93.0-99.2]). These results demonstrate an approach to reliably assess the adaptive immune response both soon after viral antigenic exposure (before antibodies are typically detectable) as well as at later time points. This blood-based molecular approach to characterizing the cellular immune response has applications in vaccine development as well as clinical diagnostics and monitoring.","Snyder, T. M.; Gittelman, R. M.; Klinger, M.; May, D. H.; Osborne, E. J.; Taniguchi, R.; Zahid, H. J.; Kaplan, I. M.; Dines, J. N.; Noakes, M. N.; Pandya, R.; Chen, X.; Elasady, S.; Svejnoha, E.; Ebert, P.; Pesesky, M. W.; De Almeida, P.; O'Donnell, H.; DeGottardi, Q.; Keitany, G.; Lu, J.; Vong, A.; Elyanow, R.; Fields, P.; Greissl, J.; Baldo, L.; Semprini, S.; Cerchione, C.; Mazza, M.; Delmonte, O. M.; Dobbs, K.; Carreno-Tarragona, G.; Barrio, S.; Imberti, L.; Sottini, A.; Quiros-Roldan, E.; Rossi, C.; Biondi, A.; Bettini, L. R.; D'Angio, M.; Bonfanti, P.; Tompkins, M. F.; Alba, C.; Dalgard, C.; Sambri, V.; Martinelli, G.; Goldman, J. D.; Heath, J. R.; Su, H. C.; Notarangelo, L. D.; Martinez-Lopez, J.; Carlson, J. M.; Robins, H. S.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165647v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165647v1?rss=1,2020-08-04,2020-08-04,,True
17,The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers,"Background: The COVID-19 pandemic has dramatically changed medical practice worldwide. It posed a significant impact on different health services, including dermatology. Methods and objectives: Two online surveys were conducted to determine the prevalence of personal protective equipment-related skin complications (200 healthcare providers were included) and to demonstrate the outbreak s impact on dermatology practice (100 dermatologists were included). Results: In the first survey, the response rate was 72.46%. PPE- related dermatoses were reported by 147 (73%) participants, including frictional dermatitis (51.9%), mechanical acne (33.1%), contact dermatitis (29.9%), nonspecific rash (17.5%), urticaria (9.1%) and skin infections (3.2%). The response rate of the second survey was 64%. COVID-19 emerging cutaneous manifestations were recognized by 20% of dermatologists, including maculopapular rash (41.67%), urticaria (37.50%), chilblain (25%) and vasculitis (16.67). Telemedicine was provided by 73% of the dermatologists. The relapse rates of psoriasis, atopic dermatitis, rosacea, vitiligo and alopecia areata were noticeably increased as observed by 62%, 50%, 20%, and 4% of dermatologists, respectively. Most dermatologists (89%) reported minimal use of immunosuppressive drugs amid the pandemic. Conclusions: This article highlights the pivotal role of dermatologists in the leading edge during the current health crisis and how they adapt to these unfamiliar circumstances to meet the challenges. It documents the emergence of PPE-related dermatoses among healthcare providers and the impact of COVID-19 on different aspects of dermatology practice.","Shanshal, M.; Ahmed, H. S.; Asfoor, H.; Salih, R. I.; Ali, S. A.; Aldabouni, Y. k.","https://www.medrxiv.org/content/10.1101/2020.07.26.20156380v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20156380v1?rss=1,2020-08-04,2020-08-04,,True
18,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,"In the first six months of its deadly spread across the world, the Covid-19 incidence has exhibited interesting dichotomy between the rich and the poor countries. Surprisingly, the incidence and the Case Fatality Rate has been much higher in the richer countries compared with the poorer countries. However, the reasons behind this dichotomy have not been explained based on data or evidence, although some of the factors for the susceptibility of populations to SARS-CoV-2 infections have been proposed. We have taken into consideration all publicly available data and mined for the possible explanations in order to understand the reasons for this phenomenon. The data included many parameters including demography of nations, prevalence of communicable and non-communicable diseases, sanitation parameters etc. Results of our analyses suggest that demography, improved sanitation and hygiene, and higher incidence of autoimmune disorders as the most plausible factors to explain higher death rates in the richer countries Thus, the much debated hygiene hypothesis appears to lend credence to the Case Fatality Rate dichotomy between the rich and the poor countries.","Chatterjee, B.; Karandikar, R. L.; Mande, S. C.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165696v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165696v1?rss=1,2020-08-04,2020-08-04,,True
19,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,"Background Effective antiviral treatments are required to contain the ongoing coronavirus disease 2019 (COVID-19) pandemic. A previous report in 814 patients COVID-19 positive in Cuba provided preliminary therapeutic efficacy evidence with interferon alpha-2b (IFN alpha-2b) from March 11 to April 14, 2020. This study, re-evaluates the contribution of IFN-2b on the evolution of all patients, after 98 days of the epidemic, in a period from March 11 to June 17, 2020. Method A prospective observational study was implemented to monitor a therapeutic intervention with IFN alpha-2b used in the national protocol for COVID-19 attending in Cuba. Were included patients with positive throat swab specimens by real time RT-PCR who gave informed consent and had no contraindications for IFN treatment. Patients received therapy as per the Cuban COVID protocol that included a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular or subcutaneous administration of IFN alpha-2b The primary endpoint was the proportion of patients discharged from hospital, secondary was the case fatality rate and several outcomes related to time variables were also evaluated. Results From March 11th until June 17th, 2295 patients had been confirmed SARS-CoV-2 positive in Cuba, 2165 were treated with Heberon Alpha R and 130 received the approved protocol without IFN. The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. The benefits of IFN were significantly supported by time variables analyzed. Conclusions This second report confirm the preliminary evidences from first for the therapeutic effectiveness of IFN alpha-2b for SARS-Cov-2 infection and postulated that Heberon Alpha R is the main component within the antiviral triad used as a therapeutic intervention in the Cuban protocol COVID-19.","Pereda, R.; Gonzalez, D.; Rivero, H. B.; Rivero, J. C.; Perez, a.; Lopez, L. d. R.; Mezquia, N.; Venegas, R.; Betancourt, J. R.; Dominguez, R. E.","https://www.medrxiv.org/content/10.1101/2020.07.28.20157974v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20157974v1?rss=1,2020-08-04,2020-08-04,,True
20,Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19,"In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.","Ivashchenko, A. A.; Dmitriev, K. A.; Vostokova, N. V.; Azarova, V. N.; Blinow, A. A.; Egorova, A. N.; Gordeev, I. G.; Ilin, A. P.; Karapetian, R. N.; Kravchenko, D. V.; Lomakin, N. V.; Merkulova, E. A.; Papazova, N. A.; Pavlikova, E. P.; Savchuk, N. P.; Simakina, E. N.; Sitdekov, T. A.; Smolyarchuk, E. A.; Tikhomolova, E. G.; Yakubova, E. V.; Ivachtchenko, A. V.","https://www.medrxiv.org/content/10.1101/2020.07.26.20154724v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20154724v1?rss=1,2020-08-04,2020-08-04,,True
21,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System,"A sudden outbreak of pneumonia caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread all over the world facilitating the declaration of the resultant disease as a pandemic in March,2020. In Lebanon, the fast action of announcing a state of emergency with strict measures was among the factors that helped in achieving a successful containment of the disease in the country. Predisposing factors for acquiring COVID-19 and for developing a severe form of this disease were postulated to be related to epidemiological and clinical characteristics as well as the genomics signature of a given population or its environment. Biological markers such as the ABO blood group system was amongst those factors that were proposed to be linked to the variability in the disease course and/or the prevalence of this infection among different groups. We therefore conducted the first retrospective case-control study in the Middle-East and North Africa that tackles the association between the blood group types and the susceptibility as well as the severity of SARS-CoV2 infection. Opposing to the current acknowledged hypothesis, our results have challenged the association significance of this system with COVID-19. Herein, we highlighted the importance of studying larger cohorts using more rigorous approaches to diminish the potential confounding effect of some underlying comorbidities and genetic variants that are known to be associated with the ABO blood group system.","Khalil, A.; Hassoun, M.; Feghali, R.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166785v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166785v1?rss=1,2020-08-04,2020-08-04,,True
22,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,"Objective: To analyze the efficacy of Hydroxychloroquine (HCQ) plus standard of care (SOC) compared with SOC alone in reducing disease progression in Mild COVID-19 Design: A single centre, open label randomized controlled trial Place and Duration: Pulmonology department, Pak emirates Military Hospital (PEMH) from 10 April 2020 to 31 May 2020. Methodology: Five hundred patients of both genders having age between 18-50 years who were PCR positive and had Mild COVID-19 were selected. Patients assigned to standard dose of HCQ (400mg 12 hourly day 1 then 200mg 12 hrly for next 4 days) plus SOC were 349 while 151 patients received SOC comprising of Vit C, Vit D, and Zinc only (control group). Primary outcome was progression of disease while secondary outcome was PCR negativity on day 7 and 14. The results were analyzed on SPSS version 23. P value <0.05 was considered significant. Results: Median age of intervention group (34 + 11.778 years) and control group (34 + 9.813 years). Disease progressed in 16 patients, 11 (3.15%) were in intervention group as compared to 5 (3.35%) in control group, (p value = 0.865). PCR negativity in intervention and control groups were (day 7, 182 (52.1%) vs. 54 (35.7%) (p value = 0.001), (day 14, 244 (69.9%) vs. 110 (72.8%) (p value = 0.508). Consecutive PCR negativity at day 7 and 14 was observed in 240 (68.8%) in intervention group compared to 108 (71.5%) in control group. (p value = 0.231). Conclusion: Addition of HCQ to standard of care treatment in Mild COVID-19 neither prevents disease progression nor is it significantly associated with successive PCR negativity on day 7 and 14.","kamran, s. m.; Mirza, Z. e. H.; Naseem, A.; Saeed, F.; Azam, R.; Ullah, N.; Ahmad, W.; Saleem, S.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v1?rss=1,2020-08-04,2020-08-04,,True
23,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective,"We sought to identify optimal temporal windows for lockdown-based mitigation strategies on infectious disease spreads. An age-structured multi-compartmental Susceptible-Infected-Recovered (SIR) model was used to estimate infection spreads under parametric variation of lockdown intensity and duration from the data of SARS-CoV2 cases in India between January to July, 2020. The resulting parameter values were used to simulate lockdown outcomes for a wide range of start times and durations. Lockdowns were simulated as intervention strategies that modified weights assigned to social contact matrices for work, school and other places. Lockdown efficacy was assessed by the maximum number of infections recorded during a simulation run. Our analysis shows that lockdown outcomes depend sensitively on the timing of imposition and that it is possible to minimize lockdown durations while limiting case loads to numbers below the hospitalization thresholds. Such timing based effects arise naturally from the non-linear nature of SIR dynamics.","Pathak, A.; Madan Mohan, V.; Banerjee, A.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165662v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165662v1?rss=1,2020-08-04,2020-08-04,,True
24,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques,"Twitter is one of the world's biggest social media platforms for hosting abundant number of user-generated posts. It is considered as a gold mine of data. Majority of the tweets are public and thereby pullable unlike other social media platforms. In this paper we are analyzing the topics related to mental health that are recently (June, 2020) been discussed on Twitter. Also amidst the on-going pandemic, we are going to find out if covid-19 emerges as one of the factors impacting mental health. Further we are going to do an overall sentiment analysis to better understand the emotions of users.","Sengupta, S.; Mugde, S.; Sharma, G.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165571v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165571v1?rss=1,2020-08-04,2020-08-04,,True
25,Early clinical characteristics of Covid-19: scoping review,"ABSTRACT Background: The Coronavirus disease 2019 (covid-19) pandemic has spread rapidly across the globe. Accurate clinical characterisation studies are essential to informing research, diagnosis and clinical management efforts, particularly early in a pandemic. In this scoping review we identify the clinical characteristics of patients admitted to hospital in the early months of the pandemic, focusing on symptoms, laboratory and imaging findings, and clinical outcomes. Methods: A scoping review. MEDLINE, EMBASE and Global Health databases were searched studies published from January 1st 2020 to April 28th 2020. Studies which reported on at least 100 hospitalised patients with covid-19 of any age were included. Results: Of 1,249 studies identified through the search 78 studies were eligible for inclusion; one randomized control trial and 77 observational studies presenting data on 77,443 patients admitted with covid-19. Most studies were conducted in China (82%), 9% in the US and 10% in Europe and two studies were set in more than one country. No studies included patients from low and middle income countries. Coagulopathy was underrecognised as a complication in the early months of the pandemic. Use of corticosteroids varied widely, and the use of anticoagulants was reported in only one study. Fever, cough and dyspnoea are less common in older adults; gastrointestinal symptoms, as the only presenting feature may be underrecognised. The most common laboratory finding was lymphocytopenia. Inflammatory biomarkers were commonly elevated, including C-reactive protein and interleukin-6. Typical computed tomography findings include bilateral infiltrates however imaging may be normal in early disease. Data on clinical characteristics in children and vulnerable populations were limited. Conclusions: Clinical characterisation studies from early in the pandemic indicated that covid-19 is a multisystem disease, with biomarkers indicating inflammation and coagulopathy. However, early data collection on symptoms and clinical outcomes did not consistently reflect this wide spectrum. Corticosteroid use varied widely, and anticoagulants were rarely used. Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea, particularly in older adults. Further characterisation studies in different at-risk populations is needed. Review registration: Available at https://osf.io/r2ch9 Keywords: Covid-19, clinical characteristics, symptoms, biochemical parameters, imaging, outcomes, pandemic research","Manoharan, L.; Cattrall, J. W. S.; Harris, C.; Newell, K.; Thomson, B.; Pritchard, M. G.; Bannister, P. G.; Sigfrid, L.; Solomon, T.; Horby, P. W.; Carson, G.; Olliaro, P. L.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165738v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165738v1?rss=1,2020-08-04,2020-08-04,,True
26,False-Negative Mitigation in Group Testing for COVID-19 Screening,"After lifting the COVID-19 lockdown restrictions and opening businesses, screening is essential to prevent the spread of the virus. Group testing could be a promising candidate for screening to save time and resources. However, due to the high false-negative rate (FNR) of the RT-PCR diagnostic test, we should be cautious about using group testing because a group's false-negative result identifies all the individuals in a group as uninfected. Repeating the test is the best solution to reduce the FNR, and repeats should be integrated with the group-testing method to increase the sensitivity of the test. The simplest way is to replicate the test twice for each group (the 2Rgt method). In this paper, we present a new method for group testing (the groupMix method), which integrates two repeats in the test. Then we introduce the adaptive version of both the groupMix and the 2Rgt methods. We compare these methods analytically regarding the sensitivity and the average number of tests. The tradeoff between the sensitivity and the average number of tests should be considered when choosing the best method for the screening strategy. We applied the non-adaptive groupMix method to screening 263 people and identified 2 infected individuals by performing 98 tests. This method achieved a 63% saving in the number of tests compared to individual testing. This method is currently applied to COVID-19 screening in the Clinical Genetic Laboratory at the Royan Institute, Tehran, Iran. Our experimental results show that in COVID-19 screening, the viral load can be low, and the group size should not be more than 6; otherwise, the FNR increases significantly. A web interface of the non-adaptive groupMix method is publicly available for laboratories to implement this method.","Alizad-Rahvar, A. R.; Vafadar, S.; Totonchi, M.; Sadeghi, M.","https://www.medrxiv.org/content/10.1101/2020.07.31.20154070v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20154070v1?rss=1,2020-08-04,2020-08-04,,True
27,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,"Importance: Antibody testing is important for understanding patterns of exposure and potential immunity to SARS-CoV-2. Prior data on seroprevalence have been subject to variations in selection of individuals and nature as well as timing of testing in relation to exposures. Objective: We sought to determine the extent of SARS-CoV-2 seroprevalance and the factors associated with seroprevelance across a diverse cohort of healthcare workers. Design: Observational cohort study of healthcare workers, including SARS-CoV-2 serology testing and participant questionaires. Participants: A diverse and unselected population of adults (n=6,062) employed in a multi-site healthcare delivery system located in Los Angeles County, including individuals with direct patient contact and others with non-patient-oriented work functions. Exposure: Exposure and infection with the SARS-CoV-2 virus, as determined by seropositivity. Main Outcomes: Using Bayesian and multi-variate analyses, we estimated seroprevalence and factors associated with seropositivity and antibody titers, including pre-existing demographic and clinical characteristics; potential Covid-19 illness related exposures; and, symptoms consistent with Covid-19 infection. Results: We observed a seroprevalence rate of 4.1%, with anosmia as the most prominently associated self-reported symptom in addition to fever, dry cough, anorexia, and myalgias. After adjusting for potential confounders, pre-existing medical conditions were not associated with antibody positivity. However, seroprevalence was associated with younger age, Hispanic ethnicity, and African-American race, as well as presence of either a personal or household member having a prior diagnosis of Covid-19. Importantly, African American race and Hispanic ethnicity were associated with antibody positivity even after adjusting for personal Covid-19 diagnosis status, suggesting the contribution of unmeasured structural or societally factors. Notably, number of people, or children, in the home was not associated with antibody positivity. Conclusion and Relevance: The demographic factors associated with SARS-CoV-2 seroprevalence among our healthcare workers underscore the importance of exposure sources beyond the workplace. The size and diversity of our study population, combined with robust survey and modeling techniques, provide a vibrant picture of the demographic factors, exposures, and symptoms that can identify individuals with susceptibility as well as potential to mount an immune response to Covid-19.","Ebinger, J.; Botwin, G. J.; Albert, C. M.; Alotaibi, M.; Arditi, M.; Berg, A. H.; Binek, A.; Botting, P. G.; Fert-Bober, J.; Figueiredo, J. C.; Grein, J. D.; Hasan, W.; Henglin, M.; Hussain, S. K.; Jain, M.; Joung, S.; Karin, M.; Kim, E. H.; Li, D.; Liu, Y.; Luong, E.; McGovern, D. P. B.; Merchant, A.; Merin, N. M.; Miles, P. B.; Minissian, M.; Nguyen, T.-T.; Raedschelders, K.; Rashid, M. A.; Riera, C. E.; Riggs, R. V.; Sharma, S.; Sternbach, S.; Sun, N.; Tourtellotte, W. G.; Van Eyk, J. E.; Sobhani, K.; Braun, J. G.; Cheng, S.","https://www.medrxiv.org/content/10.1101/2020.07.31.20163055v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20163055v1?rss=1,2020-08-04,2020-08-04,,True
28,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,"One-step RT-qPCR is the most widely applied method for COVID-19 diagnostics. Designing in-house one-step RT-qPCR kits is restricted by the patent-rights for the production of enzymes and the lack of information about the components of the commercial kits. Here, we provide a simple, economical, and powerful one-step RT-qPCR kit based on patent-free, specifically-tailored versions of Moloney Murine Leukemia Virus Reverse Transcriptase and Thermus aquaticus DNA polymerase termed the R3T (Rapid Research Response Team) One-step RT-qPCR. Our kit was routinely able to reliably detect as low as 10 copies of the synthetic RNAs of the SARS-CoV-2. More importantly, our kit successfully detected COVID-19 in clinical samples of broad viral titers with similar reliability and selectivity as that of the Invitrogen SuperScript III Platinum One-step RT-qPCR and TaqPath 1-Step RT-qPCR kits. Overall, our kit has shown robust performance in both of laboratory settings and the Saudi Ministry of Health-approved testing facility.","Takahashi, M.; Tehseen, M.; Salunke, R.; Takahashi, E.; Mfarrej, S.; Sobhy, M. A.; Alhamlan, F.; Hala, S.; Mandujano, G. R.; Al-Qahtani, A. A.; Alofi, F. S.; Alsomali, A.; Hashem, A. M.; Khogeer, A.; Almontashiri, N. A. M.; Lee, J. M.; Mon, H.; Sakashita, K.; Li, M.; Kusakabe, T.; Pain, A.; Hamdan, S. M.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165704v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165704v1?rss=1,2020-08-04,2020-08-04,,True
29,"How does public knowledge, attitudes, and behaviors correlate in relation to COVID-19? A community-based cross-sectional study in Nepal","Background: The COVID 19 pandemic has created a global health emergency requiring an effective public health response including citizens' roles in preventing the spread and controlling the pandemic. Little is known about public knowledge, beliefs, and behaviors in relation to the pandemic in Nepal. This study aims to assess knowledge, attitude, and practices (KAP) towards COVID 19 among the general public and to identify associated factors. Methods: A cross-sectional survey was conducted between May to June 2020 with a sample of 645, recruited from 26 hospitals across Nepal. We conducted telephone interviews using a semi-structured questionnaire related to KAP regarding COVID 19. T-test and one-way ANOVA was conducted to determine group differences for socio-demographic variables. Linear regression and correlational analysis were performed to identify associated factors and measure the strength and direction of relationships. Results: Overall mean scores for knowledge, attitude and practice were 11.6 (SD 4.5), 2.7 (SD 1.8), and 9.9 (SD 1.93) respectively but differed by socio-demographic characteristics. Positive but weak linear correlations were observed between knowledge-practice (r=0.19, p<0.01) and attitude-practice (r=0.08, p<0.05). The relationship between knowledge and education was fairly strong (r = 0.34, p< 0.01). Province, place of residence, ecological area, age, gender, and caste/ethnicity were also significantly associated with the KAP score of participants. Conclusion: The study found varying degrees of correlation between Knowledge, Attitude, and Practice that may increase as the pandemic evolves in Nepal. Knowledge and level of education had positive associations with attitude and adherence to precautionary measures. The findings suggest a need for targeted community awareness interventions for the most vulnerable populations, men, those with no school education, the elderly, and people living in rural areas. Keywords: COVID-19, Knowledge, Attitude, Practice, Correlates, Nepal","Devkota, H. R.; Sijali, T. R.; Bogati, R.; Clarke, A.; Adhikary, P.; Karkee, R.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165266v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165266v1?rss=1,2020-08-04,2020-08-04,,True
30,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.","Background With more than 50000 accumulated cases, Panama has one of the highest incidences of SARS-CoV-2 in Central America, despite the fast implementation of disease control strategies. We investigated the early transmission patterns of the virus and the outcomes of mitigation measures in the country. Methods We collected information from epidemiological surveillance, including contact tracing, and genetic data from SARS-CoV-2 whole genomes, of the first five weeks of the outbreak. These data were used to estimate the exponential growth rate, doubling time and the time-varying effective reproductive number (Rt) using date of symptom onset in a Bayesian framework. The time of most recent ancestor for the introduced and circulating lineages was estimated by Bayesian analysis. Findings A total of 4210 subjects were SARS-CoV-2 positive during the period evaluated, of them we sequenced 313 cases, detecting the circulation of 10 SARS-CoV-2 lineages. Whole genomes analysis identified the local transmission of one cryptic lineage as early as 2 weeks before it was detected by surveillance systems. Analysis of transmission dynamics showed that lockdown reduced Rt and increased the doubling time, however, these measures did not stop the circulation of this lineage in the country. Interpretation These results demonstrate the value of epidemiological modeling and genome surveillance to assess mitigation strategies. At the same time, an active search for cryptic transmission clusters is crucial to interrupt local transmission of SARS-CoV-2 in a region.","Franco, D.; Gonzalez, C.; Abrego, L. E.; Carrera, J. P.; Diaz, Y.; Caisedo, Y.; Moreno, A.; Chavarria, O.; Gondola, J.; Castillo, M.; Valdespino, E.; Gaitan, M.; Martinez-Mandiche, J.; Hayer, L.; Gonzalez, P.; Lange, C.; Molto, Y.; Mojica, D.; Ramos, R.; Mastelari, M.; Cerezo, L.; Moreno, L.; Donnelly, C. A.; Faria, N. R.; Pascale, J. M.; Lopez-Verges, S.; Martinez, A. A.","https://www.medrxiv.org/content/10.1101/2020.07.31.20160929v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20160929v1?rss=1,2020-08-04,2020-08-04,,True
31,Epidemiological characteristics of SARS-COV-2 in Myanmar,"Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Myanmar, first COVID-19 reported cases were identified on 23rd March 2020. There were 336 reported confirmed cases, 261 recovered and 6 deaths through 13th July 2020. The study was a retrospective case series and all COVID-19 confirmed cases from 23rd March to 13th July 2020 were included. The data series of COVID-19 cases were extracted from the daily official reports of the Ministry of Health and Sports (MOHS), Myanmar and Centers for Disease Control and Prevention (CDC), Myanmar. Among 336 confirmed cases, there were 169 cases with reported transmission events. The median serial interval was 4 days (IQR 3, 2-5) with the range of 0 - 26 days. The mean of the reproduction number was 1.44 with (95% CI = 1.30-1.60) by exponential growth method and 1.32 with (95% CI = 0.98-1.73) confident interval by maximum likelihood method. This study outlined the epidemiological characteristics and epidemic parameters of COVID-19 in Myanmar. The estimation parameters in this study can be comparable with other studies and variability of these parameters can be considered when implementing disease control strategy in Myanmar.","Thway, A. M.; Tayza, H.; Win, T. T.; Tun, Y. M.; Aung, M. M.; Win, Y. N.; Tun, K. M.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166504v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166504v1?rss=1,2020-08-04,2020-08-04,,True
32,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial","Background: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/Design: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The protocol has been prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to categories 5, 6 or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration: Trial registration at clinicaltrials.gov; Registration Number: NCT04345523; https://clinicaltrials.gov/ct2/show/NCT04345523; Registered on 30 March, 2020. First posted date: April 14, 2020. Keywords: COVID-19, randomized, controlled trial, protocol, convalescent plasma (CP), antibodies.","Diago-Sempere, E.; Bueno, J. L.; Sancho-Lopez, A.; Munez-Rubio, E.; Torres, F.; Malo de Molina, R.; Fernandez-Cruz, A.; Salcedo De Diego, I.; Velasco-Iglesias, A.; Payares Herrera, C.; Casas Flecha, I.; Avendano-Sola, C.; Palomino, R. D.; Ramos-Martinez, A.; Ruiz-Antoran, B.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165720v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165720v1?rss=1,2020-08-04,2020-08-04,,True
33,Spreading of COVID-19 in Italy as the spreading of a wave packet,"We [fi]nd that the spreading of the COVID-19 pandemic in Italy can be described as the propagation of a wave packet in a dispersive medium where the e[ff]ect of Lockdown is simulated by the dispersion relation of the medium. We start expanding a previous statistical analysis based on the o[ffi]cial data provided by the Italian civil protection during 100 days, from March 2nd to June 9th. As the total number of people infected with the virus is uncertain, we have considered the trend of ICU patients and the sum of hospitalized patients and the deceased. Both the corresponding curves are well approximated by the same function depending on four free parameters. The model allows to predict the short term behavior of the pandemic and to estimate the bene[fi]ts due to lockdown measures.","Feoli, A.; Iannella, A. L.; Benedetto, E.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167197v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167197v1?rss=1,2020-08-04,2020-08-04,,True
34,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,"Background: Countries have adopted different approaches, at different times, to reduce the transmission of coronavirus disease 2019 (COVID-19). Cross-country comparison could indicate the relative efficacy of these approaches. We assess various non-pharmaceutical interventions (NPIs) over time, comparing the effects of self-imposed (i.e. voluntary) behavior change and of changes enforced via official regulations, by statistically examining their impacts on subsequent death rates in 13 European countries. Methods and findings: We examine two types of NPI: the introduction of government-enforced closure policies over time; and self-imposed alteration of individual behaviors in response to awareness of the epidemic, in the period prior to regulations. Our proxy for the latter is Google mobility data, which captures voluntary behavior change when disease salience is sufficiently high. The primary outcome variable is the rate of change in COVID-19 fatalities per day, 16-20 days after interventions take place. Linear multivariate regression analysis is used to evaluate impacts. Voluntarily reduced mobility, occurring prior to government policies, decreases the percent change in deaths per day by 9.2 percentage points (95% CI 4.5-14.0 pp). Government closure policies decrease the percent change in deaths per day by 14.0 percentage points (95% CI 10.8-17.2 pp). Disaggregating government policies, the most beneficial are intercity travel restrictions, cancelling public events, and closing non-essential workplaces. Other sub-components, such as closing schools and imposing stay-at-home rules, show smaller and statistically insignificant impacts. Conclusions: This study shows that NPIs have substantially reduced fatalities arising from COVID-19. Importantly, the effect of voluntary behavior change is of the same order of magnitude as government-mandated regulations. These findings, including the substantial variation across dimensions of closure, have implications for the phased withdrawal of government policies as the epidemic recedes, and for the possible reimposition of regulations if a second wave occurs, especially given the substantial economic and human welfare consequences of maintaining lockdowns.","Jamison, J.; Bundy, D.; Jamison, D.; Spitz, J.; Verguet, S.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166793v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166793v1?rss=1,2020-08-04,2020-08-04,,True
35,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,"The WHO announced the epidemic of SARS-CoV2 as a public health emergency of international concern on 30th January 2020. To date, it has spread to more than 200 countries, and has been declared as a global pandemic. For appropriate preparedness, containment, and mitigation response, the stakeholders and policymakers require prior guidance on the propagation of SARS-CoV2. This study aims to provide such guidance by forecasting the cumulative COVID-19 cases up to 4 weeks ahead for 173 countries, using four data-driven methodologies; autoregressive integrated moving average (ARIMA), exponential smoothing model (ETS), random walk forecasts (RWF) with and without drift. We also evaluate the accuracy of these forecasts using the Mean Absolute Percentage Error (MAPE). The results show that the ARIMA and ETS methods outperform the other two forecasting methods. Additionally, using these forecasts, we generated heat maps to provide a pictorial representation of the countries at risk of having an increase in cases in the coming 4 weeks for June. Due to limited data availability during the ongoing pandemic, less data-hungry forecasting models like ARIMA and ETS can help in anticipating the future burden of SARS-CoV2 on healthcare systems.","Ahmad, G.; Ahmed, F.; Rizwan, M. S.; Muhammad, J.; Fatima, H.; Ikram, A.; Zeeb, H.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167189v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167189v1?rss=1,2020-08-04,2020-08-04,,True
36,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020","Background: First cases of COVID-19 were reported from Wuhan, China, in December 2019, and it progressed rapidly. On 30 January, WHO declared the new disease as a PHEIC, then as a Pandemic on 11 March. By mid-March, the virus spread widely; Djibouti was not spared and was hit by the pandemic with the first case detected on 17 March. Djibouti worked with WHO and other partners to develop a preparedness and response plan, and implemented a series of intervention measures. MoH together with its civilian and military partners, closely followed WHO recommended strategy based on four pillars: testing, isolating, early case management, and contact tracing. From 17 March to 16 May, Djibouti performed the highest per capita tests in Africa and isolated, treated and traced the contacts of each positive case, which allowed for a rapid control of the epidemic. Methods: COVID-19 data included in this study was collected through MoH Djibouti during the period from 17 March to 16 May 2020. Results: A total of 1,401 confirmed cases of COVID-19 were included in the study with 4 related deaths (CFR: 0.3%) and an attack rate of 0.15%. Males represented (68.4%) of the cases, with the age group 31-45 years old (34.2%) as the most affected. Djibouti conducted 17,532 tests, and was considered as a champion for COVID-19 testing in Africa with 18.2 tests per 1000 habitant. All positive cases were isolated, treated and had their contacts traced, which led to early and proactive diagnosis of cases and in turn yielded up to 95-98% asymptomatic cases. Recoveries reached 69% of the infected cases with R0 (0.91). The virus was detected in 4 regions in the country, with the highest percentage in the capital (83%). Conclusion: Djibouti responded to COVID-19 pandemic following an efficient and effective strategy, using a strong collaboration between civilian and military health assets that increased the response capacities of the country. Partnership, coordination, solidarity, proactivity and commitment were the pillars to confront COVID-19 pandemic.","Elhakim, M.; Tourab, S. B.; Zouiten, A.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167692v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167692v1?rss=1,2020-08-04,2020-08-04,,True
37,Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.,"In order to respond to the urgent request of massive testing, developed countries perform nucleic acid amplification tests (NAAT) of SARS-CoV-2 in centralized laboratories. Real-time RT - PCR (Reverse transcription - Polymerase Chain Reaction) is used to amplify the viral RNA and enable its detection. Although PCR is 37 years old, it is still considered, without dispute, as the gold standard. PCR is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings. In the present work, by harnessing progress made in the past two decades in DNA amplification, microfluidics and membrane technologies, we succeeded to create a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT - LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or highly fluorescent probes. Depending on the viral load, the detection takes between twenty minutes and one hour. Using pools of naso-pharyngal clinical samples, we estimated a sensitivity comparable to RT-qPCR (up to a Cycle threshold of 39, equivalent to <0.1 TCID50 per mL) and a 100% specificity, for other human coronaviruses and eight respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called COVIDISC to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment paves the way towards a large dissemination of this device. The perspective of a reliable SARS-CoV-2 point of care detection, highly performing, that would deliver on-site results in less than one hour opens up a new efficient approach to manage the pandemics.","Garneret, P.; Coz, E.; Martin, E.; Manuguerra, J.-C.; Brient-Litzler, E.; Enouf, V.; Gonzalez Obando, D. F.; Olivo-Marin, J.-C.; Monti, F.; Van der Werf, S.; Vanhomwegen, J.; Tabeling, P. J.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166538v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166538v1?rss=1,2020-08-04,2020-08-04,,True
38,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,"Background Respiratory viral infections are an important cause of acute respiratory tract infections. They are caused by both Influenza and non influenza viruses. Respiratory viral infections are known to be associated with severe clinical outcome especially in the critically ill. A constant surveillance is needed for early etiological identification which can help in timely and appropriate management and will further help in prevention of indiscriminate use of antibiotics in patients with viral etiology. Methods In this retrospective study, clinical records of all adult liver disease patients with clinically confirmed ARI, whose request for respiratory viral testing were received in the virology laboratory during September 2016 - March 2019 were reviewed. Respiratory viruses were identified by real time PCR on FilmArray 2.0 instrument (BioFire Diagnostics, Utah, USA) using Respiratory panel as per the manufacturer's instructions. Results Of the 603 patients of liver disease with clinically confirmed influenza like illness, over all incidence of respiratory viral infection was 24.3% (n= 147). Infections by non-influenza viruses (87, 59.1%) were more than influenza group of viruses. Mortality was higher in non influenza group (43, 49.4%) as compared to influenza (24, 40%) [p=0.015] being maximum in Rhinovirus, 22 (32.8%). Two peaks were observed in both influenza and non influenza groups, first in the months of January and February and the other one in August and October. Conclusion With the emergence of SARS- CoV-2 it has now become imperative for a constant surveillance of the non influenza viruses for early etiological identification of the respiratory viral infection for proper and timely management in the critically ill.","Gupta, E.; Padhi, A.; Agarwal, K.; Ramachandran, K.; Aggarwal, R.; Pasupuleti, S. S. R.; Bhattacharyya, D.; Maiwall, R.; Sarin, S. K.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166330v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166330v1?rss=1,2020-08-04,2020-08-04,,True
39,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,"Background: With the rise of the COVID-19 pandemic, a new severe life-threatening inflammatory syndrome has been reported in some pediatric populations. Global attention was shifted towards the syndrome termed multisystem inflammatory syndrome in children (MIS-C), with new case reports flooding in. Objectives: The aim of this scoping review is to summarize the existing reports on MIS-C and focus on the demographics, diagnosis, clinical presentation, laboratory investigations, imaging studies, treatment, and patient outcomes. Methods: We conducted a systemic search using LitCovid and MEDLINE electronic databases. We screened citations, titles and abstracts, then reviewed potentially relevant articles in full. After data extraction, we reported our final data under subheadings of demographics, diagnosis, clinical presentation, laboratory investigations, imaging studies, treatment, and patient outcomes. Results: Our search strategy yielded 42 original studies reporting 674 pediatric patients fitting the case definition of MIS-C. The studies included 21 case reports, 16 case series and 5 cohort studies. The most common reported symptom of MIS-C was fever (98%). Gastrointestinal symptoms were common (N=557, 83%). Interleukin-6 (IL-6) levels were measured in 125 patients and was elevated in 94 % (N=117). Echocardiography detected coronary artery lesions in 100 patients. Prophylactic and/or therapeutic heparin was required in 34% (N=227) of patients. The most commonly administered treatment modality targeting MIS-C was intravenous immunoglobulin (IVIG) (N=490). Corticosteroids (N=347) and aspirin (N=112) were also integral parts of the treatment regimens. Biologic therapy was integrated into the treatment regimen for 116 patients. Intensive care unit (ICU) admission was alarming (N=478, 71%). 9 fatalities were recorded due to MIS-C Conclusions: We believe MIS-C bears pathophysiological resemblance to the well-known Kawasaki disease but with some key differences highlighted. Understanding those differences will aid our management plan for such patients.","Sabbour, M. A.; El-Swaify, S. T.; Farrag, N.; Kamel, M.; Ali, S. H.; Amir, A.; Refaat, M. A.; Dyab, M. A.; Nabhan, A.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167361v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167361v1?rss=1,2020-08-04,2020-08-04,,True
40,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,"The unique circumstances created by the COVID-19 pandemic pose serious challenges to mood stability and emotional regulation at all ages. Although many people tend to react resiliently to stress, others appear to display emotional anxiety and depression-related symptoms. In this study, we carried out a survey (N = 10,053) during the first week of the general lockdown (quarantine) in Argentina to measure early affective reactions in Argentine adults. Respondents showed substantial anxious and depressive symptoms, with 33 % and 23% of participants reporting possible depressive andanxious syndromes, respectively, with the youngest group (18 to 25 y.o.) showing the highest prevalence of symptoms. Even if prior mental health problems predisposed or aggravated the reaction, participants without prior complaints showed signs of psychological impact. Using linear regression, the most important independent variables related to depressive symptoms was the feeling of loneliness followed by daily stress. In the case of anxious states, the strongest variables were negative repetitive thinking and feeling of loneliness. Other psychological, economic, and social factors are discussed. This study is in line with previous literature that highlights the importance of the psychological impact of pandemics but additionally demonstrates that these reactions are present at a large scale immediately after the start of quarantine with very low infectious rates as an early anticipatory adaptive reaction leading to potentially negative outcomes from adjustment disorders to major disorders. In addition, the present results provide potentially relevant information about sudden environmental impacts on affective states and specific pathways for anxiety and depression to be expressed. We end by discussing implications for public policy based on considering the most vulnerable groups.","Torrente, F.; Yoris, A. E.; Low, D.; Lopez, P.; Bekinschtein, P.; Cetkovich, M.; Manes, F.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166272v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166272v1?rss=1,2020-08-04,2020-08-04,,True
41,A variational model for computing the effective reproduction number of SARS-CoV-2,"We propose a variational model for computing the effective reproduction number (ERN) of SARS-CoV-2 from the daily count of incident cases. This computation only requires the knowledge of the serial interval. The ERN estimate is made through the minimization of a functional that includes: (i) the adjustment of the incidence curve using an epidemiological model, (ii) the regularity of the estimation of the ERN and, (iii) the adjustment of the initial value to an initial estimate of R_0 obtained from the initial exponential growth of the epidemic. The model does not assume any statistical distribution for the ERN and, more importantly, does not require truncating the serial interval when its distribution contains negative days. A comparative study has been carried out with the standard EpiEstim method. For a particular choice of the parameters of the variational model and of the serial interval, a good agreement has been obtained between the estimate provided by the variational model and a 7 days shifted estimate obtained by EpiEstim. This backward shift suggests that our estimate is closer to present than that of EpiEstim. We also examine how to forecast the value of the ERN and the number of infected in the short term by two different extrapolation techniques. An implementation of the model is available online at www.ipol.im/ern.","Alvarez, L.; Colom, M.; Morel, J.-M.","https://www.medrxiv.org/content/10.1101/2020.08.01.20165142v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20165142v1?rss=1,2020-08-04,2020-08-04,,True
42,Gender disparities in international COVID-19 clinical trial leadership,"The COVID-19 pandemic offers considerable possibilities for research and leadership that might equalize opportunity in a new field; however, our study finds instead that more than two-thirds of investigators leading COVID-19-related clinical studies are predicted to be men. These gender disparities in trial leadership during the pandemic suggest that the structural reproduction of inequalities in research has taken place once again in this new academic field. This indicates that policies are needed to facilitate the identification and implementation of strategies to correct gender bias. The active participation of women, trans and gender-nonconforming individuals are needed in research to drive scientific discovery and innovation as well as to better address health disparities.","Cevik, M.; Haque, S. A.; Manne, J.; Kuppalli, K.; Sax, P. E.; Majumder, M. S.; Orkin, C.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166751v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166751v1?rss=1,2020-08-04,2020-08-04,,True
43,Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative,"Abstract Introduction: The coronavirus disease 2019 (COVID -19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) infection. Although tests to detect anti -SARS -CoV-2 antibodies have been developed, their sensitivity and specificity in hemodialysis patients have not been previously assessed. Methods: As part of a quality improvement (QI) initiative, nasopharyngeal swabs and predialysis blood samples were collected on the same day from adult patients receiving routine hemodialysis care at clinics managed by a large dialysis organization in the greater Miami, Florida region (23 - 30 Apr 2020). Polymerase chain reaction (PCR) tests for SARS -CoV -2 and chemiluminescence immunoassays for anti -SARS -CoV2 antibodies were performed according to manufacturer-specified protocols. Results: Of 715 participants in the QI initiative, 38 had symptomatology consistent with COVID -19 prior to or during the initiative. Among these, COVID -19 was PCR -confirmed in 14 and ruled out in 20, with the remaining 4 being inconclusive. Among the 34 patients with known COVID -19 status, the sensitivity and specificity of the antibody test were 57.1% and 85.0% when either antibody was considered. The remaining 677 patients had no record of symptoms consistent with COVID -19, nor any known exposure. Of these, 38 patients (5.6%) tested positive for anti-SARS-CoV-2 antibodies. Conclusions: The operational characteristics of the laboratory-based antibody test make it sufficient to rule in, but not rule out, SARS -CoV -2 infection in the appropriate clinical circumstance. A substantial proportion of dialysis patients may have had asymptomatic SARS -CoV -2 infection.","Cohen, D. E.; Marlowe, G.; Contreras, G.; Sosa, M. A.; Mendoza, J. M.; Lenz, O.; Mithani, Z.; Teixeiro, P. M.; Queija, N.; Moneda, A.; Jeanty, J. S.; Swanzy, K.; Palecek, M.; Krishnan, M.; Giullian, J.; Brunelli, S. M.","https://www.medrxiv.org/content/10.1101/2020.08.03.20163642v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20163642v1?rss=1,2020-08-04,2020-08-04,,True
44,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,"Social factors that determine the health of a population are known as the social determinants of health. During the past few weeks, as COVID-19 cases grew exponentially, the discrepancy among the number of cases distribution was evident.By applying the social vulnerability index and analyzing data from a total of 102 counties across the state of Illinois, we investigated which factors enhanced the risk of contracting the infection and which were related to a lower risk of infection. Our results showed that social factors such as belonging to a minority group, speaking English less than well, living in a multi-unit structure, and households with individuals of age group of 17 or younger were associated with a higher risk of infection. On the other hand, we found that factors such as living in a mobile home, individuals of age group 65 or older, low income per capita and, older than age 5 with disability were protective. We propose that communities with disproportionate health burdens can be identified by the application of these factors. Future efforts need to focus on decreasing the gap of disparity by modifying these social factors.","Lara Garcia, O. E.; Alvarez Retamales, V.; Madrid Suarez, O. A.; Parajuli, P.; Hingle, S.; Robinson, R.","https://www.medrxiv.org/content/10.1101/2020.08.03.20166983v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20166983v1?rss=1,2020-08-04,2020-08-04,,True
45,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,"The study of transmission dynamics of COVID-19, have depicted the rate, patterns and predictions of the pandemic cases. In order to combat the disease transmission in India, the Government had declared lockdown on the 25th of March. Even after a strict lockdown nationwide, the cases are increasing and have crossed 4.5 lakh positive cases. A positive point to be noted amongst all that the recovered cases are slowly exceeding the active cases. The survival of the patients, taking death as the event that varies over age groups and gender wise is noteworthy. This study aims in carrying out a survival analysis to establish the variability in survivorship among age groups and sex, at different levels, that is, national, state and district level. The open database of COVID-19 tracker (covid19india.org) of India has been utilized to fulfill the objectives of the study. The study period has been taken from the beginning of the first case which was on 30th Jan 2020 till 30th June. Due to the amount of under-reporting of data and dropping missing columns a total of 26,815 sample patients were considered. The entry point of each patient is different and event of interest is death in the study. Kaplan Meier survival estimation, Cox proportional hazard model and multilevel survival model has been used to perform survival analysis. Kaplan Meier survival function, shows that the probability of survival has been declining during the study period of five months. A significant variability has been observed in the age groups, as evident from all the survival estimates, with increasing age the risk of dying from COVID-19 increases. When Western and Central India show ever decreasing survival rate in the framed time period then Eastern , North Eastern and Southern India shows a slightly better picture in terms of survival. Maharashtra, Gujarat, Delhi, Rajasthan and West bengal showed alrmingly poor survival as well. This study has depicted a grave scenario of gradation of ever decreasing survival rates in various regions and shows the variability by age and gender.","Kundu, S.; Kirti,; Mandal, D.","https://www.medrxiv.org/content/10.1101/2020.08.01.20162115v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20162115v1?rss=1,2020-08-04,2020-08-04,,True
46,"High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela","Objective: To investigate food insecurity prevalence in two favelas in Brazil in the early weeks from physical distancing policy, between March 27, 2020 to June 1, 2020. Design: A cross-sectional study using online questionnaire to elicit information on socioeconomic and demographic characteristics, the types of stores visited to buy food and food insecurity screening. Experience of food insecurity was collected according to the Brazilian Food Insecurity Scale. Factors associated with moderate or severe food insecurity were investigated using the logistic regression model. Setting: Sao Paulo city, Brazil. Participants: 909 householders. Results: 88% of the households included young women working as cleaners or kitchen assistants and in sales services. One-fifth of the participants were recieving federal cash transfer programme, called Bolsa Familia. There were 92% households with children. The most frequent experience reported was uncertainty about food acquisition or receiving more (89%), to eat less than one should (64%), not being able to eat healthy and nutritious food (46%), and skipping a meal (39%). 47% of the participants experienced moderate or severe food insecurity. Factors associated with moderate and severe food insecurity were low income, being Bolsa Familia recipient, a low level of education, and households without children. Conclusions: Half of the participants experienced moderate or severe food insecurity, and close to ten per cent was hungry. Our data suggest that families with children were at lower risk of moderate to severe food insecurity. It is possible that nationally established social programs like Bolsa Familia were protecting those families.","Manfrinato, C. V.; Marino, A.; Conde, V. F.; Franco, M. d. C. P.; Stedefeldt, E.; Tomita, L. Y.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166157v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166157v1?rss=1,2020-08-04,2020-08-04,,True
47,On the temporal spreading of the SARS-CoV-2,"The behaviour of SARS-CoV-2 virus is certainly one of the most challenging in contemporary world. Although the mathematical modelling of the virus has made relevant contributions, the unpredictable behaviour of the virus is still not fully understood. To identify some aspects of the virus elusive behaviour, we focused on the temporal characteristics of its course. We have analysed the latency trends the virus has realized worldwide, the outbreak of the hot spots, and the decreasing trends of the pandemic. We found that the spatio-temporal pandemic dynamics shows a power law distribution. As with physical systems, these changes in the pandemic's course, which we have called transitional stages of contagion, highlight shared characteristics in many countries. The main results of this work is that the pandemic progression rhythms have been clearly identified for each country, providing the processes and the stages at which the virus develops, thus giving important information on the activation of containment and control measures.","Bertacchini, F.; Bilotta, E.; Pantano, P. S.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166447v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166447v1?rss=1,2020-08-04,2020-08-04,,True
48,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,"Message The COVID-19 pandemic has severely curtailed the practice of endoscopy (as an exemplar for outpatient diagnostic procedures) worldwide. Restart and recovery processes will be influenced by the need to protect patients and staff from disease transmission, but data on the risk of COVID-19 transmission after endoscopy are sparse. This is of particular importance in later pandemic phases when the risk of harm from delayed or missed significant diagnoses is likely to far outweigh the risk of infection. The British Society of Gastroenterology (BSG) guidance for restarting endoscopy included stratification of diagnostic procedures according to aerosol generation or assessment of infectious risk as well as pragmatic guidance on the use of personal protective equipment (PPE). We sought to document the risk of COVID-19 transmission after endoscopy in this 'COVID-minimised' environment. Prospective data were collected from 18 UK centres for n=6208 procedures, with follow-up telephone assessment of patients at 7 and 14 days. No cases of COVID-19 were documented by any centre after endoscopy in either patients or staff, with 3/2611 (0.11%) asymptomatic patients testing positive for SARS-CoV-2 on nasopharyngeal swab testing pre-endoscopy. While these data cannot determine the relative contribution of each component of a COVID-minimised pathway, they provide clear support for such an approach, are reassuring and should aid planning for outpatient diagnostics in the COVID-19 recovery phase.","Hayee, B.; The SCOTS project group,; East, J. E.; Rees, C. R.; Penman, I.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166736v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166736v1?rss=1,2020-08-04,2020-08-04,,True
49,The characteristics of multi-source mobility datasets and how they reveal the luxury nature of social distancing in the U.S. during the COVID-19 pandemic,"This study reveals the human mobility from various sources and the luxury nature of social distancing in the U.S. during the COVID-19 pandemic by highlighting the disparities in mobility dynamics from lower-income and upper-income counties. We collect, process, and compute mobility data from four sources: 1) Apple mobility trend reports, 2) Google community mobility reports, 3) mobility data from Descartes Labs, and 4) Twitter mobility calculated via weighted distance. We further design a Responsive Index (RI) based on the time series of mobility change percentages to quantify the general degree of mobility-based responsiveness to COVID-19 at the U.S. county level. We find statistically significant positive correlations in the RI between either two data sources, revealing their general similarity, albeit with varying Pearson r coefficients. Despite the similarity, however, mobility from each source presents unique and even contrasting characteristics, in part demonstrating the multifaceted nature of human mobility. The positive correlation between RI and income at the county level is significant in all mobility datasets, suggesting that counties with higher income tend to react more aggressively in terms of reducing more mobility in response to the COVID-19 pandemic. Most states present a positive difference in RI between their upper-income and lower-income counties, where diverging patterns in time series of mobility changes percentages can be found. To our best knowledge, this is the first study that cross-compares multi-source mobility datasets. The findings shed light on not only the characteristics of multi-source mobility data but also the mobility patterns in tandem with the economic disparity.","Huang, X.; Li, Z.; Jiang, Y.; Ye, X.; Deng, C.; Zhang, J.; Li, X.","https://www.medrxiv.org/content/10.1101/2020.07.31.20143016v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20143016v1?rss=1,2020-08-04,2020-08-04,,True
50,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,"The use of face masks is recommended worldwide to reduce the spread of COVID-19. A plethora of facial coverings and respirators, both commercial and homemade, pervade the market, but the true filtration capabilities of many homemade measures against the virus are unclear and continue to be unexplored. In this work, we compare the efficacy of the following masks in keeping out particulate matter below 2.5 microns: N95 respirators, surgical masks, cloth masks, cloth masks with activated carbon air filters, cloth masks with HVAC air filters, lightly starch-enhanced cloth masks, and heavily-starched cloth masks. The experiments utilize an inhalation system and aerosol chamber to simulate a masked individual respiring aerosolized air. COVID-19 disproportionately affects people in low-income communities, who often lack the resources to acquire appropriate personal protective equipment and tend to lack the flexibility to shelter in place due to their public-facing occupations. This work tests low-cost enhancements to homemade masks to assist these communities in making better masks to reduce viral transmission. Experimental results demonstrate that the filtration efficacy of cloth masks with either a light or heavy starch can approach the performance of much costlier masks. This discovery supports the idea of low-cost enhancements to reduce transmission and protect individuals from contracting COVID-19.","Bhimaraju, H.; Nag, N.; Jain, R.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166637v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166637v1?rss=1,2020-08-04,2020-08-04,,True
51,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,"Background and objective: The outbreak of COVID-19 has become a global health concern. In this study, we evaluate the effectiveness and safety of convalescent plasma therapy in patients with severe and critically ill COVID-19. Methods: Sixteen COVID-19 patients received transfusion of anti-COVID-19 antibody-positive convalescent plasma. The main outcome was time for viral nucleic acid amplification (NAA) test turning negative. Clinical laboratory parameters were measured at the baseline (d0) before plasma transfusion, and day 1 (d1), day 3 (d3) after transfusion as well. Results: Among the 16 patients, 10 of them had a consistently positive result of viral NAA test before convalescent plasma transfusion. Eight patients (8/10) became negative from day 2 to day 8 after transfusion. Severe patients showed a shorter time for NAA test turning negative after transfusion (mean rank 2.17 vs 5.90, P = 0.036). Two critically ill patients transfused plasma with lower antibody level remained a positive result of NAA test. CRP level demonstrated a decline 1 day after convalescent plasma treatment, compared with the baseline (P = 0.017). No adverse events were observed during convalescent plasma transfusion. Conclusions: Viral NAA test of most patients with COVID-19 who received convalescent plasma transfusion turned negative on the 2nd to 8th days after transfusion, and the negative time of severe patients was shorter than that of critically ill patients.","Chen, S.; Lu, C.; Li, P.; Wang, L.; Wang, H.; Yang, Q.; Chen, L.; Li, J.; Ma, H.; Sang, Q.; Li, J.; Xu, L.; Song, X.; Li, F.; Zhang, Y.; Kang, Y.; Xing, L.; Zhang, G.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1?rss=1,2020-08-04,2020-08-04,,True
52,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,"Background: Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and spreads through droplet-mediated transmission on contaminated surfaces and in air. Mounting scientific evidence from observational studies suggests that face masks for the general public may reduce the spread of infections. However, results from randomized control trials (RCT) have been presented as inconclusive, and concerns related to the safety and efficacy of non-surgical face masks in non-clinical settings remain. This controversy calls for a meta-analysis which considers non-compliance in RCTs, the time-lag in benefits of universal masking, and possible adverse effects. Methods: We performed a meta-analysis of RCTs of non-surgical face masks in preventing viral respiratory infections in non-hospital and non-household settings at cumulative and maximum follow-up as primary endpoints. The search for RCTs yielded five studies published before May 29th, 2020. We pooled estimates from the studies and performed random-effects meta-analysis and mixed-effects meta-regression across studies, accounting for covariates in compliance vs. non-compliance in treatment. Results: Face masks decreased infections across all studies at maximum follow-up (p=0.0318$, RR=0.608 [0.387 - 0.956]), and particularly in studies without non-compliance bias. We found significant between-study heterogeneity in studies with bias (I^2=71.2%, p=0.0077). We also used adjusted meta-regression to account for heterogeneity. The results support a significant protective effect of masking (p=0.0006, beta=0.0214, SE= 0.0062). No severe adverse effects were detected. Interpretation: The meta-analysis of existing randomized control studies found support for the efficacy of face masks among the general public. Our results show that face masks protect populations from infections and do not pose a significant risk to users. Recommendations and clear communication concerning the benefits of face masks should be provided to limit the number of COVID-19 and other respiratory infections.","Ollila, H. M.; Partinen, M.; Koskela, J.; Savolainen, R.; Rotkirch, A.; Laine, L. T.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166116v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166116v1?rss=1,2020-08-04,2020-08-04,,True
53,Containing the Spread of Infectious Disease on College Campuses,"College campuses in the United States are highly vulnerable to infectious diseases outbreaks, and there is a mounting need to develop strategies that best mitigate their size and duration, particularly as colleges consider reopening their campuses in the midst of the COVID-19 pandemic. Towards addressing this need, we applied a stochastic transmission model to quantify the impact of university-level responses to past outbreaks on their campuses and used it to determine which control interventions are most effective. The model aims to simultaneously overcome three crucial issues: stochastic variation in small populations, missing or unobserved case data, and changes in disease transmission rates post-intervention. We tested the model and assessed various interventions using data from the 2014 and 2016 mumps outbreaks at Ohio State University and Harvard University, respectively. Our results suggest that universities should design more aggressive diagnostic procedures and stricter isolation policies to decrease infectious disease incidence on campus. Our model can be applied to data from other outbreaks in college campuses and similar small-population settings.","Shah, M.; Ferra, G.; Fitzgerald, S.; Barreira, P.; Sabeti, P.; Colubri, A.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166348v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166348v1?rss=1,2020-08-04,2020-08-04,,True
54,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,"SARS-CoV-2 rapidly spread from a regional outbreak to a global pandemic in just a few months. Global research efforts have focused on developing effective vaccines against SARS-CoV-2 and the disease it causes, COVID-19. However, some of the basic epidemiological parameters, such as the exponential epidemic growth rate and the basic reproductive number, R0, across geographic areas are still not well quantified. Here, we developed and fit a mathematical model to case and death count data collected from the United States and eight European countries during the early epidemic period before broad control measures were implemented. Results show that the early epidemic grew exponentially at rates between 0.19-0.29/day (epidemic doubling times between 2.4-3.6 days). We discuss the current estimates of the mean serial interval, and argue that existing evidence suggests that the interval is between 6-8 days in the absence of active isolation efforts. Using parameters consistent with this range, we estimated the median R0 value to be 5.8 (confidence interval: 4.7-7.3) in the United States and between 3.6 and 6.1 in the eight European countries. This translates to herd immunity thresholds needed to stop transmission to be between 73% and 84%. We further analyze how vaccination schedules depends on R0, the duration of vaccine-induced immunity to SARS-CoV-2, and show that individual-level heterogeneity in vaccine induced immunity can significantly affect vaccination schedules.","Ke, R.; Romero-Severson, E. O.; Sanche, S.; Hengartner, N.","https://www.medrxiv.org/content/10.1101/2020.07.31.20166298v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20166298v1?rss=1,2020-08-04,2020-08-04,,True
55,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage","In the context of an unprecedented shortage of nasopharyngeal swabs (NPS) or sample transport media during the coronavirus disease 2019 (COVID-19) crisis, alternative methods for sample collection are needed. To address this need, we validated a cell culture medium as a viral transport medium, and compared the analytical sensitivity of SARS-CoV-2 real-time RT-PCR in nasal wash (NW), oropharyngeal swab (OPS) and NPS specimens. Both the clinical and analytical sensitivity were comparable in these three sample types. OPS and NW specimens may therefore represent suitable alternatives to NPS for SARS-CoV-2 detection.","Calame, A.; Mazza, L.; Renzoni, A.; Kaiser, L.; Schibler, M.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166397v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166397v1?rss=1,2020-08-04,2020-08-04,,True
56,Outcome of COVID-19 with co-existing surgical emergencies in children: our initial experiences and recommendations,"Background: COVID 19 has changed the practice of surgery vividly all over the world. Pediatric surgery is not an exception. Prioritization protocols allowing us to provide emergency surgical care to the children in need while controlling the pandemic spread. The aim of this study is to share our experiences with the outcome of children with COVID 19 who had a co existing surgical emergency. Methods: This is a retrospective observational study. We reviewed the epidemiological, clinical, and laboratory data of all patients admitted in our surgery department through the emergency department and later diagnosed to have COVID 19 by RT PCR. The study duration was 3 months (April 2020 to June 2020). A nasopharyngeal swab was taken from all patients irrespective of symptoms to detect SARS CoV 2 by RT PCR with the purpose of detecting asymptomatic patients and patients with atypical symptoms. Emergency surgical services were provided immediately without delay and patients with positive test results were isolated according to the hospital protocol. We divided the test positive patients into 4 age groups for the convenience of data analysis. Data were retrieved from hospital records and analyzed using SPSS (version 25) software. Ethical permission was taken from the hospital ethical review board. Results: Total patients were 32. Seven (21.9%) of them were neonates. Twenty four (75%) patients were male. The predominant diagnosis was acute abdomen followed by infantile hypertrophic pyloric stenosis (IHPS), myelomeningocele, and intussusception. Only two patients had mild respiratory symptoms (dry cough). Fever was present in 13 (40.6%) patients. Fourteen (43.8%) patients required surgical treatment. The mean duration of hospital stay was 5.5 days. One neonate with ARM died in the postoperative ward due to cardiac arrest. No patient had hypoxemia or organ failure. Seven health care workers (5.51%) including doctors & nurses got infected with SARS Co V2 during this period. Conclusion: Our study has revealed a milder course of COVID 19 in children with minimal infectivity even when present in association with emergency surgical conditions. This might encourage a gradual restart to mitigate the impact of COVID 19 on children surgery. Keywords: COVID 19, COVID 19 in children, Children Surgery, Surgical emergency, Surgery in COVID 19 positive patients.","Hasan, M. S.; Ali, M. A.; Huq, U.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166371v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166371v1?rss=1,2020-08-04,2020-08-04,,True
57,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study,"Introduction Preterm birth is the leading cause of child mortality globally, with many survivors experiencing long-term adverse consequences. Preliminary evidence suggests that preterm births dropped dramatically following implementation of policy measures aimed at mitigating the impact of the COVID-19 pandemic. Methods We undertook a national quasi-experimental difference-in-regression-discontinuity approach to study the impact of the COVID-19 mitigation measures implemented in the Netherlands in a stepwise fashion on 9, 15, and 23 March 2020 on the incidence of preterm birth. We used data from the neonatal dried blood spot screening programme (2010-2020) and cross-validated these against national perinatal registry data. Stratified analyses were conducted according to gestational age subgroups, and sensitivity analyses to assess robustness of the findings. We explored potential effect modification by neighbourhood socio-economic status. Results Data on 1,599,549 singleton newborns were available, including 56,720 post-implementation births. Consistent reductions in preterm birth were seen across various time windows surrounding implementation of the 9 March COVID-19 mitigation measures: +/- 2 months (n=531,823): odds ratio 0.77 (95% confidence interval 0.66-0.91), p=0.002; +/- 3 months (n=796,531): 0.85 (0.73-0.98), p=0.028; +/- 4 months (n=1,066,872): 0.84 (0.73-0.97), p=0.023. Decreases observed following the 15 March measures were of smaller magnitude and not statistically significant. No changes were observed after 23 March. Preterm birth reductions after 9 March were consistent across gestational age strata and robust in sensitivity analyses. They appeared confined to high-socioeconomic status neighbourhoods, but effect modification was not statistically significant. Conclusion In this national quasi-experimental study, initial implementation of COVID-19 mitigation measures was associated with a 15-23% drop in preterm births in the following months, in agreement with preliminary observations in other countries. It is now of pivotal importance that integration of comparable data from across the globe is undertaken to further substantiate these findings and start exploring the underlying mechanisms.","Been, J. V.; Burgos Ochoa, L.; Bertens, L. C.; Schoenmakers, S.; Steegers, E. A.; Reiss, I. K.","https://www.medrxiv.org/content/10.1101/2020.08.01.20160077v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20160077v1?rss=1,2020-08-04,2020-08-04,,True
58,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,"Non-pharmaceutical interventions to control COVID-19 spread have been implemented in several countries with different intensity, timing, and impact on transmission. As a result, post-lockdown COVID-19 dynamics are heterogenous and difficult to interpret. Here we describe a set of contact surveys performed in four Chinese cities (Wuhan, Shanghai, Shenzhen, and Changsha) during the pre-pandemic, lockdown, and post-lockdown period to quantify the transmission impact of relaxing interventions via changes in age-specific contact patterns. We estimate that the mean number of contacts increased 5%-17% since the end of the lockdown but are still 3-7 times lower than their pre-pandemic levels. We find that post-lockdown contact patterns in China are still sufficiently low to keep SARS-CoV-2 transmission under control. We also find that the impact of school interventions depends non-linearly on the share of other activities being resumed. When most community activities are halted, school closure leads to a 77% decrease in the reproductive number; in contrast, when social mixing outside of schools is at pre-pandemic level, school closure leads to a 5% reduction in transmission. Moving forward, to control COVID-19 spread without resorting to a lockdown, it will be key to dose relaxation in social mixing in the community and strengthen targeted interventions.","Zhang, J.; Litvinova, M.; Liang, Y.; Zheng, W.; Shi, H.; Vespignani, A.; Viboud, C.; Ajelli, M.; Yu, H.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167056v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167056v1?rss=1,2020-08-04,2020-08-04,,True
59,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,"Unlike forward contact tracing, backward contact tracing identifies the source of newly detected cases. This approach is particularly valuable when there is high individual-level variation in the number of secondary transmissions. By using a simple branching process model, we explored the potential of combining backward contact tracing with more conventional forward contact tracing for control of COVID-19.","Endo, A.; Centre for the Mathematical Modelling of Infectious Diseases (CMMID) COVID-19 Working Group,; Leclerc, Q. J.; Knight, G. M.; Medley, G. F.; Atkins, K. E.; Funk, S.; Kucharski, A. J.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166595v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166595v1?rss=1,2020-08-04,2020-08-04,,True
60,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,"While the novel coronavirus continues to spread worldwide, the reported incubation period has varied between studies and is imprecise due to limited data. A literature search with certain selection criteria was conducted on May 30, 2020. In total, sixty-four articles were included, and 854 individual-level data were extracted from 30 studies for pooled analysis. Of these studies, 72% of them reported a median or mean incubation period of 4-7 days, while our estimated median was 4.9 days (95% confidence interval [CI]: 4.6-5.2). However, the inclusion of 81 asymptomatic and presymptomatic patients, as well as 31 cases with incubation periods exceeding 14 days, led to our estimation of 97.5th percentile with 19.2 days (95% CI: 17.4-21.4), beyond the currently suggested 14-day quarantine period. Therefore, we appeal to prolong the quarantine duration, especially for areas that have insufficient testing resources, to protect susceptible populations from being infected.","LI, Z.; Zhang, Y.; Peng, L.; Gao, R.; Jing, J.; Ren, B.; Xu, J.; Wang, T.","https://www.medrxiv.org/content/10.1101/2020.08.01.20164335v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20164335v1?rss=1,2020-08-04,2020-08-04,,True
61,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity,"Background. Reliable high-throughput serological assays for SARS-CoV-2 antibodies (Abs) are urgently needed for the effective containment of the COVID-19 pandemic, as it is of crucial importance to understand the strength and duration of immunity after infection, and to make informed decisions concerning the activation or discontinuation of physical distancing restrictions. Methods. In 184 serum samples from 130 COVID-19 patients and 54 SARS-CoV-2 negative subjects, the analytical and clinical performances of four commercially available chemiluminescent assays (Abbott SARS-Cov-2 IgG, Roche Elecsys anti-SARS-CoV-2, Ortho SARS-CoV-2 total and IgG) and one enzyme-linked immunosorbent assay (Diesse ENZY-WELL SARS-CoV-2 IgG) were evaluated and compared with the neutralization activity achieved using the plaque reduction neutralization test (PRNT). Findings. Precision results ranged from 0.9% to 11.8% for all assays. Elecsys anti-SARS-CoV-2 demonstrated linearity of results at concentrations within the cut-off value. Overall, sensitivity ranged from 78.5 to 87.8%, and specificity, from 97.6 to 100%. On limiting the analysis to samples collected 12 days after onset of symptoms, the sensitivity of all assays increased, the highest value (95.2%) being obtained with VITRO Anti-SARS-CoV-2 Total and Architect SARS-CoV-2 IgG. The strongest PRNT50 correlation with antibody levels was obtained with ENZY-Well SARS-CoV-2 IgG (rho = 0.541, p < 0.001). Interpretation. The results confirmed that all immunoassays had an excellent specificity, whereas sensitivity varied across immunoassays, depending strongly on the time interval between symptoms onset and sample collection. Further studies should be conducted to achieve a stronger correlation between antibody measurement and PRNT50 in order to obtain useful information for providing effective passive antibody therapy, and developing a vaccine against the SARS-CoV-2 virus.","Plebani, M.; Padoan, A.; Sciacovelli, L.; Bonfante, F.; Pagliari, M.; Bozzato, D.; Cosma, C.; Bortolami, A.; Negrini, D.; Zuin, S.","https://www.medrxiv.org/content/10.1101/2020.08.01.20166546v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.01.20166546v1?rss=1,2020-08-04,2020-08-04,,True
62,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan,"Abstract Background: We evaluated clinical characteristics and the clinical utility of VITROS SARS-CoV-2 antibody tests according to COVID-19 severity in patients in Japan. Methods: We analyzed 255 serum specimens from 130 COVID-19 patients and examined clinical records and laboratory data. Presence of total (IgA, IgM, and IgG) and specific IgG antibody for the spike 1 antigen of SARS-CoV2 was determined using VITROS Anti-SARS-CoV-2 antibody tests. Findings: Overall, 98 (75.4%) and 32 (24.6%) patients had mild and severe COVID-19, respectively. On admission, 76 (58.5%) and 45 (34.6%) patients were positive for total and IgG antibody assays. Among 91 patients at discharge, 90 (98.9%) and 81 (89.0%) patients were positive for total and IgG antibody, respectively. Clinical background and laboratory findings on admission, but not the prevalence or concentration of total or IgG antibody, were associated with disease prognosis. Total and IgG antibody intensity were significantly higher in severe cases than in mild cases in serum collected after 11 days from onset, but not within 10 days. Conclusion: VITROS Anti-SARS-CoV-2 Total and IgG assays will be useful as supporting diagnostic and surveillance tools and for evaluation of humoral immune response to COVID-19. Clinical background and laboratory findings are preferable predictors of disease prognosis.","Nagura-Ikeda, M.; Imai, K.; Kubota, K.; Noguchi, S.; Kitagawa, Y.; Matsuoka, M.; Tabata, S.; Miyoshi, K.; Ito, T.; Tamura, K.; Maeda, T.","https://www.medrxiv.org/content/10.1101/2020.08.02.20166256v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.02.20166256v1?rss=1,2020-08-04,2020-08-04,,True
63,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020,"Bronchoalveolar lavage samples (n=34) collected in February, 2020 prior to the wide availability of molecular testing for SARS-CoV-2 were retrospectively assayed for presence of viral RNA. None of these patients qualified for SARS-CoV-2 testing based on Centers for Disease Control criteria at the time. None of the samples tested positive for SARS-CoV-2, suggesting that the virus was not yet widespread in Minnesota at the time these samples were obtained.","Challener, D. W.; Shah, A.; Binnicker, M.; Badley, A.; O'Horo, J.","https://www.medrxiv.org/content/10.1101/2020.08.03.20167320v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.03.20167320v1?rss=1,2020-08-04,2020-08-04,,True
64,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,"RNA viruses that replicate in the cytoplasm often disrupt nucleocytoplasmic transport to preferentially translate their own transcripts and prevent host antiviral responses. The Sarbecovirus accessory protein ORF6 has previously been shown to be the major inhibitor of interferon production in both SARS-CoV and SARS-CoV-2. SARS-CoV-2 ORF6 was recently shown to co-purify with the host mRNA export factors Rae1 and Nup98. Here, we demonstrate SARS-CoV-2 ORF6 strongly represses protein expression of co-transfected reporter constructs and imprisons host mRNA in the nucleus, which is associated with its ability to co-purify with Rae1 and Nup98. These protein-protein interactions map to the C-terminus of ORF6 and can be abolished by a single amino acid mutation in Met58. Overexpression of Rae1 restores reporter expression in the presence of SARS-CoV-2 ORF6. We further identify an ORF6 mutant containing a 9-amino acid deletion, ORF6 {triangleup}22-30, in multiple SARS-CoV-2 clinical isolates that can still downregulate the expression of a co-transfected reporter and interact with Rae1 and Nup98. SARS-CoV ORF6 also interacts with Rae1 and Nup98. However, SARS-CoV-2 ORF6 more strongly co-purifies with Rae1 and Nup98 and results in significantly reduced expression of reporter proteins compared to SARS-CoV ORF6, a potential mechanism for the delayed symptom onset and pre-symptomatic transmission uniquely associated with the SARS-CoV-2 pandemic.","Addetia, A.; Lieberman, N. A. P.; Phung, Q.; Xie, H.; Roychoudhury, P.; Loprieno, M. A.; Huang, M.; Shrestha, L.; Jerome, K. R.; Greninger, A. L.","https://www.biorxiv.org/content/10.1101/2020.08.03.234559v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.234559v1?rss=1,2020-08-03,2020-08-03,,False
65,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,"Development of accurate disease models and discovery of immune-modulating drugs is challenged by the immune system's highly interconnected and context-dependent nature. Here we apply deep-learning-driven analysis of cellular morphology to develop a scalable 'phenomics' platform and demonstrate its ability to identify dose-dependent, high-dimensional relationships among and between immunomodulators, toxins, pathogens, genetic perturbations, and small and large molecules at scale. High-throughput screening on this platform demonstrates rapid identification and triage of hits for TGF-{beta}- and TNF--driven phenotypes. We deploy the platform to develop phenotypic models of active SARS-CoV-2 infection and of COVID-19-associated cytokine storm, surfacing compounds with demonstrated clinical benefit and identifying several new candidates for drug repurposing. The presented library of images, deep learning features, and compound screening data from immune profiling and COVID-19 screens serves as a deep resource for immune biology and cellular-model drug discovery with immediate impact on the COVID-19 pandemic.","Cuccarese, M. F.; Earnshaw, B. A.; Heiser, K.; Fogelson, B.; Davis, C. T.; McLean, P. F.; Gordon, H. B.; Skelly, K.-R.; Weathersby, F. L.; Rodic, V.; Quigley, I. K.; Pastuzyn, E. D.; Mendivil, B. M.; Lazar, N. H.; Brooks, C. A.; Carpenter, J.; Jacobson, P.; Glazier, S. W.; Ford, J.; Jensen, J. D.; Campbell, N. D.; Statnick, M. A.; Low, A. S.; Thomas, K. R.; Carpenter, A. E.; Hegde, S. S.; Alfa, R. W.; Victors, M. L.; Haque, I. S.; Chong, Y. T.; Gibson, C. C.","https://www.biorxiv.org/content/10.1101/2020.08.02.233064v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.233064v1?rss=1,2020-08-03,2020-08-03,,False
66,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,"Most antibodies isolated from COVID-19 patients are specific to SARS-CoV-2. COVA1-16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here we determined a crystal structure of COVA1-16 Fab with the SARS-CoV-2 RBD, and a negative-stain EM reconstruction with the spike glycoprotein trimer, to elucidate the structural basis of its cross-reactivity. COVA1-16 binds a highly conserved epitope on the SARS-CoV-2 RBD, mainly through a long CDR H3, and competes with ACE2 binding due to steric hindrance rather than epitope overlap. COVA1-16 binds to a flexible up conformation of the RBD on the spike and relies on antibody avidity for neutralization. These findings, along with structural and functional rationale for the epitope conservation, provide a blueprint for development of more universal SARS-like coronavirus vaccines and therapies.","Liu, H.; Wu, N. C.; Yuan, M.; Bangaru, S.; Torres, J. L.; Caniels, T. G.; van Schooten, J.; Zhu, X.; Lee, C.-C. D.; Brouwer, P. J. M.; van Gils, M. J.; Sanders, R. W.; Ward, A. B.; Wilson, I. A.","https://www.biorxiv.org/content/10.1101/2020.08.02.233536v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.233536v1?rss=1,2020-08-03,2020-08-03,,False
67,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,"There is an urgent need for the ability to rapidly develop effective countermeasures for emerging biological threats, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the ongoing coronavirus disease 2019 (COVID-19) pandemic. We have developed a generalized computational design strategy to rapidly engineer de novo proteins that precisely recapitulate the protein surface targeted by biological agents, like viruses, to gain entry into cells. The designed proteins act as decoys that block cellular entry and aim to be resilient to viral mutational escape. Using our novel platform, in less than ten weeks, we engineered, validated, and optimized de novo protein decoys of human angiotensin-converting enzyme 2 (hACE2), the membrane-associated protein that SARS-CoV-2 exploits to infect cells. Our optimized designs are hyperstable de novo proteins (~18-37 kDa), have high affinity for the SARS-CoV-2 receptor binding domain (RBD) and can potently inhibit the virus infection and replication in vitro. Future refinements to our strategy can enable the rapid development of other therapeutic de novo protein decoys, not limited to neutralizing viruses, but to combat any agent that explicitly interacts with cell surface proteins to cause disease.","Linsky, T. W.; Vergara, R.; Codina, N.; Nelson, J. W.; Walker, M. J.; Su, W.; Hsiang, T.-Y.; Esser-Nobis, K.; Yu, K.; Hou, Y. J.; Priya, T.; Mitsumoto, M.; Pong, A.; Lau, U. Y.; Mason, M. L.; Chen, J.; Chen, A.; Berrocal, T.; Peng, H.; Clairmont, N. S.; Castellanos, J.; Lin, Y.-R.; Josephson-Day, A.; Baric, R. S.; Walkey, C. D.; Swanson, R.; Blancas-Mejia, L. M.; Gale, M.; Yen, H.-L.; Silva, D.-A.","https://www.biorxiv.org/content/10.1101/2020.08.03.231340v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.231340v1?rss=1,2020-08-03,2020-08-03,,False
68,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein","Large research efforts are going into characterizing, mapping the spread, and studying the biology and clinical features of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report four complete SARS-CoV-2 genome sequences obtained from patients confirmed to have the disease in Stockholm, Sweden, in late April. A variant at position 23463 was found for the first time in one genome. It changes an arginine (R) residue to histidine (H) at position 364 in the S1 subunit of the spike protein. The genomes belonged to two different genetic groups, previously reported as two of the three main genetic groups found in Sweden. Three of them are from group B.1/G, corresponding to the Italian outbreak, reported by the Public Health Agency of Sweden to have declined in prevalence by late April, and more investigation is needed in order to ensure that the spread of different types of SARS-CoV-2 is fully characterized.","Soratto, T. A. T.; Darban, H.; Bjerkner, A.; Coorens, M.; Albert, J.; Allander, T.; Andersson, B.","https://www.biorxiv.org/content/10.1101/2020.08.03.233866v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.233866v1?rss=1,2020-08-03,2020-08-03,,False
69,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,"The PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Consortium has achieved its initial goal of completing the sequencing of 1000 SARS-CoV-2 genomes from nasopharyngeal and oropharyngeal swabs collected from individuals testing positive for COVID-19 by Real Time PCR. The samples were collected across 10 states covering different zones within India. Given the importance of this information for public health response initiatives investigating transmission of COVID-19, the sequence data is being released in GISAID database. This information will improve our understanding on how the virus is spreading, ultimately helping to interrupt the transmission chains, prevent new cases of infection, and provide impetus to research on intervention measures. This will also provide us with information on evolution of the virus, genetic predisposition (if any) and adaptation to human hosts. One thousand and fifty two sequences were used for phylodynamic, temporal and geographic mutation patterns and haplotype network analyses. Initial results indicate that multiple lineages of SARS-CoV-2 are circulating in India, probably introduced by travel from Europe, USA and East Asia. A2a (20A/B/C) was found to be predominant, along with few parental haplotypes 19A/B. In particular, there is a predominance of the D614G mutation, which is found to be emerging in almost all regions of the country. Additionally, mutations in important regions of the viral genome with significant geographical clustering have also been observed. The temporal haplotype diversities landscape in each region appears to be similar pan India, with haplotype diversities peaking between March-May, while by June A2a (20A/B/C) emerged as the predominant one. Within haplotypes, different states appear to have different proportions. Temporal and geographic patterns in the sequences obtained reveal interesting clustering of mutations. Some mutations are present at particularly high frequencies in one state as compared to others. The negative estimate Tajimas D (D = -2.26817) is consistent with the rapid expansion of SARS-CoV-2 population in India. Detailed mutational analysis across India to understand the gradual emergence of mutants at different regions of the country and its possible implication will help in better disease management.","Maitra, A.; Raghav, S.; Dalal, A.; Ali, F.; Paynter, V. M.; Paul, D.; Biswas, N. K.; Ghosh, A.; Jani, K.; Chinnaswamy, S.; Pati, S.; Sahu, A.; Mitra, D.; Bhat, M. K.; Mayor, S.; Sarin, A.; The PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Consortium,; Shouche, Y. S.; Seshasayee, A. S. N.; Palakodeti, D.; Bashyam, M. D.; PARIDA, A.; Das, S.","https://www.biorxiv.org/content/10.1101/2020.08.03.233718v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.233718v1?rss=1,2020-08-03,2020-08-03,,False
70,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,"This paper presents the design and study of a first-in-class cyclic peptide inhibitor against the SARS-CoV-2 main protease (Mpro). The cyclic peptide inhibitor is designed to mimic the conformation of a substrate at a C-terminal autolytic cleavage site of Mpro. Synthesis and evaluation of a first-generation cyclic peptide inhibitor reveals that the inhibitor is active against Mpro in vitro and is non-toxic toward human cells in culture. The initial hit described in this manuscript, UCI-1, lays the groundwork for the development of additional cyclic peptide inhibitors against Mpro with improved activities.","Kreutzer, A. G.; Krumberger, M.; Parrocha, C. M. T.; Morris, M. A.; Guaglianone, G.; Nowick, J. S.","https://www.biorxiv.org/content/10.1101/2020.08.03.234872v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.234872v1?rss=1,2020-08-03,2020-08-03,,False
71,Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,"There are currently no antiviral therapies specific against SARS-CoV-2, the virus responsible for the global pandemic disease COVID-19. To facilitate structure-based drug design, we conducted an X-ray crystallographic study of the nsp16/nsp10 2'-O-methyltransferase complex that methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection. Heterodimer structures are determined with the methyl donor S-adenosylmethionine (SAM), the reaction product S-adenosylhomocysteine (SAH) or the SAH analog sinefungin (SFG). Furthermore, structures of nsp16/nsp10 with the methylated Cap-0 analog (m7GpppA) and SAM or SAH bound were obtained. Comparative analysis revealed flexible loops in open and closed conformations at the m7GpppA binding pocket. Bound sulfates in several structures suggested the location of the phosphates in the ribonucleotide binding groove. Additional nucleotide binding sites were found on the face of the protein opposite the active site. These various sites and the conserved dimer interface could be exploited for development of antiviral inhibitors.","Rosas-Lemus, M.; Minasov, G.; Shuvalova, L.; Inniss, N.; Kiryukhina, O.; Brunzelle, J.; Satchell, K. J.","https://www.biorxiv.org/content/10.1101/2020.08.03.234716v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.234716v1?rss=1,2020-08-03,2020-08-03,,False
72,"Modified SIR-model applied to covid-19, similarity solutions and projections to further development","The SIR-model is adapted to the covid-19 pandemic through a modification that consists in making the basic reproduction number variable. Independent of it, another reproduction number is introduced, which is defined similarly to the usual net reproduction number. Due to its simple analytic form, it enables a clear interpretation for all values. A further parameter, provisionally called acceleration parameter, is introduced and applied, which enables a more differentiated characterization of the infection number dynamics. By a variable transformation the 3 equations of the modified SIR-model can be reduced to 2. The latter are solved up to ordinary integrations. The solutions are evaluated for current situations, yielding a pretty good match with the data reported. Encouraged by this, a variety of possible future developments is examined, including linear and exponential growth of the infection numbers as well as sub- and super-exponential growth. In particular, the behavior of the two reproduction numbers and the acceleration parameter is studied, which in some cases leads to surprising results. With regard to the number of unreported infections it is shown, that from the solution for a special one solutions for others can be derived by similarity transformations.","Rebhan, E.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165035v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165035v1?rss=1,2020-08-03,2020-08-03,,True
73,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,"An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail.","Baum, A.; Copin, R.; Ajithdoss, D.; Zhou, A.; Lanza, K.; Negron, N.; Ni, M.; Wei, Y.; Atwal, G. S.; Oyejide, A.; Goez-Gazi, Y.; Dutton, J.; Clemmons, E.; Staples, H. M.; Bartley, C.; Klaffke, B.; Alfson, K.; Gazi, M.; Gonzales, O.; Dick, E.; Carrion, R.; Pessaint, L.; Porto, M.; Cook, A.; Brown, R.; Ali, V.; Greenhouse, J.; Taylor, T.; Andersen, H.; Lewis, M. G.; Stahl, N.; Murphy, A. J.; Yancopoulos, G. D.; Kyratsous, C. A.","https://www.biorxiv.org/content/10.1101/2020.08.02.233320v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.233320v1?rss=1,2020-08-03,2020-08-03,,False
74,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,"We used two approaches to design proteins with shape and chemical complementarity to the receptor binding domain (RBD) of SARS-CoV-2 Spike protein near the binding site for the human ACE2 receptor. Scaffolds were built around an ACE2 helix that interacts with the RBD, or de novo designed scaffolds were docked against the RBD to identify new binding modes. In both cases, designed sequences were optimized first in silico and then experimentally for target binding, folding and stability. Nine designs bound the RBD with affinities ranging from 100pM to 10nM, and blocked bona fide SARS-CoV-2 infection of Vero E6 cells with IC50 values ranging from 35 pM to 35 nM; the most potent of these - 56 and 64 residue hyperstable proteins made using the second approach - are roughly six times more potent on a per mass basis (IC50 ~ 0.23 ng/ml) than the best monoclonal antibodies reported thus far. Cryo-electron microscopy structures of the SARS-CoV-2 spike ectodomain trimer in complex with the two most potent minibinders show that the structures of the designs and their binding interactions with the RBD are nearly identical to the computational models, and that all three RBDs in a single Spike protein can be engaged simultaneously. These hyperstable minibinders provide promising starting points for new SARS-CoV-2 therapeutics, and illustrate the power of computational protein design for rapidly generating potential therapeutic candidates against pandemic threats.","Baker, D.; Cao, L.; Goreshnik, I.; Coventry, B.; Case, J. B.; Miller, L.; Kozodoy, L.; Chen, R. E.; Carter, L.; Walls, A.; Park, Y.-J.; Stewart, L.; Diamond, M.; Veesler, D.","https://www.biorxiv.org/content/10.1101/2020.08.03.234914v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.03.234914v1?rss=1,2020-08-03,2020-08-03,,False
75,Mechanism of duplex unwinding by coronavirus nsp13 helicases,"The current COVID-19 pandemic urges in-depth investigation into proteins encoded with coronavirus (CoV), especially conserved CoV replicases. The nsp13 of highly pathogenic MERS-CoV, SARS-CoV-2, and SARS-CoV exhibit the most conserved CoV replicases. Using single-molecule FRET, we observed that MERS-CoV nsp13 unwound DNA in discrete steps of approximately 9 bp when ATP was used. If another NTP was used, then the steps were only 4 to 5 bp. In dwell time analysis, we detected 3 or 4 hidden steps in each unwinding process, which indicated the hydrolysis of 3 or 4 dTTP. Based on crystallographic and biochemical studies of CoV nsp13 helicases, we modeled an unwinding mechanism similar to the spring-loaded mechanism of HCV NS3 helicase, although our model proposes that flexible 1B and stalk domains, by allowing a lag greater than 4 bp during unwinding, cause the accumulated tension on the nsp13-DNA complex. The hinge region between two RecA-like domains in SARS-CoV-2 nsp13 is intrinsically more flexible than in MERS-CoV nsp13 due to the difference of a single amino acid, which causes the former to induce significantly greater NTP hydrolysis. Our findings thus establish a blueprint for determining the unwinding mechanism of a unique helicase family.","Hu, X.; Hao, W.; Qin, B.; Tian, Z.; Li, Z.; Hou, P.; Zhao, R.; Cui, S.; Diao, J.","https://www.biorxiv.org/content/10.1101/2020.08.02.233510v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.233510v1?rss=1,2020-08-03,2020-08-03,,False
76,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells","COVID-19 affects vulnerable populations including elderly individuals and patients with cancer. Natural Killer (NK) cells and innate-immune TRAIL suppress transformed and virally-infected cells. ACE2, and TMPRSS2 protease promote SARS-CoV-2 infectivity, while inflammatory cytokines IL-6, or G-CSF worsen COVID-19 severity. We show MEK inhibitors (MEKi) VS-6766, trametinib and selumetinib reduce ACE2 expression in human cells. Chloroquine or hydroxychloroquine increase cleaved active SP-domain of TMPRSS2, and this is potentiated by MEKi. In some human cells, remdesivir increases ACE2-promoter luciferase-reporter expression, ACE2 mRNA and protein, and ACE2 expression is attenuated by MEKi. We show elevated cytokines in COVID-19-(+) patient plasma (N=9) versus control (N=11). TMPRSS2, inflammatory cytokines G-CSF, M-CSF, IL-1alpha, IL-6 and MCP-1 are suppressed by MEKi alone or in combination with remdesivir. MEKi enhance NK cell (but not T-cell) killing of target-cells, without suppressing TRAIL-mediated cytotoxicity. We generated a pseudotyped SARS-CoV-2 virus with a lentiviral core but with the SARS-CoV-2 D614 or G614 SPIKE (S) protein on its envelope and used VSV-G lentivirus as a negative control. Our results show infection of human bronchial epithelial cells or lung cancer cells and that MEKi suppress infectivity of the SARS-CoV-2-S pseudovirus following infection. We show a drug class-effect with MEKi to promote immune responses involving NK cells, inhibit inflammatory cytokines and block host-factors for SARS-CoV-2 infection leading also to suppression of SARS-CoV-2-S pseudovirus infection of human cells in a model system. MEKi may attenuate coronavirus infection to allow immune responses and antiviral agents to control COVID-19 disease progression and severity.","Zhou, L.; Huntington, K.; Zhang, S.; Carlsen, L.; So, E.-Y.; Parker, C.; Sahin, I.; Safran, H.; Kamle, S.; Lee, C.-M.; Lee, C.-G.; Elias, J. A.; Campbell, K. S.; Naik, M. T.; Atwood, W. J.; Youssef, E.; Pachter, J. A.; Navaraj, A.; Seyhan, A. A.; Liang, O.; El-Deiry, W.","https://www.biorxiv.org/content/10.1101/2020.08.02.230839v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.230839v1?rss=1,2020-08-03,2020-08-03,,False
77,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), is transmitted person-to-person via respiratory droplets and, likely, via smaller droplet nuclei light enough to remain suspended in the air for hours and contaminate surfaces particularly in indoor conditions. Thus, effective measures are needed to prevent SARS-CoV-2 transmission in indoor environments. In this regard, we have investigated whether a system based on a filter combining Tungsten Trioxide-Based (WO3) photocatalysis and an antiviral fabric treated-copper nanocluster could inactivate SARS-CoV-2. To this purpose, an infectious SARS-CoV-2 suspension was introduced in the upper opening of a closed cylinder containing a WO3 filter and a lightbased system that activates WO3 and the antiviral fabric. From the bottom exit, aliquots of fluid were collected every 10 min (up to 60 min) and tested for their infectivity by means of a viral plaque assay in Vero cells whereas, in parallel, the viral RNA content was measured by quantitative PCR (qPCR). As we have previously shown for SARS-CoV, a 1:1,000 ratio of plaque forming units (PFU) vs. viral RNA copies was observed also for SARS-CoV-2. After 10 min, the infectious viral content was already decreased by 98.2% reaching 100% inactivation after 30 min whereas the SARS-CoV-2 RNA load was decreased of 1.5 log10 after 30 min. Thus, in spite of only a partial decrease of viral RNA, SARS-CoV-2 infectivity was completely abolished by the WO3 photocatalysis system by 30 min. These results support the hypothesis that this system could be exploited to achieve SARS-CoV-2 inactivation in indoor environments.","Ghezzi, S.; Pagani, I.; Poli, G.; Perboni, S.; Vicenzi, E.","https://www.biorxiv.org/content/10.1101/2020.08.01.232199v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.01.232199v1?rss=1,2020-08-02,2020-08-02,,False
78,A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity,"Chloroquine and hydroxychloroquine (H)CQ are well known anti-malarial drugs, while their use against COVID-19 is more controversial. (H)CQ activity was examined in tissue culture cells to determine if their anti-viral benefits or adverse effects might be due to altering host cell pathways. Metabolic analysis revealed (H)CQ inhibit oxidative phosphorylation in mitochondria, likely by sequestering protons needed to drive ATP synthase. This activity could cause cardiotoxicity because heart muscle relies on beta oxidation of fatty acids. However, it might also explain their therapeutic benefit against COVID-19. A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release. Oxidative phosphorylation is eventually compromised, so glycolysis is upregulated to maintain ATP levels. (H)CQ could prevent viral infection and/or slow its replication by sequestering these protons. In support of this model other potential COVID-19 therapeutics also targeted mitochondria, as did tobacco smoke, which may underlie smokers protection. The mitochondria of young people are naturally more adaptable and resilient, providing a rationale for their resistance to disease progression. Conversely, obesity and diabetes could exacerbate disease severity by providing extra glucose to infected cells dependent on glycolysis. The description of (H)CQ function presented here, together with its implications for understanding SARS-CO-V2 infection, makes testable predictions about disease progression and identifies new approaches for treating COVID-19.","Sheaff, R. J.","https://www.biorxiv.org/content/10.1101/2020.08.02.232892v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.232892v1?rss=1,2020-08-02,2020-08-02,,False
79,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,"Coronavirus possesses the largest RNA genome among all the RNA viruses. Its genome encodes about 29 proteins. Most of the viral proteins are non-structural proteins (NSP) except envelop (E), membrane (M), nucleocapsid (N) and Spike (S) proteins that constitute the viral nucleocapsid, envelop and surface. We have recently cloned all the 29 SARS-CoV-2 genes into vectors for their expressions in mammalian cells except NSP11 that has only 14 amino acids (aa). We are able to express all the 28 cloned SARS-CoV-2 genes in human cells to characterize their subcellular distributions. The proteins of SARS-CoV-2 are mostly cytoplasmic but some are both cytoplasmic and nuclear. Those punctate staining proteins were further investigated by immunofluorescent assay (IFA) using specific antibodies or by co-transfection with an organelle marker-expressing plasmid. As a result, we found that NSP15, ORF6, M and ORF7a are related to Golgi apparatus, and that ORF7b, ORF8 and ORF10 colocalize with endoplasmic reticulum (ER). Interestingly, ORF3a distributes in cell membrane, early endosome, endosome, late endosome and lysosome, which suggests that ORF3a might help the infected virus to usurp endosome and lysosome for viral use. Furthermore, we revealed that NSP13 colocalized with SC35, a protein standing for splicing compartments in the nucleus. Our studies for the first time visualized the subcellular locations of SARS-CoV-2 proteins and might provide novel insights into the viral proteins biological functions.","Zhang, J.; Cruz-cosme, R.; Zhuang, M.-W.; Liu, D.; Liu, Y.; Teng, S.; Wang, P.-H.; Tang, Q.","https://www.biorxiv.org/content/10.1101/2020.08.02.233023v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.02.233023v1?rss=1,2020-08-02,2020-08-02,,False
80,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay","Serology testing for COVID-19 is highly attractive because of the relatively short diagnosis time and the ability to test for an active immune response against the SARS-CoV-2. In many types of serology tests, the sensitivity and the specificity are directly influenced by the quality of the antigens manufactured. Protein purification of these recombinantly expressed viral antigens [e.g., spike and its receptor binding domain (RBD)] is an important step in the manufacturing process. Simple and high-capacity protein purification schemes for spike, RBD, and CR3022 mAb, recombinantly expressed in CHO and HEK293 cells, are reported in this article. The schemes consist of an affinity chromatography step and a desalting step. Purified proteins were validated in ELISA-based serological tests. Interestingly, extracellular matrix proteins [most notably heparan sulfate proteoglycan (HSPG)] were co-purified from spike-expressing CHO culture with a long cultivation time. HSPG-spike interaction could play a functional role in the pathology and the pathogenesis of SARS-CoV-2 and other coronaviruses.","Tee, K. L.; Jackson, P. J.; Scarrott, J. M.; Jaffe, S. R.; Johnson, A. O.; Johari, Y.; Pohle, T. H.; Mozzanino, T.; Price, J.; Grinham, J.; Brown, A.; Nicklin, M. J.; James, D. C.; Dickman, M. J.; Wong, T. S.","https://www.biorxiv.org/content/10.1101/2020.07.31.231282v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.231282v1?rss=1,2020-08-02,2020-08-02,,False
81,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,"Objectives To develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19. Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited between 21 May and 29 June 2020. Setting 260 hospitals across England, Scotland, and Wales. Participants Adult patients ([&ge;]18 years) admitted to hospital with covid-19 admitted at least four weeks before final data extraction. Main outcome measures In-hospital mortality. Results There were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 95% CI 0.78 - 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients with a score [&ge;]15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared with 1.0% mortality for those with a score [&le;]3 (n = 918, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73). Conclusions We have developed and validated an easy-to-use risk stratification score based on commonly available parameters at hospital presentation. This outperformed existing scores, demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic. Study registration ISRCTN66726260","Knight, S. R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T. M.; Dunning, J.; Fairfield, C. J.; Gamble, C.; Green, C. A.; Gupta, R. K.; Halpin, S.; Hardwick, H.; Holden, K.; Horby, P. W.; Jackson, C.; McLean, K. A.; Merson, L.; Nguyen-Van-Tam, J. S.; Norman, L.; Noursadeghi, M.; Olliaro, P. L.; Pritchard, M. G.; Russell, C. D.; Shaw, C. A.; Sheikh, A.; Solomon, T.; Sudlow, C.; Swann, O. V.; Turtle, L.; Openshaw, P. J.; Baillie, J. K.; Semple, M. G.; Docherty, A. B.; Harrison, E. M.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165464v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165464v1?rss=1,2020-08-02,2020-08-02,,True
82,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,"This paper presents a data-driven approach for COVID-19 outbreak modeling and forecasting, which can be used by public policy and decision makers to control the outbreak through Non-Pharmaceutical Interventions (NPI). First, we apply an extended Kalman filter (EKF) to a discrete-time stochastic augmented compartmental model to estimate the time-varying effective reproduction number Rt. We use daily confirmed cases, active cases, recovered cases, deceased cases, Case-Fatality-Rate (CFR), and infectious time as inputs for the model. Furthermore, we define a Transmission Index (TI) as a ratio between the instantaneous and the maximum value of the effective reproduction number. The value of TI shows the disease transmission in a contact between a susceptible and an infectious individual due to current measures such as physical distancing and lock-down relative to a normal condition. Based on the value of TI, we forecast different scenarios to see the effect of relaxing and tightening public measures. Case studies in three countries are provided to show the practicability of our approach.","Hasan, A.; Putri, E.; Susanto, H.; Nuraini, N.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165555v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165555v1?rss=1,2020-08-02,2020-08-02,,True
83,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,"OBJECTIVE To determine whether internal components of powered air purifying respirators (PAPR) used during the Corona virus 2019 disease (COVID-19) pandemic are contaminated with bacteria, fungi and/or any viral material. DESIGN In situ microbiological study. SETTING Single NHS Trust, UK. OUTCOME MEASURES Growth of any bacteria or fungi, or positive polymerase chain reaction results for common respiratory viruses and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RESULTS 25 PAPR hoods were swabbed; ten (40%) returned positive results. Bacterial growth was detected on six hoods (bacillus simplex, kocuria rhizophilia, bacillus weihenstephensis, microcccus luteus and staphylococcus epidermidis); five of the hoods were positive for fungal growth (non-sporulating environmental mould, NSEM); all sampled hoods tested negative for both SARS-CoV-2 and an expanded panel of respiratory viruses. There was wide variation in the storage of cleaned hoods. CONCLUSION Despite following recommended cleaning procedures, bacteria and fungi can remain on the internal components of PAPR hoods, at levels significant enough to be swabbed and cultured. PAPR hoods have the potential to cross-infect wearers and patients and are used primarily by clinicians who fail to fit disposable FFP3 respirators; the female sex and non-Caucasian people are less likely to fit FFP3 respirators. The hoods tested cannot be adequately cleaned for use in high risk healthcare environments, PAPR hoods and tubes can act as fomites, and there are evident shortcomings in their provision.","Chakladar, A.; Jones, C. G.; Siu, J.; Hassan-Ibrahim, M. O.; Khan, M.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165423v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165423v1?rss=1,2020-08-02,2020-08-02,,True
84,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,"Serological SARS-CoV-2 assays are needed to support clinical diagnosis and epidemiological investigations. Recently, assays for the large-volume detection of total antibodies (Ab) and immunoglobulin (Ig) G and M against SARS-CoV-2 antigens have been developed, but there are limited data on the diagnostic accuracy of these assays. This study was organized as a Danish national collaboration and included fifteen commercial and one in-house anti-SARS-CoV-2 assays in sixteen laboratories. Sensitivity was evaluated using 150 serum samples from individuals diagnosed with asymptomatic, mild or moderate nonhospitalized (n=129) or hospitalized (n=31) COVID-19, confirmed by nucleic acid amplification tests, collected 13-73 days from symptom onset. Specificity and cross-reactivity were evaluated in samples collected prior to the SARS-CoV-2 epidemic from > 586 blood donors and patients with autoimmune diseases or CMV or EBV infections. Predefined specificity criteria of [&ge;]99% were met by all total-Ab and IgG assays except one (Diasorin/LiaisonXL-IgG 97.2%). The sensitivities in descending order were: Wantai/ELISA total-Ab (96.7%), CUH/NOVO in-house ELISA total-Ab (96.0%), Ortho/Vitros total-Ab (95.3%), YHLO/iFlash-IgG (94.0%), Ortho/Vitros-IgG (93.3%), Siemens/Atellica total-Ab (93.2%), Roche-Elecsys total-Ab (92.7%), Abbott-Architect-IgG (90.0%), Abbott/Alinity-IgG (median 88.0%), Diasorin/LiaisonXL-IgG (84.6%), Siemens/Vista total-Ab (81.0%), Euroimmun/ELISA-IgG (78.0%), and Snibe/Maglumi-IgG (median 78.0%). The IgM results were variable, but one assay (Wantai/ELISA-IgM) had both high sensitivity (82.7%) and specificity (99%). The rate of seropositivity increased with time from symptom onset and symptom severity. In conclusion, predefined sensitivity and specificity acceptance criteria of 90%/99%, respectively, for diagnostic use were met in five of six total-Ab and three of seven IgG assays.","Harritshoej, L. H.; Gybel-Brask, M.; Afzal, S.; Kamstrup, P. R.; Joergensen, C. S.; Thomsen, M. K.; Hilsted, L. M.; Friis-Hansen, L. J.; Szecsi, P. B.; Pedersen, L.; Nielsen, L.; Hansen, C. B.; Garred, P.; Korsholm, T.-L.; Mikkelsen, S.; Nielsen, K. O.; Moeller, B. K.; Hansen, A. T.; Iversen, K. K.; Nielsen, P. B.; Hasselbalch, R. B.; Fogh, K.; Norsk, J. B.; Kristensen, J. H.; Schoenning, K.; Kirkby, N. S.; Nielsen, A. C. Y.; Landsy, L. H.; Loftager, M.; Holm, D. K.; Nilsson, A. C.; Saekmose, S. G.; Grum-Svendsen, B.; Aagaard, B.; Jensen, T. G.; Nielsen, D. M.; Ullum, H.; Dessau, R. B.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165373v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165373v1?rss=1,2020-08-02,2020-08-02,,True
85,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,"The relationship of SARS-CoV-2 lung infection and severity of pulmonary disease is not fully understood. We analyzed autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter- and intra- patient heterogeneity of pulmonary virus infection. There was a spectrum of high and low virus cases that was associated with duration of disease and activation of interferon pathway genes. Using a digital spatial profiling platform, the virus corresponded to distinct spatial expression of interferon response genes and immune checkpoint genes demonstrating the intra-pulmonary heterogeneity of SARS-CoV-2 infection.","Desai, N.; Neyaz, A.; Szabolcs, A.; Shih, A. R.; Chen, J. H.; Thapar, V.; Nieman, L. T.; Solovyov, A.; Mehta, A.; Lieb, D. J.; Kulkarni, A. S.; Jaicks, C.; Pinto, C. J.; Juric, D.; Chebib, I.; Colvin, R. B.; Kim, A. Y.; Monroe, R.; Warren, S. E.; Danaher, P.; Reeves, J. W.; Gong, J.; Rueckert, E. H.; Greenbaum, B. D.; Hacohen, N.; Lagana, S. M.; Rivera, M. N.; Sholl, L. M.; Stone, J. R.; Ting, D. T.; Deshpande, V.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165241v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165241v1?rss=1,2020-08-02,2020-08-02,,True
86,Impact of tocilizumab administration on mortality in severe COVID-19,"Background The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to a cytokine storm, which contributes to the severity of illness. There is an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID-19. Methods A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020, and May 5, 2020, was performed. Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The primary outcome was in-hospital mortality. Results A total of 132 patients were included in the matched dataset (tocilizumab=66; standard of care=66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary disease (15%) were the most common comorbidities present. There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the standard of care group (odds ratio, 1.0; 95% confidence interval, 0.465 - 2.151; p=1.00). Advanced age, history of myocardial infarction, dementia, chronic pulmonary disease, heart failure, and malignancy were significantly more common in patients who died. Interpretation The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. Use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.","Tsai, A.; Diawara, O.; Nahass, R. G.; Brunetti, L.","https://www.medrxiv.org/content/10.1101/2020.07.30.20114959v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20114959v1?rss=1,2020-08-02,2020-08-02,,True
87,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries","This study empirically investigates the complex interplay between the severity of the coronavirus pandemic, mobility changes in retail and recreation, transit stations, workplaces, and residential areas, and lockdown measures in 88 countries of the word. To conduct the study, data on mobility patterns, socioeconomic and demographic characteristics of people, lockdown measures, and coronavirus pandemic were collected from multiple sources (e.g., Google, UNDP, UN, BBC, Oxford University, Worldometer). A Structural Equation Modeling (SEM) technique is used to investigate the direct and indirect effects of independent variables on dependent variables considering the intervening effects of mediators. Results show that lockdown measures have significant effects to encourage people to maintain social distancing. However, pandemic severity and socioeconomic and institutional factors have limited effects to sustain social distancing practice. The results also explain that socioeconomic and institutional factors of urbanity and modernity have significant effects on pandemic severity. Countries with a higher number of elderly people, employment in the service sector, and higher globalization trend are the worst victims of the coronavirus pandemic (e.g., USA, UK, Italy, and Spain). Social distancing measures are reasonably effective at tempering the severity of the pandemic.","Rahman, M. M.; Thill, J.-C.; Paul, K. C.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165290v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165290v1?rss=1,2020-08-02,2020-08-02,,True
88,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.","Background Loneliness and physical activity are important targets for research into the impact of COVID-19 because they have established links with mental health, could be exacerbated by social distancing policies and are potentially modifiable. Methods We analysed mental health data collected during COVID-19 from adults aged 50 and over alongside comparable annual data collected between 2015 and 2019 from the same sample. Trajectories of depression (PHQ-9) and anxiety (GAD-7) were analysed with respect to loneliness, physical activity levels and a number of socioeconomic and demographic characteristics using zero-inflated negative binomial regression. Findings 3,281 people completed the COVID-19 mental health questionnaire, all had at least one data point prior to 2020. In 2020, the adjusted PHQ-9 score for loneliness was 3.2. (95% CI: 3.0-3.4), an increase of one point on previous years and 2 points higher than people not rated lonely, whose score did not change in 2020 (1.2, 95% CI: 1.1-1.3). PHQ-9 was 2.6 (95% CI: 2.4-2.8) in people with decreased physical activity, an increase of 0.5 on previous years. In contrast, PHQ-9 in 2020 for people whose physical activity had not decreased was 1.7 (95% CI: 1.6-1.8), similar to previous years. A similar relationship was observed for GAD-7 though the differences were smaller and the absolute burden of symptoms lower. Interpretation After accounting for pre-COVID-19 trends, we show that experiencing loneliness and decreased physical activity are risk factors for worsening mental health during the pandemic. Our findings highlight the need to examine policies which target these potentially modifiable risk factors.","Creese, B.; Khan, Z.; Henley, W.; Corbett, A.; Vasconcelos Da Silva, M.; Mills, K.; Wright, N.; Testad, I.; Aarsland, D.; Ballard, C.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165415v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165415v1?rss=1,2020-08-02,2020-08-02,,True
89,Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care,"Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), became a pandemic in early 2020. Lateral flow immunoassays for antibody testing have been viewed as a cheap and rapidly deployable method for determining previous infection with SARS-CoV-2; however, these assays have shown unacceptably low sensitivity. We report on nine lateral flow immunoassays currently available and compare their titer sensitivity in serum to a best-practice enzyme-linked immunosorbent assay (ELISA) and viral neutralization assay. For a small group of PCR-positive, we found two lateral flow immunoassay devices with titer sensitivity roughly equal to the ELISA; these devices were positive for all PCR-positive patients harboring SARS-CoV-2 neutralizing antibodies. One of these devices was deployed in Northern Italy to test its sensitivity and specificity in a real-world clinical setting. Using the device with fingerstick blood on a cohort of 27 hospitalized PCR-positive patients and seven hospitalized controls, ROC curve analysis gave AUC values of 0.7646 for IgG. For comparison, this assay was also tested with saliva from the same patient population and showed reduced discrimination between cases and controls with AUC values of 0.6841 for IgG. Furthermore, during viral neutralization testing, one patient was discovered to harbor autoantibodies to ACE2, with implications for how immune responses are profiled. We show here through a proof-of-concept study that these lateral flow devices can be as analytically sensitive as ELISAs and adopted into hospital protocols; however, additional improvements to these devices remain necessary before their clinical deployment.","Haymond, A.; Mueller, C.; Steinberg, H.; Hodge, K. A.; Lehman, C. W.; Lin, S.-C.; Collini, L.; Branscome, H.; Nguyen, T. V.; Rucker, S.; Panny, L.; Flor, R.; Guirguis, R.; Hoefer, R.; Lorenzin, G.; Petricoin, E.; Kashanchi, F.; Kehn-Hall, K.; Lanzafame, P.; Liotta, L.; Luchini, A.","https://www.medrxiv.org/content/10.1101/2020.07.30.20163824v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20163824v1?rss=1,2020-08-02,2020-08-02,,True
90,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,"The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was studied. The IgG avidity assay used a novel label-free immunoassay technology to test IgG against the virus spike protein receptor-binding domain (RBD). The technology, thin-film interferometry (TFI), is able to sense the formation of immune complex on a sensing probe without attaching a reporter (enzyme, fluorophore, etc.). It was found that there was a strong correlation between IgG antibody avidity and days since symptom onset (p < 0.0001). In addition, peak readings were significantly higher for specimens from ICU than non-ICU patients for the first month after symptom onset (1-4 weeks) and thereafter (p<0.0001). The findings are consistent for what has been reported for SARS-CoV. Given that SARS-CoV-2 specific IgG avidity is strong in ICU patients after 1 month, this suggests that antibody-mediated immune enhancement triggered by suboptimal antibodies may not play a role in COVID-19 disease progression and severity.","Luo, Y. R.; Chakraborty, I.; Yun, C.; Wu, A. H. B.; Lynch, K. L.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165522v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165522v1?rss=1,2020-08-02,2020-08-02,,True
91,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,"We analysed mortality rates in a non-metropolitan UK subregion (Northamptonshire) to understand SARS-CoV-2 disease fatalities at sub 1000000 population levels. A numerical (SEIR) model was then developed to predict the spread of Covid-19 in Northamptonshire. A combined approach using statistically-weighted data to fit the start of the epidemic to the mortality record. Parameter estimates were then derived for the transmission rate and basic reproduction number. Age standardised mortality rates are highest in Northampton (urban) and lowest in semi-rural districts. Northamptonshire has a statistically higher Covid-19 mortality rate than for the East Midlands and England as a whole. Model outputs suggest the number of infected individuals exceed official estimates, meaning less than 40 percent of the population may require immunisation. Combining published (sub-regional) mortality rate data with deterministic models on disease spread has the potential to help public health practitioners develop bespoke mitigations, guided by local population demographics.","Petford, N.; Campbell, J.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165399v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165399v1?rss=1,2020-08-02,2020-08-02,,True
92,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.","Background/Objectives: This was an out-of-hospital screening of health status and lifestyle during the Covid-19 pandemic in post-operative bariatric patients from Sao Paulo, Brazil, prevented from face-to-face health care. Subjects/Methods: In this cross-sectional study, 66 patients were remotely (via phone call) and in-person (by home visit) assessed for health status and lifestyle habits. Results: Mean age was 47.4 years. Patients were obese grade I (30.0%), II (22.0%), and III (30.0%), and 94.2% had above reference waist circumference values. Sixty-four percent displayed high blood pressure, whereas 24% showed CRP levels above normal range. Nineteen percent of patients reported irregular use of nutritional supplementation and 6.0% reported binge eating habits. Thirty-three exhibited symptoms of depression. Mild-to-moderate and moderate-to-severe anxiety symptoms were reported by 27.4% and 11.3% of the patients; 4.5% exhibited suicidal ideation and were referred to a specialist for healthcare. Of relevance, inactive patients (59.6%) had poorer global mental and physical health scores as compared to active peers (both p<0.05). Conclusion: This out-of-hospital screening revealed that the absence of face-to-face health care due to the Covid-19 pandemic is associated with suboptimal status of physical and mental health as well as lifestyle inadequacies among patients who have recently undergone bariatric surgery.","Goessler, K. F.; Nicoletti, C. F.; Rezende, D. A. N.; Sieczkowska, S. M.; Esteves, G. P.; Genario, R.; Oliveira-Junior, G. N.; Meireles, K.; Pinto, A. J.; Nakahara-Melo, M.; Cleva, R.; Santo, M. A.; Kirwan, J.; Roschel, H.; Gualano, B.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165068v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165068v1?rss=1,2020-08-02,2020-08-02,,True
93,Projecting hospital resource utilization during a surge using parametric bootstrapping,"During the initial wave of the COVID-19 pandemic in the United States, hospitals took drastic action to ensure sufficient capacity, including canceling or postponing elective procedures, expanding the number of available intensive care beds and ventilators, and creating regional overflow hospital capacity. However, in most locations the actual number of patients did not reach the projected surge leaving available, unused hospital capacity. As a result, patients may have delayed needed care and hospitals lost substantial revenue. These initial recommendations were made based on observations and worst-case epidemiological projections, which generally assume a fixed proportion of COVID-19 patients will require hospitalization and advanced resources. This assumption has led to an overestimate of resource demand as clinical protocols improve and testing becomes more widely available throughout the course of the pandemic. Here, we present a parametric bootstrap model for forecasting the resource demands of incoming patients in the near term, and apply it to the current pandemic. We validate our approach using observed cases at UCLA Health and simulate the effect of elective procedure cancellation against worst-case pandemic scenarios. Using our approach, we show that it is unnecessary to cancel elective procedures unless the actual capacity of COVID-19 patients approaches the hospital maximum capacity. Instead, we propose a strategy of balancing the resource demands of elective procedures against projected patients by revisiting the projections regularly to maintain operating efficiency. This strategy has been in place at UCLA Health since mid-April.","Chiang, J. N.; An, U.; Kordi, M.; Jew, B.; Kravit, C.; Dunne, W. J.; Perez, R.; Parikh, N. R.; Weil, D.; Azar, R. F.; Cherry, R.; Grimley, K. A.; Skootsky, S. A.; Saigal, C. E.; Manuel, V.; Eskin, E.; Halperin, E.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164475v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164475v1?rss=1,2020-08-02,2020-08-02,,True
94,Real-Time Monitoring of COVID-19 in Scotland,"To manage the public health risk posed by COVID-19 and assess the impact of interventions, policy makers must be able to closely monitor the epidemic's trajectory. Here we present a simple methodology based on basic surveillance metrics for monitoring the spread of COVID-19 and its burden on health services in Scotland. We illustrate how this has been used throughout the epidemic in Scotland and explore the underlying biases that have affected its interpretation.","Calder-Gerver, G. D.; Mazeri, S.; Haynes, S.; Simonet, C. A.; Woolhouse, M. E.; Brown, H. K.","https://www.medrxiv.org/content/10.1101/2020.07.30.20158790v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20158790v1?rss=1,2020-08-02,2020-08-02,,True
95,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,"We propose a new compartmental epidemic model taking into account people who has symptoms with no confirmatory laboratory testing (probable cases). We prove well-posedness of the model and provide an explicit expression for the basic reproduction number R0. We use the model together with an extended Kalman filter (EKF) to estimate the time-varying effective reproduction number Rt of COVID-19 in West Java province, Indonesia, where laboratory testing capacity is limited. Based on our estimation, the value of Rt is higher when the probable cases are taken into account. This correction can be used by decision and policy makers when considering re-opening policy and evaluation of measures.","Hasan, A.; Nasution, Y.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165282v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165282v1?rss=1,2020-08-02,2020-08-02,,True
96,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spread by direct, indirect, or close contact with infected people via infected respiratory droplets or saliva. Crowded indoor environments with sustained close contact and conversations are a particularly high-risk setting. Methods: We performed a meta-analysis through July 29, 2020 of SARS-CoV-2 household secondary attack rate (SAR), disaggregating by several covariates (contact type, symptom status, adult/child contacts, contact sex, relationship to index case, index case sex, number of contacts in household, coronavirus). Findings: We identified 40 relevant published studies that report household secondary transmission. The estimated overall household SAR was 18.8% (95% confidence interval [CI]: 15.4%-22.2%), which is higher than previously observed SARs for SARS-CoV and MERS-CoV. We observed that household SARs were significantly higher from symptomatic index cases than asymptomatic index cases, to adult contacts than children contacts, to spouses than other family contacts, and in households with one contact than households with three or more contacts. Interpretation: To prevent the spread of SARS-CoV-2, people are being asked to stay at home worldwide. With suspected or confirmed infections referred to isolate at home, household transmission will continue to be a significant source of transmission.","Madewell, Z. J.; Yang, Y.; Longini, I. M.; Halloran, M. E.; Dean, N. E.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164590v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164590v1?rss=1,2020-08-01,2020-08-01,,True
97,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,"Various medical treatments for COVID-19 are attempted. After patients are discharged, SARS-CoV-2 recurring cases are reported and the recurrence could profoundly impact patient healthcare and social economics. To date, no data on the effects of medical treatments on recurrence has been published. We analyzed the treatment data of combinations of ten different drugs for the recurring cases in a single medical center, Shenzhen, China. A total of 417 patients were considered and 414 of them were included in this study (3 deaths) with mild-to-critical COVID-19. Patients were treated by 10 different drug combinations and followed up for recurrence for 28 days quarantine after being discharged from the medical center between February and May, 2020. We applied the Synthetic Minority Oversampling Technique (SMOTE) to overcome the rare recurring events in certain age groups and performed Virtual Twins (VT) analysis facilitated by random forest regression for medical treatment-recurrence classification. Among those drug combinations, Methylprednisolone/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate (0.133) as compared to the average recurring rate (0.203). For the younger group (age 20-27) or the older group (age 60-70), the optimal drug combinations are different, but the above combination is still the second best. For obese patients, the combination of Ribavirin/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate for age group of 20-50, whereas the combination of Interferon/Lopinavir/Ritonavir/Arbidol led to lowest recurring rate for age group of 50-70. The insights into combinatorial therapy we provided here shed lights on the use of a combination of (biological and chemical) anti-virus therapy and/or anti-cytokine storm as a potentially effective therapeutic treatment for COVID-19.","Huang, J.; Zhai, S.; Ye, F.; Wang, S.; Zeng, M.; Way, G.; Madarha, V.; Zhu, T.; Qiu, L.; Xu, Z.; Ye, M.; Liu, L.; Cui, X.; Liao, J.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164699v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164699v1?rss=1,2020-08-01,2020-08-01,,True
98,Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients,"Recent studies have provided insights into the autoinflammation triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection, which is associated with high mortality of coronavirus disease 2019 (COVID-19). Striking similarities has been noted between COVID-19 and anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-related dermatomyositis (DM), implying a shared autoinflammatory aberrance. However, it is unclear whether anti-MDA5 Ab is present in COVID-19 and correlates with the severity and adverse outcome of COVID-19 patients. Here, we found that the positive rate of anti-MDA5 Ab in patients with COVID-19 was 48.2% and the anti-MDA5 Ab positive patients tended to develop severe disease (88.6% vs 66.9%, P<0.0001). In particular, the titer of anti-MDA5 Ab was increased in the non-survivals (5.95{+/-}5.16 vs 8.22{+/-}6.64, P=0.030) and the positive rate was also higher than that in the survivals (23.5% vs 12.0%, P=0.012). Regarding to severe COVID-19 patients, we found that high titer of anti-MDA5 Ab ([&ge;]10.0 U/mL) was more prevalent in the non-survivals (31.2% vs 14.0%, P=0.006). Moreover, early profiling of anti-MDA5 Ab could distinguish severe patients from those with non-severe ones. Overall, our data reveal that anti-MDA5 Ab is prevalent in the COVID-19 patients and high titer of this antibody is correlated with severe disease and unfavorable outcomes.","Liu, C.; Wang, Q.; Wang, Y.; Wang, G.; Wang, L.; Chen, H.; Jiao, T.; Hu, C.; Lei, X.; Guo, L.; Ren, L.; Li, M.; Zeng, X.; Zhang, D.; Cao, B.; Wang, J.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164780v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164780v1?rss=1,2020-08-01,2020-08-01,,True
99,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,"Background. Coronavirus disease-19 (COVID-19) is a respiratory illness caused by the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a novel beta-coronavirus. Although antibody response to SARS-CoV-2 can be detected early during the infection, several outstanding questions remain to be addressed regarding magnitude and persistence of antibody titer against different viral proteins and their correlation with the strength of the immune response, as measured by serum levels of pro-inflammatory mediators. Methods. An ELISA assay has been developed by expressing and purifying the recombinant SARS-CoV-2 Spike Receptor Binding Domain (RBD), Soluble Ectodomain (Spike), and full length nucleocapsid protein (N protein). Sera from healthcare workers affected by non-severe COVID-19 were longitudinally collected over four weeks, and compared to sera from patients hospitalized in Intensive Care Units (ICU) and SARS-CoV-2-negative subjects for the presence of IgM, IgG and IgA antibodies as well as soluble pro-inflammatory mediators in the sera. Results. Specificity and sensitivity of the ELISA assays were high for anti-RBD IgG and IgA (92-97%) and slightly lower for IgM and the Spike and N proteins (70-85%). The ELISA allowed quantification of IgM, IgG and IgA antibody responses against all the viral antigens tested and showed a correlation between magnitude of the antibody response and disease severity. Non-hospitalized subjects showed lower antibody titers and blood pro-inflammatory cytokine profiles as compared to patients in Intensive Care Units (ICU), irrespective of the antibodies tested. Noteworthy, in non-severe COVID-19 infections, antibody titers against RBD and Spike, but not against the N protein, as well as pro-inflammatory cytokines decreased within a month after viral clearance. Conclusions. Rapid decline in antibody titers and in pro-inflammatory cytokines may be a common feature of non-severe SARS-CoV-2 infection, suggesting that antibody-mediated protection against re-infection with SARS-CoV-2 is of short duration. These results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general population.","Bruni, M.; Cecatiello, V.; Diaz-Basabe, A.; Lattanzi, G.; Mileti, E.; Monzani, S.; Pirovano, L.; Rizzelli, F.; Visintin, C.; Bonizzi, G.; Giani, M.; Lavitrano, M.; Faravelli, S.; Forneris, F.; Caprioli, F.; Pelicci, P. G.; Natoli, G.; Pasqualato, S.; Mapelli, M.; Facciotti, F.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164368v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164368v1?rss=1,2020-08-01,2020-08-01,,True
100,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,"As the COVID-19 virus continues to infect people across the globe, there is little understanding of the long term implications for recovered patients. There have been reports of persistent symptoms after confirmed infections on patients even after three months of initial recovery. While some of these patients have documented follow-ups on clinical records, or participate in longitudinal surveys, these datasets are usually not publicly available or standardized to perform longitudinal analyses on them. Therefore, there is a need to use additional data sources for continued follow-up and identification of latent symptoms that might be underreported in other places. In this work we present a preliminary characterization of post-COVID-19 symptoms using social media data from Twitter. We use a combination of natural language processing and clinician reviews to identify long term self-reported symptoms on a set of Twitter users.","Banda, J. M.; Singh, G. V.; Alser, O.; PRIETO-ALHAMBRA, D.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164418v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164418v1?rss=1,2020-08-01,2020-08-01,,True
101,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy","For an emerging disease like COVID-19, systems immunology tools may quickly identify and quantitatively characterize cells associated with disease progression or clinical response. With repeated sampling, immune monitoring creates a real-time portrait of the cells reacting to a novel virus before disease specific knowledge and tools are established. However, single cell analysis tools can struggle to reveal rare cells that are under 0.1% of the population. Here, the machine learning workflow Tracking Responders Expanding (T-REX) was created to identify changes in both very rare and common cells in diverse human immune monitoring settings. T-REX identified cells that were highly similar in phenotype and localized to hotspots of significant change during rhinovirus and SARS-CoV-2 infections. MHC tetramers were not used during unsupervised analysis and instead  left out to serve as a test of whether T-REX identifies biologically significant cells. In the rhinovirus challenge study, T-REX identified virus-specific CD4+ T cells based on these cells being a distinct phenotype that expanded by [&ge;]95% following infection. T-REX successfully identified hotspots with virus-specific T cells using pairs of samples comparing Day 7 of infection to samples taken either after clearing the infection (Day 28) or samples taken prior to infection (Day 0). Mapping pairwise comparisons in samples according to both the direction and degree of change provided a framework to compare systems level immune changes during infectious disease or therapy response. This revealed that the magnitude and direction of systemic immune change in some COVID-19 patients was comparable to that of blast crisis acute myeloid leukemia patients undergoing induction chemotherapy and characterized the identity of the immune cells that changed the most. Other COVID-19 patients instead matched an immune trajectory like that of individuals with rhinovirus infection or melanoma patients receiving checkpoint inhibitor therapy. T-REX analysis of paired blood samples provides an approach to rapidly identify and characterize mechanistically significant cells and to place emerging diseases into a systems immunology context.","Barone, S. M.; Paul, A. G. A.; Muehling, L. M.; Lannigan, J. A.; Kwok, W. W.; Turner, R. B.; Woodfolk, J. A.; Irish, J. M.","https://www.biorxiv.org/content/10.1101/2020.07.31.190454v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.190454v1?rss=1,2020-08-01,2020-08-01,,False
102,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,"Background: SARS-CoV-2 RNA detection with real time PCR is currently the central diagnostic tool to determine ongoing active infection. Nasopharyngeal and oral swabs are the main collection tool of biological material used as the source of viral RNA outside a hospital setting. However, limitation in swabs availability, trained health professional with proper PPE and potential risk of aerosols may hinder COVID diagnosis. Self-collection with swabs, saliva and throat wash to obtain oropharyngeal wash has been suggested as having comparable performance of regular swab. We performed throat wash (TW) based surveillance with laboratory heath workers and other employees (LHW) at a laboratory research institute. Methods: Consecutive volunteer testing of LWH and external household and close contacts were included. TW self-collection was performed in 5 mL of sterile saline that was returned to original vial after approximate 5 secs of gargle. RNA extraction and rtPCR were performed as part of routine COVID protocols using Allplex (Seegene, Korea). Results: Four hundred and twenty two volunteers, 387 (93%) LHW and 43 (7%) contacts participated in the survey. One or more positive COVID rtPCR was documented in 63 (14.9% CI95 12%-19%) individuals. No correlation was observed between with direct activities with COVID samples to positivity, with infection observed in comparable rates among different laboratory areas, administrative or supportive activities. Among 63 with detected SARS-CoV-2 RNA, 59 with clinical information, 58% reported symptoms at a median of 4 days prior to collection, most with mild disease. Over a third (38%) of asymptomatic cases developed symptoms 1-3 days after collection. Although overall CT values of TW were higher than that of contemporary swab tests from hospitalized cases, TW from symptomatic cases had comparable CTs. Conclusions: The study suggests that TW may be a valid alternative to the detection of SARS-CoV-2 RNA. The proportion of asymptomatic and pre-symptomatic cases is elevated and reinforces the need of universal precautions and frequent surveys to limit the spread of the disease.","Lopez-Lopes, G. I. S.; Ahagon, C. M.; Bonega, M. A.; Santos, F. P. d.; Santos, K. C. d. O.; Cilli, A.; Prado, L. S. d.; Silva, D. B. B. d.; Luz, N. B. d.; Saraceni, C. P.; Afonso, A. M. S.; Timenetsky, M. d. C.; Brigido, L. F. d. M.","https://www.medrxiv.org/content/10.1101/2020.07.29.20163998v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20163998v1?rss=1,2020-08-01,2020-08-01,,True
103,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,"BackgroundIn response to the current COVID-19 pandemic, it is crucial to understand the origin, transmission, and evolution of SARS-CoV-2, which relies on close surveillance of genomic diversity in clinical samples. Although the mutation at the population level had been extensively investigated, how the mutations evolve at the individual level is largely unknown, partly due to the difficulty of obtaining unbiased genome coverage of SARS-CoV-2 directly from clinical samples.

MethodsEighteen time series fecal samples were collected from nine COVID-19 patients during the convalescent phase. The nucleic acids of SARS-CoV-2 were enriched by the hybrid capture method with different rounds of hybridization.

ResultsBy examining the sequencing depth, genome coverage, and allele frequency change, we demonstrated the impeccable performance of the hybrid capture method in samples with Ct value < 34, as well as significant improvement comparing to direct metatranscriptomic sequencing in samples with lower viral loads. We identified 229 intra-host variants at 182 sites in 18 fecal samples. Among them, nineteen variants presented frequency changes > 0.3 within 1-5 days, reflecting highly dynamic intra-host viral populations. Meanwhile, we also found that the same mutation showed different frequency changes in different individuals, indicating a strong random drift. Moreover, the evolving of the viral genome demonstrated that the virus was still viable in the gastrointestinal tract during the convalescent period.

ConclusionsThe hybrid capture method enables reliable analyses of inter- and intra-host variants of SARS-CoV-2 genome, which changed dramatically in the gastrointestinal tract; its clinical relevance warrants further investigation.","Li, M.; Xu, Y.; Kang, L.; Shen, Z.; Li, X.; Wu, W.; Ma, W.; Fang, C.; Yang, F.; Jiang, X.; Gong, S.; Zhang, L.","https://www.biorxiv.org/content/10.1101/2020.07.30.230102v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.230102v1?rss=1,2020-08-01,2020-08-01,,False
104,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,"An essential mechanism for SARS-CoV-1 and -2 infection begins with the viral spike protein binding to the human receptor protein angiotensin-converting enzyme II (ACE2). Here we describe a stepwise engineering approach to generate a set of affinity optimized, enzymatically inactivated ACE2 variants that potently block SARS-CoV-2 infection of cells. These optimized receptor traps tightly bind the receptor binding domain (RBD) of the viral spike protein and prevent entry into host cells. We first computationally designed the ACE2-RBD interface using a two-stage flexible protein backbone design process that improved affinity for the RBD by up to 12-fold. These designed receptor variants were affinity matured an additional 14-fold by random mutagenesis and selection using yeast surface display. The highest affinity variant contained seven amino acid changes and bound to the RBD 170-fold more tightly than wild-type ACE2. With the addition of the natural ACE2 collectrin domain and fusion to a human Fc domain for increased stabilization and avidity, the most optimal ACE2 receptor traps neutralized SARS-CoV-2 pseudotyped lentivirus and authentic SARS-CoV-2 virus with half-maximal inhibitory concentrations (IC50) in the 10-100 ng/ml range. Engineered ACE2 receptor traps offer a promising route to fighting infections by SARS-CoV-2 and other ACE2-utilizing coronaviruses, with the key advantage that viral resistance would also likely impair viral entry. Moreover, such traps can be pre-designed for viruses with known entry receptors for faster therapeutic response without the need for neutralizing antibodies isolated or generated from convalescent patients.","Glasgow, A.; Glasgow, J. E.; Limonta, D.; Solomon, P.; Lui, I.; Zhang, Y.; Nix, M. A.; Rettko, N. J.; Lim, S. A.; Zha, S.; Yamin, R.; Kao, K.; Rosenberg, O. S.; Ravetch, J. V.; Wiita, A. P.; Leung, K. K.; Zhou, X. X.; Hobman, T. C.; Kortemme, T. K.; Wells, J. A.","https://www.biorxiv.org/content/10.1101/2020.07.31.231746v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.231746v1?rss=1,2020-08-01,2020-08-01,,False
105,Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management,"Background: In the absence of evidence-based therapies for Multisystem Inflammatory Syndrome in Children (MIS-C), we aimed to describe the similarities and differences in the evaluation and treatment of MIS-C at hospitals in the United States. Methods: We conducted a cross-sectional survey from June 16 to July 16, 2020 of U.S. pediatric hospitals regarding protocols for patients with MIS-C. Elements included hospital characteristics, clinical definition of MIS-C, evaluation, treatment, and follow-up. We summarized key findings and compared results from centers that had treated >5 patients vs. those that had treated <5 patients. Results: Forty centers of varying size and experience with MIS-C participated. About half (21/40) of centers required only 1 day of fever for MIS-C to be considered. In the evaluation of patients, there was often a tiered approach. Intravenous immunoglobulin was the most widely used medication to treat MIS-C (98% of centers). Corticosteroids were listed in 93% of protocols for primarily the moderate or severe cases. Aspirin was commonly used including for mild cases, whereas heparin or low molecular weight heparin were used primarily in severe cases. In severe cases, anakinra and vasopressors were frequently recommended. Nearly all centers (39/40) recommended follow up with cardiology. There were similar findings between centers that had treated >5 patients vs. those that had treated <5 patients. A supplement containing hospital protocols is provided. Conclusion: There are many similarities yet some key differences between hospital protocols for MIS-C. These findings can help healthcare providers learn from others regarding options for managing MIS-C patients.","Dove, M.; Jaggi, P.; Kelleman, M.; Abuali, M.; Ang, J.; Ballan, W.; Basu, S.; Campbell, J.; Chikkabyrappa, S.; Choueiter, N.; Clouser, K.; Corwin, D.; Edwards, A.; Gertz, S.; Ghassemzadeh, R.; Jarrah, R.; Katz, S.; Knutson, S.; Kuebler, J.; Lighter, J.; Mikesell, C.; Mongkolrattanothai, K.; Morton, T.; Nakra, N.; Olivero, R.; Osborne, C.; Parsons, S.; Panesar, L.; Patel, R.; Schuette, J.; Thacker, D.; Tremoulet, A.; Vidwan, N.; Oster, M.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164459v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164459v1?rss=1,2020-08-01,2020-08-01,,True
106,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,"Social distancing is a central public health measure in the fight against the COVID-19 pandemic, but individuals' compliance cannot be taken for granted. We use a survey experiment to examine the prevalence of non-compliance with social distancing in nine countries and test pre-registered hypotheses about individual-level characteristics associated with less social distancing. Leveraging a list experiment to control for social desirability bias, we find large cross-national variation in adherence to social distancing guidelines. Compliance varies systematically with COVID-19 fatalities and the strictness of lockdown measures. We also find substantial heterogeneity in the role of individual-level predictors. While there is an ideological gap in social distancing in the US and New Zealand, this is not the case in European countries. Taken together, our results suggest caution when trying to model pandemic health policies on other countries' experiences. Behavioral interventions targeted towards specific demographics that work in one context might fail in another.","Becher, M.; Stegmueller, D.; Brouard, S.; Kerrouche, E.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164806v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164806v1?rss=1,2020-08-01,2020-08-01,,True
107,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,"Abstract Objectives: IFN-alpha2b and IFN-gamma combination has demonstrated favorable pharmacodynamics for genes underlying antiviral activity which might be involved in the defense of the organism from a SARS-CoV-2 infection. Considering this we conducted a randomized controlled clinical trial for efficacy and safety evaluation of subcutaneous IFN-alpha2b and IFN-gamma administration in patients positive to SARS-CoV-2. Methods: We enrolled 19-82 years-old inpatients at the Military Central Hospital Luis Diaz Soto, Havana, Cuba. They were hospitalized after confirmed diagnosis for SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction. Patients were randomly assigned in a 1:1 ratio to receive either, subcutaneous treatment with a co-lyophilized combination of 3.0 MIU IFN-alpha2b and 0.5 MIU IFN-gamma (HeberFERON, CIGB, Havana, Cuba), twice a week for two weeks, or thrice a week intramuscular injection of 3.0 MIU IFN-alpha2b (Heberon Alpha R, CIGB, Havana, Cuba). Additionally, all patients received lopinavir-ritonavir 200/50 mg every 12 h and chloroquine 250 mg every 12 h (standard of care). The primary endpoints were the time to negativization of viral RNA and the time to progression to severe COVID-19, from the start of treatment. The protocol was approved by the Ethics Committee on Clinical Investigation from the Hospital and the Center for the State Control of Medicines, Equipment and Medical Devices in Cuba. Informed consent was obtained from each participant. Results: A total of 79 patients with laboratory-confirmed SARS-CoV-2 infection, including symptomatic or asymptomatic conditions, fulfilled the inclusion criteria and underwent randomization. Thirty-three subjects were assigned to the HeberFERON group, and 33 to the Heberon Alpha R group. Sixty-three patients were analyzed for viral negativization, of them 78.6% in the HeberFERON group negativized the virus after 4 days of treatment versus 40.6% of patients in the Heberon Alpha R groups (p=0.004). Time to reach the negativization of the SARS-CoV-2 measured by RT-PCR in real time was of 3.0 and 5.0 days for the HeberFERON and Heberon Alpha R groups, respectively. A significant improvement in the reduction of time for negativization was attributable to HeberFERON (p=0.0027, Log-rank test) with a Hazard Ratio of 3.2 and 95% CI of 1.529 to 6.948, as compared to Heberon Alpha R treated group. Worsening of respiratory symptoms was detected in two (6.6%) and one (3.3%) patients in HeberFERON and IFN-alpha2b groups, respectively. None of the subjects transit to severe COVID-19 during the study or the epidemiological follow-up for 21 more days. RT-PCR on day 14 after the start of the treatment was negative to SARS-CoV-2 in 100% and 91% of patients of the combination of IFNs and IFN-alpha2b, respectively. Negativization for HeberFERON treated patients was related to a significant increase in lymphocytes counts and an also significant reduction in CRP as early as 7 days after commencing the therapeutic schedule. All the patients in both cohorts recover by day 14 and were in asymptomatic condition and laboratory parameters return to normal values by day 14 after treatment initiation. Adverse events were identified in 31.5% of patients, 28.5% in the control group, and 34.4% in the HeberFERON group, and the most frequent were headaches (17.4%). Conclusions: In a cohort of 63 hospitalized patients between 19 to 82 years-old with positive SARS-CoV-2, HeberFERON significantly negativized the virus on day 4 of treatment when comparing with IFN-alpha2b. Heberon Alpha R also showed efficacy for the treatment of the viral infection. Both treatments were safe and positively impact on the resolution of the symptoms. None of the patients developed severe COVID-19. Key words: COVID-19, treatment, drug, virus negativization, antiviral, interferon combination, SARS CoV-2.","Idelsis, E.-M.; Jesus, P.-E.; Yaquelin, D.-R.; Dania, V.-B.; Monica, B.-R.; Lisandra, B.-R.; Jesus, C.-R.; Lisbeth, C. C.; Ernesto, P.-C.; Saily, T.-P.; Claudia, M.-S.; Ivan, C.-L.; Julio Raul, F.-M.; Hamlet, C.-R.; Marisol, D.-G.; Adriana, S.-M.; Maura, G.-S.; Sara Maria, M.-M.; Marel, A.-V.; Francisco, H.-B.; Hugo, N.-C.; Dianela, B.-G.; Abrahan, B.-C.; Mary Tania, V.-C.; Gerardo, G.-N.; Verena, M.-G.; Iraldo, B.-R.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164251v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164251v1?rss=1,2020-08-01,2020-08-01,,True
108,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,"Background: Clinical diagnosis of COVID-19 poses an enormous challenge to early detection and prevention of COVID-19, which is of crucial importance for pandemic containment. Cases of COVID-19 may be hard to distinguish clinically from other acute viral diseases, resulting in an overwhelming load of laboratory screening. Sudden onset of taste and smell loss emerge as hallmark of COVID-19. The optimal ways for including these symptoms in the screening of suspected COVID-19 patients should now be established. Methods: We performed a case-control study on patients that were PCR-tested for COVID-19 (112 positive and 112 negative participants), recruited during the first wave (March 2020 - May 2020) of COVID-19 pandemic in Israel. Patients were interviewed by phone regarding their symptoms and medical history and were asked to rate their olfactory and gustatory ability before and during their illness on a 1-10 scale. Prevalence and degrees of symptoms were calculated, and odds ratios were estimated. Symptoms-based logistic-regression classifiers were constructed and evaluated on a hold-out set. Results: Changes in smell and taste occurred in 68% (95% CI 60%-76%) and 72% (64%-80%), of positive patients, with 24 (11-53 range) and 12 (6-23) respective odds ratios. The ability to smell was decreased by 0.5 {+/-} 1.5 in negatives, and by 4.5 {+/-} 3.6 in positives, and to taste by 0.4 {+/-} 1.5 and 4.9 {+/-} 3.8, respectively (mean {+/-} SD). A penalized logistic regression classifier based on 5 symptoms (degree of smell change, muscle ache, lack of appetite, fever, and a negatively contributing sore throat), has 66% sensitivity, 97% specificity and an area under the ROC curve of 0.83 (AUC) on a hold-out set. A classifier based on degree of smell change only is almost as good, with 66% sensitivity, 97% specificity and 0.81 AUC. Under the assumption of 8% positives among those tested, the predictive positive value (PPV) of this classifier is 0.68 and negative predictive value (NPV) is 0.97. Conclusions: Self-reported quantitative olfactory changes, either alone or combined with other symptoms, provide a specific and powerful tool for clinical diagnosis of COVID-19. The applicability of this tool for prioritizing COVID-19 laboratory testing is facilitated by a simple calculator presented here.","Karni, N.; Klein, H.; Asseo, K.; Benjamini, Y.; Israel, S.; Nimri, M.; Olstein, K.; Nir-Paz, R.; Hershko, A.; Muszkat, M.; Niv, M. Y.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164327v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164327v1?rss=1,2020-08-01,2020-08-01,,True
109,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,"SARS-CoV-2 causes a wide spectrum of clinical manifestations and significant mortality. Studies investigating underlying immune characteristics are needed to understand disease pathogenesis and inform vaccine design. In this study, we examined immune cell subsets in hospitalized and non-hospitalized individuals. In hospitalized patients, many adaptive and innate immune cells were decreased in frequency compared to healthy and convalescent individuals, with the exception of B lymphocytes which increased. Our findings show increased frequencies of T-cell activation markers (CD69, Ox40, HLA-DR and CD154) in hospitalized patients, with other T-cell activation/exhaustion markers (CD25, PD-L1 and TIGIT) remaining elevated in hospitalized and non-hospitalized individuals. B cells had a similar pattern of activation/exhaustion, with increased frequency of CD69 and CD95 during hospitalization, followed by an increase in PD1 frequencies in non-hospitalized individuals. Interestingly, many of these changes were found to increase over time in non-hospitalized longitudinal samples, suggesting a prolonged period of immune dysregulation following SARS-CoV-2 infection. Changes in T-cell activation/exhaustion in non-hospitalized patients were found to positively correlate with age. Severely infected individuals had increased expression of activation and exhaustion markers. These data suggest a prolonged period of immune dysregulation following SARS-CoV-2 infection highlighting the need for additional studies investigating immune dysregulation in convalescent individuals.","Files, J. K.; Boppana, S.; Perez, M. D.; Sarkar, S.; Lowman, K. E.; Qin, K.; Sterrett, S.; Carlin, E.; Bansal, A.; Sabbaj, S.; Long, D. M.; Kutsch, O.; Kobie, J.; Goepfert, P. A.; Erdmann, N.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165175v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165175v1?rss=1,2020-08-01,2020-08-01,,True
110,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,"The impact of drug-drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications. This was a cross-sectional study including all individuals diagnosed of SARS-CoV-2 infection treated with LPV-r and attended at a single center in Southern Spain (March 1st to April 30th, 2020). The frequency [95% confidence interval (95% CI)] of potential and major DDI were calculated. Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI: 69%-85%) patients, and in 33 (26%, 95% CI: 19%-35%) individuals showed major DDI. Twelve (36%) patients with major DDI and 14 (15%) individuals without major DDI died (p=0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index [&ge;]5: 85 (10-731), p <0.001]. LPV-r was discontinued due to side effects in 31 (25%) patients. Management by the Infectious Diseases Unit was associated with a lower likelihood of major DDI [adjusted odds ratio (95% CI): 0.14 (0.04-0.53), p=0.003). In conclusion, a high frequency of DDI between LPV-r for treating COVID-19 and concomitant medications was found, including major DDI. Patients with major DDI showed worse outcomes, but this association was explained by the older age and comorbidities. Patients managed by the Infectious Diseases Unit had lower risk of major DDI.","Macias, J.; Pinilla, A.; Lao-Dominguez, F. A.; Corma, A.; Contreras-Macias, E.; Gonzalez-Serna, A.; Gutierrez-Pizarraya, A.; Fernandez-Fuertes, M.; Morillo-Verdugo, R.; Trigo, M.; Real, L. M.; Pineda, J. A.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165027v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165027v1?rss=1,2020-08-01,2020-08-01,,True
111,"Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis","Background Comprehensive evidence synthesis on the associations between comorbidities and behavioural factors with hospitalisation, Intensive Care Unit (ICU) admission, and death due to COVID-19 is lacking leading to inconsistent national and international recommendations on who should be targeted for non-pharmaceutical interventions and vaccination strategies. Methods We performed a systematic review and meta-analysis on studies and publicly available data to quantify the association between predisposing health conditions, demographics, and behavioural factors with hospitalisation, ICU admission, and death from COVID-19. We provided ranges of reported and calculated effect estimates and pooled relative risks derived from a meta-analysis and meta-regression. Results 75 studies were included into qualitative and 74 into quantitative synthesis, with study populations ranging from 19 - 44,672 COVID-19 cases. The risk of dying from COVID-19 was significantly associated with cerebrovascular [pooled RR 2.7 (95% CI 1.7-4.1)] and cardiovascular [RR 3.2 (CI 2.3-4.5)] diseases, hypertension [RR 2.6 (CI 2.0-3.4)], and renal disease [RR 2.5 (CI 1.8-3.4)]. Health care workers had lower risk for death and severe outcomes of disease (RR 0.1 (CI 0.1-0.3). Our meta-regression showed a decrease of the effect of some comorbidities on severity of disease with higher median age of study populations. Associations between comorbidities and hospitalisation and ICU admission were less strong than for death. Conclusions We obtained robust estimates on the magnitude of risk for COVID-19 hospitalisation, ICU admission, and death associated with comorbidities, demographic, and behavioural risk factors. We identified and confirmed population groups that are vulnerable and that require targeted prevention approaches.","Fernandez Villalobos, N. V.; Ott, J. J.; Klett-Tammen, C. J.; Bockey, A.; Vanella, P.; Krause, G.; Lange, B.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165050v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165050v1?rss=1,2020-08-01,2020-08-01,,True
112,Visualizing and Assessing US County-Level COVID19 Vulnerability,"Objective: Like most of the world, the United States public health and economy are impacted by the COVID19 pandemic. However, discrete pandemic effects may not be fully realized on the macro-scale. With this perspective, our goal is to visualize spread of the pandemic and measure county-level features which may portend vulnerability. Materials and Methods: We accessed the New York Times GitHub repository COVID19 data and 2018 US Census data for all US Counties. The disparate datasets were merged and filtered to allow for visualization and assessments about case fatality rate (CFR%) and associated demographic, ethnic and economic features. Results: Our results suggest that county-level COVID19 fatality rates are related to advanced population age (p <0.001) and less diversity as evidenced by higher proportion of Caucasians in High CFR% counties (p < 0.001). Also, lower CFR% counties had a greater proportion of the population reporting has having 2 or more races (p <0.001). We noted no significant differences between High and Low CFR% counties with respect to mean income or poverty rate. Conclusions: Unique COVID19 impacts are realized at the county level. Use of public datasets, data science skills and information visualization can yield helpful insights to drive understanding about community-level vulnerability.","Cahill, G.; Kutac, C.; Rider, N. L.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164608v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164608v1?rss=1,2020-08-01,2020-08-01,,True
113,Mathematical modeling of the transmission of SARS-CoV-2 '' Evaluating the impact of isolation in Sao Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,"Coronavirus disease 2019 (covid-19), with the fatality rate in elder (60 years old or more) being much higher than young (60 years old or less) patients, was declared a pandemic by the World Health Organization on March 11, 2020. Taking into account this age-dependent fatality rate, a mathematical model considering young and elder subpopulations was formulated based on the natural history of covid-19 to study the transmission of the SARS-CoV-2. This model can be applied to study the epidemiological scenario resulting from the adoption of isolation or lockdown in many countries to control the rapid propagation of covid-19. We chose as examples the isolation adopted in Sao Paulo State (Brazil) in the early phase but not at the beginning of the epidemic, and the lockdown implemented in Spain when the number of severe covid-19 cases was increasing rapidly. Based on the data collected from Sa o Paulo State and Spain, the model parameters were evaluated and we obtained higher estimation for the basic reproduction number R0 (9.24 for Sao Paulo State, and 8 for Spain) compared to the currently accepted estimation of R0 around 3. The model allowed to explain the flattening of the epidemic curves by isolation in Sao Paulo State and lockdown in Spain when associated with the protective measures (face mask and social distancing) adopted by the population. However, a simplified mathematical model providing lower estimation for R0 did not explain the flattening of the epidemic curves. The implementation of the isolation in Sa o Paulo State before the rapidly increasing phase of the epidemic enlarged the period of the first wave of the epidemic and delayed its peak, which are the desirable results of isolation to avoid the overloading in the health care system.","Yang, H. M.; Lombardi, L. P.; Morato Castro, F. F.; Yang, A. C.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165191v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165191v1?rss=1,2020-08-01,2020-08-01,,True
114,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,"Initial efforts to mitigate transmission of SARS-CoV-2 relied on intensive social distancing measures such as school and workplace closures, shelter-in-place orders, and prohibitions on the gathering of people. Other non-pharmaceutical interventions for suppressing transmission include active case finding, contact tracing, quarantine, immunity or health certification, and a wide range of personal protective measures. Here we investigate the potential effectiveness of these alternative approaches to suppression. We introduce a conceptual framework represented by two mathematical models that differ in strategy. We find both strategies may be effective, although both require extensive testing and work within a relatively narrow range of conditions. Generalized protective measures such as wearing face masks, improved hygiene, and local reductions in density are found to significantly increase the effectiveness of targeted interventions.","Drake, J.; Rohani, P.; Dahlin, K.; Handel, A.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165159v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165159v1?rss=1,2020-08-01,2020-08-01,,True
115,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,"The COVID-19 pandemic, which began in 2020 is testing economic resilience and surge capacity of healthcare providers worldwide. At time of writing, positive detection of the SARS-CoV-2 virus remains the only method for diagnosing COVID-19 infection. Rapid upscaling of national SARS-CoV-2 genome testing presented challenges: 1) Unpredictable supply chains of reagents and kits for virus inactivation, RNA extraction and PCR-detection of viral genomes 2) Rapid time to result of <24 hours is required in order to facilitate timely infection control measures. We evaluated whether alternative commercially available kits provided sensitivity and accuracy of SARS-CoV-2 genome detection comparable to those used by regional National Healthcare Services (NHS), and asked if detection was altered by heat inactivation, an approach for rapid one-step viral inactivation and RNA extraction without chemicals or kits. Using purified RNA, we found the CerTest VIASURE kit to be comparable to Altona RealStar system currently in use, and further showed that both diagnostic kits performed similarly in the BioRad CFX96 and Roche LightCycler 480 II machines. Additionally, both kits were comparable to a third alternative using a combination of Quantabio qScript 1-step qRT-PCR mix and CDC-accredited N1 and N2 primer/probes when looking specifically at borderline samples. Importantly, when using the kits in an extraction-free protocol, following heat inactivation, we saw differing results, with the combined Quantabio-CDC assay showing superior accuracy and sensitivity. In particular, detection using the CDC N2 probe following the extraction-free protocol was highly correlated to results generated with the same probe following RNA extraction and reported clinically (n=127; R2=0.9259). Our results demonstrate that sample treatment can greatly affect the downstream performance of SARS-CoV-2 diagnostic kits, with varying impact depending on the kit. We also showed that one-step heat inactivation methods could reduce time from swab receipt to outcome of test result. Combined, these findings present alternatives to the protocols in use and can serve to alleviate any arising supply chain issues at different points in the workflow, whilst accelerating testing, and reducing cost and environmental impact.","Thompson, J. L.; Velasco, A. D. R.; Cardall, A.; Tarbox, R.; Richardson, J.; Clarke, G.; Lister, M.; Howson-Wells, H. C.; Fleming, V. M.; Khakh, M.; Sloan, T.; Duckworth, N.; Denning, C.; McClure, C. P.; Benest, A. V.; Seedhouse, C. H.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164988v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164988v1?rss=1,2020-08-01,2020-08-01,,True
116,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020","Objectives: To determine the trend in mortality risk over time in people with severe COVID-19 requiring critical care (high intensive unit [HDU] or intensive care unit [ICU]) management. Methods: We accessed national English data on all adult COVID-19 specific critical care admissions from the COVID-19 Hospitalisation in England Surveillance System (CHESS), up to the 29th June 2020 (n=14,958). The study period was 1st March until 30th May, meaning every patient had 30 days of potential follow-up available. The primary outcome was in-hospital 30-day all-cause mortality. Hazard ratios for mortality were estimated for those admitted each week using a Cox proportional hazards models, adjusting for age (non-linear restricted cubic spline), sex, ethnicity, comorbidities, and geographical region. Results: 30-day mortality peaked for people admitted to critical care in early April (peak 29.1% for HDU, 41.5% for ICU). There was subsequently a sustained decrease in mortality risk until the end of the study period. As a linear trend from the first week of April, adjusted mortality risk decreased by 11.2% (adjusted HR 0.89 [95% CI 0.87 - 0.91]) per week in HDU, and 9.0% (adjusted HR 0.91 [95% CI 0.88 - 0.94]) in ICU. Conclusions: There has been a substantial mortality improvement in people admitted to critical care with COVID-19 in England, with markedly lower mortality in people admitted in mid-April and May compared to earlier in the pandemic. This trend remains after adjustment for patient demographics and comorbidities suggesting this improvement is not due to changing patient characteristics. Possible causes include the introduction of effective treatments as part of clinical trials and a falling critical care burden.","Dennis, J.; McGovern, A.; Vollmer, S.; Mateen, B. A.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165134v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165134v1?rss=1,2020-08-01,2020-08-01,,True
117,Modeling latent infection transmissions through biosocial stochastic dynamics,"The events of the recent SARS-CoV-02 epidemics have shown the importance of social factors, especially given the large number of asymptomatic cases that effectively spread the virus, which can cause a medical emergency to very susceptible individuals. Besides, the SARS-CoV-02 virus survives for several hours on different surfaces, where a new host can contract it with a delay. These passive modes of infection transmission remain an unexplored area for traditional mean-field epidemic models. Here, we design an agent-based model for simulations of infection transmission in an open system driven by the dynamics of social activity; the model takes into account the personal characteristics of individuals, as well as the survival time of the virus and its potential mutations. A growing bipartite graph embodies this biosocial process, consisting of active carriers (host) nodes that produce viral nodes during their infectious period. With its directed edges passing through viral nodes between two successive hosts, this graph contains complete information about the routes leading to each infected individual. We determine temporal fluctuations of the number of exposed and the number of infected individuals, the number of active carriers and active viruses at hourly resolution. The simulated processes underpin the latent infection transmissions, contributing significantly to the spread of the virus within a large time window. More precisely, being brought by social dynamics and exposed to the currently existing infection, an individual passes through the infectious state until eventually spontaneously recovers or otherwise is moves to a controlled hospital environment. Our results reveal complex feedback mechanisms that shape the dependence of the infection curve on the intensity of social dynamics and other sociobiological factors. In particular, the results show how the lockdown effectively reduces the spread of infection and how it increases again after the lockdown is removed. Furthermore, a reduced level of social activity but prolonged exposure of susceptible individuals have adverse effects. On the other hand, virus mutations that can gradually reduce the transmission rate by hopping to each new host along the infection path can significantly reduce the extent of the infection, but can not stop the spreading without additional social strategies. Our stochastic processes, based on graphs at the interface of biology and social dynamics, provide a new mathematical framework for simulations of various epidemic control strategies with high temporal resolution and virus traceability.","Tadic, B.; Melnik, R.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164491v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164491v1?rss=1,2020-08-01,2020-08-01,,True
118,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,"The dynamic immunological characteristics of COVID-19 patients are essential for clinicians to understand the disease progression. Our data showed that the immune system and function have gradually remodeled and declined with age from 16-91 years old in 25,239 healthy controls. Analyzing the relationship between the number of lymphocytes and age showed that lymphocytes and subsets tended to decline with age significantly, whereas, the number of natural killer cells tended to increase with age significantly. SARS-CoV-2 specific immunity has declined with age in fatal cases. Furthermore, SARS-CoV-2 specific immunity is associated with survival time in fatal cases. The loss expansion of SARS-CoV-2 specific immunity could be expanded in vitro. A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. Our findings have provided a basis for further analysis of SARS-CoV-2 specific immunity and understanding the pathogenesis of fatal COVID-19 patients.","Zeng, Q.; Huang, G.; Li, Y.-z.; Xu, G.; Dong, S.-y.; Zhong, T.-y.; Chen, Z.-t.; Xu, Y.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164681v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164681v1?rss=1,2020-08-01,2020-08-01,,True
119,Estimating the total size of coronavirus epidemic in Algeria via different approaches,"In this paper, several techniques and models proposed the spread of coronavirus (Covid-19) and determines approximately the final number of coronavirus infected cases as well as infection point (peak time) in Algeria. To see the goodness of the predicting techniques, a comparative study was done by calculating error indicators such as Root-Mean-Square Error (RMSE) and the sum of squared estimate of errors (SSE). The main technique used in this study is the logistic growth regression model widely used in epidemiology. The results only relate to the two months from the beginning of the epidemic in Algeria, which should be readjusted by integrating the new data over time, because hazardous parameters like possible relaxations (decrease of vigilance or laxity of society) can affect these results and generally cause a time lag in the curve. Hence, a re-estimation of the curves is always requested.","REZKI, M.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164509v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164509v1?rss=1,2020-08-01,2020-08-01,,True
120,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity,"Rapid evidence-based decision-making and public policy based on quantitative modelling and forecasting by local and regional National Health Service (NHS-UK) managers and planners in response to the deadly severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), a virus causing COVID-19, has largely been missing. In this pilot study, we present a data-driven epidemiological modelling framework that allows to integrate quantitative modelling, validation and forecasting based on current available local and regional datasets to investigate and mitigate the impact of COVID-19 on local NHS hospitals in terms of healthcare demand and capacity as well as allowing for a systematic evaluation of the predictive accuracy of the modelling framework for long-term forecasting. We present an epidemiological model tailored and designed to meet the needs of the local health authorities, formulated to be fitted naturally to datasets which incorporate regional and local demographics. The model yields quantitative information on the healthcare demand and capacity required to manage and mitigate the COVID pandemic at the regional level. Furthermore, the model is rigorously validated using partial historical datasets, which is then used to demonstrate the forecasting power of the model and also to quantify the risk associated with the decision taken by healthcare managers and planners. Model parameters are fully justified, these are derived purely based on the time series data available at the regional level, with minimal assumptions. Using these inferred parameters, the model is able to make predictions under which secondary waves and re-infection scenarios could occur. Hence, our modelling approach addresses one of the major criticisms associated with the lack of transparency and precision of current COVID-19 models. Our approach offers a robust quantitative modelling framework where the probability of the model giving a wrong or correct prediction can be quantified.","Campillo-Funollet, E.; Van Yperen, J.; Allman, P.; Bell, M.; Beresford, W.; Clay, J.; Evans, G.; Dorey, M.; Gilchrist, K.; Gurprit, P.; Walkley, R.; Watson, M.; Madzvamuse, A.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164566v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164566v1?rss=1,2020-08-01,2020-08-01,,True
121,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,"Background: Men and older women have been shown to be at higher risk of adverse COVID-19 outcomes. Animal model studies of SARS-CoV and MERS suggest that the age and sex difference in COVID-19 symptom severity may be due to a protective effect of the female sex hormone estrogen. Females have shown an ability to mount a stronger immune response to a variety of viral infections because of more robust humoral and cellular immune responses. Objectives: We sought to determine whether COVID-19 positivity increases in women entering menopause. We also aimed to identify whether premenopausal women taking exogenous hormones in the form of the combined oral contraceptive pill (COCP) and post-menopausal women taking hormone replacement therapy (HRT) have lower predicted rates of COVID-19, using our published symptom-based model. Design: The COVID Symptom Study developed by Kings College London and Zoe Global Limited was launched in the UK on 24th March 2020. It captured self-reported information related to COVID-19 symptoms. Data used for this study included records collected between 7th May - 15th June 2020. Main outcome measures: We investigated links between COVID-19 rates and 1) menopausal status, 2) COCP use and 3) HRT use, using symptom-based predicted COVID-19, tested COVID-19, and disease severity based on requirement for hospital attendance or respiratory support. Participants: Female users of the COVID Symptom Tracker Application in the UK, including 152,637 women for menopause status, 295,689 for COCP use, and 151,193 for HRT use. Analyses were adjusted for age, smoking and BMI. Results: Post-menopausal women aged 40-60 years had a higher rate of predicted COVID (P=0.003) and a corresponding range of symptoms, with consistent, but not significant trends observed for tested COVID-19 and disease severity. Women aged 18-45 years taking COCP had a significantly lower predicted COVID-19 (P=8.03E-05), with a reduction in hospital attendance (P=0.023). Post-menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P=2.22E-05) for HRT users alone. Conclusions: Our findings support a protective effect of estrogen on COVID-19, based on positive association between predicted COVID-19 and menopausal status, and a negative association with COCP use. HRT use was positively associated with COVID-19 symptoms; however, the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential comorbidities. Trial registration: The App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210","Costerira, R.; Lee, K. A.; Murray, B.; Christiansen, C.; Castillo-Fernandez, J.; Ni Lochlainn, M.; Capdevila Pujol, J.; Buchan, I.; Kenny, L. C.; Wolf, J.; Ourselin, S.; Steves, C.; Spector, T.; Newson, L.; Bell, J.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164921v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164921v1?rss=1,2020-08-01,2020-08-01,,True
122,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,"Background In low-income countries, like Malawi, important public health measures including social distancing or a lockdown, have been challenging to implement owing to socioeconomic constraints, leading to predictions that the COVID-19 pandemic would progress rapidly. However, due to limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there are no reliable estimates of the true burden of infection and death. We, therefore, conducted a SARS-CoV-2 serosurvey amongst health care workers (HCW) in Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection in urban Malawi. Methods Five hundred otherwise asymptomatic HCWs were recruited from Blantyre City (Malawi) from 22nd May 2020 to 19th June 2020 and serum samples were collected all participants. A commercial ELISA was used to measure SARS-CoV-2 IgG antibodies in serum. We run local negative samples (2018 - 2019) to verify the specificity of the assay. To estimate the seroprevalence of SARS CoV-2 antibodies, we adjusted the proportion of positive results based on local specificity of the assay. Results Eighty-four participants tested positive for SARS-CoV-2 antibodies. The HCW with a positive SARS-CoV-2 antibody result came from different parts of the city. The adjusted seroprevalence of SARS-CoV-2 antibodies was 12.3% [CI 9.0-15.7]. Using age-stratified infection fatality estimates reported from elsewhere, we found that at the observed adjusted seroprevalence, the number of predicted deaths was 8 times the number of reported deaths. Conclusion The high seroprevalence of SARS-CoV-2 antibodies among HCW and the discrepancy in the predicted versus reported deaths, suggests that there was early exposure but slow progression of COVID-19 epidemic in urban Malawi. This highlights the urgent need for development of locally parameterised mathematical models to more accurately predict the trajectory of the epidemic in sub-Saharan Africa for better evidence-based policy decisions and public health response planning.","Chibwana, M. G.; Jere, K. C.; kamng'ona, R.; Mandolo, J.; Katunga-Phiri, V.; Tembo, D.; Mitole, N.; Musasa, S.; Sichone, S.; Lakudzala, A.; Sibale, L.; Matambo, P.; Kadwala, I.; Byrne, R. L.; Mbewe, A.; Morton, B.; Phiri, C.; Mallewa, J.; Mwandumba, H. C.; Adams, E. R.; Gordon, S. B.; Jambo, K. C.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164970v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164970v1?rss=1,2020-08-01,2020-08-01,,True
123,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,"Introduction The risks to surgeons of carrying out aerosol generating procedures during the COVID pandemic are unknown. To start to define these risks, in a systematic manner, we investigated the presence of SARS-CoV-2 virus in the abdominal fluid and lower genital tract of patients undergoing surgery. Methods We carried out a prospective cross sectional observational study of 113 patients undergoing abdominal surgery or instrumentation of the lower genital tract. We took COVID swabs from the peritoneal cavity and from the vagina from all eligible patients. Results were stratified by pre operative COVID status. Results In patients who were presumed COVID negative at the time of surgery SARS-CoV-2 virus RNA was detected in 0/102 peritoneal samples and 0/98 vaginal samples. Peritoneal and vaginal swabs were also negative in one patient who had a positive nasopharyngeal swab immediately prior to surgery. Conclusions The presence of SARS-CoV-2 RNA in the abdominal fluid or lower genital tract of presumed negative patients is nil or extremely low. These data will inform surgeons of the risks of restarting laparoscopic surgery at a time when COVID19 is endemic in the population.","Jones, D.; Faluyi, D.; Hamilton, S.; Stylianides, N.; Ma, K.; Duff, S.; Machin, N.; Edmondson, R.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165043v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165043v1?rss=1,2020-08-01,2020-08-01,,True
124,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19","Background Medical school assessments, clinical placements and teaching have been disrupted by the COVID-19 pandemic. The ADAPT consortium was formed to document and analyse the effects of the pandemic on medical education in the United Kingdom (UK), with the aim of capturing current and future snapshots of disruption to inform trends in the future performance of cohorts graduating during COVID-19. Methods Members of the consortium were recruited from various national medical student groups to ensure representation from medical schools across the UK. The groups involved were: Faculty of Medical Leadership and Management Medical Students Group (FMLM MSG); Neurology and Neurosurgery Interest Group (NANSIG); Doctors Association UK (DAUK); Royal Society of Medicine (RSM) Student Members Group and Medical Student Investigators Collaborative (MSICo.org). In total, 29 medical schools are represented by the consortium. Our members reported teaching postponement, examination status, alternative teaching provision, elective status and UK Foundation Programme Office (UKFPO) educational performance measure (EPM) ranking criteria relevant to their medical school during a data collection window (1st April 14:00 to 2nd April 23:59). Results All 29 medical schools began postponement of teaching between the 11th and 17th of March 2020. Changes to assessments were highly variable. Final year examinations had largely been completed before the onset of COVID-19. Of 226 exam sittings between Year 1 and Year 4 across 29 schools: 93 (41%) were cancelled completely; 14 (6%) had elements cancelled; 57 (25%) moved their exam sitting online. 23 exam sittings (10%) were postponed to a future date. 36% of cohorts with cancelled exams and 74% of cohorts with online exams were granted automatic progression to the next academic year. There exist 19 cohorts at 9 medical schools where all examinations (written and practical) were initially cancelled and automatic progression was granted. Conclusions The approaches taken by medical schools have differed substantially, though there has been universal disruption to teaching and assessments. The data presented in this study represent initial responses, which are likely to evolve over time. In particular, the status of future elective cancellations and UK Foundation Programme Office (UKFPO) educational performance measure (EPM) decile calculations remains unclear. The long-term implications of the heterogeneous disruption to medical education remains an area of active research. Differences in specialty recruitment and performance on future postgraduate examinations may be affected and will be a focus of future phases of the ADAPT Study.","Arora, A.; Solomou, G.; Bandyopadhyay, S.; Simons, J.; Osborne, A.; Georgiou, I.; Dominic, C.; Mahmood, S.; Badhrinarayanan, S.; Ahmed, S. R.; Wellington, J.; Kouli, O.; Borchert, R. J.; Feyi-Waboso, J.; Dickson, S.; Kalsi, S.; Karponis, D.; Boardman, T.; Daler, H.; Boyle, A.; Speller, J.; Gillespie, C. S.; Low, J. M.; Vaidya, R.; Ta, N. H.; Aldridge, S.; Martin, J. C.; Douglas, N.; Goble, M.; Goolamallee, T. A.-H.; Norton, E. J.; Chu, A.; Imtiaz, I.; Devine, O. P.","https://www.medrxiv.org/content/10.1101/2020.07.29.20163907v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20163907v1?rss=1,2020-08-01,2020-08-01,,True
125,SABCoM: A Spatial Agent-Based Covid-19 Model,"How effective are 'lockdown' measures and other policy interventions to curb the spread of Covid-19 in emerging market cities that are characterized by large heterogeneity and high levels of informality? The most commonly used models to predict the spread of Covid-19 are SEIR models which lack the spatial resolution necessary to answer this question. We develop an agent-based model of social interactions in which the distribution of agents across wards, as well as their travel and interactions are calibrated to real data for Cape Town, South Africa. We characterize the elasticity of various policy interventions including increased likelihood to self-isolate, travel restrictions, assembly bans, and behavioural interventions like washing hands or wearing masks. Even in an informal setting, where agents' ability to self-isolate is compromised, a lockdown remains an effective intervention. In our model, the lockdown enacted in South Africa reduced expected fatalities in Cape Town by 26% and the expected demand for intensive care beds by 46%. However, our best calibration predicts a substantially higher case load, demand for ICU beds, and expected number of deaths than the current best estimate published for Cape Town.","Davids, A.; Rand, G. D.; Georg, C.-P.; Koziol, T.; Schasfoort, J. A.","https://www.medrxiv.org/content/10.1101/2020.07.30.20164855v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20164855v1?rss=1,2020-08-01,2020-08-01,,True
126,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,"Objective: The potential ability for weather to affect SARS-CoV-2 transmission has been an area of controversial discussion during the COVID-19 pandemic. Individuals' perceptions of the impact of weather can inform their adherence to public health guidelines; however, there is no measure of their perceptions. We quantified Twitter users' perceptions of the effect of weather and analyzed how they evolved with respect to real-world events and time. Materials and Methods: We collected 166,005 tweets posted between January 23 and June 22, 2020 and employed machine learning/natural language processing techniques to filter for relevant tweets, classify them by the type of effect they claimed, and identify topics of discussion. Results: We identified 28,555 relevant tweets and estimate that 40.4% indicate uncertainty about weather's impact, 33.5% indicate no effect, and 26.1% indicate some effect. We tracked changes in these proportions over time. Topic modeling revealed major latent areas of discussion. Discussion: There is no consensus among the public for weather's potential impact. Earlier months were characterized by tweets that were uncertain of weather's effect or claimed no effect; later, the portion of tweets claiming some effect of weather increased. Tweets claiming no effect of weather comprised the largest class by June. Major topics of discussion included comparisons to influenza's seasonality, President Trump's comments on weather's effect, and social distancing. Conclusion: There is a major gap between scientific evidence and public opinion of weather's impacts on COVID-19. We provide evidence of public's misconceptions and topics of discussion, which can inform public health communications.","Gupta, M.; Bansal, A.; Jain, B.; Rochelle, J.; Oak, A.; Jalali, M. S.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164814v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164814v1?rss=1,2020-08-01,2020-08-01,,True
127,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,"Objective: To identify sex-specific effects of risk factors for in-hospital mortality among COVID-19 patients admitted to a hospital system in New York City. Design: Prospective observational cohort study with in-hospital mortality as the primary outcome. Setting: Five acute care hospitals within a single academic medical system in New York City. Participants: 3,086 hospital inpatients with COVID-19 admitted on or before April 13, 2020 and followed through June 2, 2020. Follow-up till discharge or death was complete for 99.3% of the cohort. Results: The majority of the cohort was male (59.6%). Men were younger (median 64 vs. 70, p<0.001) and less likely to have comorbidities such as hypertension (32.5% vs. 39.9%, p<0.001), diabetes (22.6% vs. 26%, p=0.03), and obesity (6.9% vs. 9.8%, p=0.004) compared to women. Women had lower median values of laboratory markers associated with inflammation compared to men: white blood cells (5.95 vs. 6.8 K/uL, p<0.001), procalcitonin (0.14 vs 0.21 ng/mL, p<0.001), lactate dehydrogenase (375 vs. 428 U/L, p<0.001), C-reactive protein (87.7 vs. 123.2 mg/L, p<0.001). Unadjusted mortality was similar between men and women (28.8% vs. 28.5%, p=0.84), but more men required intensive care than women (25.2% vs. 19%, p<0.001). Male sex was an independent risk factor for mortality (OR 1.26, 95% 1.04-1.51) after adjustment for demographics, comorbidities, and baseline hypoxia. There were significant interactions between sex and coronary artery disease (p=0.038), obesity (p=0.01), baseline hypoxia (p<0.001), ferritin (p=0.002), lactate dehydrogenase (p=0.003), and procalcitonin (p=0.03). Except for procalcitonin, which had the opposite association, each of these factors was associated with disproportionately higher mortality among women. Conclusions: Male sex was an independent predictor of mortality, consistent with prior studies. Notably, there were significant sex-specific interactions which indicated a disproportionate increase in mortality among women with coronary artery disease, obesity, and hypoxia. These new findings highlight patient subgroups for further study and help explain the recognized sex differences in COVID-19 outcomes.","Jun, T.; Nirenberg, S.; Kovatch, P.; Huang, K.-l.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164640v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164640v1?rss=1,2020-08-01,2020-08-01,,True
128,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,"There is ongoing debate as to whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) use is associated with poor prognosis of coronavirus disease-2019 (COVID-19). We sought to investigate the association between ACEI/ARB use and risk of poor clinical outcomes from COVID-19. We identified 1,290 patients with hypertension, of which 682 had recorded ACEI/ARB use and 608 without the use during 30 days preceding the date of COVID-19 diagnosis in completely enumerated COVID-19 cohort in South Korea. Our primary endpoint was the clinical outcomes comprised of all-cause mortality, use of mechanical ventilation, intensive care unit (ICU) admission, and sepsis. We used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and Poisson regression model to estimate the relative risks (RR) and 95% confidence intervals (CI) to compare outcomes in ACEI/ARB users with non-users. Compared to non-use, ACEI/ARB use was associated with lower clinical outcomes (IPTW adjusted RR, 0.60; 95% CI, 0.42-0.85; p=0.0046). When assessed by individual outcomes, ACEI/ARB use was not associated with all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09; p=0.0973) and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17; p=0.9043). Subgroup analysis showed a trend toward protective role of ACEIs and ARBs against overall outcomes in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03; p-for-interaction=0.008) and with pre-existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI, 0.60-0.92; p-for-interaction=0.0023). We present clinical evidence to support continuing ACE/ARB use in completely enumerated hypertensive COVID-19 cohort in South Korea.","Kim, J. H.; Baek, Y.-H.; Lee, H.; Choe, Y. J.; Shin, H. J.; Shin, J.-Y.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164822v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164822v1?rss=1,2020-08-01,2020-08-01,,True
129,Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,"Background: Current mitigation strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rely on population-wide adoption of non-pharmaceutical interventions (NPIs). Collecting demographically and geographically resolved data on NPIs and their association with SARS-CoV-2 infection history can provide critical information related to reopening geographies. Methods: We sampled 1,030 individuals in Maryland from June 17 - June 28, 2020 to capture socio-demographically and geographically resolved information about NPI adoption, access to SARS-CoV-2 testing, and examine associations with self-reported SARS-CoV-2 positivity. Results: Median age of the sample was 43 years and 45% were men; Whites and Blacks/African Americans represented 60% and 23%, respectively. Overall, 96% of the sample reported traveling outside their home for non-employment related services: most commonly cited reasons were essential services (92%) and visiting friends/family (66%). Use of public transport was reported by 18% of respondents. 68% reported always social distancing indoors and 53% always wearing masks indoors; indoor social distancing was significantly less common among younger vs. older individuals, and race/ethnicity and income were significantly associated with mask use (p<0.05 for all). 55 participants (5.3%) self-reported ever testing positive for SARS-CoV-2 with strong dose-response relationships between movement frequency and SARS-CoV-2 positivity that were significantly attenuated by social distancing. In multivariable analysis, history of SARS-CoV-2 infection was negatively associated with the practice of social distancing (adjusted Odd Ratio [aOR]: 0.10; 95% Confidence Interval: 0.03 - 0.33); the only travel associated with higher likelihood of SARS-CoV-2 infection was use of public transport (aOR for 7 or more times vs. never: 4.29) and visiting a place of worship (aOR for 3 or more times vs. never: 16.0) after adjusting for social distancing. Conclusions: Using a rapid cost-efficient approach, we highlight the role of movement and social distancing on SARS-CoV-2 transmission risk. Continued monitoring of NPI uptake, access to testing, and the subsequent impact on SARS-CoV-2 transmission will be critical for pandemic control and decisions about reopening geographies.","Clipman, S. J.; Wesolowski, A. P.; Gibson, D. G.; Agarwal, S.; Lambrou, A. S.; Kirk, G. D.; Labrique, A. B.; Mehta, S. H.; Solomon, S. S.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164665v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164665v1?rss=1,2020-08-01,2020-08-01,,True
130,Effects of COVID-19 lockdown on heart rate variability,"Introduction: Strict lockdown rules were imposed to the French population from 17 March to 11 May 2020, which may result in limited possibilities of physical activity, modified psychological and health states. This report is focused on HRV parameters kinetics before, during and after this lockdown period. Methods: 95 participants were included in this study, who underwent regular orthostatic tests (a 5-minute supine followed by a 5-minute standing recording of heart rate (HR)) on a regular basis before, during and after the lockdown (BSL, CFN and RCV, respectively). HR, power in low- and high-frequency bands (LF, HF, respectively) and root mean square of the successive differences (RMSSD) were computed for each orthostatic test, and for each positions. Subjective well-being was assessed on a 0-10 visual analogic scale (VAS). Results: Out of the 95 participants, 19 (WB+) reported an improved well-being (i.e., increase >2 in VAS score) during CFN, contradictory to the 76 other participants (WB-). There was an increase in HR and a decrease in RMSSD when measured supine in CFN and RCV, compared to BSL in WB-, whilst opposite results were found in WB+ (i.e. decrease in HR and increase in RMSSD in CFN and RCV; increase in LF and HF in RCV). There was a moderate significant correlation between VAS and HR, RMSSD, HF, respectively, in the supine position; the higher the VAS score (i.e., subjective well-being), the higher the RMSSD and HF and the lower the HR. In standing position, HRV parameters were not modified during CFN. Conclusion: The strict COVID-19 lockdown likely had opposite effects on French population as 20% of participants improved parasympathetic activation (RMSSD, HF) and rated positively this period, whilst 80% showed altered responses and deteriorated well-being. The changes in HRV parameters during and after the lockdown period were in line with subjective well-being responses. These results confirmed the usefulness of HRV as a non-invasive means for monitoring well-being and health in the general population.","Bourdillon, N.; Yazdani, S.; Schmitt, L.; Millet, G. P.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165118v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165118v1?rss=1,2020-08-01,2020-08-01,,True
131,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,"Objectives: The aim of this study was to conduct a scoping review of estimates of the relative infectiousness of asymptomatic persons infected with SARS-CoV-2 compared with symptomatic individuals. Design: Rapid scoping review of literature available until 8th April 2020. Setting: International studies on the infectiousness of individuals infected with SARS-CoV-2 Participants: Studies were selected for inclusion if they defined asymptomatics as a separate cohort distinct from pre-symptomatics and if they provided a quantitative measure of the infectiousness of asymptomatics relative to symptomatics. Primary outcome measures: The relative number of secondary cases produced by an average primary case, the relative probability of transmitting infection upon contact, and the degree of viral shedding. Results: Very few studies reported estimates of relative infectiousness of asymptomatic compared with symptomatic individuals. Significant differences exist in the definition of infectiousness. Viral shedding studies in general show no difference in shedding levels between symptomatic and asymptomatic individuals but are likely to be impacted by insufficient statistical power. Two contact tracing studies provided estimates of 0.7 and 1.0, but differences in approach and definition preclude comparison across the two studies. Finally, two modelling studies suggest a relative infectiousness of around 0.5 but one of these was more reflective of the infectiousness of undocumented rather than asymptomatic cases. Importantly, one contact tracing study showing a very low level of infectiousness of asymptomatic was not included in the analysis at this point due difficulties interpreting the reported findings. Conclusions: The present study highlights the need for additional studies in this area as a matter of urgency. For the purpose of epidemiological modelling, we cautiously suggest that at present, asymptomatics could be considered to have a degree of infectiousness which is about 0.40-0.70 that of symptomatics. However, it must be stressed that this suggestion comes from a very low evidence base and that estimates exist that are close to zero and close to 1.","Mc Evoy, D.; McAloon, C. G.; Collins, A. B.; Hunt, K.; Butler, F.; Byrne, A. W.; Casey, M.; Barber, A.; Griffin, J. M.; Lane, E. A.; Wall, P.; More, S. J.","https://www.medrxiv.org/content/10.1101/2020.07.30.20165084v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20165084v1?rss=1,2020-08-01,2020-08-01,,True
132,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,"The superfamily-1 helicase non-structural protein 13 (nsp13) is required for SARS-CoV-2 replication, making it an important antiviral therapeutic target. The mechanism and regulation of nsp13 has not been explored at the single-molecule level. Specifically, force-dependent unwinding experiments have yet to be performed for any coronavirus helicase. Here, using optical tweezers, we find that nsp13 unwinding frequency, processivity, and velocity increase substantially when a destabilizing force is applied to the dsRNA, suggesting a passive unwinding mechanism. These results, along with bulk assays, depict nsp13 as an intrinsically weak helicase that can be potently activated by picoNewton forces. Such force-dependent behavior contrasts the known behavior of other viral monomeric helicases, drawing stronger parallels to ring-shaped helicases. Our findings suggest that mechanoregulation, which may be provided by a directly bound RNA-dependent RNA polymerase, enables on-demand helicase activity on the relevant polynucleotide substrate during viral replication.","Mickolajczyk, K. J.; Shelton, P. M. M.; Grasso, M.; Cao, X.; Warrington, S. R.; Aher, A.; Liu, S.; Kapoor, T. M.","https://www.biorxiv.org/content/10.1101/2020.07.31.231274v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.231274v1?rss=1,2020-07-31,2020-07-31,,False
133,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,"The multifunctional nucleocapsid (N) protein in SARS-CoV-2 binds the ~30 kb viral RNA genome to aid its packaging into the 80-90 nm membrane-enveloped virion. The N protein is composed of N-terminal RNA-binding and C-terminal dimerization domains that are flanked by three intrinsically disordered regions. Here we demonstrate that a centrally located 40 amino acid intrinsically disordered domain drives phase separation of N protein when bound to RNA, with the morphology of the resulting condensates affected by inclusion in the RNA of the putative SARS-CoV-2 packaging signal. The SARS-CoV-2 M protein, normally embedded in the virion membrane with its C-terminus extending into the virion core, independently induces N protein phase separation that is dependent on the N proteins C-terminal dimerization domain and disordered region. Three-component mixtures of N+M+RNA form condensates with mutually exclusive compartments containing N+M or N+RNA, including spherical annular structures in which the M protein coats the outside of an N+RNA condensate. These findings support a model in which phase separation of the N protein with both the viral genomic RNA and the SARS-CoV-2 M protein facilitates RNA packaging and virion assembly.","Lu, S.; Ye, Q.; Singh, D.; Villa, E.; Cleveland, D. W.; Corbett, K. D.","https://www.biorxiv.org/content/10.1101/2020.07.30.228023v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228023v1?rss=1,2020-07-31,2020-07-31,,False
134,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,"The outbreak and spread of SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), the cause of coronavirus disease 2019 (COVID-19), is a current global health emergency and a prophylactic vaccine is needed urgently. The spike glycoprotein of SARS-CoV-2 mediates entry into host cells, and thus is a target for neutralizing antibodies and vaccine design. Here we show that adjuvanted protein immunization with SARS-CoV-2 spike trimers, stabilized in prefusion conformation 1, results in potent antibody responses in mice and rhesus macaques with neutralizing antibody titers orders of magnitude greater than those typically measured in serum from SARS-CoV-2 seropositive humans. Neutralizing antibody responses were observed after a single dose, with exceptionally high titers achieved after boosting. Furthermore, neutralizing antibody titers elicited by a dose-sparing regimen in mice were similar to those obtained from a high dose regimen. Taken together, these data strongly support the development of adjuvanted SARS-CoV-2 prefusion-stabilized spike protein subunit vaccines.","Mandolesi, M.; Sheward, D. J.; Hanke, L.; Ma, J.; Pushparaj, P.; Perez Vidakovics, L.; Kim, C.; Lore, K.; Castro Dopico, X.; Coquet, J. M.; McInerney, G.; Karlsson Hedestam, G. B.; Murrell, B.","https://www.biorxiv.org/content/10.1101/2020.07.31.228486v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.228486v1?rss=1,2020-07-31,2020-07-31,,False
135,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence","The sharp reduction of human mobility in March 2020, as observed by anonymized cellphone data, has played an important role in thwarting a runaway COVID-19 pandemic. As the world is reopening, the risks of new flare-ups are rising. We report a data-driven approach, grounded in strong correlation between mobility and growth in COVID-19 cases two weeks later, to establish a spatial-temporal model of ""critical mobility"" maps that separate relatively safe mobility levels from dangerous ones. The normalized difference between the current and critical mobility has predictive power for case trajectories during the ""opening-up"" phases. For instance, actual mobility has risen above critical mobility in many southern US counties by the end of May, foreshadowing the latest virus resurgence. Encouragingly, critical mobility has been rising throughout the USA, likely due to face mask-wearing and social distancing measures. However, critical mobility is still well below pre-COVID mobility levels in most of the country suggesting continued mobility-reduction is still necessary.","Freitag, M. O.; Schmude, J.; Siebenschuh, C.; Stolovitzky, G.; Hamann, H.; Lu, S.","https://www.medrxiv.org/content/10.1101/2020.07.30.20163790v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.30.20163790v1?rss=1,2020-07-31,2020-07-31,,True
136,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and DNA synthesis","A significant, positive association between selenium status and COVID-19 prognosis has recently been identified. The present study investigated the influence of SARS-CoV-2 on host selenoproteins which mediate many beneficial actions of selenium. We found that SARS-CoV-2 suppressed mRNA expression of selenoproteins associated with ferroptosis (GPX4), ER stress (SELENOF, SELENOK, SELENOM and SELENOS) and DNA synthesis (TXNRD3) in Vero cells, providing a deeper insight into the connection between selenium and SARS-CoV-2.","Wang, Y.; Huang, J.; Sun, Y.; He, J.; Li, W.; Liu, Z.; Taylor, E. W.; Rayman, M. P.; Wan, X.; Zhang, J.","https://www.biorxiv.org/content/10.1101/2020.07.31.230243v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230243v1?rss=1,2020-07-31,2020-07-31,,False
137,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,"A prominent feature of coronaviruses is the presence of a large glycoprotein spike protruding from a lipidic membrane. This glycoprotein spike determines the interaction of coronaviruses with the environment and the host. In this paper, we perform all atomic Molecular Dynamics simulations of the interaction between the SARS-CoV-2 trimeric glycoprotein spike and surfaces of materials. We considered a material with high hydrogen bonding capacity (cellulose) and a material capable of strong hydrophobic interactions (graphite). Initially, the spike adsorbs to both surfaces through essentially the same residues belonging to the receptor binding subunit of its three monomers. Adsorption onto cellulose stabilizes in this configuration, with the help of a large number of hydrogen bonds developed between cellulose and the three receptor binding domains (RBD) of the glycoprotein spike. In the case of adsorption onto graphite, the initial adsorption configuration is not stable and the surface induces a substantial deformation of the glycoprotein spike with a large number of adsorbed residues not pertaining to the binding subunits of the spike monomers.

The following article has been submitted to the journal Biointerphases. After it is published, it will be found at https://avs.scitation.org/journal/bip","Malaspina, D. C.; Faraudo, J.","https://www.biorxiv.org/content/10.1101/2020.07.31.230888v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230888v1?rss=1,2020-07-31,2020-07-31,,False
138,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,"In the fight against the spread of COVID-19 the emphasis is on vaccination or on reactivating existing drugs used for other purposes. The tight links that necessarily exist between the virus as it multiplies and the metabolism of its host are systematically ignored. Here we show that the metabolism of all cells is coordinated by the availability of a core building block of the cells genome, cytidine triphosphate (CTP). This metabolite is also the key to the synthesis of the viral envelope and to the translation of its genome into proteins. This unique role explains why evolution has led to the early emergence in animals of an antiviral immunity enzyme, viperin, that synthesizes a toxic analogue of CTP. The constraints arising from this dependency guide the evolution of the virus. With this in mind, we explored the real-time experiment taking place before our eyes using probabilistic modelling approaches to the molecular evolution of the virus. We have thus followed, almost on a daily basis, the evolution of the composition of the viral genome to link it to the progeny produced over time, particularly in the form of blooms that sparked a firework of viral mutations. Some of those certainly increase the propagation of the virus. This led us to make out the critical role in this evolution of several proteins of the virus, such as its nucleocapsid N, and more generally to begin to understand how the virus ties up the host metabolism to its own benefit. A way for the virus to escape CTP-dependent control in cells would be to infect cells that are not expected to grow, such as neurons. This may account for unexpected body sites of viral development in the present epidemic.","Cluzel, N.; Lambert, A.; Maday, Y.; Turinici, G.; Danchin, A.","https://www.biorxiv.org/content/10.1101/2020.07.31.230607v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230607v1?rss=1,2020-07-31,2020-07-31,,False
139,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,"A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.","Sun, W.; McCroskery, S.; Liu, W.-C.; Leist, S. R.; Liu, Y.; Albrecht, R. A.; Slamanig, S.; Oliva, J.; Amanat, F.; Schaefer, A.; Dinnon, K. H.; Innis, B. L.; Garcia-Sastre, A.; Krammer, F.; Baric, R. S.; Palese, P.","https://www.biorxiv.org/content/10.1101/2020.07.30.229120v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.229120v1?rss=1,2020-07-31,2020-07-31,,False
140,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,"The current COVID-19 pandemic has led to a devastating impact across the world. SARS-CoV-2 (the virus causing COVID-19) is known to use receptor-binding domain (RBD) at viral surface spike (S) protein to interact with the angiotensin-converting enzyme 2 (ACE2) receptor expressed on many human cell types. The RBD-ACE2 interaction is a crucial step to mediate the host cell entry of SARS-CoV-2. Recent studies indicate that the ACE2 interaction with the SARS-CoV-2 S protein has higher affinity than its binding with the structurally identical S protein of SARS-CoV-1, the virus causing the 2002-2004 SARS outbreak. However, the biophysical mechanism behind such binding affinity difference is unclear. This study utilizes a combined single-molecule force spectroscopy and steered molecular dynamics (SMD) simulation approach to quantify the specific interactions between CoV-2 or CoV-1 RBD and ACE2. Depending on the loading rates, the unbinding forces between CoV-2 RBD and ACE2 range from 70 to 110 pN, and are 30-50% higher than those of CoV-1 RBD and ACE2 under similar loading rates. SMD results indicate that CoV-2 RBD interacts with the N-linked glycan on Asn90 of ACE2. This interaction is mostly absent in the CoV-1 RBD-ACE2 complex. During the SMD simulations, the extra RBD-N-glycan interaction contributes to a greater force and prolonged interaction lifetime. The observation is confirmed by our experimental force spectroscopy study. After the removal of N-linked glycans on ACE2, its mechanical binding strength with CoV-2 RBD decreases to a similar level of the CoV-1 RBD-ACE2 interaction. Together, the study uncovers the mechanism behind the difference in ACE2 binding between SARS-CoV-2 and SARS-CoV-1, and could aid in the development of new strategies to block SARS-CoV-2 entry.

STATEMENT OF SIGNIFICANCEThis study utilizes a combined single-molecule force spectroscopy and steered molecular dynamics simulation approach to quantify the specific interactions between SARS-CoV-2 or SARS-CoV-1 receptor-binding domain and human ACE2. The study reveals the mechanism behind the difference in ACE2 binding between SARS-CoV-2 and SARS-CoV-1, and could aid in the development of new strategies to block SARS-CoV-2 entry.","Cao, W.; Dong, C.; Kim, S.; Hou, D.; Tai, W.; Du, L.; Im, W.; Zhang, X. F.","https://www.biorxiv.org/content/10.1101/2020.07.31.230730v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230730v1?rss=1,2020-07-31,2020-07-31,,False
141,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,"To accelerate the drug and vaccine development against the severe acute respiratory syndrome virus 2 (SARS-CoV-2), a comparative analysis of SARS-CoV-2 proteome has been performed in two phases by considering manually curated 31389 whole genome sequences from 84 countries. Among the 9 mutations that occur at a high significance (T85I-NPS2, L37F-NSP6, P323L-NSP12, D614G-spike, Q57H-ORF3a, G251V-ORF3a, L84S-ORF8, R203K-nucleocapsid and G204R-nucleocapsid), R203K-nucleocapsid and G204R-nucleocapsid are co-occurring mutations and P323L-NSP12 and D614G-spike often appear simultaneously. Other notable variations that appear with a moderate to low significance are, M85-NSP1 deletion, D268-NSP2 deletion, 112 amino acids deletion in ORF8, a phenylalanine insertion amidst F34-F36 (NSP6) and several co-existing substitution/deletion (I559V & P585S in NSP2, P504L & Y541C in NSP13, G82 & H83 deletions in NSP1 and K141, S142 & F143 deletions in NSP2) mutations. P323L-NSP12, D614G-spike, L37F-NSP6, L84S-ORF8 and the sequences deficient of the high significant mutations has led to 4 major SARS-CoV-2 clades. The top 5 countries bearing all the high significant and majority of the moderate significant mutations are: USA, England, Wales, Australia and Scotland. Further, the majority of the significant mutations has evolved in the first phase and has already transmitted around the globe indicating the positive selection pressure. Among the 26 SARS-CoV-2 proteins, nucleocapsid protein, ORF3a, ORF8, RNA dependent RNA polymerase and spike exhibit a higher heterogeneity compared with the rest of the proteins. However, NSP9, NSP10, NSP8, the envelope protein and NSP4 are highly resistant to mutations and can be exploited for drug/vaccine development.","Patro, L. P. P.; Sathyaseelan, C.; Uttamrao, P. P.; Rathinavelan, T.","https://www.biorxiv.org/content/10.1101/2020.07.31.230987v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230987v1?rss=1,2020-07-31,2020-07-31,,False
142,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,"India has become the third worst-hit nation by the COVID-19 pandemic caused by the SARS-CoV-2 virus. Here, we investigated the molecular, phylogenomic, and evolutionary dynamics of SARS-CoV-2 in western India, the most affected region of the country. A total of 90 genomes were sequenced. Four nucleotide variants, namely C241T, C3037T, C14408T (Pro4715Leu), and A23403G (Asp614Gly), located at 5UTR, Orf1a, Orf1b, and Spike protein regions of the genome, respectively, were predominant and ubiquitous (90%). Phylogenetic analysis of the genomes revealed four distinct clusters, formed owing to different variants. The major cluster (cluster 4) is distinguished by mutations C313T, C5700A, G28881A are unique patterns and observed in 45% of samples. We thus report a newly emerging pattern of linked mutations. The predominance of these linked mutations suggests that they are likely a part of the viral fitness landscape. A novel and distinct pattern of mutations in the viral strains of each of the districts was observed. The Satara district viral strains showed mutations primarily at the 3' end of the genome, while Nashik district viral strains displayed mutations at the 5' end of the genome. Characterization of Pune strains showed that a novel variant has overtaken the other strains.

Examination of the frequency of three mutations i.e., C313T, C5700A, G28881A in symptomatic versus asymptomatic patients indicated an increased occurrence in symptomatic cases, which is more prominent in females. The age-wise specific pattern of mutation is observed. Mutations C18877T, G20326A, G24794T, G25563T, G26152T, and C26735T are found in more than 30% study samples in the age group of 10-25. Intriguingly, these mutations are not detected in the higher age range 61-80. These findings portray the prevalence of unique linked mutations in SARS-CoV-2 in western India and their prevalence in symptomatic patients.

ImportanceElucidation of the SARS-CoV-2 mutational landscape within a specific geographical location, and its relationship with age and symptoms, is essential to understand its local transmission dynamics and control. Here we present the first comprehensive study on genome and mutation pattern analysis of SARS-CoV-2 from the western part of India, the worst affected region by the pandemic. Our analysis revealed three unique linked mutations, which are prevalent in most of the sequences studied. These may serve as a molecular marker to track the spread of this viral variant to different places.","Paul, D.; Jani, K.; Kumar, J.; Chauhan, R.; Seshadri, V.; Lal, G.; Karyakarte, R.; Joshi, S.; Tambe, M.; Sen, S.; Karade, S.; Anand, K. B.; Shergill, S. P. S.; Gupta, R. M.; Bhat, M. K.; Sahu, A.; Shouche, Y. S.","https://www.biorxiv.org/content/10.1101/2020.07.30.228460v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228460v1?rss=1,2020-07-31,2020-07-31,,False
143,Study on -Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,"It has been known that SARS-CoV-2 which is considered similar to SARS-CoV invades human respiratory epithelial cells through interaction with the human angiotensin converting enzyme II (ACE2). In this work, SARS-CoV-2S-RBD and its cell receptor ACE2 were used to investigate the blocking effect and mechanism of {beta}-chitosan to the binding of them. Besides, inhibitory effect of {beta}-chitosan on inflammation induced by SARS-CoV-2S-RBD was also studied. Firstly, Native-PAGE results showed that {beta}-chitosan could bind with ACE2 or SARS-CoV-2S-RBD and the conjugate of {beta}-chitosan and ACE2 could no longer bind with SARS-CoV-2S-RBD. HPLC analyses suggested that was found the conjugate of {beta}-chitosan and SARS-CoV-2S-RBD displayed high binding affinity under the condition of high pressure (40 MPa) compared with that of ACE2 and SARS-CoV-2S-RBD. Furthermore, immunofluorescence detections on Vero E6 cells and hACE2 mice showed that {beta}-chitosan had a significant prevention and treatment effect on SARS-CoV-2S-RBD binding. Meanwhile, SARS-CoV-2S-RBD binding could activate the inflammation signaling pathways of cells and mice, however, {beta}-chitosan could dramatically suppress the inflammations activated by SARS-CoV-2S-RBD. Subsequently, Western blot analyses revealed that the expression levels of ACE2 in experimental groups treated with {beta}-chitosan significantly reduced. However, after the intervention of ADAM17 inhibitor (TAPI), the decreased ACE2 expressions affected by {beta}-chitosan up-regulated correspondingly. The results indicated that {beta}-chitosan has a similar antibody function, which can neutralize SARS-CoV-2S-RBD and effectively block the binding of SARS-CoV-2S-RBD with ACE2. ADAM17 activated by {beta}-chitosan can enhance the cleavage of ACE2 extracellular domain with a catalytic activity of Ang II degradation, and then the extracellular region was released into the extracellular environment. So, {beta}-chitosan could prevent the binding, internalization and degradation of ACE2 with SARS-CoV-2S-RBD and inhibit the activation of inflammatory signaling pathways at the same time. This work provides a valuable reference for the prevention and control of SARS-CoV-2 by {beta}-chitosan.","Alitongbieke, G.; Li, X.-M.; Wu, Q.-C.; Lin, Z.-C.; Huang, J.-F.; Xue, Y.; Liu, J.-N.; Lin, J.-M.; Pan, T.; Chen, Y.-X.; Su, Y.; Zhang, G.-G.; Leng, B.; Liu, S.-W.; Pan, Y.-T.","https://www.biorxiv.org/content/10.1101/2020.07.31.229781v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.229781v1?rss=1,2020-07-31,2020-07-31,,False
144,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,"The massive worldwide spread of the SARS-CoV-2 virus is fueling the COVID-19 pandemic. Since the first whole-genome sequence was published in January 2020, a growing database of tens of thousands of viral genomes has been constructed. This offers opportunities to study pathways of molecular change in the expanding viral population that can help identify molecular culprits of virulence and virus spread. Here we investigate the genomic accumulation of mutations at various time points of the early pandemic to identify changes in mutationally highly active genomic regions that are occurring worldwide. We used the Wuhan NC_045512.2 sequence as a reference and sampled 15,342 indexed sequences from GISAID, translating them into proteins and grouping them by month of deposition. The per-position amino acid frequencies and Shannon entropies of the coding sequences were calculated for each month, and a map of intrinsic disorder regions and binding sites was generated. The analysis revealed dominant variants, most of which were located in loop regions and on the surface of the proteins. Mutation entropy decreased between March and April of 2020 after steady increases at several sites, including the D614G mutation site of the spike (S) protein that was previously found associated with higher case fatality rates and at sites of the NSP 12 polymerase and the NSP13 helicase proteins. Notable expanding mutations include R203K and G204R of the nucleocapsid (N) protein inter-domain linker region and G251V of the viroporin encoded by ORF3a between March and April. The regions spanning these mutations exhibited significant intrinsic disorder, which was enhanced and decreased by the N-protein and viroporin 3a protein mutations, respectively. These results predict an ongoing mutational shift from the spike and replication complex to other regions, especially to encoded molecules known to represent major {beta}-interferon antagonists. The study provides valuable information for therapeutics and vaccine design, as well as insight into mutation tendencies that could facilitate preventive control.","Tomaszewski, T.; DeVries, R. S.; Dong, M.; Bhatia, G.; Norsworthy, M. D.; Zheng, X.; Caetano-Anolles, G.","https://www.biorxiv.org/content/10.1101/2020.07.31.231472v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.231472v1?rss=1,2020-07-31,2020-07-31,,False
145,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,"We show how a common microwave oven, a coat-hanger and a coffee cup can be used to decontaminate N-95 respirators in 30 seconds. Tulane virus in artificial saliva was reduced by >3 log and Geobacillus stearothermophilus spores were reduced by >6 log. Respirators maintained filtration and fitting after 10 cycles.","Ruzic, D. N.; Oh, C.; Puthussery, J. V.; Verma, V.; Nguyen, T. H.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163915v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163915v1?rss=1,2020-07-31,2020-07-31,,True
146,"Changes in the behavioural determinants of health during the coronavirus (COVID-19) pandemic: gender, socioeconomic and ethnic inequalities in 5 British cohort studies","Background: The coronavirus (COVID-19) pandemic and consequent physical distancing measures are expected to have far-reaching consequences on population health, particularly in already disadvantaged groups. These consequences include changes in health impacting behaviours (such as exercise, sleep, diet and alcohol use) which are arguably important drivers of health inequalities. We sought to add to the rapidly developing empirical evidence base investigating the impacts of the pandemic on such behavioural outcomes. Methods: Using data from five nationally representative British cohort studies (born 2001, 1990, 1970, 1958, and 1946), we investigated sleep, physical activity (exercise), diet, and alcohol intake (N=14,297). Using measures of each behaviour reported before and during lockdown, we investigated change in each behaviour, and whether such changes differed by age/cohort, gender, ethnicity, and socioeconomic position (SEP; childhood social class, education attainment, and adult reporting of financial difficulties). Binary or ordered logistic regression models were used, adjusting for prior measures of each health behaviour and accounting for study design and non-response weights. Meta-analyses were used to pool cohort-specific estimates and formally test for heterogeneity across cohorts. Results: Changes in these outcomes occurred in in both directions ie, shifts from the middle part of the distribution to both declines and increases in sleep, exercise, and alcohol use. For all outcomes, older cohorts were less likely to report changes in behaviours compared with younger cohorts. In the youngest cohort (born 2001), the following shifts were more evident: increases in exercise, fruit and vegetable intake, sleep, and less frequent alcohol consumption. After adjustment for prior behaviour levels, during lockdown females were less likely to sleep within the typical range (6-9 hours) yet exercised more frequently; lower SEP was associated with lower odds of sleeping within the typical range (6-9 hours), lower exercise participation, and lower consumption of fruit and vegetables; and ethnic minorities were less likely than White participants to sleep within the typical range (6-9 hours), exercise less frequently, yet reported less frequent alcohol consumption. Conclusions: Our findings highlight the multiple changes to behavioural outcomes that may have occurred due to COVID-19 lockdown, and the differential impacts across generation, gender, SEP and ethnicity. Such changes require further monitoring given their possible implications to population health and the widening of health inequalities.","Bann, D.; Villadsen, A.; Maddock, J.; Hughes, A.; Ploubidis, G.; Silverwood, R.; Patalay, P.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164244v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164244v1?rss=1,2020-07-31,2020-07-31,,True
147,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,"BACKGROUND: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. METHODS: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. RESULTS: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR 2.6; 95%CI 2.19-3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95%CI 1.64-2.28; p<0.0001), hypertension (OR 2.46; 95%CI 2.07-2.93; p<0.0001), and diabetes (OR 2.11; 95%CI 1.78-2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95%CI 2.11-6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity and hypertension. Interestingly, we found that metformin treatment was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95%CI 0.13-0.84; p=0.0210). CONCLUSION: Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin, raising the possibility that metformin may provide a protective approach in this high risk population.","Crouse, A.; Grimes, T.; Li, P.; Might, M.; Ovalle, F.; Shalev, A.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164020v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164020v1?rss=1,2020-07-31,2020-07-31,,True
148,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),"In the current pandemic of SARS-CoV-2, rapid identification of infected individuals is crucial for management and control of the outbreak. However, transport of samples, sample processing and RT-qPCR analysis in laboratories are time-consuming. Here we present a nucleic acid-based test Format - pulse controlled amplification - that allows detection of SARS-CoV-2 directly from up to eight swab samples simultaneously without the need for RNA extraction within 20 min in a point-of-care setting.","Zwirglmaier, K.; Weyh, M.; Krueger, C.; Ehmann, R.; Mueller, K.; Woelfel, R.; Stoecker, K.","https://www.medrxiv.org/content/10.1101/2020.07.29.20154104v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20154104v1?rss=1,2020-07-31,2020-07-31,,True
149,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,"We used the COVID-19 dataset obtained from the Our World in Data website and investigated the associations between COVID-19 CFR and nine country-level indices of 209 countries/territories using the Matern correlation regression model. Spatial dependence among the data was controlled using the latitude and longitude of the centroid of the countries/territories. Stratified analyses were conducted by economic level and COVID-19 testing policy. The average of country/territory-specific COVID-19 CFR is about 2-3% worldwide, which is higher than previously reported at 0.7-1.3%. Statistically significant associations were observed between COVID-19 CFR and population size and proportion of female smokers. The open testing policies are associated with decreased CFR. Strictness of anti-COVID-19 measures was not statistically significantly associated with CFR overall, but the higher stringency index was associated with higher CFR in higher income countries with active testing policies. The statistically significant association between population size and COVID-19 CRF suggests the healthcare strain and lower treatment efficiency in countries with large populations. The observed association between smoking in females and COVID-19 CFR might be due to that the proportion of female smokers reflected broadly income level of a country. When testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in excess deaths in underprivileged populations.","Cao, Y.; Hiyoshi, A.; Montgomery, S.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165811v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165811v1?rss=1,2020-07-31,2020-07-31,,True
150,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,"Widespread testing for the presence novel coronavirus SARS-CoV-2 in patients remains vital for controlling the COVID-19 pandemic prior to the advent of an effective treatment. The early testing shortfall in some parts of the US can be traced to an initial shortage of supplies, expertise and/or instrumentation necessary to detect the virus by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Here we show that academic biochemistry and molecular biology laboratories equipped with appropriate expertise and infrastructure can produce the RT-qPCR assay and backfill pipeline shortages. The Georgia Tech COVID-19 Test Kit Support Group synthesized multiplexed primers and probes and formulated a master mix composed of enzymes and proteins produced in-house. We compare the performance of our in-house kit to a commercial product used for diagnostic testing and describe implementation of environmental testing to monitor surfaces across various campus laboratories for the presence of SARS-CoV-2.","Mascuch, S. J.; Fakhretaha-Aval, S.; Bowman, J. C.; Ma, M. T. H.; Thomas, G.; Bommarius, B.; Ito, C.; Zhao, L.; Newnam, G. P.; Matange, K. R.; Thapa, H. R.; Barlow, B.; Donegan, R. K.; Nguyen, N. A.; Saccuzzo, E. G.; Obianyor, C. T.; Karunakaran, S. C.; Pollet, P.; Rothschild-Mancinelli, B.; Mestre-Fos, S.; Guth-Metzler, R.; Bryksin, A. V.; Petrov, A. S.; Hazell, M.; Ibberson, C. B.; Penev, P. I.; Mannino, R. G.; Lam, W. A.; Garcia, A. J.; Kubanek, J. M.; Agarwal, V.; Hud, N. V.; Glass, J. B.; Williams, L. D.; Lieberman, R. L.","https://www.medrxiv.org/content/10.1101/2020.07.29.20163949v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20163949v1?rss=1,2020-07-31,2020-07-31,,True
151,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support","The social distancing, confinement and quarantine adopted since March 2020 to confront the COVID-19 pandemic have affected multiple vital areas, and specially work, business and productive activities. Prior research has highlighted the relation between perceptions of risk in employment and its concomitant financial risk with a myriad of consequences for people's well-being and health. In order to analyze the potential negative consequences of temporary layoffs, downsizing or closure of companies and businesses, and the consequent insecurity about the continuity of employment, the aim of this study is twofold. Firstly, to analyze the relations between the perceptions of job insecurity and financial threat and overall mental health during the first month of the COVID-19 pandemic in a sample of the Chilean adult population. And secondly, to identify the potential buffer effect of perceived social support on this relation. To analyze this, we carried out a cross-sectional study on a non-probabilistic sample aimed at a general Chilean adult population. The results show that both perceptions of job insecurity and financial threat are associated with a decline in perceived mental health. Additionally, results indicate a moderate buffer effect of perceived social support relative to the size of the social network. Thus, in relation to job insecurity and financial threat, the network size mitigates the association of both with the decline in perceived mental health. The theoretical and applied scope of these findings are analyzed, and their challenges and limitations are discussed.","Alcover, C.-M.; Salgado, S.; Nazar, G.; Ramirez-Vielma, R.; Gonzalez-Suhr, C.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165910v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165910v1?rss=1,2020-07-31,2020-07-31,,True
152,High effectiveness of multimodal infection control interventions in preventing SARS-CoV-2 infections in healthcare professionals: a prospective longitudinal seroconversion study,"Objective: To assess the effectiveness of multimodal infection control interventions in the prevention of SARS-CoV-2 infections in healthcare professionals. Design: Sequential follow-up study. Setting: Largest tertiary care centre in northern Germany. Participants: 1253 employees of the University Medical Center Hamburg-Eppendorf were sequentially assessed for the presence of SARS-CoV-2 IgG antibodies at the beginning of the covid-19 epidemic (20 March - 9 April), one month (20 April - 8 May), and another two months later (22 June - 24 July). Of those, 1026 were healthcare workers (HCWs) of whom 292 were directly involved in the care of covid-19 patients. During the study period, infection control interventions were deployed, those included i) strict barrier nursing of all known covid-19 patients including FFP2 (N95) masks, goggles, gloves, hoods and protective gowns, ii) visitor restrictions with access control at all hospital entries, iii) mandatory wearing of disposable face masks in all clinical settings, and iv) universal RT-PCR admission screening of patients. Main Outcome Measures: SARS-CoV-2 IgG seroconversion rate. Results: At the initial screening, ten participants displayed significant IgG antibody ratios. Another ten individuals showed seroconversion at the second time point one month later, only two further participants seroconverted during the subsequent two months. The overall SARS-CoV-2 seroprevalence in the study cohort at the last follow-up was 1.8%, the seroconversion rate dropped from 0.81% to 0.08% per month despite a longer observation period. Amongst HCWs seropositivity was increased in those directly involved in the care of patients with SARS-CoV-2 infections (3.8%, n=11) compared to other HCWs (1.4%, n=10, P=0.025). However, after the adoption of all multimodal infection control interventions seroconversions were observed in only two more HCWs, neither of whom were involved in inpatient care. Conclusion: Multimodal infection control and prevention interventions are highly effective in mitigating SARS-CoV-2 infections of healthcare professionals.","Brehm, T. T.; Schwinge, D.; Lampalzer, S.; Schlicker, V.; Kuechen, J.; Thompson, M.; Ullrich, F.; Huber, S.; Schmiedel, S.; Addo, M. M.; Luetgehetmann, M.; Knobloch, J. K.; Schulze zur Wiesch, J.; Lohse, A. W.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165936v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165936v1?rss=1,2020-07-31,2020-07-31,,True
153,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan","Background: Coronavirus Disease 2019 (COVID19) currently poses a global public health threat. Although no exception, Tokyo, Japan was affected at first by only a small epidemic. Medical collapse nevertheless nearly happened because no predictive method existed for counting patients. A standard SIR epidemiological model and its derivatives predict susceptible, infectious, and removed (recovered/deaths) cases but ignore isolation of confirmed cases. Predicting COVID19 trends with hospitalized and infectious people in field separately is important to prepare beds and develop quarantine strategies. Methods: Time-series COVID19 data from February 28 to May 23, 2020 in Tokyo were adopted for this study. A novel epidemiological model based on delay differential equation was proposed. The model can evaluate patients in hospitals and infectious cases in the field. Various data such as daily new cases, cumulative infections, patients in hospital, and PCR test positivity ratios were used to examine the model. This approach derived an alternative formulation equivalent to the standard SIR model. Its results were compared quantitatively with those of the present isolation model. Results: The basic reproductive number, inferred as 2.30, is a dimensionless parameter composed of modeling parameters. Effects of intervention to mitigate the epidemic spread were assessed a posteriori. An exit policy of how and when to release a statement of emergency was also assessed using the model. Furthermore, results suggest that the rapid isolation of infectious cases has a large potential to effectively mitigate the spread of infection and restores social and economic activities safely. Conclusions: A novel mathematical model was proposed and examined using COVID19 data for Tokyo. Results show that shortening the period from infection to hospitalization is effective against outbreak without rigorous public health intervention and control. Faster and precise case cluster detection and wider and quicker introduction of testing measures are strongly recommended.","Utamura, M.; Koizumi, M.; Kirikami, S.","https://www.medrxiv.org/content/10.1101/2020.07.31.20165829v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.31.20165829v1?rss=1,2020-07-31,2020-07-31,,True
154,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,"Angiotensin-converting enzyme 2 (ACE2) is the main entry point in the airways for SARS-CoV-2. ACE2 binding to SARS-CoV-2 protein Spike triggers viral fusion with the cell membrane, resulting in viral RNA genome delivery into the host. Despite ACE2s critical role in SARS-CoV-2 infection, an understanding of ACE2 expression, including in response to viral infection, remains unclear.

Until now ACE2 was thought to encode five transcripts and one 805 amino acid protein. Here we identify a novel short isoform of ACE2. Short ACE2 is expressed in the airway epithelium, the main site of SARS-CoV-2 infection; it is substantially upregulated in response to interferon stimulation and RV infection, but not in response to SARS-CoV-2 infection, and it shows differential regulation in asthma patients. This short isoform lacks SARS-CoV-2 spike glycoprotein high-affinity binding sites and altogether, our data are consistent with a model where short ACE2 may influence host susceptibility to SARS-CoV-2 infection.","Blume, C.; Jackson, C. L.; Spalluto, C. M.; Legebeke, J.; Nazlamova, L. A.; Conforti, F.; Perotin-Collard, J.-M.; Frank, M.; Crispin, M.; Coles, J.; Thompson, J.; Ridley, R. A.; Dean, L. S.; Loxham, M.; Azim, A.; Tariq, K.; Johnston, D. A.; Skipp, P. J.; Djukanovic, R.; Baralle, D.; McCormick, C. J.; Davies, D. E.; Lucas, J. S.; Wheway, G.; Mennella, V.","https://www.biorxiv.org/content/10.1101/2020.07.31.230870v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.31.230870v1?rss=1,2020-07-31,2020-07-31,,False
155,EUAdb: a resource for COVID-19 test development,"Due to the sheer number of COVID-19 (coronavirus disease 2019) cases, the prevalence of asymptomatic cases and the fact that undocumented cases appear to be significant for transmission of the causal virus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), there is an urgent need for increased SARS-CoV-2 testing capability that is both efficient and effective1. In response to the growing threat of the COVID-19 pandemic in February, 2020, the FDA (US Food and Drug Administration) began issuing Emergency Use Authorizations (EUAs) to laboratories and commercial manufacturers for the development and implementation of diagnostic tests1. So far, the gold standard assay for SARS-CoV-2 detection is the RT-qPCR (real-time quantitative polymerase chain reaction) test2. However, the authorized RT-qPCR test protocols vary widely, not only in the reagents, controls, and instruments they use, but also in the SARS-CoV-2 genes they target, what results constitute a positive SARS-CoV-2 infection, and their limit of detection (LoD). The FDA has provided a web site that lists most of the tests that have been issued EUAs, along with links to the authorization letters and summary documents describing these tests1. However, it is very challenging to use this site to compare or replicate these tests for a variety of reasons. First, at least 12 of 18 tests that were issued EUAs prior to March 31, 2020, are not listed there. Second, the data are not standardized and are only provided as longhand prose in the summary documents. Third, some details (e.g. primer sequences) are absent from several of the test descriptions. Fourth, for tests provided by commercial manufacturers, summary documents are completely missing. To address at least the first three issues, we have developed a database, EUAdb (EUAdb.org), that holds standardized information about EUA-issued tests and is focused on RT-qPCR diagnostic tests, or ""high complexity molecular-based laboratory developed tests""1. By providing a standardized ontology and curated data in a relational architecture, we seek to facilitate comparability and reproducibility, with the ultimate goal of consistent, universal and high-quality testing nationwide. Here, we document the basics of the EUAdb data architecture and simple data queries. The source files can be provided to anyone who wants to modify the database for his/her own research purposes. We ask that the original source of the files be made clear and that the database not be used in its original or modified forms for commercial purposes.","Woronik, A.; Shaffer, H. W.; Kiontke, K.; Laurent, J. M.; Zambrano, R.; Boeke, J. D.; Fitch, D. H. A.","https://www.biorxiv.org/content/10.1101/2020.07.30.228890v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228890v1?rss=1,2020-07-30,2020-07-30,,False
156,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,"The spike (S) glycoprotein in the envelope of SARS-CoV-2 is densely glycosylated but the functions of its glycosylation are unknown. Here we demonstrate that S is recognized in a glycan-dependent manner by multiple innate immune receptors including the mannose receptor MR/CD206, DC-SIGN/CD209, L-SIGN/CD209L, and MGL/CLEC10A/CD301. Single-cell RNA sequencing analyses indicate that such receptors are highly expressed in innate immune cells in tissues susceptible to SARS-CoV-2 infection. Binding of the above receptors to S is characterized by affinities in the picomolar range and consistent with S glycosylation analysis demonstrating a variety of N- and O-glycans as receptor ligands. These results indicate multiple routes for SARS-CoV-2 to interact with human cells and suggest alternative strategies for therapeutic intervention.","Gao, C.; Zeng, J.; Jia, N.; Stavenhagen, K.; Matsumoto, Y.; Zhang, H.; Li, J.; Hume, A. J.; Muehlberger, E.; van Die, I.; Kwan, J.; Tantisira, K.; Emili, A.; Cummings, R. D.","https://www.biorxiv.org/content/10.1101/2020.07.29.227462v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.227462v1?rss=1,2020-07-30,2020-07-30,,False
157,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,"The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing antibodies to the new species in humans is unclear. The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced from plasma collected in Europe and the US, highly potent neutralization of a seasonal coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen.

SUMMARYIVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.","Schwaiger, J.; Karbiener, M.; Aberham, C.; Farcet, M. R.; Kreil, T. R.","https://www.biorxiv.org/content/10.1101/2020.07.30.228213v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228213v1?rss=1,2020-07-30,2020-07-30,,False
158,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,"Developing an efficacious vaccine to SARS-CoV-2 infection is critical to stem COVID-19 fatalities and providing the global community with immune protection. We have used a bioinformatic approach to aid in the design of an epitope peptide-based vaccine against the spike protein of the virus. Five antigenic B cell epitopes with viable antigenicity and a total of 27 discontinuous B cell epitopes were mapped out structurally in the spike protein for antibody recognition. We identified eight CD8+ T cell 9-mers along with 12 CD4+ T cell 14-15-mer as promising candidate epitopes putatively restricted by a large number of MHC-I and II alleles respectively. We used this information to construct an in silico chimeric peptide vaccine whose translational rate was highly expressed when cloned in pET28a (+) vector. The vaccine construct was predicted to elicit high antigenicity and cell-mediated immunity when given as a homologous prime-boost, with triggering of toll-like receptor 5 by the adjuvant linker. The vaccine was characterized by an increase in IgM and IgG and an array of Th1 and Th2 cytokines. Upon in silico challenge with SARS-CoV-2, there was a decrease in antigen levels using our immune simulations. We therefore propose that potential vaccine designs consider this approach.","Chukwudozie, O. S.; Gray, C. M.; Fagbayi, T. A.; Chukwuanukwu, R. C.; Oyebanji, V. O.; Bankole, T. T.; Adewole, R. A.; Eze, D. M.","https://www.biorxiv.org/content/10.1101/2020.07.30.228221v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228221v1?rss=1,2020-07-30,2020-07-30,,False
159,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,"The densely glycosylated spike (S) proteins that are highly exposed on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) facilitate viral attachment, entry, and membrane fusion. We have previously reported all the 22 N-glycosites and site-specific N-glycans in the S protein protomer. Herein, we report the comprehensive and precise site-specific O-glycosylation landscapes of SARS-CoV-2 S proteins, which were characterized using high-resolution mass spectrometry. Following digestion using trypsin and trypsin/Glu-C, and de-N-glycosylation using PNGase F, we determined the mucin-type (GalNAc-type) O-glycosylation pattern of S proteins, including unambiguous O-glycosites and the 6 most common O-glycans occupying them, via Byonic identification and manual validation. Finally, 43 O-glycosites were identified in the insect cell-expressed S protein. Most glycosites were modified by non-sialylated O-glycans such as HexNAc(1) and HexNAc(1)Hex(1). In contrast, 30 O-glycosites were identified in the human cell-expressed S protein S1 subunit. Most glycosites were modified by sialylated O-glycans such as HexNAc(1)Hex(1)NeuAc(1) and HexNAc(1)Hex(1)NeuAc(2). Our results are the first to reveal that the SARS-CoV-2 S protein is a mucin-type glycoprotein; clustered O-glycans often occur in the N- and the C-termini of the S protein, and the O-glycosite and O-glycan compositions vary with the host cell type. These site-specific O-glycosylation landscapes of the SARS-CoV-2 S protein are expected to provide novel insights into the viral binding mechanism and present a strategy for the development of vaccines and targeted drugs.","Zhang, Y.; Zhao, W.; Mao, Y.; Chen, Y.; Hu, L.; Zhu, J.; Gong, M.; Cheng, J.; Yang, H.","https://www.biorxiv.org/content/10.1101/2020.07.29.227785v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.227785v1?rss=1,2020-07-30,2020-07-30,,False
160,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,"Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g. prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate. In vitro characterization demonstrated that the introduction of stabilizing substitutions (i.e., furin cleavage site mutations and two consecutive prolines in the hinge region of S1) increased the ratio of neutralizing versus non-neutralizing antibody binding, suggestive for a prefusion conformation of the S protein. Furthermore, the wild type signal peptide was best suited for the correct cleavage needed for a natively-folded protein. These observations translated into superior immunogenicity in mice where the Ad26 vector encoding for a membrane-bound stabilized S protein with a wild type signal peptide elicited potent neutralizing humoral immunity and cellular immunity that was polarized towards Th1 IFN-{gamma}. This optimized Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04436276).","Bos, R.; Rutten, L.; van der Lubbe, J. E. M.; Bakkers, M. J. G.; Hardenberg, G.; Wegmann, F.; Zuijdgeest, D.; de Wilde, A. H.; Koornneef, A.; Verwilligen, A.; van Manen, D.; Kwaks, T.; Vogels, R.; Dalebout, T. J.; Myeni, S. K.; Kikkert, M.; Snijder, E. J.; Li, Z.; Barouch, D. H.; Jort, V.; Langedijk, J. P.; Zahn, R. C.; Custers, J.; Schuitemaker, H.","https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1?rss=1,2020-07-30,2020-07-30,,False
161,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,"To control the spread of the newly developed corona viral infection diseases (COVID-19), peoples appropriate precautionary behaviors should be promoted. We conducted a series of online questionnaire survey, to gather a total of 8,000 citizens responses on March 27-28, 2020 in Japan and April 17-21 in the UK and Spain. Compared to Japan, the knowledge and anxiety level and the frequency of precautionary behaviors were higher in the UK and Spain. Participants with infected acquaintances were more concerned about COVID-19. However, participants in the UK rarely wore a medical mask. Participants in the UK and Spain were eager to get information about COVID-19 compared to those in Japan. The participants in Spain tended not to trust official information and to believe specialists' comments instead. The urgency of the spread of COVID-19, cultural backgrounds, and recent political situations appear to contribute to the differences among countries revealed herein.","Shiina, A.; Niitsu, T.; Kobori, O.; Idemoto, K.; Hashimoto, T.; Sasaki, T.; Igarashi, Y.; Shimizu, E.; Nakazato, M.; Hashimoto, K.; Iyo, M.","https://www.biorxiv.org/content/10.1101/2020.07.30.228643v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228643v1?rss=1,2020-07-30,2020-07-30,,False
162,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses","In response to the health crisis presented by the COVID-19 pandemic, rapid development of safe and effective vaccines that elicit durable immune responses is imperative. Recent reports have raised the concern that antibodies in COVID-19 convalescent patients may not be long lasting and thus even these individuals may require vaccination. Vaccine candidates currently in clinical testing have focused on the SARS-CoV-2 wild type spike (S) protein (S-WT) as the major antigen of choice and while pre-clinical and early clinical testing have shown that S elicits an antibody response, we believe the optimal vaccine candidate should be capable of inducing robust, durable T-cell responses as well as humoral responses. We report here on a next generation bivalent human adenovirus serotype 5 (hAd5) vaccine capable of inducing immunity in patients with pre-existing adenovirus immunity, comprising both an S sequence optimized for cell surface expression (S-Fusion) and a conserved nucleocapsid (N) antigen designed to be transported to the endosomal subcellular compartment, with the potential to generate durable immune protection. Our studies suggest that this bivalent vaccine is optimized for immunogenicity as evidenced by the following findings: (i) The optimized S-Fusion displayed improved S receptor binding domain (RBD) cell surface expression compared to S-WT where little surface expression was detected; (ii) the expressed RBD from S-Fusion retained conformational integrity and recognition by ACE2-Fc; (iii) the viral N protein modified with an enhanced T-cell stimulation domain (ETSD) localized to endosomal/lysosomal subcellular compartments for MHC I/II presentation; and (iv) these optimizations to S and N (S-Fusion and N-ETSD) generated enhanced de novo antigen-specific B cell and CD4+ and CD8+ T-cell responses in antigen-naive pre-clinical models. Both the T-cell and antibody immune responses to S and N demonstrated a T-helper 1 (Th1) bias. The antibody responses were neutralizing as demonstrated by two independent SARS-CoV-2 neutralization assays. Based on these findings, we are advancing this next generation bivalent hAd5 S-Fusion + N-ETSD vaccine as our lead clinical candidate to test for its ability to provide robust, durable cell-mediated and humoral immunity against SARS-CoV-2 infection. Further studies are ongoing to explore utilizing this vaccine construct in oral, intranasal, and sublingual formulations to induce mucosal immunity in addition to cell-mediated and humoral immunity. The ultimate goal of an ideal COVID-19 vaccine is to generate long-term T and B cell memory.","Rice, A.; Verma, M.; Shin, A.; Zakin, L.; Sieling, P.; Tanaka, S.; Adisetiyo, H.; Taft, J.; Patel, R. S.; Buta, S.; Martin-Fernandez, M.; Morimoto, B.; Gabitzsch, E.; Safrit, J. T.; Balint, J.; Dinkins, K.; Spilman, P.; Bogunovic, D.; Rabizadeh, S.; Niazi, K.; Soon-Shiong, P.","https://www.biorxiv.org/content/10.1101/2020.07.29.227595v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.227595v1?rss=1,2020-07-30,2020-07-30,,False
163,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,"There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. Here, we extensively characterized antibodies of the SARS-CoV structural proteins for their cross-reactivity, experimental utility, and neutralization of SARS-CoV-2. We assessed a total of 10 antibodies (six for Spike, two for Membrane, and one for Nucleocapsid and Envelope viral protein). We evaluated the utility of these antibodies against SARS-CoV-2 in a variety of assays, including immunofluorescence, ELISA, biolayer interferometry, western blots, and micro-neutralization. Remarkably, a high proportion of the antibodies we tested showed cross-reactivity, indicating a potentially generalizable theme of cross-reactivity between SARS-CoV and SARS-CoV-2 antibodies. These antibodies should help facilitate further research into SARS-CoV-2 basic biology. Moreover, our study provides critical information about the propensity of SARS-CoV antibodies to cross-react with SARS-CoV-2 and highlights its relevance in defining the clinical significance of such antibodies to improve testing and guide the development of novel vaccines and therapeutics.","Bates, T. A.; Weinstein, J. B.; Farley, S. E.; Leier, H. C.; Messer, W. B.; Tafesse, F. G.","https://www.biorxiv.org/content/10.1101/2020.07.30.229377v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.229377v1?rss=1,2020-07-30,2020-07-30,,False
164,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,"Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released by damaged solid organs. Whether the appearance of cell-free MT-DNA is linked to poor COVID-19 outcomes remains undetermined. Here, we quantified circulating MT-DNA in prospectively collected, cell-free plasma samples from 97 subjects with COVID-19 at the time of hospital presentation. Circulating MT-DNA were sharply elevated in patients who eventually died, required ICU admission or intubation. Multivariate regression analysis revealed that high circulating MT-DNA levels is an independent risk factor for all of these outcomes after adjusting for age, sex and comorbidities. Additionally, we found that circulating MT-DNA has a similar or superior area-under-the curve when compared to clinically established measures of systemic inflammation, as well as emerging markers currently of interest as investigational targets for COVID-19 therapy. These results show that high circulating MT-DNA levels is a potential indicator for poor COVID-19 outcomes.","Scozzi, D.; Cano, M.; MA, L.; Zhou, D.; Zhu, J. H.; O'Halloran, J. A.; Goss, C.; Rauseo, A.; Liu, Z.; Peritore, V.; Rocco, M.; Ricci, A.; Amodeo, R.; Aimati, L.; Ibrahim, M.; Hachem, R.; Kreisel, D.; Mudd, P. A.; Kulkarni, H. S.; Gelman, A. E.","https://www.biorxiv.org/content/10.1101/2020.07.30.227553v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.227553v1?rss=1,2020-07-30,2020-07-30,,False
165,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,"The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is the core machinery responsible for the viral genome replication and transcription and also a major antiviral target. Here we report the cryo-electron microscopy structure of a post-translocated SARS-CoV-2 RdRp core complex, comprising one nsp12, one separate nsp8(I) monomer, one nsp7-nsp8(II) subcomplex and a replicating RNA substrate. Compared with the recently reported SARS-CoV-2 RdRp complexes, the nsp8(I)/nsp7 interface in this RdRp complex shifts away from the nsp12 polymerase. Further functional characterizations suggest that specific interactions between the nsp8(I) and nsp7, together with the rearrangement of nsp8(I)/nsp7 interface, ensure the efficient and processive RNA synthesis by the RdRp complex. Our findings provide a mechanistic insight into how nsp7 and nsp8 cofactors regulate the polymerase activity of nsp12 and suggest a potential new intervention interface, in addition to the canonical polymerase active center, in RdRp for antiviral design.

Author summarySince it was first discovered and reported in late 2019, the coronavirus disease 2019 (COVID-19) pandemic caused by highly contagious SARS-CoV-2 virus is wreaking havoc around the world. Currently, no highly effective and specific antiviral drug is available for clinical treatment. Therefore, the threat of COVID-19 transmission necessitates the discovery of more effective antiviral strategies. Viral RNA-dependent RNA polymerase (RdRp) is an important antiviral drug target. Here, our cryo-EM structure of a SARS-CoV-2 RdRp/RNA replicating complex reveals a previously uncharacterized overall shift of the cofactor nsp8(I)/nsp7 interface, leading to its rearrangement. Through in vitro functional test, we found that the specific interactions on the interface are important to the efficient RNA polymerase activity of SARS-CoV-2 RdRp. These observations let us to suggest this interface as a potential new drug intervention site, outside of the canonical polymerase active center, in RdRp for antiviral design. Our findings would provide new insights into regulatory mechanism of this novel SARS-CoV-2 RdRp, contribute to the design of antiviral drugs against SARS-CoV-2, and benefit the global public health.","Shi, W.; Chen, M.; Yang, Y.; Zhou, W.; Chen, S.; Hu, Y.; Liu, B.","https://www.biorxiv.org/content/10.1101/2020.07.30.229187v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.229187v1?rss=1,2020-07-30,2020-07-30,,False
166,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,"The ongoing COVID-19 pandemic exemplifies the general need to better understand viral infections. The positive single strand RNA genome of its causative agent, the SARS coronavirus 2 (SARS-CoV-2) encodes all viral enzymes. In this work, we focus on one particular methyltransferase (MTase), nsp16, which in complex with nsp10 is capable of methylating the first nucleotide of a capped RNA strand at the 2'-O position. This process is part of a viral capping system and is crucial for viral evasion of the innate immune reaction. In light of recently discovered non-canonical RNA caps, we tested various dinucleoside polyphosphate-capped RNAs as substrates for nsp10-nsp16 MTase. We developed an LC-MS-based method and discovered five types of capped RNA (m7Gp3A(G)-, Gp3A(G)- and Gp4A-RNA) that are substrates of the nsp10-nsp16 MTase. Our technique is an alternative to the classical isotope labelling approach for measurement of 2'-O-MTase activity. Further, we determined the IC50 value of sinefungin (286 {+/-} 66 nM) to illustrate the value of our approach for inhibitor screening. In the future, this approach can be used for screening inhibitors of any type of 2'-O-MTase.","Benoni, R.; Krafcikova, P.; Baranowski, M.; Kowalska, J.; Boura, E.; Cahova, H.","https://www.biorxiv.org/content/10.1101/2020.07.30.228478v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.30.228478v1?rss=1,2020-07-30,2020-07-30,,False
167,Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19,"COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.","Chen, X.; Pan, Z.; Yue, S.; Yu, F.; Zhang, J.; Yang, Y.; Li, R.; Liu, B.; Yang, X.; Gao, L.; Li, Z.; Lin, Y.; Huang, Q.; Xu, L.; Tang, J.; Hu, L.; Zhao, J.; Liu, P.; Zhang, G.; Chen, Y.; Deng, K.; Ye, L.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164285v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164285v1?rss=1,2020-07-30,2020-07-30,,True
168,Reduced susceptibility to SARS-CoV-2 in metropolitan regions,"The coronavirus pandemic is wreaking public health, social, and economic havoc across the globe, and to date a variety of strategies have been implemented to attempt to control the spread of disease [1, 2]. A critical unknown for policy planning is the number of people who have been infected and are no longer susceptible [3]. Tests for active SARS-CoV-2 infection or antibody presence can provide an indication, but both are prone to selection bias, under-representative population sampling and insufficient reliability [4, 5]. Here, we present an alternative to determine residual susceptibilities based on the analysis of observed population-wide disease dynamics data. For four highly-affected countries, we directly compared the dynamics in the largest metropolitan regions with the rest of the countries. We show that substantial susceptibility reductions are measurable in the metropolitan regions, which all continued in a phase of exponential growth of case numbers for a relatively longer time before public health interventions were introduced. Compared to these interventions, the reduction in metropolitan region susceptibility had a substantial role in the post-growth decline in infection rates. Reduced population susceptibility has far reaching consequences on future policy responses and disease forecasts including vaccine trial planning and, in the case of a second epidemic wave, higher population-normalised mortality rates for non-metropolitan regions.","Barrett, T. J.; Patterson, K. C.; James, T. M.; Kruger, P.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163154v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163154v1?rss=1,2020-07-30,2020-07-30,,True
169,Estimating missing deaths in Delhi's COVID-19 data,"A sero-prevalence survey in Delhi measured an infection rate of 23.48% and an implied infection fatality rate (IFR) of 0.06%. Modeling using age group based IFRs from France, Spain and Lombardia project an average IFR that is significantly higher than currently estimated. We show that at least 1500-2500 COVID-19 deaths in the 60+ age group are missing.","Chakravarty, S.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164392v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164392v1?rss=1,2020-07-30,2020-07-30,,True
170,The Role of Weather Conditions in COVID-19 Transmission: A Study of a Global Panel of 1236 Regions,"Weather condition may impact COVID-19 transmission. The effects of temperature and humidity on COVID-19 transmission are not clear due to the difficulties in separating impacts of social distancing. We collected COVID-19 data and social-economic features of 1236 regions in the world (1112 regions at the provincial level and 124 countries with small land area). Moreover, a large-scale satellite data was combined with these data with a regression analysis model to explore effects of temperature and relative humidity on COVID-19 spreading, as well as the possible transmission risk due to temperature change driven by seasonal cycles. The result showed every degree Celsius increase in average temperature appears to cause a 2.88% decrease in the fraction of new daily cases 6 days later and a 0.62 percent point decrease in the reproductive number (R0). Every percentage point increase in relative humidity is found to lead to a 0.19% decrease in the fraction of new daily cases and a 0.02 percent point decrease in R0 6 days later. Further, the effect of temperature and humidity is near to linear based on our samples. Government intervention (e.g. lockdown policies) and lower population movement contributed to the decrease the new daily case ratio. The conclusions withstand several robustness checks, such as observation scales and maximum/minimum temperature. The conclusion indicates air temperature and relative humidity are shown to be negatively correlated with COVID-19 transmission throughout the world. Given the diversity in both climate and social-economic conditions, the risk of transmission varies globally and possibly amplifies existing global health inequalities. Weather conditions are not the decisive factor in COVID-19 transmission, in that government intervention as well as public awareness, could contribute to the mitigation of the spreading of the virus.","Zhang, C.; Liao, H.; Strol, E.; Li, H.; Li, R.; Jensen, S. S.; Zhang, Y.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164152v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164152v1?rss=1,2020-07-30,2020-07-30,,True
171,"Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France","Abstract Introduction Several studies have reported an unexpectedly low prevalence of current smoking among hospitalized patients with Covid-19. However, these studies mostly compared observed to expected rates of smoking without direct comparison with individual controls. Objective To examine the association of nicotine-replacement therapy, as a surrogate of smoking, with hospitalization and all-cause mortality during the first wave of SARS-CoV-2 epidemic in France. Methods We conducted a nationwide matched exposed/unexposed cohort study using information from the French national health data system which covers the entire French population. We conducted two separate analyses, the first in individuals exposed to nicotine-replacement therapy without major smoking-related diseases (cancer, cardiovascular and/or respiratory diseases) and the second in those presenting these conditions. We included all individuals, aged between 18 and 75 years, who had been reimbursed at least one nicotine-replacement therapy between November 15, 2019, and February 15, 2020. For each exposed individual, we randomly selected, from the entire Metropolitan French population, up to two non-exposed individuals (1:2) matched for the following variables: age (same year of birth), sex, department of residence (n=96 in Metropolitan France), and complementary universal health insurance (CMU-C). The three end points were a hospitalization with Covid-19, a death or an intubation in hospitalized patients with Covid-19, and all-cause mortality. We compared outcomes in individuals who were exposed to nicotine-replacement therapy with those in individuals who were not, using a multivariable Cox model with inverse probability weighting according to the propensity score. Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. Individuals were aged on average 45.6 years (standard deviation: 12.7) and 48.8% were male. From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals (hazard ratio, 0.50; 95% CI, 0.41 to 0.61). Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19 (13 vs. 73 patients, hazard ratio, 0.31; 95% CI, 0.17 to 0.57) but with an increased risk of all-cause mortality (251 vs. 231 deaths, hazard ratio, 1.49; 95% CI, 1.24 to 1.80). In the second analysis, 128,768 individuals with major smoking-related diseases exposed to nicotine-replacement therapy were matched with 243,793 unexposed individuals. Individuals were aged on average 55.3 years (standard deviation: 11.4) and 53.3% were male. In the main multivariable analysis, nicotine-replacement therapy exposure was neither associated with risk of hospitalization with Covid-19 (240 patients in the nicotine-replacement therapy group and 398 patients in the unexposed group, hazard ratio, 1.13; 95% CI, 0.94 to 1.38) nor with risk of death or an intubation in hospitalized individuals with Covid-19 (48 vs. 61 patients, hazard ratio, 1.00; 95% CI, 0.65 to 1.54). All-cause mortality was higher in the nicotine-replacement therapy group (1040 vs. 366 deaths, hazard ratio, 3.83; 95% CI, 3.41 to 4.31). Conclusions This large-scale observational study suggests that smoking, measured by exposure to nicotine-replacement therapy, was associated with an increased risk of overall mortality during the first wave of SARS-CoV-2 epidemic in France, although it was associated with a lower risk of severe Covid-19 in individuals without major related-smoking diseases. Experimental and clinical studies are needed to disentangle the potential mechanisms of nicotine and/or smoking in Covid-19 risk. Whatever the nature of these associations, the global impact of smoking is harmful for health even over a short epidemic period.","Zureik, M.; Baricault, B.; Vabre, C.; SEMENZATO, L.; Drouin, J.; cuenot, F.; penso, L.; Herlemont, P.; Sbidian, E.; Weill, A.; Molimard, M.; Dray-Spira, R.; Botton, J.","https://www.medrxiv.org/content/10.1101/2020.07.28.20160630v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20160630v1?rss=1,2020-07-30,2020-07-30,,True
172,COVID-19: Time-Dependent Effective Reproduction Number and Sub-notification Effect Estimation Modeling,"Background: Since the beginning of the COVID-19 pandemic, researchers and health authorities have sought to identify the different parameters that govern their infection and death cycles, in order to be able to make better decisions. In particular, a series of reproduction number estimation models have been presented, with different practical results. Objective: This article aims to present an effective and efficient model for estimating the Reproduction Number and to discuss the impacts of sub-notification on these calculations. Methods: The concept of Moving Average Method with Initial value (MAMI) is used, as well as a model for Rt, the Reproduction Number, is derived from experimental data. The models are applied to real data and their performance is presented. Results: Analyses on Rt and sub-notification effects for Germany, Italy, Sweden, United Kingdom, South Korea, and the State of New York are presented to show the performance of the methods here introduced. Conclusions: We show that, with relatively simple mathematical tools, it is possible to obtain reliable values for time-dependent Reproduction Numbers (Rt), as well as we demonstrate that the impact of sub-notification is relatively low, after the initial phase of the epidemic cycle has passed.","De Carvalho, E. A.; De Carvalho, R. A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20164087v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20164087v1?rss=1,2020-07-30,2020-07-30,,True
173,Stochastic modelling of the effects of human-mobility restriction and viral infection characteristics on the spread of COVID-19,"After several weeks of ""lockdown"" as the sole answer to the COVID-19 pandemic, many countries are restarting their economic and social activities. However, balancing the re-opening of society against the implementation of non-pharmaceutical measures needed for minimizing interpersonal contacts requires a careful assessment of the risks of infection as a function of the confinement relaxation strategies. Here, we present a stochastic coarse grained model that examines this problem. In our model, people are allowed to move between discrete positions on a one-dimensional grid with viral infection possible when two people are collocated at the same site. Our model features three sets of adjustable parameters, which characterize (i) viral transmission, (ii) viral detection, and (iii) degree of personal mobility, and as such, it is able to provide a qualitative assessment of the potential for second-wave infection outbreaks based on the timing, extent, and pattern of the lockdown relaxation strategy. In line with general expectations, our model predicts that a full lockdown yields the best results, namely, the lowest number of total infections. A less anticipated result was that when personal mobility is increased beyond a critical level, the risk of infection rapidly reaches a constant value, which depends solely on the population density. Furthermore, according to our model, confinement alone is not effective if it is not accompanied by a detection capacity (coupled with quarantine) that surpasses 40% of the patients during their symptomatic phase. The results of our simulation also showed that keeping the virus transmission probability to less than 0.4, which can be achieved in real life by respecting social distancing or wearing masks, is as effective as imposing a mild lockdown. Finally, we note that detection and quarantine of pre-symptomatic patients, even with a probability as low as 0.2, would reduce the final numbers of infections by a factor of ten or more.","Ando, S.; Matsuzawa, Y.; Tsurui, H.; Mizutani, T.; Hall, D.; Kuroda, Y.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163980v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163980v1?rss=1,2020-07-30,2020-07-30,,True
174,Multimorbidity patterns among COVID-19 deaths: considerations for a better medical practice,"Medical care of individuals diagnosed with severe COVID-19 is complex, especially when patients are older adults with multimorbidity. The objective of this study was to describe patterns of multimorbidity among fatal cases of COVID-19. Data of Colombian confirmed deaths of COVID-19 until June 11, 2020, were included in this analysis (1488 deaths). Relationships between COVID-19, combinations of health conditions and age were explored using locally weighted polynomial regressions. Some multimorbidity patterns increase probability of death among older individuals, whereas other patterns are not age-related, or decreases the probability of death among older people. Consider multimorbidity in the medical management of COVID-19 patients is important to determine the more adequate medical interventions. In addition to the co-occurrence of COVID-19 with diseases of high prevalence in the world, in Colombia there are cases more complex with COVID-19 co-occur with endemic and orphan tropical diseases. In these cases, although its occurrence may be low, clinical management requires adjusting to its complex clinical condition.","Fernandez-Nino, J. A.; Guerra-Gomez, J. A.; Idrovo-Velandia, A. J.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163816v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163816v1?rss=1,2020-07-30,2020-07-30,,True
175,The basic reproduction number of SARS-CoV-2: a scoping review of available evidence,"Background: The transmissibility of SARS-CoV-2 determines both the ability of the virus to invade a population and the strength of intervention that would be required to contain or eliminate the spread of infection. The basic reproduction number, R0, provides a quantitative measure of the transmission potential of a pathogen. Objective: Conduct a scoping review of the available literature providing estimates of R0 for SARS-CoV-2, provide an overview of the drivers of variation in R0 estimates and the considerations taken in the calculation of the parameter. Design: Scoping review of available literature between the 01 December 2019 and 07 May 2020. Data sources: Both peer-reviewed and pre-print articles were searched for on PubMed, Google Scholar, MedRxiv and BioRxiv. Selection criteria: Studies were selected for review if (i) the estimation of R0 represented either the initial stages of the outbreak or the initial stages of the outbreak prior to the onset of widespread population restriction (lockdown), (ii) the exact dates of the study period were provided and (iii) the study provided primary estimates of R0. Results: A total of 20 R0 estimates were extracted from 15 studies. There was substantial variation in the estimates reported. Estimates derived from mathematical models fell within a wider range of 1.94-6.94 than statistical models which fell between the range of 2.2 to 4.4. Several studies made assumptions about the length of the infectious period which ranged from 5.8-20 days and the serial interval which ranged from 4.41-14 days. For a given set of parameters a longer duration of infectiousness or a longer serial interval equates to a higher R0. Several studies took measures to minimise bias in early case reporting, to account for the potential occurrence of super-spreading events, and to account for early sub-exponential epidemic growth. Conclusions: The variation in reported estimates of R0 reflects the complex nature of the parameter itself, including the context (i.e. social/spatial structure), the methodology used to estimate the parameter, and model assumptions. R0 is a fundamental parameter in the study of infectious disease dynamics however it provides limited practical applicability outside of the context in which it was estimated, and should be calculated and interpreted with this in mind.","Barber, A.; Griffin, J. M.; Casey, M.; Collins, A.; Lane, E. A.; Ten Bosch, Q.; De Jong, M.; Mc Evoy, D.; Byrne, A. W.; McAloon, C. G.; Butler, F.; Hunt, K.; More, S. J.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163535v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163535v1?rss=1,2020-07-30,2020-07-30,,True
176,Determining the period of communicability of SARS-CoV-2: A rapid review of the literature,"Introduction: How long individuals may transmit virus after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Understanding the communicability period of SARS-CoV-2 is important to inform the period of isolation required to prevent nosocomial and community spread. The objective of this study was to identify the reported communicable period of SARS-CoV-2, based on a rapid review of existing literature. Methods: Studies reporting empirical data on the period of communicability of SARS-CoV-2 through investigations of duration of communicability based on in-person contact ('contact transmission'), isolation and culture of virus ('viral isolation'), and viral shedding by detection of nucleic acids by RT-PCR ('viral shedding') were identified through searches of peer-reviewed and pre-print health sciences literature databases (Ovid MEDLINE, Embase, Google Scholar, medRxiv and arXiv) and the grey literature. Articles were screened for relevance, then data were extracted, analyzed, and synthesized. Results: Out of the 165 studies included for qualitative analysis, one study investigated contact transmission, three investigated viral isolation, 144 investigated viral shedding, and 17 studies focused on both viral shedding and viral isolation. The median length of time until viral clearance across all viral isolation studies was nine days; however, the maximum identified duration was 32 days. Studies with data on both viral isolation and viral shedding showed a prolonged maximum time until viral clearance for viral shedding (9 days vs 24 days). Discussion: Findings from this review support a minimum 10-day period of isolation; however, additional observation should be considered for individuals being released into high-risk settings.","Park, M.; Pawliuk, C.; Nguyen, T.; Griffitt, A.; Dix-Cooper, L.; Fourik, N.; Dawes, M.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163873v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163873v1?rss=1,2020-07-30,2020-07-30,,True
177,Initial evaluation of a mobile SARS-CoV-2 RT-LAMP testing strategy,"SARS-CoV-2 control in the United States is hampered by limited testing capacity. We evaluated a simple, outdoor, mobile RT-LAMP assay workflow where self-collected saliva is tested for SARS-CoV-2 RNA. 195 volunteers were tested over 8 days. Testing results were 100% concordant with qRT-PCR, with all but one person testing SARS-CoV-2-negative.","Newman, C.; Dudley, D. M.; Wiseman, R. W.; McLaughlin, M. T.; Karl, J. A.; Stauss, M.; Weiler, A. M.; Bliss, M. I.; Ramuta, M. D.; Shortreed, C. G.; Haj, A. K.; Heffron, A. S.; Burmeister, C. B.; Hall, K. L.; Friedrich, T. C.; O'Connor, S. L.; O'Connor, D. H.","https://www.medrxiv.org/content/10.1101/2020.07.28.20164038v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20164038v1?rss=1,2020-07-30,2020-07-30,,True
178,SARS-CoV-2 detection with de novo designed synthetic riboregulators,"Sars-CoV-2 is a human pathogen and is the main cause of COVID-19 disease. COVID-19 is announced as a global pandemic by World Health Organization. COVID-19 is characterized by severe conditions and early diagnosis can make dramatic changes both for personal and public health. In order to increase the reach for low cost equipment which requires a very limited technical knowledge can be beneficial to diagnose the viral infection. Such diagnostic capabilities can have a very critical role to control the transmission of the disease. Here we are reporting a state-of-the-art diagnostic tool developed by using an in vitro synthetic biology approach by employing engineered de novo riboregulators. Our design coupled with a home-made point-of-care device setting can detect and report presence of Sars-CoV-2 specific genes. The presence of Sars-CoV-2 related genes triggers translation of sfGFP mRNAs, resulting in green fluorescence output. The approach proposed here has the potential of being a game changer in Sars-COV-2 diagnostics by providing an easy-to-run, low-cost-demanding diagnostic capability.","Koksaldi, I. C.; Ahan, R. E.; Kose, S.; Haciosmanoglu, N.; Kehribar, E. S.; Gungen, M. A.; Ozkul, A.; Seker, U. O. S.","https://www.medrxiv.org/content/10.1101/2020.07.28.20164004v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20164004v1?rss=1,2020-07-30,2020-07-30,,True
179,An Outpatient Telehealth Elective for Displaced Clinical Learners during the Coronavirus Pandemic,"Introduction: In response to the Coronavirus pandemic, medical schools suspended clinical rotations. This displacement of students from the wards has limited experiential learning opportunities. Concurrently, outpatient practices are experiencing reduced volumes of in-person visits and shifting towards virtual healthcare. This transition comes with its own logistical challenges. Here, we discuss a workflow that enabled students to engage in meaningful clinical education while helping the RWJMS outpatient practices implement remote telehealth visits. Methods: A four-week virtual elective was designed to offer clerkship students the opportunity to participate in virtual telehealth patient encounters. Students were prepared with EMR training and introduced to an outpatient workflow that supports healthcare providers in the ambulatory setting. Patients were consented to telehealth services before encounters with students. All collected clinical information was documented in the EMR, after which students transitioned patients to a virtual Doxy.me video call appointment. Clinical and educational outcomes of students' participation were evaluated. Results: Survey results showed students felt well-prepared to initiate patient encounters. They also expressed comfort while engaging with patients virtually during telehealth appointments. Students further identified educational value, citing opportunities to develop patient management plans consistent with in-person clinical experiences. A significant healthcare burden was also alleviated by student involvement. Over 1000 total scheduled appointments were serviced by students who transitioned over 80% of patients into virtual provider waiting rooms. Discussion: After piloting this elective with rising fourth-year students, pre-clerkship students were also recruited to act in a role normally associated with clinical learners (e.g., elicit patient histories, conduct a review of systems, etc.). An additional telehealth elective is being designed so medical students can contribute to inpatient care without risk of exposure to SARS-CoV-2. These efforts are designed","Weber, A. M.; Dua, A.; Chang, K.; Jupalli, H.; Rizwan, F.; Chouthai, A.; Chen, C.","https://www.medrxiv.org/content/10.1101/2020.07.28.20146522v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20146522v1?rss=1,2020-07-30,2020-07-30,,True
180,Determinants of SARS-CoV-2 infection in Italian healthcare workers: a multicenter study,"Background. Healthcare workers (HCW) are at increased risk of being infected with SARS-CoV-2, yet limited information is available on risk factors of infection. Methods. We pooled data on occupational surveillance of 10,654 HCW who were tested for SARS-CoV-2 infection in six Italian centers. Information was available on demographics, job title, department of employment, source of exposure, use of personal protective equipment (PPE), and COVID-19-related symptoms. We fitted multivariable logistic regression models to calculate odds ratios (OR) and 95% confidence intervals (CI). Findings. The prevalence of infection varied across centers and ranged from 3.0% to 22.0%, being strongly correlated with that of the respective areas. Women were at lower risk of infection compared to men. Fever, cough, dyspnea and malaise were the symptoms most strongly associated with infection, together with anosmia and ageusia. No differences in the risk of infection were detected between job titles, or working in a COVID-19 designated department. Reported contact with a patient inside or outside the workplace was a risk factor. Use of a mask was strongly protective against risk of infection as was use of gloves. The use of a mask by the source of exposure (patient or colleague) had an independent effect in reducing infection risk.","Boffetta, P.; Violante, F.; Durando, P.; De Palma, G.; Pira, E.; Vimercati, L.; Cristaudo, A.; Icardi, G.; Sala, E.; Coggiola, M.; Tafuri, S.; Gattini, V.; Apostoli, P.; Spatari, G.; Working Group on SARS-CoV-2 infection in Italian healthcare workers,","https://www.medrxiv.org/content/10.1101/2020.07.29.20158717v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20158717v1?rss=1,2020-07-30,2020-07-30,,True
181,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,"Background COVID-19 has put unprecedented pressure on healthcare systems worldwide, leading to a reduction of the available healthcare capacity. Our objective was to develop a decision model that supports prioritization of care from a utilitarian perspective, which is to minimize population health loss. Methods A cohort state-transition model was developed and applied to 43 semi-elective non-paediatric surgeries commonly performed in academic hospitals. Scenarios of delaying surgery from two weeks were compared with delaying up to one year, and no surgery at all. Model parameters were based on registries, scientific literature, and the World Health Organization global burden of disease study. For each surgery, the urgency was estimated as the average expected loss of Quality-Adjusted Life-Years (QALYs) per month. Results Given the best available evidence, the two most urgent surgeries were bypass surgery for Fontaine III/IV peripheral arterial disease (0.23 QALY loss/month, 95%-CI: 0.09-0.24) and transaortic valve implantation (0.15 QALY loss/month, 95%-CI: 0.09-0.24). The two least urgent surgeries were placing a shunt for dialysis (0.01, 95%-CI: 0.005-0.01) and thyroid carcinoma resection (0.01, 95%-CI: 0.01-0.02): these surgeries were associated with a limited amount of health lost on the waiting list. Conclusion Expected health loss due to surgical delay can be objectively calculated with our decision model based on best available evidence, which can guide prioritization of surgeries to minimize population health loss in times of scarcity. This tool should yet be placed in the context of different ethical perspectives and combined with capacity management tools to facilitate large-scale implementation.","Gravesteijn, B.; Krijkamp, E.; Busschbach, J.; Geleijnse, G.; Retel Helmrich, I.; Bruinsma, S.; van Lint, C.; van Veen, E.; Steyerberg, E.; Verhoef, C.; van Saase, J.; Lingsma, H.; Baatenburg de Jong, R.; Value Based Operation Room Triage team collaborators,","https://www.medrxiv.org/content/10.1101/2020.07.26.20157040v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20157040v1?rss=1,2020-07-30,2020-07-30,,True
182,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization,"Background In observational studies, Alzheimer's disease (AD) has been associated with an increased risk of Coronavirus disease 2019 (COVID-19), and the prognosis of COVID-19 can affect nervous systems. However, the causality between these conditions remains to be determined. Methods This study sought to investigate the bidirectional causal relations of AD with COVID-19 using two-sample Mendelian randomization (MR) analysis. Results We found that genetically predicted AD was significantly associated with higher risk of severe COVID-19 (odds ratio [OR], 3.329; 95% confidence interval [CI], 1.139-9.725; P=0.028). It's interesting that genetically predicted severe COVID-19 was also significantly associated with higher risk of AD (OR, 1.004; 95% CI, 1.001-1.007; P=0.018). In addition, the two strong genetic variants associated with severe COVID-19 was associated with higher AD risk (OR, 1.018; 95% CI, 1.003-1.034; P=0.018). There is no evidence to support that genetically predicted AD was significantly associated with COVID-19 susceptibility, and vice versa. No obvious pleiotropy bias and heterogeneity were observed. Conclusion Overall, AD may causally affect severe COVID-19, and vice versa, performing bidirectional regulation through independent biological pathways.","Liu, D.; Zhang, X.; Cao, W.; Zhang, J.; Song, M.; Xing, W.; Wang, W.; Meng, Q.; Wang, Y.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163212v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163212v1?rss=1,2020-07-30,2020-07-30,,True
183,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,"Abstract Introduction: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of Coronavirus Disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which nineteen elderly residents were positive for SARS-CoV-2. Methods: Based on the increased susceptibility to viral-induced cytokine release syndrome inducing respiratory and systemic complications in this population, the patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody. Results: All the patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable and 18 out of 19 (94.7%) patients were discharged clinically recovered with negative RT-PCR at 13 days (median). One dose of itolizumab, circulating IL-6 decreased in the first 24-48 hours in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminary assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control subjects were well-matched regarding age, comorbidities and severity of the disease. Every three moderately ill patients treated with itolizumab, one admission in intensive care unit (ICU) was prevented. Discussion/Conclusion: Itolizumab was well tolerated. Its effect is associated with a reduction and controlling IL-6 serum levels. Moreover, treated patients had a favorable clinical outcome, considering their poor prognosis. This treatment is associated significantly with a decrease the risk to be admitted in ICU and reduced 10 times the risk of death. This study corroborates that the timely use of itolizumab, in combination with other antiviral and anticoagulant therapies, is associated with a reduction the COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19 and suggests its possible use in patients with cytokine release syndrome from other pathologies.","Ramos-Suzarte, M.; Diaz, Y.; Martin, Y.; Calderon, N. A.; Santiago, W.; Vinet, O.; La O, Y.; Perez, J.; Oyarzabal, A.; Perez, Y.; Lorenzo, G.; Cepeda, M.; Saavedra, D.; Mazorra, Z.; Estevez, D.; Lorenzo-Luaces, P.; Valenzuela, C.; Caballero, A.; leon, K.; Crombet, T.; Hidalgo, C. J.","https://www.medrxiv.org/content/10.1101/2020.07.24.20153833v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20153833v1?rss=1,2020-07-30,2020-07-30,,True
184,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,"Abstract Background There is an urgent need for an efficacious and safe treatment for COVID19. Several trials testing a variety of therapeutics are on-going. Some in-vitro studies found the anti-malarial drug chloroquine (CQ), and its derivative, hydroxychloroquine (HCQ), are effective against COVID19. However, systematic reviews and meta-analyses of clinical trials in humans have produced conflicting findings on the efficacy and safety of these drugs. Guidelines vary considerably and are hotly debated at political and scientific levels. Therefore, it has become necessary to provide a summary of the effectiveness and safety of these drugs in treating COVID19 infection, using an overview of the existing systematic reviews and meta-analyses. Objective To synthesize the findings presented in systematic reviews and meta-analyses as well as to update the evidence using a meta-analysis in evaluating the efficacy and safety of CQ and HCQ with or without Azithromycin for the treatment of COVID19 infection. Methods The design of this meta-review followed the Preferred Reporting Items for Overviews of Systematic Reviews including harms checklist (PRIO-harms). A comprehensive search included several electronic databases in identifying all systematic reviews and meta-analyses as well as experimental studies which investigated the efficacy and safety of CQ, HCQ with or without antibiotics as COVID19 treatment. Manual searches of the reference list of all included studies and a citation search of the top 20 papers supplemented the search. Findings from the systematic reviews and meta-analyses were reported using a structured summary including tables and forest plots. The updated meta-analysis of experimental studies was carried out using the distributional-assumption-free quality effects model. Risk of bias was assessed using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool for reviews and the MethodologicAl STandard for Epidemiological Research (MASTER) scale for the experimental studies. The main outcomes for both the meta-review and the updated meta-analysis were; mortality, transfer to the intensive care unit (ICU), intubation or the need for mechanical ventilation, worsening of illness, viral clearance and the occurrence of adverse events. Results A total of 13 reviews with 40 primary studies comprising 113,000 participants were included. Most of the primary studies were observational (n=27) and the rest were experimental studies. Two meta-analyses reported a high risk of mortality with similar ORs of 2.5 for HCQ with Azithromycin. However, four other meta-analyses reported contradictory results with two reporting a high risk of mortality (OR ~ 2.2 to 3.0) and the other two reporting no significant association between HCQ with mortality. Most reviews reported that HCQ with or without Azithromycin had no significant effect on virological cure, disease exacerbation or the risk of transfer to the ICU, need for intubation or mechanical ventilation. After exclusion of studies that did not meet the eligibility criteria, the updated meta-analysis contained eight experimental studies (7 RCTs and 1 quasi-experimental trial), with a total of 5279 participants of whom 1856 were on either CQ/HCQ or combined with Azithromycin. CQ/HCQ with or without Azithromycin was significantly associated with a higher risk of adverse events (RR 5.7, 95%CI 2.4-13.7, I2 =55%, n = 5 studies). HCQ was not effective in reducing mortality (RR 1.0, 95%CI 1.0-1.2, I2 =0%, n=6 studies), transfer to the ICU, intubation or need for mechanical ventilation (RR 1.1, 95%CI 0.9-1.4, I2 =0%, n=3 studies) virological cure (RR 1.0, 95%CI 0.9-1.2, I2 =55%, n=5 studies) nor disease exacerbation (RR 1.2, 95%CI 0.3-5.0, I2 =29%, n=3 studies). Conclusion There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19 or its exacerbation.","Chivese, T.; Musa, O. A. H.; Hindy, G.; Wattary, N.; Badran, S.; Soliman, N.; Aboughalia, A. T.; Matizanadzo, J. T.; Emara, M. M.; Thalib, L.; Doi, S.","https://www.medrxiv.org/content/10.1101/2020.07.28.20164012v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20164012v1?rss=1,2020-07-30,2020-07-30,,True
185,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.","The current gold-standard molecular diagnosis for COVID-19 is based on a multi-step assay involving RNA-extraction and RT-PCR analysis for the detection of SARS-CoV-2. RNA-extraction step has been a major rate-limiting step in implementing high-throughput screening for COVID-19 during this pandemic. Moreover, clinical laboratories are facing several challenges that include cost, reagents, instrumentation, turn-around time, trained personnel, and supply-chain constraints to efficiently implement and sustain testing. Cognizant of these limitations, we evaluated the extraction-free methods described in the literature and have developed an innovative, simplified and easy protocol employing limited reagents to extract RNA for subsequent RT-PCR analysis. Nasopharyngeal-swab samples were subjected to the following individual conditions: 65{degrees}C for 15 minutes; 80{degrees}C for 5 minutes; 90{degrees}C for 5 minutes or 80{degrees}C for 1 minute, and processed for direct RT-PCR. These groups were also compared with a supplemental protocol adding isopropanol-ethanol-water elution steps followed by RT-PCR assay. The direct RT-PCR assay did not detect SARS-CoV-2 within the various temperature incubation only groups, whereas, the 90{degrees}C for 5 minutes-isopropanol-ethanol-water method was found to be comparable to the FDA-EUA method. Evaluation of the performance metrics for 100 clinical samples demonstrated a sensitivity of 94.2% and a specificity of 100%. The limit of detection was ascertained to be ~40 copies/ml by absolute-quantification. The protocol presented for this assay employs limited reagents and yields results with high sensitivity. Additionally, it presents a simplified methodology that would be easier to implement in laboratories in limited resource countries in order to meet the high current COVID-19 testing needs.","Sahajpal, N. S.; Mondal, A. K.; Njau, A.; Ananth, S.; Kothandaraman, A.; Hegde, M.; Chaubey, A.; Padala, S.; Kota, V.; Caspary, K.; Tompkins, S. M.; Ross, T. M.; Rojiani, A. M.; Kolhe, R.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163626v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163626v1?rss=1,2020-07-30,2020-07-30,,True
186,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,"Background: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC","Wells, P. M.; Doores, K. M.; Couvreur, S.; Martin Martinez, R.; Seow, J.; Graham, C.; Acors, S.; Kouphou, N.; Neil, S.; Tedder, R.; Matos, P.; Poulton, K.; Jose Lista, M.; Dickenson, R.; Sertkaya, H.; Maguire, T.; Scourfield, E.; Bowyer, R.; Hart, D.; O'Byrne, A.; Steele, K.; Hemmings, O.; Rosadas, C.; McClure, M.; Capedevila-Pujol, J.; wolf, J.; Ourseilin, S.; Brown, M.; Malim, M.; Spector, T.; Steves, C.","https://www.medrxiv.org/content/10.1101/2020.07.29.20162701v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20162701v1?rss=1,2020-07-30,2020-07-30,,True
187,Red blood cells injuries and hypersegmented neutrophils in COVID-19 peripheral blood film,"In the current investigation, peripheral blood films of 15 COVID-19 patients (44.78{+/-}16.55 years), proven by computed tomographic imaging and RT-PCR for coronavirus SARS-CoV-2, were analyzed at the moment of hospital admission. Blood tests showed raised inflammatory markers (C-reactive protein 58.2{+/-}61.2 mg/L) with normal values for hemoglobin (126.2{+/-}2.6 g/L), WBC (6.8{+/-}18.74 109/L) RBC (4.55{+/-}0.99 1012/L) platelets (262.4{+/-}41.8, 109/L) MCV (79.84{+/-}8.2 fL) MCH (28{+/-}3.31 pg) and MCHC (350.3{+/-}1.15 g/L). The results revealed the presence of hypersegmented neutrophils in 66.66%% of the patients. The percentages of neutrophils with 4 and 5 lobes were 46.25{+/-}4.83% and 31.5{+/-}14.84%, respectively. Three major red blood cells morphological alteration were observed: (1) erythrocytes in double primerouleauxdouble prime formation represented by linear erythrocytes aggregation, (2) spherocytes with the disappearance of the usual biconcave disk, and (3) echinocytes showing spiky projections. Apparent reorganization of hemoglobin is found in the majority of the analyzed erythrocytes. Rouleaux formation is observed in 33.33% of patients and spherocytes and echinocytes are present at variable levels in the all analyzed patients. The current results revealed erythrocytes injuries in COVID-19 peripheral blood, in association with hypersegmented neutrophils, alterations that could be involved in the respiratory syndrome.","Lakhdari, N.; Tabet, B.; Boudraham, L.; Laoussati, M.; Aissanou, S.; Beddou, L.; Bensalem, S.; Bellik, Y.; Bournine, L.; Fatmi, S.; Iguer-Ouada, M.","https://www.medrxiv.org/content/10.1101/2020.07.24.20160101v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20160101v1?rss=1,2020-07-30,2020-07-30,,True
188,"Early Clinical Factors Predicting the Development of Critical Disease in Japanese Patients with COVID-19: A Single-Center Retrospective, Observational Study","Background: Insufficient evidence of factors predicting the COVID-19 progression from mild to moderate to critical has been established. We retrospectively evaluated risk factors for critical progression in Japanese COVID-19 patients. Method: Seventy-four laboratory-confirmed COVID-19 patients were hospitalized in our hospital between February 20, 2020, and June 10, 2020. We excluded asymptomatic, non-Japanese, and child patients. We divided patients into the stable group (SG) and the progression group (PG) (patients requiring mechanical ventilation). We compared the clinical factors in both groups. We established the cutoff values (COVs) for significantly different factors via receiver operating characteristic (ROC) curve analysis and evaluated risk factors by univariate regression. Results: We enrolled 57 COVID-19 patients (median age 52 years, 56.1% male). The median progression time from symptom onset was eight days. Seven patients developed critical disease (PG: 12.2%), two (3.5%) of whom died; 50 had stable disease. Univariate logistic analysis identified elevated lactate dehydrogenase (LDH) (COV: 309 U/l), decreased estimated glomerular filtration rate (eGFR) (COV: 68 ml/min), lymphocytopenia (COV: 980/l), and statin use as significantly associated with disease progression. However, in Cox proportional hazards analysis, lymphocytopenia at symptom onset was not significant. Conclusions: We identified three candidate risk factors for adult Japanese patients with mild to moderate COVID-19: statin use, elevated LDH level, and decreased eGFR.","Higuchi, T.; Nishida, T.; Iwahashi, H.; Morimura, O.; Otani, Y.; Okauchi, Y.; Yokoe, M.; Suzuki, N.; Inada, M.; Abe, K.","https://www.medrxiv.org/content/10.1101/2020.07.29.20159442v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20159442v1?rss=1,2020-07-30,2020-07-30,,True
189,Incidence and outcomes of healthcare-associated COVID-19 infections: significance of delayed diagnosis and correlation with staff absence,"Background: The sudden increase in COVID-19 admissions in hospitals during the SARS-CoV2 pandemic of 2020 has led to onward transmissions among vulnerable inpatients. Aims: This study was performed to evaluate the prevalence and clinical outcomes of Healthcare-associated COVID-19 infections (HA-COVID-19) during the 2020 epidemic and study factors which may promote or correlate with its incidence and transmission in a London Teaching Hospital Trust. Methods: Electronic laboratory, patient and staff self-reported sickness records were interrogated for the period 1st March to 18th April 2020. HA-COVID-19 was defined as symptom onset >14d of admission. Test performance of a single combined throat and nose swab (CTNS) for patient placement and the effect of delayed RNA positivity (DRP, defined as >48h delay) on patient outcomes was evaluated. The incidence of staff self-reported COVID-19 sickness absence, hospital bed occupancy, community incidence and DRP was compared HA-COVID-19. The incidence of other significant hospital-acquired bacterial infections (OHAI) was compared to previous years. Results: 58 HA-COVID-19 (7.1%) cases were identified. As compared to community-acquired cases, significant differences were observed in age (p=0.018), ethnicity (p<0.001) and comorbidity burden (p<0.001) but not in 30d mortality. CTNS negative predictive value was 60.3%. DRP was associated with greater mortality (p=0.034) and 34.5% HA-COVID-19 cases could be traced to delayed diagnosis in CA-COVID-19. Incidence of HA-COVID-19 correlated positively with DRP (R=0.7108) and staff sickness absence (R=0.7815). OHAI rates were similar to previous 2 years. Conclusion: Early diagnosis and isolation of COVID-19 would help reduce transmission. A single CTNS has limited value in segregating patients into positive and negative pathways.","Khonyongwa, K.; Taori, S. K.; Soares, A.; Desai, N.; Sudhanva, M.; Bernal, W.; Schelenz, S.; Curran, L. A.","https://www.medrxiv.org/content/10.1101/2020.07.24.20148262v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20148262v1?rss=1,2020-07-30,2020-07-30,,True
190,"The relationship between demographic, psychosocial and health-related parameters and the impact of COVID-19: a study of twenty-four Indian regions","Objectives: The impact of the COVID-19 pandemic has varied widely across nations and even in different regions of the same nation. Some of this variability may be due to the interplay of pre-existing demographic, psychological, social and health-related factors in a given population. Methods: Data on the COVID-19 prevalence, crude mortality and case fatality rates were obtained from official government statistics for 24 regions of India. The relationship between these parameters and demographic, social, psychological and health-related indices in these states was examined using both bivariate and multivariate analyses. Results: A variety of factors - state population, sex ratio, and burden of diarrhoeal disease and ischemic heart disease - were associated with measures of the impact of COVID-19 on bivariate analyses. On multivariate analyses, prevalence and crude mortality rate were both significantly and negatively associated with the sex ratio. Conclusions: These results suggest that the transmission and impact of COVID-19 in a given population may be influenced by a number of variables, with demographic factors showing the most consistent association.","Rajkumar, R. P.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163287v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163287v1?rss=1,2020-07-30,2020-07-30,,True
191,Mechanistic modelling of coronavirus infections and the impact of confined neighbourhoods on a short time scale,"Background: To mitigate the spread of the COVID-19 coronavirus, some countries have adopted more stringent non-pharmaceutical interventions in contrast to those widely used (for e.g. the state of Kuwait). In addition to standard practices such as enforcing curfews, social distancing, and closure of non-essential service industries, other non-conventional policies such as the total confinement of highly populated areas has also been implemented. Methods: In this paper, we model the movement of a host population using a mechanistic approach based on random walks, which are either diffusive or super-diffusive. Infections are realised through a contact process, whereby a susceptible host may be infected if in close spatial proximity of the infectious host. Our focus is only on the short-time scale prior to the infectious period, so that no further transmission is assumed. Results: We find that the level of infection depends heavily on the population dynamics, and increases in the case of slow population diffusion, but remains stable for a high or super-diffusive population. Also, we find that the confinement of homogeneous or overcrowded sub-populations has minimal impact in the short term. Conclusions: Our results indicate that on a short time scale, confinement restrictions or complete lock down of whole residential areas may not be effective. Finally, we discuss the possible implications of our findings for total confinement in the context of the current situation in Kuwait.","Ahmed, D. A.; Ansari, A. R.; Imran, M.; Dingle, K.; Ahmed, N.; Bonsall, M. A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163634v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163634v1?rss=1,2020-07-30,2020-07-30,,True
192,"Performance of Abbott Architect, Ortho Vitros, and Euroimmun Assays in Detecting Prior SARS-CoV-2 Infection","Background: Several serological assays have been developed to detect anti-SARS-CoV-2 IgG antibodies, but evidence about their comparative performance is limited. We sought to assess the sensitivity of four anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assays (ELISA) in individuals with evidence of prior SARS-CoV-2 infection. Methods: We obtained sera from 36 individuals with PCR-confirmed SARS-CoV-2 infection between March and May 2020. We evaluated samples collected at around 21 days ({+/-}14 days) after their initial PCR test using 3 commercially available ELISA assays, two anti-spike (Ortho-Clinical Diagnostics Vitros, and Euroimmun) and one anti-nucleocapsid (Abbott Architect), and a Yale-developed anti-spike ELISA test. We determined the sensitivity of the tests and compared their results. The Euroimmun and Yale ELISA had an equivocal and indeterminate category, which were considered as both negative and positive. Results: Among the 36 individuals with SARS-CoV-2 infection, mean age was 43 ({+/-}13) years and 19 (53%) were female. The sensitivities of the tests were not significantly different (Abbott Architect, Ortho Vitros, Euroimmmun, and Yale assays: 86% (95% confidence interval [CI], 71-95), 94% (95% CI, 81-99), 86% (95% CI, 71-95), and 94% (95% CI, 81-99), respectively; p-value=0.464). The sensitivities of the Euroimmun and Yale ELISA tests increased when the equivocal/indeterminate results were considered positive (97% [95% CI, 85-100] and 100% [95% CI, 90-100], respectively), but were not significantly different from other tests (p=0.082). The cross-correlation coefficient ranged from 0.85-0.98 between three anti-spike protein assays (Ortho Vitros, Euroimmun, Yale) and was 0.58-0.71 between the three anti-spike protein assays and the anti-nucleocapsid assay (Abbott). Conclusion: The sensitivities of four anti-SARS-CoV-2 protein assays did not significantly differ, although the sample size was small. Sensitivity also depended on the interpretation of equivocal and indeterminate results. The strongest correlations were present for the three anti-spike proteins assays. These findings suggest that individual test characteristics and the correlation between different tests should be considered when comparing or aggregating data across different populations studies for serologic surveillance of past SARS-CoV-2 infection.","Mahajan, S.; Redlich, C. A.; Wisnewski, A. V.; Fazen, L. E.; Rao, L. V.; Kuppusamy, K.; Ko, A. I.; Krumholz, H. M.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164343v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164343v1?rss=1,2020-07-30,2020-07-30,,True
193,Disparities in Case Frequency and Mortality of Coronavirus Disease 2019 (COVID-19) Among Various States in the United States,"Objective: To utilize publicly reported, state-level data to identify factors associated with the frequency of cases, tests, and mortality in the US. Materials & Methods: Retrospective study using publicly reported data collected included the number of COVID-19 cases, tests, and mortality from March 14th through April 30th, 2020. Publicly available state-level data was collected which included: demographics comorbidities, state characteristics and environmental factors. Univariate and multivariate regression analyses were performed to identify the significantly associated factors with percent mortality, case and testing frequency. All analyses were state-level analyses and not patient-level analyses. Results: A total of 1,090,500 COVID-19 cases were reported during the study period. The calculated case and testing frequency were 3,332 and 19,193 per 1,000,000 patients. There were 63,642 deaths during this period which resulted in a mortality of 5.8%. Factors including to but not limited to population density (beta coefficient 7.5, p< 0.01), transportation volume (beta coefficient 0.1, p< 0.01), tourism index (beta coefficient -0.1, p=0.02) and older age (beta coefficient 0.2, p=0.01) are associated with case frequency and percent mortality. Conclusions: There were wide variations in testing and case frequencies of COVID-19 among different states in the US. States with higher population density had a higher case and testing rate. States with larger population of elderly and higher tourism had a higher mortality.","Loomba, R. S.; Aggarwal, G.; Aggarwal, S.; Flores, S.; Villarreal, E. G.; Farias, J. S.; Lavie, C. J.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163931v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163931v1?rss=1,2020-07-30,2020-07-30,,True
194,"Back to school: use of Dried Blood Spot for the detection of SARS-CoV-2-specific immunoglobulin G (IgG) among schoolchildren in Milan, Italy.","Abstract Serological surveillance is necessary to the reestablishment of school activities in safe conditions and to avoid school-related outbreaks. In this study, DBS (Dried Blood Spots) have proven to be a simple, rapid and reliable sample collection tool for detecting antibodies against SARS-CoV-2 by ELISA test compared to matched serum samples from venous sampling (R2=0.9553; Pearson's coefficient=0.98; Cohen's unweighted k=0.93; overall agreement=96.2%). This approach may facilitate sample collection from schoolchildren for serological surveys useful to an adequate risk-assessment.","Amendola, A.; Bianchi, S.; Gori, M.; Barcellini, L.; Colzani, D.; Canuti, M.; Giacomet, V.; Fabiano, V.; Folgori, L.; Zuccotti, G. V.; Tanzi, E.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164186v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164186v1?rss=1,2020-07-30,2020-07-30,,True
195,The potential health and economic impact of dexamethasone treatment for patients with COVID-19,"Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries.","AGUAS, R.; Mahdi, A.; SHRETTA, R.; Horby, P.; Landray, M.; White, L. J.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164269v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164269v1?rss=1,2020-07-30,2020-07-30,,True
196,Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic,"INTRODUCTION Hypoxemia in Severe Acute Respiratory Syndrome due to Novel Coronavirus of 2019 (SARS-CoV-2) is mediated by severe inflammation that may be mitigated by corticosteroids. We evaluated pattern and effects of corticosteroid use in these patients during an early surge of the pandemic. METHODS Observational study of 136 SARS-CoV-2 patients admitted to the Intensive care Unit between March 1 and April 27, 2020 at a tertiary care hospital in Indianapolis, USA. Statistical comparison between cohorts and dosing pattern analysis was done. Outcome measures included number of patients requiring intubation, duration of mechanical ventilation, length of ICU stay and inpatient mortality. RESULTS: Of 136 patients, 72 (53%) received corticosteroids. Groups demographics: Age (60.5 vs. 65; p .083), sex (47% male vs. 39% female; p .338) and comorbidities were similar. Corticosteroid group had increased severity of illness: PaO2/FiO2 (113 vs. 130; p .014) and SOFA (8 vs. 5.5; p < .001). Overall mortality (21% vs. 30%; p .234) or proportion of patients intubated (78 vs. 64%; p .078) was similar. Mortality was similar among mechanically ventilated (27% vs. 15%; p .151) however there were no deaths among patients who were not mechanically ventilated and received corticosteroids (0% vs. 57%; p <.001). Early administration (within 48 hours) showed decrease in proportion of intubation (66% vs. 87 vs. 100%; p.045), ICU days (6 vs., 16 vs. 18; p <.001), and ventilator days (3 vs. 12 & 14; p <.001). 45% received methylprednisolone. CONCLUSION: Corticosteroids were used more frequently in SARS CoV-2 patients with higher severity of illness. Early administration of corticosteroids improved survival in non-mechanically ventilated patients; decreased ICU stay and may have prevented intubation.","Rahman, O.; Trigonis, R. A.; Craft, M. K.; Kruer, R. M.; Miller, E. M.; Terry, C. L.; Persaud, S. A.; Kapoor, R.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164277v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164277v1?rss=1,2020-07-30,2020-07-30,,True
197,Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection,"Fatigue is a common symptom in those presenting with symptomatic COVID-19 infection. However, it is unknown if COVID-19 results in persistent fatigue in those recovered from acute infection. We examined the prevalence of fatigue in individuals recovered from the acute phase of COVID-19 illness using the Chalder Fatigue Score (CFQ-11). We further examined potential predictors of fatigue following COVID-19 infection, evaluating indicators of COVID-19 severity, markers of peripheral immune activation and circulating pro-inflammatory cytokines. Of 128 participants (49.5 {+/-} 15 years; 54% female), more than half reported persistent fatigue (52.3%; 45/128) at 10 weeks (median) after initial COVID-19 symptoms. There was no association between COVID-19 severity (need for inpatient admission, supplemental oxygen or critical care) and fatigue following COVID-19. Additionally, there was no association between routine laboratory markers of inflammation and cell turnover (leukocyte, neutrophil or lymphocyte counts, neutrophil-to-lymphocyte ratio, lactate dehydrogenase, C-reactive protein) or pro-inflammatory molecules (IL-6 or sCD25) and fatigue post COVID-19. Female gender and those with a pre-existing diagnosis of depression/anxiety were over-represented in those with fatigue. Our findings demonstrate a significant burden of post-viral fatigue in individuals with previous SARS-CoV-2 infection after the acute phase of COVID-19 illness. This study highlights the importance of assessing those recovering from COVID-19 for symptoms of severe fatigue, irrespective of severity of initial illness, and may identify a group worthy of further study and early intervention.","Townsend, L.; Dyer, A. H.; Jones, K.; Dunne, J.; Kiersey, R.; Gaffney, F.; O'Connor, L.; Mooney, A.; Leavy, D.; Ridge, K.; King, C.; Cox, F.; O'Brien, K.; Dowds, J.; Sugrue, J.; Hopkins, D.; Byrne, P.; Kingston, T.; Ni Cheallaigh, C.; Nadarajan, P.; McLaughlin, A. M.; Bourke, N. M.; Bergin, C.; O'Farrelly, C.; Bannan, C.; Conlon, N.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164293v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164293v1?rss=1,2020-07-30,2020-07-30,,True
198,Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.,"Background: Hyperinflammation is a key feature of the pathogenesis of COVID-19 with a central role of the interleukin-6 pathway. We aimed to study the impact of the IL-6 receptor antagonist tocilizumab on the outcome of patients admitted to the intensive care unit (ICU) with acute respiratory distress syndrome (ARDS) related to COVID-19. Methods: Eighty-seven patients with confirmed SARS-CoV-2 infection and moderate to severe ARDS were included (n tocilizumab = 29, n controls = 58). A matched cohort was created using a propensity score. The primary endpoint was 30-day all-cause mortality, secondary endpoints included ventilation-free days and length of stay. Results: No difference was found in 30-day all-cause mortality in patients treated with tocilizumab compared to controls (17.2% vs. 32.8%, p = 0.2; HR = 0.52 [0.19 - 1.39], p = 0.19). Ventilator-free days were 19.0 (IQR 12.5 - 20.0) versus 9 (IQR 0.0 - 18.5; p = 0.04), respectively. A higher rate of freedom from mechanical ventilation at 30 days was achieved in patients receiving tocilizumab (HR 2.83 [1.48 - 5.40], p < 0.002). Median length of stay in ICU and total length of stay were reduced by 8 and 9.5 days in patients treated with tocilizumab. Similar results were obtained in the analysis of the propensity score matched cohort. Conclusions: Treatment of critically ill patients with ARDS due to COVID-19 with tocilizumab was not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support as well as shorter overall length of stay in hospital and in ICU.","Eimer, J.; Vesterbacka, J.; Svensson, A.-K.; Stojanovic, B.; Wagrell, C.; Sonnerborg, A.; Nowak, P.","https://www.medrxiv.org/content/10.1101/2020.07.29.20164160v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20164160v1?rss=1,2020-07-30,2020-07-30,,True
199,"Rationing and triage of scarce, lifesaving therapy in the context of the COVID-19 pandemic - a cross-sectional, social media-driven, scenario-based online query of societal attitudes","Background: The recent COVID-19 pandemic made us aware that medical resources are limited. When demand for essential resources surpasses availability, difficult triaging decisions are necessary. While algorithms exist, almost nothing is known on societal attitudes regarding triage criteria. Methods: A cross-sectional survey was conducted via social media channels to query a broad sample of society. Participants were asked to make triage decisions in case-based vignettes, exploring a variety of factors. They also were asked to assess how sure they were about their decisions, and how such decisions should be reached. Results: The survey was completed in full by 1626 participants in April 2020. Median age was 39 years (range 12-80 years), 984 (61%) were female. Patient prognosis, responsibility towards others, the absence of behavior-induced co-morbidities, and younger age were rated the most important triage criteria, while participants found that insurance status, social status, and nationality should not play a substantial role. Ethics-committees and point systems were regarded potentially helpful for triage decision-making, while decisions based on order of presentation (first-come first-serve) or on a legal basis were viewed critically. Participants were least sure about their decision when dealing with age or behavior-induced co-morbidities. Overall, women were surer about their decisions than men, participants of Christian faith were also more secure about their decision than atheists-agnostics. Conclusions: This study uses social media to generate insight into public opinion and attitudes regarding triage criteria and modalities. These findings may be helpful for the development of future medical triage algorithms.","Muensterer, O. J.; Gianicolo, E. A.; Paul, N. W.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163360v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163360v1?rss=1,2020-07-30,2020-07-30,,True
200,Brazilian dental students and COVID-19: a survey on knowledge and perceptions,"This study evaluated the knowledge and perception of Brazilian dental students about COVID-19 and the undergraduate clinical practice during the outbreak by a self-administered web-based questionnaire. A social network campaign on Instagram was raised to approach the reach population. The survey covered demographic and academic profile, general knowledge, preventive measures, and perception about the COVID-19. Descriptive statistics were used to identify frequencies and distributions of variables, which were compared by type of institution and current year of enrollment using Chi-square or Fishers exact tests (alpha=0.05). A total of 833 valid responses were received over 10 days. Students were able to identify the incubation period, main symptoms, and contagious routes of the disease but struggled in recognizing the name of the virus responsible for the pandemics. Hand washing before and after a dental appointment with a patient (97.7%) followed by use of barriers to protect mucosa (97.2%) were the more frequently recognized measures to prevent COVID-19 spread in the dental office. As for the perception of COVID-19, 73.2% of the dental students perceive the disease as severe, while only 11.1% of them think that COVID-19 is severe only for people presenting risk factors. Dental students knowledge and perception were associated with the type of institution and year of enrollment. In summary, the dental students demonstrated an acceptable general knowledge about COVID-19, but dental schools will need to address gaps in knowledge and control measures and perceptions to ensure a safer return to practical activities.","Aragao, M. G. B.; Fernandes Gomes, F. I.; Pinho Maia Paixao de Melo, L.; Milori Corona, S. A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163964v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163964v1?rss=1,2020-07-30,2020-07-30,,True
201,Transmission of SARS-CoV-2 following exposure in school settings: experience from two Helsinki area exposure incidents.,"Background: The role of children in SARS-CoV-2 transmission is unclear. We investigated two COVID-19 school exposure incidents in the Helsinki area. Methods: We conducted two retrospective cohort studies after schools exposures, with a household transmission extension. We defined a case as an exposed person with either a positive RT-PCR, or positive microneutralisation testing (MNT) as confirmation of SARS-CoV-2 nucleoprotein IgG antibodies detection via fluorescent microsphere immunoassay (FMIA). We recruited close school contacts and families of school cases, calculated attack rates (AR) on school level and families, and identified transmission chains. Findings: In incident A, the index was a pupil. Participation rate was 74% (89/121), and no cases were identified. In incident B, the index was a member of school personnel. Participation rate was 81% (51/63). AR was 16% (8/51): 6 pupils and 1 member of school personnel were MNT and FMIA positive; 1 pupil had a positive RT-PCR, but negative serology samples. We visited all school cases' families (n=8). The AR among close household contacts was 42% (9/20 in 3/8 families) but other plausible sources were always reported. At three months post-exposure, 6/8 school cases were re-sampled and still MNT positive. Interpretation: When the index was a child, no school transmission was identified, while the occurrence of an adult case led to a 16% AR. Further cases were evidenced in 3 families, but other transmission chains were plausible. It is likely that transmission from children to adults is limited. Funding: The Finnish Institute for Health and Welfare funded this study.","Dub, T.; Erra, E.; Hagberg, L.; Sarvikivi, E.; Virta, C.; Jarvinen, A.; Osterlund, P.; Ikonen, N.; Haveri, A.; Melin, M.; Lukkarinen, T. J.; Nohynek, H.","https://www.medrxiv.org/content/10.1101/2020.07.20.20156018v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20156018v1?rss=1,2020-07-30,2020-07-30,,True
202,Unemployment insurance and food insecurity among people who lost employment in the wake of COVID-19,"Forty million U.S. residents lost their jobs in the first two months of the coronavirus disease 2019 (COVID-19) pandemic. In response, the Federal Government expanded unemployment insurance benefits in both size ($600 supplement) and scope (to include caregivers and self-employed workers). We assessed the role of unemployment insurance in mitigating the impact of job loss on food insecurity during COVID-19 in low-income households. We analyzed data from the Understanding Coronavirus in America (UAC) cohort, a longitudinal survey collected by the University of Southern California Center for Economic and Social Research (CESR) every two weeks between April 1 and July 8, 2020. We limited the sample to individuals living in households earning less than $75,000 in February 2020 who lost their jobs during COVID-19. Using difference-in-differences and event study regression models, we evaluated the association between receipt of unemployment insurance and self-reported food insecurity and eating less due to financial constraints. We found that 40.5% of those living in households earning less than $75,000 and employed in February 2020 experienced unemployment during the COVID-19 pandemic. Of those who lost their jobs, 31% reported food insecurity and 33% reported eating less due to financial constraints. Food insecurity peaked in April 2020 and declined over time, but began to increase again among people receiving unemployment insurance during the final wave of the survey ahead of the federal supplement to unemployment insurance ending. Food insecurity and eating less were more common among people who were non-White, lived in lower-income households, younger, and who were sexual or gender minorities. Receipt of unemployment insurance was associated with a 4.4 percentage point (95% CI: -7.8 to -0.9 percentage points) decline in food insecurity (a 30.3% relative decline compared to the average level of food insecurity during the study period). Receipt of unemployment insurance was also associated with a 6.1 percentage point (95% CI: -9.6 to -2.7 percentage point) decline in eating less due to financial constraints (a 42% relative decline). Estimates from event study specifications revealed that reductions in food insecurity and eating less were greatest in the four-week period immediately following receipt of unemployment insurance, with no evidence of differential pre-existing trends in either outcome. We conclude that UI benefits during the period when the $600/week federal supplement was in place was associated with large reductions in food insecurity.","Raifman, J.; Bor, J.; Venkataramani, A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163618v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163618v1?rss=1,2020-07-30,2020-07-30,,True
203,Quality controlled SARS-CoV-2 duplex procedure to reduce time and scarce molecular biology diagnosis reagents,"The aim of this study was to provide validated procedures allowing to detect the SARS-CoV-2 and an internal control in a unique one-step duplex RT-qPCR. Two internal controls were tested, targeting either the Schmallenberg virus RNA provided by the NARILIS laboratory (University of Namur) with a HEX-labelled probe or a Diagenode Diagnostics internal control with a Cy5-labelled probe. Our results showed that Ct values of the RT-qPCR duplex assay were even smaller in the optimized working conditions, allowing to use the optimized qPCR conditions in routine diagnosis.","Collin, A.; Chaboteaux, C.; Fontaine, V.; Lefevre, P.","https://www.medrxiv.org/content/10.1101/2020.07.28.20154153v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20154153v1?rss=1,2020-07-30,2020-07-30,,True
204,A Non-Adaptive Combinatorial Group Testing Strategy to Facilitate Healthcare Worker Screening During the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Outbreak,"Background: Regular SARS-CoV-2 testing of healthcare workers (HCWs) has been proposed to prevent healthcare facilities becoming persistent reservoirs of infectivity. Using monoplex testing, widespread screening would be prohibitively expensive, and throughput may not meet demand. We propose a non-adaptive combinatorial (NAC) group-testing strategy to increase throughput and facilitate rapid turnaround via a single round of testing. Methods: NAC matrices were constructed for sample sizes of 700, 350 and 250 with replicates of 2, 4 and 5, respectively. Matrix performance was tested by simulation under different SARS-CoV-2 prevalence scenarios of 0.1-10%, with each simulation ran for 10,000 iterations. Outcomes included the proportions of re-tests required and the proportion of true negatives identified. NAC matrices were compared to Dorfman Sequential (DS) approaches. A web application (www.samplepooling.com) was designed to decode results. Findings: NAC matrices performed well at low prevalence levels with an average number of 585 tests saved per assay in the n=700 matrix at a 1% prevalence. As prevalence increased, matrix performance deteriorated with n=250 most tolerant. In simulations of low to medium (0.1%-3%) prevalence levels all NAC matrices were superior, as measured by fewer repeated tests required, to the DS approaches. At very high prevalence levels (10%) the DS matrix was marginally superior, however both group testing approaches performed poorly at high prevalence levels. Interpretation: This testing strategy maximises the proportion of samples resolved after a single round of testing, allowing prompt return of results to staff members. Using the methodology described here, laboratories can adapt their testing scheme based on required throughput and the current population prevalence, facilitating a data-driven testing strategy.","McDermott, J. H.; Stoddard, D.; Woolf, P.; Ellingford, J. M.; Gokhale, D.; Taylor, A.; Demain, L. A.; Newman, W. G.; Black, G.","https://www.medrxiv.org/content/10.1101/2020.07.21.20157677v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20157677v1?rss=1,2020-07-30,2020-07-30,,True
205,Evaluation of a novel community-based COVID-19 	'Test-to-Care model' for low-income populations,"Background: After a COVID-19 diagnosis, vulnerable populations face considerable logistical and financial challenges to isolate and quarantine. We developed and evaluated a novel, community-based approach (Test-to-Care Model) designed to address these barriers for socioeconomically vulnerable Latinx individuals with newly diagnosed COVID-19 and their households. Methods: This three-week demonstration project was nested within an epidemiologic surveillance study in a primarily Latinx neighborhood in the Mission district of San Francisco, California. The Test-to-Care model was developed with input from community members and public health leaders. Key components included: (1) provision of COVID-19-related education and information about available community resources, (2) home deliveries of material goods to facilitate safe isolation and quarantine (groceries, personal protective equipment and cleaning supplies), and (3) longitudinal clinical and social support. Newly SARS-CoV-2 PCR-positive participants were eligible to participate. Components of the model were delivered by the Test-to-Care team which was comprised of healthcare providers and community health workers (CHWs) who provided longitudinal clinic- and community-based support for the duration of the isolation period to augment existing services from the Department of Public Health (DPH). We evaluated the Test-to-Care Model using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Framework and drew upon multiple data sources including: programmatic data, informal interviews with participants and providers/CHWs and structured surveys among providers/CHWs. Results: Overall, 83 participants in the surveillance study were diagnosed with COVID-19, of whom 95% (79/83) were Latinx and 88% (65/74) had an annual household income <$50,000. Ninety-six percent (80/83) of participants were reached for results disclosure, needs assessment and DPH linkage for contact tracing. Among those who underwent an initial needs assessment, 45% (36/80) were uninsured and 55% (44/80) were not connected to primary care. Sixty-seven percent (56/83) of participants requested community-based CHW support to safely isolate at their current address and 65% (54/83) of all COVID-19 participants received ongoing community support via CHWs for the entire self-isolation period. Participants reported that the intervention was highly acceptable and that their trust increased over time - this resulted in 9 individuals who disclosed a larger number of household members than first reported, and 6 persons who requested temporary relocation to a hotel room for isolation despite initially declining this service; no unintended harms were identified. The Test-to-Care Model was found to be both acceptable and feasible to providers and CHWs. Challenges identified included a low proportion of participants linked to primary care despite support (approximately 10% after one month), and insufficient access to financial support for wage replacement. Conclusions: The Test-to-Care Model is a feasible and acceptable intervention for supporting self-isolation and quarantine among newly diagnosed COVID-19 patients and their households by directly addressing key barriers faced by vulnerable populations.","Kerkhoff, A. D.; Sachdev, D.; Mizany, S.; Rojas, S.; Gandhi, M.; Peng, J.; Black, D.; Jones, D.; Rojas, S.; Jacobo, J.; Tulier-Laiwa, V.; Petersen, M.; Martinez, J.; Chamie, G.; Havlir, D. V.; Marquez, C.","https://www.medrxiv.org/content/10.1101/2020.07.28.20161646v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20161646v1?rss=1,2020-07-30,2020-07-30,,True
206,Model stability of COVID-19 mortality prediction with biomarkers,"Coronavirus disease 2019 (COVID-19) is an unprecedented and fast evolving pandemic, which has caused a large number of critically ill patients and deaths globally. It is an acute public health crisis leading to overloaded critical care capacity. Timely prediction of the clinical outcome (death/survival) of hospital-admitted COVID-19 patients can provide early warnings to clinicians, allowing improved allocation of medical resources. In a recently published paper, an interpretable machine learning model was presented to predict the mortality of COVID-19 patients with blood biomarkers, where the model was trained and tested on relatively small data sets. However, the model or performance stability was not explored and assessed. By re-analyzing the data, we reveal that the reported mortality prediction performance was likely over-optimistic and its uncertainty was underestimated or overlooked, with a large variability in predicting deaths.","Huang, C.; Long, X.; Zhan, Z.; van den Heuvel, E.","https://www.medrxiv.org/content/10.1101/2020.07.29.20161323v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20161323v1?rss=1,2020-07-30,2020-07-30,,True
207,Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy,"To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, and case-series studies. Fixed-effects analyses demontrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a a57% reduction in mortality rate (13%) compared to matched-patients receiving standard treatments (25%; OR: 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.","Joyner, M. J.; Klassen, S. A.; Senefeld, J.; Johnson, P. W.; Carter, R. E.; Wiggins, C. C.; Shoham, S.; Grossman, B. J.; Henderson, J. P.; Musser, J. M.; Salazar, E.; Hartman, W. R.; Bouvier, N. M.; Liu, S. T. H.; Pirofski, L.-a.; Baker, S. E.; Van Helmond, N.; Wright, R. S.; Fairweather, D.; Bruno, K. A.; Paneth, N. S.; Casadevall, A.","https://www.medrxiv.org/content/10.1101/2020.07.29.20162917v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.29.20162917v1?rss=1,2020-07-30,2020-07-30,,True
208,On the molecular mechanism of SARS-CoV-2 retention in the upper respiratory tract,"Cell surface receptor engagement is a critical aspect of viral infection. At low pH, binding of SARS-CoV and its ACE2 receptor has a tight interaction that catalyzes the fusion of the spike and endosomal membranes followed by genome release. Largely overlooked has been the role of neutral pH in the respiratory tract, where we find that SARS-CoV stabilizes a transition state that enhances the off-rate from its receptor. An alternative pH-switch is found in CoV-2-like coronaviruses of tropical pangolins, but with a reversed phenotype where the tight interaction with ACE2 is at neutral pH. We show that a single point mutation in pangolin-CoV, unique to CoV-2, that deletes the last His residue in their receptor binding domain perpetuates this tight interaction independent of pH. This tight bond, not present in previous respiratory syndromes, implies that CoV-2 stays bound to the highly expressed ACE2 receptors in the nasal cavity about 100 times longer than CoV. This finding supports the unfamiliar pathology of CoV-2, observed virus retention in upper respiratory tract1, longer incubation times and extended periods of shedding. Implications to combat pandemics that, like SARS-CoV-2, export evolutionarily successful strains via higher transmission rates due to retention in nasal epithelium and their evolutionary origin are discussed.","Paris, K. A.; Santiago, U.; Camacho, C. J.","https://www.biorxiv.org/content/10.1101/2020.07.29.227389v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.227389v1?rss=1,2020-07-29,2020-07-29,,False
209,Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis,"The novel betacoronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic (COVID-19) after initially emerging in Wuhan, China. Here we applied a novel, comprehensive bioinformatic strategy to public RNA sequencing and viral genome sequencing data, to better understand how SARS-CoV-2 interacts with human cells. To our knowledge, this is the first meta-analysis to predict host factors that play a specific role in SARS-CoV-2 pathogenesis, distinct from other respiratory viruses. We identified differentially expressed genes, isoforms and transposable element families specifically altered in SARS-CoV-2 infected cells. Well-known immunoregulators including CSF2, IL-32, IL-6 and SERPINA3 were differentially expressed, while immunoregulatory transposable element families were overexpressed. We predicted conserved interactions between the SARS-CoV-2 genome and human RNA-binding proteins such as hnRNPA1, PABPC1 and eIF4b, which may play important roles in the viral life cycle. We also detected four viral sequence variants in the spike, polymerase, and nonstructural proteins that correlate with severity of COVID-19. The host factors we identified likely represent important mechanisms in the disease profile of this pathogen, and could be targeted by prophylactics and/or therapeutics against SARS-CoV-2.","Ferrarini, M. G.; Lal, A.; Rebollo, R.; Gruber, A.; Guarracino, A.; Martinez Gonzalez, I.; Floyd, T.; Siqueira de Oliveira, D.; Shanklin, J.; Beausoleil, E.; Pusa, T.; Pickett, B.; Aguiar-Pulido, V.","https://www.biorxiv.org/content/10.1101/2020.07.28.225581v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225581v1?rss=1,2020-07-29,2020-07-29,,False
210,Divide in Vaccine Belief in COVID-19 Conversations: Implications for Immunization Plans,"The development of a viable COVID-19 vaccine is a work in progress, but the success of the immunization campaign will depend upon public acceptance. In this paper, we classify Twitter users in COVID-19 discussion into vaccine refusers (anti-vaxxers) and vaccine adherers (vaxxers) communities. We study the divide between anti-vaxxers and vaxxers in the context of whom they follow. More specifically, we look at followership of 1) the U.S. Congress members, 2) four major religions (Christianity, Hinduism, Judaism and Islam), 3) accounts related to the healthcare community, and 4) news media accounts. Our results indicate that there is a partisan divide between vaxxers and anti-vaxxers. We find a religious community with a higher than expected fraction of anti-vaxxers. Further, we find that the variance of vaccine belief within the news media accounts operated by Russian and Iranian governments is higher compared to news media accounts operated by other governments. Finally, we provide messaging and policy implications to inform the COVID-19 vaccine and future vaccination plans.","Tyagi, A.; Carley, K. M.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160887v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160887v1?rss=1,2020-07-29,2020-07-29,,True
211,Impact Analysis of SARS-CoV2 on Signaling Pathways during COVID19 Pathogenesis using Codon Usage Assisted Host-Viral Protein Interactions,"Understanding the molecular mechanism of COVID19 disease pathogenesis helps in the rapid development of therapeutic targets. Usually, viral protein targets host proteins in an organized fashion. The pathogen may target cell signaling pathways to disrupt the pathway genes regular activities, resulting in disease. Understanding the interaction mechanism of viral and host proteins involved in different signaling pathways may help decipher the attacking mechanism on the signal transmission during diseases, followed by discovering appropriate therapeutic solutions.

The expression of any viral gene depends mostly on the host translational machinery. Recent studies report the great significance of codon usage biases in establishing host-viral protein-protein interactions (PPI). Exploiting the codon usage patterns between a pair of co-evolved host and viral proteins may present novel insight into the host-viral protein interactomes during disease pathogenesis. Leveraging the codon usage pattern similarity (and dissimilarity), we propose a computational scheme to recreate the hostviral protein interaction network (HVPPI). We use seventeen (17) essential signaling pathways for our current work and study the possible targeting mechanism of SARS-CoV2 viral proteins on such pathway proteins. We infer both negatively and positively interacting edges in the network. We can find a relationship where one host protein may target by more than one viral protein.

Extensive analysis performed to understand the network topologically and the attacking behavior of the viral proteins. Our study reveals that viral proteins, mostly utilize codons, rare in the targeted host proteins (negatively correlated interaction). Among non-structural proteins, NSP3 and structural protein, Spike (S) protein, are the most influential proteins in interacting multiple host proteins. In ranking the most affected pathways, MAPK pathways observe to be worst affected during the COVID-19 disease. A good number of targeted proteins are highly central in host protein interaction networks. Proteins participating in multiple pathways are also highly connected in their own PPI and mostly targeted by multiple viral proteins.","Das, J.; Chakrobarty, S.; Roy, S.","https://www.biorxiv.org/content/10.1101/2020.07.29.226217v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.226217v1?rss=1,2020-07-29,2020-07-29,,False
212,SARS-CoV-2 Infection and Stroke: Coincident or Causal?,"Neurological manifestations of SARS-CoV-2 infection described in isolated case reports and single institutions do not accurately reflect the clinical spectrum of disease across all geographies in a global pandemic. Data collected during peak of the Covid-19 pandemic from stroke centers in five states reveal few similarities to what has recently been published. Given the diversity in phenotype, we caution policymakers and health care providers when considering cerebrovascular complications from SARS-CoV-2 infection.","Walker, M.; Young, C. C.; Sharma, M.; Levitt, M. R.; Tirschwell, D. L.; WWAMI Stroke Investigators,","https://www.medrxiv.org/content/10.1101/2020.07.17.20156463v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.17.20156463v1?rss=1,2020-07-29,2020-07-29,,True
213,Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model,"Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has had a dramatic global impact on public health, social, and economic infrastructures. Here, we assess immunogenicity and anamnestic protective efficacy in rhesus macaques of the intradermal (ID)-delivered SARS-CoV-2 spike DNA vaccine, INO-4800. INO-4800 is an ID-delivered DNA vaccine currently being evaluated in clinical trials. Vaccination with INO-4800 induced T cell responses and neutralizing antibody responses against both the D614 and G614 SARS-CoV-2 spike proteins. Several months after vaccination, animals were challenged with SARS-CoV-2 resulting in rapid recall of anti-SARS-CoV-2 spike protein T and B cell responses. These responses were associated with lower viral loads in the lung and with faster nasal clearance of virus. These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease.","Patel, A.; Walters, J.; Reuschel, E. L.; Schultheis, K.; Parzych, E.; Gary, E. N.; Maricic, I.; Purwar, M.; Eblimit, Z.; Walker, S. N.; Guimet, D.; Bhojnagarwala, P.; Doan, A.; Xu, Z.; Elwood, D.; Reeder, S. M.; Pessaint, L.; Kim, K. Y.; Cook, A.; Chokkalingam, N.; Finneyfrock, B.; Tello-Ruiz, E.; Dodson, A.; Choi, J.; Generotti, A.; Harrison, J.; Tursi, N. J.; Andrade, V. M.; Dia, Y.; Zaidi, F. I.; Anderson, H.; Lewis, M. G.; Muthumani, K.; Kim, J. J.; Kulp, D. W.; Humeau, L. M.; Ramos, S.; Smith, T. R.; Weiner, D. B.; Broderick, K. E.","https://www.biorxiv.org/content/10.1101/2020.07.28.225649v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225649v1?rss=1,2020-07-29,2020-07-29,,False
214,Infection of human lymphomononuclear cells by SARS-CoV-2,"Although SARS-CoV-2 severe infection is associated with a hyperinflammatory state, lymphopenia is an immunological hallmark, and correlates with poor prognosis in COVID-19. However, it remains unknown if circulating human lymphocytes and monocytes are susceptible to SARS-CoV-2 infection. In this study, SARS-CoV-2 infection of human peripheral blood mononuclear cells (PBMCs) was investigated both in vitro and in vivo. We found that in vitro infection of whole PBMCs from healthy donors was productive of virus progeny. Results revealed that monocytes, as well as B and T lymphocytes, are susceptible to SARS-CoV-2 active infection and viral replication was indicated by detection of double-stranded RNA. Moreover, flow cytometry and immunofluorescence analysis revealed that SARS-CoV-2 was frequently detected in monocytes and B lymphocytes from COVID-19 patients, and less frequently in CD4+T lymphocytes. The rates of SARS-CoV-2-infected monocytes in PBMCs from COVID-19 patients increased over time from symptom onset. Additionally, SARS-CoV-2-positive monocytes and B and CD4+T lymphocytes were detected by immunohistochemistry in post mortem lung tissue. SARS-CoV-2 infection of blood circulating leukocytes in COVID-19 patients may have important implications for disease pathogenesis, immune dysfunction, and virus spread within the host.","Pontelli, M. C.; Castro, I. A.; Martins, R. B.; Veras, F. P.; LaSerra, L.; Nascimento, D. C.; Cardoso, R. S.; Rosales, R.; Caetite, D. B.; Lima, M. H.; Lima, T. M.; Souza, J. P.; Kawahisa, J. T.; Giannini, M. C.; Bonjorno, L. P.; Lopes, M. I.; Batah, S. S.; Siyuan, L.; Assad, R. L.; Almeida, S. C.; Oliveira, F. R.; Benatti, M. N.; Pontes, L. L.; Santana, R. C.; Villar, F. C.; Martins, M. A.; Cunha, T. M.; Calado, R. T.; Alves-Filho, J. C.; Zamboni, D. S.; Fabro, A.; Louzada-Junior, P.; Louzada-Junior, P.; Oliveira, R. D.; Cunha, F. Q.; Arruda, E.","https://www.biorxiv.org/content/10.1101/2020.07.28.225912v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225912v1?rss=1,2020-07-29,2020-07-29,,False
215,Allosteric inhibition of the SARS-CoV-2 main protease - insights from mass spectrometry-based assays,"Following translation of the SARS-CoV-2 RNA genome into two viral polypeptides, the main protease Mpro cleaves at eleven sites to release non-structural proteins required for viral replication. MPro is an attractive target for antiviral therapies to combat the coronavirus-2019 disease (COVID-19). Here, we have used native mass spectrometry (MS) to characterize the functional unit of Mpro. Analysis of the monomer-dimer equilibria reveals a dissociation constant of Kd = 0.14 {+/-} 0.03 M, revealing MPro has a strong preference to dimerize in solution. Developing an MS-based kinetic assay we then characterized substrate turnover rates by following temporal changes in the enzyme-substrate complexes, which are effectively ""flash-frozen"" as they transition from solution to the gas phase. We screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the catalytically active dimer, slow the rate of substrate processing by ~35%. This information was readily obtained and, together with analysis of the x-ray crystal structures of these enzyme-small molecule complexes, provides a starting point for the development of more potent molecules that allosterically regulate MPro activity.","El-Baba, T. J.; Lutomski, C. A.; Kantsadi, A. L.; Malla, T. R.; John, T.; Mikhailov, V.; Bolla, J. R.; Schofield, C. J.; Zitzmann, N.; Vakonakis, I.; Robinson, C. V.","https://www.biorxiv.org/content/10.1101/2020.07.29.226761v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.226761v1?rss=1,2020-07-29,2020-07-29,,False
216,Structural and functional analysis of female sex hormones against SARS-Cov2 cell entry,"Emerging evidence suggests that males are more susceptible to severe infection by the SARS-CoV-2 virus than females. A variety of mechanisms may underlie the observed gender-related disparities including differences in sex hormones. However, the precise mechanisms by which female sex hormones may provide protection against SARS-CoV-2 infectivity remains unknown. Here we report new insights into the molecular basis of the interactions between the SARS-CoV-2 spike (S) protein and the human ACE2 receptor. We further observed that glycosylation of the ACE2 receptor enhances SARS-CoV-2 infectivity. Importantly estrogens can disrupt glycan-glycan interactions and glycan-protein interactions between the human ACE2 and the SARS-CoV2 thereby blocking its entry into cells. In a mouse model, estrogens reduced ACE2 glycosylation and thereby alveolar uptake of the SARS-CoV-2 spike protein. These results shed light on a putative mechanism whereby female sex hormones may provide protection from developing severe infection and could inform the development of future therapies against COVID-19.","Aguilar Pineda, J.; Albaghdadi, M.; Jiang, W.; Vera Lopez, K. J.; Lindsay, M. E.; Davila del-Carpio, G.; Gomez Valdez, B.; Malhotra, R.; Lino Cardenas, C. L.","https://www.biorxiv.org/content/10.1101/2020.07.29.227249v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.227249v1?rss=1,2020-07-29,2020-07-29,,False
217,Direct exposure to SARS-CoV-2 and cigarette smoke increases infection severity and alters the stemcell-derived airway repair response,"Most demographic studies are now associating current smoking status with increased risk of severe COVID-19 and mortality from the disease but there remain many questions about how direct cigarette smoke exposure affects SARS-CoV-2 airway cell infection. We directly exposed mucociliary air-liquid interface (ALI) cultures derived from primary human nonsmoker airway basal stem cells (ABSCs) to short term cigarette smoke and infected them with live SARS-CoV-2. We found an increase in the number of infected airway cells after cigarette smoke exposure as well as an increased number of apoptotic cells. Cigarette smoke exposure alone caused airway injury that resulted in an increased number of ABSCs, which proliferate to repair the airway. But we found that acute SARS-CoV-2 infection or the combination of exposure to cigarette smoke and SARS-CoV-2 did not induce ABSC proliferation. We set out to examine the underlying mechanism governing the increased susceptibility of cigarette smoke exposed ALI to SARS-CoV-2 infection. Single cell profiling of the cultures showed that infected airway cells displayed a global reduction in gene expression across all airway cell types. Interestingly, interferon response genes were induced in SARS-CoV-2 infected airway epithelial cells in the ALI cultures but smoking exposure together with SARS-CoV-2 infection reduced the interferon response. Treatment of cigarette smoke-exposed ALI cultures with Interferon {beta}-1 abrogated the viral infection, suggesting that the lack of interferon response in the cigarette smoke-exposed ALI cultures allows for more severe viral infection and cell death. In summary, our data show that acute smoke exposure allows for more severe proximal airway epithelial disease from SARS-CoV-2 by reducing the mucosal innate immune response and ABSC proliferation and has implications for disease spread and severity in people exposed to cigarette smoke.","Purkayastha, A.; Sen, C.; Garcia, G.; Langerman, J.; Vijayaraj, P.; Shia, D. W.; Meneses, L. K.; Rickabaugh, T. M.; Mulay, A.; Konda, B.; Sim, M. S.; Stripp, B. R.; Plath, K.; Arumugaswami, V.; Gomperts, B. N.","https://www.biorxiv.org/content/10.1101/2020.07.28.226092v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.226092v1?rss=1,2020-07-29,2020-07-29,,False
218,The genetic variants analysis of circulating SARS-CoV-2 in Bangladesh.,"Genomic mutation of the virus may impact the viral adaptation to the local environment, their transmission, disease manifestation, and the effectiveness of existing treatment and vaccination. The objectives of this study were to characterize genomic variations, non-synonymous amino acid substitutions, especially in target proteins, mutation events per samples, mutation rate, and overall scenario of coronaviruses across the country. To investigate the genetic diversity, a total of 184 genomes of virus strains sampled from different divisions of Bangladesh with sampling dates between the 10th of May 2020 and the 27th of June 2020 were analyzed. To date, a total of 634 mutations located along the entire genome resulting in non-synonymous 274 amino acid substitutions in 22 different proteins were detected with nucleotide mutation rate estimated to be 23.715 substitutions per year. The highest non-synonymous amino acid substitutions were observed at 48 different positions of the papain-like protease (nsp3). Although no mutations were found in nsp7, nsp9, nsp10, and nsp11, yet orf1ab accounts for 56% of total mutations. Among the structural proteins, the highest non-synonymous amino acid substitution (at 36 positions) observed in spike proteins, in which 9 unique locations were detected relative to the global strains, including 516E>Q in the boundary of the ACE2 binding region. The most dominated variant G614 (95%) based in spike protein is circulating across the country with co-evolving other variants including L323 (94%) in RNA dependent RNA polymerase (RdRp), K203 (82%) and R204 (82%) in nucleocapsid, and F120 (78%) in NSP2. These variants are mostly seen as linked mutations and are part of a haplotype observed in Europe. Data suggest effective containment of clade G strains (4.8%) with sub-clusters GR 82.4%, and GH clade 6.4%.

HighlightsO_LIWe have sequenced 137 and analyzed 184 whole-genomes sequences of SARS-CoV-2 strains from different divisions of Bangladesh.
C_LIO_LIA total of 634 mutation sites across the SARS-CoV-2 genome and 274 non-synonymous amino acid substitutions were detected.
C_LIO_LIThe mutation rate of SARS-CoV-2 estimated to be 23.715 nucleotide substitutions per year.
C_LIO_LINine unique variants were detected based on non-anonymous amino acid substitutions in spike protein relative to the global SARS-CoV-2 strains.
C_LI","Mahmud, A. S. M.; Taznin, T.; Sarkar, M. M. H.; Uzzaman, M. S.; Osman, E.; Habib, M. A.; Akter, S.; Banu, T. A.; Goswami, B.; Jahan, I.; Hossain, M. S.; Khan, M. S.","https://www.biorxiv.org/content/10.1101/2020.07.29.226555v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.29.226555v1?rss=1,2020-07-29,2020-07-29,,False
219,The Pandemics in Artificial Society: Agent-Based Model to Reflect Strategies on COVID-19,"Various social policies and strategies have been deliberated and used within many countries to handle the COVID-19 pandemic. Some of those basic ideas are strongly related to the understanding of human social interactions and the nature of disease transmission and spread. In this paper, we present an agent- based approach to model epidemiological phenomena as well as the interventions upon it. We elaborate on micro-social structures such as social-psychological factors and distributed ruling behaviors to grow an artificial society where the interactions among agents may exhibit the spreading of the virus. Capturing policies and strategies during the pandemic, four types of intervention are also applied in society. Emerged macro-properties of epidemics are delivered from sets of simulations, lead to comparisons between each effectivity of the policy/strategy.","Situngkir, H.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162511v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162511v1?rss=1,2020-07-29,2020-07-29,,True
220,Persistent heterogeneity not short-term overdispersion determines herd immunity to COVID-19,"It has become increasingly clear that the COVID-19 epidemic is characterized by overdispersion whereby the majority of the transmission is driven by a minority of infected individuals. Such a strong departure from the homogeneity assumptions of traditional well-mixed compartment model is usually hypothesized to be the result of short-term super-spreader events, such as individual's extreme rate of virus shedding at the peak of infectivity while attending a large gathering without appropriate mitigation. However, heterogeneity can also arise through long-term, or persistent variations in individual susceptibility or infectivity. Here, we show how to incorporate persistent heterogeneity into a wide class of epidemiological models, and derive a non-linear dependence of the effective reproduction number R_e on the susceptible population fraction S. Persistent heterogeneity has three important consequences compared to the effects of overdispersion: (1) It results in a major modification of the early epidemic dynamics; (2) It significantly suppresses the herd immunity threshold; (3) It significantly reduces the final size of the epidemic. We estimate social and biological contributions to persistent heterogeneity using data on real-life face-to-face contact networks and age variation of the incidence rate during the COVID-19 epidemic, and show that empirical data from the COVID-19 epidemic in New York City (NYC) and Chicago and all 50 US states provide a consistent characterization of the level of persistent heterogeneity. Our estimates suggest that the hardest-hit areas, such as NYC, are close to the persistent heterogeneity herd immunity threshold following the first wave of the epidemic, thereby limiting the spread of infection to other regions during a potential second wave of the epidemic. Our work implies that general considerations of persistent heterogeneity in addition to overdispersion act to limit the scale of pandemics.","Tkachenko, A. V.; Maslov, S.; Elbanna, A.; Wong, G.; Weiner, Z.; Goldenfeld, N.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162420v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162420v1?rss=1,2020-07-29,2020-07-29,,True
221,Impact of the COVID-19 Pandemic on the Short-term Course of Obsessive-Compulsive Disorder,"Background: There is an understandable concern that obsessive-compulsive disorder (OCD) may worsen during the COVID-19 pandemic, but there is little empirical data. We report the impact of COVID-19 pandemic on the short-term course of OCD. We also assessed for predictors of relapse and emergence of COVID-19-themed obsessive-compulsive symptoms. Methods: A cohort of patients with a primary diagnosis of OCD (n=240) who were on regular follow-up at a tertiary care specialty OCD Clinic in India were assessed telephonically, about 2 months after the declaration of the pandemic ('pandemic' cohort). Data from the medical records of an independent set of patients with OCD (n=207) who were followed-up during the same period, one year prior, was used for comparison (historical controls). Results: The 'pandemic' group and historical controls did not differ in the trajectories of the Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores (Chi-square for likelihood-ratio test of the Group x Time interaction = 2.73, p= 0.255) and relapse rate [21% vs 20%, adjusted odds ratio = 0.81 (95% CI 0.41 -1.59, p=0.535]. Pre-existing contamination symptoms and COVID-19-related health anxiety measured by the COVID-Threat Scale did not predict relapse. Only a small proportion of patients (6%) reported COVID-19-themed obsessive-compulsive symptoms. Limitations: Follow-up 2 months after pandemic declaration may be too early understand the true impact. Conclusions: The COVID-19 pandemic, at least in the short-run, did not influence the course of illness in those who were on medications. It would be pertinent to evaluate the long-term impact of the pandemic on the course of OCD.","Sharma, L. P.; Balachander, S.; Thamby, A.; Bhattacharya, M.; Kishore, C.; Shanbhag, V.; TS, J.; Narayanaswamy, J. C.; Arumugham, S. S.; Reddy, Y. J.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162495v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162495v1?rss=1,2020-07-29,2020-07-29,,True
222,Mathematical Modelling the Impact Evaluation ofLockdown on Infection Dynamics of COVID-19 inItaly.,"The Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2), the cause of the coronavirus disease-2019 (COVID-19), within months of emergence from Wuhan, China, has rapidly spread, exacting a devastating human toll across around the world reaching the pandemic stage at the the beginning of March 2020. Thus, COVID-19s daily increasing cases and deaths have led to worldwide lockdown, quarantine and some restrictions. Covid-19 epidemic in Italy started as a small wave of 2 infected cases on January 31. It was followed by a bigger wave mainly from local transmissions reported in 6387 cases on March 8. It caused the government to impose a lockdown on 8 March to the whole country as a way to suppress the pandemic. This study aims to evaluate the impact of the lockdown and awareness dynamics on infection in Italy over the period of January 31 to July 17 and how the impact varies across different lockdown scenarios in both periods before and after implementation of the lockdown policy. The findings SEIR reveal that implementation lockdown has minimised the social distancing flattening the curve. The infections associated with COVID-19 decreases with quarantine initially then easing lockdown will not cause further increasing transmission until a certain period which is explained by public high awareness. Completely removing lockdown may lead to sharp transmission second wave. Policy implementation and limitation of the study were evaluated at the end of the paper. Keywords COVID-19 - Lockdown - Epidemic model - SEIR - Awareness - Dynamical systems.","Yergesh, D.; Kadyrov, S.; Saydaliev, H.; Orynbassar, A.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162537v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162537v1?rss=1,2020-07-29,2020-07-29,,True
223,Non-COVID-19 deaths in the United States during the imposition of sheltering-in-place,"Public debate over imposed sheltering-in-place in the United States (US) includes the claim that non-COVID-19 deaths increased above those expected from history and from such deaths in Sweden. We test this claim by applying Box-Jenkins transfer function modeling to weekly deaths between December 29, 2013 and May 16, 2020 in the US and Sweden. In the eight weeks of imposed sheltering-in-place in the US, assumed begun in the week of March 22, an average of 715 fewer non-COVID-19 deaths (95% CI: -1428, -2) occurred per week implying a total of 5720 less than expected from those in Sweden and from history. Results changed little (i.e., 5472 fewer deaths than expected) when we excluded deaths in New York City. Contrary to speculation, non-COVID-19 mortality appeared to decline in the US after shelter-in-place orders.","Catalano, R.; Casey, J. A.; Gemmill, A.; Bruckner, T.-A.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162396v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162396v1?rss=1,2020-07-29,2020-07-29,,True
224,Understanding the patterns of repeated testing for COVID-19: Association with patient characteristics and outcomes,"Importance The diagnostic tests for COVID-19 have a high false negative rate, but not everyone with an initial negative result is re-tested. Michigan Medicine, being one of the primary regional centers accepting COVID-19 cases, provided an ideal setting for studying COVID-19 repeated testing patterns during the first wave of the pandemic. Objective To identify the characteristics of patients who underwent repeated testing for COVID-19 and determine if repeated testing was associated with patient characteristics and with downstream outcomes among positive cases. Design This cross-sectional study described the pattern of testing for COVID-19 at Michigan Medicine. The main hypothesis under consideration is whether patient characteristics differed between those tested once and those who underwent multiple tests. We then restrict our attention to those that had at least one positive test and study repeated testing patterns in patients with severe COVID-19 related outcomes (testing positive, hospitalization and ICU care). Setting Demographic and clinical characteristics, test results, and health outcomes for 15,920 patients presenting to Michigan Medicine between March 10 and June 4, 2020 for a diagnostic test for COVID-19 were collected from their electronic medical records on June 24, 2020. Data on the number and types of tests administered to a given patient, as well as the sequences of patient-specific test results were derived from records of patient laboratory results. Participants Anyone tested between March 10 and June 4, 2020 at Michigan Medicine with a diagnostic test for COVID-19 in their Electronic Health Records were included in our analysis. Exposures Comparison of repeated testing across patient demographics, clinical characteristics, and patient outcomes Main Outcomes and Measures Whether patients underwent repeated diagnostic testing for SARS CoV-2 in Michigan Medicine Results Between March 10th and June 4th, 19,540 tests were ordered for 15,920 patients, with most patients only tested once (13596, 85.4%) and never testing positive (14753, 92.7%). There were 5 patients who got tested 10 or more times and there were substantial variations in test results within a patient. After fully adjusting for patient and neighborhood socioeconomic status (NSES) and demographic characteristics, patients with circulatory diseases (OR: 1.42; 95% CI: (1.18, 1.72)), any cancer (OR: 1.14; 95% CI: (1.01, 1.29)), Type 2 diabetes (OR: 1.22; 95% CI: (1.06, 1.39)), kidney diseases (OR: 1.95; 95% CI: (1.71, 2.23)), and liver diseases (OR: 1.30; 95% CI: (1.11, 1.50)) were found to have higher odds of undergoing repeated testing when compared to those without. Additionally, as compared to non-Hispanic whites, non-Hispanic blacks were found to have higher odds (OR: 1.21; 95% CI: (1.03, 1.43)) of receiving additional testing. Females were found to have lower odds (OR: 0.86; 95% CI: (0.76, 0.96)) of receiving additional testing than males. Neighborhood poverty level also affected whether to receive additional testing. For 1% increase in proportion of population with annual income below the federal poverty level, the odds ratio of receiving repeated testing is 1.01 (OR: 1.01; 95% CI: (1.00, 1.01)). Focusing on only those 1167 patients with at least one positive result in their full testing history, patient age in years (OR: 1.01; 95% CI: (1.00, 1.03)), prior history of kidney diseases (OR: 2.15; 95% CI: (1.36, 3.41)) remained significantly different between patients who underwent repeated testing and those who did not. After adjusting for both patient demographic factors and NSES, hospitalization (OR: 7.44; 95% CI: (4.92, 11.41)) and ICU-level care (OR: 6.97; 95% CI: (4.48, 10.98)) were significantly associated with repeated testing. Of these 1167 patients, 306 got repeated testing and 1118 tests were done on these 306 patients, of which 810 (72.5%) were done during inpatient stays, substantiating that most repeated tests for test positive patients were done during hospitalization or ICU care. Additionally, using repeated testing data we estimate the ""real world"" false negative rate of the RT-PCR diagnostic test was 23.8% (95% CI: (19.5%, 28.5%)). Conclusions and Relevance This study sought to quantify the pattern of repeated testing for COVID-19 at Michigan Medicine. While most patients were tested once and received a negative result, a meaningful subset of patients (2324, 14.6% of the population who got tested) underwent multiple rounds of testing (5,944 tests were done in total on these 2324 patients, with an average of 2.6 tests per person), with 10 or more tests for five patients. Both hospitalizations and ICU care differed significantly between patients who underwent repeated testing versus those only tested once as expected. These results shed light on testing patterns and have important implications for understanding the variation of repeated testing results within and between patients.","Salerno, S.; Zhao, Z.; Prabhu Sankar, S.; Salvatore, M.; Gu, T.; Fritsche, L. G.; Lee, S.; Lisabeth, L. D.; Valley, T. S.; Mukherjee, B.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162453v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162453v1?rss=1,2020-07-29,2020-07-29,,True
225,Mental Health of Medical Workers During the COVID-19 Pandemic in Russia: Results of a Cross-Sectional Study,"This is the first study in Russia regarding the mental health of medical workers during a pandemic. In this survey, the study of medical workers during pandemic COVID-19 in Russia reported high rates of symptoms of depression and anxiety. There is a higher risk of developing symptoms of anxiety and depression among young employees working directly in high-risk areas of the infection. Protecting medical workers is an important component of public health measures for addressing the COVID-19 pandemic. Special measures to improve the mental health of medical workers should be based on their needs. Special attention needs to be paid to young medical workers working in areas with a high risk of infection.","Bachilo, E.; Barylnik, J.; Shuldyakov, A.; Efremov, A.; Novikov, D.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162610v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162610v1?rss=1,2020-07-29,2020-07-29,,True
226,"An Analysis of Territorial Patterns in COVID-19 Mortality in France, Spain, Italy and the UK","This paper provides an overview of territorial patterns of COVID-19 deaths in four European countries severely affected by the pandemic, Spain, France, Italy, and the United Kingdom. The analysis focuses on cumulated COVID-19 mortality at the sub-regional level, following the territorial subdivision of countries adopted by the European Union. The paper builds upon a dataset with highly granular information on COVID-19 deaths assembled from various sources. The analysis shows remarkable differences in territorial patterns of COVID-19 mortality, both within and across the four countries reviewed. Results somewhat differ depending on the aspect considered (concentration of deaths or mortality rates) but, in general, Italy, France and Spain display significant territorial disparities, with selected sub-regions being disproportionately affected by the pandemic. Instead, the picture is more uniform in the UK, with comparatively lower differences across the various sub-regions. These findings suggest that analyses of COVID-19 mortality at the national level (and, sometimes, even at the regional level) may conceal major differences and therefore be of limited use, both analytically and from an operational viewpoint.","Zavatta, R.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162677v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162677v1?rss=1,2020-07-29,2020-07-29,,True
227,Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography in severe COVID-19,"Introduction: D-dimer concentration has been used to identify candidates for intensified anticoagulant treatment for both venous thromboembolism prevention and mitigation of the microthrombotic complications associated with COVID-19. Thromboelastography (TEG) maximum amplitude (MA) has been validated as an indicator of hypercoagulability and MA [&ge;] 68 mm has been utilized as a marker of hypercoagulability in other conditions. We evaluated the relationship between coagulation, inflammatory, and TEG parameters in patients with COVID-19 on extracorporeal membrane oxygenation (ECMO). Methods: We performed a single center retrospective analysis of consecutive patients that received ECMO for the treatment of COVID-19. TEG, inflammatory, and coagulation markers were compared in patients with and without thrombotic complications. Correlation tests were performed to identify the coagulation and inflammatory markers that best predict hypercoagulability as defined by an elevated TEG MA. Results: 168 TEGs were available in 24 patients. C-reactive protein and fibrinogen were significantly higher in patients that developed a thrombotic event versus those that did not (p=0.038 and p=0.043 respectively). D-dimer was negatively correlated with TEG MA (p<0.001) while fibrinogen was positively correlated (p<0.001). A fibrinogen > 441 mg/dL had a sensitivity of 91.2% and specificity of 85.7% for the detection of MA [&ge;] 68 mm. Conclusions: In critically ill patients with COVID-19, D-dimer concentration had an inverse relationship with hypercoagulability as measured by TEG MA. D-dimer elevation may reflect severity of COVID-19 related sepsis rather than designate patients likely to benefit from anticoagulation. Fibrinogen concentration may represent a more useful marker of hypercoagulability in this population.","Chandel, A.; Patolia, S.; Looby, M.; Dalton, H.; Bade, N.; Khangoora, V.; Desai, M.; Lantry, J.; Osborn, E.; Djurkovic, S.; Tang, D.; Nathan, S. D.; King, C. S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162842v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162842v1?rss=1,2020-07-29,2020-07-29,,True
228,"A novel predictive mathematical model for COVID-19 pandemic with quarantine, contagion dynamics, and environmentally mediated transmission","This work presents an ODE model for COVID-19 named SINDROME that incorporates quarantine, contagion dynamics, and environmentally mediated transmission based on the compartments. The SINDROME model introduces a new parameter that allows environmentally mediated transmission, moving quarantined individuals to the infected compartment. We developed a gray box model with the SINDROME, and fit over 169 worldwide regions.","Carvalho, D.; Barbastefano, R.; Pastore, D.; Lippi, M. C.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163063v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163063v1?rss=1,2020-07-29,2020-07-29,,True
229,Severity detection for the coronavirus disease 2019 (COVID-19) patients using a machine learning model based on the blood and urine tests,"The recent outbreak of the coronavirus disease-2019 (COVID-19) caused serious challenges to the human society in China and across the world. COVID-19 induced pneumonia in human hosts and carried a highly inter-person contagiousness. The COVID-19 patients may carry severe symptoms, and some of them may even die of major organ failures. This study utilized the machine learning algorithms to build the COVID-19 severeness detection model. Support vector machine (SVM) demonstrated a promising detection accuracy after 32 features were detected to be significantly associated with the COVID-19 severeness. These 32 features were further screened for inter-feature redundancies. The final SVM model was trained using 28 features and achieved the overall accuracy 0.8148. This work may facilitate the risk estimation of whether the COVID-19 patients would develop the severe symptoms. The 28 COVID-19 severeness associated biomarkers may also be investigated for their underlining mechanisms how they were involved in the COVID-19 infections.","Yao, H.; Zhang, N.; Zhang, R.; Duan, M.; Xie, T.; Pan, J.; Peng, E.; Huang, J.; Zhang, Y.; Xu, X.; Xu, H.; Zhou, F.; Wang, G.","https://www.medrxiv.org/content/10.1101/2020.07.27.20044990v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20044990v1?rss=1,2020-07-29,2020-07-29,,True
230,Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain.,"Background. The COVID-19 pandemic has posed a huge challenge to healthcare systems and their personnel worldwide. The study of the impact of SARS-CoV-2 infection among healthcare workers, through prevalence studies, will let us know viral expansion, individuals at most risk and the most exposed areas. The aim of this study is to gauge the impact of SARS-CoV-2 pandemic in our hospital workforce and identify groups and areas at increased risk. Methods and Findings. This is a cross-sectional and longitudinal study carried out on healthcare workers based on molecular and serological diagnosis of SARS-CoV-2 infection. Of the 3013 HCW invited to participate, finally 2439 (80.9%) were recruited, including 674 (22.4%) who had previously consulted at the OHS for confirmed exposure and/or presenting symptoms suggestive of COVID-19. A total of 411 (16.9%) and 264 (10.8%) healthcare workers were SARS-CoV-2 IgG and rRT-PCR positive, respectively. The cumulative prevalence considering all studies (IgG positive HCW and/or rRT-PCR positive detection) has been 485 (19.9%). SARS-CoV-2 IgG-positive patients in whom the virus was not detected were 221 (9.1%); up to 151 of them (68.3%) did not report any compatible symptoms nor consult at the OHS for this reason. Men became more infected than women (25% vs 18.5%, p=0.0009), including when data were also classified by age. COVID-19 cumulative prevalence among the HCW assigned to medical departments was higher (25.2%) than others, as well as among medical staff (25.4%) compared with other professional categories (p<0.01). Conclusions. Global impact of the COVID-19 pandemic on HCW of our centre has been 19.9%. Doctors and medical services personnel have had the highest prevalence of SARS-CoV-2 infection, but many of them have not presented compatible symptoms. This emphasizes the performance of continuous surveillance methods of the most exposed health personnel and not only based on the appearance of symptoms.","Garralda Fernandez, J.; Molero Vilches, I.; Bermejo Rodriguez, A.; Cano de Torres, I.; Colino Romay, E. I.; Garcia-Arata, I.; Jaqueti Aroca, J.; Lillo, R.; Lopez Lacomba, D.; Mazon Cuadrado, L.; Molina Esteban, L. M.; Morales Garcia, L. J.; Moratilla Monzo, L.; Nieto-Borrajo, E.; Pacheco Delgado, M.; Prieto Menchero, S.; Sanchez Hernandez, C.; Sanchez Testillano, E.; Garcia-Martinez, J.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162529v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162529v1?rss=1,2020-07-29,2020-07-29,,True
231,Transport effect of COVID-19 pandemic in France,"An extension of the classical pandemic SIRD model is considered for the regional spread of COVID-19 in France under lockdown strategies. This compartment model divides the infected and the recovered individuals into undetected and detected compartments respectively. By fitting the extended model to the real detected data during the lockdown, an optimization algorithm is used to derive the optimal parameters, the initial condition and the epidemics start date of regions in France. Considering all the age classes together, a network model of the pandemic transport between regions in France is presented on the basis of the regional extended model and is simulated to reveal the transport effect of COVID-19 pandemic after lockdown. Using the the measured values of displacement of people mobilizing between each city, the pandemic network of all cities in France is simulated by using the same model and method as the pandemic network of regions. Finally, a discussion on an integro-differential equation is given and a new model for the network pandemic model of each age class is provided.","Guan, L.; Prieur, C.; Zhang, L.; Prieur, C.; Georges, D.; Bellemain, P.","https://www.medrxiv.org/content/10.1101/2020.07.27.20161430v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20161430v1?rss=1,2020-07-29,2020-07-29,,True
232,SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals,"Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and calls for diagnostic tools to monitor and understand the transmission, pathogenesis and epidemiology, as well as to evaluate future vaccination strategies. Here we have developed novel flexible ELISA-based assays for specific detection of SARS-CoV-2 antibodies against the receptor-binding domain (RBD): An antigen sandwich-ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the antibody responses to different areas on protein N and S and showed that the IgM, A and G antibody responses against RBD are significantly correlated to the disease severity. These assays-and the data generated from them-are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.","Hansen, C. B.; Jarlhelt, I.; Perez-Alos, L.; Hummelshoj Landsy, L.; Loftager, M.; Rosbjerg, A.; Helgstrand, C.; Bjelke, J. R.; Egebjerg, T.; Jardine, J. G.; Svaerke Jorgensen, C.; Iversen, K.; Bayarri-Olmos, R.; Garred, P.; Skjoedt, M.-O.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162321v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162321v1?rss=1,2020-07-29,2020-07-29,,True
233,Efficacy and tolerability of bevacizumab in patients with severe Covid -19,"On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate [&ge;]30 times/min, oxygen saturation [&le;]93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and [&le;]300 mmHg, and diffuse pneumonia confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood were significantly increased and CRP levels were markedly decreased as shown in available data. Our findings suggested bevacizumab plus standard care was highly beneficial for treating patients with severe Covid-19. Clinical efficacy of bevacizumab warrants double blind, randomized, placebo-controlled trials.","Pang, J.; Xu, F.; Aondio, G.; Li, Y.; Fumagalli, A.; Lu, M.; Valmadre, G.; Wei, J.; Bian, Y.; Canesi, M.; Damiani, G.; Zhang, Y.; Yu, D.; Chen, J.; Ji, X.; Sui, W.; Wang, B.; Wu, S.; Kovacs, A.; Revera, M.; Wang, H.; Zhang, Y.; Chen, Y.; Cao, Y.","https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1?rss=1,2020-07-29,2020-07-29,,True
234,Baseline Cardiometabolic Profiles and SARS-CoV-2 Risk in the UK Biobank,"Abstract Background SARS-CoV-2 is a rapidly spreading coronavirus with a high incidence of severe upper respiratory infection that first presented in Wuhan, China in December 2019. Many factors have been identified as risk factors for SARS-CoV-2, with much attention being paid to body mass index (BMI), but little investigation has been done to investigate dysregulation of lipid profiles and diabetes, which are often comorbid in high BMI patients. Objective This study seeks to describe the impact of BMI, HDL, LDL, ApoA, ApoB, triglycerides, hemoglobin A1c (HbA1c), diabetes, alcohol and red wine intake on SARS-CoV-2 risk in UK Biobank (UKB) study participants. Methods We examined the effect of BMI, lipid profiles, diabetes and alcohol intake on the risk of testing positive for SARS-Cov-2 among 9,005 UKB participants tested for SARS-CoV-2 from March 16 through June 29, 2020. Logistic regression was performed on the target variables controlling for age, sex and ancestry. Results BMI, Type II diabetes and HbA1c were associated with increased SARS-CoV-2 risk (p < 0.05) while HDL and ApoA were associated with decreased risk (p < 0.001). Additionally, red wine intake was associated with reduced SARS-CoV-2 risk (p < 0.05). LDL, ApoB and triglyceride levels were not found to be significantly associated with increased risk. Conclusion Elevated HDL and ApoA levels and alcohol intake, specifically red wine intake, were associated with reduced risk of testing positive for SARS-CoV-2, while type II diabetes and HbA1c were associated with increased risk. The effects of alcohol, type II diabetes and HbA1c levels may be indirect, mediated in part through regulation of HDL levels. In summary, our study corroborates the emerging picture that high HDL levels may confer protection against SARS-CoV-2.","Scalsky, R. J.; Desai, K.; Chen, Y.-J.; O'Connell, J. R.; Perry, J. A.; Hong, C. C.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161091v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161091v1?rss=1,2020-07-29,2020-07-29,,True
235,A HYBRID KNOWLEDGE-BASED AND MODIFIED REGRESSION ANALYSIS APPROACH FOR COVID-19 TRACKING IN USA,"Since its appearance in 2019, the covid-19 virus deluged the world with unprecedented data in short time. Despite the countless worldwide pertinent studies and advanced technologies, the spread is neither contained nor defeated. In fact, there is a record surge in the number of confirmed new cases since July 2020. This article presents a new predictive Knowledge-based (KB) toolkit named CORVITT (Corona Virus Tracking Toolkit) and modified linear regression model. This hybrid approach uses the confirmed new cases and demographic data, implemented. CORVITT is not an epidemiological model, in the sense that it does not model disease transmission, nor does it use underlying epidemiological parameters like the reproductive rate. It forecasts the spread in order to assist the official to make proactive intervention.","Hussein, R.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162347v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162347v1?rss=1,2020-07-29,2020-07-29,,True
236,"PLEXIT - Therapeutic plasma exchange (TPE) for Covid-19 cytokine release storm (CRS), a retrospective propensity matched control study","Importance: Cytokine release storm (CRS) plays pivotal role in pathophysiology and progression of COVID-19. Objective: To evaluate the outcomes of COVID-19 patients having CRS treated with Therapeutic Plasma Exchange (TPE) as compared to controls not receiving TPE. Design: Retrospective propensity score (PS) matched analysis, 1st April to 30th June 2020. Setting: Tertiary care hospital, single centre based. Participants: Using PS 1:1 matching, 90 patients were assigned 2 groups (45 receiving TPE and 45 controls). Forced matching and covariate matching was done to overcome bias between two groups. Main outcomes and measures: Primary outcome was 28 days overall survival. Secondary outcomes were duration of hospitalization, CRS resolution time and timing of PCR negativity. Results: Median age was 60 years (range 32-73 in TPE, 37-75 in non-TPE group), p= 0.325. Median symptoms duration 7 days (range 3-22 days TPE and 3-20 days non-TPE), p=0.266. Disease severity in both groups was 6.6% moderate, 44.4% severe and 49% critical. Twenty-eight-day survival was significantly superior in TPE group (91.1%) as compared to controls (61.5%), HR 0.21, 95% CI for HR 0.09-0.53, log rank 0.002. Median duration of hospitalization was significantly reduced in TPE treated group as compared to non-TPE controls 10 days and 15 days respectively (p< 0.01). CRS resolution time was also significantly reduced in TPE treated group (6 days vs. 12 days) (p< 0.001). Conclusion and Relevance: Use of TPE is associated with superior overall survival, early CRS resolution and time to discharge as compared to standard therapy for COVID-19 triggered CRS.","kamran, s. m.; Mirza, Z. -e. H.; Naseem, A.; Liaqat, J.; Fazal, I.; Alamgir, W.; Saeed, F.; Azam, R.; Hussain, M.; Yousaf, M. A.; Ashraf, N.; Nisar, S.; Ali, M. Z.; Saleem, S.; Sajjad, K.; Zaman, A.; Azam, M. N.; Hussain, M.; iftikhar, r.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160796v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160796v1?rss=1,2020-07-29,2020-07-29,,True
237,"Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States","BACKGROUND: Despite the significant morbidity and mortality caused by the 2019 novel coronavirus disease (COVID-19), our understanding of basic disease epidemiology remains limited. This study aimed to describe key patient characteristics, comorbidities, treatments, and outcomes of a large U.S.-based cohort of patients hospitalized with COVD-19 using electronic health records (EHR). METHODS: We identified patients in the Optum De-identified COVID-19 EHR database who had laboratory-confirmed COVID-19 or a presumptive diagnosis between 20 February 2020 and 6 June 2020. We included hospitalizations that occurred 7 days prior to, or within 21 days after, COVID-19 diagnosis. Among hospitalized patients we describe the following: vital statistics and laboratory results on admission, relevant comorbidities (using diagnostic, procedural, and revenue codes), medications (NDC, HCPC codes), ventilation, intensive care unit (ICU) stay, length of stay (LOS), and mortality. RESULTS: We identified 76,819 patients diagnosed with COVID-19, 16,780 of whom met inclusion criteria for COVID-related hospitalization. Over half the cohort was over age 50 (74.5%), overweight or obese (77.2%), or had hypertension (58.1%). At admission, 30.3% of patients presented with fever (>38C) and 32.3% had low oxygen saturation (<90%). Among the 16,099 patients with complete hospital records, we observed that 58.9% had hypoxia, 23.4% had an ICU stay during hospitalization, 18.1% were ventilated, and 16.2% died. The median LOS was 6 days (IQR: 4, 11). CONCLUSIONS: To our knowledge, this is the largest descriptive study of patients hospitalized with COVID-19 in the United States. We report summary statistics of key clinical outcomes that provide insights to better understand COVID-19 disease epidemiology.","Rizzo, S.; Chawla, D.; Zalocusky, K.; Keebler, D.; Chia, J.; Lindsay, L.; Yau, V.; Kamath, T.; Tsai, L.","https://www.medrxiv.org/content/10.1101/2020.07.17.20156265v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.17.20156265v1?rss=1,2020-07-29,2020-07-29,,True
238,Endpoint PCR Detection of Sars-CoV-2 RNA,"Quantitative real-time PCR methods have been used to perform approximately 278 million tests for COVID-19 up to mid-July 2020. Real-time PCR involves a rate limiting step where the samples are measured in situ during each PCR amplification cycle. This creates a bottleneck limiting scalability and as a consequence reducing access to inexpensive reliable testing at national and international scales. We investigated endpoint PCR for the qualitative detection of SARS-CoV-2 sequences on synthetic RNA standards and hospital patient samples. The endpoint PCR detection limit is constrained only by the stochastics of low copy numbers and reliably detected single copies of synthetic RNA standards. On a set of 30 patient samples, endpoint PCR found one additional positive sample and was able to confirm an indeterminate sample as negative. These results were found using 4 l reagent and 1 l of sample representing an 80% reduction relative to the NHS protocol (20 l reagent and 5 l sample). These results indicate that endpoint PCR should be the method of choice for large scale testing programmes. Based on the experience from ultra-high throughput genotyping efforts a single workflow using 384-well plates has similar PCR capacity (250 Million) to that required for all testing done worldwide during the first 7 month of the pandemic.","Moses, S. E.; Warren, C.; Robinson, P.; Curtis, J.; Asquith, S.; Holme, J.; Jain, N.; Brookes, K. J.; Hanley, Q. S.","https://www.medrxiv.org/content/10.1101/2020.07.21.20158337v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20158337v1?rss=1,2020-07-29,2020-07-29,,True
239,ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma,"Rationale: COVID-19 is complicated by acute lung injury, and death in some individuals. It is caused by SARS-CoV-2 that requires the ACE2 receptor and serine proteases to enter airway epithelial cells (AECs). Objective: To determine what factors are associated with ACE2 expression particularly in patients with asthma and chronic obstructive pulmonary disease (COPD). Methods: We obtained upper and lower AECs from 145 people from two independent cohorts, aged 2-89, Newcastle (n=115), and from Perth (n= 30) Australia. The Newcastle cohort was enriched with people with asthma (n=37) and COPD (n=38). Gene expression for ACE2 and other genes potentially associated with SARS-CoV-2 cell entry were assessed by quantitative PCR, protein expression was confirmed with immunohistochemistry on endobronchial biopsies and cultured AECs. Results: Increased gene expression of ACE2 was associated with older age (p=0.02) and male sex (p=0.03), but not pack-years smoked. When we compared gene expression between adults with asthma, COPD and healthy controls, mean ACE2 expression was lower in asthma (p=0.01). Gene expression of furin, a protease that facilitates viral endocytosis, was also lower in asthma (p=0.02), while ADAM-17, a disintegrin that cleaves ACE2 from the surface was increased (p=0.02). ACE2 protein levels were lower in endobronchial biopsies from asthma patients. Conclusions: Increased ACE2 expression occurs in older people and males. Asthma patients have reduced expression. Altered ACE2 expression in the lower airway may be an important factor in virus tropism and may in part explain susceptibility factors and why asthma patients are not over-represented in those with COVID-19 complications.","Wark, P.; Pathinyake, P.; Kaiko, G.; Nichol, K.; Ali, A.; Chen, L.; Suntanto, E.; Garrat, L.; Sohal, S. S.; Lu, W.; Eapen, M.; Oldmeadow, C.; Bartlett, N.; Reid, A.; Veerati, P.; Hsu, A.; Iosifides, T.; Stick, S.; Hansbro, P. M.; Kicic, A.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162248v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162248v1?rss=1,2020-07-29,2020-07-29,,True
240,How much reserve capacity is justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany,"Introduction: In preparation for a possible second COVID-19 pandemic wave, expanding intensive care unit (ICU) bed capacity is an important consideration. The purpose of this study was to determine the costs and benefits of this strategy in Germany. Methods: This study compared the provision of additional capacity to no intervention from a societal perspective. A decision model was developed using, e.g., information on age-specific fatality rates, ICU costs and outcomes, and the herd protection threshold. The net monetary benefit (NMB) was calculated based upon the willingness to pay for new medicines for the treatment of cancer, a condition with a similar disease burden in the near term. Results: The marginal cost-effectiveness ratio (MCER) of supplying one additional ICU bed is 24,815 euros per life year gained and increases with the number of additional beds. The NMB remains positive for utilization rates as low as 1.5% and, assuming full capacity utilization, for multiples of the currently available bed capacity. Expanding the ICU bed capacity by 10,000 beds is projected to result in societal costs of 41 billion euros and to reduce mortality of ICU candidates by 20% compared with no intervention (assuming full capacity utilization). In a sensitivity analysis, the variables with the highest impact on the MCER were the mortality rates in the ICU and after discharge. Conclusions: In Germany, the provision of additional ICU bed capacity appears to be cost-effective over a large increase in the number of beds. Nevertheless, bed utilization is constrained by labor supply and possibly other input factors.","Gandjour, A.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162743v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162743v1?rss=1,2020-07-29,2020-07-29,,True
241,"Magnetic bead-based ELISA allow inexpensive, rapid and quantitative detection of human antibodies against SARS-CoV-2","Here we describe a novel immunogenic method to detect COVID-19. The method is a chromogenic magnetic bead-based ELISA which allows inexpensive and quantitative detection of human IgG or IgM antibodies against SARS-CoV-2 in serum or whole blood samples in just 12 minutes. As a proof of concept, we compared the performance of our new method to classical ELISA. Person correlation between optical densities obtained using the two methods was 0.98. The novel magnetic bead-based ELISA performed better than classic ELISA to discriminate one COVID-19 case carrying low antibody titer. The chromogenic magnetic bead-based ELISA method described here can be applied in formats for both point of care and high throughput analysis. The method is readily adaptable to use other protein-based antigens and is readily adaptable to investigate other diseases and other applications.","Huergo, L. F.; Conzentino, M. S.; Gerhardt, E. C. M.; Santos, A. R. S.; Pedrosa, F. d. O.; Souza, E. M.; Nogueira, M. B.; Forchhammer, K.; Rego, F. G. M.; Raboni, S. M.; Reis, R. A.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162255v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162255v1?rss=1,2020-07-29,2020-07-29,,True
242,A rapid and sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry,"In the last few months, there has been a global catastrophic outbreak of severe acute respiratory syndrome disease caused by the novel corona virus SARS-CoV-2 affecting millions of people worldwide. Early diagnosis and isolation is key to contain the rapid spread of the virus. Towards this goal, we report a simple, sensitive and rapid method to detect the virus using a targeted mass spectrometric approach, which can directly detect the presence of virus from naso-oropharyngeal swabs. Using a multiple reaction monitoring we can detect the presence of two peptides specific to SARS-CoV-2 in a 2.3 minute gradient run with 100% specificity and 90.4 % sensitivity when compared to RT-PCR. Importantly, we further show that these peptides could be detected even in the patients who have recovered from the symptoms and have tested negative for the virus by RT-PCR highlighting the sensitivity of the technique. This method has the translational potential of in terms of the rapid diagnostics of symptomatic and asymptomatic COVID-19 and can augment current methods available for diagnosis of SARS-CoV-2.","Singh, P.; Chakraborty, R.; Marwal, R.; V S, R.; Bhaskar, A. K.; Vashisht, H.; Dhar, M. S.; Pradhan, S.; Ranjan, G.; Imran, M.; Raj, A.; Sharma, U.; Singh, P.; Lall, H.; Dutta, M.; Garg, P.; Ray, A.; Dash, D.; Sivasubbu, S.; Gogia, H.; Madan, P.; Kabra, S.; Singh, S. K.; Agrawal, A.; Rakhit, P.; Kumar, P.; Sengupta, S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20161836v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20161836v1?rss=1,2020-07-29,2020-07-29,,True
243,A machine learning explanation of the pathogen-immune relationship of SARS-CoV-2 and machine learning models of prognostic biomarkers to predict asymptomatic or symptomatic infections,"Asymptomatic people infected during the SARS-CoV-2 (COVID-19) pandemic have outnumbered symptomatic people by an approximate ratio of 4:1 with little understanding to date as to why; therefore, they have been impossible to identify in advance. Moreover, studies indicate that most asymptomatic virus-positive patients are infectious, thereby creating a new public health danger via a plethora of ""silent spreaders."" This data science study identified four novel discoveries that may significantly impact our understanding of the pathogen-immune relationship: (1) Spearman rho correlation coefficients and associated P-values identified 34 of 53 common immune factors have statistically significant associations with SARS-CoV-2 morbidity, their direction (+/-) and strength to inform research and therapies; (2) five machine learning algorithms were applied to 74 observations of these 33 immunological variables and identified three models of prognostic biomarkers that can classify and predict who will be asymptomatic or symptomatic if infected with 94.8% to 100% accuracy; (3) a random forest of 200 decision trees ordinally ranked the 33 statistically significant independent predictor variables by their relative importance in predicting SARS-CoV-2 symptoms; and, (4) three different decision-tree algorithms separately identified and validated three immunological biomarkers and levels that nearly always differentiate asymptomatic patients: SCGF-Beta; (> 127637), IL-16 (> 45), and M-CSF (> 57). The first potentially important implication of these findings is they suggest that SCGF-Beta; could be a viable biomarker for prognoses, screenings, and triaging people exposed to SARS-CoV-2, which could be a valuable tool at the point-of-care for managing and preventing outbreaks. It may be able to predict who will get sick or not, and who has a probability of living or dying. A second potentially important implication is the results suggest SCGF-Beta; may be a viable therapeutic for SARS-Cov-2.","Luellen, E.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162867v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162867v1?rss=1,2020-07-29,2020-07-29,,True
244,The German Corona Consensus Dataset (GECCO): A standardized dataset for COVID-19 research,"Background: The current COVID-19 pandemic has led to a surge of research activity. While this research provides important insights, the multitude of studies results in an increasing segmentation of information. To ensure comparability across projects and institutions, standard datasets are needed. Here, we introduce the ""German Corona Consensus Dataset"" (GECCO), a uniform dataset that uses international terminologies and health IT standards to improve interoperability of COVID-19 data. Methods: Based on previous work (e.g., the ISARIC-WHO COVID-19 case report form) and in coordination with experts from university hospitals, professional associations and research initiatives, data elements relevant for COVID-19 research were collected, prioritized and consolidated into a compact core dataset. The dataset was mapped to international terminologies, and the Fast Healthcare Interoperability Resources (FHIR) standard was used to define interoperable, machine-readable data formats. Results: A core dataset consisting of 81 data elements with 281 response options was defined, including information about, for example, demography, anamnesis, symptoms, therapy, medications or laboratory values of COVID-19 patients. Data elements and response options were mapped to SNOMED CT, LOINC, UCUM, ICD-10-GM and ATC, and FHIR profiles for interoperable data exchange were defined. Conclusion: GECCO provides a compact, interoperable dataset that can help to make COVID-19 research data more comparable across studies and institutions. The dataset will be further refined in the future by adding domain-specific extension modules for more specialized use cases.","Sass, J.; Bartschke, A.; Lehne, M.; Essenwanger, A.; Rinaldi, E.; Rudolph, S.; Heitmann, K. U.; Vehreschild, J. J.; von Kalle, C.; Thun, S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162636v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162636v1?rss=1,2020-07-29,2020-07-29,,True
245,"Contact tracing during Phase I of the COVID-19 pandemic in the Province of Trento, Italy: key findings and recommendations","Introduction Contact tracing is a key pillar of COVID-19 control. In response to the COVID-19 epidemic in the Autonomous Province of Trento (Italy) a software was developed to standardize data collection and facilitate surveillance of contacts and outbreaks and map the links between bases and contacts. In this paper, we present the results of contact tracing efforts during Phase I of the epidemic (March-April, 2020, mostly under lockdown), including sociodemographic characteristics of contacts who became cases and of the cases who infected one or more contact. Methods A contact tracing website was developed that included components for geolocation and linking of cases and contacts using open source software. Information on community-based confirmed and probable cases and their contacts was centralized on the website. Information on cases came directly from the central case database, information on contacts was collected by telephone interviews following a standard questionnaire. Contacts were followed via telephone, emails, or an app. Results The 2,812 laboratory-diagnosed community cases of COVID-19 had 6,690 community contacts, of whom 890 (13.3%) developed symptoms. Risk of developing symptomatic disease increased with age and was higher in workplace contacts than cohabitants or non-cohabiting family or friends. The greatest risk of transmission to contacts was found for the 14 cases <15 years of age (22.4%); 8 of the 14, who ranged in age from <1 to 11 years) infected 11 of 49 contacts. Overall, 606 outbreaks were identified, 74% of which consisted of only two cases. Discussion The open-source software program permitted the centralized tracking of contacts and rapid identification of links between cases. Workplace contacts were at higher risk of developing symptoms. Although childhood contacts were less likely to become cases, children were more likely to infect household members, perhaps because of the difficulty of successfully isolating children in household settings.","Fateh-Moghadam, P.; Battisti, L.; Molinaro, S.; Fontanari, S.; Dallago, G.; Binkin, N.; Zuccali, M.","https://www.medrxiv.org/content/10.1101/2020.07.16.20127357v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.16.20127357v1?rss=1,2020-07-29,2020-07-29,,True
246,Children with COVID-19 like symptoms in Italian Pediatric Surgeries: the dark side of the coin,"BACKGROUND: Symptoms of SARS-CoV-2 infection in children are nonspecific and shared with other common acute viral illnesses (fever, respiratory or gastrointestinal symptoms, and cutaneous signs), thus making clinical differential diagnosis tricky. In Italy, first line management of pediatric care is handed over to Primary Care Pediatricians (PCPs), who were not allowed to directly perform diagnostic tests during the recent COVID-19 outbreak. Without a confirmatory diagnosis, PCPs could only collect information on ''COVID-19 like symptoms'' rather than identify typical COVID-19 symptoms. AIM: To evaluate the prevalence of COVID-19 like symptoms in outpatient children, during Italian lockdown. To provide PCPs a risk score to be used in clinical practice during the differential diagnosis process. METHODS: A survey was submitted to 50 PCPs (assisting 47,500 children) from 7 different Italian regions between the 4th of March and the 23rd of May 2020 (total and partial lockdown period). COVID-19 like symptoms in the assisted children were recorded, as well as presence of confirmed/suspected cases in children's families, which was taken as proxy of COVID-19. Multivariable logistic regression was accomplished to estimate the risk of having suspected/confirmed cases in families, considering symptoms as potential determinants. RESULTS: 2,300 children (4.8% of overall survey population) fell ill with COVID-19 like symptoms, 3.1% and 1.7% during total and partial lockdown period respectively. The concurrent presence of fatigue, cough, and diarrhea in children, in absence of sore throat/earache and abnormal skin signs, represents the maximum risk level of having a suspected/confirmed case of COVID-19 at home. CONCLUSIONS: The percentage of children presenting COVID-19 like symptoms at home has been remarkable also during the total lockdown period. The present study identified a pattern of symptoms which could help, in a cost-effective perspective, PCPs in daily clinical practice to define priorities in addressing children to the proper diagnostic procedure.","Trapani, G.; Fanos, V.; Bertino, E.; Maiocco, G.; Al Jamal, O.; Fiore, M.; Bembo, V.; Careddu, D.; Barberio, L.; Zanino, L.; Verlato, G.","https://www.medrxiv.org/content/10.1101/2020.07.27.20149757v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20149757v1?rss=1,2020-07-29,2020-07-29,,True
247,The Impact of COVID-19 on Mental Health outcomes among hospital fever clinic attendants across Nepal: A community-based cross-sectional study,"Background: The COVID 19 pandemic has been creating a panic and distressing situations among the entire population globally including Nepal. No study has been conducted assessing the psychological impact of this pandemic on the general public in Nepal. The objective of this study is to assess the mental health status during COVID 19 outbreak and explore the potential influencing factors among the population attending the hospital fever clinics with COVID 19 symptoms. Methods: A cross sectional survey was conducted between May to June, 2020 with a sample of 645 participants aged 18 and above in 26 hospitals across Nepal. Telephone interviews were conducted using a semi-structured questionnaire along with a validated psychometric tool, the Depression, Anxiety and Stress (DASS21) scale. The metrics and scores of symptoms and their severity were created and analyzed. Multivariate logistic regression was used to determine the association of potential covariates with outcome variables. Results: The prevalence of anxiety, depression and stress were 14%, 7% and 5% respectively. Participants from Bagmati province reported higher level of anxiety (OR 3.87, 95% CI 1.42 10.59), while stress (OR 4.78, 95% CI 1.09 21.29) and depressive symptoms (OR 3.37, 95% CI 1.10 10.35) observed higher among the participants in Province 1. Women were more at risk of anxiety (OR 4.26, 95% CI 2.21 8.20) and depression (2.75, 95% CI 1.16 6.51) than men. Similarly, people with primary level education found more prone to all factors, stress (OR 20.35, 95% CI 2.06 201.19), anxiety (OR 3.10, 95% CI 1.24 7.91), and depression (OR 4.41, 95% CI 1.29 15.07). More farmers than labors showed higher odds (OR 2.25, 95% CI 1.01 5.01) for anxiety, while individuals surveyed who reported their health status as poor-had higher odds (OR 5.95, 95% CI 1.08 32.68) for depression. Also, people currently living in rented houses reported more stress (OR 3.11, 95% CI 1.07 9.05) and those living far from family reported higher rates of depressive symptoms (OR 3.57, 95% CI 1.01 12.58). Conclusion: The study identified increased prevalence of stress, anxiety and depressive symptoms during the initial stage of COVID 19 pandemic in Nepal. Considering the findings, there is urgent need to develop and implement appropriate community-based mental health programs targeting individuals who have had COVID 19 symptoms and who are prone to develop adverse mental health outcomes. Key words: COVID 19, Depression, Anxiety, Stress, Pandemic, Public Health, Nepal","Devkota, H. R.; Sijali, T. R.; Bogati, R.; Ahmad, M.; Shakya, K. L.; Adhikary, P.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163295v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163295v1?rss=1,2020-07-29,2020-07-29,,True
248,Association between stress and depressive symptoms and the Covid-19 pandemic,"Objective: To date, cross-sectional surveys reported frequency and distribution of mental health disorders on convenience samples impacted by Covid-19. Longitudinal assessment of mental health during Covid-19 in a representative population-based sample, however, is currently largely missing. The aim of this study was to investigate changes in perceived stress levels and depressive symptoms measured before and during Covid-19 pandemic in a representative population-based sample. Methods: Baseline data on stress levels and depressive symptoms from a well-established population-based sample were compared with those obtained from self-administered e-questionnaires distributed during Covid-19 pandemic. A total of 715 participants completed e-questionnaires. Wilcoxon signed-rank test was used to test repeated-measure differences, while between-group differences were analysed using Mann-Whitney and the Kruskal-Wallis tests. Results: Perceived stress levels and depressive symptoms increased 1.4 and 5.5 times, respectively, during the Covid-19 pandemic compared to the time prior Covid-19. Changes in stress and depressive symptoms were most significant in females and did not depend on whether one quarantined alone or with others. Feeling of loneliness during Covid-19 pandemic had the greatest impact on increased stress levels and depressive symptoms. Conclusions: This population-based longitudinal study showed that Covid-19 related measures had significant impact on mental health in a general population with the feeling of loneliness identified as the biggest risk factor. This impact indicates the need of timely and tailored treatment of mental health disorders and integration of preventive mental health measures into global public health policies to protect mental health during future pandemics.","Novotny, J. S.; Gonzalez Rivas, J. P.; Kunzova, S.; Skladana, M.; Pospisilova, A.; Polcrova, A.; Medina Inojosa, J. R.; Lopez-Jimenez, F.; Geda, Y. E.; Stokin, G. B.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163113v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163113v1?rss=1,2020-07-29,2020-07-29,,True
249,Predicting Onset of COVID-19 with Mobility-Augmented SEIR Model,"Timely interventions and early preparedness of healthcare resources are crucial measures to tackle the mbox{COVID-19} disease. To aid these efforts, we developed the Mobility-Augmented SEIR model (mbox{MA-SEIR}) that leverages Google's aggregate and anonymized mobility data to augment classic compartmental models. We show in a retrospective analysis how this method can be applied at an early stage in the mbox{COVID-19} epidemic to forecast its subsequent spread and onset in different geographic regions, with minimal parameterization of the model. This provides insight into the role of near real-time aggregate mobility data in disease spread modeling by quantifying substantial changes in how populations move both locally and globally. These changes would be otherwise very hard to capture using less timely data.","Wu, N.; Ben, X.; Green, B.; Rough, K.; Venkatramanan, S.; Marathe, M.; Eastham, P.; Sadilek, A.; O'Banion, S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20159996v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20159996v1?rss=1,2020-07-29,2020-07-29,,True
250,Comorbidities associated with regional variations in COVID-19 mortality revealed by population-level analysis,"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has developed into a global health crisis. Understanding the risk factors for poor outcomes of COVID-19 is thus important for successful management and control of the pandemic. However, the progress and severity of the epidemic across different regions show great differentiations. We hypothesized the origination of these differences are based on location-dependent variations in underlying population-wide health factors. Disease prevalence or incidence data of states and counties of the United States were collected for a group of chronic diseases, including hypertension, diabetes, obesity, stroke, coronary heart disease, heart failure, physical inactivation, and common cancers (e.g., lung, colorectal, stomach, kidney and renal). Correlation and regression analysis identified the prevalence of heart failure as a significant positive factor for region-level COVID-19 mortality. Similarly, the incidence of gastric cancer and thyroid cancer were also identified as significant factors contributing to regional variation in COVID-19 mortality. To explore the implications of these results, we re-analyzed the RNA-seq data for stomach adenocarcinoma (STAD) and colon carcinoma (COAD) from The Cancer Genome Atlas (TCGA) project. We found that expression of genes in the immune response pathways were more severely disturbed in STAD than in COAD, implicating higher probability for STAD patients or individuals with precancerous chronic stomach diseases to develop cytokine storm once infected with COVID-19. Taken together, we conclude that location variations in particular chronic diseases and cancers contribute significantly to the regional variations in COVID-19 mortality.","Yang, H.; Zhong, F.","https://www.medrxiv.org/content/10.1101/2020.07.27.20158105v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20158105v1?rss=1,2020-07-29,2020-07-29,,True
251,"Impact Assessment of Full and Partial Stay-at-Home Orders, Face Mask Usage, and Contact Tracing: An Agent-Based Simulation Study of COVID-19 for an Urban Region","Purpose: Various social intervention strategies to mitigate COVID-19 are examined using a comprehensive agent-based simulation model. A case study is conducted using a large urban region, Miami-Dade County, Florida, USA. Results are intended to serve as a planning guide for public health decision-makers. Methods: The simulation model mimics the daily social mixing behavior of the susceptible and infected generating the spread. Data representing demographics of the region, virus epidemiology, and social interventions shapes model behavior. Results include daily values of infected, reported, hospitalized, and dead. Results: Study results show that stay-at-home order is quite effective in flattening and then reversing the case growth curve subsiding the pandemic with only 5.8% of the population infected. Whereas, following the current Phase II reopening plan could end the pandemic via herd immunity with 75% people infected. Use of surgical variety face masks reduced infected by 20%. A further reduction of 66% was achieved through contact tracing. Conclusions: For Miami-Dade County, a strategy comprising mandatory use of face masks and aggressive contact tracing to identify 50% of the asymptomatic and pre-symptomatic, if adopted now, can potentially steer the COVID-19 pandemic to subside within next 3 months with approximately one-fifth of the population infected.","Tatapudi, H.; Das, R.; Das, T. K.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163121v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163121v1?rss=1,2020-07-29,2020-07-29,,True
252,Global Determinants of Covid-19 Deaths: Lockdown Dates and Social Distancing Measures Mattered,"Objectives: The objective of this paper is to examine the influence that various contextual variables have upon the number of deaths due to covid-19, across the world. Setting Level: This study utilizes data for 125 countries for contextual variables from 1st January 2020 until the 15th June 2020. Participants: This study considers deaths from covid-19. Primary and secondary outcome measures: The contextual variables considered in this study are stringency index, stringency variability, lockdown date, population density, level of airline passengers and country health security index. Results: It is shown there is a very strong association between the level of airline passengers and covid-19 deaths. The results from regression analysis conducted in this study show significant positive relationships at the 5% level of statistical significance between Deaths from covid-19 and airline passenger levels and stringency variability; significant negative relationships are revealed for stringency index and lockdown date supporting the notion that lock down and social distancing measures mattered and were effective. The Global health security index and population density did not significantly affect deaths. Conclusion: This study highlights the strong link between a country's airline passengers and covid-19 deaths and found that the lockdown date and stringency measures had a significant effect upon deaths. The implications of the research is that lockdown and stringency measures implemented by governments around the world worked and mattered. Further, the fact that global health security did not affect deaths may indicate better preparedness required to confront future pandemics.","HOOPER, V. J.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163394v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163394v1?rss=1,2020-07-29,2020-07-29,,True
253,"Whence the next pandemic? The intersecting global geography of the animal-human interface, poor health systems and air transit centrality reveals conduits for high-impact spillover","The health and economic impacts of infectious disease pandemics are catastrophic as most recently manifested by coronavirus disease 2019 (COVID-19). The emerging infections that lead to substantive epidemics or pandemics are typically zoonoses that cross species boundaries at vulnerable points of animal-human interface. The sharing of space between wildlife and humans, and their domesticated animals, has dramatically increased in recent decades and is a key driver of pathogen spillover. Increasing animal-human interface has also occurred in concert with both increasing globalisation and failing health systems, resulting in a trifecta with dire implications for human and animal health. Nevertheless, to date we lack a geographical description of this trifecta that can be applied strategically to pandemic prevention. This investigation provides the first geographical quantification of the intersection of animal-human interfaces, poor human health system performance and global connectivity via the network of air travel. In so doing, this work provides a systematic, data-driven approach to classifying spillover hazard based on the distribution of animal-human interfaces while simultaneously identifying globally connected cities that are adjacent to these interfaces and which may facilitate global pathogen dissemination. We present this geography of high-impact spillover as a tool for developing targeted surveillance systems and improved health infrastructure in vulnerable areas that may present conduits for future pandemics.","Walsh, M. G.; Sawleshwarkar, S.; Hossain, S.; Mor, S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163196v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163196v1?rss=1,2020-07-29,2020-07-29,,True
254,Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients,"A global effort is currently undertaken to restrain the COVID-19 pandemic. Host immunity has come out as a determinant for COVID-19 clinical outcome, and several studies investigated the immune profiling of SARS-CoV-2 infected people to properly direct the clinical management of the disease. Thus, lymphopenia, T-cell exhaustion, and the increased levels of inflammatory mediators have been described in COVID-19 patients, in particular in severe cases1. Age represents a key factor in COVID-19 morbidity and mortality2. Understanding age-associated immune signatures of patients is therefore important to identify preventive and therapeutic strategies. In this study, we investigated the immune profile of COVID-19 hospitalized patients identifying a distinctive age-dependent immune signature associated with disease severity. Indeed, defined circulating factors - CXCL8, IL-10, IL-15, IL-27 and TNF- - positively correlate with older age, longer hospitalization, and a more severe form of the disease and may thus represent the leading signature in critical COVID-19 patients.","Angioni, R.; Sanchez-Rodriguez, R.; Munari, F.; Bertoldi, N.; Arcidiacono, D.; Cavinato, S.; Marturano, D.; Cattelan, A.; Viola, A.; Molon, B.","https://www.medrxiv.org/content/10.1101/2020.07.28.20162735v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20162735v1?rss=1,2020-07-29,2020-07-29,,True
255,"DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19","Background Association between DPP4 inhibitors and respiratory infection remains unclear. CardioVascular Outcomes Trials (CVOTs) conducted before the COVID-19 pandemic are available. We aimed to estimate the effect of DPP4 inhibitors on the risk of respiratory infections. Methods We updated a previous systematic review and meta-analysis, searching for CVOTs assessing a DPP4 inhibitor in patients with type 2 diabetes mellitus. We focused on placebo-controlled CVOTs. Our primary outcome was 'any respiratory infection'. We added a sensitivity analysis integrating non-CVOTs and active-controlled CVOTs. Findings We included 47 714 patients in five placebo-controlled CVOTs. Median follow-up ranged from 1.5 years to 3 years. 4 369 events of overall respiratory infection were reported (rate of 9.2%). DPP4 inhibitors were not associated with a different risk compared to placebo (RR = 0.99 [95%CI: 0.93; 1.04]). The sensitivity analysis integrating the non-CVOTs studies and the active-controlled CVOT reached 11 349 events among 82 644 participants (rate of 13.7%). DPP4 inhibitors were not associated with a different risk of overall respiratory infection (RR = 1.00 [95% CI: 0.97; 1.03]). Interpretation Our up-dated meta-analysis provides the most powerful and least biased estimation of the association of DPP4 inhibitors and the risk of overall (non COVID-19) respiratory infection. We did not find any effect of the DPP4 inhibitors on the risk of respiratory infection. Our results support the recently published practical recommendations for the management of diabetes in patients with COVID-19, suggesting that DPP4 inhibitors should not be discontinued regarding the COVID-19 pandemic.","Grenet, G.; Mekhaldi, S.; MAINBOURG, S.; AUFFRET, M.; Cornu, C.; Cracowski, J.-L.; Gueyffier, F.; Lega, J.-C.; CUCHERAT, M.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163386v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163386v1?rss=1,2020-07-29,2020-07-29,,True
256,Eleven Routine Clinical Features Predict COVID-19 Severity,"Severity prediction of COVID-19 remains one of the major clinical challenges for the ongoing pandemic. Here, we have recruited a 144 COVID-19 patient cohort consisting of training, validation, and internal test sets, longitudinally recorded 124 routine clinical and laboratory parameters, and built a machine learning model to predict the disease progression based on measurements from the first 12 days since the disease onset when no patient became severe. A panel of 11 routine clinical factors, including oxygenation index, basophil counts, aspartate aminotransferase, gender, magnesium, gamma glutamyl transpeptidase, platelet counts, activated partial thromboplastin time, oxygen saturation, body temperature and days after symptom onset, constructed a classifier for COVID-19 severity prediction, achieving accuracy of over 94%. Validation of the model in an independent cohort containing 25 patients achieved accuracy of 80%. The overall sensitivity, specificity, PPV and NPV were 0.70, 0.99, 0.93 and 0.93, respectively. Our model captured predictive dynamics of LDH and CK while their levels were in the normal range. This study presents a practical model for timely severity prediction and surveillance for COVID-19, which is freely available at webserver https://guomics.shinyapps.io/covidAI/.","Zhou, K.; Sun, Y.; Li, L.; Zang, Z.; Wang, J.; Li, J.; Liang, J.; Zhang, F.; Zhang, Q.; Ge, W.; Chen, H.; Sun, X.; Yue, L.; Wu, X.; Shen, B.; Xu, J.; Zhu, H.; Chen, S.; Yang, H.; Huang, S.; Peng, M.; Lv, D.; Zhang, C.; Zhao, H.; Hong, L.; Zhou, Z.; Chen, H.; Dong, X.; Tu, C.; Li, M.; Zhu, Y.; Chen, B.; Li, S. Z.; Guo, T.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163022v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163022v1?rss=1,2020-07-29,2020-07-29,,True
257,"Examining Australian's beliefs, misconceptions, and sources of information for COVID-19: A national online survey","Objective: Public cooperation to practice preventive health behaviours is essential to manage the transmission of infectious diseases such as COVID-19. We aimed to investigate beliefs about COVID-19 diagnosis, transmission and prevention that have the potential to impact the uptake of recommended public health strategies. Design: An online cross-sectional survey conducted May 8 to May 11 2020. Participants: A national sample of 1500 Australian adults with representative quotas for age and gender provided by online panel provider. Main outcome measure: Proportion of participants with correct/incorrect knowledge of COVID-19 preventive behaviours and reasons for misconceptions. Results: Of the 1802 potential participants contacted, 289 were excluded, 13 declined, and 1500 participated in the survey (response rate 83%). Most participants correctly identified washing your hands regularly with soap and water (92%) and staying at least 1.5m away from others (90%) could help prevent COVID-19. Over 40% (incorrectly) considered wearing gloves outside of the home would prevent them contracting COVID-19. Views about face masks were divided. Only 66% of participants correctly identified that regular use of antibiotics would not prevent COVID-19. Most participants (90%) identified fever, fatigue and cough as indicators of COVID-19. However, 42% of participants thought that being unable to hold your breath for 10 seconds without coughing was an indicator of having the virus. The most frequently reported sources of COVID-19 information were commercial television channels (56%), the Australian Broadcasting Corporation (43%), and the Australian Government COVID-19 information app (31%). Conclusions: Public messaging about hand hygiene and physical distancing to prevent transmission appear to have been effective. However, there are clear, identified barriers for many individuals that have the potential to impede uptake or maintenance of these behaviours in the long-term. Currently these non-drug interventions are our only effective strategy to combat this pandemic. Ensuring ongoing adherence to is critical.","Thomas, R.; Greenwood, H.; Michaleff, Z. A.; Abukmail, E.; Hoffmann, T.; McCaffery, K. J.; Hardiman, L.; Glasziou, P.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163204v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163204v1?rss=1,2020-07-29,2020-07-29,,True
258,"Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity","COVID-19 primarily affects the lungs, but evidence of systemic disease with multi-organ involvement is emerging. Here, we developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19, using genome-wide methylation profiling of circulating cell-free DNA in plasma. We assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls. We found evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. The concentration of cfDNA correlated with the WHO ordinal scale for disease progression and was significantly increased in patients requiring intubation. This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19.","Cheng, A. P.; Cheng, M. P.; Gu, W.; Lenz, J. S.; Hsu, E.; Schurr, E.; Bourque, G.; Bourgey, M.; Ritz, J.; Marty, F. M.; Chiu, C. Y.; Vinh, D. C.; De Vlaminck, I.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163188v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163188v1?rss=1,2020-07-29,2020-07-29,,True
259,Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System,"Background: Identification of risk factors for COVID-19-associated hospitalization is needed to guide prevention and clinical care. Objective: To examine if age, sex, race/ethnicity, and underlying medical conditions is independently associated with COVID-19-associated hospitalizations. Design: Cross-sectional. Setting: 70 counties within 12 states participating in the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) and a population-based sample of non-hospitalized adults residing in the COVID-NET catchment area from the Behavioral Risk Factor Surveillance System. Participants: U.S. community-dwelling adults ([&ge;]18 years) with laboratory-confirmed COVID-19-associated hospitalizations, March 1- June 23, 2020. Measurements: Adjusted rate ratios (aRR) of hospitalization by age, sex, race/ethnicity and underlying medical conditions (hypertension, coronary artery disease, history of stroke, diabetes, obesity [BMI [&ge;]30 kg/m2], severe obesity [BMI[&ge;]40 kg/m2], chronic kidney disease, asthma, and chronic obstructive pulmonary disease). Results: Our sample included 5,416 adults with COVID-19-associated hospitalizations. Adults with (versus without) severe obesity (aRR:4.4; 95%CI: 3.4, 5.7), chronic kidney disease (aRR:4.0; 95%CI: 3.0, 5.2), diabetes (aRR:3.2; 95%CI: 2.5, 4.1), obesity (aRR:2.9; 95%CI: 2.3, 3.5), hypertension (aRR:2.8; 95%CI: 2.3, 3.4), and asthma (aRR:1.4; 95%CI: 1.1, 1.7) had higher rates of hospitalization, after adjusting for age, sex, and race/ethnicity. In models adjusting for the presence of an individual underlying medical condition, higher hospitalization rates were observed for adults [&ge;]65 years, 45-64 years (versus 18-44 years), males (versus females), and non-Hispanic black and other race/ethnicities (versus non-Hispanic whites). Limitations: Interim analysis limited to hospitalizations with underlying medical condition data. Conclusion: Our findings elucidate groups with higher hospitalization risk that may benefit from targeted preventive and therapeutic interventions.","Ko, J. Y.; Danielson, M. L.; Town, M.; Derado, G.; Greenland, K. J.; Daily Kirley, P.; Alden, N. B.; Yousey-Hindes, K.; Anderson, E. J.; Ryan, P. A.; Kim, S.; Lynfield, R.; Torres, S. M.; Barney, G. R.; Bennett, N. M.; Sutton, M.; Talbot, H. K.; Hill, M.; Hall, A. J.; Fry, A. M.; Garg, S.; Kim, L.; COVID-NET Investigation Group,","https://www.medrxiv.org/content/10.1101/2020.07.27.20161810v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20161810v1?rss=1,2020-07-29,2020-07-29,,True
260,The effective reproductive number (Rt) of COVID-19 and its relationship with social distancing,"The expansion of the new coronavirus disease (COVID-19) triggered a renewed public interest in epidemiological models and on how parameters can be estimated from observed data. Here we investigated the relationship between average number of transmissions though time, the reproductive number Rt, and social distancing index as reported by mobile phone data service inloco, for Goias State, Brazil, between March and June 2020. We calculated Rt values using EpiEstim package in R-plataform for confirmed cases incidence curves. We found a correlation equal to -0.72 between Rt values for confirmed cases and isolation index at a time lag of 8 days. As the Rt values were paired with center of the moving window of 7 days, the delay matches the mean incubation period of the virus. Our findings reinforce that isolation index can be an effective surrogate for modeling and epidemiological analyses and, more importantly, can be an useful metrics for anticipating the need for early interventions, a critical issue in public health.","Jardim, L.; Diniz-Filho, J. A.; Rangel, T. F.; Toscano, C. M.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163493v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163493v1?rss=1,2020-07-29,2020-07-29,,True
261,High-throughput SARS-CoV-2 and host genome sequencing from single nasopharyngeal swabs,"During COVID19 and other viral pandemics, rapid generation of host and pathogen genomic data is critical to tracking infection and informing therapies. There is an urgent need for efficient approaches to this data generation at scale. We have developed a scalable, high throughput approach to generate high fidelity low pass whole genome and HLA sequencing, viral genomes, and representation of human transcriptome from single nasopharyngeal swabs of COVID19 patients.","Gorzynski, J. E.; De Jong, H. N.; Amar, D.; Hughes, C. R.; Ioannidis, A.; Bierman, R.; Liu, D.; Tanigawa, Y.; Kistler, A.; Kamm, J.; Kim, J.; Cappello, L.; Neff, N. F.; Rubinacci, S.; Delaneua, O.; Shoura, M. J.; Seo, K.; Kirillova, A.; Raja, A.; Sutton, S.; Huang, C.; Sahoo, M. K.; Mallempati, K. C.; Montero-Martin, G.; Osoegawa, K.; Watson, N.; Hammond, N.; Joshi, R.; Fernandez-Vina, M.; Christle, J. W.; Wheeler, M. T.; Febbo, P.; Farh, K.; Schroth, G.; Desouza, F.; Palacios, J.; Salzman, J.; Pinsky, B. A.; Rivas, M. A.; Bustamante, C. D.; Ashley, E. A.; Parikh, V. N.","https://www.medrxiv.org/content/10.1101/2020.07.27.20163147v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20163147v1?rss=1,2020-07-29,2020-07-29,,True
262,"Serial population based serosurvey of antibodies to SARS-CoV-2 in a low and high transmission area of Karachi, Pakistan","Background Pakistan is among the first low- and middle-income countries affected by COVID-19 pandemic. Monitoring progress through serial sero-surveys, particularly at household level, in densely populated urban communities can provide insights in areas where testing is non-uniform. Methods Two serial cross-sectional household surveys were performed in April (phase 1) and June (phase 2) 2020 each in a low- (District Malir) and high-transmission (District East) area of Karachi, Pakistan. Household were selected using simple random sampling (Malir) and systematic random sampling (East). Individual participation rate from consented households was 82.3% (1000/1215 eligible) in phase 1 and 76.5% (1004/1312 eligible) in phase 2. All household members or their legal guardians answered questions related to symptoms of Covid-19 and provided blood for testing with commercial Elecsys Anti-SARS-CoV-2 immunoassay targeting combined IgG and IgM. Seroprevalence estimates were computed for each area and time point independently. Given correlation among household seropositivity values, a Bayesian regression model accounting for household membership, age and gender was used to estimate seroprevalence. These estimates by age and gender were then post-stratified to adjust for the demographic makeup of the respective district. The household conditional risk of infection was estimated for each district and its confidence interval were obtained using a non-parametric bootstrap of households. Findings Post-stratified seroprevalence was estimated to be 0.2% (95% CI 0-0.7) in low-and 0.4% (95% CI 0 - 1.3) in high-transmission areas in phase 1 and 8.7% (95% CI 5.1-13.1) in low- and 15.1% (95% CI 9.4 -21.7) in high-transmission areas in phase 2, with no consistent patterns between prevalence rates for males and females. Conditional risk of infection estimates (possible only for phase 2) were 0.31 (95% CI 0.16-0.47) in low- and 0.41(95% CI 0.28-0.52) in high-transmission areas. Of the 166 participants who tested positive, only 9(5.4%) gave a history of any symptoms. Interpretation A large increase in seroprevalence to SARS-CoV-2 infection is seen, even in areas where transmission is reported to be low. Mostly the population is still seronegative. A large majority of seropositives do not report any symptoms. The probability that an individual in a household is infected, given that another household member is infected is high in both the areas. These results emphasise the need to enhance surveillance activities of COVID-19 especially in low-transmission sites and provide insights to risks of household transmission in tightly knit neighbourhoods in urban LMIC settings.","Nisar, M. I.; Ansari, N.; Amin, M.; Khalid, F.; Hotwani, A.; Rehman, N.; Rizvi, A.; Memon, A.; Ahmed, Z.; Ahmed, A.; Iqbal, J.; Saleem, A. F.; Aamir, U. B.; Larremore, D. B.; Fosdick, B.; Jehan, F.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163451v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163451v1?rss=1,2020-07-29,2020-07-29,,True
263,Close-range exposure to a COVID-19 carrier: transmission trends in the respiratory tract and estimation of infectious dose,"How respiratory physiology and airflow therein proceed to impact SARS-CoV-2 transmission, leading to the initial infection, is an open question. An answer can help determine the susceptibility of an individual on exposure to a COVID-2019 carrier and can also quantify the still-unknown infectious dose for the disease. Combining computational fluid mechanics-based tracking of respiratory transport in anatomic domains with sputum assessment data from hospitalized patients and earlier measurements of ejecta size distribution during regular speech - this study shows that targeted deposition at the initial nasopharyngeal infection sites peaks over the droplet size range of 2.5 - 19 , and reveals that the number of virions that can establish the infection is at most of O(100).","Basu, S.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162362v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162362v1?rss=1,2020-07-29,2020-07-29,,True
264,Modeling the initial phase of SARS-CoV-2 deposition in the respiratory tract mimicked by the 11C radionuclide,"The knowledge on the deposition and retention of the viral particle of SARS-CoV-2 in the respiratory tract during the very initial intake from the ambient air is of prime importance to understand the infectious process and COVID-19 initial symptoms. To give some light on that, we propose to use a modified version of a widely tested lung deposition model developed by the ICRP, in the context of the ICRP Publication 66, that provides deposition patterns of microparticles in different lung compartments. In the model, we mimicked the environmental decay of the virus, determined by controlled experiments related to normal speeches, by the radionuclide 11C that presents comparable decay rates. Our results confirm clinical observations on the high virus retentions observed in the extrathoracic region and the lesser fraction on the alveolar section (in the order of 5), which relevance is a subject to be investigated.","Evangelista, H.; Amaral, C.; Porto, L. C.; Goncalves, S. J.; Sodre, E. D.; Nogueira, J.; dos Santos, A. M. G.; Cataldo, M.","https://www.medrxiv.org/content/10.1101/2020.07.27.20156836v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20156836v1?rss=1,2020-07-29,2020-07-29,,True
265,"Predicting PPE use, post-traumatic stress, and physical symptoms during the early weeks of COVID-19 lockdowns in the USA","Abstract: The COVID-19 pandemic combined with inconsistent governmental and public health recommendations, media communications emphasizing threat, and widespread lockdowns created a complex psychological environment for Americans. In this study, 450 MTurk workers completed measures of (a) risk for COVID-19, (b) perceived vulnerability to disease, (c) intolerance of uncertainty, (d) mindfulness, (e) COVID-19 preventive health behaviors, (f) post-Trauma symptoms, and (g) stress related physical symptoms. The surveys were completed between April 9, 2020 and April 18, 2020 which is a period that corresponded to the first 2-3 weeks of lockdown for most participants. A substantial number of participants reported a reduction employment status and 69% were in self-isolation. The participants reported a high degree of perceived vulnerability with 68% indicating they felt there was a 50/50 chance or greater they would contract COVID-19. Mask wearing was variable: 16% not at all, 20% some of the time, 42% a good part of the time, and 26% most of the time. Using clinical cutoff on the post-trauma scale, 70% of the sample would be considered to have symptoms consistent with PTSD. The mean level of physical symptoms was significantly (p < .001) and substantially higher (d = 1.46) than norms. PPE use was positively associated with level of education and mindfulness nonreactivity and negatively associated with age, having a current medical condition, and mindfulness nonjudgment. Post trauma and physical health symptoms were strongly predicted by susceptibility variables and intolerance of uncertainty.","OBrien, W. H.; Wang, S.; Varga, A. V.; Xu, H.; Sims, T. E.; Horan, K. A.; Lim, C. X.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162057v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162057v1?rss=1,2020-07-29,2020-07-29,,True
266,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors,"Background There are no data on SARS-CoV-2 seroprevalence in Africa though the COVID-19 epidemic curve and reported mortality differ from patterns seen elsewhere. We estimated the anti-SARS-CoV-2 antibody prevalence among blood donors in Kenya. Methods We measured anti-SARS-CoV-2 spike IgG prevalence by ELISA on residual blood donor samples obtained between April 30 and June 16, 2020. Assay sensitivity and specificity were 83% (95% CI 59, 96%) and 99.0% (95% CI 98.1, 99.5%), respectively. National seroprevalence was estimated using Bayesian multilevel regression and post-stratification to account for non-random sampling with respect to age, sex and region, adjusted for assay performance. Results Complete data were available for 3098 of 3174 donors, aged 15-64 years. By comparison with the Kenyan population, the sample over-represented males (82% versus 49%), adults aged 25-34 years (40% versus 27%) and residents of coastal Counties (49% versus 9%). Crude overall seroprevalence was 5.6% (174/3098). Population-weighted, test-adjusted national seroprevalence was 5.2% (95% CI 3.7, 7.1%). Seroprevalence was highest in the 3 largest urban Counties; Mombasa (9.3% [95% CI 6.4, 13.2%)], Nairobi (8.5% [95% CI 4.9, 13.5%]) and Kisumu (6.5% [95% CI 3.3, 11.2%]). Conclusions We estimate that 1 in 20 adults in Kenya had SARS-CoV-2 antibodies during the study period. By the median date of our survey, only 2093 COVID-19 cases and 71 deaths had been reported through the national screening system. This contrasts, by several orders of magnitude, with the numbers of cases and deaths reported in parts of Europe and America when seroprevalence was similar.","Uyoga, S.; Adetifa, I. M. O.; Karanja, H. K.; Nyagwange, J.; Tuju, J.; Wanjiku, P.; Aman, R.; Mwangangi, M.; Amoth, P.; Kasera, K.; Ng'ang'a, W.; Rombo, C.; Yegon, C. K.; Kithi, K.; Odhiambo, E.; Rotich, T.; Orgut, I.; Kihara, S.; Otiende, M.; Bottomley, C.; Mupe, Z. N.; Kagucia, E. W.; Gallagher, K.; Etyang, A.; Voller, S.; Gitonga, J.; Mugo, D.; Agoti, C. N.; Otieno, E.; Ndwiga, L.; Lambe, T.; Wright, D.; Barasa, E.; Tsofa, B.; Bejon, P.; Ochola-Oyier, L. I.; Agweyu, A.; Scott, J. A. G.; Warimwe, G. M.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162693v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162693v1?rss=1,2020-07-29,2020-07-29,,True
267,Computer-aided medical microbiology monitoring tool: a strategy to adapt to the SARS-CoV-2 epidemic and that highlights RT-PCR consistency,"Since the beginning of the COVID-19 pandemic, important health and regulatory decisions relied on the SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) results. Our diagnostic laboratory faced a rapid increase in the number of SARS-CoV-2 RT-PCR, with up to 1,007 tests per day. To maintain a rapid turnaround time to support patient management and public health authorities' decisions, we moved from a case-by-case validation of RT-PCR to an automated validation and immediate transmission of the results to clinicians. To maintain high quality and to track possible aberrant results, we developed a quality-monitoring tool based on a homemade algorithm coded in R. We present the results of this quality-monitoring tool applied to 35,137 RT-PCR results corresponding to 30,198 patients. Patients tested several times led to 4,939 pairwise comparisons; 88% concordant and 12% discrepant. Among the 573 discrepancies, 428 were automatically solved by the algorithm. The most likely explanation for these 573 discrepancies was related for 44.9% of the situations to ""Clinical evolution"", 27.9% to ""Preanalytical"" problems, and 25.3% to ""Stochastic"". Finally, 11 discrepant results could not be explained, including 8 received from external partners for which clinical data were not available. The implemented quality-monitoring strategy allowed to: i) assist the investigation of discrepant results ii) focus the attention of medical microbiologists onto results requiring a specific expertise and iii) maintain an acceptable TAT. This work highlighted the high RT-PCR consistency for the detection of SARS-CoV-2 and the importance of automated processes to handle a huge number of samples while preserving quality.","Mueller, L.; Scherz, V.; Greub, G.; Jaton, K.; Opota, O.","https://www.medrxiv.org/content/10.1101/2020.07.27.20162123v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20162123v1?rss=1,2020-07-29,2020-07-29,,True
268,Prevalence of amyloid blood clots in COVID-19 plasma,"The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated whether the individual was infected or not would be highly desirable. Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within the lungs. We show here that microclots can be detected in the native plasma of COVID-19 patient, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the early detection and prevention of such clotting could have an important role in therapy.","Pretorius, E.; Venter, C.; Laubscher, G. J.; Lourens, P. J.; Steenkamp, J.; Kell, D. B.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163543v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163543v1?rss=1,2020-07-29,2020-07-29,,True
269,"Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera","Surrogate neutralization assays for SARS-CoV-2 that can be done without biosafety-level-3 containment and across multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT90) in human, canine, cat and hamster sera and found excellent concordance between the two assays. Using a panel of immune sera to other coronaviruses, we confirm the lack of cross reactivity in sVNT and PRNT90 assays.","Peiris, J. S. M.; Perera, R. A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20163592v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20163592v1?rss=1,2020-07-29,2020-07-29,,True
270,Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in Covid-19-naive individuals,"We have developed a novel multiplexed flow cytometric bead array (C19BA) for the detection of SARS-CoV-2 seroconversion that allows sensitive identification of IgG and IgM antibodies against three immunogenic proteins: the spike receptor-binding domain (RBD), the spike protein subunit 1 (S1) and the nucleoprotein (N) simultaneously. This assay is more sensitive than ELISA, and the combination of three antigens allows for the interrogation of full seroconversion. Importantly, we have detected N-reactive antibodies in COVID-19-negative individuals.","Egia-Mendikute, L.; Bosch, A.; Prieto-Fernandez, E.; Lee, S. Y.; Jimenez-Lasheras, B.; Garcia del Rio, A.; Antonana-Vildosola, A.; Bruzzone, C.; Bizkarguenaga, M.; Embade, N.; Abrescia, N. G. A.; Mato, J. M.; Millet, O.; Palazon, A.","https://www.medrxiv.org/content/10.1101/2020.07.28.20162941v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.28.20162941v1?rss=1,2020-07-29,2020-07-29,,True
271,"Rapid, sensitive and specific SARS coronavirus-2 detection: a multi-center comparison between standard qRT-PCR and CRISPR based DETECTR.","Recent advances in CRISPR-based diagnostics suggest that DETECTR, a combination of isothermal reverse transcriptase loop mediated amplification (RT-LAMP) and subsequent Cas12 bystander nuclease activation by amplicon targeting ribonucleoprotein complexes, could be a faster and cheaper alternative to qRT-PCR without sacrificing sensitivity/specificity. Here we compare qRT-PCR with DETECTR to diagnose COVID-19 on 378 patient samples and report a 95% reproducibility. Patient sample dilution assays suggest a higher analytical sensitivity of DETECTR compared to qRT-PCR, however, this was not confirmed in a large patient cohort. The data showed that both techniques are equally sensitive in detecting SARS-CoV-2 providing an added value of DETECTR to the currently used qRT-PCR platforms. For DETECTR, different gRNAs can be used simultaneously to obviate negative results due to mutations in N-gene. Lateral flow strips, suitable as a point of care test (POCT), showed a 100% correlation to the high-throughput DETECTR assay. Importantly, DETECTR was 100% specific for SARS-CoV-2 and did not detect other human coronaviruses. As there is no need for specialized equipment, DETECTR could be rapidly implemented as a complementary technically independent approach to qRT-PCR thereby increasing the testing capacity of medical microbiological laboratories and relieving the existent PCR-platforms for routine non- SARS-CoV-2 diagnostic testing.","Brandsma, E.; Verhagen, H. J.; van de Laar, T. J. W.; Claas, E. C. J.; Cornelissen, M.; van den Akker, E.","https://www.medrxiv.org/content/10.1101/2020.07.27.20147249v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20147249v1?rss=1,2020-07-29,2020-07-29,,True
272,A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,"Background Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. Ayurveda has been recommended by preventative and clinical management guidelines in India and several clinical trials are ongoing. But there is no study to assess impact of Ayurveda on Covid-19. Methods Objective of present study was to evaluate the clinical outcome in Covid-19 confirmed asymptomatic to mild symptomatic patients who had received Ayurveda and compare with control (who has not received Ayurveda or any support therapy). Patients having Ayurveda intervention (Guduchi Ghan Vati-extract of Tinospora cordifolia) were included from Jodhpur Covid Care Centre and non-recipients were taken from Jaipur Covid Care Centre between May 15 to June 15, 2020. Total 91 patients, who were asymptomatic at the time of hospital admission and between 18 -75 years of age, were included in the study to analyse retrospectively. Results In control group, 11.7% developed mild symptoms after average 1.8 days and none in Ayurveda group reported any symptoms. Significant difference was reported between the group of patients taking Guduchi Ghan Vati (n=40) and patients in standard care (n=51) in terms of virologic clearance at day-7 (97.5% vs 15.6% respectively; p=0.000), at day 14 (100% vs 82.3%) days to stay in hospital ( 6.4 vs 12.8 respectively; p< 0.0001) . Conclusion Results of the study suggest that Guduchi Ghan Vati, a common and widely used Ayurveda preparation, could benefit treating asymptomatic Covid-19 patients. Larger, randomised controlled Trials are required to confirm the findings. Keywords: Ayurveda, Guduchi Ghan","Kumar, A.; Prasad, G.; Srivastav, S.; Gautam, V. K.; Sharma, N.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160424v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160424v1?rss=1,2020-07-29,2020-07-29,,True
273,Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002),"Background To be universally applicable in treatment of severe COVID-19, novel therapies, especially those with little toxicity and low cost, are urgently needed. We report here the use of one such therapeutic combination involving two commonly used nutraceuticals, namely resveratrol and copper in patients with this disease. This study was prompted by pre-clinical reports that sepsis-related cytokine storm and fatality in mice can be prevented by oral administration of small quantities of resveratrol and copper. Since cytokine storm and sepsis are major causes of death in severe COVID-19, we retrospectively analyzed outcomes of patients with this condition who had received resveratrol and copper. Methods & Findings Our analysis comprised of 230 patients with severe COVID-19 requiring inhaled oxygen who were admitted in a single tertiary care hospital in Mumbai between April 1 and May 13 2020. Thirty of these patients received, in addition to standard care, resveratrol and copper at doses of 5.6 mg and 560 ng, respectively, orally, once every 6 hours, until discharge or death. These doses were based on our pre-clinical studies, and were nearly 50 times and 2000 times less, respectively, than those recommended as health supplements. A multivariable-adjusted analysis was used to model the outcome of death in these patients and evaluate factors associated with this event. A binary logistic regression analysis was used, with age, sex, presence of comorbidities and receipt of resveratrol-copper as covariates. Data were updated as of May 30 2020. The number of deaths in resveratrol-copper and standard care only groups were 7/30 (23.3%, 95% CI 8.1%-38.4%) and 89/200 (44.5%, 95% CI 37.6%-51.3%), respectively. In multivariable analysis, age >50 years [odds ratio (OR) 2.558, 95% CI 1.454-4.302, P=0.0011] and female sex (OR 1.939, 95% CI 1.079-3.482, P=0.0267) were significantly associated, while presence of co-morbidities was not significantly associated (OR 0.713, 95% CI 0.405-1.256, P=0.2421) with death. There was a trend towards reduction in death in patients receiving resveratrol-copper (OR 0.413, 95% CI 0.164-1.039, P= 0.0604). Conclusions We provide preliminary results of a novel approach to the treatment of severe COVID-19 using a combination of small amounts of commonly used nutraceuticals, which is non-toxic and inexpensive, and therefore could be widely accessible globally. The nearly two-fold reduction in mortality with resveratrol-copper observed in our study needs to be confirmed in a randomized controlled trial.","Mittra, I.; de Souza, R.; Bhadade, R.; Madke, T.; Shankpal, P. D.; Joshi, M.; Qayyumi, B.; Bhattacharya, A.; Gota, V.; Gupta, S.; Chaturvedi, P.; Badwe, R.","https://www.medrxiv.org/content/10.1101/2020.07.21.20151423v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20151423v1?rss=1,2020-07-29,2020-07-29,,True
274,Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints,"Background The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) have precipitated a global pandemic heavily challenging our social behavior, economy, and healthcare infrastructure. Public health practices currently represent the primary interventions for managing the spread of the pandemic. We hypothesized that frequent, longitudinal workplace disease surveillance would represent an effective approach to controlling SARS-CoV-2 transmission among employees and their household members, reducing potential economic consequences and loss of productivity of standard isolation methods, while providing new insights into viral-host dynamics. Methodology and Findings On March 23, 2020 a clinical study (OCIS-05) was initiated at a small Southern California organization. Results from the first 3 months of the ongoing study are presented here. Study participants (27 employees and 27 household members) consented to provide frequent nasal or oral swab samples that were analyzed by RT-qPCR for SARS-CoV-2 RNA using CDC protocols. Only participants testing negative were allowed to enter the ""safe zone"" workplace facility. Optional blood samples were collected at baseline and throughout the 3-month study. Serum virus-specific antibody concentrations (IgG, IgM, and IgA) were measured using a selective, sensitive, and quantitative ELISA assay developed in house. A COVID-19 infection model, based on traditional SEIR compartmental models combined with Bayesian non-linear mixed models and modern machine learning, was used to predict the number of employees and household members who would have become infected in the absence of workplace surveillance. Two study participants were found to be infected by SARS-CoV-2 during the study. One subject, a household member, tested positive clinically by RT-qPCR prior to enrollment and experienced typical COVID-19 symptoms that did not require hospitalization. While on study, the participant was SARS-CoV-2 RNA positive for at least 71 days and had elevated virus-specific antibody concentrations (medians: IgM, 9.83 ug mL-1; IgG, 11.5 ug mL-1; IgA, 1.29 ug mL-1) in serum samples collected at three timepoints. A single, unrelated employee became positive for SARS-CoV-2 RNA over the course of the study, but remained asymptomatic with low associated viral RNA copy numbers. The participant did not have detectable serum IgM and IgG concentrations, and IgA concentrations decayed rapidly (half-life: 1.3 d). The employee was not allowed entry to the safe zone workplace until testing negative three consecutive times over 7 d. No other employees or household members contracted COVID-19 over the course of the study. Our model predicted that under the current prevalence in Los Angeles County without surveillance intervention, up to 7 employees (95% CI = 3-10) would have become infected with at most 1 of them requiring hospitalizations and 0 deaths. Conclusions Our clinical study met its primary objectives by using intense longitudinal testing to provide a safe work environment during the COVID-19 pandemic, and elucidating SARS-CoV-2 dynamics in recovering and asymptomatic participants. The surveillance plan outlined here is scalable and transferrable. The study represents a powerful example on how an innovative public health initiative can be dovetailed with scientific discovery.","Gunawardana, M.; Breslin, J.; Cortez, J. M.; Rivera, S.; Webster, S.; Ibarrondo, F. J.; Yang, O. O.; Pyles, R. B.; Ramirez, C. M.; Adler, A. P.; Anton, P. A.; Baum, M. M.","https://www.medrxiv.org/content/10.1101/2020.07.25.20160812v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20160812v1?rss=1,2020-07-28,2020-07-28,,True
275,Changes in Cause-of-Death Attribution During the Covid-19 Pandemic: Association with Hospital Quality Metrics and Implications for Future Research,"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often comorbid with conditions subject to quality metrics (QM) used for hospital performance assessment and rate-setting. Although diagnostic coding change in response to financial incentives is well documented, no study has examined the association of QM with SARS-CoV-2 cause-of-death attribution (CODA). Calculations of excess all-cause deaths overlook the importance of accurate CODA and of distinguishing policy-related from virus-related mortality. Objective: Examine CODA, overall and for QM and non-QM diagnoses, in 3 pandemic periods: awareness (January 19-March 14), height (March 15-May 16), and late (May 17-June 20). Methods: Retrospective analysis of publicly available national weekly COD data, adjusted for population growth and reporting lags, October 2014-June 20, 2020. CODA in 5 pre-pandemic influenza seasons was compared with 2019-20. Suitability of the data to distinguish policy-related from virus-related effects was assessed. Results: Following federal guidance permitting SARS-CoV-2 CODA without laboratory testing, mortality from the QM diagnoses cancer and chronic lower respiratory disease declined steadily relative to prior-season means, reaching 4.4% less and 12.1% less, respectively, in late pandemic. Deaths for non-QM diagnoses increased, by 21.0% for Alzheimers disease and 29.0% for diabetes during pandemic height. Increases in competing CODs over historical experience, suggesting SARS-CoV-2 underreporting, more than offset declines during pandemic height. However, in the late-pandemic period, declines slightly numerically exceeded increases, suggesting SARS-CoV-2 overreporting. In pandemic-height and late-pandemic periods, respectively, only 83.5% and 69.7% of increases in all-cause deaths were explained by changes in the reported CODs, including SARS-CoV-2, preventing assessment of policy-related mortality or of factors contributing to increased all-cause deaths. Conclusions: Substitution of SARS-CoV-2 for competing CODs may have occurred, particularly for QM diagnoses and late in the pandemic. Continued monitoring of these trends, qualitative research on pandemic CODA, and the addition of place-of-death data and psychiatric CODs to the file would facilitate assessment of policy-related and virus-related effects on mortality.","Fairman, K. A.; Goodlet, K. J.; Rucker, J. D.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162198v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162198v1?rss=1,2020-07-28,2020-07-28,,True
276,The performance of Mobile Cabin Hospital in combatting COVID-19 in China,"Background: Since the end of 2019 to the present day, the outbreak of the coronavirus disease 2019 (COVID-19) has had an immense impact on China and on other countries worldwide. This outbreak represents a serious threat to the lives and health of people all around the world. The epidemic first broke out in Wuhan, where the Chinese government was unable to prevent the spread of the disease by implementing home quarantine measures. Mobile cabin hospitals were used to relieve pressure on hospitals due to the need for beds while also isolating the sources of the infection through a centralized quarantine and treatment of mild cases. Method: This paper reviewed and summarized the treatment of patients with mild illness and symptoms during the period from the construction to the closing of the Hanyang Mobile Cabin Hospital in Wuhan, China, and presented the operational elements and possible improvements of running this hospital. Results: Mobile cabin hospitals helped China to curb the epidemic in only 2 incubation periods in 28 days.The basic conditions required for a normal operation of mobile cabin hospitals included the selection of the environment, medical staff to patient ratio, organizational structure, management model, admission criteria, treatment approaches, discharge process, livelihood guarantee, security, and other safeguarding measures. All of these components were performed carefully in Wuhan Hanyang Mobile Cabin Hospital, without medical staff being infected. Conclusion: The mobile cabin hospital compulsory quarantine for mild patients was an alternative method to combat COVID-19. It is hoped that the presented work in this manuscript can serve as a reference for the emergency prevention and control measures for global epidemic outbreaks.","Li, H.; Lin, J.; Lian, H.; Chen, K.; Lyu, Y.; Chen, Y.; Ren, L.; Zheng, L.; Lin, Z.; Yu, X.; Chen, Z.; Rensing, C.; Qian, X.; Yang, X.","https://www.medrxiv.org/content/10.1101/2020.07.26.20162206v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20162206v1?rss=1,2020-07-28,2020-07-28,,True
277,"Magnitude, demographics and dynamics of the impact of the first phase of the Covid-19 pandemic on all-cause mortality in 17 industrialised countries","The Covid-19 pandemic affects mortality directly through infection as well as through changes in the social, environmental and healthcare determinants of health. The impacts on mortality are likely to vary across countries in magnitude, timing, and age and sex composition. Here, we applied an ensemble of 16 Bayesian probabilistic models to vital statistics data, by age group and sex, to consistently and comparably estimate the impacts of the first phase of the pandemic on all-cause mortality for 17 industrialised countries. The models accounted for factors that affect death rates including seasonality, temperature, and public holidays, as well as for medium-long-term secular trends and the dependency of death rates in each week on those in preceding week(s). From mid-February through the end of May 2020, an estimated 202,900 (95% credible interval 179,400-224,900) more people died in these 17 countries than would have had the pandemic not taken place. Nearly three quarters of these excess deaths occurred in England and Wales, Italy and Spain, where less than half of the total population of these countries live. When all-cause mortality is considered, the total number of deaths, deaths per 100,000 people, and relative increase in deaths were similar between men and women in most countries. Further, in many countries, the balance of excess deaths changed from male-dominated early in the pandemic to being equal or female-dominated later on. Taken over the entire first phase of the pandemic, there was no detectable rise in all-cause mortality in New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland and for women in Austria and Switzerland (posterior probability of an increase in deaths <90%). Women in Portugal and men in Austria experienced relatively small increases in all-cause mortality, with posterior probabilities of 90-99%. For men in Switzerland and Portugal, and both sexes in the Netherlands, France, Sweden, Belgium, Italy, Scotland, Spain and England and Wales, all-cause mortality increased as a result of the pandemic with a posterior probability >99%. After accounting for population size, England and Wales and Spain experienced the highest death toll, nearly 100 deaths per 100,000 people; they also had the largest relative (percent) increase in deaths (37% (95% credible interval 30-44) in England and Wales; 38% (31-44) in Spain). New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland experienced changes in deaths that ranged from possible slight declines to increases of no more than 5%. The large impact in England and Wales stems partly from having experienced (together with Spain) the highest weekly increases in deaths, more than doubling in some weeks, and having had (together with Sweden) the longest duration when deaths exceeded levels that would be expected in the absence of the pandemic. The heterogeneous magnitude and character of the excess deaths due to the Covid-19 pandemic reflect differences in how well countries have managed the pandemic (e.g., timing, extent and adherence to lockdowns and other social distancing measures; effectiveness of test, trace and isolate mechanisms), and the resilience and preparedness of the health and social care system (e.g., effective facility and community care pathways; minimising spread of infection within hospitals and care homes, and between them and the community).","Kontis, V.; Bennett, J. E.; Rashid, T.; Parks, R. M.; Pearson-Stuttard, J.; Guillot, M.; Asaria, P.; Zhou, B.; Battaglini, M.; Corsetti, G.; McKee, M.; Di Cesare, M.; Mathers, C. D.; Ezzati, M.","https://www.medrxiv.org/content/10.1101/2020.07.26.20161570v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20161570v1?rss=1,2020-07-28,2020-07-28,,True
278,Social Listening: A Thematic Analysis of COVID-19 Discussion on Social Media,"COVI19 is a variant of corona virus diseases that has destabilised the entire world and whose cure as at mid-2020 has become elusive. Social media is ablaze with discussions around the pandemic. There is the dire need to delineate the on-going conversations on the infection with the intention of creating awareness on peoples reaction, opinion, action and recommendation that are inimical to the well being of the populace. Hence, this study is geared towards performing thematic analysis of the discussions on social media about COVID19. We programmatically retrieved data from twitter between 1st March, 2020 to 30th June 2020 with covid19 related keywords. We processed the data and later categorized them into themes that evolved from the tweets namely Herbs and Vegetables as COVID-10 Panacea, Self-Medication Due to Prescription by Non-Medical Practitioners on Social Media, Conspiracy Theories on COVID19 and Fear and Anxiety Associated with COVID19. The results show that many are resulting to herbs to protect themselves against the disease; taking drugs without doctors prescription; believing in conspiracy theories and having certain degree of fear.","Afolabi, D. S. A.; Folorunso, S. O.; Bunyula, Z. S.; Banjo, O. O.; Matshika, S. S.; Warrie, W. U.; Ngqambela, N.; Adepoju, A. E.; Rabophala, H.; Abimbola, O. V.; Olanipekun, M. S.; Odukoya, A. L.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162040v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162040v1?rss=1,2020-07-28,2020-07-28,,True
279,Impact of climatic parameters on COVID-19 pandemic progression in India: analysis and prediction,"COVID-19 is spreading rapidly worldwide and various factors of it have to be analysed. We analyze the effect of climatic parameters (Average Temperature (AT), Atmospheric Pressure (AP), Relative Humidity (RH), Solar Radiation (SR) and Wind Speed (WS)) on the COVID-19 epidemic during 25 March 2020 to 15 June 2020 in most affected states of India i.e. Maharashtra, Delhi and Tamilnadu. We quantitatively establish the correlation between these parameters by using Kendall & Spearman rank correlation test. The results indicate that the positive cases are highly correlated with the AT (r^2 >0.6,p<0.001) in Delhi where as a moderate correlation ( r^2<0.6,p<0.001) has been estimated for Maharashtra and Tamilnadu. Similarly, an intermediate range of correlation coefficient has been observed for other climatic parameters. The range of climatic parameters have been found corresponding to maximum number of cases results as AT (25~40 0 C), RH (40~70%), AT (740~965 mmHg), SR (200-250 W/mt2) and WS (.5~14 m/sec). Time series analysis depicts that the positive cases and mortality are increasing rapidly. COVID-19 epidemic peak is predicted and would be appearing October 2020 using SIR model for capital of India (New Delhi). The outcomes of this study will be helpful for the containment of COVID-19 worldwide.","Deyal, N.; Tiwari, V.; Bisht, N.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161919v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161919v1?rss=1,2020-07-28,2020-07-28,,True
280,The mutational analysis unveils the distribution of G614 genotype of SARS-CoV-2in different Indian states and its association with case fatality rate of COVID-19,"Pan genomic analysis of the global SARS-CoV-2 isolates has resulted in the identification of several regions of increased genetic variation but there is absence of research on its association with the clinical outcome. The present study fills the vacuum and does mutational analysis of genomic sequence of Indian SARS-CoV-2 isolates. Results reveal the existence of non-synonymous G614 spike protein mutation in 61.45% of the total study genome along with three other mutations. Further, temporal variation in the frequencies of G614 genotype in the country is observed. The examination of the probable association of G614 genotype with COVID-19 severity shows that CFR G614 genotype in India is positively and strongly correlated. It appears that the clinical outcome of the COVID-19 cases in India are significantly and adversely affected by the increasing trend in the G614 genotype; which needs to be addressed combining both laboratory experiments and epidemiological investigations.","Kumar, B. K.; Venkatraja, B.; Prithvisagar, K. S.; Rai, P.; Rohit, A.; Hegde, M. N.; Karunasagar, I.; Karunasagar, I.","https://www.biorxiv.org/content/10.1101/2020.07.27.222562v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.222562v1?rss=1,2020-07-28,2020-07-28,,False
281,Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS?,"There is an immediate need for therapies related to coronavirus disease 2019 (COVID-19), especially candidate drugs that possess anti-inflammatory and immunomodulatory effects with low toxicity profiles. We hypothesized the application of pleiotropic tetracyclines as potential therapeutic candidates. Here, we present a retrospective multi-institutional cohort study evaluating ventilatory status in patients who had taken a tetracycline antibiotic within a year prior to diagnosis of acute respiratory distress syndrome (ARDS). The primary outcomes were the need for mechanical ventilation and duration of mechanical ventilation. The secondary outcome was the duration of intensive care unit (ICU) stay. Data was evaluated using logistic regression and treatment effects regression models. Minocycline or doxycycline treatment within a year prior to ARDS diagnosis was associated with a 75% reduced likelihood for mechanical ventilation during hospital stay. Furthermore, tetracycline antibiotic therapy corresponded to significant reductions in duration of mechanical ventilation and ICU stay in ARDS patients. These data suggest tetracyclines may provide prophylactic benefit in reducing ventilatory support for ARDS patients and support further evaluation in a randomized prospective trial.","Byrne, J. D.; Shakur, R.; Collins, J.; Becker, S. L.; Young, C. C.; Boyce, H.; Traverso, C.","https://www.medrxiv.org/content/10.1101/2020.07.22.20154542v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20154542v1?rss=1,2020-07-28,2020-07-28,,True
282,Mononeuritis multiplex: an unexpectedly common feature of severe COVID-19,"The prolonged mechanical ventilation required by patients with severe COVID-19 is expected to result in significant Intensive Care Unit - Acquired Weakness (ICUAW) in many of the survivors. However, in our post-COVID-19 follow up clinic we have found that, as well as the anticipated global weakness related to loss of muscle mass, a significant proportion of these patients also have disabling focal neurological deficits relating to an axonal mononeuritis multiplex. Amongst the 69 patients with severe COVID-19 that have been discharged from the intensive care units in our hospital, we have seen 11 individuals (16%) with such neuropathies. In many instances, the multi-focal nature of the weakness in these patients was initially unrecognised as symptoms were wrongly assumed to simply relate to ""critical illness neuropathy"". While mononeuropathy is well recognised as an occasional complication of intensive care, our experience suggests that such deficits are common and frequently disabling in patients recovering from COVID-19.","Needham, E.; Newcombe, V.; Michell, A.; Thornton, R.; Grainger, A.; Anwar, F.; Warburton, E.; Menon, D.; Trivedi, M.; Sawcer, S.","https://www.medrxiv.org/content/10.1101/2020.07.19.20149898v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.19.20149898v1?rss=1,2020-07-28,2020-07-28,,True
283,Association of olfactory dysfunction with hospitalization for COVID-19: a multicenter study in Kurdistan,"Objective: To evaluate the association of olfactory dysfunction (OD) with hospitalization for COVID-19. Study Design: Multi-center cohort study. Setting: Emergency departments of thirteen COVID-19-designed hospitals in Kurdistan province, Iran. Subjects and Methods: Patients presenting with flu-like symptoms who tested positive by RT-PCR for COVID-19 between May 1st and 31st, 2020. At the time of presentation and enrollment, patients were asked about the presence of OD, fever, cough, shortness of breath, headache, rhinorrhea and sore throat. The severity of OD was assessed on an 11-point scale from 0 (none) to 10 (anosmia). Patients were either hospitalized or sent home for outpatient care based on standardized criteria. Results: Of 203 patients, who presented at a mean of 6 days into the COVID-19 disease course, 25 patients (12.3%) had new OD and 138 patients (68.0%) were admitted for their COVID-19. Patients admitted for COVID-19 had a higher prevalence of all symptoms assessed, including OD (p<0.05 in all cases), and OD identified admitted patients with 84.0% sensitivity and 34.3% specificity. On univariate logistic regression, hospitalization was associated with OD (odds ratio [OR] = 2.47, 95%CI: 1.085-6.911, p=0.049). However, hospitalization for COVID-19 was not associated with OD (OR=3.22, 95% CI: 0.57-18.31, p=0.188) after controlling for confounding demographics and comorbidities. Conclusion: OD may be associated with hospitalization for (and therefore more severe) COVID-19. However, this association between OD and COVID-19 severity is more likely driven by patient characteristics linked to OD, such as greater numbers of COVID-19 symptoms experienced or high-risk comorbidities.","Zobairy, H.; Shamsoddin, E.; Rasouli, M. A.; Veisi Khodlan, N.; Moradi, G.; Zareie, B.; Teymori, S.; Asadi, J.; Sofi-Mahmudi, A.; Sedaghat, A. R.","https://www.medrxiv.org/content/10.1101/2020.07.26.20158550v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20158550v1?rss=1,2020-07-28,2020-07-28,,True
284,"Modeling Control, Lockdown & Exit Strategies for COVID-19 Pandemic in India","COVID-19--a viral infectious disease--has quickly emerged as a global pandemic infecting millions of people with a significant number of deaths across the globe. The symptoms of this disease vary widely. Depending on the symptoms an infected person is broadly classified into two categories namely, asymptomatic and symptomatic. Asymptomatic individuals display mild or no symptoms but continue to transmit the infection to otherwise healthy individuals. This particular aspect of asymptomatic infection poses a major obstacle in managing and controlling the transmission of the infectious disease. In this paper, we attempt to mathematically model the spread of COVID-19 in India under various intervention strategies. We consider SEIR type epidemiological models, incorporated with India specific social contact matrix representing contact structures among different age groups of the population. Impact of various factors such as presence of asymptotic individuals, lockdown strategies, social distancing practices, quarantine, and hospitalization on the disease transmission is extensively studied. Numerical simulation of our model is matched with the real COVID-19 data of India till May 15, 2020, for the purpose of estimating the model parameters. Our model with zone-wise lockdown is seen to give a decent prediction for July 20, 2020.","Barman, M.; Nayak, S.; Yadav, M. K.; Raha, S.; Mishra, N.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161992v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161992v1?rss=1,2020-07-28,2020-07-28,,True
285,AutoSEIR: Accurate Forecasting from Real-time Epidemic Data Using Machine Learning,"Since the SARS-CoV-2 virus outbreak has been recognized as a pandemic on March 11, 2020, several models have been proposed to forecast its evolution following the governments' interventions. In particular, the need for fine-grained predictions, based on real-time and fluctuating data, has highlighted the limitations of traditional SEIR models and parameter fitting, encouraging the study of new models for greater accuracy. In this paper we propose a novel approach to epidemiological parameter fitting and epidemic forecasting, based on an extended version of the SEIR compartmental model and on an auto-differentiation technique for partially observable ODEs (Ordinary Differential Equations). The results on publicly available data show that the proposed model is able to fit the daily cases curve with greater accuracy, obtaining also a lower forecast error. Furthermore, the forecast accuracy allows to predict the peak with an error margin of less than one week, up to 50 days before the peak happens.","Rizzo, S. G.; Vantini, G.; Saad, M.; Chawla, S.","https://www.medrxiv.org/content/10.1101/2020.07.25.20159715v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20159715v1?rss=1,2020-07-28,2020-07-28,,True
286,A Bayesian Framework for Estimating the Risk Ratio of Hospitalization for People with Comorbidity Infected by the SARS-CoV-2 Virus,"Estimating the hospitalization risk for people with certain comorbidities infected by the SARS-CoV-2 virus is important for developing public health policies and guidance based on risk stratification. Traditional biostatistical methods require knowing both the number of infected people who were hospitalized and the number of infected people who were not hospitalized. However, the latter may be undercounted, as it is limited to only those who were tested for viral infection. In addition, comorbidity information for people not hospitalized may not always be readily available for traditional biostatistical analyses. To overcome these limitations, we developed a Bayesian approach that only requires the observed frequency of comorbidities in COVID-19 patients in hospitals and the prevalence of comorbidities in the general population. By applying our approach to two different large-scale datasets in the U.S., our results consistently indicated that cardiovascular diseases carried the highest hospitalization risk for COVID-19 patients, followed by diabetes, chronic respiratory disease, hypertension, and obesity, respectively.","Gao, X.; Dong, Q.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162131v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162131v1?rss=1,2020-07-28,2020-07-28,,True
287,Public Reactions towards the COVID-19 Pandemic on Twitter in the United Kingdom and the United States,"Background: The coronavirus disease 2019 (COVID-19) has spread globally since December 2019. Twitter is a popular social media platform with active discussions about the COVID-19 pandemic. The public reactions on Twitter about the COVID-19 pandemic in different countries have not been studied. This study aims to compare the public reactions towards the COVID-19 pandemic between the United Kingdom and the United States from March 6, 2020 to April 2, 2020. Data: The numbers of confirmed COVID-19 cases in the United Kingdom and the United States were obtained from the 1Point3Acres website. Twitter data were collected using COVID-19 related keywords from March 6, 2020 to April 2, 2020. Methods: Temporal analyses were performed on COVID-19 related Twitter posts (tweets) during the study period to show daily trends and hourly trends. The sentiment scores of the tweets on COVID-19 were analyzed and associated with the policy announcements and the number of confirmed COVID-19 cases. Topic modeling was conducted to identify related topics discussed with COVID-19 in the United Kingdom and the United States. Results: The number of daily new confirmed COVID-19 cases in the United Kingdom was significantly lower than that in the United States during our study period. There were 3,556,442 COVID-19 tweets in the United Kingdom and 16,280,065 tweets in the United States during the study period. The number of COVID-19 tweets per 10,000 Twitter users in the United Kingdom was lower than that in the United States. The sentiment scores of COVID-19 tweets in the United Kingdom were less negative than those in the United States. The topics discussed in COVID-19 tweets in the United Kingdom were mostly about the gratitude to government and health workers, while the topics in the United States were mostly about the global COVID-19 pandemic situation. Conclusion: Our study showed correlations between the public reactions towards the COVID-19 pandemic on Twitter and the confirmed COVID-19 cases as well as the policies related to the COVID-19 pandemic in the United Kingdom and the United States.","Zou, C.; Wang, X.; Xie, Z.; Li, D.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162024v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162024v1?rss=1,2020-07-28,2020-07-28,,True
288,Capping Mobility to Control COVID-19: A Collision-based Infectious Disease Transmission Model,"We developed a mobility-informed disease-transmission model for COVID-19, inspired by collision theory in gas-phase chemistry. This simple kinetic model leads to a closed-form infectious population as a function of time and cumulative mobility. This model uses fatality data from Johns Hopkins to infer the infectious population in the past, and mobility data from Google, without social-distancing policy, geological or demographic inputs. It was found that the model appears to be valid for twenty hardest hit counties in the United States. Based on this model, the number of infected people grows (shrinks) exponentially once the relative mobility exceeds (falls below) a critical value (~30% for New York City and ~60% for all other counties, relative to a median mobility from January 3 to February 6, 2020). A simple mobility cap can be used by government at different levels to control COVID-19 transmission in reopening or imposing another shutdown.","Shi, Y.; Ban, X.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162016v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162016v1?rss=1,2020-07-28,2020-07-28,,True
289,Serial co-expression analysis of host factors from SARS-CoV viruses highly converges with former high-throughput screenings and proposes key regulators and co-option of cellular pathways,"The current genomics era is bringing an unprecedented growth in the amount of gene expression data, only comparable to the exponential growth of sequences in databases during the last decades. This data now allows the design of secondary analyses that take advantage of this information to create new knowledge through specific computational approaches. One of these feasible analyses is the evaluation of the expression level for a gene through a series of different conditions or cell types. Based on this idea, we have developed ASACO, Automatic and Serial Analysis of CO-expression, which performs expression profiles for a given gene along hundreds of normalized and heterogeneous transcriptomics experiments and discover other genes that show either a similar or an inverse behavior. It might help to discover co-regulated genes, and even common transcriptional regulators in any biological model, including human diseases or microbial infections. The present SARS-CoV-2 pandemic is an opportunity to test this novel approach due to the wealth of data that is being generated, which could be used for validating results. In addition, new cell mechanisms identified could become new therapeutic targets. Thus, we have identified 35 host factors in the literature putatively involved in the infectious cycle of SARS-CoV and/or SARS-CoV-2 and searched for genes tightly co-expressed with them. We have found around 1900 co-expressed genes whose assigned functions are strongly related to viral cycles. Moreover, this set of genes heavily overlap with those identified by former laboratory high-throughput screenings (with p-value near 0). Some of these genes aim to cellular structures such as the stress granules, which could be essential for the virus replication and thereby could constitute potential targets in the current fight against the virus. Additionally, our results reveal a series of common transcription regulators, involved in immune and inflammatory responses, that might be key virus targets to induce the coordinated expression of SARS-CoV-2 host factors. All of this proves that ASACO can discover gene co-regulation networks with potential for proposing new genes, pathways and regulators participating in particular biological systems.

HighlightsO_LIASACO identifies regulatory associations of genes using public transcriptomics data.
C_LIO_LIASACO highlights new cell functions likely involved in the infection of coronavirus.
C_LIO_LIComparison with high-throughput screenings validates candidates proposed by ASACO.
C_LIO_LIGenes co-expressed with hosts genes used by SARS-CoV-2 are related to stress granules.
C_LIO_LIZNF91 and TRIM14 might be putative targets to interfere with the viral infection.
C_LI","Perez-Pulido, A. J.; Asencio-Cortes, G.; Brokate-Llanos, A. M.; Brea-Calvo, G.; Rodriguez-Grinolo, R.; Garzon, A.; Munoz, M. J.","https://www.biorxiv.org/content/10.1101/2020.07.28.225078v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225078v1?rss=1,2020-07-28,2020-07-28,,False
290,Does sampling saliva increase detection of SARS-CoV-2 by RT-PCR? Comparing saliva with oro-nasopharyngeal swabs,"The gold standard method in the diagnosis of SARS-CoV-2 infection is the detection of viral RNA in nasopharyngeal sample by RT-PCR. Recently, saliva samples has been suggested as an alternative due to being fast, reliable and non-invasive, rather than nasopharyngeal samples. We compared RT-PCR results in nasopharyngeal, oro-nasopharyngeal and saliva samples of COVID-19 patients. 98 of 200 patients were positive in RT-PCR analysis performed before the hospitalization. In day 0, at least one sample was positive in 67% of 98 patients. Positivity rate was 83% for both oro-nasopharyngeal and nasopharyngeal samples, while it was 63% for saliva samples (p<0.001). On day 5, RT-PCR was performed in 59 patients, 34% had at least one positive result. The positivity rate was 55% for saliva and nasopharyngeal samples, while it was 60% for oro-nasopharyngeal samples. Our study shows that the sampling saliva does not increase the sensitivity of RT-PCR tests at early stages of infection. However, on 5th day, viral RNA detection rates in saliva were similar to nasopharyngeal and oro-nasopharyngeal samples. In conclusion, we suggest that, in patients receiving treatment, virus presence in saliva, in addition to the standard samples, is important to determine the isolation period and to control the transmission.","Akgun Dogan, O.; Kose, B.; Agaoglu, N. B.; Yildiz, J.; Alkurt, G.; Kendir Demirkol, Y.; Irvem, A.; Dinler-Doganay, G.; Doganay, L.","https://www.medrxiv.org/content/10.1101/2020.07.26.20158618v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.26.20158618v1?rss=1,2020-07-28,2020-07-28,,True
291,"SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis","Background Viral load kinetics and the duration of viral shedding are important determinants for disease transmission. We aim i) to characterise viral load dynamics, duration of viral RNA, and viable virus shedding of SARS-CoV-2 in various body fluids and ii) to compare SARS-CoV-2 viral dynamics with SARS-CoV-1 and MERS-CoV. Methods: Medline, EMBASE, Europe PMC, preprint servers and grey literature were searched to retrieve all articles reporting viral dynamics and duration of SARS-CoV-2, SARS-CoV-1 and MERS-CoV shedding. We excluded case reports and case series with < 5 patients, or studies that did not report shedding duration from symptom onset. PROSPERO registration: CRD42020181914. Findings: Seventy-nine studies on SARS-CoV-2, 8 on SARS-CoV-1, and 11 on MERS-CoV were included. Mean SARS-CoV-2 RNA shedding duration in upper respiratory tract, lower respiratory tract, stool and serum were 17.0, 14.6, 17.2 and 16.6 days, respectively. Maximum duration of SARS-CoV-2 RNA shedding reported in URT, LRT, stool and serum was 83, 59, 35 and 60 days, respectively. Pooled mean duration of SARS-CoV-2 RNA shedding was positively associated with age (p=0.002), but not gender (p = 0.277). No study to date has detected live virus beyond day nine of illness despite persistently high viral loads. SARS-CoV-2 viral load in the upper respiratory tract appears to peak in the first week of illness, while SARS-CoV-1 and MERS-CoV peak later. Conclusion: Although SARS-CoV-2 RNA shedding in respiratory and stool can be prolonged, duration of viable virus is relatively short-lived. Thus, detection of viral RNA cannot be used to infer infectiousness. High SARS-CoV-2 titres are detectable in the first week of illness with an early peak observed at symptom onset to day 5 of illness. This review underscores the importance of early case finding and isolation, as well as public education on the spectrum of illness. However, given potential delays in the isolation of patients, effective containment of SARS-CoV-2 may be challenging even with an early detection and isolation strategy. Funding: No funding was received.","Cevik, M.; Tate, M.; Lloyd, O.; Maraolo, A. E.; Schafers, J.; Ho, A.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v1?rss=1,2020-07-28,2020-07-28,,True
292,"Levels of the TNF related cytokine, LIGHT increase in hospitalized COVID-19 patients with Cytokine Release Syndrome and ARDS","Many COVID-19 patients demonstrate lethal respiratory complications caused by cytokine release syndrome (CRS). Multiple cytokines have been implicated in CRS, but TNFSF14 (LIGHT) has not been previously measured in this setting. In this study, we observed significantly elevated serum LIGHT levels in hospitalized COVID-19 patients as compared to healthy age and gender matched control patients. The assay detected bioavailable LIGHT unbound to the inhibitor Decoy receptor-3 (DcR3). Bioavailable LIGHT levels were elevated in patients both on and off ventilatory support, with a trend toward higher levels in patients requiring mechanical ventilation. In hospitalized patients over the age of 60, who exhibited a mortality rate of 82%, LIGHT levels were significantly higher (p=0.0209) in those who died compared to survivors. As previously reported, interleukin 6 (IL-6) levels were also elevated in these patients with significantly (p=0.0076) higher levels observed in patients who died vs. survivors, paralleling the LIGHT levels. Although attempts to block IL-6 binding to its receptor have shown limited effect in COVID-19 CRS, neutralization of LIGHT may prove to be more effective owing to its more central role in regulating antiviral immune responses.","Perlin, D. S.; Zafir-Lavie, I.; Roadcap, L.; Raines, S.; Ware, C. F.; Neil, G. A.","https://www.medrxiv.org/content/10.1101/2020.07.27.20152892v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20152892v1?rss=1,2020-07-28,2020-07-28,,True
293,Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations,"Multiple clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05). These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms. We note that the findings in this study are preliminary and are subject to change as more data becomes available and as further analysis is conducted.","Pawlowski, C.; Puranik, A.; Bandi, H.; Venkatakrishnan, A.; Agarwal, V.; Kennedy, R.; O'Horo, J. C.; Gores, G. J.; Williams, A. W.; Halamka, J.; Badley, A. D.; Soundararajan, V.","https://www.medrxiv.org/content/10.1101/2020.07.27.20161976v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.27.20161976v1?rss=1,2020-07-28,2020-07-28,,True
294,Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis,"Many recent studies have investigated the role of either Chloroquine (CQ) alone, Hydroxychloroquine (HCQ) alone, or CQ/HCQ in combination with azithromycin (AZM) in management of the emerging coronavirus. This systematic review and meta-analysis of either published or preprint observational or interventional studies were conducted to assess the cure rate, duration of hospital stay, radiological progression, clinical worsening, need for mechanical ventilation, the occurrence of side effects, and mortality. A search of the online database through June 2020 was performed and examined the reference lists of pertinent articles for in-vivo studies only. Pooled relative risks (RRs), standard mean, of 95 % confidence intervals (CIs) were calculated with the random-effects model. Results: The duration of hospital stay was shorter in the standard care in comparison with HCQ group, the standard mean of hospital stay was 0.57, 95% CI, and 0.20-0.94. Overall virological cure, or more specifically at day 4, 10, and 14 among patients exposed to HCQ did not differ significantly from the standard care [(RR=0.92, 95% CI 0.78-1.15), (RR=1.11, 95% CI 0.74-1.65), (RR=1.21, 95%CI 0.70-2.01), and (RR=0.98, 95% CI, 0.76-1.27)] respectively. Radiological improvement or clinical worsening was not statistically different between HCQ and standard care [(RR=1.11, 95% CI 0.64-1.65) and (RR=1.28, 95% CI 0.33-4.99)]. The need for mechanical ventilation (MV) was not significant between the HCQ group and the standard care (RR= 1.5, 95%CI 0.78-2.89). Side effects were more reported in the HCQ group than the standard care (RR=3.14, 95% CI 1.58- 6.24). Mortality among HCQ was not affected by receiving HCQ (RR=3.14, 95% CI 1.58-6.24), meta-regression analysis revealed that country is a strong predictor of mortality. The duration of hospital stay among the HCQ and AZM didn not differ significantly from the standard care (standard mean= 0.77, 95% CI 0.46-1.08). Despite virological cure and need for MV did not differ significantly [(RR= 3.23, 95% CI 0.70-14.97) and (RR=1.27, 95%CI 0.7-2.13)] respectively. Mortality among the HCQ+AZM was more significantly higher than among the standard care (RR= 1.8, 95% CI 1.19-2.27). Conclusion: Despite the scarcity of published data of good quality, the effectiveness and safety of either HCQ alone or in combination with AZM in treating the pandemic of COVID-19 cannot be assured. Future randomized control trials need to be carried out to verify this conclusion.","Ghazy, R. M.; Almaghraby, A.; Shaaban, R.; Kamal, A.; Beshir, H.; Moursi, A.; Taha, S. H. N.; Ramadan, A.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162073v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162073v1?rss=1,2020-07-28,2020-07-28,,True
295,30-day mortality and morbidity in COVID-19 versus influenza: A populationbased study,"Background As of July 2020, COVID-19 has caused 500,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to influenza and individuals tested negative for COVID-19 are lacking. We aimed to investigate COVID-19 30-day mortality and newonset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza. Methods and findings This population-based cohort study utilized electronic health records covering roughly half (n=2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals [&ge;]18 years tested for COVID-19 and individuals tested for influenza were followed from November 1, 2017 to June 30, 2020. The main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza. In total, 224,639 individuals were tested for COVID-19. Among inpatients positive for COVID-19, 356 of 1657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p<0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to influenza and COVID-19-negative patients, respectively (all p<0.001). Compared to hospitalized patients with influenza, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p<0.05). Conclusions In this population-based study comparing COVID-19 with influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality, which is likely even higher than the stated 3.0 to 5.5-fold increase owing to more extensive testing for COVID-19.","Nersesjan, V.; Amiri, M.; Christensen, H. K.; Benros, M. E.; Kondziella, D.","https://www.medrxiv.org/content/10.1101/2020.07.25.20162156v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20162156v1?rss=1,2020-07-28,2020-07-28,,True
296,Rapid host response to an infection with Coronavirus. Study of transcriptional responses with Porcine Epidemic Diarrhea Virus,"The transcriptional response in Vero cells (ATCC(R) CCL-81) infected with the coronavirus Porcine Epidemic Diarrhea Virus (PEDV) was measured by RNAseq analysis 4 and 6 hours after infection. Differential expressed genes (DEGs) in PEDV infected cells were compared to DEGs responding in Vero cells infected with Mammalian Orthoreovirus (MRV). Functional analysis of MRV and PEDV DEGs showed that MRV increased the expression level of several cytokines and chemokines (e.g. IL6, CXCL10, IL1A, CXCL8 [alias IL8]) and antiviral genes (e.g. IFI44, IFIT1, MX1, OASL), whereas for PEDV no enhanced expression was observed for these ""hallmark"" antiviral and immune effector genes. Pathway and Gene Ontology ""enrichment analysis"" revealed that PEDV infection did not stimulate expression of genes able to activate an acquired immune response, whereas MRV did so within 6h. Instead, PEDV down-regulated the expression of a set of zinc finger proteins with putative antiviral activity and enhanced the expression of the transmembrane serine protease gene TMPRSS13 (alias MSPL) to support its own infection by virus-cell membrane fusion (Shi et al, 2017, Viruses, 9(5):114). PEDV also down-regulated expression of Ectodysplasin A, a cytokine of the TNF-family able to activate the canonical NFKB-pathway responsible for transcription of inflammatory genes like IL1B, TNF, CXCL8 and PTGS2. The only 2 cytokine genes found up-regulated by PEDV were Cardiotrophin-1, an IL6-type cytokine with pleiotropic functions on different tissues and types of cells, and Endothelin 2, a neuroactive peptide with vasoconstrictive properties. Furthermore, by comprehensive datamining in biological and chemical databases and consulting related literature we identified sets of PEDV-response genes with potential to influence i) the metabolism of biogenic amines (e.g. histamine), ii) the formation of cilia and ""synaptic clefts"" between cells, iii) epithelial mucus production, iv) platelets activation, and v) physiological processes in the body regulated by androgenic hormones (like blood pressure, salt/water balance and energy homeostasis). The information in this study describing a ""very early"" response of epithelial cells to an infection with a coronavirus may provide pharmacologists, immunological and medical specialists additional insights in the underlying mechanisms of coronavirus associated severe clinical symptoms including those induced by SARS-CoV-2. This may help them to fine-tune therapeutic treatments and apply specific approved drugs to treat COVID-19 patients.","Hou, W.; Liu, F.; van der Poel, W. H. M.; Hulst, M. M.","https://www.biorxiv.org/content/10.1101/2020.07.28.224576v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.224576v1?rss=1,2020-07-28,2020-07-28,,False
297,Comparative Analysis of Human Coronaviruses Focusing on Nucleotide Variability and Synonymous Codon Usage Pattern,"Prevailing pandemic across the world due to SARSCoV-2 drawing great attention towards discovering its evolutionary origin. We perform an exploratory study to understand the variability of the whole coding region of possible proximal evolutionary neighbours of SARSCoV-2. We consider seven (07) human coronavirus strains from six different species as a candidate for our study.

First, we observe a good variability of nucleotides across candidate strains. We did not find a significant variation of GC content across the strains for codon position first and second. However, we interestingly see huge variability of GC-content in codon position 3rd (GC3), and pairwise mean GC-content (SARSCoV, MERSCoV), and (SARSCoV-2, hCoV229E) are quite closer. While observing the relative abundance of dinucleotide feature, we find a shared typical genetic pattern, i.e., high usage of GC and CT nucleotide pair at the first two positions (P12) of codons and the last two positions (P23) of codons, respectively. We also observe a low abundance of CG pair that might help in their evolution bio-process. Secondly, Considering RSCU score, we find a substantial similarity for mild class coronaviruses, i.e., hCoVOC43, hCoVHKU1, and hCoVNL63 based on their codon hit with high RSCU value ([&ge;] 1.5), and minim number of codons hit (count-9) is observed for MERSCoV. We see seven codons ATT, ACT, TCT, CCT, GTT, GCT and GGT with high RSCU value, which are common in all seven strains. These codons are mostly from Aliphatic and Hydroxyl amino acid group. A phylogenetic tree built using RSCU feature reveals proximity among hCoVOC43 and hCoV229E (mild). Thirdly, we perform linear regression analysis among GC content in different codon position and ENC value. We observe a strong correlation (significant p-value) between GC2 and GC3 for SARSCoV-2, hCoV229E and hCoVNL63, and between GC1 and GC3 for hCoV229E, hCoVNL63, SARSCoV. We believe that our findings will help in understanding the mechanism of human coronavirus.","Das, J.; Roy, S.","https://www.biorxiv.org/content/10.1101/2020.07.28.224386v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.224386v1?rss=1,2020-07-28,2020-07-28,,False
298,Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries,"Antibodies with high affinity against the receptor binding domain (RBD) of the SARS-CoV-2 S1 ectodomain were identified from screens using the Retained Display (ReD) platform employing a 1 x 1011 clone single-chain antibody (scFv) library. Numerous unique scFv clones capable of inhibiting binding of the viral S1 ectodomain to the ACE2 receptor in vitro were characterized. To maximize avidity, selected clones were reformatted as bivalent diabodies and monoclonal antibodies (mAb). The highest affinity mAb completely neutralized live SARS-CoV-2 virus in cell culture for four days at a concentration of 6.7 nM, suggesting potential therapeutic and/or prophylactic use. Furthermore, scFvs were identified that greatly increased the interaction of the viral S1 trimer with the ACE2 receptor, with potential implications for vaccine development.","Beasley, M. D.; Aracic, S.; Gracey, F. M.; Kannan, R.; Masarati, A.; Premaratne, S. R.; Udawela, M.; Wood, R. E.; Jabar, S.; Church, N.; Le, T.-K.; Makris, D.; McColl, B. K.; Kiefel, B. R.","https://www.biorxiv.org/content/10.1101/2020.07.27.224089v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.224089v1?rss=1,2020-07-28,2020-07-28,,False
299,Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories,"Host immune responses play central roles in controlling SARS-CoV2 infection, yet remain incompletely characterized and understood. Here, we present a comprehensive immune response map spanning 454 proteins and 847 metabolites in plasma integrated with single-cell multi-omic assays of PBMCs in which whole transcriptome, 192 surface proteins, and T and B cell receptor sequence were co-analyzed within the context of clinical measures from 50 COVID19 patient samples. Our study reveals novel cellular subpopulations, such as proliferative exhausted CD8+ and CD4+ T cells, and cytotoxic CD4+ T cells, that may be features of severe COVID-19 infection. We condensed over 1 million immune features into a single immune response axis that independently aligns with many clinical features and is also strongly associated with disease severity. Our study represents an important resource towards understanding the heterogeneous immune responses of COVID-19 patients and may provide key information for informing therapeutic development.","Su, Y.; Chen, D.; Lausted, C.; Yuan, D.; Choi, J.; Dai, C.; Voillet, V.; Scherler, K.; Troisch, P.; Duvvuri, V. R.; Baloni, P.; Qin, G.; Smith, B.; Kornilov, S.; Rostomily, C.; Xu, A.; Li, J.; Dong, S.; Rothchild, A.; Zhou, J.; Murray, K.; Edmark, R.; Hong, S.; Jones, L.; Zhou, Y.; Roper, R.; Mackay, S.; O'Mahony, D. S.; Dale, C. R.; Wallick, J. A.; Algren, H. A.; Michael, Z. A.; Magis, A.; Wei, W.; Price, N. D.; Huang, S.; Subramanian, N.; Wang, K.; Hadlock, J.; Hood, L.; Aderem, A.; Bluestone, J. A.; Lanier, L. L.; Greenberg, P.; Gottardo, R.; Davis, M. M.; Goldman, J. D.; Heath, J. R.; the ISB-Swedish COVID19 Biobanking Unit,","https://www.biorxiv.org/content/10.1101/2020.07.27.224063v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.224063v1?rss=1,2020-07-28,2020-07-28,,False
300,A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors,"The COVID-19 pathogen, SARS-CoV-2, requires its main protease (SC2MPro) to digest two of its translated polypeptides to form a number of mature proteins that are essential for viral replication and pathogenesis. Inhibition of this vital proteolytic process is effective in preventing the virus from replication in infected cells and therefore provides a potential COVID-19 treatment option. Guided by previous medicinal chemistry studies about SARS-CoV-1 main protease (SC1MPro), we have designed and synthesized a series of SC2MPro inhibitors that contain {beta}-(S-2-oxopyrrolidin-3-yl)-alaninal (Opal) for the formation of a reversible covalent bond with the SC2MPro active site cysteine C145. All inhibitors display high potency with IC50 values at or below 100 nM. The most potent compound MPI3 has as an IC50 value as 8.5 nM. Crystallographic analyses of SC2MPro bound to 7 inhibitors indicated both formation of a covalent bond with C145 and structural rearrangement from the apoenzyme to accommodate the inhibitors. Virus inhibition assays revealed that several inhibitors have high potency in inhibiting the SARS-CoV-2-induced cytopathogenic effect in both Vero E6 and A549 cells. Two inhibitors MP5 and MPI8 completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 M and A549 cells at 0.16-0.31 M. Their virus inhibition potency is much higher than some existing molecules that are under preclinical and clinical investigations for the treatment of COVID-19. Our study indicates that there is a large chemical space that needs to be explored for the development of SC2MPro inhibitors with extreme potency. Due to the urgent matter of the COVID-19 pandemic, MPI5 and MPI8 may be quickly advanced to preclinical and clinical tests for COVID-19.","Liu, W. R.; Yang, K. S.; Ma, X. R.; Ma, Y.; Alugubelli, Y. R.; Scott, D. A.; Vatansever, E. C.; Drelich, A. K.; Geng, Z. Z.; Blankenship, L. R.; Sankaran, B.; Ward, H. E.; Sheng, Y. J.; Hsu, J. C.; Kratch, K. K.; Zhao, B.; Liu, J.; Li, P.; Fierke, C. A.; Tseng, C.-T. K.; Xu, S.; Hayatshahi, H. S.","https://www.biorxiv.org/content/10.1101/2020.07.28.223784v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.223784v1?rss=1,2020-07-28,2020-07-28,,False
301,Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza,"Since the first human case was reported in Wuhan Province, China in December 2019, SARS-CoV-2 has caused millions of human infections in more than 200 countries worldwide with an approximately 4.01% case-fatality rate (as of 27 July, 2020; based on a WHO situation report), and COVID-19 pandemic has paralyzed our global community. Even though a few candidate drugs, such as remdesivir (a broad antiviral prodrug) and hydroxychloroquine, have been investigated in human clinical trials, their therapeutic efficacy needs to be clarified further to be used to treat COVID-19 patients. Here we show that pyronaridine and artesunate, which are the chemical components of anti-malarial drug Pyramax(R), exhibit antiviral activity against SARS-CoV-2 and influenza viruses. In human lung epithelial (Calu-3) cells, pyronaridine and artesunate were highly effective against SARS-CoV-2 while hydroxychloroquine did not show any effect at concentrations of less than 100 M. In viral growth kinetics, both pyronaridine and artesunate inhibited the growth of SARS-CoV-2 and seasonal influenza A virus in Calu-3 cells. Taken together, we suggest that artesunate and pyronaridine might be effective drug candidates for use in human patients with COVID-19 and/or influenza, which may co-circulate during this coming winter season.","Bae, J.-Y.; Lee, G. E.; Park, H.; Cho, J.; Kim, Y.-E.; Lee, J.-Y.; Ju, C.; Kim, W.-K.; Kim, J. I.; Park, M.-S.","https://www.biorxiv.org/content/10.1101/2020.07.28.225102v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225102v1?rss=1,2020-07-28,2020-07-28,,False
302,SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan,"In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mediated by the spike glycoprotein (SGP). Recently, a SARS-CoV-2 Spike Pseudotyped Lentivirus (SSPL) was developed that allows studying spike-mediated cell entry via luciferase reporter activity in a BSL2 environment. Here, we show that iota-carrageenan can inhibit the cell entry of SSPL in a dose dependent manner. SSPL particles were efficiently neutralized with an IC50 value of 2.6 {micro}g/ml iota-carrageenan. In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.","Morokutti-Kurz, M.; Graf, P.; Grassauer, A.; Prieschl-Grassauer, E.","https://www.biorxiv.org/content/10.1101/2020.07.28.224733v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.224733v1?rss=1,2020-07-28,2020-07-28,,False
303,Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism,"Neurological complications are common in patients with COVID-19. While SARS-CoV-2, the causal pathogen of COVID-19, has been detected in some patient brains, its ability to infect brain cells and impact their function are not well understood, and experimental models using human brain cells are urgently needed. Here we investigated the susceptibility of human induced pluripotent stem cell (hiPSC)-derived monolayer brain cells and region-specific brain organoids to SARS-CoV-2 infection. We found modest numbers of infected neurons and astrocytes, but greater infection of choroid plexus epithelial cells. We optimized a protocol to generate choroid plexus organoids from hiPSCs, which revealed productive SARS-CoV-2 infection that leads to increased cell death and transcriptional dysregulation indicative of an inflammatory response and cellular function deficits. Together, our results provide evidence for SARS-CoV-2 neurotropism and support use of hiPSC-derived brain organoids as a platform to investigate the cellular susceptibility, disease mechanisms, and treatment strategies for SARS-CoV-2 infection.","Jacob, F.; Pather, S.; Huang, W.-K.; Wong, S. Z. H.; Zhou, H.; Zhang, F.; Cubitt, B.; Chen, C. Z.; Xu, M.; Pradhan, M.; Zhang, D. Y.; Zheng, W.; Bang, A. G.; Song, H.; de la Torre, J. C.; Ming, G.-l.","https://www.biorxiv.org/content/10.1101/2020.07.28.225151v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.28.225151v1?rss=1,2020-07-28,2020-07-28,,False
304,Antiviral effects of miRNAs in extracellular vesicles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mutations in SARS-CoV-2 RNA virus,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 2019 (COVID-19). No treatment is available. Micro-RNAs (miRNAs) in mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are potential novel therapeutic agents because of their ability to regulate gene expression by inhibiting mRNA. Thus, they may degrade the RNA genome of SARS-CoV-2. EVs can transfer miRNAs to recipient cells and regulate conditions within them. MSC-EVs harbor major therapeutic miRNAs that play important roles in the biological functions of virus-infected host cells. Here, we examined their potential impact on viral and immune responses. MSC-EVs contained 18 miRNAs predicted to interact directly with the 3 UTR of SARS-CoV-2. These EVs suppressed SARS-CoV-2 replication in Vero E6 cells. In addition, five major miRNAs suppressed virus activity in a luciferase reporter assay by binding the 3 UTR. MSC-EVs showed strong regenerative effects and potent anti-inflammatory activity which may prevent lethal cytokine storms. We confirmed that EVs regulated inflammatory responses by several cell types, including human brain cells that express the viral receptor ACE2, suggesting that the brain may be targeted by SARS-CoV-2. miRNAs in MSC-EVs have several advantages as therapeutic agents against SARS-CoV-2: 1) they bind specifically to the viral 3 UTR, and are thus unlikely to have side effects; 2) because the 3 UTR is highly conserved and rarely mutates, MSC-EV miRNAs could be used against novel variants arising during viral replication; and 3) unique cargoes carried by MSC-EVs can have diverse effects, such as regenerating damaged tissue and regulating immunity.","Moon, J.; Park, J. H.; Choi, Y.; Lim, C.-W.; Park, J.-M.; Yu, S.-H.; Kim, Y.; Han, H. J.; Kim, C.-H.; Song, Y.-S.; Kim, C.","https://www.biorxiv.org/content/10.1101/2020.07.27.190561v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.190561v1?rss=1,2020-07-27,2020-07-27,,False
305,Targeting the endolysosomal host-SARS-CoV-2 interface by the clinically licensed antidepressant fluoxetine,"The Corona Virus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, and globally available pharmaceuticals that inhibit SARS-CoV-2 entry and ameliorate COVID-19. In this study, we explored the use of small compounds acting on the homeostasis of the endolysosomal host-pathogen interface, to fight SARS-CoV-2 infection. We find that fluoxetine, a widely used antidepressant and a functional inhibitor of acid sphingomyelinase (FIASMA), efficiently inhibits the entry and propagation of SARS-CoV-2 in the cell culture model without cytotoxic effects. Mechanistically, fluoxetine induced both impaired endolysosomal acidification and the accumulation of cholesterol within the endosomes. As the FIASMA group consists of a large number of small compounds that are well-tolerated and widely used for a broad range of clinical applications, exploring these licensed pharmaceuticals may offer a variety of promising antivirals for host-directed therapy to counteract SARS-CoV-2 and COVID 19.

SignificanceOnly very limited therapeutic options are clinically available for treatment of Corona Virus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2), and the development of safe, effective, and globally available pharmaceuticals are urgently required. We report that the widely used antidepressant fluoxetine efficiently inhibits the early entry and propagation of SARS-CoV-2 in the cell culture model, and may offer a promising approach for host-directed therapy to counteract SARS-CoV-2 and COVID 19.","Schloer, S.; Brunotte, L.; Goretzko, J.; Mecate-Zambrano, A.; Korthals, N.; Gerke, V.; Ludwig, S.; Rescher, U.","https://www.biorxiv.org/content/10.1101/2020.07.27.222836v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.222836v1?rss=1,2020-07-27,2020-07-27,,False
306,Oligonucleotide capture sequencing of the SARS-CoV-2 genome and subgenomic fragments from COVID-19 individuals,"The newly emerged and rapidly spreading SARS-CoV-2 causes coronavirus disease 2019 (COVID-19). To facilitate a deeper understanding of the viral biology we developed a capture sequencing methodology to generate SARS-CoV-2 genomic and transcriptome sequences from infected patients. We utilized an oligonucleotide probe-set representing the full-length genome to obtain both genomic and transcriptome (subgenomic open reading frames [ORFs]) sequences from 45 SARS-CoV-2 clinical samples with varying viral titers. For samples with higher viral loads (cycle threshold value under 33, based on the CDC qPCR assay) complete genomes were generated. Analysis of junction reads revealed regions of differential transcriptional activity and provided evidence of expression of ORF10. Heterogeneous allelic frequencies along the 20kb ORF1ab gene suggested the presence of a defective interfering viral RNA species subpopulation in one sample. The associated workflow is straightforward, and hybridization-based capture offers an effective and scalable approach for sequencing SARS-CoV-2 from patient samples.","Doddapaneni, H. V.; Cregeen, S. J.; Sucgang, R.; Meng, Q.; Qing, X.; Avadhanula, V.; Chao, H.; Menon, V.; Nicholson, E.; Henke, D.; Piedra, F.-A.; Rajan, A.; Momin, Z.; Kottapalli, K.; Hoffman, K. L.; Sedlazeck, F. J.; Metcalf, G.; Piedra, P. A.; Muzny, D. M.; Petrosino, J. F.; Gibbs, R. A.","https://www.biorxiv.org/content/10.1101/2020.07.27.223495v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.223495v1?rss=1,2020-07-27,2020-07-27,,False
307,Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures,"The distal lung contains terminal bronchioles and alveoli that facilitate gas exchange and is affected by disorders including interstitial lung disease, cancer, and SARS-CoV-2-associated COVID-19 pneumonia. Investigations of these localized pathologies have been hindered by a lack of 3D in vitro human distal lung culture systems. Further, human distal lung stem cell identification has been impaired by quiescence, anatomic divergence from mouse and lack of lineage tracing and clonogenic culture. Here, we developed robust feeder-free, chemically-defined culture of distal human lung progenitors as organoids derived clonally from single adult human alveolar epithelial type II (AT2) or KRT5+ basal cells. AT2 organoids exhibited AT1 transdifferentiation potential, while basal cell organoids progressively developed lumens lined by differentiated club and ciliated cells. Organoids consisting solely of club cells were not observed. Upon single cell RNA-sequencing (scRNA-seq), alveolar organoids were composed of proliferative AT2 cells; however, basal organoid KRT5+ cells contained a distinct ITGA6+ITGB4+ mitotic population whose proliferation segregated to a TNFRSF12Ahi subfraction. Clonogenic organoid growth was markedly enriched within the TNFRSF12Ahi subset of FACS-purified ITGA6+ITGB4+ basal cells from human lung or derivative organoids. In vivo, TNFRSF12A+ cells comprised ~10% of KRT5+ basal cells and resided in clusters within terminal bronchioles. To model COVID-19 distal lung disease, we everted the polarity of basal and alveolar organoids to rapidly relocate differentiated club and ciliated cells from the organoid lumen to the exterior surface, thus displaying the SARS-CoV-2 receptor ACE2 on the outwardly-facing apical aspect. Accordingly, basal and AT2 ""apical-out"" organoids were infected by SARS-CoV-2, identifying club cells as a novel target population. This long-term, feeder-free organoid culture of human distal lung alveolar and basal stem cells, coupled with single cell analysis, identifies unsuspected basal cell functional heterogeneity and exemplifies progenitor identification within a slowly proliferating human tissue. Further, our studies establish a facile in vitro organoid model for human distal lung infectious diseases including COVID-19-associated pneumonia.","Salahudeen, A. A.; Choi, S. S.; Rustagi, A.; Zhu, J.; de la O, S. M.; Flynn, R. A.; Margalef-Catala, M.; Santos, A. J. M.; Ju, J.; Batish, A.; van Unen, V.; Usui, T.; Zheng, G. X. Y.; Edwards, C. E.; Wagar, L. E.; Luca, V.; Anchang, B.; Nagendran, M.; Nguyen, K.; Hart, D. J.; Terry, J. M.; Belgrader, P.; Ziraldo, S. B.; Mikkelsen, T. S.; Harbury, P. B.; Glenn, J. S.; Garcia, K. C.; Davis, M. M.; Baric, R. S.; Sabatti, C.; Amieva, M. R.; Blish, C. A.; Desai, T. J.; Kuo, C. J.","https://www.biorxiv.org/content/10.1101/2020.07.27.212076v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.212076v1?rss=1,2020-07-27,2020-07-27,,False
308,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling,"The coronavirus disease 2019 (COVID-19) caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread worldwide and has infected more than ten million individuals. One of the typical features of COVID-19 is that both type I and III interferon (IFN)-mediated antiviral immunity are suppressed. However, the molecular mechanism by which SARS-CoV-2 evades this antiviral immunity remains elusive. Here, we report that the SARS-CoV-2 membrane (M) protein inhibits the production of type I and III IFNs induced by the cytosolic dsRNA-sensing pathway of RIG-I/MDA-5-MAVS signaling. The SARS-CoV2 M protein also dampens type I and III IFN induction stimulated by Sendai virus infection or poly (I:C) transfection. Mechanistically, the SARS-CoV-2 M protein interacts with RIG-I, MAVS, and TBK1 and prevents the formation of a multi-protein complex containing RIG-I, MAVS, TRAF3, and TBK1, thus impeding IRF3 phosphorylation, nuclear translocation, and activation. Consequently, the ectopic expression of the SARS-CoV2 M protein facilitates the replication of vesicular stomatitis virus (VSV). Taken together, the SARS-CoV-2 M protein antagonizes type I and III IFN production by targeting RIG-I/MDA-5 signaling, which subsequently attenuates antiviral immunity and enhances viral replication. This study provides insight into the interpretation of the SARS-CoV-2-induced antiviral immune suppression and sheds light on the pathogenic mechanism of COVID-19.","Wang, P.-H.; Zheng, Y.; Zhuang, M.-W.; Han, L.; Zhang, J.; Nan, M.-L.; Gao, C.","https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1?rss=1,2020-07-27,2020-07-27,,False
309,Assessing the quality of nontraditional N95 filtering face-piece respirators available during the COVID-19 pandemic,"Background: During the current COVID-19 pandemic, supply chains for Personal Protective Equipment (PPE) have been severely disrupted and many products, particularly surgical N95 filtering facepiece respirators (FFRs; ""masks"") are in short supply. As a consequence, an Emergency Use Authorization (EUA) from the FDA has allowed importation of N95-type masks manufactured to international standards; these include KN95 masks from China and FFP2 masks from the European Union. Methods: We conducted a survey of mask in the inventory of major academic medical centers in Boston, MA to determine provenance and manufacturer. We then assembled a simple apparatus for performing a necessary (but not sufficient) test of filtration performance and tested masks from the inventory; an accompanying website shows how to build and use the testing apparatus. Results: Our survey showed that, seven months after the start of the COVID-19 pandemic, over 100 different makes and models of N95-type masks are in the inventory of local hospitals as opposed to 2-5 models under normal circumstances. A substantial number of unfamiliar masks are from unknown manufacturers. Many did not perform to accepted standards and are likely to be counterfeit. Due to the absence of publicly available information on mask suppliers in the FDA EUA and confusing or inconsistent labeling of KN95 masks, it is difficult to distinguish legitimate and counterfeit products. Conclusions: Many of the FFR masks available for procurement during the COVID-19 pandemic do not provide levels of fit and filtration similar to those of N95 masks and are not acceptable for use in healthcare settings. Based on these results, and in consultation with occupational health officers, we make six recommendations for end users to assist in acquiring legitimate products. In particular, institutions should always assess masks from non-traditional supply chains by checking their markings and manufacturer information against data provided by NIOSH and the latest FDA EUA Appendix A. In the absence of verifiable information on the legitimacy of mask source, institutions should consider measuring mask fit and filtration directly. We also make suggestions for U.S and Chinese regulatory agencies with regard to labeling and public disclosure aimed at increase pandemic resilience.","Plana, D.; Tian, E.; Cramer, A. K.; Yang, H.; Carmack, M. M.; Sinha, M. S.; Bourgeois, F. T.; Yu, S. H.; Masse, P.; Boyer, J.; Kim, M.; Mo, J.; LeBoeuf, N. R.; Li, J.; Sorger, P. K.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161968v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161968v1?rss=1,2020-07-27,2020-07-27,,True
310,Using social contact data to predict and compare the impact of social distancing policies with implications for school re-opening,"Background Social distancing measures, including school closures, are being used to control SARS-CoV-2 transmission in many countries. Once ""lockdown"" has driven incidence to low levels, selected activities are being permitted. Re-opening schools is a priority because of the welfare and educational impact of closures on children. However, the impact of school re-opening needs to be considered within the context of other measures. Methods We use social contact data from the UK to predict the impact of social distancing policies on the reproduction number. We calibrate our tool to the COVID-19 epidemic in the UK using publicly available death data and Google Community Mobility Reports. We focus on the impact of re-opening schools against a back-drop of wider social distancing easing. Results We demonstrate that pre-collected social contact data, combined with incidence data and Google Community Mobility Reports, is able to provide a time-varying estimate of the reproduction number (R). From an pre-control setting when R=2.7 (95%CI 2.5, 2.9), we estimate that the minimum reproduction number that can be achieved in the UK without limiting household contacts is 0.45 (95%CI:0.41-0.50); in the absence of other changes, preventing leisure contacts has a smaller impact (R=2.0,95%CI:1.8-2.4) than preventing work contacts (R=1.5,95%CI:1.4-1.7). We find that following lockdown (when R=0.7 (95% CI 0.6, 0.8)), opening primary schools in isolation has a modest impact on transmission R=0.83 (95%CI:0.77-0.90) but that high adherence to other measures is needed. Opening secondary schools as well as primary school is predicted to have a larger overall impact (R=0.95,95%CI:0.85-1.07), however transmission could still be controlled with effective contact tracing. Conclusions Our findings suggest that primary school children can return to school without compromising transmission, however other measures, such as social distancing and contract tracing, are required to control transmission if all age groups are to return to school. Our tool provides a mapping from policies to the reproduction number and can be used by policymakers to compare the impact of social-easing measures, dissect mitigation strategies and support careful localized control strategies.","Brooks-Pollock, E.; Read, J. M.; McLean, A. R.; Keeling, M. J.; Danon, L.","https://www.medrxiv.org/content/10.1101/2020.07.25.20156471v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20156471v1?rss=1,2020-07-27,2020-07-27,,True
311,Mathematical modelling based study and prediction of COVID-19 epidemic dissemination under the impact of lockdown in India,"COVID-19 (SARS-CoV-2) is rapidly spreading in South Asian countries especially in India. India is the fourth most COVID-19 affected country at present (as on July 10, 2020). With limited medical facilities and high transmission rate, study of COVID-19 progression and its subsequence trajectory need to be analyzed in India. Epidemiologic mathematical models have the potential to predict the epidemic peak of COVID-19 under different scenario. Lockdown is one of the most effective mitigation policy adapted worldwide to control the transmission rate of COVID-19 cases. In this study, we use an improvised five compartment mathematical model i.e. Susceptible (S) - exposed (E)- infected (I)- recovered (R)- death (D) (SEIRD) to investigate the progression of COVID-19 and predict the epidemic peak under the impact of lockdown in India. The aim of this study to provide the most accurate prediction of epidemic peak and to evaluate the impact of lockdown on epidemic peak shift in India. For this purpose, we examine most recent data (up to July 10, 2020) to enhance the accuracy of outcomes from the proposed model. The obtained results indicate that COVID-19 epidemic peak would appear on around mid-August 2020 in India and corresponding estimated cases would be 2.5X10^6 under current scenario. In addition, our study indicates that existence of under-reported cases (~10^5) during post-lockdown period in India. It is expected that nationwide lockdown would lead to epidemic peak suppression in India. The obtained results would be beneficial for determining further COVID-19 mitigation policies not only in India but globally.","Tiwari, V.; Bisht, N.; Deyal, N.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161885v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161885v1?rss=1,2020-07-27,2020-07-27,,True
312,Molecular mechanisms of Cardiac Injury associated with myocardial SARS-CoV-2 infection,"BackgroundCoronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread around the world. Developing cardiac injury is a common condition in COVID-19 patients, but the pathogenesis remains unclear.

MethodsThe RNA-Seq dataset (GES150392) compared expression profiling of mock human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and SARS-cov-2-infected hiPSC-CMs were obtained from Gene Expression Omnibus (GEO). We identified the differentially expressed genes (DEGs) between those two groups. Through gene set enrichment analysis (GSEA), Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and CLINVAR human diseases analysis to identify the main effect of SARS-CoV-2 on cardiomyocytes. A protein-protein interaction (PPI) network was constructed to visualize interactions and functions of the hub genes.

ResultsA total of 1554 DEGs were identified (726 upregulated genes and 828 downregulated genes). Gene enrichment analysis shown that SARS-CoV-2 activate immuno-inflammatory responses via multiple signal pathways, including TNF, IL6-JAK-STAT3, IL2-STAT5, NF-{kappa}B, IL17, and Toll-like receptor signaling pathway in hiPSC-CMs. Whereas, the muscle contraction, cellular respiration and cell cycle of hiPSC-CMs were inhibited by SARS-CoV-2. CLINVAR human diseases analysis shown SRAS-Cov-2 infection was associated with myocardial infarction, cardiomyopathy and Limb-girdle muscular dystrophy. 15 hub genes were identified based on PPI network. Function analysis revealed that 11 upregulated hub genes were mainly enriched in cytokine activity, chemokine activity, Inflammatory response, leukocyte chemotaxis, and lipopolysaccharide-mediated signaling pathway. Furthermore, 4 downregulated hub genes were related to cell cycle regulation.

ConclusionThe present study elucidates that the SARS-CoV-2 infection induced a strong defensive response in cardiomyocyte, leading to excessive immune inflammation, cell hypoxia, functional contractility reduction and apoptosis, ultimately result in myocardial injury.","Liu, X.; Lou, L.; Zhou, L.","https://www.biorxiv.org/content/10.1101/2020.07.27.220954v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.220954v1?rss=1,2020-07-27,2020-07-27,,False
313,A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19,"Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. Results: Clinical agreement studies were performed in 77 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 42.86% (95% CI: 9.90% to 81.59%), 55.56% (95% CI: 21.20% to 86.30%), and 96.72% (95% CI: 88.65% to 99.60%) for samples collected on 0-7 days, 8-14 days, and [&ge;]15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% to 99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgG testing.","Du, J.; Chu, E.; Zhang, D.; Lu, C. M.; Zhang, A.; Sha, M. Y.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160804v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160804v1?rss=1,2020-07-27,2020-07-27,,True
314,The Outcome of COVID-19 Patients with Acute Myocardial Infarction,"Background Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction (AMI). The aim of this study is to conduct detailed analysis on patients with AMI and COVID-19. Methods We included all patients admitted with AMI and actively known or found to be COVID-19 positive by PCR between the 4th February 2020 and the 11th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction (STEMI) and Non-STE (NSTEMI). Results There were 68 patients (67 men and 1 woman) admitted between the 4th of February 2020 and the 11th of June 2020 with AMI and COVID-19. The mean age was 49.1, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus, 31% had hypertension, 16% were smokers, 13% had dyslipidemia, and 14.7% had prior cardiovascular disease. Chest pain and dyspnea were the presenting symptoms in 90% and 12% of patients respectively. Fever (15%) and cough (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease. Overall in-hospital MACE was low; 1 patient developed stroke and 2 died. Conclusion Contrary to previous small reports, overall in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI. We hypothesize patient profile including younger age contributed to these findings. Further studies are required to confirm this observation.","Altamimi, H.; Alahmad, Y.; Khazal, F.; Elhassan, M.; AlBinali, H.; Arabi, A.; AlQahtani, A.; Asaad, N.; Al-Hijji, M.; Hamid, T.; Rafie, I.; Omrani, A. S.; AlKaabi, S.; Alkhal, A.; AlMalslmani, M.; Ali, M.; Alkhani, M.; AlNesf, M.; Abu Jalala, S.; Arafa, S.; ElSousy, R.; AlTamimi, O.; Soaly, E.; Abi khalil, C.; Al Suwaidi, J.","https://www.medrxiv.org/content/10.1101/2020.07.21.20156349v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20156349v1?rss=1,2020-07-27,2020-07-27,,True
315,A-to-I RNA editing in SARS-COV-2: real or artifact?,"ADAR1-mediated deamination of adenosines in long double stranded RNAs plays an important role in modulating the innate immune response. However, recent investigations based on metatranscriptomic samples of COVID-19 patients and SARS-COV-2 infected Vero cells have recovered contrasting findings. Using RNAseq data from time course experiments of infected human cell lines and transcriptome data from Vero cells and clinical samples, we prove that A-to-G changes observed in SARS-COV-2 genomes represent genuine RNA editing events, likely mediated by ADAR1. While the A-to-I editing rate is generally low, changes are distributed along the entire viral genome, are overrepresented in exonic regions and are, in the majority of cases, nonsynonymous. The impact of RNA editing on virus-host interactions could be relevant to identify potential targets for therapeutic interventions.","Picardi, E.; Mansi, L.; Pesole, G.","https://www.biorxiv.org/content/10.1101/2020.07.27.223172v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.223172v1?rss=1,2020-07-27,2020-07-27,,False
316,Evolution And Genetic Diversity Of SARSCoV-2 In Africa Using Whole Genome Sequences,"The ongoing SARSCoV-2 pandemic was introduced into Africa on 14th February 2020 and has rapidly spread across the continent causing severe public health crisis and mortality. We investigated the genetic diversity and evolution of this virus during the early outbreak months using whole genome sequences. We performed; recombination analysis against closely related CoV, Bayesian time scaled phylogeny and investigated spike protein amino acid mutations. Results from our analysis showed recombination signals between the AfrSARSCoV-2 sequences and reference sequences within the N and S genes. The evolutionary rate of the AfrSARSCoV-2 was 4.133 x 10-4 high posterior density HPD (4.132 x 10-4 to 4.134 x 10-4) substitutions/site/year. The time to most recent common ancestor TMRCA of the African strains was December 7th 2019. The AfrSARCoV-2 sequences diversified into two lineages A and B with B being more diverse with multiple sub-lineages confirmed by both maximum clade credibility MCC tree and PANGOLIN software. There was a high prevalence of the D614-G spike protein amino acid mutation (82.61%) among the African strains. Our study has revealed a rapidly diversifying viral population with the G614 spike protein variant dominating, we advocate for up scaling NGS sequencing platforms across Africa to enhance surveillance and aid control effort of SARSCoV-2 in Africa.","Motayo, B. O.; Oluwasemowo, O. O.; Akinduti, P. A.; Olusola, B. A.; Arege, O. T.; Faneye, A. O.","https://www.biorxiv.org/content/10.1101/2020.07.27.222901v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.222901v1?rss=1,2020-07-27,2020-07-27,,False
317,Predicting the Emergence of SARS-CoV-2 Clades,"Evolution is a process of change where mutations in the viral RNA are selected based on their fitness for replication and survival. Given that current phylogenetic analysis of SARS-CoV-2 identifies new viral clades after they exhibit evolutionary selections, one wonders whether we can identify the viral selection and predict the emergence of new viral clades? Inspired by the Kolmogorov complexity concept, we propose a generative complexity (algorithmic) framework capable to analyze the viral RNA sequences by mapping the multiscale nucleotide dependencies onto a state machine, where states represent subsequences of nucleotides and state-transition probabilities encode the higher order interactions between these states. We apply computational learning and classification techniques to identify the active state-transitions and use those as features in clade classifiers to decipher the transient mutations (still evolving within a clade) and stable mutations (typical to a clade). As opposed to current analysis tools that rely on the edit distance between sequences and require sequence alignment, our method is computationally local, does not require sequence alignment and is robust to random errors (substitution, insertions and deletions). Relying on the GISAID viral sequence database, we demonstrate that our method can predict clade emergence, potentially aiding with the design of medications and vaccines.","Jain, S.; Xiao, X.; Bogdan, P.; Bruck, J.","https://www.biorxiv.org/content/10.1101/2020.07.26.222117v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222117v1?rss=1,2020-07-27,2020-07-27,,False
318,Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2,"The recent global pandemic caused by the new coronavirus SARS-CoV-2 presents an urgent need for new therapeutic candidates. While the importance of traditional in silico approaches such as QSAR in such efforts in unquestionable, these models fundamentally rely on structural similarity to infer biological activity and are thus prone to becoming trapped in the very nearby chemical spaces of already known ligands. For novel and unprecedented threats such as COVID-19 much faster and efficient paradigms must be devised to accelerate the identification of new chemical classes for rapid drug development. Here we report the development of a new biological activity-based modeling (BABM) approach that builds on the hypothesis that compounds with similar activity patterns tend to share similar targets or mechanisms of action. In BABM, compound activity profiles established on massive scale across multiple assays are used as signatures to predict compound activity in a new assay or against a new target. We first trained and validated this approach by identifying new antiviral lead candidates for Zika and Ebola based on data from ~0.5 million compounds screened against ~2,000 assays. BABM models were then applied to predict ~300 compounds not previously reported to have activity for SARS-CoV-2, which were then tested in a live virus assay with high (>30%) hit rates. The most potent compounds showed antiviral activities in the nanomolar range. These potent confirmed compounds have the potential to be further developed in novel chemical space into new anti-SARS-CoV-2 therapies. These results demonstrate unprecedented ability using BABM to predict novel structures as chemical leads significantly beyond traditional methods, and its application in rapid drug discovery response in a global public health crisis.","Huang, R.; Xu, M.; Zhu, H.; Chen, C. Z.; Lee, E.; He, S.; Shamim, K.; Bougie, D.; Huang, W.; Hall, M.; Lo, D.; Simeonov, A.; Austin, C.; Qiu, X.; Tang, H.; Zheng, W.","https://www.biorxiv.org/content/10.1101/2020.07.27.223578v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.223578v1?rss=1,2020-07-27,2020-07-27,,False
319,Trends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and Mortality in the United States,"Importance: Assessment of the use of angiotensin receptor blockers (ARBs) in the United States provides insight into prescribing practices, and may inform guidelines, policy measures and research during the COVID-19 pandemic. Objective: To evaluate trends in ARB use among adults in the United States who have preexisting conditions and sociodemographic risk factors that put them at a higher risk of SARS-CoV-2 infection and COVID-19-related complications and mortality. Design, setting and participants: This study uses the nationally representative cross-sectional data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES). Participants included 39,749 non-institutionalized U.S. civilian adults who were 20 years and older and those with the most common preexisting conditions and risk factors reported among patients with COVID-19. Main outcomes and measures: Use of ARBs in the prior 30 days from survey interview. Results: ARB use ranged from 7.4% [95% CI, 6.5%-8.4%] to 26.2% [95% CI, 19.4%-34.4%] among those with one or two metabolic, renal, respiratory, and/or cardiovascular diseases. Among individuals with the three most common preexisting conditions in patients with COVID-19 including hypertension, diabetes and obesity, ARB use was higher among the elderly, females, non-Hispanic whites, and those with health insurance coverage. Conclusions and relevance: In this nationally representative survey, ARB use was found to be widespread, but unevenly distributed among individuals with conditions and sociodemographic risk factors that place them at a higher risk of COVID-19 morbidity and mortality.","Perez, A.; Speth, R.; Saavedra, J.","https://www.medrxiv.org/content/10.1101/2020.07.24.20161851v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161851v1?rss=1,2020-07-27,2020-07-27,,True
320,An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain,"IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 due to structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing antibodies here demonstrate that a longer CDR H3 can be accommodated in a different binding mode (mode B). These two classes of IGHV3-53 antibodies both target the ACE2 receptor binding site, but with very different angles of approach and molecular interactions. Overall, these findings emphasize the versatility of IGHV3-53 in this common antibody response to SARS-CoV-2, where conserved IGHV3-53 germline-encoded features can be combined with very different CDR H3 lengths and light chains for SARS-CoV-2 RBD recognition and virus neutralization.","Wu, N. C.; Yuan, M.; Liu, H.; Lee, C.-C. D.; Zhu, X.; Bangaru, S.; Torres, J. L.; Caniels, T. G.; Brouwer, P. J. M.; van Gils, M. J.; Sanders, R. W.; Ward, A. B.; Wilson, I. A.","https://www.biorxiv.org/content/10.1101/2020.07.26.222232v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222232v1?rss=1,2020-07-27,2020-07-27,,False
321,An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys,"Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with Fc{gamma}RIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity was eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Most importantly, potent prophylactic and therapeutic effects against SARS-CoV-2 were observed in rhesus monkeys. A single dose of MW05/LALA completely blocked the infection of SARS-CoV-2 in a study of its prophylactic effect and totally cleared SARS-CoV-2 in three days in a treatment setting. These results pave the way for the development of MW05/LALA as an effective strategy for combating COVID-19.","Gui, X.","https://www.biorxiv.org/content/10.1101/2020.07.26.222257v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222257v1?rss=1,2020-07-27,2020-07-27,,False
322,CAR Macrophages for SARS-CoV-2 Immunotherapy,"Targeted therapeutics for the treatment of coronavirus disease 2019 (COVID-19), especially severe cases, are currently lacking. As macrophages have unique effector functions as a first-line defense against invading pathogens, we genetically armed human macrophages with chimeric antigen receptors (CARs) to reprogram their phagocytic activity against SARS-CoV-2. After investigation of CAR constructs with different intracellular receptor domains, we found that although cytosolic domains from MERTK (CARMERTK) did not trigger antigen-specific cellular phagocytosis or killing effects, unlike those from MEGF10, FcR{gamma} and CD3{zeta} did, these CARs all mediated similar SARS-CoV-2 clearance in vitro. Notably, we showed that CARMERTK macrophages notably reduced the virion load without upregulation of proinflammatory cytokine expression. These results suggest that CARMERTK drives an  immunologically silent scavenger effect in macrophages and pave the way for further investigation of CARs for the treatment of individuals with COVID-19, particularly those with severe cases at a high risk of hyperinflammation.","Fu, W.; Lei, C.; Qian, K.; Ma, Z.; Li, T.; Lin, F.; Zhao, J.; Hu, S.","https://www.biorxiv.org/content/10.1101/2020.07.26.222208v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222208v1?rss=1,2020-07-27,2020-07-27,,False
323,Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV,"A high-resolution understanding of the antibody response to SARS-CoV-2 is important for the design of effective diagnostics, vaccines and therapeutics. However, SARS-CoV-2 antibody epitopes remain largely uncharacterized, and it is unknown whether and how the response may cross-react with related viruses. Here, we use a multiplexed peptide assay ( PepSeq) to generate an epitope-resolved view of reactivity across all human coronaviruses. PepSeq accurately detects SARS-CoV-2 exposure and resolves epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the Spike S2 subunit, regions that we show are also targeted for the endemic coronaviruses in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. Our analyses reveal new diagnostic and therapeutic targets, including a site at which SARS-CoV-2 may recruit common pre-existing antibodies and with the potential for broadly-neutralizing responses.","Ladner, J. T.; Henson, S. N.; Boyle, A. S.; Engelbrektson, A. L.; Fink, Z. W.; Rahee, F.; D'ambrozio, J.; Schaecher, K. E.; Stone, M.; Dong, W.; Dadwal, S.; Yu, J.; Caligiuri, M. A.; Cieplak, P.; Bjoras, M.; Fenstad, M. H.; Nordbo, S. A.; Kainov, D. E.; Muranaka, N.; Chee, M. S.; Shiryaev, S. A.; Altin, J. A.","https://www.biorxiv.org/content/10.1101/2020.07.27.222943v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.222943v1?rss=1,2020-07-27,2020-07-27,,False
324,Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L,"The main protease (Mpro) of SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic, is a key antiviral drug target. While most SARS-CoV-2 Mpro inhibitors have a {gamma}-lactam glutamine surrogate at the P1 position, we recently discovered several Mpro inhibitors have hydrophobic moieties at the P1 site, including calpain inhibitors II/XII, which are also active against human cathepsin L, a host-protease that is important for viral entry. To determine the binding mode of these calpain inhibitors and establish a structure-activity relationship, we solved X-ray crystal structures of Mpro in complex with calpain inhibitors II and XII, and three analogues of GC-376, one of the most potent Mpro inhibitors in vitro. The structure of Mpro with calpain inhibitor II confirmed the S1 pocket of Mpro can accommodate a hydrophobic methionine side chain, challenging the idea that a hydrophilic residue is necessary at this position. Interestingly, the structure of calpain inhibitor XII revealed an unexpected, inverted binding pose where the P1 pyridine inserts in the S1 pocket and the P1 norvaline is positioned in the S1 pocket. The overall conformation is semi-helical, wrapping around the catalytic core, in contrast to the extended conformation of other peptidomimetic inhibitors. Additionally, the structures of three GC-376 analogues UAWJ246, UAWJ247, and UAWJ248 provide insight to the sidechain preference of the S1, S2, S3 and S4 pockets, and the superior cell-based activity of the aldehyde warhead compared with the -ketoamide. Taken together, the biochemical, computational, structural, and cellular data presented herein provide new directions for the development of Mpro inhibitors as SARS-CoV-2 antivirals.","Sacco, M. D.; Ma, C.; Lagarias, P.; Gao, A.; Townsend, J. A.; Meng, X.; Dube, P.; Zhang, X.; Hu, Y.; Kitamura, N.; Hurst, B.; Tarbet, B.; Marty, M. T.; Kolocouris, A.; Xiang, Y.; Chen, Y.; Wang, J.","https://www.biorxiv.org/content/10.1101/2020.07.27.223727v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.27.223727v1?rss=1,2020-07-27,2020-07-27,,False
325,Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing,"Remdesivir, an investigational broad-spectrum antiviral agent, has shown in vitro activity against SARS-CoV-2. To maximize direct delivery to the target site, the lungs, we aim to develop remdesivir as a dry powder for inhalation using thin film freezing (TFF). TFF produces a brittle matrix of nanostructured aggregates that can be sheared into respirable low-density microparticles upon aerosolization from a passive dry powder inhaler. In vitro aerodynamic testing demonstrated that drug loading and excipient type affected the aerosol performance of remdesivir. Remdesivir combined with optimal excipients (e.g. Captisol(R), mannitol, lactose, leucine) exhibited suitable aerosol performance (up to 92.4% FPF and 0.86 {micro}m MMAD). Remdesivir was amorphous after the TFF process, which we hypothesize will provide a benefit for drug dissolution once administered to the lungs. Neither the organic/water processing cosolvent or the rapid freezing rate used during the TFF process affected the chemical stability of remdesivir during processing. In conclusion, TFF is a suitable technology for producing remdesivir dry powder formulations suitable for pulmonary administration.","Moon, C.; Sahakijpijarn, S.; Koleng, J. J.; Williams, R. O.","https://www.biorxiv.org/content/10.1101/2020.07.26.222109v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.222109v1?rss=1,2020-07-27,2020-07-27,,False
326,Covid-19 automated diagnosis and risk assessment through Metabolomics and Machine-Learning,"COVID-19 is still placing a heavy health and financial burden worldwide. Impairments in patient screening and risk management play a fundamental role on how governments and authorities are directing resources, planning reopening, as well as sanitary countermeasures, especially in regions where poverty is a major component in the equation. An efficient diagnostic method must be highly accurate, while having a cost-effective profile. We combined a machine learning-based algorithm with instrumental analysis using mass spectrometry to create an expeditious platform that discriminate COVID-19 in plasma samples within minutes, while also providing tools for risk assessment, to assist healthcare professionals in patient management and decision-making. A cohort of 728 patients (369 confirmed COVID-19 and 359 controls) was enrolled from three Brazilian epicentres (Sao Paulo capital, Sao Paulo countryside and Manaus) in the months of April, May, June and July 2020. We were able to elect and identify 21 molecules that are related to the disease's pathophysiology and 26 features to patient's health-related outcomes. With specificity >97% and sensitivity >83% from blinded data, this screening approach is understood as a tool with great potential for real-world application.","Delafiori, J.; Navarro, L. C.; Siciliano, R. F.; de Melo, G. C.; Busanello, E. N. B.; Nicolau, J. C.; Sales, G. M.; de Oliveira, A. N.; Val, F. F. A.; de Oliveira, D. N.; Eguti, A.; dos Santos, L. A.; Dalcoquio, T. F.; Bertolin, A. J.; Alonso, J. C. C.; Abreu-Netto, R. L.; Salsoso, R.; Baia-da-Silva, D.; Sampaio, V. S.; Judice, C. C.; Costa, F. M. T.; Duran, N.; Perroud, M. W.; Sabino, E. C.; Lacerda, M. V. G.; Reis, L. O.; Favaro, W. J.; Monteiro, W. M.; Rocha, A. R.; Catharino, R. R.","https://www.medrxiv.org/content/10.1101/2020.07.24.20161828v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161828v1?rss=1,2020-07-27,2020-07-27,,True
327,Population Data-Driven Formulation of a COVID-19 Therapeutic,"This study is designed to utilize computer modeling of the US population through NHANES to reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral (BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to the clinic.","Campbell, H. R.; Cecil, R. P.; Lodder, R.","https://www.medrxiv.org/content/10.1101/2020.07.24.20161547v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161547v1?rss=1,2020-07-27,2020-07-27,,True
328,COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2,"Development of effective strategies to detect, treat, or prevent COVID-19 requires a robust understanding of the natural immune response to SARS-CoV-2, including the cellular response mediated by T cells. We used an unbiased, genome-wide screening technology, termed T-Scan, to identify specific epitopes in SARS-CoV-2 that are recognized by the memory CD8+ T cells of 25 COVID-19 convalescent patients, focusing on epitopes presented by the six most prevalent Human Leukocyte Antigen (HLA) types: A*02:01, A*01:01, A*03:01, A*11:01, A*24:02, and B*07:02. For each HLA type, the patients' T cells recognized 3-8 immunodominant epitopes that are broadly shared among patients. Remarkably, 94% of screened patients had T cells that recognized at least one of the three most dominant epitopes for a given HLA, and 53% of patients had T cells that recognized all three. Subsequent validation studies in 18 additional A*02:01 patients confirmed the presence of memory CD8+ T cells specific for the top six identified A*02:01 epitopes, and single-cell sequencing revealed that patients often have many different T cell clones targeting each epitope, but that the same T cell receptor Valpha regions are predominantly used to recognize these epitopes, even across patients. In total, we identified 29 shared epitopes across the six HLA types studied. T cells that target most of these immunodominant epitopes (27 of 29) do not cross-react with the endemic coronaviruses that cause the common cold, and the epitopes do not occur in regions with high mutational variation. Notably, only 3 of the 29 epitopes we identified reside in the spike protein, highlighting the need to design new classes of vaccines that recapitulate natural CD8+ T cell responses to SARS-CoV-2.","Ferretti, A. F. P.; Kula, T.; Wang, Y.; Nguyen, D. M.; Weinheimer, A.; Dunlap, G. S.; Xu, Q.; Nabilsi, N.; Perullo, C. R.; Cristofaro, A. W.; Olivier, K. J.; Baiamonte, L. B.; Alistar, A. T.; Whitman, E. D.; Bertino, S. A.; Chattopadhyay, S.; MacBeath, G.","https://www.medrxiv.org/content/10.1101/2020.07.24.20161653v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161653v1?rss=1,2020-07-27,2020-07-27,,True
329,Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19,"Background Understanding risk factors for death in Covid 19 is key to providing good quality clinical care. Due to a paucity of robust evidence, we sought to assess the presenting characteristics of patients with Covid 19 and investigate factors associated with death. Methods Retrospective analysis of adults admitted with Covid 19 to Royal Oldham Hospital, UK. Logistic regression modelling was utilised to explore factors predicting death. Results 470 patients were admitted, of whom 169 (36%) died. The median age was 71 years (IQR 57 to 82), and 255 (54.3%) were men. The most common comorbidities were hypertension (n=218, 46.4%), diabetes (n=143, 30.4%) and chronic neurological disease (n=123, 26.1%). The most frequent complications were acute kidney injury (n=157, 33.4%) and myocardial injury (n=21, 4.5%). Forty three (9.1%) patients required intubation and ventilation, and 39 (8.3%) received non-invasive ventilation Independent risk factors for death were increasing age (OR per 10 year increase above 40 years 1.87, 95% CI 1.57 to 2.27), hypertension (OR 1.72, 1.10 to 2.70), cancer (OR 2.20, 1.27 to 3.81), platelets <150x103/microlitre (OR 1.93, 1.13 to 3.30), C-reactive protein >100 micrograms/mL (OR 1.68, 1.05 to 2.68), >50% chest radiograph infiltrates, (OR 2.09, 1.16 to 3.77) and acute kidney injury (OR 2.60, 1.64 to 4.13). There was no independent association between death and gender, ethnicity, deprivation level, fever, SpO2/FiO2 (oxygen saturation index), lymphopenia or other comorbidities. Conclusions We characterised the first wave of patients with Covid 19 in one of Englands highest incidence areas, determining which factors predict death. These findings will inform clinical and shared decision making, including the use of respiratory support and therapeutic agents.","Thompson, J. V.; Meghani, N.; Powell, B. M.; Newell, I.; Craven, R.; Skilton, G.; Bagg, L. J.; Yaqoob, I.; Dixon, M. J.; Evans, E. J.; Kambele, B.; Rehman, A.; Ng Man Kwong, G.","https://www.medrxiv.org/content/10.1101/2020.07.21.20153650v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20153650v1?rss=1,2020-07-27,2020-07-27,,True
330,Trends of in-hospital and 30-day mortality after percutaneous coronary intervention in England before and after the COVID-19 era,"Objectives: To examine short-term primary causes of death after percutaneous coronary intervention (PCI) in a national cohort before and during COVID-19. Background: Public reporting of PCI outcomes is a performance metric and a requirement in many healthcare systems. There are inconsistent data on the causes of death after PCI, and what proportion of these are attributable to cardiac causes. Methods: All patients undergoing PCI in England between 1st January 2017 and 10th May 2020 were retrospectively analysed (n=273,141), according to their outcome from the date of PCI; no death and in-hospital, post-discharge, and 30-day death. Results: The overall rates of in-hospital and 30-day death were 1.9% and 2.8%, respectively. The rate of 30-day death declined between 2017 (2.9%) and February 2020 (2.5%), mainly due to lower in-hospital death (2.1% vs. 1.5%), before rising again from 1st March 2020 (3.2%) due to higher rates of post-discharge mortality. Only 59.6% of 30-day deaths were due to cardiac causes, the most common being acute coronary syndrome, cardiogenic shock and heart failure, and this persisted throughout the study period. 10.4% of 30-day deaths after 1st March 2020 were due to confirmed COVID-19. Conclusions: In this nationwide study, we show that 40% of 30-day deaths are due to non-cardiac causes. Non-cardiac deaths have increased even more from the start of the COVID-19 pandemic, with one in ten deaths from March 2020 being COVID-19 related. These findings raise a question of whether public reporting of PCI outcomes should be cause-specific.","Mohamed, M. O.; Kinnaird, T.; Curzen, N.; Ludman, P.; Wu, J.; Rashid, M.; Shoaib, A.; de Belder, M.; Deanfield, J.; Gale, C.; Mamas, M. A.","https://www.medrxiv.org/content/10.1101/2020.07.18.20155549v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.18.20155549v1?rss=1,2020-07-27,2020-07-27,,True
331,New Insights on Excess Deaths and COVID-19,"Background: Weinberger and colleagues estimated that 27,065 of the 122,300 excess deaths in the United States between March 1 and May 30, 2020 did not have a COVID-19 cause of death. Methods: The Centers for Disease Control and Prevention (CDC) post weekly data on mortality for 13 causes of death from the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death. The 2015-2019 data for weeks 10 through 22 were used to forecast the number of deaths from the 13 causes in the absence of COVID-19 during 2020. The forecast was subtracted from the observed number of deaths for each cause during the period March 1 to May 30, 2020. Results: The total of the differences for each of the 13 causes of death, 18,489 deaths, accounts for over two-thirds of the 27,065 excess deaths not due to COVID-19. Conclusion: Combining the 95,235 reported COVID-19 deaths with the 18,489 from the 13 most frequent comorbid conditions reported on death certificates where COVID-19 was a cause suggests that as many as 93% of the excess deaths were due to COVID-19 and implies that COVID-19 deaths were undercounted. Ongoing assessment of excess deaths and causes of death is needed to provide a better understanding of the pandemics dynamics.","Wetzler, H. P.; Cobb, H. W.","https://www.medrxiv.org/content/10.1101/2020.07.24.20051508v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20051508v1?rss=1,2020-07-27,2020-07-27,,True
332,An effective COVID-19 response in South America: the Uruguayan Conundrum,"Background: South America has become the new epicenter of the COVID-19 pandemic with more than 1.1M reported cases and >50,000 deaths (June 2020). Conversely, Uruguay stands out as an outlier managing this health crisis with remarkable success. Methods: We developed a molecular diagnostic test to detect SARS-CoV-2. This methodology was transferred to research institutes, public hospitals and academic laboratories all around the country, creating a COVID-19 diagnostic lab network. Uruguay also implemented active epidemiological surveillance following the Test, Trace and Isolate (TETRIS) strategy coupled to real-time genomic epidemiology. Results: Three months after the first cases were detected, the number of positive individuals reached 826 (23 deaths, 112 active cases and 691 recovered). The Uruguayan strategy was based in a close synergy established between the national health authorities and the scientific community. In turn, academia rapidly responded to develop national RT-qPCR tests. Consequently, Uruguay was able to perform ~1,000 molecular tests per day in a matter of weeks. The COVID-19 diagnostic lab network performed more than 54% of the molecular tests in the country. This, together with real-time genomics, were instrumental to implement the TETRIS strategy, helping to contain domestic transmission of the main outbreaks registered so far. Conclusions: Uruguay has successfully navigated the first trimester of the COVID-19 health crisis in South America. A rapid response by the scientific community to increase testing capacity, together with national health authorities seeking out the support from the academia were fundamental to successfully contain, until now, the COVID-19 outbreak in the country.","Moreno, P.; Moratorio, G. A.; Iraola, G.; Fajardo, A.; Aldunate, F.; Pereira, M.; Perbolianachis, P.; Costabile, A.; Lopez-Tort, F.; Simon, D.; Salazar, C.; Ferres, I.; Diaz-Viraque, F.; Abin, A.; Bresque, M.; Fabregat, M.; Maidana, M.; Rivera, B.; Cruces, M.; Rodriguez, J.; Scavone, P.; Alegretti, M.; Nabon, A.; Gagliano, G.; Rosa, R.; Henderson, E.; Bidegain, E.; Zarantonelli, L.; Piattoni, C.; Greif, G.; Francia, M.; Robello, C.; Duran, R.; Brito, G.; Bonnecarrere, V.; Sierra, M.; Colina, R.; Marin, M.; Cristina, J.; Erlich, R.; Paganini, F.; Cohen, H.; Radi, R.; Barbeito, L.; Badano, J.; Pritsch, O.; Fernandez, C.; Arim, R.; Batthyany, C.; Interinstitutional COVID-19 Working Group,","https://www.medrxiv.org/content/10.1101/2020.07.24.20161802v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161802v1?rss=1,2020-07-27,2020-07-27,,True
333,Power Law in COVID-19 Cases in China,"The novel coronavirus (COVID-19) was first identified in China in December 2019. Within a short period of time, the infectious disease has spread far and wide. This study focuses on the distribution of COVID-19 confirmed cases in China---the original epicenter of the outbreak. We show that the upper tail of COVID-19 cases in Chinese cities is well described by a power law distribution, with exponent less than one, and that a random proportionate growth model predicated by Gibrat's law is a plausible explanation for the emergence of the observed power law behavior. This finding is significant because it implies that COVID-19 cases in China is heavy-tailed and disperse, that a few cities account for a disproportionate share of COVID-19 cases, and that the distribution has no finite mean or variance. The power-law distributedness has implications for effective planning and policy design as well as efficient use of government resources.","Ahundjanov, B. B.; Akhundjanov, S. B.; Okhunjanov, B. B.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161984v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161984v1?rss=1,2020-07-27,2020-07-27,,True
334,Effects of non-pharmaceutical interventions on COVID-19: A Tale of Two Models,"In this paper, we compare the inference regarding the effectiveness of the various non-pharmaceutical interventions (NPIs) for COVID-19 obtained from two SIR models, both produced by the Imperial College COVID-19 Response Team. One model was applied to European countries and published in Nature, concluding that complete lockdown was by far the most effective measure and 3 million deaths were avoided in the examined countries. The Imperial College team applied a different model to the USA states. Here, we show that inference is not robust to model specification and indeed changes substantially with the model used for the evolution of the time-varying reproduction number. Applying to European countries the model that the Imperial College team used for the USA states shows that complete lockdown has no or little impact, since it was introduced typically at a point when the time-varying reproduction number was already very low. We also show that results are not robust to the inclusion of additional follow-up data.","Chin, V.; Ioannidis, J.; Tanner, M.; Cripps, S.","https://www.medrxiv.org/content/10.1101/2020.07.22.20160341v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20160341v1?rss=1,2020-07-27,2020-07-27,,True
335,Predicting Critical State after COVID-19 Diagnosis Using Real-World Data from 20152 Confirmed US Cases,"The global COVID-19 pandemic caused by the virus SARS-CoV-2 has led to over 10 million confirmed cases, half a million deaths, and is challenging healthcare systems worldwide. With limited medical resources, early identification of patients with a high risk of progression to severe disease or a critical state is crucial. We present a prognostic model predicting critical state within 28 days following COVID-19 diagnosis trained on data from US electronic health records (EHR) within IBM Explorys, including demographics, comorbidities, symptoms, laboratory test results, insurance types, and hospitalization. Our entire cohort included 20152 COVID-19 cases, of which 3160 patients went into critical state or died. Random, stratified train-test splits were repeated 100 times to obtain a distribution of performance. The median and interquartile range of the areas under the receiver operating characteristic curve (ROC AUC) and the precision recall curve (PR AUC) were 0.863 [0.857, 0.866] and 0.539 [0.526, 0.550], respectively. Optimizing the decision threshold lead to a sensitivity of 0.796 [0.775, 0.821] and a specificity of 0.784 [0.769, 0.805]. Good model calibration was achieved, showing only minor tendency to over-forecast probabilities above 0.6. The validity of the model was demonstrated by the interpretability analysis confirming existing evidence on major risk factors (e.g., higher age and weight, male gender, diabetes, cardiovascular disease, and chronic kidney disease). The analysis also revealed higher risk for African Americans and ""self-pay patients"". To the best of our knowledge, this is the largest dataset based on EHR used to create a prognosis model for COVID-19. In contrast to large-scale statistics computing odds ratios for individual risk factors, the present model combining a rich set of covariates can provide accurate personalized predictions enabling early treatment to prevent patients from progressing to a severe or critical state.","Rinderknecht, M. D.; Klopfenstein, Y.","https://www.medrxiv.org/content/10.1101/2020.07.24.20155192v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20155192v1?rss=1,2020-07-27,2020-07-27,,True
336,"Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients","Abstract The World Health Organization (WHO) declared coronavirus disease-2019 (COVID-19) a global pandemic on March 11th. In Ecuador, the first case of COVID-19 was recorded on February 29th. Despite efforts to control its spread, SARS-CoV-2 overrun the Ecuadorian public health system which became one of the most affected in Latin America with 22,719 cases reported up to April, 24th. Public health control measures, including social distancing and lockdowns, were implemented at different times in the biggest cities of the country: Guayaquil and Quito. The Hospital General del Sur de Quito (HGSQ) had to transition from a general to a specific COVID-19 health center in a short period of time to fulfill the health demand from patients with respiratory afflictions. Here, we summarized the implementations applied in the HGSQ to become a COVID-19 exclusive hospital, including the rearrangement of hospital rooms and a triage strategy based on a severity score calculated through an artificial intelligence (AI)-assisted chest computed tomography (CT). Moreover, we present clinical, epidemiological, and laboratory data from 75 laboratory tested COVID-19 patients, which represent the first outbreak of Quito city.","Garzon-Chavez, D.; Romero-Alvarez, D.; Bonifaz, M.; Gaviria, J.; Mero, D.; Gunsha, N.; Perez, A.; Garcia, M.; Espejo, H.; Espinosa, F.; Ligna, E.; Espinel, M.; Quentin, E.; Teran, E.; Mora, F.; Reyes, J.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161661v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161661v1?rss=1,2020-07-27,2020-07-27,,True
337,"Why (and how) COVID-19 could move us closer to the ""health information for all"" goal","In this manuscript, we present an analysis of open access (OA) rates of papers concerning COVID-19 and other important human diseases, whose results helped develop an evidence-based scalable strategy aimed at increasing the full and timely access to medical literature. We show that COVID-19 papers are much more openly available (OA rate of 89.5%) than those concerning the four most recent viral outbreaks (Avian influenza, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, Swine influenza; OA rates (from 26.2% to 51.3%) and the ten non COVID-19 disease categories responsible for the highest number of deaths worldwide (OA rates from 44.0% for Maternal and neonatal disorders to 58.9% for Respiratory infections and tuberculosis). This evidence confronts us with an inevitable question: how can we bridge the gap between OA rates for COVID-19 and other high-impact human diseases? Based on empirical data and projections, we show that it is possible to increase substantially immediate OA to publicly-funded research and complement more demanding initiatives for access to medical literature in developing countries working on the sharing of post-prints at individual, group and multi stakeholder partnership level. However, to make our plan effective in bringing us closer to the health information for all goal a more widespread culture of cooperation is fundamental. We argue that the lesson taught by COVID-19 is a unique opportunity to raise awareness among researchers and stakeholders about the importance of open science for human health and to demonstrate that a real change is now possible.","Capocasa, M.; Destro Bisol, G.; Anagnostou, P.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160481v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160481v1?rss=1,2020-07-27,2020-07-27,,True
338,Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay,"Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and inexpensive. Current assays are either labour-intensive and require specialised facilities (e.g. virus neutralization assays), or expensive with suboptimal specificity (e.g. commercial ELISAs). Bead-based assays offer a cost-effective alternative and allow for multiplexing to test for antibodies of other pathogens. Here, we compare the performance of four antigens for the detection of SARS-CoV-2 specific IgG antibodies in a panel of sera that includes both severe (n=40) and mild (n=52) cases, using a neutralization and a Luminex bead-based assay. While we show that neutralising antibody levels are significantly lower in mild than in severe cases, we demonstrate that a combination of recombinant nucleocapsid protein (NP), receptor-binding domain (RBD) and the whole spike protein (S1S2) results in a highly sensitive (96%) and specific (99%) bead-based assay that can detect IgG antibodies in both groups. Although S1-specific IgG levels correlate most strongly with neutralizing antibody levels, they fall below the detection threshold in 10% of the cases in our Luminex assay. In conclusion, our data supports the use of RBD, NP and S1S2 for the development of SARS-CoV-2 serological bead-based assays. Finally, we argue that low antibody levels in mild/asymptomatic cases might complicate the epidemiological assessment of large-scale surveillance studies.","Marien, J.; Michiels, J.; Heyndrickx, L.; Kerkhof, K.; Foque, N.; Widdowson, M.-A.; Desombere, I.; Jansens, H.; Van Esbroeck, M.; Arien, K. K.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161943v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161943v1?rss=1,2020-07-27,2020-07-27,,True
339,Functional mapping of B-cell linear epitopes 1 of SARS-CoV-2 in COVID-19 convalescent population,"Pandemic SARS-CoV-2 has infected over 10 million people and caused over 500,000 mortalities. Vaccine development is in urgent need to stop the pandemic. Despite great progresses on SARS-CoV-2 vaccine development, the efficacy of the vaccines remains to be determined. Deciphering the interactions of the viral epitopes with their elicited neutralizing antibodies in the convalescent COVID-19 population inspires the vaccine development. In this study, we devised a peptide array composed of 20-mer overlapped peptides of spike (S), membrane (M) and envelope (E) proteins, and performed a screening with 120 COVID-19 convalescent serums and 24 non-COVID-19 serums. We identified five SARS-CoV-2-specific dominant epitopes that reacted with above 40% COVID-19 convalescent serums. Epitopes in the receptor-binding domain (RBD) of S ill reacted with the convalescent serums. Of note, two peptides non-specifically interacted with most of the non-COVID-19 serums. Neutralization assay indicated that only five serums completely blocked viral infection at the dilution of 1:200. By using a peptide-compete neutralizing assay, we found that three dominant epitopes partially competed the neutralization activity of several convalescent serums, suggesting antibodies elicited by these epitopes played an important role in neutralizing viral infection. The epitopes we identified in this study may serve as vaccine candidates to elicit neutralizing antibodies in most vaccinated people or specific antigens for SARS-CoV-2 diagnosis.","Yi, Z.; Ling, Y.; Zhang, X.; Chen, J.; Hu, K.; Wang, Y.; Song, W.; Ying, T.; Zhang, R.; Lu, H.; Yuan, Z.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161869v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161869v1?rss=1,2020-07-27,2020-07-27,,True
340,Safety and Efficacy Concerns of Lopinavir/Ritonavir in COVID-19 Affected Patients: A Retrospective Series,"Context: Originally developed for the treatment of human immunodeficiency virus (HIV), the antiviral combination lopinavir/ritonavir (LPV/r) is being investigated for use against coronavirus disease (COVID-19). We present a case series raising safety and efficacy concerns in COVID-19 affected patients. Methods: We measured LPV trough concentrations in 12 patients treated at our center and reviewed their clinical charts for side effects known to occur in HIV patients. Results: Compared to established LPV trough concentrations in HIV treated patients, concentrations in COVID-19 affected patients were 3-fold greater (20.64 +/- 10.14 mcg/mL versus 6.25 mcg/mL). In addition, cholestasis and dyslipidemia toxicity thresholds were exceeded in 12/12 and 11/12 patients respectively. No patients achieved the presumed therapeutic concentration. The side effects noted were mainly gastrointestinal symptoms (5/12, 42%), electrolytes imbalances (4/12, 33%), liver enzyme disturbances (5/12, 42%), and triglyceride elevations (2/12, 17%). Conclusion: None of our patients reached presumed therapeutic LPV concentrations despite experiencing side effects and exceeding cholestasis and dyslipidemia toxicity thresholds. This raises concerns for the safety and efficacy of LPV/r. Clinicians should consider closely monitoring for side effects and not necessarily attribute them to COVID-19 itself.","Lepage, M.-A.; Rozza, N.; Kremer, R.; Grunbaum, A.","https://www.medrxiv.org/content/10.1101/2020.07.23.20153932v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20153932v1?rss=1,2020-07-27,2020-07-27,,True
341,"Impact of COronaVirus Disease -2019 (COVID-19) pandemic on Haemodialysis care delivery pattern in Karnataka, India- a cross-sectional, questionnaire based survey.","The COVID-19 pandemic has disrupted health care delivery globally. Patients on in-centre haemodialysis(HD) are particularly affected due to their multiple hospital visits and the need for uninterrupted care for their well-being and survival. We studied the impact of the pandemic and the national policy for pandemic control on the HD care delivery in Karnataka state in India in April 2020, when the first and second national lockdown were in place. An online, questionnaire based survey of dialysis facilities was conducted and the responses analysed. The questions were pertaining to the key areas such as changes in number of dialysis treatments, frequency, duration, expenses, transportation to and from dialysis units, impact on availability of consumables, effect on dialysis personnel and on machine maintenance. 62 centres participated. Median of dialysis treatments for the months of March and April 2020 were 695.5 and 650 respectively. Reduction in dialysis treatments was noted in 29(46.8%) facilities , decreased frequency reported by 60 centres. In at least 35(56.5%) centres, dialysis patients had to bear increased expenses. Cost and availability of dialysis consumables were affected in 40(64.5%) and 55(88.7%) centres respectively. Problems with transportation and movement restriction were the two key factors affecting both patients and dialysis facilities.This survey documents the collateral impact of COVID -19 on the vulnerable group of patients on HD, even when not affected by COVID. It identifies the key areas of challenges faced by the patients and the facilities and implores the care-providers for finding newer avenues for mitigation of the problems. Key words: COVID-19, India, Haemodialysis , dialysis care delivery, questionnaire-based survey","Y J, A.; Conjeevaram, A.; Prabhu A, R.; Doshetty, M.; Srinivasa, S.; Moger, V.","https://www.medrxiv.org/content/10.1101/2020.07.25.20151225v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20151225v1?rss=1,2020-07-27,2020-07-27,,True
342,"SEIHCRD Model for COVID-19 spread scenarios, disease predictions and estimates the basic reproduction number, case fatality rate, hospital, and ICU beds requirement","We have proposed a new mathematical method, SEIHCRD-Model that is an extension of the SEIR-Model adding hospitalized and critical twocompartments. SEIHCRD model has seven compartments: susceptible (S), exposed (E), infected (I), hospitalized (H), critical (C), recovered (R), and deceased or death (D), collectively termed SEIHCRD. We have studied COVID- 19 cases of six countries, where the impact of this disease in the highest are Brazil, India, Italy, Spain, the United Kingdom, and the United States. SEIHCRD model is estimating COVID-19 spread and forecasting under uncertainties, constrained by various observed data in the present manuscript. We have first collected the data for a specific period, then fit the model for death cases, got the values of some parameters from it, and then estimate the basic reproduction number over time, which is nearly equal to real data, infection rate, and recovery rate of COVID-19. We also compute the case fatality rate over time of COVID-19 most affected countries. SEIHCRD model computes two types of Case fatality rate one is CFR daily and the second one is total CFR. We analyze the spread and endpoint of COVID-19 based on these estimates. SEIHCRD model is time-dependent hence we estimate the date and magnitude of peaks of corresponding to the number of exposed cases, infected cases, hospitalized cases, critical cases, and the number of deceased cases of COVID-19 over time. SEIHCRD model has incorporated the social distancing parameter, different age groups analysis, number of ICU beds, number of hospital beds, and estimation of how much hospital beds and ICU beds are required in near future.","Singh, A.; Bajpai, M. K.","https://www.medrxiv.org/content/10.1101/2020.07.24.20161752v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20161752v1?rss=1,2020-07-27,2020-07-27,,True
343,"Epidemiological investigation and prevention control analysis of longitudinal distribution of COVID-19 in Henan province, China","Objective: To analyze the vertical distribution of six cities in Henan Province,China from January 21, 2020 to June17, 2020: Xinyang City (including Gushi County), Nanyang City (including Dengzhou City), Zhumadian City (including XincaiCounty), Zhengzhou City (including Gongyi City), Puyang City and Anyang City (including Hua County) corona virus disease 2019(COVID-19) epidemiological characteristics and local prevention and control measures.Methods: Data were collected and analyzed through the COVID-19 information published on the official websites of health commissions of Henan Province and six cities.Results: As of June 17, 2020, the cumulative incidence rate of COVID-19 in Henan province was 1.33/100,000, the cumulative cure rate was 98.27%, the cumulative mortality rate was 1.73%, the age range of diagnosed cases was 5days-85years old, and the male to female ratio was 1.09:1.The confirmed cases of COVID-19 in Henan province were mainly imported cases from Hubei, accounting for 87.74%, of which the highest number was 70.50% in Zhumadian. The contact cases and local cases increased in a fluctuating manner over time.Significance: In this paper, epidemiological characteristics of COVID-19 in Henan province from the outbreak to the effective control within 60 days were analyzed, and effective and distinctive prevention and control measures in various cities were summarized, so as to provide a favorable reference for the further formulation and implementation of epidemic prevention and control and a valuable theoretical basis for effectively avoiding the second outbreak.","Yang, X.; Chen, X.; Ding, C.; Bai, Z.; Zhu, J.; Sun, G.; Yu, G.","https://www.medrxiv.org/content/10.1101/2020.07.25.20161844v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.25.20161844v1?rss=1,2020-07-27,2020-07-27,,True
344,Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study,"Objectives -- To investigate the relation of severe COVID-19 to prior drug prescribing. Design -- Matched case-control study (REACT-SCOT) based on record linkage to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Setting -- Scottish population. Main outcome measure -- Severe COVID-19, defined by entry to critical care or fatal outcome. Participants -- All 4272 cases of severe COVID-19 in Scotland since the start of the epidemic, with 36948 controls matched for age, sex and primary care practice. Results -- Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in care homes, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.7, 13.2), and was not accounted for by treatment of conditions designated as conferring increased risk. Of 17 drug classes postulated at the start of the epidemic to be ""medications compromising COVID"", all were associated with increased risk of severe COVID-19. The largest effect was for antipsychotic agents: rate ratio 4.14 (3.39, 5.07). Other drug classes with large effects included proton pump inhibitors (rate rato 2.19 (1.70, 2.80) for >= 2 defined daily doses/day), opioids (3.62 (2.65, 4.94) for >= 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates, and were stronger with recent than with non-recent exposure. Conclusions -- Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Although the evidence for causality is not conclusive, these results support existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy as a potential means of reducing COVID-19 risk. Registration -- ENCEPP number EUPAS35558","McKeigue, P. M.; Kennedy, S.; Weir, A.; Bishop, J.; McGurnaghan, S. J.; McAllister, D.; Robertson, C.; Wood, R.; Lone, N.; Murray, J.; Caparrotta, T. M.; Smith-Palmer, A.; Goldberg, D.; McMenamin, J.; Ramsay, C.; Guthrie, B.; Hutchinson, S.; Colhoun, H. M.","https://www.medrxiv.org/content/10.1101/2020.07.23.20160747v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20160747v1?rss=1,2020-07-27,2020-07-27,,True
345,Association of contact to small children with mild course of COVID-19,"It is known that severe COVID-19 cases in small children are rare. If a childhood-related infection would be protective against severe course of COVID-19, it would be expected that adults with intensive and regular contact to small children also may have a mild course of COVID-19 more frequently. To test this hypothesis, a survey among 4,010 recovered COVID-19 patients was conducted in Germany. 1,186 complete answers were collected. 6.9% of these patients reported frequent and regular job-related contact to children below 10 years of age and 23.2% had own small children, which is higher than expected. In the relatively small subgroup with intensive care treatment (n=19), patients without contact to small children were overrepresented. These findings are not well explained by age, gender or BMI distribution of those patients and should be validated in other settings.","Dugas, M.; Schrempf, I. M.; Ochs, K.; Froemmel, C.; Greulich, L.; Neuhaus, P.; Tepasse, P.-R.; Schmidt, H. H.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157149v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157149v1?rss=1,2020-07-26,2020-07-26,,True
346,The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.,"Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), may elicit uncontrolled and damaging inflammatory reactions, due to an excessive immune response and dysregulated production of cytokines and chemokines. Thus, it is critical to identify compounds able to inhibit virus replication and thwart the excessive inflammatory reaction and tissue lesions secondary to SARS-CoV-2 infection. Here, we show that the neuropeptides VIP and PACAP, molecules endowed with immunoregulatory properties, were able to inhibit SARS-CoV-2 RNA synthesis/replication in human monocytes and viral production in lung epithelial cells. VIP and PACAP protected these cells from virus-induced cytopathicity, reduced the production of proinflammmatory mediators, and prevented the SARS-CoV-2-induced NF-kB activation, which is critically involved in the production of inflammatory mediators. Both neuropeptides promoted CREB activation in infected monocytes, a transcription factor with antiapoptotic activity and also a negative regulator of NF-kB. As a possible host response to control patient inflammation, we identified that VIP levels were elevated in plasma from patients with severe forms of COVID-19, correlating with the inflammatory marker CRP and survival on those patients. Since a synthetic form of VIP is clinically approved in Europe and under two clinical trials for patients with COVID-19, our results provide the scientific evidence to further support clinical investigation of these neuropeptides against COVID-19.","Temerozo, J. R.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Pao, C. R. R.; de Freitas, C. S.; Dias, S. d. S. G.; Ferreira, A. C.; Mattos, M.; Soares, V. C.; Teixeira, L.; de Azevedo-Quintanilha, I. G.; Kurtz, P.; Bozza, F. A.; Bozza, P. T.; Souza, T. M. L.; Bou-Habib, D. C.","https://www.biorxiv.org/content/10.1101/2020.07.25.220806v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.220806v1?rss=1,2020-07-26,2020-07-26,,False
347,Healthcare Workers' Mental Health and Wellbeing During the COVID-19 Pandemic in the UK: Contrasting Guidelines with Experiences in Practice,"Background Substantial evidence has highlighted the importance of considering healthcare workers' (HCW) mental health during the COVID-19 pandemic, and several organisations have issued guidelines with recommendations. However, the definition of wellbeing and the evidence-base behind such guidelines remains unclear. Objectives Assessing the applicability of wellbeing guidelines in practice; identify unaddressed HCWs' needs; and provide recommendations for supporting frontline staff during the current and future pandemics. Methods and Design This paper discusses the findings of a qualitative study based on interviews with frontline healthcare staff in the UK and examines them in relation to a rapid review of wellbeing guidelines developed in response to the COVID-19 pandemic. Results 14 guidelines were included in the rapid review and 33 interviews with HCWs were conducted in the qualitative study. As a whole, the guidelines placed greater emphasis on wellbeing at an individual level, while HCWs placed greater emphasis on structural conditions at work, such as understaffing and the invaluable support of the community. This in turn had implications for the focus of wellbeing intervention strategies; staff reported an increased availability of formal mental health support, however, understaffing or clashing schedules prevented them from participating in these activities. Conclusion HCWs expressed wellbeing needs which align with social-ecological conceptualisations of wellbeing related to quality of life. This approach to wellbeing has been highlighted in literature about HCWs support in previous health emergencies, yet it has not been monitored during this pandemic. Wellbeing guidelines should explore staff's needs and contextual characteristics affecting the implementation of recommendations.","Vera San Juan, N.; Aceituno, D.; Djellouli, N.; Sumray, K.; Regenold, N.; Syversen, A.; Mulcahy Symmons, S.; Dowrick, A.; Mitchinson, L.; Singleton, G.; Vindrola-Padros, C.","https://www.medrxiv.org/content/10.1101/2020.07.21.20156711v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20156711v1?rss=1,2020-07-26,2020-07-26,,True
348,Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study,Background Effective antiviral therapy against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) remains elusive. Convalescent plasma is an anti-viral approach currently under investigation. We aimed to assess the laboratory and clinical parameters of patients with COVID-19 pneumonia treated with convalescent plasma containing high levels of neutralizing anti-SARS-CoV-2 antibodies.,"Donato, M.; Park, S.; Baker, M.; Korngold, R.; Morawski, A.; Geng, X.; Tan, M. T.; Rowley, S.; Chow, K.; Brown, E.; Zenreich, J.; McKiernan, P.; Buttner, K.; Ullrich, A.; Long, L.; Kemp, M.; Vendivil, M.; Ricourt, A.; Feinman, R.; Suh, H.; Bindu, B.; Cicogna, C.; Sebti, R.; Al-Khan, A.; Sperber, S.; Desai, S.; Fanning, S.; Arad, D.; Go, R.; Tam, E.; Rose, K.; Sadikot, S.; Siegel, D. S.; Gutierrez, M.; Ip, A.; Goldberg, S.; Feldman, T.; Goy, A.; Pecora, A.; Biran, N.; Leslie, L.; Gillio, A.; Timmapuri, S.; Boonstra, M.; Singer, S.; Kaur, S.; Richards, E.; Perlin, D.","https://www.medrxiv.org/content/10.1101/2020.07.20.20156398v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20156398v1?rss=1,2020-07-26,2020-07-26,,True
349,A new model to prioritize and optimize access to elective surgery throughout the COVID-19 pandemic: A feasibility & pilot study.,"Background The COVID-19 outbreak burdens non-COVID elective surgery patients with figures similar to the SARS-Cov-2, by creating an overwhelming demand, increasing waiting times and costs. New tools are urgently needed to manage elective access. The study assesses the SWALIS-2020 model ability to prioritize and optimize access to surgery during the pandemic. Methods A 2020 March - May feasibility-pilot study, tested a software-aided, inter-hospital, multidisciplinary pathway. All specialties patients in the Genoa Departments referred for urgent elective surgery were included in a multidisciplinary pathway adopting a modified Surgical Waiting List InfoSystem (SWALIS) cumulative prioritization method (PAT-2020) based on waiting time and clinical urgency, in three subcategories: A1-15 days (certain rapid disease progression), A2-21 days (probable progression), and A3-30 days (potential progression). Results Following the feasibility study (N=55 patients), 240 referrals were evaluated in 4 weeks without major criticalities (M/F=73/167, Age=68.7 +/- 14.0). Waiting lists were prioritized and monitored, and theatres allocated based on demand. The SWALIS-2020 score (% of waited-against-maximum time) at operation was 88.7 +/- 45.2 at week 1 and then persistently over 100% (efficiency), over a controlled variation (equity), with a difference between A3 (153.29 +/- 103.52) vs. A1 (97.24 +/- 107.93) (p <0.001), and A3 vs. A2 (88.05 +/- 77.51) (p <0.001). 222 patients underwent surgery, without related complications or delayed/failed discharges. Conclusions The pathway has selected the very few patients with the greatest need, optimizing access even with +30% capacity weekly modifications. We will use the pathway to manage active, backlog, and hidden waiting lists throughout the further pandemic phases, and are looking for collaboration for multi-center research. https://www.isrctn.com/ISRCTN11384058.","Valente, R.; Di Domenico, S.; Santori, G.; Mascherini, M.; Papadia, F.; Orengo, G.; Gratarola, A.; Cafiero, F.; De Cian, F.","https://www.medrxiv.org/content/10.1101/2020.07.21.20157719v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20157719v1?rss=1,2020-07-26,2020-07-26,,True
350,COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19,"Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking monoclonal antibody, has been repurposed for Covid-19, but prospective trials and dose-finding studies in Covid-19 are lacking. Methods We conducted a phase 2 trial of low-dose tocilizumab in hospitalized adult patients with Covid-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) >= 40 mg/L who did not require mechanical ventilation. Dose cohorts were determined by a trial Operations Committee, stratified by CRP and epidemiologic risk factors. A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with allowance for one repeat dose at 24-48 hours. The primary objective was to assess the relationship of dose to fever resolution and CRP response. Outcomes were compared with retrospective controls with Covid-19. Correlative studies evaluating host antibody response were performed in parallel. Findings A total of 32 patients received low-dose tocilizumab. This cohort had improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41). The probabilities of fever resolution or CRP decline did not appear to be dose-related in this small study (p=0.80 and p=0.10, respectively). Within the 28-day follow-up, 5 (15.6%) patients died. For patients who recovered, median time to clinical recovery was 3 days (IQR, 2-5). Clinically presumed and/or cultured bacterial superinfections were reported in 5 (15.6%) patients. Correlative biological studies demonstrated that tocilizumab-treated patients produced anti-SARS-CoV-2 antibodies comparable to controls. Interpretation Low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with Covid-19. Results of this trial and its correlative biological studies provide rationale for a randomized, controlled trial of low-dose tocilizumab in Covid-19.","Strohbehn, G. W.; Heiss, B. L.; Rouhani, S. J.; Trujillo, J. A.; Yu, J.; Kacew, A. J.; Higgs, E. F.; Bloodworth, J. C.; Cabanov, A.; Wright, R. C.; Koziol, A.; Weiss, A.; Danahey, K.; Karrison, T. G.; Edens, C. C.; Ventura, I. B.; Pettit, N. N.; Patel, B.; Pisano, J.; Strek, M. E.; Gajewski, T. F.; Ratain, M. J.; Reid, P. D.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1?rss=1,2020-07-26,2020-07-26,,True
351,3D Printed frames to enable reuse and improve the fit of N95 and KN95 respirators,"Background: In response to supply shortages during the COVID-19 pandemic, N95 filtering facepiece respirators (FFRs or ""masks""), which are typically single-use devices in healthcare settings, are routinely being used for prolonged periods and in some cases decontaminated under ""reuse"" and ""extended use"" policies. However, the reusability of N95 masks is often limited by degradation or breakage of elastic head bands and issues with mask fit after repeated use. The purpose of this study was to develop a frame for N95 masks, using readily available materials and 3D printing, which could replace defective or broken bands and improve fit. Results: An iterative design process yielded a mask frame consisting of two 3D-printed side pieces, malleable wire links that users press against their face, and cut lengths of elastic material that go around the head to hold the frame and mask in place. Volunteers (n= 41; average BMI= 25.5), of whom 31 were women, underwent qualitative fit with and without mask frames and one or more of four different brands of FFRs conforming to US N95 or Chinese KN95 standards. Masks passed qualitative fit testing in the absence of a frame at rates varying from 48-92% (depending on mask model and tester). For individuals for whom a mask passed testing, 75-100% (average = 86%) also passed testing with a frame holding the mask in place. Among users for whom a mask failed in initial fit testing, 41% passed using a frame. Success varied with mask model and across individuals. Conclusions: The use of mask frames can prolong the lifespan of N95 and KN95 masks by serving as a substitute for broken or defective bands without adversely affecting fit. Frames also have the potential to improve fit for some individuals who cannot fit existing masks. Frames therefore represent a simple and inexpensive way of extending the life and utility of PPE in short supply. For clinicians and institutions interested in mask frames, designs and specifications are provided without restriction for use or modification. To ensure adequate performance in clinical settings, qualitative fit testing with user-specific masks and frames is required.","McAvoy, M.; Bui, A.-T. N.; Hansen, C.; Plana, D.; Said, J. T.; Yu, Z.; Yang, H.; Freake, J.; Van, C.; Krikorian, D.; Cramer, A.; Smith, L.; Jiang, L.; Lee, K. J.; Li, S. J.; Beller, B.; Short, M.; Yu, S. H.; Mostaghimi, A.; Sorger, P. K.; LeBoeuf, N. R.","https://www.medrxiv.org/content/10.1101/2020.07.20.20151019v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20151019v1?rss=1,2020-07-26,2020-07-26,,True
352,Working from a distance: Who can afford to stay home during COVID-19? Evidence from mobile device data,"As local and state governments reopen parts of the economy while balancing public health through social distancing, it is important to understand the heterogeneity in how the population has reacted to the COVID-19 pandemic. We match census block group level Safegraph mobile device data with demographic data from the American Community Survey to identify trends amongst different subgroups of the population. We find evidence that people's ability to work from home is a determinant of time spent at home since the beginning of the pandemic. On April 15th, census block groups classified as being better able to work from home spent 3 more hours at home compared to those who were not. We see supporting trends amongst block groups with differences in income and educational attainment.","Dimke, C.; Lee, M. C.; Bayham, J.","https://www.medrxiv.org/content/10.1101/2020.07.20.20153577v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20153577v1?rss=1,2020-07-26,2020-07-26,,True
353,"The adequacy of health system measures in reducing vulnerability to COVID 19 among the health care providers working in primary health care in Rajasthan, India A Cross sectional Study","Background This paper examines the role of individual, facility and system level preparedness in reducing the physiological and psychological vulnerability among primary-level health care providers (HCPs) of COVID19 pandemic in Rajasthan, India. Method and Material Online and telephonic interviews are conducted among 274 HCPs working in 24 PHCs (17 rural and 7 urban), across 13 districts of Rajasthan. Five dimensions of vulnerability covering awareness, exposure to infection (daily contact; contact with high risk individuals), physical and mental health conditions, while three aspects of preparedness at individual (personal care) and facility (provider safety; management and supervision) level are measured by employing factor analysis. Generalized ordered logit regression model is used to measure the effect of preparedness on COVID19 related vulnerability. Result: Among the 274 HCPs, majority of the staff are from rural PHCs (76 %), less than 35 years (87%), female (57%) and married (57 %). Almost half have high level exposure to COVID19, with mean contact rate is 90. Overall, 26% have comprehensive knowledge on COVID19, and 32% have any mental health issues. Although more than 70% of HCPs have reported more than one individual level preparedness, mental health measures adopted by the HCPs are comparably low. The facility level preparedness for enhancing safety are high such as social distance (79%) and maintaining record of each visitor (75%). However, management related measures adopted by the PHCs are perceived to be lower than the safety measures. The regression analyses suggest that safety related preparedness is significantly associated with reduction of vulnerability by 50%. The management-level preparedness has statistically no significant effect in explaining the variations in level of vulnerability. Conclusion: The facility-level safety measures, which lowers chances of acquiring infection has a positive effect on reducing vulnerability of COVID19. However, the HCPs do not have adequate preparedness at individual, facility management (PHC) and system level to reduce COVID19 vulnerability. Findings suggest that there is a need for a non-conventional approach of monitoring and supervision, in the absence of such measures there is a chance of moral injury that will make the HCPs at the primary level vulnerable to both physiologically and psychologically.","Das, A. K.; Srivastava, A. K.; Ghosh, S.; Bhargava, R.; Gupt, R. K.; Singh, R. R.","https://www.medrxiv.org/content/10.1101/2020.07.21.20149443v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20149443v1?rss=1,2020-07-26,2020-07-26,,True
354,COVID-19 and Rheumatoid Arthritis share myeloid pathogenic and resolving pathways,"BackgroundWe recently delineated the functional biology of pathogenic and inflammation resolving synovial tissue macrophage clusters in rheumatoid arthritis (RA). Whilst RA is not a viral respiratory syndrome, it represents a pro-inflammatory cytokine-driven chronic articular condition often accompanied by cardiovascular and lung pathologies. We hypothesised that functionally equivalent macrophage clusters in the lung might govern inflammation and resolution of COVID-19 pneumonitis.

MethodsTo provide insight into the targetable functions of COVID-19 bronchoalveolar lavage (BALF) macrophage clusters, a comparative analysis of BALF macrophage single cell transcriptomics (scRNA-seq) with synovial tissue (ST) macrophage scRNA-seq and functional biology was performed. The function of shared BALF and ST MerTK inflammation-resolving pathway was confirmed with inhibitor in primary macrophage-synovial fibroblast co-cultures. Results. Distinct BALF FCNpos and FCNposSPP1pos macrophage clusters emerging in severe COVID-19 patients were closely related to ST CD48highS100A12pos and CD48posSPP1pos clusters driving synovitis in active RA. They shared transcriptomic profile and pathogenic mechanisms. Healthy lung resident alveolar FABP4pos macrophages shared a regulatory transcriptomic profile, including TAM (Tyro, Axl, MerTK) receptors pathway with synovial tissue TREM2pos macrophages that govern RA remission. This pathway was substantially altered in BALF macrophages of severe COVID-19. In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function.

ConclusionPathogenesis and resolution of COVID-19 pneumonitis and RA synovitis might be driven by similar macrophage clusters and pathways. The MerTK-dependent anti-inflammatory mechanisms of dexamethasone, and the homeostatic function of TAM pathways that maintain RA in remission advocate the therapeutic MerTK agonism to ameliorate the cytokine storm and pneumonitis of severe COVID-19.","MacDonald, L.; Otto, T. D.; Elmesmari, A.; Tolusso, B.; Somma, D.; McSharry, C.; Gremese, E.; McInnes, I. B.; Alivernini, S.; Kurowska-Stolarska, M.","https://www.biorxiv.org/content/10.1101/2020.07.26.221572v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.221572v1?rss=1,2020-07-26,2020-07-26,,False
355,No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor,"The spike protein of SARS-CoV-2 is known to enable viral invasion into human cells through direct binding to host receptors including ACE2. An alternate entry receptor for the virus was recently proposed to be basigin/CD147. These early studies have already prompted a clinical trial and multiple published hypotheses of the role of this host receptor in viral infection and pathogenesis. We sought to independently characterize the basigin-spike protein interaction. After conducting several lines of experiments, we report that we are unable to find evidence supporting the role of basigin as a putative spike-binding receptor. Recombinant forms of both the entire ectodomain and S1 domain of the SARS-CoV-2 spike protein that directly bind ACE2 do not interact with basigin expressed on the surface of human cells. Using specialized assays tailored to detect receptor interactions as weak or weaker than the proposed basigin-spike binding, we report no evidence for direct binding of the viral spike to either of the two common isoforms of basigin. Given the pressing need for clarity on which targets of SARS-CoV-2 may lead to promising therapeutics, we present these findings to allow more informed decisions about the translational relevance of this putative mechanism in the race to understand and treat COVID-19.","Shilts, J.; Wright, G. J.","https://www.biorxiv.org/content/10.1101/2020.07.25.221036v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.221036v1?rss=1,2020-07-26,2020-07-26,,False
356,North American deer mice are susceptible to SARS-CoV-2,"The zoonotic spillover of the pandemic SARS-coronavirus 2 (SARS-CoV-2) from an animal reservoir, currently presumed to be the Chinese horseshoe bat, into a naive human population has rapidly resulted in a significant global public health emergency. Worldwide circulation of SARS-CoV-2 in humans raises the theoretical risk of reverse zoonosis events with wildlife, reintroductions of SARS-CoV-2 into permissive non-domesticated animals, potentially seeding new host reservoir species and geographic regions in which bat SARS-like coronaviruses have not historically been endemic. Here we report that North American deer mice (Peromyscus maniculatus) and some closely related members of the Cricetidae family of rodents possess key amino acid residues within the angiotensin-converting enzyme 2 (ACE2) receptor known to confer SARS-CoV-2 spike protein binding. Peromyscus rodent species are widely distributed across North America and are the primary host reservoirs of several emerging pathogens that repeatedly spill over into humans including Borrelia burgdorferi, the causative agent of Lyme disease, deer tick virus, and Sin Nombre orthohantavirus, the causative agent of hantavirus pulmonary syndrome (HPS). We demonstrate that adult deer mice are susceptible to SARS-CoV-2 infection following intranasal exposure to a human isolate, resulting in viral replication in the upper and lower respiratory tract with little or no signs of disease. Further, shed infectious virus is detectable in nasal washes, oropharyngeal and rectal swabs, and viral RNA is detectable in feces and occasionally urine. We further show that deer mice are capable of transmitting SARS-CoV-2 to naive deer mice through direct contact. The extent to which these observations may translate to wild deer mouse populations remains unclear, and the risk of reverse zoonosis and/or the potential for the establishment of Peromyscus rodents as a North American reservoir for SARS-CoV-2 is unknown. Nevertheless, efforts to monitor wild, peri-domestic Peromyscus rodent populations are likely warranted as the SARS-CoV-2 pandemic progresses.","Griffin, B. D.; Chan, M.; Tailor, N.; Mendoza, E. J.; Leung, A.; Warner, B. M.; Duggan, A. T.; Moffat, E.; He, S.; Garnett, L.; Tran, K. N.; Banadyga, L.; Albietz, A.; Tierney, K.; Audet, J.; Bello, A.; Vendramelli, R.; Boese, A. S.; Fernando, L.; Lindsay, L. R.; Jardine, C. M.; Wood, H.; Poliquin, G.; Strong, J. E.; Drebot, M.; Safronetz, D.; Embury-Hyatt, C.; Kobasa, D.","https://www.biorxiv.org/content/10.1101/2020.07.25.221291v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.221291v1?rss=1,2020-07-26,2020-07-26,,False
357,"Comparison of viral levels in individuals with or without symptoms at time of COVID-19 testing among 32,480 residents and staff of nursing homes and assisted living facilities in Massachusetts.","Background Transmission of COVID-19 from people without symptoms poses considerable challenges to public health containment measures. The distribution of viral loads in individuals with and without symptoms remains uncertain. Comprehensive cross-sectional screening of all individuals in a given setting provides an unbiased way to assess viral loads independent of symptoms, which informs transmission risks. COVID-19 cases initially peaked in Massachusetts in mid-April 2020 before declining through June, and congregate living facilities were particularly affected during this early surge. We performed a retrospective analysis of data from a large public health-directed outbreak response initiative that involved comprehensive screening within nursing homes and assisted living facilities in Massachusetts to compare nasopharyngeal (NP) viral loads (as measured by RT-PCR cycle threshold (Ct) levels) in residents and staff to inform our ability to detect SARS-CoV-2 in individuals with or without symptoms in the population. Methods Between April 9 and June 9, 2020, we tested NP swabs from 32,480 unique individuals comprising staff and residents of the majority of nursing homes and assisted living facilities in Massachusetts. Under the direction of the MA Department of Public Health (MDPH), symptomatology at the time of sampling and demographic information was provided by each facility for each individual to facilitate reporting to health officials. NP swabs were collected, RNA extracted, and SARS-CoV-2 testing performed using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Results The nursing home and assisted living facilities resident cohort (N =16,966) was 65% female with a mean age of 82 years (SD 13 yrs). The staff cohort (N = 15,514) was 76% female with a median age of 45 (SD 15 yrs). A total 2654 residents (15.5%) and 624 staff (4.1%) tested positive for SARS-CoV-2. 12.7% of residents and 3.7% of staff without symptoms tested positive for SARS-CoV-2, compared to 53.1% of residents and 18.2% of staff with symptoms. Of the individuals who tested positive, 70.8% of residents and 92.4% of staff lacked symptoms at the time of testing. In aggregate, the distributions of Cts for viral probes used in the qRT-PCR assay were very similar, with a statistically but not meaningfully different mean ({triangleup}Ct 0.71 cycles, p = 0.006) and a similar range (12-38 cycles), between populations with and without symptoms over the entire time period, across all sub-categories examined (age, race, ethnicity, sex, resident/staff). Importantly, the Ct mean values and range were indistinguishable between the populations by symptom class during the peak of the outbreak in Massachusetts, with a Ct gap appearing only later in the survey period, reaching >3 cycles (p [&le;] 0.001) for facilities sampled during the last two weeks of the study. Conclusions In a large cohort of individuals screened for SARS-CoV-2 by qRT-PCR, we found strikingly similar distributions of viral load in patients with or without symptoms at the time of testing during the local peak of the epidemic; as the epidemic waned, individuals without symptoms at the time of testing had lower viral loads. The size of the study population, including both staff and residents spanning a wide range of ages, provides a comprehensive cross-sectional point prevalence measurement of viral burden in a study spanning 2 months. Because the distributions of viral loads in infected individuals irrespective of symptomatology are very similar, existing testing modalities that have been validated for detection of SARS-CoV-2 RNA in symptomatic patients should perform similarly in individuals without symptoms at the time of testing.","Lennon, N. J.; Bhattacharyya, R. P.; Mina, M. J.; Rehm, H. L.; Hung, D. T.; Smole, S.; Woolley, A.; Lander, E. S.; Gabriel, S. B.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157792v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157792v1?rss=1,2020-07-26,2020-07-26,,True
358,The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State,"The COVID-19 pandemic underwent a rapid transition with the emergence of a SARS-CoV-2 variant that carried the amino acid substitution D614G in the Spike protein that became globally prevalent. The G-form is both more infectious in vitro and associated with increased viral loads in infected people. To gain insight into the mechanism underlying these distinctive characteristics, we employed multiple replicas of microsecond all-atom simulations to probe the molecular-level impact of this substitution on Spikes closed and open states. The open state enables Spike interactions with its human cellular receptor, ACE2. Here we show that changes in the inter-protomer energetics due to the D614G substitution favor a higher population of infection-capable (open) states. The inter-protomer interactions between S1 and S2 subunits in the open state of the D-form are asymmetric. This asymmetry is resolved in the G-form due to the release of tensile hydrogen bonds resulting in an increased population of open conformations. Thus, the increased infectivity of the G-form is likely due to a higher rate of profitable binding encounters with the host receptor. It is also predicted to be more neutralization sensitive due to enhanced exposure of the receptor binding domain, a key target region for neutralizing antibodies.","Mansbach, R. A.; Chakraborty, S.; Nguyen, K.; Montefiori, D.; Korber, B.; Gnanakaran, S.","https://www.biorxiv.org/content/10.1101/2020.07.26.219741v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.219741v1?rss=1,2020-07-26,2020-07-26,,False
359,Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate,"Due to the lack of protective immunity of humans towards the newly emerged SARS-CoV-2, this virus has caused a massive pandemic across the world resulting in hundreds of thousands of deaths. Thus, a vaccine is urgently needed to contain the spread of the virus. Here, we describe Newcastle disease virus (NDV) vector vaccines expressing the spike protein of SARS-CoV-2 in its wild type or a pre-fusion membrane anchored format. All described NDV vector vaccines grow to high titers in embryonated chicken eggs. In a proof of principle mouse study, we report that the NDV vector vaccines elicit high levels of antibodies that are neutralizing when the vaccine is given intramuscularly. Importantly, these COVID-19 vaccine candidates protect mice from a mouse-adapted SARS-CoV-2 challenge with no detectable viral titer and viral antigen in the lungs.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe spike (S) protein of the SARS-CoV-2 is the major antigen that notably induces neutralizing antibodies to block viral entry. Many COVID-19 vaccines are under development, among them viral vectors expressing the S protein of SARS-CoV-2 exhibit many benefits. Viral vector vaccines have the potential of being used as both live or inactivated vaccines and they can induce Th1 and Th2-based immune responses following different immunization regimens. Additionally, viral vector vaccines can be handled under BSL-2 conditions and they grow to high titers in cell cultures or other species restricted-hosts. For a SARS-CoV-2 vaccine, several viral vectors are being tested, such as adenovirus, measles virus and Modified vaccinia Ankara.

Added value of this studyThe NDV vector vaccine against SARS-CoV-2 described in this study has advantages similar to those of other viral vector vaccines. But the NDV vector can be amplified in embryonated chicken eggs, which allows for high yields and low costs per dose. Also, the NDV vector is not a human pathogen, therefore the delivery of the foreign antigen would not be compromised by any pre-existing immunity in humans. Finally, NDV has a very good safety record in humans, as it has been used in many oncolytic virus trials. This study provides an important option for a cost-effective SARS-CoV-2 vaccine.

Implications of all the available evidenceThis study informs of the value of a viral vector vaccine against SARS-CoV-2. Specifically, for this NDV based SARS-CoV-2 vaccine, the existing egg-based influenza virus vaccine manufactures in the U.S. and worldwide would have the capacity to rapidly produce hundreds of millions of doses to mitigate the consequences of the ongoing COVID-19 pandemic.","Sun, W.; Leist, S. R.; McCroskery, S.; Liu, Y.; Slamanig, S.; Oliva, J.; Amanat, F.; Schaefer, A.; Dinnon, K.; Garcia-Sastre, A.; Krammer, F.; Baric, R. S.; Palese, P.","https://www.biorxiv.org/content/10.1101/2020.07.26.221861v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.26.221861v1?rss=1,2020-07-26,2020-07-26,,False
360,Daily Forecasting of New Cases for Regional Epidemics of Coronavirus Disease 2019 with Bayesian Uncertainty Quantification,"To increase situational awareness and support evidence-based policy-making, we formulated two types of mathematical models for COVID-19 transmission within a regional population. One is a fitting function that can be calibrated to reproduce an epidemic curve with two timescales (e.g., fast growth and slow decay). The other is a compartmental model that accounts for quarantine, self-isolation, social distancing, a non-exponentially distributed incubation period, asymptomatic individuals, and mild and severe forms of symptomatic disease. Using Bayesian inference, we have been calibrating our models daily for consistency with new reports of confirmed cases from the 15 most populous metropolitan statistical areas in the United States and quantifying uncertainty in parameter estimates and predictions of future case reports. This online learning approach allows for early identification of new trends despite considerable variability in case reporting. We infer new significant upward trends for five of the metropolitan areas starting between 19-April-2020 and 12-June-2020.","Lin, Y. T.; Neumann, J.; Miller, E. F.; Posner, R. G.; Mallela, A.; Stafa, C.; Ray, J.; Thakur, G.; Chinthavali, S.; Hlavacek, W. S.","https://www.medrxiv.org/content/10.1101/2020.07.20.20151506v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20151506v1?rss=1,2020-07-26,2020-07-26,,True
361,Serial Profiling of SARS-CoV-2 Antigens and Antibodies in COVID-19 Patient Plasma,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide. PCR tests are currently the gold standard for diagnosis of the current coronavirus disease (COVID-19) and serology tests are used to detect seroconversion in infected patients. However, there is a lack of quantitative and ultra-sensitive viral antigen tests for COVID-19. Here we show that Single Molecule Array (Simoa) assays can quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of COVID-19 patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we show correlation between production of antibodies and clearance of viral antigens from serial plasma samples from COVID-19 patients. Furthermore, we demonstrate the presence of viral antigens in blood correlates with disease severity in hospitalized COVID-19 patients. These data suggest that SARS-CoV-2 viral antigens in the blood could be a marker for severe COVID-19 cases.","Ogata, A. F.; Maley, A. M.; Wu, C.; Gilboa, T.; Norman, M.; Lazarovits, R.; Mao, C.-P.; Newton, G.; Chang, M.; Nguyen, K.; Kamkaew, M.; Zhu, Q.; Gibson, T. E.; Ryan, E.; Charles, R.; Marasco, W. A.; Walt, D. R.","https://www.medrxiv.org/content/10.1101/2020.07.20.20156372v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20156372v1?rss=1,2020-07-26,2020-07-26,,True
362,"Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study","Background: The number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan are substantially lower in comparison to the US and UK, potentially due to the under-implementation of polymerase chain reaction (PCR) tests. Studies reported that more than half of the SARS-CoV-2 infections are asymptomatic, confirming the importance for conducting seroepidemiological studies. Although the seroepidemiological studies in Japan observed a reported prevalence of 0.10% in Tokyo, 0.17% in Osaka, and 0.03% in Miyagi, sampling bias was not considered. The study objective was to assess the seroprevalence of SARS-CoV-2 in a random sample of households in Utsunomiya City in Tochigi Prefecture, Greater Tokyo, Japan. Methods: We launched the Utsunomiya COVID-19 seROprevalence Neighborhood Association (U-CORONA) Study to assess the seroprevalence of COVID-19 in Utsunomiya City. The survey was conducted between 14 June 2020 and 5 July 2020, in between the first and second wave of the pandemic. Invitations enclosed with a questionnaire were sent to 2,290 people in 1,000 households randomly selected from Utsunomiya basic resident registry. Written informed consent was obtained from all participants. The level of IgG antibodies to SARS-CoV-2 was assessed by chemiluminescence immunoassay analysis. Results: Among 2,290 candidates, 753 returned the questionnaire and 742 received IgG tests (32.4 % participation rate). Of the 742 participants, 86.8% were 18 years or older, 52.6% were women, 71.1% were residing within 10 km from the test clinic, and 89.2% were living with another person. The age and sex distribution, distance to clinic and police district were similar with those of non-participants, while the proportion of single-person households was higher among non-participants than participants (16.2% vs. 10.8%). We confirmed three positive cases through quantitative antibody testing. No positive cases were found among the people who live in the same household as someone with positive. All cases were afebrile. The estimated unweighted and weighted prevalence of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08-1.18%) and 1.23% (95% confidence interval: 0.17-2.28%), respectively. Conclusion: This study suggests the importance of detecting all cases using PCR or antigen testing, not only at a hospital, but also in areas where people assemble. Further prospective studies using this cohort are needed to monitor SARS-CoV-2 antibody levels.","Nawa, N.; Kuramochi, J.; Sonoda, S.; Yamaoka, Y.; Nukui, Y.; Miyazaki, Y.; Fujiwara, T.","https://www.medrxiv.org/content/10.1101/2020.07.20.20155945v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20155945v1?rss=1,2020-07-26,2020-07-26,,True
363,"Recent smell loss is the best predictor of COVID-19: a preregistered, cross-sectional study","Background: COVID-19 has heterogeneous manifestations, though one of the most common symptoms is a sudden loss of smell (anosmia or hyposmia). We investigated whether olfactory loss is a reliable predictor of COVID-19. Methods: This preregistered, cross-sectional study used a crowdsourced questionnaire in 23 languages to assess symptoms in individuals self-reporting recent respiratory illness. We quantified changes in chemosensory abilities during the course of the respiratory illness using 0-100 visual analog scales (VAS) for participants reporting a positive (C19+; n=4148) or negative (C19-; n=546) COVID-19 laboratory test outcome. Logistic regression models identified singular and cumulative predictors of COVID-19 status and post-COVID-19 olfactory recovery. Results: Both C19+ and C19- groups exhibited smell loss, but it was significantly larger in C19+ participants (mean{+/-}SD, C19+: -82.5{+/-}27.2 points; C19-: -59.8{+/-}37.7). Smell loss during illness was the best predictor of COVID-19 in both single and cumulative feature models (ROC AUC=0.72), with additional features providing no significant model improvement. VAS ratings of smell loss were more predictive than binary chemosensory yes/no-questions or other cardinal symptoms, such as fever or cough. Olfactory recovery within 40 days was reported for ~50% of participants and was best predicted by time since illness onset. Conclusions: As smell loss is the best predictor of COVID-19, we developed the ODoR-19 tool, a 0-10 scale to screen for recent olfactory loss. Numeric ratings [&le;]2 indicate high odds of symptomatic COVID-19 (10<OR<4), especially when viral lab tests are impractical or unavailable.","Gerkin, R. C.; Ohla, K.; Veldhuizen, M. G.; Joseph, P. V.; Kelly, C. E.; Bakke, A. J.; Steele, K. E.; Farruggia, M. C.; Pellegrino, R.; Pepino, M. Y.; Bouysset, C.; Soler, G. M.; Pereda-Loth, V.; Dibattista, M.; Cooper, K. W.; Croijmans, I.; Di Pizio, A.; Ozdener, M. H.; Fjaeldstad, A. W.; Lin, C.; Sandell, M. A.; Singh, P. B.; Brindha, V. E.; Olsson, S. B.; Saraiva, L. R.; Ahuja, G.; Alwashahi, M. K.; Bhutani, S.; D'Errico, A.; Fornazieri, M. A.; Golebiowski, J.; Hwang, L.-D.; Ozturk, L.; Roura, E.; Spinelli, S.; Whitcroft, K. L.; Faraji, F.; Fischmeister, F. P. S.; Heinbockel, T.; Hsieh, J. W.; Huart, C.; Konstantinidis, I.; Menini, A.; Morini, G.; Olofsson, J. K.; Philpott, C. M.; Pierron, D.; Shields, V. D. C.; Voznessenskaya, V. V.; Albayay, J.; Altundag, A.; Bensafi, M.; Bock, M. A.; Calcinoni, O.; Fredborg, W.; Laudamiel, C.; Lim, J.; Lundstrom, J. N.; Macchi, A.; Meyer, P.; Moein, S. T.; Santamaria, E.; Sengupta, D.; Dominguez, P. P.; Yank, H.; Boesveldt, S.; de Groot, J. H. B.; Dinnella, C.; Freiherr, J.; Laktionova, T.; Marino, S.; Monteleone, E.; Nunez-Parra, A.; Abdulrahman, O.; Ritchie, M.; Thomas-Danguin, T.; Walsh-Messinger, J.; Al Abri, R.; Alizadeh, R.; Bignon, E.; Cantone, E.; Cecchini, M. P.; Chen, J.; Guardia, M. D.; Hoover, K. C.; Karni, N.; Navarro, M.; Nolden, A. A.; Mazal, P. P.; Rowan, N. R.; Sarabi-Jamab, A.; Archer, N. S.; Chen, B.; Di Valerio, E. A.; Feeney, E. L.; Frasnelli, J.; Hannum, M.; Hopkins, C.; Klein, H.; Mignot, C.; Mucignat, C.; Ning, Y.; Ozturk, E. E.; Peng, M.; Saatci, O.; Sell, E. A.; Yan, C. H.; Alfaro, R.; Cecchetto, C.; Coureaud, G.; Herriman, R. D.; Justice, J. M.; Kaushik, P. K.; Koyama, S.; Overdevest, J. B.; Pirastu, N.; Ramirez, V. A.; Roberts, S. C.; Smith, B. C.; Cao, H.; Wang, H.; Balungwe, P.; Baguma, M.; Hummel, T.; Hayes, J. E.; Reed, D. R.; Niv, M. Y.; Munger, S. D.; Parma, V.","https://www.medrxiv.org/content/10.1101/2020.07.22.20157263v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20157263v1?rss=1,2020-07-26,2020-07-26,,True
364,Evidence of gender bias in the diagnosis and management of COVID-19 patients: A Big Data analysis of Electronic Health Records,"Background: It remains unknown whether the frequency and severity of COVID-19 affect women differently than men. Here, we aim to describe the characteristics of COVID-19 patients at disease onset, with special focus on the diagnosis and management of female patients with COVID-19. Methods: We explored the unstructured free text in the electronic health records (EHRs) within the SESCAM Healthcare Network (Castilla La-Mancha, Spain). The study sample comprised the entire population with available EHRs (1,446,452 patients) from January 1st to May 1st, 2020. We extracted patients' clinical information upon diagnosis, progression, and outcome for all COVID-19 cases. Results: A total of 4,780 patients with a test-confirmed diagnosis of COVID-19 were identified. Of these, 2,443 (51%) were female, who were on average 1.5 years younger than males (61.7{+/-}19.4 vs. 63.3{+/-}18.3, p=0.0025). There were more female COVID-19 cases in the 15-59 yr.-old interval, with the greatest sex ratio (SR; 95% CI) observed in the 30-39 yr.-old interval (1.69; 1.35-2.11). Upon diagnosis, headache, anosmia, and ageusia were significantly more frequent in females than males. Imaging by chest X-ray or blood tests were performed less frequently in females (65.5% vs. 78.3% and 49.5% vs. 63.7%, respectively), all p<0.001. Regarding hospital resource use, females showed less frequency of hospitalization (44.3% vs. 62.0%) and ICU admission (2.8% vs. 6.3%) than males, all p<0.001. Conclusion: Our results indicate important sex-dependent differences in the diagnosis, clinical manifestation, and treatment of patients with COVID-19. These results warrant further research to identify and close the gender gap in the ongoing pandemic.","Ancochea, J.; Izquierdo, J. L.; Savana COVID-19 Research Group,; Soriano, J. B.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157735v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157735v1?rss=1,2020-07-26,2020-07-26,,True
365,SIDIR: Extending SIR with Detected and Isolated Populations for Pandemic Modeling,"We extend the Susceptible Infected Recovered (SIR) model to include Detected (D) and Isolated (I) compartments (SIDIR). SIDIR improves COVID-19 outbreak behavior modeling by identifying infected populations as subsequently quarantined to reduce the spread of the infection (either in a hospital or self-quarantined). We present the model and provide a case study on COVID-19. The model estimates undetected cases (i.e., those infected but unconfirmed) and extrapolates when no additional undetected active (rogue) cases will remain, potentially guiding policy decisions that help control the spread of COVID-19 and future epidemics. A live demonstration of SIDIR on COVID-19 is available at: http://ir.cs.georgetown.edu/sidir.","Garman, J.; MacAvaney, S.; Yang, E.; Frieder, O.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157834v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157834v1?rss=1,2020-07-26,2020-07-26,,True
366,Potential impact of individual exposure histories to endemic human coronaviruses on age-dependence in severity of COVID-19,"Cross-reactivity to SARS-CoV-2 from previous exposure to endemic coronaviruses (eHCoV) is gaining increasing attention as a possible driver of both protection against infection and severity of COVID-19 disease. Here, we use a stochastic individual-based model to show that heterogeneities in individual exposure histories to endemic coronaviruses are able to explain observed age patterns of hospitalisation due to COVID-19 in EU/EEA countries and the UK, provided there is (i) a decrease in cross-protection to SARS-CoV-2 with the number of eHCoV exposures and (ii) an increase in potential disease severity with number of eHCoV exposures or as a result of immune senescence. We also show that variation in health care capacity and testing efforts is compatible with country-specific differences in hospitalisation rates. Our findings call for further research on the role of cross-reactivity to endemic coronaviruses and highlight potential challenges arising from heterogeneous health care capacity and testing.","Pinotti, F.; Wikramaratna, P. S.; Obolski, U.; Paton, R.; Damineli, D. S. C.; Alcantara, L. C. J.; Giovanetti, M.; Gupta, S.; Lourenco, J.","https://www.medrxiv.org/content/10.1101/2020.07.23.20154369v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.23.20154369v1?rss=1,2020-07-26,2020-07-26,,True
367,"Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study","Background Managing discharged COVID-19 (DC) patients with recurrent positive (RP) SARS-CoV-2 RNA test results is challenging. We aimed to comprehensively characterize the viral RNA level and serum antibody responses in RP-DC patients and evaluate their viral transmission risk. Methods A population-based observational cohort study was performed on 479 DC patients discharged from February 1 to May 5, 2020 in Shenzhen, China. We conducted RT-qPCR, antibody assays, neutralisation assays, virus isolation, whole genome sequencing (WGS), and epidemiological investigation of close contacts. Findings Of 479 DC patients, the 93 (19%) RP individuals, including 36 with multiple RP results, were characterised by young age (median age: 34 years, 95% confidence interval [CI]: 29-38 years). The median discharge-to-RP length was 8 days (95% CI: 7-14 days; maximum: 90 days). After readmission, RP-DC patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in RP-DC patients ranged from 1.9-5.7 log10 copies/mL (median: 3.2, 95% CI: 3.1-3.5). At RP detection, the IgM, IgG, IgA, total antibody, and neutralising antibody (NAb) seropositivity rates in RP-DC patients were 38% (18/48), 98% (47/48), 63% (30/48), 100% (48/48), and 91% (39/43), respectively. Regarding antibody levels, there was no significant difference between RP-DC and non-RP-DC patients. The antibody level remained constant in RP-DC patients pre- and post-RP detection. Virus isolation of nine representative specimens returned negative results. WGS of six specimens yielded only genomic fragments. No clinical symptoms were exhibited by 96 close contacts of 23 RP-DC patients; their viral RNA (96/96) and antibody (20/20) test results were negative. After full recovery, 60% of patients (n=162, 78 no longer RP RP-DC and 84 non-RP-DC) had NAb titres of [&ge;]1:32. Interpretation RP may occur in DC patients following intermittent and non-stable excretion of low viral RNA levels. RP-DC patients pose a low risk of transmitting SARS-CoV-2. An NAb titre of [&ge;]1:32 may provide a reference indicator for evaluating humoral responses in COVID-19 vaccine clinical trials.","Yang, C.; Jiang, M.; Wang, X.; Tang, X.; Fang, S.; Li, H.; Zuo, L.; Jiang, Y.; Zhong, Y.; Chen, Q.; Zheng, C.; Wang, L.; Wu, S.; Wu, W.; Liu, H.; Yuan, J.; Liao, X.; Zhang, Z.; Lin, Y.; Geng, Y.; Zhang, H.; Zheng, H.; Wan, M.; Lu, L.; Ren, X.; Cui, Y.; Zou, X.; Feng, T.; Xia, J.; Yang, R.; Liu, Y.; Mei, S.; Li, B.; Yang, Z.; Hu, Q.","https://www.medrxiv.org/content/10.1101/2020.07.21.20125138v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20125138v1?rss=1,2020-07-26,2020-07-26,,True
368,Previous and active tuberculosis in COVID-19 patients increases risk of death and prolongs recovery,"Background: There is a growing literature on the association of SARS-CoV-2 and other chronic conditions, such as noncommunicable diseases. However, little is known about the impact of coinfection with tuberculosis. We aimed to compare the risk of death and recovery, as well as time-to-death and time-to-recovery, in COVID-19 patients with and without TB. Methods: We created a 4:1 propensity score matched sample of COVID-19 patients without and with tuberculosis, using COVID-19 surveillance data in the Philippines. We conducted a longitudinal cohort analysis of matched COVID-19 patients as of May 17, 2020, following them until June 15, 2020. The primary analysis estimated the risk ratios of death and recovery in patients with and without tuberculosis. Kaplan-Meier curves described time-to-death and time-to-recovery stratified by tuberculosis status, and differences in survival were assessed using the Wilcoxon test. Results: The risk of death in COVID-19 patients with tuberculosis was 2.17 times higher than in those without (95% CI: 1.40-3.37). The risk of recovery in COVID-19 patients with tuberculosis was 25% lower than in those without (RR=0.75, 95% CI 0.63-0.91). Similarly, time-to-death was significantly shorter (p=0.0031) and time-to-recovery significantly longer in patients with tuberculosis (p=0.0046). Conclusions: Our findings show that coinfection with tuberculosis increased morbidity and mortality in COVID-19 patients. Our findings highlight the need to prioritize routine and testing services for tuberculosis, although health systems are disrupted by the heavy burden of the SARS-CoV-2 pandemic.","Sy, K. T. L.; Haw, N. J. L.; Uy, J.","https://www.medrxiv.org/content/10.1101/2020.07.22.20154575v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20154575v1?rss=1,2020-07-26,2020-07-26,,True
369,Covid-19 serology in nephrology health care workers,"Background: Chronic kidney disease patients show a high mortality in case of a SARS-CoV-2 infection. Thus, to be informed on Nephrology personnel's sero-status might be crucial for patient protection. However, limited information exists about the presence of SARS-CoV-2 antibodies in asymptomatic individuals. Methods: We examined the seroprevalence of SARS-CoV-2 IgG and IgM antibodies among health care workers of a tertiary care kidney center during the peak phase of the Covid-19 crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein based assays as well as Western blotting and a neutralization assay. Results: At baseline 60 of 235 study participants (25.5%, 95% CI: 20.4-31.5) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity/low specificity threshold in one test system. Follow-up analysis after about two weeks revealed IgG positivity in 12 (5.1%, 95% CI: 2.9-8.8) and IgM positivity in six (2.6%, 95% CI: 1.1-5.6) in at least one assay. 2.1% (95% CI: 0.8-5.0) of health care workers showed IgG nucleocapsid antibodies in at least two assays. By contrast, positive controls with proven Covid-19 showed antibody positivity among almost all test systems. Moreover, serum samples obtained from health care workers did not show SARS-CoV-2 neutralizing capacity, in contrast to positive controls. Conclusions: Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.","Reiter, T.; Pajenda, S.; Wagner, L.; Gaggl, M.; Atamaniuk, J.; Holzer, B.; Zimpernik, I.; Gerges, D.; Mayer, K.; Aigner, C.; Strassl, R.; Jansen-Skoupy, S.; Fodinger, M.; Sunder-Plassmann, G.; Schmidt, A.","https://www.medrxiv.org/content/10.1101/2020.07.21.20136218v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20136218v1?rss=1,2020-07-26,2020-07-26,,True
370,Dysregulated transcriptional responses to SARS-CoV-2 in the periphery support novel diagnostic approaches,"In order to elucidate novel aspects of the host response to SARS-CoV-2 we performed RNA sequencing on peripheral blood samples across 77 timepoints from 46 subjects with COVID-19 and compared them to subjects with seasonal coronavirus, influenza, bacterial pneumonia, and healthy controls. Early SARS-CoV-2 infection triggers a conserved transcriptomic response in peripheral blood that is heavily interferon-driven but also marked by indicators of early B-cell activation and antibody production. Interferon responses during SARS-CoV-2 infection demonstrate unique patterns of dysregulated expression compared to other infectious and healthy states. Heterogeneous activation of coagulation and fibrinolytic pathways are present in early COVID-19, as are IL1 and JAK/STAT signaling pathways, that persist into late disease. Classifiers based on differentially expressed genes accurately distinguished SARS-CoV-2 infection from other acute illnesses (auROC 0.95). The transcriptome in peripheral blood reveals unique aspects of the immune response in COVID-19 and provides for novel biomarker-based approaches to diagnosis.","McClain, M. T.; Constantine, F. J.; Henao, R.; Liu, Y.; Tsalik, E. L.; Burke, T. W.; Steinbrink, J. M.; Petzold, E.; Nicholson, B. P.; Rolfe, R.; Kraft, B. D.; Kelly, M. S.; Sempowski, G. D.; Denny, T. N.; Ginsburg, G. S.; Woods, C. W.","https://www.medrxiv.org/content/10.1101/2020.07.20.20155507v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20155507v1?rss=1,2020-07-26,2020-07-26,,True
371,Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study,"Background The number of proposed prognostic models for COVID-19, which aim to predict disease outcomes, is growing rapidly. It is not known whether any are suitable for widespread clinical implementation. We addressed this question by independent and systematic evaluation of their performance among hospitalised COVID-19 cases. Methods We conducted an observational cohort study to assess candidate prognostic models, identified through a living systematic review. We included consecutive adults admitted to a secondary care hospital with PCR-confirmed or clinically diagnosed community-acquired COVID-19 (1st February to 30th April 2020). We reconstructed candidate models as per their original descriptions and evaluated performance for their original intended outcomes (clinical deterioration or mortality) and time horizons. We assessed discrimination using the area under the receiver operating characteristic curve (AUROC), and calibration using calibration plots, slopes and calibration-in-the-large. We calculated net benefit compared to the default strategies of treating all and no patients, and against the most discriminating predictor in univariable analyses, based on a limited subset of a priori candidates. Results We tested 22 candidate prognostic models among a cohort of 411 participants, of whom 180 (43.8%) and 115 (28.0%) met the endpoints of clinical deterioration and mortality, respectively. The highest AUROCs were achieved by the NEWS2 score for prediction of deterioration over 24 hours (0.78; 95% CI 0.73-0.83), and a novel model for prediction of deterioration <14 days from admission (0.78; 0.74-0.82). Calibration appeared generally poor for models that used probability outcomes. In univariable analyses, admission oxygen saturation on room air was the strongest predictor of in-hospital deterioration (AUROC 0.76; 0.71-0.81), while age was the strongest predictor of in-hospital mortality (AUROC 0.76; 0.71-0.81). No prognostic model demonstrated consistently higher net benefit than using the most discriminating univariable predictors to stratify treatment, across a range of threshold probabilities. Conclusions Oxygen saturation on room air and patient age are strong predictors of deterioration and mortality among hospitalised adults with COVID-19, respectively. None of the prognostic models evaluated offer incremental value for patient stratification to these univariable predictors.","Gupta, R. K.; Marks, M.; Samuels, T. H. A.; Luintel, A.; Rampling, T.; Chowdhury, H.; Quartagno, M.; Nair, A.; Lipman, M.; Abubakar, I.; van Smeden, M.; Wong, W. K.; Williams, B.; Noursadeghi, M.","https://www.medrxiv.org/content/10.1101/2020.07.24.20149815v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20149815v1?rss=1,2020-07-26,2020-07-26,,True
372,COVID-19 induces a hyperactive phenotype in circulating platelets,"Background Coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has to date affected over 13.3 million globally. Although high rates of venous thromboembolism and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic risk associated with COVID-19 infection remains to be fully elucidated. Objectives Here, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and non-severe COVID-19. Methods An assessment of clinical blood parameters in patients with severe COVID-19 disease (requiring intensive care), patients with non-severe disease (not requiring intensive care), general medical in-patients without COVID-19 and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis. Results We show that routine clinical blood parameters including increased MPV and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit admission. Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19. Conclusion Distinct differences exist in routine full blood count and other clinical laboratory parameters between patients with severe and non-severe COVID-19. Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets. These data suggest that abnormal platelet reactivity may contribute to hypercoagulability in COVID-19. Further investigation of platelet function in COVID-19 may provide additional insights into the aetiology of thrombotic risk in this disease and may contribute to the optimisation of thrombosis prevention and treatment strategies.","Comer, S. P.; Cullivan, S.; Szklanna, P. B.; Weiss, L.; Cullen, S.; Kelliher, S.; Smolenski, A.; Moran, N.; Murphy, C.; Altaie, H.; Curran, J.; O'Reilly, K.; Marsh, B.; Gaine, S.; McCullagh, B.; Ni Ainle, F.; Kevane, B.; Maguire, P. B.","https://www.medrxiv.org/content/10.1101/2020.07.24.20156240v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.24.20156240v1?rss=1,2020-07-26,2020-07-26,,True
373,INDEPENDENT ASSOCIATION OF METEOROLOGICAL CHARACTERISTICS WITH INITIAL SPREAD OF COVID-19 IN INDIA,"Whether weather plays a part in the transmissibility of the novel COronaVIrus Disease-19 (COVID-19) is still not established. We tested the hypothesis that meteorological factors (air temperature, relative humidity, air pressure, wind speed and rainfall) are independently associated with transmissibility of COVID-19 quantified using the basic reproduction rate (R0). We used publicly available datasets on daily COVID-19 case counts (total n = 108,308), three-hourly meteorological data and community mobility data over a three-month period. Estimated R0 varied between 1.15-1.28. Mean daily air temperature (inversely) and wind speed (positively) were significantly associated with time dependent R0, but the contribution of countrywide lockdown to variability in R0 was over three times stronger as compared to that of temperature and wind speed combined. Thus, abating temperatures and easing lockdown may concur with increased transmissibility of COVID-19.","Kulkarni, H.; Khandait, H. V.; Narlawar, U. W.; Rathod, P. G.; Mamtani, M.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157784v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157784v1?rss=1,2020-07-26,2020-07-26,,True
374,"Covid19 2020 projection report: Germany, Israel, Italy and USA. Mid-July 2020","A notion of implied susceptible population size ISPS was introduced in the context of the SIR differential equations in Epidemiology, in a companion paper. It is the potential target population size for which the solution to the SIR equations would yield the current number of new affected cases. This notion is applied to the analysis and projection of Covid19 2020, illustrated on the data of Germany, Israel, Italy and USA.","Meilijson, I.","https://www.medrxiv.org/content/10.1101/2020.07.21.20131664v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.21.20131664v1?rss=1,2020-07-26,2020-07-26,,True
375,CoVaccine HT adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation,"The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT or Alhydrogel. CoVaccine HT induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.","Haun, B. K.; Lai, C.-Y.; Williams, C. A.; Wong, T. A. S.; Lieberman, M. M.; Pessaint, L.; Elyard, H. A.; Lehrer, A. T.","https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1?rss=1,2020-07-26,2020-07-26,,False
376,A logistic model of CoV-2 propagation,"We describe an elemental logistic model for the propagation of CoV-2 in a community and illustrate the sensitivity of the model to key parameters such as R0, the initial rate of infections per infected person, and A0 , the fraction of infected people developing neutralizing antibodies. We demonstrate the importance of the duration of immunity in the population, the development of waves of new cases of infection, and the effect of premature opening of local economies.","Weiss, R. F.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157826v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157826v1?rss=1,2020-07-26,2020-07-26,,True
377,DYNAMICS OF THE COVID-19 PANDEMICS: GLOBAL PATTERN AND BETWEEN COUNTRIES VARIATIONS,"The COVID-19 pandemic affected 203 countries between December 2019 and July 2020. The early epidemic ""wave"" affected countries which now report a few sporadic cases, achieving a stable late phase of the epidemic. Other countries are beginning their epidemic expansion phase. The objective of our study is to characterize the dynamics of the COVID-19 spread. Data science methods were applied to pandemic, focusing on the daily fatality in 24 countries with more than 2,000 deaths, our analysis kin the end retaining 14 countries that have completed a full cycle. The analysis demonstrates a COVID-19 dynamic similar in these studied countries. This 3-phase dynamic is like that of common viral respiratory infections. This pattern, however, shows variability and therefore specificity which the method categorizes into clusters of ""differentiated epidemic patterns"". Among the 5 detected clusters, 2 main ones regroup 11 of these countries, representing 65% of the world deaths (as of June 24, 2020). The pattern seems common to a very large number of countries, and congruent with that of epidemics of other respiratory syndromes, opens the hypothesis that the COVID-19 pandemic would have developed its ""natural history"" by spreading spontaneously despite the measures taken to contain it. The diversity highlighted by the classification into ""formal clusters"" suggests explanations involving the notion of demographic and geographic epicenters.","Krywyk, J.; Oettgen, W.; Messier, M.; Mulot, M.; Toubiana, L.","https://www.medrxiv.org/content/10.1101/2020.07.20.20155390v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20155390v1?rss=1,2020-07-26,2020-07-26,,True
378,Optimal Testing Strategy for the Identification of COVID-19 Infections,"The systematic identification of infectious, yet unreported, individuals is critical for the containment of the COVID-19 pandemic. We present a strategy for identifying the location, timing and extent of testing that maximizes information gain for such infections. The optimal testing strategy relies on Bayesian experimental design and forecasting epidemic models that account for time dependent interventions. It is applicable at the onset and spreading of the epidemic and can forewarn for a possible recurrence of the disease after relaxation of interventions. We examine its application in Switzerland and show that it can provide timely and systematic guidance for the effective identification of infectious individuals with finite testing resources. The methodology and the open source code are readily adaptable to countries around the world.","Chatzimanolakis, M.; Weber, P.; Arampatzis, G.; Walchli, D.; Karnakov, P.; Kicic, I.; Papadimitriou, C.; Koumoutsakos, P.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157818v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157818v1?rss=1,2020-07-26,2020-07-26,,True
379,Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats,"Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available. We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2,008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. These data imply that seroconversion, and thus infection, is likely not widespread within this population. Daily new case rates peaked in RI in late April 2020. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.","Nesbitt, D. J.; Jin, D.; Hogan, J. W.; Chan, P. A.; Simon, M. J.; Vargas, M.; King, E.; Huard, R. C.; Bandy, U.; Hillyer, C. D.; Luchsinger, L. L.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157743v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157743v1?rss=1,2020-07-26,2020-07-26,,True
380,Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19,"Background: This study is the first of its kind to assess the impact of preemptive therapeutic dose anticoagulation on mortality compared to prophylactic anticoagulation among COVID-19 patients. Its findings provide insight to clinicians regarding the management of COVID-19, particularly with the known prothrombotic state. Research Question: To determine the impact of anticoagulation on in-hospital mortality among COVID-19 positive patients with the a priori hypothesis that there would be a lower risk of in-hospital mortality with use of preemptive therapeutic over prophylactic dose enoxaparin or heparin. Study Design and Methods: Study Design: Retrospective cohort study from April 1 - April 25, 2020. The date of final follow-up was June 12, 2020. Setting: Two large, acute care hospitals in Western Connecticut. Participants: Five hundred and one inpatients were identified after discharge as 18 years or older and positive for SARS-CoV-2. The final sample size included 374 patients after applying exclusion criteria. Demographic variables were collected via hospital billing inquiries, while the clinical variables were abstracted from patients medical records. Exposure: Preemptive enoxaparin or heparin at a therapeutic or prophylactic dose. Main Outcome: In-hospital mortality. Results: When comparing preemptive therapeutic to prophylactic anticoagulation through multi-variable analysis, risk of in-hospital mortality was 2.3 times greater in patients receiving preemptive therapeutic anticoagulation (95% CI = 1.0, 4.9; p = 0.04). Interpretation: An increase in in-hospital mortality was observed with preemptive therapeutic anticoagulation. Thus, in the management of COVID-19 and its complications, we recommend further research and cautious use of preemptive therapeutic over prophylactic anticoagulation.","Motta, J. K.; Ogunnaike, R. O.; Shah, R.; Stroever, S.; Cedeno, H. V.; Thapa, S. K.; Chronakos, J. J.; Jimenez, E. J.; Petrini, J.; Hegde, A.","https://www.medrxiv.org/content/10.1101/2020.07.20.20147769v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20147769v1?rss=1,2020-07-26,2020-07-26,,True
381,A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease,"Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking. Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days. Results The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported. Conclusions Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure prophylaxis for Covid-19.","Mitja, O.; Ubals, M.; Corbacho, M.; Alemany, A.; Suner, C.; Tebe, C.; Tobias, A.; Penafiel, J.; Ballana, E.; Perez, C. A.; Admella, P.; Riera-Marti, N.; Laporte, P.; Mitja, J.; Clua, M.; Bertran, L.; Gavilan, S.; Ara, J.; Sarquella, M.; Argimon, J. M.; Cuatrecasas, G.; Canadas, P.; Elizalde-Torrent, A.; Fabregat, R.; Farre, M.; Forcada, A.; Flores-Mateo, G.; Lopez, C.; Muntada, E.; Nadal, N.; Narejos, S.; Gil-Ortega, A. N.; Prat, N.; Puig, J.; Quinones, C.; Ramirez-Viaplana, F.; Reyes-Uruena, J.; Riveira-Munoz, E.; Ruiz, L.; Sanz, S.; Sentis, A.; Sierra, A.; Velasco, C.; Vivanco-Hidalgo, R. M.; Zamora, J.; Casabona, J.; Vall-Mayans, M.; G-Beiras, C.; Clotet, B.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157651v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157651v1?rss=1,2020-07-26,2020-07-26,,True
382,High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2,"Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Heterologous polyclonal antibodies of animal origin have been used to fight against infectious agents and are a possible alternative to the use of CP in SARS-CoV-2 disease. However, heterologous polyclonal antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrate epitopes, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal alpha1,3-galactose (a-Gal), ultimately forming immune complexes and potentially leading to serum sickness or allergy. To circumvent these drawbacks, we engineered animals lacking the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and alpha1,3-galactosyltransferase (GGTA1) enzymes to produce glyco-humanized polyclonal antibodies (GH-pAb) lacking Neu5Gc and a-Gal epitopes. We also found that these IgG Fc domains fail to interact with human Fc receptors and thereby should confer the safety advantage to avoiding macrophage dependent exacerbated inflammatory responses or elicit antibody-dependent enhancement (ADE), two drawbacks possibly associated with antibody responses against SARS-CoV-2. Therefore, we immunized CMAH/GGTA1 double knockout (DKO) pigs with the SARS-CoV-2 spike receptor binding domain (RBD) domain to elicit neutralizing antibodies. Animals rapidly developed hyperimmune sera with end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10,000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized Spike/ACE-2 interaction at a concentration < 1microgram/mL and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. These data and the accumulating safety advantages of using glyco-humanized swine antibodies in humans warrant clinical assessment of XAV-19 to fight against COVID-19.","Vanhove, B.; Duvaux, O.; Rousse, J.; Royer, P.-J.; Evanno, G.; Ciron, C.; Lheriteau, E.; Vacher, L.; Gervois, N.; Oger, R.; Jacques, Y.; Salama, A.; Duchi, R.; Perota, A.; Delahaut, P.; Ledure, M.; Paulus, M.; So, R.; Mok, C. K. P.; Bruzzone, R.; Bouillet, M.; Brouard, S.; Cozzi, E.; Galli, C.; Blanchard, D.; Bach, J.-M.; Soulillou, J.-P.","https://www.biorxiv.org/content/10.1101/2020.07.25.217158v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.217158v1?rss=1,2020-07-25,2020-07-25,,False
383,Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters through the airways and infects the lungs, causing lethal pulmonary damage in vulnerable patients. This virus contains spike proteins on its envelope that binds to human angiotensin-converting enzyme 2 (hACE2) expressed on the surface of airway cells, enabling entry of the virus for causing infection1,2. In severe cases, the virus enters the circulatory system, contributing to multiorgan failure. Soluble form of hACE2 binds to SARS-CoV-2 spike protein and prevents viral entry into target cells3. Moreover, soluble recombinant ACE2 ameliorates lung injury4 but its short half-life limits its therapeutic utility5. Here, we engineered synthetic mRNA to encode a soluble form of hACE2 (hsACE2) to prevent viral infection. Novel lipid nanoparticles (LNPs) were used to package mRNA and transfect mammalian cells for enhanced production of secreted proteins. Intravenously administered LNP led to hepatic delivery of the mRNA. This elicited secretion of hsACE2 into the blood circulation within 2 h, and levels of circulating hsACE2 peaked at 6 h and gradually decreased over several days. Since the primary site of entry and pathogenesis for SARS-CoV-2 is the lungs, we instilled LNPs into the lungs and were able to detect hsACE2 in the bronchoalveolar lavage fluid within 24 h and lasted for 48 h. Through co-immunoprecipitation, we found that mRNA-generated hsACE2 was able to bind with the receptor binding domain of the SARS-CoV-2 spike protein. Furthermore, hsACE2 was able to strongly inhibit (over 90%) SARS-CoV-2 pseudovirus infection. Our proof of principle study shows that mRNA-based nanotherapeutics can be potentially deployed for pulmonary and extrapulmonary neutralization of SARS-CoV-2 and open new treatment opportunities for COVID-19.","Kim, J.; Mukherjee, A.; Nelson, D.; Jozic, A.; Sahay, G.","https://www.biorxiv.org/content/10.1101/2020.07.24.205583v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.205583v1?rss=1,2020-07-25,2020-07-25,,False
384,SARS-CoV-2 differs from SARS-CoV in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is not inhibited by Bromhexine,"The SARS-Coronavirus-2 (SARS-CoV-2) infects cells through interaction of its spike protein (SARS-CoV-2-S) with the ACE2 receptor and activation by proteases, in particular TMPRSS2. Viruses can also spread through fusion of infected with uninfected cells. We therefore analyzed cell-cell fusion activity of SARS-CoV-2-S with regard to the requirements for ACE2 expression, proteolytic activation, and sensitivity to inhibitors and compared it to SARS-CoV-S. We compared S-protein-driven fusion with target cells recombinantly overexpressing ACE2, TMPRSS2, or both. SARS-CoV-2-S-driven fusion was moderately increased by TMPRSS2 and strongly by ACE2, while the reverse observation was made for SARS-CoV-S. TMPRSS2-mediated effects were inhibited by the serine protease inhibitor Camostat. Effector-target-cell fusion by SARS-CoV-2-S was only affected by Camostat when receptor expression was limiting or when the S1/S2 cleavage site was mutated. Mutational ablation of the SARS-CoV-2-S S2 cleavage site abrogated any effects of TMPRSS2 on fusion. Mutation of the SARS-CoV-2-S S1/S2 cleavage site reduced effector-target-cell fusion when ACE2 or TMPRSS2 were limiting. When both factors were abundant, initial target-effector-cell fusion was unaltered, but syncytia remained smaller over time. Overall, its polybasic cleavage site renders SARS-CoV-2-S-mediated cell-cell fusion less dependent on TMPRSS2 activity on target cells. Unexpectedly, we observed enhancement of SARS-CoV-2-S-mediated fusion by Bromhexine, another TMPRSS2 inhibitor. This effect required intact proteolytic cleavage sites, suggesting interference of Bromhexine with proteolytic priming, but not in a therapeutically desired way. Infection with SARS-CoV-2-S-pseudotyped particles clearly differed in the requirements for proteolytic activation from cell-cell fusion. TMPRSS2 strongly enhanced infection, which was reversed by Camostat but not by Bromhexine.

IMPORTANCECell-cell fusion allows the virus to infect additional target cells without the need to produce free virus. Fusion likely also contributes to tissue damage by creating virus-infected syncytia. Our results demonstrate that the S2 cleavage site is essential for activation by TMPRSS2 in trans and unravel important differences between SARS-CoV and SARS-CoV-2. Bromhexine, an inhibitor of the TMPRSS2 protease, is currently tested in clinical trials against COVID-19. Our results indicate that Bromhexine does not inhibit SARS-CoV-2-S-mediated particle entry and enhances fusion. We therefore caution against overly optimistic use of Bromhexine in higher dosage in clinical trials or as a therapy, at least until its effects on SARS-CoV-2 spike activation are better understood. The related compound Ambroxol, which similar to Bromhexine is clinically used as an expectorant, did not exhibit activating effects on SARS-CoV-2-S-mediated fusion and may therefore currently represent a better choice in therapeutic regimens for COVID-19.","Hornich, B. F.; Grosskopf, A. K.; Schlagowski, S.; Tenbusch, M.; Neipel, F.; Hahn, A. S.","https://www.biorxiv.org/content/10.1101/2020.07.25.221135v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.221135v1?rss=1,2020-07-25,2020-07-25,,False
385,-Coronaviruses use lysosomal organelles for cellular egress.,"{beta}-Coronaviruses are a family of positive-strand enveloped RNA viruses that include the severe acute respiratory syndrome-CoV2 (SARS-CoV2). While much is known regarding their cellular entry and replication pathways, their mode of egress remains uncertain; however, this is assumed to be via the biosynthetic secretory pathway by analogy to other enveloped viruses. Using imaging methodologies in combination with virus-specific reporters, we demonstrate that {beta}-Coronaviruses utilize lysosomal trafficking for egress from cells. This pathway is regulated by the Arf-like small GTPase Arl8b; thus, virus egress is insensitive to inhibitors of the biosynthetic secretory pathway. Coronavirus infection results in lysosome deacidification, inactivation of lysosomal degradation and disruption of antigen presentation pathways. This coronavirus-induced exploitation of lysosomes provides insights into the cellular and immunological abnormalities observed in patients and suggests new therapeutic modalities.","Altan-Bonnet, N.; Altan-Bonnet, G. Y.; Ghosh, S.; Dellibovi-Ragheb, T.; Pak, E.; Qiu, Q.; Fisher, M.; Takvorian, P.; Bleck, C.; Hsu, V.; Fehr, A.; Perlman, S.; Straus, M.; Whittaker, G.; de Haan, C. A.","https://www.biorxiv.org/content/10.1101/2020.07.25.192310v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.25.192310v1?rss=1,2020-07-25,2020-07-25,,False
386,Confirmed and Unreported COVID-19 Death Counts: An Assessment of Reporting Discrepancy,"Objective: To assess the reporting discrepancy between officially confirmed COVID-19 death counts and unreported COVID-19-like illness (CLI) death counts. Study Design: The study is based on secondary time-series data. Methods: We used publicly available data to explore the differences between confirmed COVID-19 death counts and deaths with probable COVID-19 symptoms in Bangladesh between March 8, 2020, and July 18, 2020. Both tabular analysis and statistical tests were performed. Results: During the week ending May 9, 2020, the unreported CLI death count was higher than the confirmed COVID-19 death count; however, it was lower in the following weeks. On average, unreported CLI death counts were almost equal to the confirmed COVID-19 death counts during the study period. However, the reporting authority neither considers CLI deaths nor adjusts for potential seasonal influenza-like illness or other related deaths, which might produce incomplete and unreliable COVID-19 data and respective mortality rates. Conclusions: Deaths with probable COVID-19 symptoms needs to be included in provisional death counts in order to estimate an accurate COVID-19 mortality rate and to offer data-driven pandemic response strategies. An urgent initiative is needed to prepare a comprehensive guideline for reporting COVID-19 deaths.","Ahamad, M. G.; Tanin, F.","https://www.medrxiv.org/content/10.1101/2020.07.20.20158139v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20158139v1?rss=1,2020-07-25,2020-07-25,,True
387,Factors Associated with COVID-19 Mitigation Behavior among US Adults,"In January 2020, the US declared the coronavirus outbreak a public health emergency and subsequently the CDC issued guidelines for personal mitigation behavior, such as mask-wearing, hand-washing, and social-distancing. We examine individual socio-economic factors that potentially predict mitigation compliance using public data. We hypothesize that health risk factors, presence of symptoms, and psychological wellbeing predict mitigation behavior. Understanding what factors are associated with mitigation behavior will be important for policy makers in their efforts to curb the COVID-19 pandemic. The pandemic prompted strong mitigation behavior by adults, especially among females, non-whites, urban dwellers, and the psychological unwell. Other positive predictors were post-secondary education and higher income. Health symptoms and clinical risk factors did not predict increased mitigation practices, nor did age 65+ and proximity to infected persons. Our study findings are congruent with a report that pointed to a lack of increased pandemic mitigation practices in households with confirmed infections and health risks. Our results also point to lower levels of psychological resilience, lower socio-economic status, and non-urban location as potential explanatory factors for lack of mitigation behavior.","Lemke, D.; Lemke, K.","https://www.medrxiv.org/content/10.1101/2020.07.20.20157925v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.20.20157925v1?rss=1,2020-07-25,2020-07-25,,True
388,"Clustering, diffusion and evolution of COVID19 infections during lock-down","Epidemics such as the spreading of COVID19-virus are highly non linear, and therefore difficult to predict. In the present pandemy as time evolves, it appears more and more clearly that a clustered dynamics is a key element of description. This means that the disease rapidly evolves within spatially localized networks, that diffuse and eventually create new clusters. We improve upon the simplest possible compartmental model, the SIR model, by adding an additional compartment associated with the clustered individuals. The so-obtained SBIR model compares satisfactorily with results on the pandemic propagation in a number of European countries, during and immediately after lock-down. Especially, the decay exponent of the number of new cases after the first peak of the epidemic, is observed to be very similar for countries in which a strict lock-down is applied. We derive an analytical expression for the value of this exponent, relating it to the initial exponential growth phase of the epidemic and to the time-scale of cluster-diffusion.","Bos, W.; Bertoglio, J.-P.; Gostiaux, L.","https://www.medrxiv.org/content/10.1101/2020.07.22.20159830v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20159830v1?rss=1,2020-07-25,2020-07-25,,True
389,Adopting STING agonist cyclic dinucleotides as a potential adjuvant for SARS-CoV-2 vaccine,"A novel STING agonist CDGSF unilaterally modified with phosphorothioate and fluorine was synthesized. CDGSF displayed better STING activity over dithio CDG. Immunization of SARS-CoV-2 Spike protein with CDGSF as an adjuvant elicited an exceptional high antibody titer and a robust T cell response, which were better than the group using aluminium hydroxide as a adjuvant. These results highlighted the adjuvant potential of STING agonist in SARS-CoV-2 vaccine preparation for the first time.","Wu, J.-J.; Chen, Y.-X.; Li, Y.-M.","https://www.biorxiv.org/content/10.1101/2020.07.24.217570v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.217570v1?rss=1,2020-07-24,2020-07-24,,False
390,The answer lies in the energy: how simple atomistic molecular dynamics simulations may hold the key to epitope prediction on the fully glycosylated SARS-CoV-2 spike protein,"Betacoronavirus SARS-CoV-2 is posing a major threat to human health and its diffusion around the world is having dire socioeconomical consequences. Thanks to the scientific communitys unprecedented efforts, the atomic structure of several viral proteins has been promptly resolved. As the crucial mediator of host cell infection, the heavily glycosylated trimeric viral Spike protein (S) has been attracting the most attention and is at the center of efforts to develop antivirals, vaccines, and diagnostic solutions.

Herein, we use an energy-decomposition approach to identify antigenic domains and antibody binding sites on the fully glycosylated S protein. Crucially, all that is required by our method are unbiased atomistic molecular dynamics simulations; no prior knowledge of binding properties or ad hoc combinations of parameters/measures extracted from simulations is needed. Our method simply exploits the analysis of energy interactions between all intra-protomer aminoacid and monosaccharide residue pairs, and cross-compares them with structural information (i.e., residueresidue proximity), identifying potential immunogenic regions as those groups of spatially contiguous residues with poor energetic coupling to the rest of the protein.

Our results are validated by several experimentally confirmed structures of the S protein in complex with anti- or nanobodies. We identify poorly coupled sub-domains: on the one hand this indicates their role in hosting (several) epitopes, and on the other hand indicates their involvement in large functional conformational transitions. Finally, we detect two distinct behaviors of the glycan shield: glycans with stronger energetic coupling are structurally relevant and protect underlying peptidic epitopes; those with weaker coupling could themselves be poised for antibody recognition. Predicted Immunoreactive regions can be used to develop optimized antigens (recombinant subdomains, synthetic (glyco)peptidomimetics) for therapeutic applications.","Serapian, S.; Marchetti, F.; Triveri, A.; Morra, G.; Meli, M.; Moroni, E.; Sautto, G. A.; Rasola, A.; Colombo, G.","https://www.biorxiv.org/content/10.1101/2020.07.22.214254v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.214254v1?rss=1,2020-07-24,2020-07-24,,False
391,Single-cell landscape of immunological responses in COVID-19 patients,"In COVID-19 caused by SARS-CoV-2 infection, the relationship between disease severity and the host immune response is not fully understood. Here we performed single-cell RNA sequencing in peripheral blood samples of five healthy donors and 13 COVID-19 patients including moderate, severe and convalescent cases. Through determining the transcriptional profiles of immune cells, coupled with assembled T cell receptor and B cell receptor sequences, we analyzed the functional properties of immune cells. Most cell types in COVID-19 patients showed a strong interferon-alpha response, and an overall acute inflammatory response. Moreover, intensive expansion of highly cytotoxic effector T cell subsets, such as CD4+ Effector-GNLY (Granulysin), CD8+ Effector-GNLY and NKT CD160, was associated with convalescence in moderate patients. In severe patients, the immune landscape featured a deranged interferon response, profound immune exhaustion with skewed T cell receptor repertoire and broad T cell expansion. These findings illustrate the dynamic nature of immune responses during the disease progression.","Wang, F.-S.; Zhang, J.-Y.; Wang, X.; Xing, X.; Xu, Z.; Zhang, C.; Song, J.-W.; Fan, X.; Xia, P.; Fu, J.-L.; Wang, S.-Y.; Xu, R.-N.; Dai, X.-P.; Shi, L.; Huang, L.; Jiang, T.-J.; Shi, M.; Zhang, Y.; Zumla, A.; Maeurer, M.; Bai, F.","https://www.biorxiv.org/content/10.1101/2020.07.23.217703v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217703v1?rss=1,2020-07-24,2020-07-24,,False
392,Elucidation of cryptic and allosteric pockets within the SARS-CoV-2 protease,"The SARS-CoV-2 pandemic has rapidly spread across the globe, posing an urgent health concern. Many quests to computationally identify treatments against the virus rely on in silico small molecule docking to experimentally determined structures of viral proteins. One limit to these approaches is that protein dynamics are often unaccounted for, leading to overlooking transient, druggable conformational states. Using Gaussian accelerated molecular dynamics to enhance sampling of conformational space, we identified cryptic pockets within the SARS-CoV-2 main protease, including some within regions far from the active site and assed their druggability. These pockets can aid in virtual screening efforts to identify a protease inhibitor for the treatment of COVID-19.

O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY","Sztain, T.; Amaro, R. E.; McCammon, J. A.","https://www.biorxiv.org/content/10.1101/2020.07.23.218784v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.218784v1?rss=1,2020-07-24,2020-07-24,,False
393,"An in-silico study on SARS-CoV-2: Its compatibility with human tRNA pool, and the polymorphism arising in a single lineage over a month","SARS-CoV-2 has caused a global pandemic that has costed enormous human lives in the recent past. The present study is an investigation of the viral codon adaptation, ORFs stability and tRNA co-adaptation with humans. We observed that for the codon usage bias in viral ssRNA, ORFs have near values of folding free energies and codon adaptation index with mRNAs of the human housekeeping CDS. However, the correlation between the stability of the ORFs in ssRNA and CAI is stronger than the mRNA stability and CAI of HKG, suggesting a greater expression capacity of SARS-CoV-2. Mutational analysis reflects polymorphism in the virus for ORF1ab, surface glycoprotein and nucleocapsid phosphoprotein ORFs. Non-synonymous mutations have shown non-polar substitutions. Out of the twelve mutations nine are for a higher t-RNA copy number. Viruses in general have high mutation rates. To understand the chances of survival for the mutated SARS-CoV-2 we did simulation for synonymous mutations. It resulted in 50% ORFs with higher stability than their native equivalents. Thus, considering only the synonymous mutations the virus can exhibit a lot of polymorphism. Collectively our data provides new insights for SARS-CoV-2 mutations and the human t-RNA compatibility.

SignificanceSurvivability of SARS-CoV-2 in humans is essential for its spread. It has overlapping genes exhibiting a high codon optimization with humans even after a higher codon usage bias. They seem to possess cognizance for high copy number t-RNA (cognate or near-cognate) in humans, while mutating. Even though, it has been well established that native transcripts posses the highest stability, our in-silico studies show that SARS-CoV-2 under mutations give rise to ORFs with higher stability. These results significantly present the viruss ability and the credibility of survival for the mutants. Despite its focus on a geographical location it explains the ongoing behavior of SARS-CoV-2 for a steady existence in humans as all the different lineages have a common origin. Wuhan, China.","Victor, M.; Das, R.; Ghosh, T.","https://www.biorxiv.org/content/10.1101/2020.07.23.217083v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217083v1?rss=1,2020-07-24,2020-07-24,,False
394,"Identification, Mapping and Relative Quantitation of SARS-Cov2 Spike Glycopeptides by Mass-Retention Time Fingerprinting","We describe a novel analytical method for rapid and robust identification, mapping and relative quantitation of glycopeptides from SARS-CoV-2 Spike protein. The method may be executed using any LC-TOF mass spectrometer, requires no specialised knowledge of glycan analysis and makes use of the differential resolving power of reversed phase HPLC. While this separation technique resolves peptides with high efficiency, glycans are resolved poorly, if at all. Consequently, glycopeptides consisting of the same peptide bearing different glycan structures will all possess very similar retention times and co-elute. While this has previously been viewed as a disadvantage, we show that shared retention time can be used to map multiple glycan species to the same peptide and location. In combination with MSMS and pseudo MS3, we have constructed a detailed mass-retention time database for Spike. This database allows any ESI-TOF equipped lab to reliably identify and quantify spike glycans from a single overnight elastase protein digest in less than 90 minutes.","Chalk, R.; Greenland, W.; Moreira, T.; Coker, J.; Mukhopadhyay, S.; Williams, E.; Manning, C.; Bohstedt, T.; McCrorie, R.; Fernandez-Cid, A.; Burgess-Brown, N. A.","https://www.biorxiv.org/content/10.1101/2020.07.24.217562v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.217562v1?rss=1,2020-07-24,2020-07-24,,False
395,Immuno-informatics approach for multi-epitope vaccine designing against SARS-CoV-2,"The novel Corona Virus Disease (COVID-19) pandemic has spread a blaze of increasing fatality rates across the world. The dearth of potential vaccines has left the survival of mankind with doubts. The development of multi-epitope vaccine in this current situation could be a possible COVID treatment. We have designed a novel multi-epitope, multi-protein vaccine with different proteins of Severe Acute Respiratory Syndrome - Corona Virus -2 (SARS-CoV-2) with immuno-informatics approaches, which has been validated in silico to be stable and potential. It has been prepared with Cytotoxic T-cell (TC) and Helper T-cell (TH) binding epitopes overlapping with B-cell binding epitopes predicted for 6 proteins conserved among 4 different viral strains isolated across the world. Both the humoral and cell-mediated immune responses are ensured due to the presence of T cell and B-cell inducing epitopes along with interferon-gamma inducing epitopes present in the vaccine. The final vaccine construct comprises of an adjuvant at the N terminal, Cytotoxic T Lymphocyte and Helper T Lymphocyte epitopes. The construct showed potential antigenicity and was non-allergic. The molecular docking of the refined, validated tertiary structure model of the vaccine was performed with immune-stimulatory Toll Like Receptors (TLR), TLR-2,3,4. The study of binding energetics of the docked complexes revealed binding interactions of receptor with vaccine. The immune simulation of the vaccine even confirmed the initiation of elevated host immune responses. The efficient translation of the vaccine in an expression vector was confirmed with in silico cloning approach. Certainly, the development of such vaccine candidate could possibly be an effective therapy for COVID-19.","Banerjee, S.; Majumder, K.; Gutierrez, G. J.; Gupta, D.; Mittal, B.","https://www.biorxiv.org/content/10.1101/2020.07.23.218529v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.218529v1?rss=1,2020-07-24,2020-07-24,,False
396,Tissue-specific and interferon-inducible expression of non-functional ACE2 through endogenous retrovirus co-option,"Angiotensin-converting enzyme 2 (ACE2) is an entry receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), as well as a regulator of several physiological processes. ACE2 has recently been proposed to be interferon-inducible, suggesting that SARS-CoV-2 may exploit this phenomenon to enhance viral spread and questioning the efficacy of interferon treatment in Coronavirus disease 2019 (COVID-19). Using a recent de novo transcript assembly that captured previously unannotated transcripts, we describe a novel isoform of ACE2, generated by co-option of an intronic long terminal repeat (LTR) retroelement promoter. The novel transcript, termed LTR16A1-ACE2, exhibits specific expression patterns across the aerodigestive and gastrointestinal tracts and, importantly, is highly responsive to interferon stimulation. In stark contrast, expression of canonical ACE2 is completely unresponsive to interferon stimulation. Moreover, the LTR16A1-ACE2 translation product is a truncated, unstable ACE2 form, lacking domains required for SARS-CoV-2 binding and therefore unlikely to contribute to or enhance viral infection.","Ng, K.; Attig, J.; Bolland, W.; Young, G.; Major, J.; Wack, A.; Kassiotis, G.","https://www.biorxiv.org/content/10.1101/2020.07.24.219139v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.219139v1?rss=1,2020-07-24,2020-07-24,,False
397,Co-expression of Mitochondrial Genes and ACE2 in Cornea Involved in COVID-19 Infection,"The Coronavirus disease 2019 (COVID-19) pandemic severely challenges public health and necessitates the need for increasing our understanding of COVID-19 pathogenesis, especially host factors facilitating virus infection and propagation. Here, the co-expression network was constructed by mapping the well-known ACE2, TMPRSS2 and host susceptibility genes implicated in COVID-19 GWAS onto a cornea, retinal pigment epithelium and lung. We found a significant co-expression module of these genes in the cornea, revealing that cornea is potential extra-respiratory entry portal of SARS-CoV-2. Strikingly, both co-expression and interaction networks show a significant enrichment in mitochondrial function, which are the hub of cellular oxidative homeostasis, inflammation and innate immune response. We identified a corneal mitochondrial susceptibility module (CMSM) of 14 mitochondrial genes by integrating ACE2 co-expression cluster and SARS-CoV-2 interactome. Gene ECSIT, as a cytosolic adaptor protein involved in inflammatory responses, exhibits the strongest correlation with ACE2 in CMSM, which has shown to be an important risk factor for SARS-CoV-2 infection and prognosis. Our co-expression and protein interaction network analysis uncover that the mitochondrial function related genes in cornea contribute to the dissection of COVID-19 susceptibility and potential therapeutic interventions.","Yuan, J.; Fan, d.; Xue, Z.; Qu, J.; Su, J.","https://www.biorxiv.org/content/10.1101/2020.07.23.216770v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.216770v1?rss=1,2020-07-24,2020-07-24,,False
398,Host transcriptional responses and SARS-CoV-2 isolates from the nasopharyngeal samples of Bangladeshi COVID-19 patients,"As the COVID-19 pandemic progresses, fatality and cases of new infections are also increasing at an alarming rate. SARS-CoV-2 follows a highly variable course and it is becoming more evident that individuals immune system has a decisive influence on the progression of the disease. However, the detailed underlying molecular mechanisms of the SARS-CoV-2 mediate disease pathogenesis are largely unknown. Only a few host transcriptional responses in COVID-19 have been reported so far from the Western world, but no such data has been generated from the South-Asian region yet to correlate the conjectured lower fatality around this part of the globe. In this context, we aimed to perform the transcriptomic profiling of the COVID-19 patients from Bangladesh along with the reporting of the SARS-CoV-2 isolates from these patients. Moreover, we performed a comparative analysis to demonstrate how differently the various SARS-CoV-2 infection systems are responding to the viral pathogen. We detected a unique missense mutation at 10329 position of ORF1ab gene, annotated to 3C like proteinase, which is found in 75% of our analyzed isolates; but is very rare globally. Upon the functional enrichment analyses of differentially modulated genes, we detected a similar host induced response reported earlier; this response was mainly mediated by the innate immune system, interferon stimulation, and upregulated cytokine expression etc. in the Bangladeshi patients. Surprisingly, we did not perceive the induction of apoptotic signaling, phagosome formation, antigen presentation and production, hypoxia response within these nasopharyngeal samples. Furthermore, while comparing with the other SARS-CoV-2 infection systems, we spotted that lung cells trigger the more versatile immune and cytokine signaling which was several folds higher compared to our reported nasopharyngeal samples. We also observed that lung cells did not express ACE2 in a very high amount as suspected, however, the nasopharyngeal cells are found overexpressing ACE2. But the amount of DPP4 expression within the nasal samples was significantly lower compared to the other cell types. Surprisingly, we observed that lung cells express a very high amount of integrins compared to the nasopharyngeal samples, which might suggest the putative reasons for an increased amount of viral infections in the lungs. From the network analysis, we got clues on the probable viral modulation for the overexpression of these integrins. Our data will provide valuable insights in developing potential studies to elucidate the roles of ethnicity effect on the viral pathogenesis, and incorporation of further data will enrich the search of an effective therapeutics.","Islam, A. B. M. M. K.; Khan, M. A.-A.-K.; Ahmed, R.; Hossain, M. S.; Kabir, S. M. T.; Islam, M. S.; Siddiki, A. M. A. M. Z.","https://www.biorxiv.org/content/10.1101/2020.07.23.218198v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.218198v1?rss=1,2020-07-24,2020-07-24,,False
399,Homebound by COVID19: The Benefits and Consequences of Non-Pharmaceutical Intervention Strategies,"Objectives. To evaluate the tradeoffs between potential benefits (e.g., reduction in infection spread and deaths) of non-pharmaceutical interventions for COVID19 and being homebound (i.e., refraining from community/workplace interactions). Methods. An agent-based simulation model to project the disease spread and estimate the number of homebound people and person-days under multiple scenarios, including combinations of shelter-in-place, voluntary quarantine, and school closure in Georgia from March 1 to September 1, 2020. Results. Compared to no intervention, under voluntary quarantine, voluntary quarantine with school closure, and shelter-in-place with school closure scenarios 3.43, 19.8, and 200+ homebound adult-days were required to prevent one infection, with the maximum number of adults homebound on a given day in the range of 121K-268K, 522K-567K, 5,377K-5,380K, respectively. Conclusions. Voluntary quarantine combined with school closure significantly reduced the number of infections and deaths with a considerably smaller number of homebound person-days compared to shelter-in-place.","Oruc Aglar, B. E.; Baxter, A.; Keskinocak, P.; Asplund, J.; Serban, N.","https://www.medrxiv.org/content/10.1101/2020.07.22.20160085v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.07.22.20160085v1?rss=1,2020-07-24,2020-07-24,,True
400,PACIFIC: A lightweight deep-learning classifier of SARS-CoV-2 and co-infecting RNA viruses,"Viral co-infections occur in COVID-19 patients, potentially impacting disease progression and severity. However, there is currently no dedicated method to identify viral co-infections in patient RNA-seq data. We developed PACIFIC, a deep-learning algorithm that accurately detects SARS-CoV-2 and other common RNA respiratory viruses from RNA-seq data. Using in silico data, PACIFIC recovers the presence and relative concentrations of viruses with >99% precision and recall. PACIFIC accurately detects SARS-CoV-2 and other viral infections in 63 independent in vitro cell culture and patient datasets. PACIFIC is an end-to-end tool that enables the systematic monitoring of viral infections in the current global pandemic.","Acera Mateos, P.; Balboa, R. F.; Easteal, S.; Eyras, E.; Patel, H. R.","https://www.biorxiv.org/content/10.1101/2020.07.24.219097v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.219097v1?rss=1,2020-07-24,2020-07-24,,False
401,High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme,"There are currently no approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12-15 kDa single-domain antibody fragments that are more stable and amenable to large-scale production compared to conventional antibodies. Nanobodies can also be administered in an inhaled form directly to the lungs. We have isolated several nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) receptor. The SARS-CoV-2 spike protein is responsible for viral entry into human cells via interaction with ACE2 on the cell surface. The lead therapeutic candidate, NIH-CoVnb-112, binds to the SARS-CoV-2 spike protein receptor binding domain at approximately 5 nM affinity, and blocks spike protein interaction with the human ACE2 receptor at approximately 0.02 micrograms/mL EC50 (1.1 nM). The affinity and blocking potency of NIH-CoVnb-112 are substantially better than previously reported candidate nanobody therapeutics for SARS-CoV-2, and bind to a distinct site. Furthermore, NIH-CoVnb-112 blocks interaction between ACE2 and several high affinity variant forms of the spike protein. When multimerized or combined with other nanobodies, the effective affinity and blocking interactions may be even more potent, as has been well described for other nanobody therapeutics. These resulting nanobodies have therapeutic, preventative, and diagnostic potential.","Esparza, T. J.; Brody, D. L.","https://www.biorxiv.org/content/10.1101/2020.07.24.219857v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.24.219857v1?rss=1,2020-07-24,2020-07-24,,False
402,SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 is expressed in human pancreatic islet -cells and is upregulated by inflammatory stress,"Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data highlighting an association between COVID-19 and diabetes, a detailed analysis aimed at evaluating ACE2 expression pattern distribution in human pancreas is still lacking. Here, we took advantage of INNODIA network EUnPOD biobank collection to thoroughly analyse ACE2, both at mRNA and protein level, in multiple human pancreatic tissues and using several methodologies. We showed that ACE2 is indeed present in human pancreatic islets, where is preferentially expressed by insulin producing {beta}-cells. Of note, pro-inflammatory cytokines increased ACE2 expression in {beta}-cells, thus putatively suggesting an enhancement of {beta}-cells sensitivity to SARS-CoV-2 during inflammatory conditions. Taken together, our data indicate a potential link between SARS-CoV-2 infection and diabetes, through direct {beta}-cell virus tropism.

Highlights- Human pancreatic islets express SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2)
- In human pancreatic islets, ACE2 is preferentially expressed by {beta}-cells
- In human {beta}-cells, ACE2 expression is increased upon inflammatory stress","Fignani, D.; Licata, G.; Brusco, N.; Nigi, L.; Grieco, G. E.; Marselli, L.; Overbergh, L.; Gysemans, C.; Colli, M. L.; Marchetti, P.; Mathieu, C.; Eizirik, D. L.; Sebastiani, G.; Dotta, F.","https://www.biorxiv.org/content/10.1101/2020.07.23.208041v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.208041v1?rss=1,2020-07-23,2020-07-23,,False
403,Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2,"Towards the end of 2019, a novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), genetically similar to severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1), emerged in Wuhan, Hubei province of China, and has been responsible of coronavirus disease 2019 (COVID-19) in humans. Since its first report, SARS-CoV-2 has resulted in a global pandemic, with over 10 million human infections and over 560,000 deaths reported worldwide at the end of June 2020. Currently, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines and/or antivirals licensed against SARS-CoV-2, and the high economical and health impact of SARS-CoV-2 has placed global pressure on the scientific community to identify effective prophylactic and therapeutic treatments for the treatment of SARS-CoV-2 infection and associated COVID-19 disease. While some compounds have been already reported to reduce SARS-CoV-2 infection and a handful of monoclonal antibodies (mAbs) have been described that neutralize SARS-CoV-2, there is an urgent need for the development and standardization of assays which can be used in high through-put screening (HTS) settings to identify new antivirals and/or neutralizing mAbs against SARS-CoV-2. Here, we described a rapid, accurate and highly reproducible plaque reduction microneutralization (PRMNT) assay that can be quickly adapted for the identification and characterization of both neutralizing mAbs and antivirals against SARS-CoV-2. Importantly, our MNA is compatible with HTS settings to interrogate large and/or complex libraries of mAbs and/or antivirals to identify those with neutralizing and/or antiviral activity, respectively, against SARS-CoV-2.","Oark, J.-G.; Oladduni, F. S.; Chiem, K.; Ye, C.; Pipenbrink, M.; Moran, T.; Walter, M.; Kobie, J.; Martinez-Sobrido, L.","https://www.biorxiv.org/content/10.1101/2020.07.22.216648v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.216648v1?rss=1,2020-07-23,2020-07-23,,False
404,From people to Panthera: Natural SARS-CoV-2 infection in tigers and lions at the Bronx Zoo,"We describe the first cases of natural SARS-CoV-2 infection detected in animals in the United States. In March 2020, four tigers and three lions at the Bronx Zoo developed mild respiratory signs. SARS-CoV-2 RNA was detected by rRT-PCR in respiratory secretions and/or feces from all seven affected animals; viral RNA and/or antibodies were detected in their keepers. SARS-CoV-2 was isolated from respiratory secretions or feces from three affected animals; in situ hybridization co-localized viral RNA with cellular damage. Whole genome sequence and haplotype network analyses showed tigers and lions were infected with two different SARS-CoV-2 strains, suggesting independent viral introductions. The source of SARS-CoV-2 infection in the lions is unknown. Epidemiological data and genetic similarities between keeper and tiger viruses indicate human to animal transmission.","McAloose, D.; Laverack, M.; Wang, L.; Killian, M. L.; Caserta, L. C.; Mitchell, P. K.; Queen, K.; Mauldin, M. R.; Cronk, B. D.; Bartlett, S. L.; Sykes, J. M.; Zec, S.; Ingerman, K.; Stokol, T.; Frederikson, R.; Delaney, M. A.; Ivancic, M.; Jenkins-Moore, M.; Mozingo, K.; Franzen, K.; Hines Bergeson, N.; Goodman, L.; Wang, H.; Wang, S.; Yuan, F.; Fang, Y.; Olmstead, C.; McCann, C.; Thomas, P.; Goodrich, E.; Elvinger, F.; Slavinski, S.; Smith, D. C.; Calle, P. P.; Terio, K.; Torchetti, M. K.; Diel, D. G.","https://www.biorxiv.org/content/10.1101/2020.07.22.213959v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.213959v1?rss=1,2020-07-23,2020-07-23,,False
405,"The new silicone N99 half-piece respirator, VJR-NMU N99: A novel and effective tool to prevent COVID-19","Filter facepiece respirators (FFRs) are critical for preventing the transmission of respiratory tract infection disease, especially the dreadful coronavirus 2 (SARs-CoV-2). The N95 mask is a prototype, high-efficiency protective device that can effectively protect against airborne pathogens of less than 0.3 m. The N95 mask is tightly fitting and has high filtration capacity. The ongoing COVID-19 pandemic has led to a greater requirement for FFR. This rising demand greatly exceeds current production capabilities and stockpiles, resulting in shortages. To address this, our team has invented a new type of half-piece respirator made from silicone and assembled with HEPA or elastostatic filter. A variety of methods have been used to evaluate this new device, including a qualitative fit test with the Bitrex(R) test kit and filtration test. The preliminary results showed that the new N99 respirators pass the fit test. The filtration tests also confirmed the superiority of N99 over traditional N95 masks, with a mean performance of protection greater than 95%. For the filters, we used two types: SafeStar, which is a kind of HEPA filter; and CareStar, which is considered an elastostatic filler. CareStar was developed to filter virus and bacteria in the operating room, with a limit duration of use up to 24 h, while the safe star was designed for 72 h use and has the quality equivalent to a HEPA filter. Our study demonstrated superior filtration efficacy of both filters, more than 98% even after 24 h of use. CareStar has significantly more filtration efficacy than a safe star (p < 0.001). In conclusion, the development of our new N99 half-piece respirator should ultimately be applicable to healthcare workers with at least non-inferiority to the previously used N 95 respirators.. Currently, the adequate supply of such equipment is not feasible. The advent of the new protective device will help protect healthcare workers and replenish the shortage of N95 respirators during the COVID-19 pandemic.","Trakarnvanich, T.; Manomaipiboon, A.; Pupipatpab, S.; Chomdee, P. C.; Boonyapatkul, P.","https://www.biorxiv.org/content/10.1101/2020.07.23.217372v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217372v1?rss=1,2020-07-23,2020-07-23,,False
406,Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy,"Dexamethasone, a widely used corticosteroid, has recently been reported as the first drug to increase the survival chances of patients with severe COVID-19. Therapeutic agents, including dexamethasone, are mostly transported through the body by binding to serum albumin. Herein, we report the first structure of serum albumin in complex with dexamethasone. We show that it binds to Drug Site 7, which is also the binding site for commonly used nonsteroidal anti-inflammatory drugs and testosterone, suggesting potentially problematic binding competition. This study bridges structural findings with our analysis of publicly available clinical data from Wuhan and suggests that an adjustment of dexamethasone regimen should be considered for patients affected by two major COVID-19 risk-factors: low albumin levels and diabetes.

One Sentence SummaryStructure of serum albumin with dexamethasone reveals why the drug may not always help COVID-19 patients.","Shabalin, I. G.; Czub, M. P.; Majorek, K. A.; Brzezinski, D.; Grabowski, M.; Cooper, D. R.; Panasiuk, M.; Chruszcz, M.; Minor, W.","https://www.biorxiv.org/content/10.1101/2020.07.21.212704v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.212704v1?rss=1,2020-07-23,2020-07-23,,False
407,Phylogeny of the COVID-19 Virus SARS-CoV-2 by Compression,"We analyze the phylogeny and taxonomy of the SARS-CoV-2 virus using compression. This is a new alignment-free method called the ""normalized compression distance"" (NCD) method. It discovers all effective similarities based on Kolmogorov complexity. The latter being incomputable we approximate it by a good compressor such as the modern zpaq. The results comprise that the SARS-CoV-2 virus is closest to the RaTG13 virus and similar to two bat SARS-like coronaviruses bat-SL-CoVZXC21 and bat-SL-CoVZC4. The similarity is quantified and compared with the same quantified similarities among the mtDNA of certain species. We treat the question whether Pangolins are involved in the SARS-CoV-2 virus.","Vitanyi, P. M. B.; Cilibrasi, R. L.","https://www.biorxiv.org/content/10.1101/2020.07.22.216242v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.216242v1?rss=1,2020-07-23,2020-07-23,,False
408,Transcriptional response modules characterise IL-1 and IL-6 activity in COVID-19,"Dysregulated IL-1 and IL-6 responses have been implicated in the pathogenesis of severe Coronavirus Disease 2019 (COVID-19). Innovative approaches for evaluating the biological activity of these cytokines in vivo are urgently needed to complement clinical trials of therapeutic targeting of IL-1 and IL-6 in COVID-19. We show that the expression of IL-1 or IL-6 inducible transcriptional signatures (modules) reflects the bioactivity of these cytokines in juvenile idiopathic arthritis (JIA) and rheumatoid arthritis, and discerns the effect of therapeutic cytokine blockade in JIA. In COVID-19, elevated expression of IL-1 and IL-6 response modules, but not these cytokines per se, is a feature of disease both in blood and in affected organs. We propose that IL-1 and IL-6 transcriptional response modules can provide a dynamic readout of the activity of these cytokine pathways in vivo, with potential applications for identifying COVID-19 patients who may benefit from IL-1 or IL-6 blocking therapy, and to aid quantification of the biological effects of these treatments.","Bell, L. C. K.; Noursadeghi, M.; Pollara, G.","https://www.biorxiv.org/content/10.1101/2020.07.22.202275v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.202275v1?rss=1,2020-07-23,2020-07-23,,False
409,SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan,"The aim of this study is to understand adaptive immunity to SARS-CoV-2 through the analysis of B cell epitope and neutralizing activity in coronavirus disease 2019 (COVID-19) patients. We obtained serum from thirteen COVID-19 patients. Most individuals revealed neutralizing activity against SARS-CoV-2 assessed by a pseudotype virus-neutralizing assay. The antibody production against the spike glycoprotein (S protein) or receptor-binding domain (RBD) of SARS-CoV-2 was elevated, with large individual differences, as assessed by ELISA. In the analysis of the predicted the linear B cell epitopes, two regions (671-690 aa. and 1146-1164 aa.), which were located in S1 and S2 but not in the RBD, were highly reactive with the sera from patients. In the further analysis of the B cell epitope within the S protein by utilizing a B cell epitope array, a hot spot in the N-terminal domain of the S protein but not the RBD was observed in individuals with neutralizing activity. Overall, the analysis of antibody production and B cell epitopes of the S protein from patient serum may provide a novel target for the vaccine development against SARS-CoV-2.","Yoshida, S.; Ono, C.; Hayashi, H.; Shiraishi, S.; Kazunori, T.; Arase, H.; Matsuura, Y.; Nakagami, H.","https://www.biorxiv.org/content/10.1101/2020.07.22.212761v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.212761v1?rss=1,2020-07-23,2020-07-23,,False
410,Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy,"BackgroundThe novel coronavirus (SARS-CoV-2) pandemic spread rapidly worldwide increasing exponentially in Italy. To date, there is lack of studies describing clinical characteristics of the population most at risk of infection. Hence, we aimed to identify clinical predictors of SARS-CoV-2 infection risk and to develop and validate a score predicting SARS-CoV-2 infection risk comparing it with unspecific surrogates.

MethodsRetrospective case/control study using administrative health-related database was carried out in Southern Italy (Campania region) among beneficiaries of Regional Health Service aged over than 30 years. For each subject with Covid-19 confirmed diagnosis (case), up to five controls were randomly matched for gender, age and municipality of residence. Odds ratios and 90% confidence intervals for associations between candidate predictors and risk of infection were estimated by means of conditional logistic regression. SARS-CoV-2 Infection Score (SIS), was developed by generating a total aggregate score obtained from assignment of a weight at each selected covariate using coefficients estimated from the model. Finally, the score was categorized by assigning increasing values from 1 to 4. SIS was validated by comparison with specific and unspecific predictors of SARS-CoV-2 infection.

ResultsSubjects suffering from diabetes, anaemias, Parkinsons disease, mental disorders, cardiovascular and inflammatory bowel and kidney diseases showed increased risk of SARS-CoV-2 infection. Similar estimates were recorded for men and women and younger and older than 65 years. Fifteen conditions significantly contributed to the SIS. As SIS value increases, risk progressively increases, being odds of SARS-CoV-2 infection among people with the highest SIS value (SIS=4), 1.74 times higher than those unaffected by any SIS contributing conditions (SIS=1).

ConclusionThis study identified conditions and diseases making individuals more vulnerable to SARS-CoV-2 infection. Our results are a decision-maker support tool for identifying population most at risk allowing adoption of preventive measures to minimize a potential new relapse damage.","Orlando, V.; Rea, F.; savare, L.; Guarino, I.; Mucherino, S.; Perrella, A.; Trama, U.; Coscioni, E.; Menditto, E.; Corrao, G.","https://www.biorxiv.org/content/10.1101/2020.07.23.217331v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217331v1?rss=1,2020-07-23,2020-07-23,,False
411,SARS-CoV2 genome analysis of Indian isolates and molecular modelling of D614G mutated spike protein with TMPRSS2 depicted its enhanced interaction and virus infectivity,"COVID-19 that emerged as a global pandemic is caused by SARS-CoV-2 virus. The virus genome analysis during disease spread reveals about its evolution and transmission. We did whole genome sequencing of 225 clinical strains from the state of Odisha in eastern India using ARTIC protocol-based amplicon sequencing. Phylogenetic analysis identified the presence of all five reported clades 19A, 19B, 20A, 20B and 20C in the population. The analyses revealed two major routes for the introduction of the disease in India i.e. Europe and South-east Asia followed by local transmission. Interestingly, 19B clade was found to be much more prevalent in our sequenced genomes (17%) as compared to other genomes reported so far from India. The haplogroup analysis for clades showed evolution of 19A and 19B in parallel whereas the 20B and 20C appeared to evolve from 20A. Majority of the 19A and 19B clades were present in cases that migrated from Gujarat state in India suggesting it to be one of the major initial points of disease transmission in India during month of March and April. We found that with the time 20A and 20B clades evolved drastically that originated from central Europe. At the same time, it has been observed that 20A and 20B clades depicted selection of four common mutations i.e. 241 C>T (5UTR), P323L in RdRP, F942F in NSP3 and D614G in the spike protein. We found an increase in the concordance of G614 mutation evolution with the viral load in clinical samples as evident from decreased Ct value of spike and Orf1ab gene in qPCR. Molecular modelling and docking analysis identified that D614G mutation enhanced interaction of spike with TMPRSS2 protease, which could impact the shedding of S1 domain and infectivity of the virus in host cells.","Raghav, S.; Ghosh, A.; Turuk, J.; Kumar, S.; Jha, A.; Madhulika, S.; Priyadarshini, M.; Biswas, V. K.; Shyamli, P. S.; Singh, B.; Singh, N.; Singh, D.; Kiran, A.; Smita, S.; Sabat, J.; Bhattacharya, D.; Dash, R.; Senapati, S.; Beuria, T. K.; Swain, R.; Chattopadhyay, S.; Syed, G. H.; Dixit, A.; Prasad, P.; Pati, S.; Parida, A.","https://www.biorxiv.org/content/10.1101/2020.07.23.217430v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217430v1?rss=1,2020-07-23,2020-07-23,,False
412,Oral delivery of SARS-CoV-2 DNA vaccines using attenuated Salmonella typhimurium as a carrier in rat,"The 2019 novel coronavirus disease (COVID-19) is the disease that has been identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the prophylactic treatment of SARS-CoV-2 is still under investigation. The effective delivery of eukaryotic expression plasmids to the immune systems inductive cells constitutes an essential requirement for the generation of effective DNA vaccines. Here, we have explored the use of Salmonella typhimurium as vehicles to deliver expression plasmids orally. Attenuated Salmonella phoP harboring eukaryotic expression plasmids that encoded spike protein of SARS-CoV-2 was administered orally to Wistar rats. Rats were immunized orally with Salmonella that carried a eukaryotic expression plasmid once a week for three consecutive weeks. The efficiency of the vaccination procedure was due to the transfer of the expression plasmid from the bacterial carrier to the mammalian host. Evidence for such an event could be obtained in vivo and in vitro. Our results showed that all immunized animals generated humoral immunity against the SARS-CoV-2 spike protein, indicating that a Salmonella-based vaccine carrying the Spike gene can elicit SARS-CoV-2-specific humoral immune responses in rats, and may be useful for the development of a protective vaccine against SARS-CoV-2 infection.","Yang, D.; Zhu, D.; Meng, Y.; Qimuge, A.; Bilige, B.; Baiyin, T.; Temuqile, T.; Chen, S.; Borjigen, S.; Baigude, H.","https://www.biorxiv.org/content/10.1101/2020.07.23.217174v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.217174v1?rss=1,2020-07-23,2020-07-23,,False
413,Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2,"A safe and durable vaccine is urgently needed to tackle the COVID19 pandemic that has infected >15 million people and caused >620,000 deaths worldwide. As with other respiratory pathogens, the nasal compartment is the first barrier that needs to be breached by the SARS-CoV-2 virus before dissemination to the lung. Despite progress at remarkable speed, current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity. We report the development of an intranasal subunit vaccine that contains the trimeric or monomeric spike protein and liposomal STING agonist as adjuvant. This vaccine induces systemic neutralizing antibodies, mucosal IgA responses in the lung and nasal compartments, and T-cell responses in the lung of mice. Single-cell RNA-sequencing confirmed the concomitant activation of T and B cell responses in a germinal center-like manner within the nasal-associated lymphoid tissues (NALT), confirming its role as an inductive site that can lead to long-lasting immunity. The ability to elicit immunity in the respiratory tract has can prevent the initial establishment of infection in individuals and prevent disease transmission across humans.","An, X.; Martinez, M. P.; Rezvan, A.; Fathi, M.; Singh, S.; Biswas, S.; Pourpak, M.; Yee, C.; Liu, X.; Varadarajan, N.","https://www.biorxiv.org/content/10.1101/2020.07.23.212357v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.23.212357v1?rss=1,2020-07-23,2020-07-23,,False
414,FDA approved calcium channel blockers inhibit SARS CoV 2 infectivity in epithelial lung cells,"Covid-19 has infected more than 14 million people worldwide causing over 600.000 deaths1. The disease is caused by the severe acute respiratory syndrome coronavirus (CoV) 2 (SARS-CoV-2), which shares a high sequence similarity to SARS CoV2. Currently there are no vaccinations available to provide protection and the only antiviral therapy in active use in patients is remdesivir, which currently provides only limited benefit3. Hence, there is an urgent need for antiviral therapies against SARS CoV 2. SARS CoV requires Ca2+ ions for host cell entry4 and based on the similarity between SARS CoV and SARS CoV 25 it is highly likely that the same requirements exist for the two viruses. Here, we tested whether FDA-approved calcium channel blocker (CCB) drugs are efficacious to inhibit the spread of SARS CoV 2 in cell culture. Our data shows that amlodipine, felodipine and nifedipine limit the growth of SARS CoV 2 in epithelial kidney (Vero E6) and epithelial lung (Calu-3) cells. We observed some differences in the inhibition efficacy of the drugs in the two different cell lines, but with felodopine and nifedipine having the greatest effect. Overall, our data suggest that CCBs have a high potential to treat SARS CoV 2 infections and their current FDA approval would allow for a fast repurposing of these drugs.","Straus, M. R.; Bidon, M.; Tang, T.; Whittaker, G.; Daniel, S.","https://www.biorxiv.org/content/10.1101/2020.07.21.214577v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214577v1?rss=1,2020-07-22,2020-07-22,,False
415,The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner,"The SARS-CoV2 coronavirus responsible for the current COVID19 pandemic has been reported to have a relatively low mutation rate. Nevertheless, a few prevalent variants have arisen that give the appearance of undergoing positive selection as they are becoming increasingly widespread over time. Most prominent among these is the D614G amino acid substitution in the SARS-CoV2 Spike protein, which mediates viral entry. The D614G substitution, however, is in linkage disequilibrium with the ORF1b P314L mutation where both mutations almost invariably co-occur, making functional inferences problematic. In addition, the possibility of repeated new introductions of the mutant strain does not allow one to distinguish between a founder effect and an intrinsic genetic property of the virus. Here, we synthesized and expressed the WT and D614G variant SARS-Cov2 Spike protein, and report that using a SARS-CoV2 Spike protein pseudotyped lentiviral vector we observe that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor. The increased binding/fusion activity of the D614G Spike protein was corroborated in a cell fusion assay using Spike and ACE2 proteins expressed in different cells. These results are consistent with the possibility that the Spike D614G mutant increases the infectivity of SARS-CoV2.","Ogawa, J.; Zhu, W.; Tonnu, N.; Singer, O.; Hunter, T.; Ryan (Firth), A. L.; Pao, G. M.","https://www.biorxiv.org/content/10.1101/2020.07.21.214932v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214932v1?rss=1,2020-07-22,2020-07-22,,False
416,Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants,"Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.","Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Luchsinger, L.; Hillyer, C. D.; Caskey, M.; Robbiani, D. F.; Rice, C.; Nussenzweig, M. C.; Hatziioannou, T.; Bieniasz, P. D.","https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1?rss=1,2020-07-22,2020-07-22,,False
417,Neonatal hyperoxia enhances age-dependent expression of SARS-CoV-2 receptors in mice,"The severity of COVID-19 lung disease is higher in the elderly and people with pre-existing co-morbidities. People who were born preterm may be at greater risk for COVID-19 because their early exposure to oxygen at birth increases their risk of being hospitalized when infected with RSV and other respiratory viruses. Our prior studies in mice showed how high levels of oxygen (hyperoxia) between postnatal days 0-4 increases the severity of influenza A virus infections by reducing the number of alveolar epithelial type 2 (AT2) cells. Because AT2 cells express the SARS-CoV-2 receptors angiotensin converting enzyme (ACE2) and transmembrane protease/serine subfamily member 2 (TMPRSS2), we expected their expression would decline as AT2 cells were depleted by hyperoxia. Instead, we made the surprising discovery that expression of Ace2 and Tmprss2 mRNA increases as mice age and is accelerated by exposing mice to neonatal hyperoxia. ACE2 is primarily expressed at birth by airway Club cells and becomes detectable in AT2 cells by one year of life. Neonatal hyperoxia increases ACE2 expression in Club cells and makes it detectable in 2-month-old AT2 cells. This early and increased expression of SARS-CoV-2 receptors was not seen in adult mice who had been administered the mitochondrial superoxide scavenger mitoTEMPO during hyperoxia. Our finding that early life insults such as hyperoxia enhances the age-dependent expression of SARS-CoV-2 receptors in the respiratory epithelium helps explain why COVID-19 lung disease is greater in the elderly and people with pre-existing co-morbidities.","Yee, M.; Cohen, E. D.; Haak, J.; Dylag, A. M.; O'Reilly, M. A.","https://www.biorxiv.org/content/10.1101/2020.07.22.215962v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.215962v1?rss=1,2020-07-22,2020-07-22,,False
418,Rescue of SARS-CoV-2 from a single bacterial artificial chromosome,"An infectious coronavirus disease 2019 (COVID-19) emerged in the city of Wuhan (China) in December 2019, causing a pandemic that has dramatically impacted public health and socioeconomic activities worldwide. A previously unknown coronavirus, Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2), has been identified as the causative agent of COVID-19. To date, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines or therapeutics available for the prevention or treatment of SARS-CoV-2 infection and/or associated COVID-19 disease, which has triggered a large influx of scientific efforts to develop countermeasures to control SARS-CoV-2 spread. To contribute to these efforts, we have developed an infectious cDNA clone of the SARS-CoV-2 USA-WA1/2020 strain based on the use of a bacterial artificial chromosome (BAC).

Recombinant (r)SARS-CoV-2 was readily rescued by transfection of the BAC into Vero E6 cells. Importantly, the BAC-derived rSARS-CoV-2 exhibited growth properties and plaque sizes in cultured cells comparable to those of the SARS-CoV-2 natural isolate. Likewise, rSARS-CoV-2 showed similar levels of replication to that of the natural isolate in nasal turbinates and lungs of infected golden Syrian hamsters. This is, to our knowledge, the first BAC based reverse genetics system for the generation of infectious rSARS-CoV-2 that displays similar features in vivo to that of a natural viral isolate. This SARS-CoV-2 BAC-based reverse genetics will facilitate studies addressing several important questions in the biology of SARS-CoV-2, as well as the identification of antivirals and development of vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19 disease.","Ye, C.; Park, J.-G.; Oladunni, F.; Platt, R. N.; Anderson, T.; Almazan, F.; de la Torre, J. C.; Martinez-Sobrido, L.","https://www.biorxiv.org/content/10.1101/2020.07.22.216358v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.216358v1?rss=1,2020-07-22,2020-07-22,,False
419,Elucidation of Genome Polymorphisms in Emerging SARS-CoV-2,"The COVID-19 pandemic is having a devastating effect on the healthcare system and the economy of the world. The unavailability of a specific treatment regime and a candidate vaccine yet opens up scope for new approaches and discoveries of drugs for mitigation of the sufferings of humankind due to the disease. The present isolated whole-genome sequences of SARS-CoV-2 from 11 different nations subjected to evolutionary study and genome-wide association study through in silico approaches including multiple sequence alignment, phylogenetic study through MEGA7 and have been analyzed through DNAsp respectively. These investigations recognized the nucleotide varieties and single nucleotide mutations/polymorphisms on the genomic regions as well as protein-coding regions. The resulted mutations have diversified the genomic contents of SARS-CoV-2 according to the altered nucleotides found in 11 genome sequences. India and Nepal have found to have progressively more distinct species of SARS-CoV-2 with variations in Spike protein and Nucleocapsid protein-coding sites. These genomic variations might be the explanation behind the less case fatality rate of India and Nepal dependent on the populaces. The anticipated idea of this investigation upgrades the information about genomic medication and might be useful in the planning of antibodies against SARS-CoV-2.","Ray, M.; Sarkar, S.; Rath, S. N.; Sable, M. N.","https://www.biorxiv.org/content/10.1101/2020.07.22.215731v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.215731v1?rss=1,2020-07-22,2020-07-22,,False
420,Virus-free and live-cell visualizing SARS-CoV-2 cell entry for studies of neutralizing antibodies and compound inhibitors,"The ongoing COVID-19 pandemic, caused by SARS-CoV-2 infection, has resulted in hundreds of thousands of deaths. Cellular entry of SARS-CoV-2, which is mediated by the viral spike protein and host ACE2 receptor, is an essential target for the development of vaccines, therapeutic antibodies, and drugs. Using a mammalian cell expression system, we generated a recombinant fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry process. In ACE2-expressing cells, we found that the STG probe has excellent performance in the live-cell visualization of receptor binding, cellular uptake, and intracellular trafficking of SARS-CoV-2 under virus-free conditions. The new system allows quantitative analyses of the inhibition potentials and detailed influence of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, providing a versatile tool for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This approach may also be adapted to develop a viral entry visualization system for other viruses.","Zhang, Y.; Wang, S.; Wu, Y.; Hou, W.; Yuan, L.; Sheng, C.; Wang, J.; Ye, J.; Zheng, Q.; Ma, J.; Xu, J.; Wei, M.; Li, Z.; Nian, S.; Xiong, H.; Zhang, L.; Shi, Y.; Fu, B.; Cao, J.; Yang, C.; Li, Z.; Yang, T.; Liu, L.; Yu, H.; Hu, J.; Ge, S.; Chen, Y.; Zhang, T.; Zhang, J.; Cheng, T.; Yuan, Q.; Xia, N.","https://www.biorxiv.org/content/10.1101/2020.07.22.215236v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.215236v1?rss=1,2020-07-22,2020-07-22,,False
421,"Inadequate level of knowledge, mixed outlook and poor adherence to COVID-19 prevention guideline among Ethiopians","COVID-19 has a potential to cause chaos in Ethiopia due to the countrys already daunting economic and social challenges. Living and working conditions are highly conducive for transmission, as people live in crowded inter-generational households that often lack running water and other basic sanitary facilities. Thus, the aim of this study was to investigate the knowledge, attitudes and practices (KAP) of Ethiopians toward COVID-19 following the introduction of state of emergency by the Ethiopian government to curb the spread of the disease. A cross-sectional study design was conducted in nine reginal states and two chartered cities. Data for demographic, Knowledge, attitude and practice toward COVID-19 were collected through telephone interview from 1570 participants. Descriptive and bivariate analyses using chi-square test, t-test or analysis of variance were performed as appropriate. Binary and multiple logistic regression analysis were used to measure the relationship between the categorical dependent variables and one or more socio-demographic independent variables with two-tailed at =0.05 significance level and 95% of confidence interval. The level of good knowledge, favourable attitude and good practice among the respondents were 42%, 53.8% and 24.3% respectively. Being rural resident, older than 50 years, having at least primary education, being resident of Amhara and Oromia regions were independent predictors of knowledge level. While being rural resident, married, employed, having at least basic education, being residents of Afar, Amhara, Gambela, Oromia and Somali regions were found to be the best predictors of the attitude, being rural resident, government employee, having at least basic education, and living outside of the capital were the independent predictors of practice level of the respondents. The finding revealed that Ethiopians have inadequate level of knowledge and are generally have a mixed outlook on overcoming the pandemic with poor adherence to COVID-19 prevention practice. reinforcing preventive measures and intensifying sensitization campaigns to fill the knowledge gap and persuading people to follow the preventive measures set by the government with concurrent evaluation of the impacts of these measures on knowledge and practice is highly recommended to mitigate the disease.","Negera, E.; Demissie, T. M.; Tafess, K.","https://www.biorxiv.org/content/10.1101/2020.07.22.215590v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.215590v1?rss=1,2020-07-22,2020-07-22,,False
422,Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2,"Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry. The plasma membrane-associated protease TMPRSS2 can similarly cleave these S proteins and activate viral entry at the cell surface. Here we show that the SARS-CoV-2 entry process is more dependent than that of SARS-CoV-1 on TMPRSS2 expression. This difference can be reversed when the furin-cleavage site of the SARS-CoV-2 S protein is ablated. We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone. These studies identify functional differences between SARS-CoV-1 and -2 entry processes, and provide a mechanistic explanation for the limited in vivo utility of hydroxychloroquine as a treatment for COVID-19.

Author SummaryThe novel pathogenic coronavirus SARS-CoV-2 causes COVID-19 and remains a threat to global public health. Chloroquine and hydroxychloroquine have been shown to prevent viral infection in cell-culture systems, but human clinical trials did not observe a significant improvement in COVID-19 patients treated with these compounds. Here we show that hydroxychloroquine interferes with only one of two somewhat redundant pathways by which the SARS-CoV-2 spike (S) protein is activated to mediate infection. The first pathway is dependent on the endosomal protease cathepsin L and sensitive to hydroxychloroquine, whereas the second pathway is dependent on TMPRSS2, which is unaffected by this compound. We further show that SARS-CoV-2 is more reliant than SARS coronavirus (SARS-CoV-1) on the TMPRSS2 pathway, and that this difference is due to a furin cleavage site present in the SARS-CoV-2 S protein. Finally, we show that combinations of hydroxychloroquine and a clinically tested TMPRSS2 inhibitor work together to effectively inhibit SARS-CoV-2 entry. Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy.","Ou, T.; Mou, H.; Zhang, L.; Ojha, A.; Choe, H.; Farzan, M.","https://www.biorxiv.org/content/10.1101/2020.07.22.216150v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.216150v1?rss=1,2020-07-22,2020-07-22,,False
423,The discovery of a recombinant SARS2-like CoV strain provides insights into SARS and COVID-2019 pandemics,"In December 2019, the world awoke to a new zoonotic strain of coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In the present study, we classified betacoronavirus subgroup B into the SARS-CoV-2, SARS-CoV and SARS-like CoV clusters, and the ORF8 genes of these three clusters into types 1, 2 and 3, respectively. One important result of our study is that the recently reported strain RmYN02 was identified as a recombinant SARS2-like CoV strain that belongs to the SARS-CoV-2 cluster, but has an ORF8 from a SARS-like CoV. This result provides substantial proof for long-existing hypotheses regarding the recombination and biological functions of ORF8. Based on the analysis of recombination events in the Spike gene, we propose that the Spike protein of SARS-CoV-2 may have more than one specific receptor for its function as gp120 of HIV has CD4 and CCR5. We concluded that the furin protease cleavage site acquired by SARS-CoV-2 may increase the efficiency of viral entry into cells, while the type 2 ORF8 acquired by SARS-CoV may increase its replication efficiency. These two most critical events provide the most likely explanation for SARS and COVID-2019 pandemics.","Li, X.; Jin, X.; Chen, S.; Wang, L.; Yau, T. O.; Yang, J.; Hong, Z.; Ruan, J.; Duan, G.; Gao, S.","https://www.biorxiv.org/content/10.1101/2020.07.22.213926v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.22.213926v1?rss=1,2020-07-22,2020-07-22,,False
424,The PRRA insert at the S1/S2 site modulates cellular tropism of SARS-CoV-2 and ACE2 usage by the closely related Bat raTG13,"Biochemical and structural analyses suggest that SARS-CoV-2 is well-adapted to infecting human and the presence of four residues (PRRA) at the S1/S2 site within the Spike protein may lead to unexpected tissue or host tropism. Here we report that SARS-CoV-2 efficiently utilized ACE2 of 9 species except mouse to infect 293T cells. Similarly, pseudoviruses bearing spike protein derived from either the bat raTG13 or pangolin GX, two closely related animal coronaviruses, utilized ACE2 of a diverse range of animal species to gain entry. Removal of PRRA from SARS-CoV-2 Spike displayed distinct effects on pseudoviral entry into different cell types. Strikingly, insertion of PRRA into the raTG13 Spike selectively abrogated the usage of horseshoe bat and pangolin ACE2 but conferred usage of mouse ACE2 by the relevant pseudovirus to enter cells. Together, our findings identified a previously unrecognized effect of the PRRA insert on SARS-CoV-2 and raTG13 spike proteins.","Liu, S.; Selvaraj, P.; Lien, C.; Wu, W. W.; Chou, C.-K.; Wang, T.","https://www.biorxiv.org/content/10.1101/2020.07.20.213280v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.213280v1?rss=1,2020-07-21,2020-07-21,,False
425,"Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates","We investigated the immune events following SARS-COV-2 infection, from the acute inflammatory state up to four weeks post infection, in non-human primates (NHP) with heterogeneous pulmonary pathology. The acute phase was characterized by a rapid migration of CD16+ monocytes from the blood and concomitant increase in CD16+ macrophages in the lungs. We identified two subsets of interstitial macrophages (HLA- DR+ CD206-), a transitional CD11c+ CD16+ population that was directly associated with IL-6 levels in plasma, and one long lasting CD11b+ CD16+ population. Strikingly, monocytes were a correlate of viral replication in bronchial brushes and levels of TARC (CCL17), and worse disease outcomes were associated with high levels of cell infiltration in lungs and CD11b+ CD16+ macrophages accumulation. Importantly, this accumulation was long-lasting and detectable even in animals with mild or no signs of disease. Interestingly, animals with less signs of disease had a high IL-10:IL-6 ratio. Our results unravel cellular mechanisms of COVID-19 and validate NHP as models to test immune therapies.","Fahlberg, M. D.; Blair, R. V.; Doyle-Meyers, L. A.; Midkiff, C. C.; Zenere, G.; Russell-Lodrigue, K. E.; Monjure, C. J.; Haupt, E. H.; Penney, T. P.; Lehmicke, G.; Threeton, B. M.; Golden, N.; Datta, P. K.; Roy, C. J.; Bohm, R. P.; Maness, N. J.; Fischer, T.; Rappaport, J.; Vaccari, M.","https://www.biorxiv.org/content/10.1101/2020.07.21.213777v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.213777v1?rss=1,2020-07-21,2020-07-21,,False
426,Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2.,"BackgroundThe emergence of SARS-CoV-2 has led to the development of new serological assays that could aid in diagnosis and evaluation of seroprevalence to inform an understanding of the burden of COVID-19 disease. Many available tests lack rigorous evaluation and therefore results may be misleading.

ObjectivesThe aim of this study was to assess the performance of a novel multiplexed immunoassay for the simultaneous detection of antibodies against SARS-CoV-2 trimeric spike (S), spike receptor binding domain (RBD), spike N terminal domain and nucleocapsid antigen and a novel pseudo-neutralisation assay.

MethodsA multiplexed solid-phase chemiluminescence assay (Meso Scale Discovery) was evaluated for the simultaneous detection of IgG binding to four SARS-CoV-2 antigens and the quantification of antibody-induced ACE-2 binding inhibition (pseudo-neutralisation assay). Sensitivity was evaluated with a total of 196 COVID-19 serum samples (169 confirmed PCR positive and 27 anti-nucleocapsid IgG positive) from individuals with mild symptomatic or asymptomatic disease. Specificity was evaluated with 194 control serum samples collected from adults prior to December 2019.

ResultsThe specificity and sensitivity of the binding IgG assay was highest for S protein with a specificity of 97.4% and sensitivity of 96.2% for samples taken 14 days and 97.9% for samples taken 21 days following the onset of symptoms. IgG concentration to S and RBD correlated strongly with percentage inhibition measured by the pseudo-neutralisation assay.

ConclusionExcellent sensitivity for IgG detection was obtained over 14 days since onset of symptoms for three SARS-CoV-2 antigens (S, RBD and N) in this multiplexed assay which can also measure antibody functionality.","Johnson, M.; Wagstaffe, H.; Gilmour, K. C.; Mai, A. L.; Lewis, J.; Hunt, A.; Sirr, J.; Bengt, C.; Grandjean, L.; Goldblatt, D.","https://www.biorxiv.org/content/10.1101/2020.07.20.213249v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.213249v1?rss=1,2020-07-21,2020-07-21,,False
427,S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit,"The high susceptibility of humans to SARS-CoV-2 infection, the cause of COVID-19, reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and PBMCs from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBCs. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 in convalescent subjects were higher than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane.

IMPORTANCERecent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key questions are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and post-infection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study also suggests that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation.","Nguyen-Contant, P.; Embong, A. K.; Kanagaiah, P.; Chaves, F.; Yang, H.; Branche, A. R.; Topham, D. J.; Sangster, M.","https://www.biorxiv.org/content/10.1101/2020.07.20.213298v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.213298v1?rss=1,2020-07-21,2020-07-21,,False
428,Discovery of potential imaging and therapeutic targets for severe inflammation in COVID-19 patients,"The COVID-19 pandemic has caused more than 540,000 deaths globally. Hyperinflammation mediated by dysregulated monocyte/macrophage function is considered to be the key factor that triggers severe illness in COVID-19. However, no specific targeting molecule has been identified for detecting or treating hyperinflammation related to dysregulated macrophages in severe COVID-19. Herein, we suggest candidate targets for imaging and therapy in severe COVID-19 by analyzing single-cell RNA-sequencing data based on bronchoalveolar lavage fluid of COVID-19 patients. We found that expression of SLC2A3, which can be imaged by [18F]fluorodeoxyglucose, was higher in macrophages from severe COVID-19 patients. Furthermore, by integrating the surface target database and drug-target binding database with RNA-sequencing data of severe COVID-19, we identified CCR1 and FPR1 as surface and druggable targets for drug delivery as well as molecular imaging. Our results provide a resource for candidate targets in the development of specific imaging and therapy for COVID-19-related hyperinflammation.","Lee, H.; Im, H.-J.; Na, K. J.; Choi, H.","https://www.biorxiv.org/content/10.1101/2020.07.20.213082v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.213082v1?rss=1,2020-07-21,2020-07-21,,False
429,SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-B,"SARS-CoV-2 is a novel virus that has rapidly spread, causing a global pandemic. In the majority of infected patients, SARS-CoV-2 leads to mild disease; however, in a significant proportion of infections, individuals develop severe symptoms that can lead to permanent lung damage or death. These severe cases are often associated with high levels of pro-inflammatory cytokines and low antiviral responses which can lead to systemic complications. We have evaluated transcriptional and cytokine secretion profiles from infected cell cultures and detected a distinct upregulation of inflammatory cytokines that parallels samples taken from infected patients. Building on these observations, we found a specific activation of NF-{kappa}B and a block of IRF3 nuclear translocation in SARS-CoV-2 infected cells. This NF-{kappa}B response is mediated by cGAS-STING activation and could be attenuated through STING targeting drugs. Our results show that SARS-CoV-2 curates a cGAS-STING mediated NF-{kappa}B driven inflammatory immune response in epithelial cells that likely contributes to inflammatory responses seen in patients and might be a target to suppress severe disease symptoms.","Neufeldt, C. J.; Cerikan, B.; Cortese, M.; Frankish, J.; Lee, J.-Y.; Plociennikowska, A.; Heigwer, F.; Joecks, S.; Burkart, S. S.; Zander, D. Y.; Gendarme, M.; El Debs, B.; Halama, N.; Merle, U.; Boutros, M.; Binder, M.; Bartenschlager, R.","https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1?rss=1,2020-07-21,2020-07-21,,False
430,Integrative Vectors for Regulated Expression of SARS-CoV-2 Proteins Implicated in RNA Metabolism,"Infection with SARS-CoV-2 is expected to result in substantial reorganization of host cell RNA metabolism. We identified 14 proteins that were predicted to interact with host RNAs or RNA binding proteins, based on published data for SARS-CoV and SARS-CoV-2. Here, we describe a series of affinity-tagged and codon-optimized expression constructs for each of these 14 proteins. Each viral gene was separately tagged at the N-terminus with Flag-His8, the C-terminus with His8-Flag, or left untagged. The resulting constructs were stably integrated into the HEK293 Flp-In TREx genome. Each viral gene was expressed under the control of an inducible Tet-On promoter, allowing expression levels to be tuned to match physiological conditions during infection. Expression time courses were successfully generated for most of the fusion proteins and quantified by western blot. A few fusion proteins were poorly expressed, whereas others, including Nsp1, Nsp12, and N protein, were toxic unless care was taken to minimize background expression. All plasmids can be obtained from Addgene and cell lines are available. We anticipate that availability of these resources will facilitate a more detailed understanding of coronavirus molecular biology.","Bresson, S.; Robertson, N.; Sani, E.; Turowski, T. W.; Shchepachev, V.; Kompauerova, M.; Spanos, C.; Helwak, A.; Tollervey, D.","https://www.biorxiv.org/content/10.1101/2020.07.20.211623v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.211623v1?rss=1,2020-07-21,2020-07-21,,False
431,THE ORIGIN OF A NEW HUMAN VIRUS: PHYLOGENETIC ANALYSIS OF THE EVOLUTION OF SARS-COV-2,"ObjectivesDuring the first months of SARS-CoV-2 evolution in a new host, contrasting hypotheses have been proposed about the way the virus has evolved and diversified worldwide. The aim of this study was to perform a comprehensive evolutionary analysis to describe the human outbreak and the evolutionary rate of different genomic regions of SARS-CoV-2.

MethodsThe molecular evolution in nine genomic regions of SARS-CoV-2 was analyzed using three different approaches: phylogenetic signal assessment, emergence of amino acid substitutions, and Bayesian evolutionary rate estimation in eight successive fortnights since the virus emergence.

ResultsAll observed phylogenetic signals were very low and consistent trees were obtained. However, after four months of evolution, it was possible to identify regions revealing an incipient viral lineages formation despite the low phylogenetic signal, since fortnight 3. Finally, the SARS-CoV-2 evolutionary rate for regions nsp3 and S, the ones presenting greater variability, was estimated to range from 1.37 to 2.19 x 10-3 substitution/site/year.

ConclusionsIn conclusion, results obtained in this work about the variable diversity of crucial viral regions and the determination of the evolutionary rate are consequently decisive to understanding essential feature of viral emergence. In turn, findings may allow identifying the best targets for antiviral treatments and vaccines development.","Pereson, M. J.; Mojsiejczuk, L.; Martinez, A. P.; Flichman, D. M.; Garcia, G. H.; Di Lello, F. A.","https://www.biorxiv.org/content/10.1101/2020.07.21.212860v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.212860v1?rss=1,2020-07-21,2020-07-21,,False
432,Multi-site co-mutations and 5'UTR CpG immunity escape drive the evolution of SARS-CoV-2,"The SARS-CoV-2 infected cases and the caused mortalities have been surging since the COVID-19 pandemic. Viral mutations emerge during the virus circulating in the population, which is shaping the viral infectivity and pathogenicity. Here we extensively analyzed 6698 SARS-CoV-2 whole genome sequences with specific sample collection dates in NCBI database. We found that four mutations, i.e., 5UTR_c-241-t, NSP3_c-3037-t, NSP12_c-14408-t, and S_a-23403-g, became the dominant variants and each of them represented nearly 100% of all virus sequences since the middle May, 2020. Notably, we found that co-occurrence rates of three significant multi-site co-mutational patterns, i.e., (i) S_a-23403-g, NSP12_c-14408-t, 5UTR_c-241-t, NSP3_c-3037-t, and ORF3a_c-25563-t; (ii) ORF8_t-28144-c, NSP4_c-8782-t, NSP14_c-18060-t, NSP13_a-17858-g, and NSP13_c-17747-t; and (iii) N_g-28881-a, N_g-28882-a, and N_g-28883-c, reached 66%, 90%, and nearly 100% of recent sequences, respectively. Moreover, we found significant decrease of CpG dinucleotide at positions 241(c)-242(g) in the 5UTR during the evolution, which was verified as a potential target of human zinc finger antiviral protein (ZAP). The four dominant mutations, three significant multi-site co-mutations, and the potential escape mutation of ZAP-target in 5UTR region contribute to the rapid evolution of SARS-CoV-2 virus in the population, thus shaping the viral infectivity and pathogenicity. This study provides valuable clues and frameworks to dissect the viral replication and virus-host interactions for designing effective therapeutics.

One Sentence SummaryFour dominant mutations, three significant multi-site co-mutations, and 5UTR CpG escape contribute to the rapid evolution of SARS-CoV-2 virus.","Zhang, J.; Kang, J.; Liu, M.; Han, B.; Li, L.; He, Y.; Yi, Z.; Chen, L.","https://www.biorxiv.org/content/10.1101/2020.07.21.213405v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.213405v1?rss=1,2020-07-21,2020-07-21,,False
433,Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy,"SARS-CoV-2 originated in animals and is now easily transmitted between people. Sporadic detection of natural cases in animals alongside successful experimental infections of pets, such as cats, ferrets and dogs, raises questions about the susceptibility of animals under natural conditions of pet ownership. Here we report a large-scale study to assess SARS-CoV-2 infection in 817 companion animals living in northern Italy, sampled at a time of frequent human infection. No animals tested PCR positive. However, 3.4% of dogs and 3.9% of cats had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive households being significantly more likely to test positive than those from COVID-19 negative households. Understanding risk factors associated with this and their potential to infect other species requires urgent investigation.

One Sentence SummarySARS-CoV-2 antibodies in pets from Italy.","Patterson, E. I.; Elia, G.; Grassi, A.; Giordano, A.; Desario, C.; Medardo, M.; Smith, S. L.; Anderson, E. R.; Lorusso, E.; Lucente, M. S.; Lanave, G.; Lauzi, S.; Bonfanti, U.; Stranieri, A.; Martella, V.; Solari Basano, f.; Barrs, V. R.; Radford, A. D.; Hughes, G. L.; Paltrinieri, S.; Decaro, N.","https://www.biorxiv.org/content/10.1101/2020.07.21.214346v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214346v1?rss=1,2020-07-21,2020-07-21,,False
434,Implications of the COVID-19 lockdown on dengue transmission and the occurrence of Aedes aegypti (Linnaeus) and Aedes albopictus (Skuse) in Malaysia,"The impact of movement restrictions (MRs) during the COVID-19 lockdown on the existing endemic infectious disease dengue fever has generated considerable research interest. We compared the curve of weekly epidemiological records of dengue incidences during the period of lockdown to the trend of previous years (2015 to 2019) and a simulation at the corresponding period that expected no MRs and found that the dengue incidence declined significantly with a greater magnitude at phase 1 of lockdown, with a negative gradient of 3.2-fold steeper than the trend observed in previous years, indicating that the control of population movement did reduce dengue transmission. However, starting from phase 2 of lockdown, the dengue incidences demonstrated an elevation and earlier rebound by 4 weeks and grew with an exponential pattern. Together with our data on Aedes mosquitoes, we proposed a stronger diffusive effect of vector dispersal that led to a higher rate of transmission. From the result of the Aedes survey using human landing caught (HLC), we revealed that Aedes albopictus is the predominant species for both indoor and outdoor environments, with the abundance increasing steadily during the period of lockdown. We only recovered Aedes aegypti from the indoor environment, which is relatively fewer than Ae. albopictus, by contrasting their population growth, which suggested that Ae. albopictus invaded and colonized the habitat of Ae. aegypti during the period of lockdown. These findings would help authorities review the direction and efforts of the vector control strategy.

Author summaryCOVID-19 pandemic is taking hold globally and dengue fever transmission is not on the top of the list of concerns. With a partial lockdown implemented by Malaysia on 18 March, we postulate the movement restrictions (MRs) of people in large-scale would hamper the regular dengue transmission and aim to reveal the impact of MRs on both dengue incidences and Aedes mosquitoes. We showed a significant decline of dengue incidences at the beginning of lockdown but later rebounded at an earlier time and higher rate compared to the corresponding period of previous years. Our result also reviews how adaptive the Ae. albopictus with the movement of the host, as the human contained in the house, the abundance of the mosquitoes increased significantly during the period of lockdown. We also suggest that Ae. albopictus could be the key substitution vector that contributes significantly to dengue virus circulation, and therefore, the vector control direction and strategies should be redesigned.","Ong, S.-Q.; Ahmad, H.; Mohd. Ngesom, A. M.","https://www.biorxiv.org/content/10.1101/2020.07.21.214056v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214056v1?rss=1,2020-07-21,2020-07-21,,False
435,Intranasal Immunization with a Lentiviral Vector Coding for SARS-CoV-2 Spike Protein Confers Vigorous Protection in Pre-Clinical Animal Models,"We developed a potent vaccination strategy, based on lentiviral vector (LV), capable of inducing neutralizing antibodies specific to the Spike glycoprotein (S) of SARS-CoV-2, the etiologic agent of CoronaVirus Disease 2019 (COVID-19). Among several LV encoding distinct variants of S, a single one encoding the full-length, membrane anchored S (LV::SFL) triggered high antibody titers in mice, with neutralization activities comparable to patients recovered from COVID-19. LV::SFL systemic vaccination in mice, in which the expression of the CoV2 receptor hACE2 was induced by transduction of the respiratory tract cells by an adenoviral type 5 (Ad5) vector, despite an intense serum neutralizing activity, only {approx}1 log10 reduction of lung viral loads was observed after SARS-CoV2 challenge.

We thus explored the strategy of targeting the immune response to the upper respiratory tract through an intranasal boost administration. Even though, after a prime and target regimen, the systemic neutralizing activity did not increase substantially, {approx}5 log10 decrease in lung viral loads was achieved, with the loads in some animals under the limit of detection of a highly sensitive RT-PCR assay. The conferred protection also avoided largely pulmonary inflammation.

We confirmed the vaccine efficacy and inhibition of lung inflammation using both integrative and non-integrative LV platforms in golden hamsters, naturally permissive to SARS-CoV2 replication and restituting human COVID-19 physiopathology. Our results provide the proof-of-principle evidence of marked prophylactic effects of an LV-based vaccination strategy against SARS-CoV-2 in two pre-clinical animal models and designate the intranasal LV::SFL-based immunization as a vigorous and promising vaccine approach against COVID-19.","MAJLESSI, L.; Ku, M.-W.; Bourgine, M.; Authie, P.; Lopez, J.; Nemirov, K.; Moncoq, F.; Noirat, A.; Vesin, B.; Nevo, F.; Blanc, C.; Souque, P.; Simon, E.; Tabbal, H.; Mouquet, H.; Anna, F.; Martin, A.; Escriou, N.; Charneau, P.","https://www.biorxiv.org/content/10.1101/2020.07.21.214049v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214049v1?rss=1,2020-07-21,2020-07-21,,False
436,Molecular mechanism of SARS-CoV-2 cell entry inhibition via TMPRSS2 by Camostat and Nafamostat mesylate,"The entry of the coronavirus SARS-CoV-2 into human cells can be inhibited by the approved drugs camostat and nafamostat. Here we elucidate the molecular mechanism of these drugs by combining experiments and simulations. In vitro assays confirm the hypothesis that both drugs act by inhibiting the human protein TMPRSS2. As no experimental structure is available, we provide a model of the TMPRSS2 equilibrium structure and its fluctuations by relaxing an initial homology structure with extensive 280 microseconds of all-atom molecular dynamics (MD) and Markov modeling. We describe the binding mode of both drugs with TMPRSS2 in a Michaelis complex (MC) state preceding the formation of a long-lived covalent inhibitory state. We find that nafamostat to has a higher MC population, which in turn leads to the more frequent formation of the covalent complex and thus higher inhibition efficacy, as confirmed in vitro and consistent with previous virus cell entry assays. Our TMPRSS2-drug structures are made public to guide the design of more potent and specific inhibitors.","Hempel, T.; Raich, L.; Olsson, S.; Azouz, N. P.; Klingler, A. M.; Rothenberg, M. E.; Noe, F.","https://www.biorxiv.org/content/10.1101/2020.07.21.214098v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.21.214098v1?rss=1,2020-07-21,2020-07-21,,False
437,Single cell RNA sequencing of blood antigen-presenting cells in severe Covid-19 reveals multi-process defects in antiviral immunity,"COVID-19 can lead to life-threatening acute respiratory failure, characterized by simultaneous increase in inflammatory mediators and viral load. The underlying cellular and molecular mechanisms remain unclear. We performed single-cell RNA-sequencing to establish an exhaustive high-resolution map of blood antigen-presenting cells (APC) in 7 COVID-19 patients with moderate or severe pneumonia, at day-1 and day-4 post-admission, and two healthy donors. We generated a unique dataset of 31,513 high quality APC, including monocytes and rare dendritic cell (DC) subsets. We uncovered multiprocess and previously unrecognized defects in anti-viral immune defense in specific APC compartments from severe patients: i) increase of pro-apoptotic genes exclusively in pDC, which are key effectors of antiviral immunity, ii) sharp decrease of innate sensing receptors, TLR7 and DHX9, in pDC and cDC1, respectively, iii) down-regulation of antiviral effector molecules, including Interferon stimulated genes (ISG) in all monocyte subsets, and iv) decrease of MHC class II-related genes, and MHC class II transactivator (CIITA) activity in cDC2, suggesting a viral inhibition of antigen presentation. These novel mechanisms may explain patient aggravation and suggest strategies to restore defective immune defense.","Saichi, M.; Ladjemi, M. Z.; Korniotis, S.; Rousseau, C.; Ait-Hamou, Z.; Massenet, L.; Amblard, E.; Noel, F.; Marie, Y.; Bouteiller, D.; Medvedovic, J.; Pene, F.; Soumelis, V.","https://www.biorxiv.org/content/10.1101/2020.07.20.212837v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.212837v1?rss=1,2020-07-21,2020-07-21,,False
438,CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target,"The reuse of pre-existing small molecules for a novel emerging disease threat is a rapid measure to discover unknown applications for previously validated therapies. A pertinent and recent example where such strategy could be employed is in the fight against COVID-19. Therapies designed or discovered to target viral proteins also have off-target effects on the host proteome when employed in a complex physiological environment. This study aims to assess these host cell targets for a panel of FDA approved antiviral compounds including Remdesivir, using the cellular thermal shift assay (CETSA(R)) coupled to mass spectrometry (CETSA MS) in non-infected cells. CETSA MS is a powerful method to delineate direct and indirect interactions between small molecules and protein targets in intact cells. Biologically active compounds can induce changes in thermal stability, in their primary binding partners as well as in proteins that in turn interact with the direct targets. Such engagement of host targets by antiviral drugs may contribute to the clinical effect against the virus but can also constitute a liability. We present here a comparative study of CETSA molecular target engagement fingerprints of antiviral drugs to better understand the link between off-targets and efficacy.","Friman, T.; Chernobrovkin, A.; Martinez Molina, D.; Arnold, L. H.","https://www.biorxiv.org/content/10.1101/2020.07.19.210492v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.210492v1?rss=1,2020-07-20,2020-07-20,,False
439,De novo design of modular and tunable allosteric biosensors,"Naturally occurring allosteric protein switches have been repurposed for developing novel biosensors and reporters for cellular and clinical applications 1, but the number of such switches is limited, and engineering them is often challenging as each is different. Here, we show that a very general class of allosteric protein-based biosensors can be created by inverting the flow of information through de novo designed protein switches in which binding of a peptide key triggers biological outputs of interest 2. Using broadly applicable design principles, we allosterically couple binding of protein analytes of interest to the reconstitution of luciferase activity and a bioluminescent readout through the association of designed lock and key proteins. Because the sensor is based purely on thermodynamic coupling of analyte binding to switch activation, only one target binding domain is required, which simplifies sensor design and allows direct readout in solution. We demonstrate the modularity of this platform by creating biosensors that, with little optimization, sensitively detect the anti-apoptosis protein Bcl-2, the hIgG1 Fc domain, the Her2 receptor, and Botulinum neurotoxin B, as well as biosensors for cardiac Troponin I and an anti-Hepatitis B virus (HBV) antibody that achieve the sub-nanomolar sensitivity necessary to detect clinically relevant concentrations of these molecules. Given the current need for diagnostic tools for tracking COVID-19 3, we use the approach to design sensors of antibodies against SARS-CoV-2 protein epitopes and of the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. The latter, which incorporates a de novo designed RBD binder, has a limit of detection of 15pM with an up to seventeen fold increase in luminescence upon addition of RBD. The modularity and sensitivity of the platform should enable the rapid construction of sensors for a wide range of analytes and highlights the power of de novo protein design to create multi-state protein systems with new and useful functions.","Quijano-Rubio, A.; Yeh, H.-W.; Park, J.; Lee, H.; Langan, R. A.; Boyken, S. E.; Lajoie, M. J.; Cao, L.; Chow, C. M.; Miranda, M. C.; Wi, J.; Hong, H. J.; Stewart, L.; Oh, B.-H.; Baker, D.","https://www.biorxiv.org/content/10.1101/2020.07.18.206946v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.206946v1?rss=1,2020-07-20,2020-07-20,,False
440,Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication,"Therapeutics targeting replication of SARS coronavirus 2 (SARS-CoV-2) are urgently needed. Coronaviruses rely on host membranes for entry, establishment of replication centers and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we tested small molecule inhibitors that target membrane dynamics or lipid metabolism. Included were inhibitors of the PI3 kinase VPS34, which functions in autophagy, endocytosis and other processes; Orlistat, an inhibitor of lipases and fatty acid synthetase, is approved by the FDA as a treatment for obesity; and Triacsin C which inhibits long chain fatty acyl-CoA synthetases. VPS34 inhibitors, Orlistat and Triacsin C inhibited virus growth in Vero E6 cells and in the human airway epithelial cell line Calu-3, acting at a post-entry step in the virus replication cycle. Of these the VPS34 inhibitors exhibit the most potent activity.","Silvas, J. A.; Jureka, A. S.; Nicolini, A. M.; Chvatal, S. A.; Basler, C. F.","https://www.biorxiv.org/content/10.1101/2020.07.18.210211v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210211v1?rss=1,2020-07-20,2020-07-20,,False
441,Cryo-electron Microscopy and Exploratory Antisense Targeting of the 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome,"Drug discovery campaigns against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are beginning to target the viral RNA genome1, 2. The frameshift stimulation element (FSE) of the SARS-CoV-2 genome is required for balanced expression of essential viral proteins and is highly conserved, making it a potential candidate for antiviral targeting by small molecules and oligonucleotides3-6. To aid global efforts focusing on SARS-CoV-2 frameshifting, we report exploratory results from frameshifting and cellular replication experiments with locked nucleic acid (LNA) antisense oligonucleotides (ASOs), which support the FSE as a therapeutic target but highlight difficulties in achieving strong inactivation. To understand current limitations, we applied cryogenic electron microscopy (cryo-EM) and the Ribosolve7 pipeline to determine a three-dimensional structure of the SARS-CoV-2 FSE, validated through an RNA nanostructure tagging method. This is the smallest macromolecule (88 nt; 28 kDa) resolved by single-particle cryo-EM at subnanometer resolution to date. The tertiary structure model, defined to an estimated accuracy of 5.9 [A], presents a topologically complex fold in which the 5' end threads through a ring formed inside a three-stem pseudoknot. Our results suggest an updated model for SARS-CoV-2 frameshifting as well as binding sites that may be targeted by next generation ASOs and small molecules.","Zhang, K.; Zheludev, I. N.; Hagey, R. J.; Wu, M. T.-P.; Haslecker, R.; Hou, Y. J.; Kretsch, R.; Pintilie, G. D.; Rangan, R.; Kladwang, W.; Li, S.; Pham, E. A.; Bernardin, C.; Baric, R. S.; Sheahan, T. P.; Dsouza, V.; Glenn, J. S.; Chiu, W.; Das, R.","https://www.biorxiv.org/content/10.1101/2020.07.18.209270v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.209270v1?rss=1,2020-07-20,2020-07-20,,False
442,Probing the dynamic structure-function and structure-free energy relationships of the corona virus main protease with Biodynamics theory,"The SARS-CoV-2 Main protease (Mpro) is of major interest as an anti-viral drug target. Structure-based virtual screening efforts, fueled by a growing list of apo and inhibitor-bound SARS-CoV/CoV-2 Mpro crystal structures, are underway in many labs. However, little is known about the dynamic enzyme mechanism, which is needed to inform both structure-based design and assay development. Here, we apply Biodynamics theory to characterize the structural dynamics of substrate-induced Mpro activation, and explore the implications thereof for efficacious inhibition under non-equilibrium conditions. The catalytic cycle (including tetrahedral intermediate formation and hydrolysis) is governed by concerted dynamic structural rearrangements of domain 3 and the m-shaped loop (residues 132-147) on which Cys145 (comprising the thiolate nucleophile and one-half of the oxyanion hole) and Gly143 reside (comprising the other half of the oxyanion hole). In particular: O_LIDomain 3 undergoes dynamic rigid-body rotations about the domain 2-3 linker, alternately visiting two conformational states (denoted as [Formula]).
C_LIO_LIThe Gly143-containing crest of the m-shaped loop (denoted as crest B) undergoes up and down translations in concert with the domain 3 rotations (denoted as [Formula], whereas the Cys145-containing crest (denoted as crest A) remains statically in the up position. The crest B translations are driven by conformational transitions within the rising leg of the loop (Lys137-Asn142).
C_LI

We propose that substrates associate to the [Formula] state, which promotes the [Formula] state, dimerization (denoted as [Formula]-substrate), and catalysis. The structure resets to the dynamic monomeric form upon dissociation of the N-terminal product. We describe the energetics of the aforementioned state transitions, and address the implications of our proposed mechanism for efficacious Mpro inhibition under native-like conditions.","Wan, H.; Aravamuthan, V.; Pearlstein, R. A.","https://www.biorxiv.org/content/10.1101/2020.07.19.211185v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.211185v1?rss=1,2020-07-20,2020-07-20,,False
443,The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models,"The search for successful therapies of infections with the coronavirus SARS-CoV-2 is ongoing. We tested inhibition of host cell nucleotide synthesis as a promising strategy to decrease the replication of SARS-CoV-2-RNA, thus diminishing the formation of virus progeny. Methotrexate (MTX) is an established drug for cancer therapy and to induce immunosuppression. The drug inhibits dihydrofolate reductase and other enzymes required for the synthesis of nucleotides. Strikingly, the replication of SARS-CoV-2 was inhibited by MTX in therapeutic concentrations around 1 M, leading to more than 1000-fold reductions in virus progeny in Vero C1008 (Vero E6) as well as Calu-3 cells. Virus replication was more sensitive to equivalent concentrations of MTX than of the established antiviral agent remdesivir. MTX strongly diminished the synthesis of viral structural proteins and the amount of released virus RNA. Virus replication and protein synthesis were rescued by folinic acid (leucovorin) and also by inosine, indicating that purine depletion is the principal mechanism that allows MTX to reduce virus RNA synthesis. The combination of MTX with remdesivir led to synergistic impairment of virus replication, even at 300 nM MTX. The use of MTX in treating SARS-CoV-2 infections still awaits further evaluation regarding toxicity and efficacy in infected organisms, rather than cultured cells. Within the frame of these caveats, however, our results raise the perspective of a two-fold benefit from repurposing MTX for treating COVID-19. Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress. In addition, its direct antiviral activity described here would limit the dissemination of the virus.

SIGNIFICANCEO_LIMTX is one of the earliest cancer drugs to be developed, giving rise to seven decades of clinical experience. It is on the World Health Organizations List of Essential Medicines, can be administered orally or parenterally, and its costs are at single digit {euro} or $ amounts/day for standard treatment. In case of its successful further preclinical evaluation for treating SARS-CoV-2 infections, its repurposing to treat COVID-19 would thus be feasible, especially under low-resource conditions.
C_LIO_LIAdditional drugs exist to interfere with the synthesis of nucleotides, e.g. additional folate antagonists, inhibitors of GMP synthetase, or inhibitors of dihydroorotate dehydrogenase (DHODH). Such inhibitors have been approved as drugs for different purposes and might represent further therapeutic options against infections with SARS-CoV-2
C_LIO_LIRemdesivir is currently the most established drug for treating COVID-19. Our results argue that MTX and remdesivir, even at moderate concentrations, can act in a synergistic fashion to repress virus replication to a considerably greater extent than either drug alone.
C_LIO_LICOVID-19, in its severe forms, is characterized by pneumonia and acute respiratory distress syndrome, and additional organ involvements. These manifestations are not necessarily a direct consequence of virus replication and cytopathic effects, but rather a result of an uncontrolled inflammatory and immune response. Anti-inflammatory drugs such as glucocorticoids are thus being evaluated for treating COVID-19. However, this bears the risk of re-activating virus spread by suppressing a sufficient and specific immune response. In this situation, it is tempting to speculate that MTX might suppress both excessive inflammation as well as virus replication at the same time, thus limiting both the pathogenesis of pneumonia and also the spread of virus within a patient.
C_LI","Stegmann, K. M.; Dickmanns, A.; Gerber, S.; Nikolova, V.; Klemke, L.; Manzini, V.; Schloesser, D.; Bierwirth, C.; Freund, J.; Sitte, M.; Lugert, R.; Salinas, G.; Goerlich, D.; Wollnik, B.; Gross, U.; Dobbelstein, M.","https://www.biorxiv.org/content/10.1101/2020.07.18.210013v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210013v1?rss=1,2020-07-20,2020-07-20,,False
444,Haplotype Explorer: an infection cluster visualization tool for spatiotemporal dissection of the COVID-19 pandemic,"The worldwide eruption of COVID-19 that began in Wuhan, China in late 2019 reached 10 million cases by late June 2020. In order to understand the epidemiological landscape of the COVID-19 pandemic, many studies have attempted to elucidate phylogenetic relationships between collected viral genome sequences using haplotype networks. However, currently available applications for network visualization are not suited to understand the COVID-19 epidemic spatiotemporally, due to functional limitations That motivated us to develop Haplotype Explorer, an intuitive tool for visualizing and exploring haplotype networks. Haplotype Explorer enables people to dissect epidemiological consequences via interactive node filters to provide spatiotemporal perspectives on multimodal spectra of infectious diseases, including introduction, outbreak, expansion, and containment, for given regions and time spans. Here, we demonstrate the effectiveness of Haplotype Explorer by showing an example of its visualization and features. The demo using SARS-CoV-2 genome sequences is available at https://github.com/TKSjp/HaplotypeExplorer

SummaryA lot of software for network visualization are available, but existing software have not been optimized to infection cluster visualization against the current worldwide invasion of COVID-19 started since 2019. To reach the spatiotemporal understanding of its epidemics, we developed Haplotype Explorer. It is superior to other applications in the point of generating HTML distribution files with metadata searches which interactively reflects GISAID IDs, locations, and collection dates. Here, we introduce the features and products of Haplotype Explorer, demonstrating the time-dependent snapshots of haplotype networks inferred from total of 4,282 SARS-CoV-2 genomes.","Kawano-Sugaya, T.; Yatsu, K.; Sekizuka, T.; Itokawa, K.; Hashino, M.; Tanaka, R.; Kuroda, M.","https://www.biorxiv.org/content/10.1101/2020.07.19.179101v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.179101v1?rss=1,2020-07-20,2020-07-20,,False
445,In silico comparative genomics of SARS-CoV-2 to determine the source and diversity of the pathogen in Bangladesh,"The COVID19 pandemic has originated in China, immobilized the whole world including Bangladesh. Herein using whole-genome sequencing data of 64 COVID 19 viruses from Bangladesh, we tried to predict the possible viral transmission route to Bangladesh and divergence among theses sequences. Phylogenetic analysis indicated that the pathogen arrived in Bangladesh from multiple countries. The virus of Chattogram was found to be originated from Saudi Arabia but Dhaka was infected with the viruses from the United Kingdom and France. The total 64 sequences of Bangladesh generate three clusters. Besides, 180 mutations were present in the coding regions of these viruses, and 110 of them were missense. Among the missense mutations 99 were predicted to destabilize the protein structures. Specifically a mutation at NSP2 1163A>T (I300F) was highly prevalent in Bangladeshi sequences and predicted to have a destabilizing effect on NSP2, which modulates host cell survival strategy.","Ahmed, T. S.; Naser, I. B.; Faruque, S. M.","https://www.biorxiv.org/content/10.1101/2020.07.20.212563v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.212563v1?rss=1,2020-07-20,2020-07-20,,False
446,The short and long-range RNA-RNA Interactome of SARS-CoV-2,"The Coronaviridae are a family of positive-strand RNA viruses that includes SARS-CoV-2, the etiologic agent of the COVID-19 pandemic. Bearing the largest single-stranded RNA genomes in nature, coronaviruses are critically dependent on long-distance RNA-RNA interactions to regulate the viral transcription and replication pathways. Here we experimentally mapped the in vivo RNA-RNA interactome of the full-length SARS-CoV-2 genome and its subgenomic mRNAs. We uncovered a network of RNA-RNA interactions spanning tens of thousands of nucleotides. These interactions reveal that the viral genome adopts alternative topologies inside cells and undergoes genome cyclization. In addition, the SARS-CoV-2 genome and subgenomic mRNAs engage in different interactions with host RNAs. Most importantly, we discovered a long-range RNA-RNA interaction - the FSE-arch - that encircles the programmed ribosomal frame-shifting element. The FSE-arch is conserved in the related MERS-CoV virus and is under purifying selection. Our findings illuminate RNA-based mechanisms governing replication, discontinuous transcription, and translation of coronaviruses, and will aid future efforts to develop antiviral strategies.","Ziv, O.; Price, J.; Shalamova, L.; Kamenova, T.; Goodfellow, I.; Weber, F.; Miska, E. A.","https://www.biorxiv.org/content/10.1101/2020.07.19.211110v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.211110v1?rss=1,2020-07-20,2020-07-20,,False
447,Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2,"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into target cells. ACE2 has been proposed as an interferon-stimulated gene (ISG). Thus, interferon-induced variability in ACE2 expression levels could be important for susceptibility to COVID-19 or its outcomes. Here, we report the discovery of a novel, primate-specific isoform of ACE2, which we designate as deltaACE2 (dACE2). We demonstrate that dACE2, but not ACE2, is an ISG. In vitro, dACE2, which lacks 356 N-terminal amino acids, was non-functional in binding the SARS-CoV-2 spike protein and as a carboxypeptidase. Our results reconcile current knowledge on ACE2 expression and suggest that the ISG-type induction of dACE2 in IFN-high conditions created by treatments, inflammatory tumor microenvironment, or viral co-infections is unlikely to affect the cellular entry of SARS-CoV-2 and promote infection.","Onabajo, O. O.; Banday, A. R.; Yan, W.; Obajemu, A.; Stanifer, M. L.; Santer, D. M.; Florez-Vargas, O.; Piontkivska, H.; Vargas, J.; Kee, C.; Tyrrell, D. L.; Mendoza, J. L.; Boulant, S.; Prokunina-Olsson, L.","https://www.biorxiv.org/content/10.1101/2020.07.19.210955v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.210955v1?rss=1,2020-07-20,2020-07-20,,False
448,A human disease model of SARS-CoV-2-induced lung injury and immune responses with a microengineered organ chip,"Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that seriously endangers human health. There is an urgent need to build physiological relevant human models for deep understanding the complex organ-level disease processes and facilitating effective therapeutics for COVID-19. Here, we first report the use of microengineered alveolus chip to create a human disease model of lung injury and immune responses induced by native SARS-CoV-2 at organ-level. This biomimetic system is able to reconstitute the key features of human alveolar-capillary barrier by co-culture of alveolar epithelial and microvascular endothelial cells under microfluidic flow. The epithelial cells on chip showed higher susceptibility to SARS-CoV-2 infection than endothelial cells identified by viral spike protein expression. Transcriptional analysis showed distinct responses of two cell types to SARS-CoV-2 infection, including activated type I interferon (IFN-I) signaling pathway in epithelium and activated JAK-STAT signaling pathway in endothelium. Notably, in the presence of circulating immune cells, a series of alveolar pathological changes were observed, including the detachment of endothelial cells, recruitment of immune cells, and increased production of inflammatory cytokines (IL-6, IL-8, IL-1{beta} and TNF-). These new findings revealed a crucial role of immune cells in mediating lung injury and exacerbated inflammation. Treatment with antiviral compound remdesivir could suppress viral copy and alleviate the disruption of alveolar barrier integrity induced by viral infection. This bioengineered human organ chip system can closely mirror human-relevant lung pathogenesis and immune responses to SARS-CoV-2 infection, not possible by other in vitro models, which provides a promising and alternative platform for COVID-19 research and preclinical trials.","Zhang, M.; Wang, P.; Luo, R.; Wang, Y.; Li, Z.; Guo, Y.; Yao, Y.; Li, M.; Tao, T.; Chen, W.; Han, J.; Liu, H.; Cui, K.; Zhang, X.; Zheng, Y.; Qin, J.","https://www.biorxiv.org/content/10.1101/2020.07.20.211789v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.211789v1?rss=1,2020-07-20,2020-07-20,,False
449,SARS-CoV2 spike protein displays biologically significant similarities with paramyxovirus surface proteins; a bioinformatics study,"Recent emergence of SARS-CoV2 and associated COVID-19 pandemic has posed a great challenge for the scientific community. Understanding various aspects of SARS-CoV2 biology, virulence and pathogenesis as well as determinants of immune response have become a global research priority. In this study, we performed bioinformatic analyses on SAR-CoV2 protein sequences, trying to unravel biologically important similarities between this newly emerged virus with other RNA viruses. Comparing the proteome of SARS-CoV2 with major positive and negative strand ssRNA viruses showed significant homologies between SARS-CoV2 spike protein with pathogenic paramyxovirus fusion proteins. This  spike-fusion homology was not limited to SARS-CoV2 and it existed for some other pathogenic coronaviruses; nonetheless, SARS-CoV2 spike-fusion homology was orders of magnitude stronger than homologies observed for other known coronaviruses. Moreover, this homology did not seem to be a consequence of general ssRNA virus phylogenetic relations. We also explored potential immunological significance of this spike-fusion homology. Spike protein epitope analysis using experimentally verified data deposited in Immune Epitope Database (IEDB) revealed that the majority of spikes T cell epitopes as well as many B cell and MHC binding epitopes map within the spike-fusion homology region. Overall, our data indicate that there might be a relation between SARS-CoV2 and paramyxoviruses at the level of their surface proteins and this relation could be of crucial immunological importance.","Ahmadi, E.; Zabihi, M. R.; Hosseinzadeh, R.; Noorbakhsh, F.","https://www.biorxiv.org/content/10.1101/2020.07.20.210534v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.210534v1?rss=1,2020-07-20,2020-07-20,,False
450,Computational optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2,"The coronavirus SARS-CoV-2, that is responsible for the COVID-19 pandemic, and the closely related SARS-CoV coronavirus enter cells by binding at the human angiotensin converting enzyme 2 (hACE2). The stronger hACE2 affinity of SARS-CoV-2 has been connected with its higher infectivity. In this work, we study hACE2 complexes with the receptor binding domains (RBDs) of the human SARS-CoV-2 and human SARS-CoV viruses, using all-atom molecular dynamics (MD) simulations and Computational Protein Design (CPD) with a physics-based energy function. The MD simulations identify charge-modifying substitutions between the CoV-2 and CoV RBDs, which either increase or decrease the hACE2 affinity of the SARS-CoV-2 RBD. The combined effect of these mutations is small, and the relative affinity is mainly determined by substitutions at residues in contact with hACE2. Many of these findings are in line and interpret recent experiments. Our CPD calculations redesign positions 455, 493, 494 and 501 of the SARS-CoV-2 RBM, which contact hACE2 in the complex and are important for ACE2 recognition. Sampling is enhanced by an adaptive importance sampling Monte Carlo method. Sequences with increased affinity replace CoV-2 glutamine by a negative residue at position 493, and serine by nonpolar, aromatic or a threonine at position 494. Substitutions at positions positions 455 and 501 have a smaller effect on affinity. Substitutions suggested by our design are seen in viral sequences encountered in other species, including bat and pangolin. Our results might be used to identify potential virus strains with higher human infectivity and assist in the design of peptide-based or peptidomimetic compounds with the potential to inhibit SARS-CoV-2 binding at hACE2.

SIGNIFICANCEThe coronavirus SARS-CoV-2 is responsible for the current COVID-19 pandemic. SARS-CoV-2 and the earlier, closely related SARS-CoV virus bind at the human angiotensin converting enzyme 2 (hACE2) receptor at the cell surface. The higher human infectivity of SARS-CoV-2 may be linked to its stronger affinity for hACE2. Here, we study by computational methods complexes of hACE2 with the receptor binding domains (RBDs) of viruses SARS-CoV-2 and SARS-CoV. We identify residues affecting the affinities of the two domains for hACE2. We also propose mutations at key SARS-CoV-2 positions, which might enhance hACE2 affinity. Such mutations may appear in viral strains with increased human infectivity and might assist the design of peptide-based compounds that inhibit infection of human cells by SARS-CoV-2.","Polydorides, S.; Archontis, G.","https://www.biorxiv.org/content/10.1101/2020.07.20.212068v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.20.212068v1?rss=1,2020-07-20,2020-07-20,,False
451,Population genetic analysis of Indian SARS-CoV-2 isolates reveals a unique phylogenetic cluster,"The SARS-CoV-2 pandemic originated from Wuhan, China in December 2019 raised an alarming situation all over the globe. Sequencing of this novel virus provides an opportunity to evaluate the genetic polymorphism present in the viral population. Herein, we analysed 173 sequences isolated from Indian patients and performed SNP linkage, clustering and phylogenetic analysis to understand the local genetic diversity. We found that the SNP linkages that lead to the identification of some global clades, do not hold true for the local clade classification. In addition to the unique cluster, established by another Indian study, we identified a new cluster (I-20D) that encompasses 28% of the analysed sequences. This cluster is defined by two linked variations - C22444T and C28854T. A detailed study of such polymorphisms can be useful for drug and vaccine development.","Das, D.; Akkipeddi, V. S. S. N. R.","https://www.biorxiv.org/content/10.1101/2020.07.19.197129v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.19.197129v1?rss=1,2020-07-20,2020-07-20,,False
452,"Evaluation of diversity levels in HIV-1 virus integrase gene sequences, supporting the lack of target specificity of ivermectin versus the integrase-importin complex in SARS-CoV-2 infection","Therapies with new drugs have been appearing in tests worldwide as potential inhibitors of sars-cov-2 virus replication. Recently, one of these drugs, Ivermectin, was reported as an inhibitor of the nuclear import of HIV-1 proteins in vitro, soon becoming the target of an international prospecting work (not yet published), with patients tested for COVID-19. However, understanding the evolutionary aspects of the biological components involved in the complex drug-nuclear import helps in understanding how these relationships exist in the deactivation of viral infections. Thus, 153 sequences of the HIV-1 integrase gene were analyzed for their genetic structure and molecular diversity and the presence of two distinct groups for the Gene and not only one, was detected; As well as different degrees of structuring for each of these groups. These results support the interpretation of the lack of conservation of the HIV-1 gene and that the number of existing polymorphisms, only for this structure of the complex, implies the non-efficiency of a drug at population levels. Thus, the molecular diversity found in HIV-1 can be extrapolated to other viruses, such as Including, SARS-CoV-2 and the functionality of the drug, interacting with the integrase-importin complex, can be further decreased.","Felix, P. T.","https://www.biorxiv.org/content/10.1101/2020.07.18.210096v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210096v1?rss=1,2020-07-20,2020-07-20,,False
453,High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients,"Angiotensin-converting enzyme-2 (ACE2) has been recognized as the binding receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that infects host cells, causing the development of the new coronavirus infectious disease (COVID-19). To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages. Flow cytometry demonstrated that there was little to no expression of ACE2 on most of the human peripheral blood-derived immune cells including CD4+ T, CD8+ T, activated CD4+ T, activated CD8+ T, CD4+CD25+CD127low/- regulatory T cells (Tregs), Th17 cells, NKT cells, B cells, NK cells, monocytes, dendritic cells (DCs), and granulocytes. Additionally, there was no ACE2 expression (< 1%) found on platelets. Compared with interleukin-4-treated type 2 macrophages (M2), the ACE2 expression was markedly increased on the activated type 1 macrophages (M1) after the stimulation with lipopolysaccharide (LPS). Immunohistochemistry demonstrated that high expressions of ACE2 were colocalized with tissue macrophages, such as alveolar macrophages found within the lungs and Kupffer cells within livers of mice. Flow cytometry confirmed the very low level of ACE2 expression on human primary pulmonary alveolar epithelial cells. These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.","Song, X.; Hu, W.; Yu, H.; Zhao, L.; Zhao, Y.; Zhao, Y.","https://www.biorxiv.org/content/10.1101/2020.07.18.210120v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210120v1?rss=1,2020-07-20,2020-07-20,,False
454,Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice,"ABSTRACTVaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease currently lacks a validated small animal model. Here, we show that transgenic mice expressing human angiotensin converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18 hACE2) represent a susceptible rodent model. K18 hACE2-transgenic mice succumbed to SARS-CoV-2 infection by day 6, with virus detected in lung airway epithelium and brain. K18 ACE2-transgenic mice produced a modest TH1/2/17 cytokine storm in the lung and spleen that peaked by day 2, and an extended chemokine storm that was detected in both lungs and brain. This chemokine storm was also detected in the brain at day 4. K18 hACE2-transgenic mice are, therefore, highly susceptible to SARS-CoV-2 infection and represent a suitable animal model for the study of viral pathogenesis, and for identification and characterization of vaccines (prophylactic) and antivirals (therapeutics) for SARS-CoV-2 infection and associated severe COVID-19 disease.","Oladunni, F.; Park, J.-G.; Pino Tamayo, P.; Gonzalez, O.; Ahkter, A.; Allue Guardia, A.; Olmo-Fontanez, A.; Gautam, S.; Garcia Vilanova, A.; Ye, C.; Chiem, K.; Headley, C.; Dwivedi, V.; Parodi, L.; Alfson, K.; Staples, H.; Schami, A.; Garcia, J.; Whigham, A.; Platt, R. N.; Gazi, M.; Martinez, J. C.; Chuba, C.; Earley, S.; Rodriguez, O.; Davis Mdaki, S.; Kavelish, K.; Escalona, R.; Hallam, C.; Christie, C.; Patterson, J.; Anderson, T.; Carrion, R.; Dick, E.; Hall-Ursone, S.; Schlesinger, L. S.; Kaushal, D.; Giavedoni, L. D.; Alvarez, X.; Turner, J.; Martinez-Sobrido, L.; Torrelles, J. B.","https://www.biorxiv.org/content/10.1101/2020.07.18.210179v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210179v1?rss=1,2020-07-19,2020-07-19,,False
455,An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19,"Pro-inflammatory immune responses are necessary for effective pathogen clearance, but cause severe tissue damage if not shut down in a timely manner1,2. Excessive complement and IFN-{gamma}-associated responses are known drivers of immunopathogenesis3 and are among the most highly induced immune programs in hyper-inflammatory SARS-CoV2 lung infection4. The molecular mechanisms that govern orderly shutdown and retraction of these responses remain poorly understood. Here, we show that complement triggers contraction of IFN-{gamma} producing CD4+ T helper (Th) 1 cell responses by inducing expression of the vitamin D (VitD) receptor (VDR) and CYP27B1, the enzyme that activates VitD, permitting T cells to both activate and respond to VitD. VitD then initiates the transition from pro-inflammatory IFN-{gamma}+ Th1 cells to suppressive IL-10+ Th1 cells. This process is primed by dynamic changes in the epigenetic landscape of CD4+ T cells, generating superenhancers and recruiting c-JUN and BACH2, a key immunoregulatory transcription factor5-7. Accordingly, cells in psoriatic skin treated with VitD increased BACH2 expression, and BACH2 haplo-insufficient CD4+ T cells were defective in IL-10 production. As proof-of-concept, we show that CD4+ T cells in the bronchoalveolar lavage fluid (BALF) of patients with COVID-19 are Th1-skewed and that VDR is among the top regulators of genes induced by SARS-CoV2. Importantly, genes normally down-regulated by VitD were de-repressed in CD4+ BALF T cells of COVID-19, indicating that the VitD-driven shutdown program is impaired in this setting. The active metabolite of VitD, alfacalcidol, and cortico-steroids were among the top predicted pharmaceuticals that could normalize SARS-CoV2 induced genes. These data indicate that adjunct therapy with VitD in the context of other immunomodulatory drugs may be a beneficial strategy to dampen hyperinflammation in severe COVID-19.","McGregor, R.; Chauss, D.; Freiwald, T.; Yan, B.; Wang, L.; Nova-Lamperti, E.; Zhang, Z.; Teague, H.; West, E.; Bibby, J.; Kelly, A.; Malik, A.; Freeman, A.; Schwartz, D.; Portilla, D.; John, S.; Lavender, P.; Lionakis, M. S.; Mehta, N. N.; Kemper, C.; Cooper, N.; Lombardi, G.; Laurence, A.; Kazemian, M.; Afzali, B.","https://www.biorxiv.org/content/10.1101/2020.07.18.210161v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.210161v1?rss=1,2020-07-19,2020-07-19,,False
456,Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions,"Antibody neutralization is an important prognostic factor in many viral diseases. To easily and rapidly measure titers of neutralizing antibodies in serum or plasma, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia virus capsids and a modified minimal MLV genome encoding firefly luciferase. These pseudovirions provide a practical means of assessing immune responses under laboratory conditions consistent with biocontainment level 2.","Zheng, Y.; Larragoite, E. T.; Lama, J.; Cisneros, I.; Delgado, J. C.; Slev, P.; Rychert, J.; Coiras, M.; Rondina, M.; Spivak, A. M.; Planelles, V.","https://www.biorxiv.org/content/10.1101/2020.07.17.207563v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.207563v1?rss=1,2020-07-18,2020-07-18,,False
457,Interplay of Monocytes and T Lymphocytes in COVID-19 Severity,"The COVID-19 pandemic represents an ongoing global crisis that has already impacted over 13 million people. The responses of specific immune cell populations to the disease remain poorly defined, which hinders improvements in treatment and care management. Here, we utilized mass cytometry (CyTOF) to thoroughly phenotype peripheral myeloid cells and T lymphocytes from 30 convalescent patients with mild, moderate, and severe cases of COVID-19. We identified 10 clusters of monocytes and dendritic cells and 17 clusters of T cells. Examination of these clusters revealed that both CD14+CD16+ intermediate and CD14dimCD16+ nonclassical monocytes, as well as CD4+ stem cell memory T (TSCM) cells, correlated with COVID-19 severity, coagulation factor levels, and/or inflammatory indicators. We also identified two nonclassical monocyte subsets distinguished by expression of the sugar residue 6-Sulfo LacNac (Slan). One of these subsets (Slanlo, nMo1) was depleted in moderately and severely ill patients, while the other (Slanhi, nMo2) increased with disease severity and was linked to CD4+ T effector memory (TEM) cell frequencies, coagulation factors, and inflammatory indicators. Intermediate monocytes tightly correlated with loss of naive T cells as well as an increased abundance of effector memory T cells expressing the exhaustion marker PD-1. Our data suggest that both intermediate and non-classical monocyte subsets shape the adaptive immune response to SARS-CoV-2. In summary, our study provides both broad and in-depth characterization of immune cell phenotypes in response to COVID-19 and suggests functional interactions between distinct cell types during the disease.

One Sentence SummaryUse of mass cytometry on peripheral blood mononuclear cells from convalescent COVID-19 patients allows correlation of distinct monocyte and T lymphocyte subsets with clinical factors.","Padgett, L. E.; Dinh, H. Q.; Chee, S. J.; Olingy, C. E.; Wu, R.; Araujo, D. J.; Vijayanand, P.; Ottensmeier, C. H.; Hedrick, C. C.","https://www.biorxiv.org/content/10.1101/2020.07.17.209304v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.209304v1?rss=1,2020-07-18,2020-07-18,,False
458,SARS-CoV-2 Spike protein hijacks VEGF-A/Neuropilin-1 receptor signaling to induce analgesia,"Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues unabated. Binding of SARS-CoV-2s Spike protein to host angiotensin converting enzyme 2 triggers viral entry, but other proteins may participate, including neuropilin-1 receptor (NRP-1). As both Spike protein and vascular endothelial growth factor-A (VEGF-A) - a pronociceptive and angiogenic factor, bind NRP-1, we tested if Spike could block VEGF-A/NRP-1 signaling. VEGF-A-triggered sensory neuronal firing was blocked by Spike protein and NRP-1 inhibitor EG00229. Pro-nociceptive behaviors of VEGF-A were similarly blocked via suppression of spontaneous spinal synaptic activity and reduction of electrogenic currents in sensory neurons. Remarkably, preventing VEGF-A/NRP-1 signaling was antiallodynic in a neuropathic pain model. A  silencing of pain via subversion of VEGF-A/NRP-1 signaling may underlie increased disease transmission in asymptomatic individuals.

One Sentence SummarySARS-CoV-2s Spike protein promotes analgesia by interfering with VEGF-A/NRP1 pathway, which may affect disease transmission dynamics.","Moutal, A.; Martin, L. F.; Boinon, L.; Gomez, K.; Ran, D.; Zhou, Y.; Stratton, H. J.; Song, C.; Luo, S.; Gonzalez, K. B.; Perez-Miller, S.; Patwardhan, A.; Ibrahim, M.; Khanna, R.","https://www.biorxiv.org/content/10.1101/2020.07.17.209288v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.209288v1?rss=1,2020-07-18,2020-07-18,,False
459,Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules,"SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic. The SARS-CoV-2 papain-like cysteine protease has been implicated in virus maturation, dysregulation of host inflammation and antiviral immune responses. We showed that PLpro preferably cleaves the K48-ubiquitin linkage while also being capable of cleaving ISG15 modification. The multiple functions of PLpro render it a promising drug target. Therefore, we screened an FDA-approved drug library and also examined available inhibitors against PLpro. Inhibitor GRL0617 showed a promising IC50 of 2.1 M. The co-crystal structure of SARS-CoV-2 PLpro-C111S in complex with GRL0617 suggests that GRL0617 is a non-covalent inhibitor. NMR data indicate that GRL0617 blocks the binding of ISG15 to PLpro. The antiviral activity of GRL0617 reveal that PLpro is a promising drug target for therapeutically treating COVID-19.

One Sentence SummaryCo-crystal structure of PLpro in complex with GRL0617 reveals the druggability of PLpro for SARS-CoV-2 treatment.","Fu, Z.; Huang, B.; Tang, J.; Liu, S.; Liu, M.; Ye, Y.; Liu, Z.; Xiong, Y.; Cao, D.; Li, J.; Niu, X.; Zhou, H.; Zhao, Y. J.; Zhang, G.; Huang, H.","https://www.biorxiv.org/content/10.1101/2020.07.17.208959v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.208959v1?rss=1,2020-07-18,2020-07-18,,False
460,The landscape of SARS-CoV-2 RNA modifications,"In 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the first documented cases of severe lung disease COVID-19. Since then, SARS-CoV-2 has been spreading around the globe resulting in a severe pandemic with over 500.000 fatalities and large economical and social disruptions in human societies. Gaining knowledge on how SARS-Cov-2 interacts with its host cells and causes COVID-19 is crucial for the intervention of novel therapeutic strategies. SARS-CoV-2, like other coronaviruses, is a positive-strand RNA virus. The viral RNA is modified by RNA-modifying enzymes provided by the host cell. Direct RNA sequencing (DRS) using nanopores enables unbiased sensing of canonical and modified RNA bases of the viral transcripts. In this work, we used DRS to precisely annotate the open reading frames and the landscape of SARS-CoV-2 RNA modifications. We provide the first DRS data of SARS-CoV-2 in infected human lung epithelial cells. From sequencing three isolates, we derive a robust identification of SARS-CoV-2 modification sites within a physiologically relevant host cell type. A comparison of our data with the DRS data from a previous SARS-CoV-2 isolate, both raised in monkey renal cells, reveals consistent RNA modifications across the viral genome. Conservation of the RNA modification pattern during progression of the current pandemic suggests that this pattern is likely essential for the life cycle of SARS-CoV-2 and represents a possible target for drug interventions.","Miladi, M.; Fuchs, J.; Maier, W.; Weigang, S.; Diaz i Pedrosa, N.; Weiss, L.; Lother, A.; Nekrutenko, A.; Ruzsics, Z.; Panning, M.; Kochs, G.; Gilsbach, R.; Gruening, B. A.","https://www.biorxiv.org/content/10.1101/2020.07.18.204362v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.18.204362v1?rss=1,2020-07-18,2020-07-18,,False
461,COVID-19 Detection on Chest X-Ray and CT Scan Images Using Multi-image Augmented Deep Learning Model,"COVID-19 is posed as very infectious and deadly pneumonia type disease until recent time. Novel coronavirus or SARS-COV-2 strain is responsible for COVID-19 and it has already shown the deadly nature of respiratory disease by threatening the health of millions of lives across the globe. Clinical study reveals that a COVID-19 infected person may experience dry cough, muscle pain, headache, fever, sore throat and mild to moderate respiratory illness. At the same time, it affects the lungs badly with virus infection. So, the lung can be a prominent internal organ to diagnose the gravity of COVID-19 infection using X-Ray and CT scan images of chest. Despite having lengthy testing time, RT-PCR is a proven testing methodology to detect coronavirus infection. Sometimes, it might give more false positive and false negative results than the desired rates. Therefore, to assist the traditional RT-PCR methodology for accurate clinical diagnosis, COVID-19 screening can be adopted with X-Ray and CT scan images of lung of an individual. This image based diagnosis will bring radical change in detecting coronavirus infection in human body with ease and having zero or near to zero false positives and false negatives rates. This paper reports a convolutional neural network (CNN) based multi-image augmentation technique for detecting COVID-19 in chest X-Ray and chest CT scan images of coronavirus suspected individuals. Multi-image augmentation makes use of discontinuity information obtained in the filtered images for increasing the number of effective examples for training the CNN model. With this approach, the proposed model exhibits higher classification accuracy around 95.38% and 98.97% for CT scan and X-Ray images respectively. CT scan images with multi-image augmentation achieves sensitivity of 94.78% and specificity of 95.98%, whereas X-Ray images with multi-image augmentation achieves sensitivity of 99.07% and specificity of 98.88%. Evaluation has been done on publicly available databases containing both chest X-Ray and CT scan images and the experimental results are also compared with ResNet-50 and VGG-16 models.","Purohit, K.; Kesarwani, A.; Kisku, D. R.; Dalui, M.","https://www.biorxiv.org/content/10.1101/2020.07.15.205567v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.205567v1?rss=1,2020-07-17,2020-07-17,,False
462,Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase,"Nucleotide analogs targeting viral RNA polymerase have been approved to be an effective strategy for antiviral treatment and are attracting antiviral drugs to combat the current SARS-CoV-2 pandemic. In this report, we develop a robust in vitro nonradioactive primer extension assay to evaluate the incorporation efficiency of nucleotide analog by SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) quantitively. Our results show that many nucleotide analogs can be incorporated into RNA by SARS-CoV-2 RdRp, and that the incorporation of some of them leads to chain termination. The discrimination values of nucleotide analog over those of natural nucleotide were measured to evaluate the incorporation efficiency of nucleotide analog by RdRp. We found that the incorporation efficiency of Remdesivir-TP is higher than ATP, and we did not observe chain termination or delayed chain termination caused by single Remdesivir-TP incorporation, while multiple incorporations of Remdesivir-TP caused chain termination in our assay condition. The incorporation efficiency of Ribavirin-TP and Favipiravir-TP is very low either as ATP or GTP analogs, which suggested that mutagenesis may not be the mechanism of action of those two drugs against SARS-CoV-2. Incorporation of Sofosbuvir-TP is also very low suggesting that sofosbuvir may not be very effective in treating SARS-CoV-2 infection. As a comparison, 2-C-Methyl-GTP can be incorporated into RNA efficiently, and the derivative of 2-C-Methyl-GTP may have therapeutic application in treating SARS-CoV-2 infection. This report provides a simple screening method that should be useful in evaluating nucleotide-based drugs targeting SARS-CoV-2 RdRp, and for studying the mechanism of action of selected nucleotide analog.","Lu, G.; Zhang, X.; Zheng, W.; Sun, J.; Hua, L.; Xu, L.; Chu, X.-j.; Ding, S.; Xiong, W.","https://www.biorxiv.org/content/10.1101/2020.07.16.205799v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.205799v1?rss=1,2020-07-17,2020-07-17,,False
463,A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection,"The Coronavirus Disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of systemic and mucosal IgA and T cell responses, completely prevents SARS-CoV-2 infection in the upper and lower respiratory tracts, and likely confers sterilizing immunity in most animals. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission, and curtailing pandemic spread.","Hassan, A. O.; Kafai, N. M.; Dmitriev, I. P.; Fox, J. M.; Smith, B.; Harvey, I. B.; Chen, R. E.; Winkler, E. S.; Wessel, A. W.; Case, J. B.; Kashentseva, E.; McCune, B. T.; Bailey, A. L.; Zhao, H.; VanBlargan, L. A.; Dai, Y.; Ma, M.; Adams, L. J.; Shrihari, S.; Gralinski, L. E.; Hou, Y. J.; Schaefer, A.; Kim, A. S.; Keeler, S. P.; Weiskopf, D.; Baric, R. S.; Holtzman, M. J.; Fremont, D. H.; Curiel, D. T.; Diamond, M. S.","https://www.biorxiv.org/content/10.1101/2020.07.16.205088v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.205088v1?rss=1,2020-07-17,2020-07-17,,False
464,Systematic modeling of SARS-CoV-2 protein structures,"In response to the COVID-19 pandemic caused by the SARS-CoV-2 virus, structural biologists are using experimental structural determination methods to better understand the viral proteome. Our goal in this work was to help researchers use these rapidly emerging structural data to gain detailed insights into the molecular mechanisms underlying COVID-19 infection. Our analysis was based on the protein sequences defined by UniProt as comprising the viral proteome. We systematically compared each SARS-CoV-2 protein sequence against all available protein 3D structures derived from any organism (164,250 PDB entries), using pairs of hidden Markov models built with the HHblits tool. We found 872 sequence-to-structure alignments assessed to have significant similarity (E < 10e-10) to infer structural similarity. The resulting 872 3D template models now provide a wealth of new detail, currently not available from related resources. To help make this large, complex dataset accessible and usable for other researchers, we also developed a tailored layout strategy to visually organise the 3D models by mapping them to the viral genome. The resulting graph provides an immediate and comprehensive visual overview of what is known - and not known - about the 3D structure of the viral proteome, thereby helping direct future research. The graph also clearly reveals all available structural evidence of viral mimicry or hijacking of human proteins, as well as all evidence of interactions between viral proteins. We have created PDF and online versions of the graph, in which users can click on any node in the graph to open the corresponding 3D model in the Aquaria molecular graphics system. In Aquaria, these models can then be colored to show sequence features, such as single nucleotide polymorphisms and posttranslational modifications. Previous versions of Aquaria showed only features from UniProt; however, as part of this study, we have now added features from PredictProtein and CATH, thus providing a total of 32,717 features for SARS-CoV-2 protein sequences. In this work, we present novel insights found, using the above approach, into how SARS-CoV-2 mimics and hijacks host proteins, and how viral proteins self-assemble during infection. The resulting Aquaria-COVID resource is freely available online at https://aquaria.ws/covid19, and an accompanying video (https://youtu.be/J2nWQTlJNaY) explains how researchers can use the resource.","O'Donoghue, S. I.; Schafferhans, A.; Sikta, N.; Stolte, C.; Kaur, S.; Ho, B.; Anderson, S.; Procter, J. B.; Adcock, M.; Dallago, C.; Bordin, N.; Rost, B.","https://www.biorxiv.org/content/10.1101/2020.07.16.207308v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.207308v1?rss=1,2020-07-17,2020-07-17,,False
465,SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts,"Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 emerged in December 2019 and has spread globally. Although Thailand has been effective at controlling the spread of COVID-19, disease surveillance and information on antibody responses in infected cases and close contacts are needed because there is still no specific treatment or vaccine available. We investigated 217 recovered COVID-19 cases to monitor their viral RNA shedding and production of antibodies against SARS-CoV-2. The presence of antibodies in blood samples from 308 close contacts of COVID-19 cases was also determined. Viral RNA was still detectable in 6.6 % of recovered COVID-19 cases. The most prolonged duration of viral RNA shedding detected in this study was 105 days. IgM, IgG, and IgA antibodies against SARS-CoV-2 were detected in 13.82, 88.48, and 83.41 % of the recovered cases 4-12 weeks after disease onset, respectively. Although the patients had recovered from their illness, the levels of antibodies detected showed association with their symptoms during their stay in hospital. Fifteen of the 308 contacts (4.87 %) of COVID-19 cases tested positive for IgG antibodies. The presence of antibodies against SARS-CoV-2 suggested that there was viral exposure among close contacts. Viral clearance and the pattern of antibody responses in infected individuals are both crucial for effectively combatting SARS-CoV-2. Our study provides additional information on the natural history of this newly emerging disease related to both natural host defenses and a strategy for vaccine development.","Chirathaworn, C.; Sripramote, M.; Chalongviriyalert, P.; Jirajariyavej, S.; Kiatpanabhikul, P.; Saiyarin, J.; Soudon, C.; Thienfaidee, O.; Palakawong Na Ayuthaya, T.; Brukesawan, C.; Chaiwanichsiri, D.; Intharasongkroh, D.; Wanlapakorn, N.; Chansaenroj, J.; Puenpa, J.; Yorsaeng, R.; Thitithanyanont, A.; Kitphati, R.; Mungaomklang, A.; Nagavajara, P.; Poovorawan, Y.","https://www.biorxiv.org/content/10.1101/2020.07.17.208439v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.208439v1?rss=1,2020-07-17,2020-07-17,,False
466,Mutational dynamics and transmission properties of SARS-CoV-2 superspreading events in Austria,"Superspreading events shape the COVID-19 pandemic. Here we provide a national-scale analysis of SARS-CoV-2 outbreaks in Austria, a country that played a major role for virus transmission across Europe and beyond. Capitalizing on a national epidemiological surveillance system, we performed deep whole-genome sequencing of virus isolates from 576 samples to cover major Austrian SARS-CoV-2 clusters. Our data chart a map of early viral spreading in Europe, including the path from low-frequency mutations to fixation. Detailed epidemiological surveys enabled us to calculate the effective SARS-CoV-2 population bottlenecks during transmission and unveil time-resolved intra-patient viral quasispecies dynamics. This study demonstrates the power of integrating deep viral genome sequencing and epidemiological data to better understand how SARS-CoV-2 spreads through populations.

Graphical Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY","Popa, A.; Genger, J.-W.; Nicholson, M.; Penz, T.; Schmid, D.; Aberle, S. W.; Agerer, B.; Lercher, A.; Endler, L.; Colaco, H.; Smyth, M.; Schuster, M.; Grau, M.; Martinez Jimenez, F.; Pich, O.; Borena, W. T.; Pawelka, E.; Keszei, Z.; Senekowitsch, M.; Laine, J.; Aberle, J.; Redlberger-Fritz, M.; Karolyi, M.; Zoufaly, A.; Maritschnik, S.; Borkovec, M.; Hufnagl, P.; Nairz, M.; Weiss, G.; Wolfinger, M. T.; von Laer, D.; Superti-Furga, G.; Lopez-Bigas, N.; Puchhammer-Stoeckl, E.; Allerberger, F.; Michor, F.; Bock, C.; Bergthaler, A.","https://www.biorxiv.org/content/10.1101/2020.07.15.204339v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.204339v1?rss=1,2020-07-17,2020-07-17,,False
467,Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors,"Hema-Quebec, the blood supplier in the Province of Quebec, Canada, collects and tests convalescent plasma used in a clinical trial to determine the clinical efficacy of this product for the treatment of hospitalized COVID-19 patients. So far, we have collected 1159 plasma units from 282 COVID-19 convalescent donors. The presence of antibodies to the receptor binding domain (RBD) of SARS-CoV-2 spike protein in convalescent donors was established at the first donation. Seropositive donors were asked to donate additional plasma units every six days. Until now, 15 donors have donated at least four times and, in some cases, up to nine times. This allowed us to perform a longitudinal analysis of the persistence of SARS-CoV-2 RBD-specific antibodies in these repeat donors, with the first donation occurring 33-77 days after symptoms onset and donations up to 71-114 days after symptoms onset thereafter. In all donors, the level of antibodies remained relatively stable up to about 76 days after symptoms onset but then started to decrease more rapidly to reach, in some convalescent donors, a seronegative status within 100-110 days after symptoms onset. The decline in anti-RBD antibodies was not related to the number of donations but strongly correlated with the numbers of days after symptoms onset (r = 0.821). This suggests that de novo secretion of SARS-CoV-2 RBD antibodies by short-lived plasma cells stopped about 2-3 months after disease onset, an observation that has important implications for convalescent plasma collection and seroprevalence studies undertaken several months after the peak of infection.","Perreault, J.; Tremblay, T.; Fournier, M.-J.; Drouin, M.; Beaudoin-Bussieres, G.; Prevost, J.; Lewin, A.; Begin, P.; Finzi, A.; Bazin, R.","https://www.biorxiv.org/content/10.1101/2020.07.16.206847v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.206847v1?rss=1,2020-07-17,2020-07-17,,False
468,Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening,"Background and PurposeThe COVID-19 caused by SARS-CoV-2 has emphasized the urgent need for therapeutic development. Drug repurposing screening is the most practical and rapid approach for discovery of such therapeutics. The 3CLpro, or main protease (Mpro) of SARS-CoV-2 is a valid drug target as it is a viral enzyme with an essential role in viral replication, and cleavage specificity that is distinct from host proteases.

Experimental ApproachWe employed and miniaturized a fluorogenic 3CLpro enzyme assay in which 3CLpro cleaves a quenched peptide substrate and releases a fluorescent fragment, resulting an increase in fluorescence signal. By using this SARS-CoV-2 3CLpro assay, we conducted a qHTS of 10,755 compounds consisting of approved and investigational drugs, and bioactive compounds, at 4 compound concentrations. The confirmed 3CLpro inhibitors were also tested in a SARS-CoV-2 cytopathic effect assay to determine their effects on rescuing of cell death caused by the virus infection.

Key ResultsTwenty-seven small molecule inhibitors of SARS-CoV-2 3CLpro have been identified with IC50s ranging from 0.26 to 27.1 M with a greater than 80% maximal inhibition. Walrycin B (IC50 = 0.26 M), Hydroxocobalamin (IC50 = 3.29 M), Suramin sodium (IC50 = 6.50 M), Z-DEVD-FMK (IC50 = 6.81 M), and LLL-12 (IC50 = 9.84 M) are the most potent 3CLpro inhibitors with IC50s under 10 M. The activities of anti-SARS-CoV-2 viral infection were confirmed in 11 of 27 compounds.

Conclusion and ImplicationsSome of the newly identified inhibitors of SARS-CoV-2 3CLpro may be used in combination therapy with other drugs for synergistic effect to treat COVID-19 patients. The other inhibitors found in this study can provide starting points for medicinal chemistry optimizations.

Bullet point summaryWhat is already known

O_LISARS-CoV-2 3CLpro is a valid target for drug development.
C_LI

What this study adds

O_LIIdentification of 27 inhibitors of SARS-CoV-2 3CLpro by a qHTS of 10,755 compounds consisting of approved and investigational drugs, and bioactive compounds.
C_LI

Clinical significance

O_LISome of the newly identified 3CLpro inhibitors can be evaluated in drug combination therapy for synergistic effect to treat COVID-19 patients, while the others can serve as starting points for medicinal chemistry optimization to improve potency and drug like properties for drug development.
C_LI","Zhu, W.; Xu, M.; Chen, C. Z.; Guo, H.; Shen, M.; Hu, X.; Shinn, P.; Klumpp-Thomas, C.; Michael, S. G.; Zheng, W.","https://www.biorxiv.org/content/10.1101/2020.07.17.207019v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.207019v1?rss=1,2020-07-17,2020-07-17,,False
469,COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis,"Observational studies of the ongoing coronavirus disease 2019 (COVID-19) outbreak suggest that a cytokine storm is involved in the pathogenesis of severe illness. However, the molecular mechanisms underlying the altered pathological inflammation in COVID-19 are largely unknown. We report here that toll-like receptor (TLR) 4-mediated inflammatory signaling molecules are upregulated in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients, compared with healthy controls. Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels. These data support a link between TLR4 signaling and pathological inflammation during COVID-19 and contribute to develop therapeutic approaches through targeting TLR4-mediated inflammation.","Sohn, K. M.; Lee, S.-G.; Kim, H. J.; Cheon, S.; Jeong, H.; Lee, J.; Kim, I. S.; Silwal, P.; Kim, Y. J.; Park, C.; Kim, Y.-S.; Jo, E.-K.","https://www.biorxiv.org/content/10.1101/2020.07.17.207878v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.207878v1?rss=1,2020-07-17,2020-07-17,,False
470,Vinegar and Its Active Component Acetic Acid Inhibit SARS-CoV-2 Infection In Vitro and Ex Vivo,"Effective and economical measures are needed to either prevent or inhibit the replication of SARS-CoV-2, the causative agent of COVID-19, in the upper respiratory tract. As fumigation of vinegar at low concentration (0.34%) ameliorated the symptoms of mild SARS-CoV-2 infection, we tested in vitro the potential antiviral activity of vinegar and of its active component, acetic acid. We here demonstrate that both vinegar and acetic acid indeed strongly inactivate SARS-CoV-2 infectivity in Vero cells. Furthermore, vinegar treatment caused a 90% inhibition of the infectious titer when directly applied to a nasopharyngeal swab transfer medium of a COVID-19 patient. These effects were potentiated if conduced at a temperature of 45 {degrees}C vs. 37 {degrees}C, a condition that is transiently generated in the upper respiratory tract during fumigation. Our findings are consistent and extend the results of studies performed in the early and mid-20th century on the disinfectant capacity of organic acids and can provide an affordable home-made aid to prevent or contain SARS-CoV-2 infection of the upper respiratory tract.","Pagani, I.; Ghezzi, S.; Clementi, M.; Poli, G.; Bussi, M.; Pianta, L.; Trimarchi, M.; Vicenzi, E.","https://www.biorxiv.org/content/10.1101/2020.07.08.193193v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.193193v1?rss=1,2020-07-17,2020-07-17,,False
471,Modeling the Impact of Lock-down on COVID-19 Spread in Malaysia,"After a breakdown notified in Wuhan, China in December 2019, COVID-19 is declared as pandemic diseases. To the date more than 13 million confirmed cases and more than half a million are dead around the world. This virus also attached Malaysia in its immature stage where 8718 cases were confirmed and 122 were declared as death. Malaysia responsibly controlled the spread by enforcing MCO. Hence, it is required to visualize the pattern of Covid-19 spread. Also, it is necessary to estimate the impact of the enforced prevention measures. In this paper, an infectious disease dynamic modeling (SEIR) is used to estimate the epidemic spread in Malaysia. The main assumption is to update the reproduction number Rt with respect to the implemented prevention measures. For a time-frame of five month, the Rt was assumed to vary between 2.9 and 0.3. Moreover, the manuscript includes two possible scenarios: the first will be the extension of the stricter measures all over the country, and the second will be the gradual lift of the lock-down. After implementing several stages of lock-down we have found that the estimated values of the Rt with respect to the strictness degree varies between 0.2 to 1.1. A continuous strict lock-down may reduce the Rt to 0.2 and accordingly the estimated active cases will be reduced to 20 by the beginning of September 2020. In contrast, the second scenario considers a gradual lift of the enforced prevention measures by the end of June 2020, here we have considered three possible outcomes according to the MCO relaxation. Thus, the estimated values of Rt = 0.7, 0.9, 1.1, which shows a rapid increase in the number of active cases. The implemented SEIR model shows a close resemblance with the actual data recorded from 10, March till 7, July 2020.

Author summaryConceptualization, A.A.A; methodology, A.A.A, N.M; validation, A.A.A, N.M; formal analysis, A.A.A; investigation, N.M, A.A.A; resources, G.E.M.A, L.T; data collection, L.T, N.M; writing--original draft preparation, A.A.A, L.T, G.E.M.A, N.M; writing--review and editing, V.S.A, S.C.D, B.S.G, P.S, S.A.B.M.Z, N.M; visualization, N.M; supervision, V.S.A; project administration, V.S.A. All authors have read and agreed to the published version of the manuscript","Altahir, A. A.; Mathur, N.; Thiruchelvam, L.; Abro, G. E. M.; Radzi, S. S. M.; Dass, S. C.; Gill, B. S.; Sebastian, P.; Zulkifli, S. A.; Asirvadam, V. S.","https://www.biorxiv.org/content/10.1101/2020.07.17.208371v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.17.208371v1?rss=1,2020-07-17,2020-07-17,,False
472,Simulations support the interaction of the SARS-CoV-2 spike protein with nicotinic acetylcholine receptors and suggest subtype specificity,"Changeux et al. recently suggested that the SARS-CoV-2 spike (S) protein may interact with nicotinic acetylcholine receptors (nAChRs). Such interactions may be involved in pathology and infectivity. Here, we use molecular simulations of validated atomically detailed structures of nAChRs, and of the S protein, to investigate this  nicotinic hypothesis. We examine the binding of the Y674-R685 loop of the S protein to three nAChRs, namely the human 4{beta}2 and 7 subtypes and the muscle-like {beta}{gamma}{delta} receptor from Tetronarce californica. Our results indicate that Y674-R685 has affinity for nAChRs and the region responsible for binding contains the PRRA motif, a four-residue insertion not found in other SARS-like coronaviruses. In particular, R682 has a key role in the stabilisation of the complexes as it forms interactions with loops A, B and C in the receptors binding pocket. The conformational behaviour of the bound Y674-R685 region is highly dependent on the receptor subtype, adopting extended conformations in the 4{beta}2 and 7 complexes and more compact ones when bound to the muscle-like receptor. In the 4{beta}2 and {beta}{gamma}{delta} complexes, the interaction of Y674-R685 with the receptors forces the loop C region to adopt an open conformation similar to other known nAChR antagonists. In contrast, in the 7 complex, Y674-R685 penetrates deeply into the binding pocket where it forms interactions with the residues lining the aromatic box, namely with TrpB, TyrC1 and TyrC2. Estimates of binding energy suggest that Y674-R685, forms stable complexes with all three nAChR subtypes, but has highest affinity for the muscle-type receptor. Analyses of the simulations of the full-length S protein show that the Y674-R685 region is accessible for binding, and suggest a potential binding orientation of the S protein with nAChRs.","Oliveira, A. S.; Ibarra, A. A.; Bermudez, I.; Casalino, L.; Gaieb, Z.; Shoemark, D. K.; Gallagher, T.; Sessions, R. B.; Amaro, R. E.; Mulholland, A. J.","https://www.biorxiv.org/content/10.1101/2020.07.16.206680v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.206680v1?rss=1,2020-07-17,2020-07-17,,False
473,Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate,"Antiviral strategies to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the pathogenic consequences of COVID-19 are urgently required. Here we demonstrate that the NRF2 anti-oxidant gene expression pathway is suppressed in biopsies obtained from COVID-19 patients. Further, we uncover that NRF2 agonists 4-octyl-itaconate (4-OI) and the clinically approved dimethyl fumarate (DMF) induce a cellular anti-viral program, which potently inhibits replication of SARS-CoV2 across cell lines. The anti-viral program extended to inhibit the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism. In addition, induction of NRF2 by 4-OI and DMF limited host inflammatory responses to SARS-CoV2 infection associated with airway COVID-19 pathology. In conclusion, NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in limiting virus replication and suppressing the pro-inflammatory responses of human pathogenic viruses, including SARS-CoV2.

One Sentence SummaryNRF2 agonists 4-octyl-itaconate (4-OI) and dimethyl fumarate inhibited SARS-CoV2 replication and virus-induced inflammatory responses, as well as replication of other human pathogenic viruses.","Olagnier, D.; Farahani, E.; Thyrsted, J.; Cadanet, J. B.; Herengt, A.; Idorn, M.; Hait, A.; Hernaez, B.; Knudsen, A.; Iversen, M. B.; Schilling, M.; Jorgensen, S. E.; Thomsen, M.; Reinert, L.; Lappe, M.; Hoang, H.-D.; Gilchrist, V. H.; Hansen, A.-L.; Ottosen, R.; Gunderstofte, C.; Moller, C.; van der Horst, D.; Peri, S.; Balachandran, S.; Huang, J.; Jakobsen, M.; Svenningsen, E. B.; Poulsen, T. B.; Bartsch, L.; Thielke, A. L.; Luo, Y.; Alain, T.; Rehwinkel, J.; Alcami, A.; Hiscott, J.; Mogensen, T.; Paludan, S. R.; Holm, C. K.","https://www.biorxiv.org/content/10.1101/2020.07.16.206458v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.16.206458v1?rss=1,2020-07-17,2020-07-17,,False
474,Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization,"In vitro antibody selection against pathogens from naive combinatorial libraries can yield various classes of antigen-specific binders that are distinct from those evolved from natural infection1-4. Also, rapid neutralizing antibody discovery can be made possible by a strategy that selects for those interfering with pathogen and host interaction5. Here we report the discovery of antibodies that neutralize SARS-CoV-2, the virus responsible for the COVID-19 pandemic, from a highly diverse naive human Fab library. Lead antibody 5A6 blocks the receptor binding domain (RBD) of the viral spike from binding to the host receptor angiotensin converting enzyme 2 (ACE2), neutralizes SARS-CoV-2 infection of Vero E6 cells, and reduces viral replication in reconstituted human nasal and bronchial epithelium models. 5A6 has a high occupancy on the viral surface and exerts its neutralization activity via a bivalent binding mode to the tip of two neighbouring RBDs at the ACE2 interaction interface, one in the ""up"" and the other in the ""down"" position, explaining its superior neutralization capacity. Furthermore, 5A6 is insensitive to several spike mutations identified in clinical isolates, including the D614G mutant that has become dominant worldwide. Our results suggest that 5A6 could be an effective prophylactic and therapeutic treatment of COVID-19.","Wang, B.; Asarnow, D.; Lee, W.-H.; Huang, C.-W.; Faust, B.; Ng, P. M. L.; Ngoh, E. Z. X.; Bohn, M.; Bulkley, D.; Pizzorno, A.; Tan, H. C.; Lee, C. Y.; Minhat, R. A.; Terrier, O.; Soh, M. K.; Teo, F. J.; Yeap, Y. Y. C.; Hu, Y.; Seah, S. G. K.; Maurer-Stroh, S.; Renia, L.; Hanson, B. J.; Rosa-Calatrava, M.; Manglik, A.; Cheng, Y.; Craik, C. S.; Wang, C.-I.","https://www.biorxiv.org/content/10.1101/2020.07.14.203414v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.203414v1?rss=1,2020-07-15,2020-07-15,,False
475,Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: An endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations,"Accumulation of mutations within the genome is the primary driving force for viral evolution within an endemic setting. This inherent feature often leads to altered virulence, infectivity and transmissibility as well as antigenic shift to escape host immunity, which might compromise the efficacy of vaccines and antiviral drugs. Therefore, we aimed at genome-wide analyses of circulating SARS-CoV-2 viruses for the emergence of novel co-existing mutations and trace their spatial distribution within India. Comprehensive analysis of whole genome sequences of 441 Indian SARS-CoV-2 strains revealed the occurrence of 33 different mutations, 21 being distinctive to India. Emergence of novel mutations were observed in S glycoprotein (7/33), NSP3 (6/33), RdRp/NSP12 (4/33), NSP2 (2/33) and N (2/33). Non-synonymous mutations were found to be 3.4 times more prevalent than synonymous mutations. We classified the Indian isolates into 22 groups based on the co-existing mutations. Phylogenetic analyses revealed that representative strain of each group divided themselves into various sub-clades within their respective clades, based on the presence of unique co-existing mutations. India was dominated by A2a clade (55.60%) followed by A3 (37.38%) and B (7%), but exhibited heterogeneous distribution among various geographical regions. The A2a clade mostly predominated in East India, Western India and Central India, whereas A3 clade prevailed in South and North India. In conclusion, this study highlights the divergent evolution of SARS-CoV-2 strains and co-circulation of multiple clades in India. Monitoring of the emerging mutations would pave ways for vaccine formulation and designing of antiviral drugs.","Sarkar, R.; Mitra, S.; Chandra, P.; Saha, P.; Banerjee, A.; Dutta, S.; Chawla-Sarkar, M.","https://www.biorxiv.org/content/10.1101/2020.07.14.203463v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.203463v1?rss=1,2020-07-15,2020-07-15,,False
476,Bioinformatic analysis of shared B and T cell epitopes amongst relevant coronaviruses to human health: Is there cross-protection?,"Within the last 30 years 3 coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2, have evolved and adapted to cause disease and spread amongst the human population. From the three, SARS-CoV-2 has spread world-wide and to July 2020 it has been responsible for more than 11 million confirmed cases and over half a million deaths. In the absence of an effective treatment or vaccine, social distancing has been the most effective measure to control the pandemic. However it has become evident that as the virus spreads the only tool that will allow us to fully control it is an effective vaccine. There are currently more than 150 vaccine candidates in different stages of development using a variety of viral antigens, with the S protein being the most targeted antigen. Although some new experimental evidence suggests cross-reacting responses between coronaviruses are present in the population, it remains unknown whether potential shared antigens between different coronaviruses could provide cross-protection. Given that coronaviruses are emerging pathogens and continue to represent a threat to global health, the development of a SARS-Cov-2 vaccine that could provide  universal protection against other coronaviruses should be pushed forward. Here we present a thorough review of reported B and T cell epitopes shared between SARS-CoV-2 and other relevant coronaviruses, in addition we used web-based tools to predict novel B and T cell epitopes that have not been reported before. Analysis of experimental evidence that is constantly emerging complemented with the findings of this study allow us support the hypothesis that cross-reactive responses, particularly those coming from T cells, might play a key role in controlling infection by SARS-CoV-2. We hope that with the evidence presented in this manuscript we provide arguments to encourage the study of cross-reactive responses in order to elucidate their role in immunity to SARS-CoV-2. Finally we expect our findings will aid targeted analysis of antigen-specific immune responses and guide future vaccine design aiming to develop a cross reactive effective vaccine against respiratory diseases caused by coronaviruses.","Pacheco-Olvera, D. L.; Saint Remy-Hernandez, S.; Acevedo-Ochoa, E.; Arriaga-Pizano, L.; Cerbulo-Vazquez, A.; Ferat-Osorio, E.; Rivera-Hernandez, T.; Lopez-Macias, C.","https://www.biorxiv.org/content/10.1101/2020.07.14.202887v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.202887v1?rss=1,2020-07-15,2020-07-15,,False
477,Antigenic variation of SARS-CoV-2 in response to immune pressure,"The ongoing evolution of SARS-CoV-2 is expected to be at least partially driven by the selective pressure imposed by the human immune system. We exploited the availability of a large number of high-quality SARS-CoV-2 genomes, as well as of validated epitope predictions, to show that B cell epitopes in the spike glycoprotein (S) and in the nucleocapsid protein (N) have higher diversity than non-epitope positions. Similar results were obtained for other human coronaviruses. Conversely, in the SARS-CoV-2 population, epitopes for CD4+ and CD8+ T cells were not more variable than non-epitope positions. A significant reduction in epitope variability was instead observed for some of the most immunogenic proteins (S, N, ORF8, and ORF3a). Analysis over longer evolutionary time-frames indicated that this effect is not due to differential constraints. These data indicate that SARS-CoV-2 is evolving to elude the host humoral immune response, whereas recognition by T cells might benefit the virus.","Forni, D.; Cagliani, R.; Pontremoli, C.; Mozzi, A.; Pozzoli, U.; Clerici, M.; Sironi, M.","https://www.biorxiv.org/content/10.1101/2020.07.15.204610v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.204610v1?rss=1,2020-07-15,2020-07-15,,False
478,Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies,"Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2. Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence. A better understanding of the basic molecular mechanisms mediating changes in virulence is needed. Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication. We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold. This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains. We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca2+ signaling and mitochondria biogenesis. We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2. Common nsp4 interactors include N-linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors. Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites. Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains. Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins. Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.","Davies, J. P.; Almasy, K. M.; McDonald, E. F.; Plate, L.","https://www.biorxiv.org/content/10.1101/2020.07.13.201517v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.201517v1?rss=1,2020-07-15,2020-07-15,,False
479,Alignment-free machine learning approaches for the lethality prediction of potential novel human-adapted coronavirus using genomic nucleotide,"A newly emerging novel coronavirus appeared and rapidly spread worldwide and World Health Organization declared a pandemic on March 11, 2020. The roles and characteristics of coronavirus have captured much attention due to its power of causing a wide variety of infectious diseases, from mild to severe on humans. The detection of the lethality of human coronavirus is key to estimate the viral toxicity and provide perspective for treatment. We developed alignment-free machine learning approaches for an ultra-fast and highly accurate prediction of the lethality of potential human-adapted coronavirus using genomic nucleotide. We performed extensive experiments through six different feature transformation and machine learning algorithms in combination with digital signal processing to infer the lethality of possible future novel coronaviruses using previous existing strains. The results tested on SARS-CoV, MERS-Cov and SARS-CoV-2 datasets show an average 96.7% prediction accuracy. We also provide preliminary analysis validating the effectiveness of our models through other human coronaviruses. Our study achieves high levels of prediction performance based on raw RNA sequences alone without genome annotations and specialized biological knowledge. The results demonstrate that, for any novel human coronavirus strains, this alignment-free machine learning-based approach can offer a reliable real-time estimation for its viral lethality.","YIN, R.; Luo, Z.; Kwoh, C. K.","https://www.biorxiv.org/content/10.1101/2020.07.15.176933v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.176933v1?rss=1,2020-07-15,2020-07-15,,False
480,Evidence of SARS-CoV2 entry protein ACE2 in the human nose and olfactory bulb,"Usually, pandemic COVID-19 disease, caused by SARS-CoV2, presents with mild respiratory symptoms such as fever, cough but frequently also with anosmia and neurological symptom. Virus-cell fusion is mediated by Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) with their organ expression pattern determining viral tropism. Clinical presentation suggests rapid viral dissemination to central nervous system leading frequently to severe symptoms including viral meningitis. Here, we provide a comprehensive expression landscape of ACE2 and TMPRSS2 proteins across human, post-mortem nasal and olfactory tissue. Sagittal sections through the human nose complemented with immunolabelling of respective cell types represent different anatomically defined regions including olfactory epithelium, respiratory epithelium of the nasal conchae and the paranasal sinuses along with the hardly accessible human olfactory bulb. ACE2 can be detected in the olfactory epithelium, as well as in the respiratory epithelium of the nasal septum, the nasal conchae and the paranasal sinuses. ACE2 is located in the sustentacular cells and in the glandular cells in the olfactory epithelium, as well as in the basal cells, glandular cells and epithelial cells of the respiratory epithelium. Intriguingly, ACE2 is not expressed in mature or immature olfactory receptor neurons and basal cells in the olfactory epithelium. Similarly ACE2 is not localized in the olfactory receptor neurons albeit the olfactory bulb is positive. Vice versa, TMPRSS2 can also be detected in the sustentacular cells and the glandular cells of the olfactory epithelium.

Our findings provide the basic anatomical evidence for the expression of ACE2 and TMPRSS2 in the human nose, olfactory epithelium and olfactory bulb. Thus, they are substantial for future studies that aim to elucidate the symptom of SARS-CoV2 induced anosmia of via the olfactory pathway.","Klingenstein, M.; Klingenstein, S.; Neckel, P. H.; Mack, A. F.; Wagner, A. P.; Kleger, A.; Liebau, S.; Milazzo, A.","https://www.biorxiv.org/content/10.1101/2020.07.15.204602v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.204602v1?rss=1,2020-07-15,2020-07-15,,False
481,A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells,"SARS-CoV-2 infections pose a global threat to human health and an unprecedented research challenge. Among the most urgent tasks is obtaining a detailed understanding of the molecular interactions that facilitate viral replication or contribute to host defense mechanisms in infected cells. While SARS-CoV-2 co-opts cellular factors for viral translation and genome replication, a comprehensive map of the host cell proteome in direct contact with viral RNA has not been elucidated. Here, we use RNA antisense purification and mass spectrometry (RAP-MS) to obtain an unbiased and quantitative picture of the human proteome that directly binds the SARS-CoV-2 RNA in infected human cells. We discover known host factors required for coronavirus replication, regulators of RNA metabolism and host defense pathways, along with dozens of potential drug targets among direct SARS-CoV-2 binders. We further integrate the SARS-CoV-2 RNA interactome with proteome dynamics induced by viral infection, linking interactome proteins to the emerging biology of SARS-CoV-2 infections. Validating RAP-MS, we show that CNBP, a regulator of proinflammatory cytokines, directly engages the SARS-CoV-2 RNA. Supporting the functional relevance of identified interactors, we show that the interferon-induced protein RYDEN suppresses SARS-CoV-2 ribosomal frameshifting and demonstrate that inhibition of SARS-CoV-2-bound proteins is sufficient to manipulate viral replication. The SARS-CoV-2 RNA interactome provides an unprecedented molecular perspective on SARS-CoV-2 infections and enables the systematic dissection of host dependency factors and host defense strategies, a crucial prerequisite for designing novel therapeutic strategies.","Schmidt, N.; Lareau, C. A.; Keshishian, H.; Melanson, R.; Zimmer, M.; Kirschner, L.; Ade, J.; Werner, S.; Caliskan, N.; Lander, E. S.; Vogel, J.; Carr, S. A.; Bodem, J.; Munschauer, M.","https://www.biorxiv.org/content/10.1101/2020.07.15.204404v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.204404v1?rss=1,2020-07-15,2020-07-15,,False
482,"The S1 protein of SARS-CoV-2 crosses the blood-brain barrier: Kinetics, distribution, mechanisms, and influence of ApoE genotype, sex, and inflammation","Evidence strongly suggests that SARS-CoV-2, the cause of COVID-19, can enter the brain. SARS-CoV-2 enters cells via the S1 subunit of its spike protein, and S1 can be used as a proxy for the uptake patterns and mechanisms used by the whole virus; unlike studies based on productive infection, viral proteins can be used to precisely determine pharmacokinetics and biodistribution. Here, we found that radioiodinated S1 (I-S1) readily crossed the murine blood-brain barrier (BBB). I-S1 from two commercial sources crossed the BBB with unidirectional influx constants of 0.287 {+/-} 0.024 L/g-min and 0.294 {+/-} 0.032 L/g-min and was also taken up by lung, spleen, kidney, and liver. I-S1 was uniformly taken up by all regions of the brain and inflammation induced by lipopolysaccharide reduced uptake in the hippocampus and olfactory bulb. I-S1 crossed the BBB completely to enter the parenchymal brain space, with smaller amounts retained by brain endothelial cells and the luminal surface. Studies on the mechanisms of transport indicated that I-S1 crosses the BBB by the mechanism of adsorptive transcytosis and that the murine ACE2 receptor is involved in brain and lung uptake, but not that by kidney, liver, or spleen. I-S1 entered brain after intranasal administration at about 1/10th the amount found after intravenous administration and about 0.66% of the intranasal dose entered blood. ApoE isoform or sex did not affect whole brain uptake, but had variable effects on olfactory bulb, liver, spleen, and kidney uptakes. In summary, I-S1 readily crosses the murine BBB, entering all brain regions and the peripheral tissues studied, likely by the mechanism of adsorptive transcytosis.

Graphical Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY","Rhea, E. M.; Logsdon, A. F.; Hansen, K. M.; Williams, L.; Reed, M.; Baumann, K.; Holden, S.; Raber, J.; Banks, W. A.; Erickson, M. A.","https://www.biorxiv.org/content/10.1101/2020.07.15.205229v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.205229v1?rss=1,2020-07-15,2020-07-15,,False
483,An Antioxidant Enzyme Therapeutic for COVID-19,"The COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. We report herein a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS-CoV-2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID-19.","Qin, M.; Cao, Z.; Wen, J.; Yu, Q.; Liu, C.; Wang, F.; Yang, F.; Li, Y.; Fishbein, G. A.; Yan, S.; Xu, B.; Hou, Y.; Ning, Z.; Nie, K.; Jiang, N.; Liu, Z.; Wu, J.; Yu, Y.; Li, H.; Zheng, H.; Li, J.; Jin, W.; Pan, S.; Wang, S.; Chen, J.; Gan, Z.; He, Z.; Lu, Y.","https://www.biorxiv.org/content/10.1101/2020.07.15.205211v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.205211v1?rss=1,2020-07-15,2020-07-15,,False
484,Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin,"With continued expansion of the COVID-19 pandemic, antiviral drugs are desperately needed to treat patients at high risk of life-threatening disease and even to limit spread if administered early during infection. Typically, the fastest route to identifying and licensing a safe and effective antiviral drug is to test those already shown safe in early clinical trials for other infections or diseases. Here, we tested in vitro oleandrin, derived from the Nerium oleander plant and shown previously to have inhibitory activity against several viruses. Using Vero cells, we found that prophylactic oleandrin administration at concentrations down to 0.05 g/ml exhibited potent antiviral activity against SARS-CoV-2, with an 800-fold reduction in virus production, and a 0.1 g/ml dose resulted in a greater than 3,000-fold reduction in infectious virus production. The EC50 values were 11.98ng/ml when virus output was measured at 24 hours post-infection, and 7.07ng/ml measured at 48 hours post-infection. Therapeutic (post-infection) treatment up to 24 hours after infection of Vero cells also reduced viral titers, with the 0.1 g/ml dose causing greater than 100-fold reductions as measured at 48 hours, and the 0.05 g/ml dose resulting in a 78-fold reduction. The potent prophylactic and therapeutic antiviral activities demonstrated here strongly support the further development of oleandrin to reduce the severity of COVID-19 and potentially also to reduce spread by persons diagnosed early after infection.

IMPORTANCECOVID-19, a pandemic disease caused by infection with SARS-CoV-2, has swept around the world to cause millions of infections and hundreds-of-thousands of deaths due to the lack of vaccines and effective therapeutics. We tested oleandrin, derived from the Nerium oleander plant and shown previously to reduce the replication of several viruses, against SARS-CoV-2 infection of Vero cells. When administered both before and after virus infection, nanogram doses of oleandrin significantly inhibited replication by up to 3,000-fold, indicating the potential to prevent disease and virus spread in persons recently exposed to SARS-CoV-2, as well as to prevent severe disease in persons at high risk. These results indicate that oleandrin should be tested in animal models and in humans exposed to infection to determine its medical usefulness in controlling the pandemic.","Plante, K. S.; Plante, J. A.; Fernandez, D.; Mirchandani, D.; Bopp, N. E.; Aguilar, P. V.; Sastry, K. J.; Newman, R. A.; Weaver, S. C.","https://www.biorxiv.org/content/10.1101/2020.07.15.203489v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.203489v1?rss=1,2020-07-15,2020-07-15,,False
485,Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation,"Since the beginning of the COVID-19 outbreak, SARS-CoV-2 whole-genome sequencing (WGS) has been performed at unprecedented rate worldwide with the use of very diverse Next Generation Sequencing (NGS) methods. Herein, we compare the performance of four NGS-based approaches for SARS-CoV-2 WGS. Twenty four clinical respiratory samples with a large scale of Ct values (from 10.7 to 33.9) were sequenced with four methods. Three used Illumina sequencing: an in-house metagenomic NGS (mNGS) protocol and two newly commercialized kits including a hybridization capture method developed by Illumina (DNA Prep with Enrichment kit and Respiratory Virus Oligo Panel, RVOP) and an amplicon sequencing method developed by Paragon Genomics (CleanPlex SARS-CoV-2 kit). We also evaluated the widely used amplicon sequencing protocol developed by ARTIC Network and combined with Oxford Nanopore Technologies (ONT) sequencing. All four methods yielded near-complete genomes (>99%) for high viral loads samples, with mNGS and RVOP producing the most complete genomes. For mid viral loads, 2/8 and 1/8 genomes were incomplete (<99%) with mNGS and both CleanPlex and RVOP, respectively. For low viral loads (Ct [&ge;]25), amplicon-based enrichment methods were the most sensitive techniques yielding complete genomes for 7/8 samples. All methods were highly concordant in terms of identity in complete consensus sequence. Just one mismatch in two samples was observed in CleanPlex vs the other methods, due to the dedicated bioinformatics pipeline setting a high threshold to call SNP compared to reference sequence. Importantly, all methods correctly identified a newly observed 34-nt deletion in ORF6 but required specific bioinformatic validation for RVOP. Finally, as a major warning for targeted techniques, a default of coverage in any given region of the genome should alert to a potential rearrangement or a SNP in primer annealing or probe-hybridizing regions and would require regular updates of the technique according to SARS-CoV-2 evolution.","Charre, C.; Ginevra, C.; Sabatier, M.; Regue, H.; Brun, S.; Burfin, G.; Scholtes, C.; Morfin, F.; Valette, M.; Lina, B.; Bal, A.; Josset, L.","https://www.biorxiv.org/content/10.1101/2020.07.14.201947v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.201947v1?rss=1,2020-07-15,2020-07-15,,False
486,The Effect Of Famotidine On SARS-CoV-2 Proteases And Virus Replication,"The lack of coronavirus-specific antiviral drugs has instigated multiple drug repurposing studies to redirect previously approved medicines for the treatment of SARS-CoV-2, the coronavirus behind the ongoing COVID-19 pandemic. A recent, large-scale, retrospective clinical study showed that famotidine, when administered at a high dose to hospitalized COVID-19 patients, reduced the rates of intubation and mortality. A separate, patient-reported study associated famotidine use with improvements in mild to moderate symptoms such as cough and shortness of breath. While a prospective, multi-center clinical study is ongoing, two parallel in silico studies have proposed one of the two SARS-CoV-2 proteases, 3CLpro or PLpro, as potential molecular targets of famotidine activity; however, this remains to be experimentally validated. In this report, we systematically analyzed the effect of famotidine on viral proteases and virus replication. Leveraging a series of biophysical and enzymatic assays, we show that famotidine neither binds with nor inhibits the functions of 3CLpro and PLpro. Similarly, no direct antiviral activity of famotidine was observed at concentrations of up to 200 M, when tested against SARS-CoV-2 in two different cell lines, including a human cell line originating from lungs, a primary target of COVID-19. These results rule out famotidine as a direct-acting inhibitor of SARS-CoV-2 replication and warrant further investigation of its molecular mechanism of action in the context of COVID-19.","Loffredo, M.; Lucero, H.; Chen, D.-Y.; O'Connell, A.; Bergqvist, S.; Munawar, A.; Bandara, A.; DeGraef, S.; Weeks, S. D.; Douam, F.; Saeed, M.; Munawar, A. H.","https://www.biorxiv.org/content/10.1101/2020.07.15.203059v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.15.203059v1?rss=1,2020-07-15,2020-07-15,,False
487,SARS-CoV-2 uses clathrin-mediated endocytosis to gain access into cells,"With more than 13 million cases and 570,000 deaths, and with the resulting social upheaval, the COVID-19 pandemic presents one of the greatest challenges ever to the scientific community. It is thus vital to fully understand the biology of SARS-CoV-2, the causative agent of COVID-19. SARS-CoV-2 uses the spike glycoprotein to interact with the cell surface and to drive fusion of the viral membrane with cellular membranes, thus allowing transfer of viral RNA to the cytosol. Here we use purified spike glycoprotein protein and lentivirus pseudotyped with spike glycoprotein to determine that SARS-CoV-2 undergoes rapid endocytosis following binding to the plasma membrane. Using chemical inhibitors and loss of function approaches, we demonstrate that this cellular entry is through clathrin-mediated endocytosis. Thus, it appears that SARS-CoV-2 first engages the plasma membrane, then rapidly enters the lumen of the endosomal system, strongly suggesting that fusion of the viral membrane occurs with the lumenal membrane of endosomes. This discovery has important implications for the development of chemical probes to reduce or block infection.","Bayati, A.; Kumar, R.; Francis, V.; McPherson, P. S.","https://www.biorxiv.org/content/10.1101/2020.07.13.201509v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.201509v1?rss=1,2020-07-14,2020-07-14,,False
488,Syncytia formation by SARS-CoV-2 infected cells,"Severe cases of COVID-19 are associated with extensive lung damage and the presence of infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms regulating the formation of these syncytia are not well understood. Here, we show that SARS-CoV-2 infected cells express the viral Spike protein (S) at their surface and fuse with ACE2-positive neighbouring cells. Expression of S without any other viral proteins triggers syncytia formation. Type-I interferon (IFN)-induced transmembrane proteins (IFITMs), a family of restriction factors that block the entry of many viruses, inhibit S-mediated fusion, with IFITM1 being more active than IFITM2 and IFITM3. On the contrary, the TMPRSS2 serine protease, which is known to enhance infectivity of cell-free virions, processes both S and ACE2 and increases syncytia formation by accelerating the fusion process. TMPRSS2 thwarts the antiviral effect of IFITMs. Our results show that the pathological effects of SARS-CoV-2 are modulated by cellular proteins that either inhibit or facilitate syncytia formation.

One Sentence SummarySyncytia produced by SARS-CoV-2 infected cells and regulation of their formation by IFITMs and TMPRSS2.","Buchrieser, J.; Dufloo, J.; Hubert, M.; Monel, B.; Planas, D.; Rajah, M. M.; Planchais, C.; Porrot, F.; Guivel-Benhassine, F.; van der Werf, S.; Casartelli, N.; Mouquet, H.; Bruel, T.; Schwartz, O.","https://www.biorxiv.org/content/10.1101/2020.07.14.202028v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.202028v1?rss=1,2020-07-14,2020-07-14,,False
489,SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2,"We show that SARS-CoV-2 spike protein interacts with cell surface heparan sulfate and angiotensin converting enzyme 2 (ACE2) through its Receptor Binding Domain. Docking studies suggest a putative heparin/heparan sulfate-binding site adjacent to the domain that binds to ACE2. In vitro, binding of ACE2 and heparin to spike protein ectodomains occurs independently and a ternary complex can be generated using heparin as a template. Contrary to studies with purified components, spike protein binding to heparan sulfate and ACE2 on cells occurs codependently. Unfractionated heparin, non-anticoagulant heparin, treatment with heparin lyases, and purified lung heparan sulfate potently block spike protein binding and infection by spike protein-pseudotyped virus and SARS-CoV-2 virus. These findings support a model for SARS-CoV-2 infection in which viral attachment and infection involves formation of a complex between heparan sulfate and ACE2. Manipulation of heparan sulfate or inhibition of viral adhesion by exogenous heparin may represent new therapeutic opportunities.","Clausen, T. M.; Sandoval, D. R.; Spliid, C. B.; Pihl, J.; Painter, C. D.; Thacker, B. E.; Glass, C. A.; Narayanan, A.; Majowicz, S. A.; Zhang, Y.; Torres, J. L.; Golden, G. J.; Porell, R.; Garretson, A. F.; Laubach, L.; Feldman, J.; Yin, X.; Pu, Y.; Hauser, B.; Caradonna, T. M.; Kellman, B. P.; Martino, C.; Gordts, P. L. S. M.; Leibel, S. L.; Chanda, S. K.; Schmidt, A. G.; Godula, K.; Jose, J.; Corbett, K. D.; Ward, A. B.; Carlin, A. F.; Esko, J. D.","https://www.biorxiv.org/content/10.1101/2020.07.14.201616v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.201616v1?rss=1,2020-07-14,2020-07-14,,False
490,The antibody response to the glycan -Gal correlates with COVID-19 disease symptoms,"The coronavirus disease 19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide. The characterization of the immunological mechanisms involved in disease symptomatology and protective response is important to advance in disease control and prevention. Humans evolved by losing the capacity to synthesize the glycan Gal1-3Gal{beta}1-(3)4GlcNAc-R (-Gal), which resulted in the development of a protective response against pathogenic viruses and other microorganisms containing this modification on membrane proteins mediated by anti--Gal IgM/IgG antibodies produced in response to bacterial microbiota. In addition to anti--Gal antibody-mediated pathogen opsonization, this glycan induces various immune mechanisms that have shown protection in animal models against infectious diseases without inflammatory responses. In this study, we hypothesized that the immune response to -Gal may contribute to the control of COVID-19. To address this hypothesis, we characterized the antibody response to -Gal in patients at different stages of COVID-19 and in comparison with healthy control individuals. The results showed that while the inflammatory response and the anti-SARS-CoV-2 (Spike) IgG antibody titers increased, reduction in anti--Gal IgE, IgM and IgG antibody titers and alteration of anti--Gal antibody isotype composition correlated with COVID-19 severity. The results suggested that the inhibition of the -Gal-induced immune response may translate into more aggressive viremia and severe disease inflammatory symptoms. These results support the proposal of developing interventions such as probiotics based on commensal bacteria with -Gal epitopes to modify the microbiota and increase the -Gal-induced protective immune response and reduce the severity of COVID-19.","Urra, J. M.; Ferreras-Colino, E.; Contreras, M.; Cabrera, C. M.; Fernandez de Mera, I. G.; Villar, M.; Cabezas-Cruz, A.; Gortazar, C.; de la Fuente, J.","https://www.biorxiv.org/content/10.1101/2020.07.14.201954v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.201954v1?rss=1,2020-07-14,2020-07-14,,False
491,Dynamic tracking of variant frequencies depicts the evolution of mutation sites amongst SARS-CoV-2 genomes from India,"With the exponential spread of COVID-19 pandemic across the world within the last six months, SARS-CoV-2 strains are continuously trying to adapt themselves in their host environment by random mutations. While doing so, some variants with evolutionary advantages such as better human to human transmissibility potential should get naturally selected. This short communication demonstrates how the mutation probability patterns are evolving in 864 SAR-CoV-2 strains isolated from COVID-19 patients across diverse Indian states. We have identified 30 such variants showing contrasting mutational probabilities in the span of four months. Out of these, the mutational probabilities of 25 variants including C14408T (in RdRp gene), A23403G (in spike gene), C6312A (nsp3 gene) are continuously increasing suggesting that these mutations are being propagated with time due to their unexplored evolutionary advantages. In contrast, the mutational probabilities of five variants including C6312A (nsp3 gene), G11083T (nsp6 gene), C28311T (N gene) have significantly decreased in May-June as compared to March-April, suggesting these mutations are being terminated with time. Further in-depth investigation of these identified variants will provide valuable knowledge about the evolution, infection strategies, transmission rates, and epidemiology of SARS-CoV-2 in India.","Sharma, G.; Kolte, V.; Hudson B., S.; Khan, A.","https://www.biorxiv.org/content/10.1101/2020.07.14.201905v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.201905v1?rss=1,2020-07-14,2020-07-14,,False
492,Targeting heparan sulfate proteoglycan-assisted endocytosis as a COVID-19 therapeutic option,"Drugs capable of blocking the infectious cycle of the coronavirus SARS-CoV-2 are urgently needed to tackle the ongoing COVID-19 pandemic. To this end, the cell entry of SARS-CoV-2, initiated by the binding of the viral Spike (S) protein to human ACE2, has emerged as an attractive drug repurposing target. Here we use murine leukemia viruses pseudotyped with Spike from SARS-CoV or SARS-CoV-2 to demonstrate that ACE2-mediated coronavirus entry can be mitigated by heparin, a heparan sulfate-related glycan, or by genetic ablation of biosynthetic enzymes for the cell surface heparan sulfate proteoglycans (HSPGs). A drug repurposing screen targeting HSPG-dependent endocytosis identifies pharmacologically active endocytosis inhibitors that also abrogate coronavirus cell entry. Among them, Mitoxantrone (EC50=~10 nM) targets HSPGs directly, whereas Sunitinib and BNTX disrupt the actin network to impair HSPG-assisted viral entry. Gene expression profiling suggests potential combination regimens that optimally target HSPG-dependent viral entry. Altogether, our study establishes HSPGs as an assisting factor for ACE2 in endocytosis-mediated coronavirus entry and identifies drugs that can be repurposed to target this important stage in the viral life cycle.","Zhang, Q.; Chen, C.; Swaroop, M.; Xu, M.; Wang, L.; Lee, J.; Pradhan, M.; Shen, M.; Luo, Z.; Xu, Y.; Huang, W.; Zheng, W.; Ye, Y.","https://www.biorxiv.org/content/10.1101/2020.07.14.202549v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.14.202549v1?rss=1,2020-07-14,2020-07-14,,False
493,Single-nucleotide conservation state annotation of SARS-CoV-2 genome,"Given the global impact and severity of COVID-19, there is a pressing need for a better understanding of the SARS-CoV-2 genome and mutations. Multi-strain sequence alignments of coronaviruses (CoV) provide important information for interpreting the genome and its variation. We apply a comparative genomics method, ConsHMM, to the multi-strain alignments of CoV to annotate every base of the SARS-CoV-2 genome with conservation states based on sequence alignment patterns among CoV. The learned conservation states show distinct enrichment patterns for genes, protein domains, and other regions of interest. Certain states are strongly enriched or depleted of SARS-CoV-2 mutations, and the state annotations are more predictive than existing genomic annotations in prioritizing bases without non-singleton mutations, which are likely enriched for important genomic bases. We expect the conservation states to be a resource for interpreting the SARS-CoV-2 genome and mutations.","Kwon, S. B.; Ernst, J.","https://www.biorxiv.org/content/10.1101/2020.07.13.201277v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.201277v1?rss=1,2020-07-14,2020-07-14,,False
494,"Tobacco, but not nicotine and flavor-less electronic cigarettes, induces ACE2 and immune dysregulation","COVID-19, caused by the virus SARS-CoV-2, has infected millions worldwide. This pandemic overlaps with the ongoing epidemics of cigarette smoking and electronic cigarette (e-cig) vaping, with over 1 billion smokers and vapers worldwide. However, there is scarce data relating COVID-19 risks and outcome with cigarette or e-cig use. In this study, we mined 3 independent RNA expression datasets from smokers and vapers to understand the potential relationship between vaping/smoking and the dysregulation of key genes and pathways related to COVID-19. We found that smoking, but not vaping, upregulates ACE2, the cellular receptor that SARS-CoV-2 requires for infection. Both smoking and use of nicotine and flavor-containing e-cig led to upregulations of pro-inflammatory cytokine production and expression of genes related to inflammasomes. Vaping flavor-less and nicotine-less e-cig, however, did not lead to significant cytokine dysregulation and inflammasome activation. Release of inflammasome products, such as IL-1B, and cytokine storms are hallmarks of COVID-19 infection, especially in severe cases. Therefore, our findings demonstrated that smoking or vaping, specifically use of flavored or nicotine-containing e-cigs, may critically exacerbate COVID-19-related inflammation or increase susceptibility to the disease. Further scientific and public health investigations should be undertaken to address these concerning links between COVID-19 and e-cig/smoking.","Lee, A. C.; Chakladar, J.; Li, W. T.; Chen, C.; Chang, E. Y.; Wang-Rodriguez, J.; Ongkeko, W. M.","https://www.biorxiv.org/content/10.1101/2020.07.13.198630v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.198630v1?rss=1,2020-07-13,2020-07-13,,False
495,Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses,"For yet unknown reasons, severely ill COVID-19 patients often become critically ill around the time of activation of adaptive immunity. Here, we show that anti-Spike IgG from serum of severely ill COVID-19 patients induces a hyper-inflammatory response by human macrophages, which subsequently breaks pulmonary endothelial barrier integrity and induces microvascular thrombosis. The excessive inflammatory capacity of this anti-Spike IgG is related to glycosylation changes in the IgG Fc tail. Moreover, the hyper-inflammatory response induced by anti-Spike IgG can be specifically counteracted in vitro by use of the active component of fostamatinib, an FDA- and EMA-approved therapeutic small molecule inhibitor of Syk.

One sentence summaryAnti-Spike IgG promotes hyper-inflammation.","Hoepel, W.; Chen, H.-J.; Allahverdiyeva, S.; Manz, X.; Aman, J.; Bonta, P.; Brouwer, P.; de Taeye, S.; Caniels, T.; van der Straten, K.; Golebski, K.; Griffith, G.; Jonkers, R.; Larsen, M.; Linty, F.; Neele, A.; Nouta, J.; van Baarle, F.; van Drunen, C.; Vlaar, A.; de Bree, G.; Sanders, R.; Willemsen, L.; Wuhrer, M.; Bogaard, H. J.; van Gils, M.; Vidarsson, G.; de Winther, M. P. J.; den Dunnen, J.","https://www.biorxiv.org/content/10.1101/2020.07.13.190140v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.190140v1?rss=1,2020-07-13,2020-07-13,,False
496,Cold sensitivity of the SARS-CoV-2 spike ectodomain,"The SARS-CoV-2 spike (S) protein, a primary target for COVID-19 vaccine development, presents two conformations of its Receptor Binding Domain - a receptor-accessible ""up"" conformation, or a receptor-inaccessible ""down"" conformation. Here, we report unexpected cold sensitivity of a commonly used S ectodomain construct, and resolution of this cold sensitivity in a ""down"" state stabilized spike. Our results will impact structural, functional and vaccine studies that use the SARS-CoV-2 S ectodomain.","Edwards, R. J.; Mansouri, K.; Stalls, V.; Manne, K.; Watts, B.; Parks, R.; Gobeil, S. M. C.; Janowska, K.; Li, D.; Lu, X.; Deyton, M.; Sprenz, J.; Williams, W.; Saunders, K.; Sempowski, G. D.; Henderson, R.; Alam, M.; Haynes, B. F.; Acharya, P.","https://www.biorxiv.org/content/10.1101/2020.07.12.199588v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199588v1?rss=1,2020-07-13,2020-07-13,,False
497,PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.,"PT150 is a clinical stage molecule, taken orally, with a strong safety profile having completed Phase 1 and Phase 2 clinical trials for its original use as an anti-depressant. It has an active IND for COVID-19. Antiviral activities have been found for PT150 and other members of its class in a variety of virus families; thus, it was now tested against SARS-CoV-2 in human bronchial epithelial lining cells and showed effective 90% inhibitory antiviral concentration (EC90) of 5.55 M. PT150 is a member of an extended platform of novel glucocorticoid receptor (GR) and androgen receptor (AR) binding molecules. In vivo, their predominant net effect is one of systemic glucocorticoid antagonism, but they also show direct downregulation of AR and minor GR agonism at the cellular level. We hypothesize that anti-SARS-CoV-2 activity depends in part on this AR downregulation through diminished TMPRSS2 expression and modulation of ACE2 activity. Given that hypercortisolemia is now suggested to be a significant co-factor for COVID-19 progression, we also postulate an additive role for its potent immunomodulatory effects through systemic antagonism of cortisol.","Theise, N. D.; Arment, A. R.; Chakravarty, D.; Gregg, J. M. H.; Jacobson, I. M.; Jung, K. H.; Nair, S. S.; Tiwari, A.; Thurston, A. W.; Van Drie, J.; Westover, J. B.","https://www.biorxiv.org/content/10.1101/2020.07.12.199505v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199505v1?rss=1,2020-07-13,2020-07-13,,False
498,Comparisons of the genome of SARS-CoV-2 and those of other betacoronaviruses,"The genome of SARS-CoV-2 virus causing the worldwide pandemic of COVID-19 is most closely related to viral metagenomes isolated from bats and, more distantly, pangolins. All are of sarbecoviruses of the genus Betacoronavirus. We have unravelled their recombinational and mutational histories. All showed clear evidence of recombination, most events involving the 3 half of the genomes. The 5 region of their genomes was mostly recombinant free, and a phylogeny calculated from this region confirmed that SARS-CoV-2 is closer to RmYN02 than RaTG13, and showed that SARS-CoV-2 diverged from RmYN02 at least 26 years ago, and both diverged from RaTG13 at least 37 years ago; recombinant regions specific to these three viruses provided no additional information as they matched no other Genbank sequences closely. Simple pairwise comparisons of genomes show that there are three regions where most non-synonymous changes probably occurred; the DUF3655 region of the nsp3, the S gene and ORF 8 gene. Differences in the last two of those regions have probably resulted from recombinational changes, however differences in the DUF3655 region may have resulted from selection. A hexamer of the proteins encoded by the nsp3 region may form the molecular pore spanning the double membrane of the coronavirus replication organelle (Wolff et al., 2020), and perhaps the acidic polypeptide encoded by DUF3655 lines it, and presents a novel target for pharmaceutical intervention.","Rodriguez-Roman, E.; Gibbs, A. J.","https://www.biorxiv.org/content/10.1101/2020.07.12.199521v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199521v1?rss=1,2020-07-13,2020-07-13,,False
499,Worldwide Geographical and Temporal Analysis of SARS-CoV-2 Haplotypes shows Differential Distribution Patterns,"Since the identification of SARS-CoV-2 in December 2019, a large number of SARS-CoV-2 genomes has been sequenced with unprecedented speed around the world and deposited in several databases. This marks a unique opportunity to study how a virus spreads and evolves in a worldwide context. However, currently there is not a useful haplotype classification system to help tracking the virus evolution. Here we identified eleven mutations with 10 % or more frequency in a data set of 7848 genomes. Using these mutations, we identified 6 SARS-CoV-2 haplotypes or OTUs (Operational Taxonomic Unit) that correlate well with a phylogenomic tree. After that, we analyzed the geographical and temporal distribution of these OTUs, as well as their correlation with patient status. Our geographical analysis showed different OTUs prevalence between continents and the temporal distribution analysis revealed an evolution-like pattern in SARS-CoV-2. Finally, we observed a homogenous distribution of OTUs in mild and severe patients and a great prevalence of OTU 2 in asymptomatic patients. However, genomes in the asymptomatic category, comes from isolates on three consecutive days in February (15 to 17), weakening this observation and highlighting the need to increase genomic analyzes in asymptomatic and severe patients. Our classification system is phylogenetically consistent and allows us to easily track geographic and temporal distribution of important mutations around the world. In the next months, it could be updated using similar steps that we used here.","Justo Arevalo, S.; Zapata Sifuentes, D.; Huallpa Robles, C.; Landa Bianchi, G.; Castillo Chavez, A.; Garavito-Salini Casas, R.; Uceda-Campos, G.; Pineda Chavarria, R.","https://www.biorxiv.org/content/10.1101/2020.07.12.199414v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199414v1?rss=1,2020-07-13,2020-07-13,,False
500,Single-cell analysis reveals the function of lung progenitor cells in COVID-19 patients,"The high mortality of severe 2019 novel coronavirus disease (COVID-19) cases is mainly caused by acute respiratory distress syndrome (ARDS), which is characterized by increased permeability of the alveolar epithelial barriers, pulmonary edema and consequently inflammatory tissue damage. Some but not all patients showed full functional recovery after the devastating lung damage, and so far there is little knowledge about the lung repair process1. Here by analyzing the bronchoalveolar lavage fluid (BALF) of COVID-19 patients through single cell RNA-sequencing (scRNA-Seq), we found that in severe (or critical) cases, there is remarkable expansion of TM4SF1+ and KRT5+ lung progenitor cells. The two distinct populations of progenitor cells could play crucial roles in alveolar cell regeneration and epithelial barrier re-establishment, respectively. In order to understand the function of KRT5+ progenitors in vivo, we transplanted a single KRT5+ cell-derived cell population into damaged mouse lung. Time-course single-cell transcriptomic analysis showed that the transplanted KRT5+ progenitors could long-term engrafted into host lung and differentiate into HOPX+ OCLN+ alveolar barrier cell which restored the epithelial barrier and efficiently prevented inflammatory cell infiltration. Similar barrier cells were also identified in some COVID-19 patients with massive leukocyte infiltration. Altogether this work uncovered the mechanism that how various lung progenitor cells work in concert to prevent and replenish alveoli loss post severe SARS-CoV-2 infection.","Zuo, W.; Zhao, Z.; Zhao, Y.; Zhou, Y.; Wang, X.; Zhang, T.","https://www.biorxiv.org/content/10.1101/2020.07.13.200188v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.200188v1?rss=1,2020-07-13,2020-07-13,,False
501,Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds,"To interfere with the biology of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, we focused on restoring the transcriptional response induced by infection. Utilizing expression patterns of SARS-CoV-2-infected cells, we identified a region in gene expression space that was unique to virus infection and inversely proportional to the transcriptional footprint of known compounds characterized in the Library of Integrated Network-based Cellular Signatures. Here we demonstrate the successful identification of compounds that display efficacy in blocking SARS-CoV-2 replication based on their ability to counteract the virus-induced transcriptional landscape. These compounds were found to potently reduce viral load despite having no impact on viral entry or modulation of the host antiviral response in the absence of virus. RNA-Seq profiling implicated the induction of the cholesterol biosynthesis pathway as the underlying mechanism of inhibition and suggested that targeting this aspect of host biology may significantly reduce SARS-CoV-2 viral load.","Hoagland, D. A.; Clarke, D. J. B.; Moeller, R.; Han, Y.; Yang, L.; Wojciechowicz, M. L.; Lachmann, A.; Oguntuyo, K. Y.; Stevens, C.; Lee, B.; Chen, S.; Ma'ayan, A.; tenOever, B. R.","https://www.biorxiv.org/content/10.1101/2020.07.12.199687v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199687v1?rss=1,2020-07-13,2020-07-13,,False
502,Identifying Key Determinants of SARS-CoV-2/ACE2 Tight Interaction,"SARS-CoV-2 virus, the causative agent of Covid-19, has fired up a global pandemic. The virus interacts with the human receptor angiotensin-converting enzyme 2 (ACE2) for invasion via receptor binding domain (RBD) on its spike protein. To provide a deeper understanding of this interaction, we performed microsecond simulations of the RBD-ACE2 complex for SARS- CoV-2 and compared it with the closely related SARS-CoV discovered in 2003. We show residues in the RBD of SARS-CoV-2 that were mutated from SARS-CoV, collectively help make RBD anchor much stronger to the N-terminal part of ACE2 than the corresponding residues on RBD of SARS-CoV. This would result in reduced dissociation rate of SARS-CoV-2 from human recep- tor protein compared to SARS-CoV. This phenomenon was consistently observed in simulations beyond 500 ns and was reproducible across different force fields. Altogether, our study shed light on the key residues and their dynamics at the virus spike and human receptor binding interface and advance our knowledge for the development of diagnostics and therapeutics to combat the pandemic efficiently.","Ngo, V. A.; Jha, R. K.","https://www.biorxiv.org/content/10.1101/2020.07.13.199562v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.13.199562v1?rss=1,2020-07-13,2020-07-13,,False
503,Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro,Tafenoquine [TQ] exhibited EC50/90s of ~ 2.6/5.1 M against SARS-CoV-2 in VERO E6 cells and was 4-fold more potent than hydroxychloroquine [HCQ]. Time-of-addition experiments were consistent with a different mechanism for TQ v HCQ. Physiologically based pharmacokinetic (PBPK) modeling suggested that lung unbound concentrations of TQ in COVID-19 patients may exceed the EC90 for at least 8 weeks after administration. The therapeutic potential for TQ in management of COVID-19 should be further evaluated.,Geoffrey Dow; Angela Luttick; Jen Fenner; David Wesche; Karen Rowland Yeo; Craid Rayner,"https://www.biorxiv.org/content/10.1101/2020.07.12.199059v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199059v1?rss=1,2020-07-12,2020-07-12,,False
504,Flexibility and mobility of SARS-CoV-2-related protein structures,"The worldwide CoVid-19 pandemic has led to an unprecedented push across the whole of the scientific community to develop a potent antiviral drug and vaccine as soon as possible. Existing academic, governmental and industrial institutions and companies have engaged in large-scale screening of existing drugs, in vitro, in vivo and in silico. Here, we are using in silico modelling of SARS-CoV-2 drug targets, i.e. SARS-CoV-2 protein structures as deposited on the Protein Databank (PDB). We study their flexibility, rigidity and mobility, an important first step in trying to ascertain their dynamics for further drug-related docking studies. We are using a recent protein flexibility modelling approach, combining protein structural rigidity with possible motion consistent with chemical bonds and sterics. For example, for the SARS-CoV-2 spike protein in the open configuration, our method identifies a possible further opening and closing of the S1 subunit through movement of SB domain. With full structural information of this process available, docking studies with possible drug structures are then possible in silico. In our study, we present full results for the more than 200 thus far published SARS-CoV-2-related protein structures in the PDB.",Rudolf A Roemer; Navodya Sophie Roemer; Anne Katrine Wallis,"https://www.biorxiv.org/content/10.1101/2020.07.12.199364v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.12.199364v1?rss=1,2020-07-12,2020-07-12,,False
505,ACE2-expressing endothelial cells in aging mouse brain,"Angiotensin-converting enzyme 2 (ACE2) is a key receptor mediating the entry of SARS-CoV-2 into the host cell. Through a systematic analysis of publicly available mouse brain sc/snRNA-seq data, we found that ACE2 is specifically expressed in small sub-populations of endothelial cells and mural cells, namely pericytes and vascular smooth muscle cells. Further, functional changes in viral mRNA transcription and replication, and impaired blood-brain barrier regulation were most prominently implicated in the aged, ACE2-expressing endothelial cells, when compared to the young adult mouse brains. Concordant EC transcriptomic changes were further found in normal aged human brains. Overall, this work reveals an outline of ACE2 distribution in the mouse brain and identify putative brain host cells that may underlie the selective susceptibility of the aging brain to viral infection.",SU Bin Lim; Valina L. Dawson; Ted M. Dawson; Sung-Ung Kang,"https://www.biorxiv.org/content/10.1101/2020.07.11.198770v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.11.198770v1?rss=1,2020-07-11,2020-07-11,,False
506,A simple protein-based SARS-CoV-2 surrogate neutralization assay,"With the COVID-19 pandemic surpassing 12M confirmed cases and 550K deaths worldwide, defining the key components of the immune response to SARS-CoV-2 infection is critical. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present and validate a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) with its receptor, angiotensin converting-enzyme 2 (ACE2). This test is performed on the same platform and in parallel with an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against the RBD and serves as a surrogate neutralization assay.",Kento T Abe; Zhijie Li; Reuben Samson; Payman Samavarchi-Tehrani; Emelissa J Valcourt; Heidi Wood; Patrick Budylowski; Alan Dupuis; Roxie C Girardin; Bhavisha Rathod; Karen Colwill; Allison McGeer; Samira Mubareka; Jennifer L. Gommerman; Yves Durocher; Mario  A Ostrowski; Kathleen McDonough; Michael A. Drebot; Steven J. Drews; James M Rini; Anne-Claude Gingras,"https://www.biorxiv.org/content/10.1101/2020.07.10.197913v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197913v1?rss=1,2020-07-11,2020-07-11,,False
507,Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles,"While vaccine development will hopefully quell the global pandemic of COVID-19 caused by SARS-CoV-2, small molecule drugs that can effectively control SARS-CoV-2 infection are urgently needed. Here inhibitors of two coronavirus spike proteins (S) were identified by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Using high-throughput screening technology, we discovered three compounds (cepharanthine, abemaciclib and trimipramine) to be broad spectrum inhibitors for spike-mediated entry. This work should contribute to the development of effective treatments against the initial stage of viral infection, thus reducing viral burden in COVID-19 patients.",Catherine Z. Chen; Miao Xu; Manisha Pradhan; Kirill Gorshkov; Jennifer Petersen; Marco R. Straus; Wei Zhu; Paul Shinn; Hui Guo; Min Shen; Carleen Klumpp-Thomas; Samuel G. Michael; Joshua Zimmerberg; Wei Zheng; Gary R Whittaker,"https://www.biorxiv.org/content/10.1101/2020.07.10.197988v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197988v1?rss=1,2020-07-11,2020-07-11,,False
508,A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine,"The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread world-wide with millions of cases and hundreds of thousands of deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines.

Author ContributionsCH performed research, analyzed data, and wrote the paper; CS performed research and analyzed data; AA performed research and analyzed data; AE performed research and analyzed data; SM performed research, analyzed data, and wrote the paper; MH developed the bioinformatics pipeline and analyzed data; BS contributed new reagents and concepts; MDM designed and supervised research, analyzed data and wrote the paper; all authors read, corrected and approved the final manuscript.

Significance StatementThe COVID-19 pandemic has caused hundreds of thousands of deaths, yet. Therefore, effective vaccine concepts are urgently needed. In search for such a concept, we have analysed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity with the desired immune bias. Therefore, occurrence of immunopathologies such as antibody-dependent enhancement or enhanced respiratory disease is rather unlikely. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are entrapped to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.",Cindy Hoerner; Christoph Schuermann; Arne Auste; Aileen Ebenig; Samada Muraleedharan; Maike Herrmann; Barbara Schnierle; Michael D Muehlebach,"https://www.biorxiv.org/content/10.1101/2020.07.11.198291v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.11.198291v1?rss=1,2020-07-11,2020-07-11,,False
509,Genomic variations in SARS-CoV-2 genomes from Gujarat: Underlying role of variants in disease epidemiology,"Humanity has seen numerous pandemics during its course of evolution. The list includes many such as measles, Ebola, SARS, MERS, etc. Latest edition to this pandemic list is COVID-19, caused by the novel coronavirus, SARS-CoV-2. As of 4th July 2020, COVID-19 has affected over 10 million people from 170+ countries, and 5,28,364 deaths. Genomic technologies have enabled us to understand the genomic constitution of the pathogens, their virulence, evolution, rate of mutations, etc. To date, more than 60,000 virus genomes have been deposited in the public depositories like GISAID and NCBI. While we are writing this, India is the 3rd most-affected country with COVID-19 with 0.6 million cases, and >18000 deaths. Gujarat is the fourth highest affected state with 5.44 percent death rate compared to national average of 2.8 percent.

Here, 361 SARS-CoV-2 genomes from across Gujarat have been sequenced and analyzed in order to understand its phylogenetic distribution and variants against global and national sequences. Further, variants were analyzed from diseased and recovered patients from Gujarat and the World to understand its role in pathogenesis. From missense mutations, found from Gujarat SARS-CoV-2 genomes, C28854T, deleterious mutation in nucleocapsid (N) gene was found to be significantly associated with mortality in patients. The other significant deleterious variant found in diseased patients from Gujarat and the world is G25563T, which is located in Orf3a and has a potential role in viral pathogenesis. SARS-CoV-2 genomes from Gujarat are forming distinct cluster under GH clade of GISAID.",Madhvi Joshi; Apurvasinh C Puvar; Dinesh Kumar; Afzal Ansari; Maharshi Pandya; Janvi Raval; Zarna Patel; Pinal Trivedi; Monica Gandhi; Labdhi Pandya; Komal Patel; Nitin Savaliya; Snehal Bagatharia; Sachin Kumar; Chaitanya Joshi,"https://www.biorxiv.org/content/10.1101/2020.07.10.197095v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197095v1?rss=1,2020-07-10,2020-07-10,,False
510,"SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function","Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) emerged in late 2019 and has spread worldwide resulting in the Coronavirus Disease 2019 (COVID-19) pandemic. Although animal models have been evaluated for SARS-CoV-2 infection, none have recapitulated the severe lung disease phenotypes seen in hospitalized human cases. Here, we evaluate heterozygous transgenic mice expressing the human ACE2 receptor driven by the epithelial cell cytokeratin-18 gene promoter (K18-hACE2) as a model of SARS-CoV-2 infection. Intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice results in high levels of viral infection in lung tissues with additional spread to other organs. Remarkably, a decline in pulmonary function, as measured by static and dynamic tests of respiratory capacity, occurs 4 days after peak viral titer and correlates with an inflammatory response marked by infiltration into the lung of monocytes, neutrophils, and activated T cells resulting in pneumonia. Cytokine profiling and RNA sequencing analysis of SARS-CoV-2-infected lung tissues show a massively upregulated innate immune response with prominent signatures of NF-kB-dependent, type I and II interferon signaling, and leukocyte activation pathways. Thus, the K18-hACE2 model of SARS-CoV-2 infection recapitulates many features of severe COVID-19 infection in humans and can be used to define the mechanistic basis of lung disease and test immune and antiviral-based countermeasures.",Emma S Winkler; Adam L Bailey; Natasha M Kafai; Sharmila Nair; Broc T McCune; Jinsheng Yu; Julie M Fox; Rita E Chen; James T Earnest; Shamus P Keeler; Jon H Ritter; Liang-I Kang; Sarah Dort; Annette Robichaud; Richard Head; Michael J Holtzman; Michael S Diamond,"https://www.biorxiv.org/content/10.1101/2020.07.09.196188v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196188v1?rss=1,2020-07-10,2020-07-10,,False
511,Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8+ T cells,"The molecular properties of CD8+ T cells that respond to SARS-CoV-2 infection are not fully known. Here, we report on the single-cell transcriptomes of >80,000 virus-reactive CD8+ T cells from 39 COVID-19 patients and 10 healthy subjects. COVID-19 patients segregated into two groups based on whether the dominant CD8+ T cell response to SARS-CoV-2 was  exhausted or not. SARS-CoV-2-reactive cells in the exhausted subset were increased in frequency and displayed lesser cytotoxicity and inflammatory features in COVID-19 patients with mild compared to severe illness. In contrast, SARS-CoV-2-reactive cells in the non-exhausted subsets from patients with severe disease showed enrichment of transcripts linked to co-stimulation, pro-survival NF-{kappa}B signaling, and anti-apoptotic pathways, suggesting the generation of robust CD8+ T cell memory responses in patients with severe COVID-19 illness. CD8+ T cells reactive to influenza and respiratory syncytial virus from healthy subjects displayed polyfunctional features. Cells with such features were mostly absent in SARS-CoV-2 responsive cells from both COVID-19 patients and healthy controls non-exposed to SARS-CoV-2. Overall, our single-cell analysis revealed substantial diversity in the nature of CD8+ T cells responding to SARS-CoV-2.",Anthony Kusnadi; Ciro Ramrez-Sustegui; Vicente Fajardo; Serena J Chee; Benjamin J Meckiff; Hayley Simon; Emanuela Pelosi; Grgory Seumois; Ferhat Ay; Pandurangan Vijayanand; Christian H Ottensmeier,"https://www.biorxiv.org/content/10.1101/2020.07.09.194027v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.194027v1?rss=1,2020-07-10,2020-07-10,,False
512,Robust three-dimensional expansion of human adult alveolar stem cells and SARS-CoV-2 infection,"Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), which is the cause of a present global pandemic, infects human lung alveolar cells (hACs). Characterising the pathogenesis is crucial for developing vaccines and therapeutics. However, the lack of models mirroring the cellular physiology and pathology of hACs limits the study. Here, we develop a feeder-free, long-term three-dimensional (3D) culture technique for human alveolar type 2 (hAT2) cells, and investigate infection response to SARS-CoV-2. By imaging-based analysis and single-cell transcriptome profiling, we reveal rapid viral replication and the increased expression of interferon-associated genes and pro-inflammatory genes in infected hAT2 cells, indicating robust endogenous innate immune response. Further tracing of viral mutations acquired during transmission identifies full infection of individual cells effectively from a single viral entry. Our study provides deep insights into the pathogenesis of SARS-CoV-2, and the application of long-term 3D hAT2 cultures as models for respiratory diseases.",Jeonghwan Youk; Taewoo Kim; Kelly V. Evans; Young-Il Jeong; Yongsuk Hur; Seon Pyo Hong; Je Hyoung Kim; Kijong Yi; Su Yeon Kim; Kwon Joong Na; Thomas Bleazard; Ho Min Kim; Natasha Ivory; Krishnaa T. Mahbubani; Kourosh Saeb-Parsy; Young Tae Kim; Gou Young Koh; Byeong-Sun Choi; Young Seok Ju; Joo-Hyeon Lee,"https://www.biorxiv.org/content/10.1101/2020.07.10.194498v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.194498v1?rss=1,2020-07-10,2020-07-10,,False
513,Comprehensive in-vivo secondary structure of SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms,"SARS-CoV-2 is the positive-sense RNA virus that causes COVID-19, a disease that has triggered a major human health and economic crisis. The genome of SARS-CoV-2 is unique among viral RNAs in its vast potential to form stable RNA structures and yet, as much as 97% of its 30 kilobases have not been structurally explored in the context of a viral infection. Our limited knowledge of SARS-CoV-2 genomic architecture is a fundamental limitation to both our mechanistic understanding of coronavirus life cycle and the development of COVID-19 RNA-based therapeutics. Here, we apply a novel long amplicon strategy to determine for the first time the secondary structure of the SARS-CoV-2 RNA genome probed in infected cells. In addition to the conserved structural motifs at the viral termini, we report new structural features like a conformationally flexible programmed ribosomal frameshifting pseudoknot, and a host of novel RNA structures, each of which highlights the importance of studying viral structures in their native genomic context. Our in-depth structural analysis reveals extensive networks of well-folded RNA structures throughout Orf1ab and reveals new aspects of SARS-CoV-2 genome architecture that distinguish it from other single-stranded, positive-sense RNA viruses. Evolutionary analysis of RNA structures in SARS-CoV-2 shows that several features of its genomic structure are conserved across beta coronaviruses and we pinpoint individual regions of well-folded RNA structure that merit downstream functional analysis. The native, complete secondary structure of SAR-CoV-2 presented here is a roadmap that will facilitate focused studies on mechanisms of replication, translation and packaging, and guide the identification of new RNA drug targets against COVID-19.",Nicholas C Huston; Han Wan; Rafael de Cesaris Araujo Tavares; Craig B Wilen; Anna Marie Pyle,"https://www.biorxiv.org/content/10.1101/2020.07.10.197079v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197079v1?rss=1,2020-07-10,2020-07-10,,False
514,Which animals are at risk? Predicting species susceptibility to Covid-19,"In only a few months, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, leaving physicians, scientists, and public health officials racing to understand, treat, and contain this zoonotic disease. SARS-CoV-2 has made the leap from animals to humans, but little is known about variations in species susceptibility that could identify potential reservoir species, animal models, and the risk to pets, wildlife, and livestock. While there is evidence that certain species, such as cats, are susceptible, the vast majority of animal species, including those in close contact with humans, have unknown susceptibility. Hence, methods to predict their infection risk are urgently needed. SARS-CoV-2 spike protein binding to angiotensin converting enzyme 2 (ACE2) is critical for viral cell entry and infection. Here we identified key ACE2 residues that distinguish susceptible from resistant species using in-depth sequence and structural analyses of ACE2 and its binding to SARS-CoV-2. Our findings have important implications for identification of ACE2 and SARS-CoV-2 residues for therapeutic targeting and identification of animal species with increased susceptibility for infection on which to focus research and protection measures for environmental and public health.",Matthew R Alexander; Clara T. Schoeder; Jacquelyn A. Brown; Charles D. Smart; Christopher W. Moth; John P. Wikswo; John Anthony Capra; Jens Meiler; Wenbiao Chen; Meena S. Madhur,"https://www.biorxiv.org/content/10.1101/2020.07.09.194563v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.194563v1?rss=1,2020-07-10,2020-07-10,,False
515,SARS-CoV-2 induces activation and diversification of human plasmacytoid pre-dendritic cells.,"Several studies have analyzed antiviral immune pathways in severe COVID-19 patients. However, the initial steps of antiviral immunity are not known. Here, we have studied the interaction of isolated primary SARS-CoV-2 viral strains with human plasmacytoid pre-dendritic cells (pDC), a key player in antiviral immunity. We show that pDC are not permissive to SARS-CoV-2 infection. However, they efficiently diversified into activated P1-, P2-, and P3-pDC effector subsets in response to viral stimulation. They expressed checkpoint molecules at levels similar to influenza virus-induced activation. They rapidly produced high levels of interferon-, interferon-{lambda}1, IL-6, IP-10, and IL-8. Importantly, all major aspects of SARS-CoV-2-induced pDC activation were inhibited by hydroxychloroquine, including P2- and P3-pDC differentiation, the expression of maturation markers, and the production of interferon- and inflammatory cytokines. Our results indicate that pDC may represent a major player in the first line of defense against SARS-CoV-2 infection, and call for caution in the use of hydroxychloroquine in the early treatment of the disease.",Fanny Onodi; Lucie Bonnet-Madin; La Karpf; Laurent Meertens; Justine Poirot; Jerme LeGoff; Constance Delaugerre; Ali AMARA; Vassili Soumelis,"https://www.biorxiv.org/content/10.1101/2020.07.10.197343v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197343v1?rss=1,2020-07-10,2020-07-10,,False
516,Discriminating Mild from Critical COVID-19 by Innate and Adaptive Immune Single-cell Profiling of Bronchoalveolar Lavages,"How innate and adaptive lung immune responses to SARS-CoV-2 synchronize during COVID-19 pneumonitis and regulate disease severity is poorly established. To address this, we applied single-cell profiling to bronchoalveolar lavages from 44 patients with mild or critical COVID-19 versus non-COVID-19 pneumonia as control. Viral RNA-tracking delineated the infection phenotype to epithelial cells, but positioned mainly neutrophils at the forefront of viral clearance activity during COVID-19. In mild disease, neutrophils could execute their antiviral function in an immunologically  controlled fashion, regulated by fully-differentiated T-helper-17 (TH17)-cells, as well as T-helper-1 (TH1)-cells, CD8+ resident-memory (TRM) and partially-exhausted (TEX) T-cells with good effector functions. This was paralleled by  orderly phagocytic disposal of dead/stressed cells by fully-differentiated macrophages, otherwise characterized by anti-inflammatory and antigen-presenting characteristics, hence facilitating lung tissue repair. In critical disease, CD4+ TH1- and CD8+ TEX-cells were characterized by inflammation-associated stress and metabolic exhaustion, while CD4+ TH17- and CD8+ TRM-cells failed to differentiate. Consequently, T-cell effector function was largely impaired thereby possibly facilitating excessive neutrophil-based inflammation. This was accompanied by impaired monocyte-to-macrophage differentiation, with monocytes exhibiting an ATP-purinergic signalling-inflammasome footprint, thereby enabling COVID-19 associated fibrosis and worsening disease severity. Our work represents a major resource for understanding the lung-localised immunity and inflammation landscape during COVID-19.",Els Wauters; Pierre Van Mol; Abhishek D. Garg; Sander Jansen; Yannick Van Herck; Lore Vanderbeke; Ayse Bassez; Bram Boeckx; Bert Malengier-Devlies; Anna Timmerman; Thomas Van Brussel; Tina Van Buyten; Rogier Schepers; Elisabeth Heylen; Dieter Dauwe; Christophe Dooms; Jan Gunst; Greet Hermans; Philippe Meersseman; Dries Testelmans; Jonas Yserbyt; Patrick Matthys; Sabine Tejpar; CONTAGIOUS collaborators; Johan Neyts; Joost Wauters; Junbin Qian; Diether Lambrechts,"https://www.biorxiv.org/content/10.1101/2020.07.09.196519v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196519v1?rss=1,2020-07-10,2020-07-10,,False
517,Genomic Mutations and Changes in Protein Secondary Structure and Solvent Accessibility of SARS-CoV-2 (COVID-19 Virus),"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly pathogenic virus that has caused the global COVID-19 pandemic. Tracing the evolution and transmission of the virus is crucial to respond to and control the pandemic through appropriate intervention strategies. This paper reports and analyses genomic mutations in the coding regions of SARS-CoV-2 and their probable protein secondary structure and solvent accessibility changes, which are predicted using deep learning models. Prediction results suggest that mutation D614G in the virus spike protein, which has attracted much attention from researchers, is unlikely to make changes in protein secondary structure and relative solvent accessibility. Based on 6,324 viral genome sequences, we create a spreadsheet dataset of point mutations that can facilitate the investigation of SARS-CoV-2 in many perspectives, especially in tracing the evolution and worldwide spread of the virus. Our analysis results also show that coding genes E, M, ORF6, ORF7a, ORF7b and ORF10 are most stable, potentially suitable to be targeted for vaccine and drug development.",Thanh Thi Nguyen; Pubudu N. Pathirana; Thin Nguyen; Henry Nguyen; Asim Bhatti; Dinh C. Nguyen; Dung Tien Nguyen; Ngoc Duy Nguyen; Douglas Creighton; Mohamed Abdelrazek,"https://www.biorxiv.org/content/10.1101/2020.07.10.171769v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.171769v1?rss=1,2020-07-10,2020-07-10,,False
518,Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19,"The disease caused by SARS-CoV2, covid-19, rapidly spreads worldwide, causing the greatest threat to global public health in the last 100 years. This scenario has become catastrophic as there are no approved vaccines to prevent the disease, and the main measures to contain the virus transmission are confinement and social distancing. One priority strategy is based on drug repurposing by pursuing antiviral chemotherapy that can control transmission and prevent complications associated with covid-19. With this aim, we performed a high content screening assay for the discovery of anti-SARS-CoV-2 compounds. From the 65 screened compounds, we have found four drugs capable to selectively inhibit SARS-CoV-2 in vitro infection: brequinar, abiraterone acetate, neomycin, and the extract of Hedera helix. Brequinar and abiraterone acetate had higher inhibition potency against SARS-CoV-2 than neomycin and Hedera helix extract, respectively. Drugs with reported antiviral activity and in clinical trials for covid-19, chloroquine, ivermectin, and nitazoxanide, were also included in the screening, and the last two were found to be non-selective. We used a data mining approach to build drug-host molecules-biological function-disease networks to show in a holistic way how each compound is interconnected with host node molecules and virus infection, replication, inflammatory response, and cell apoptosis. In summary, the present manuscript identified four drugs with active inhibition effect on SARS-CoV-2 in vitro infection, and by network analysis, we provided new insights and starting points for the clinical evaluation and repurposing process to treat SARS-CoV-2 infection.

Summary sentenceDiscovery of drug repurposing candidates, inhibitors of SARS-CoV-2 infection in vitro, using a phenotypic screening strategy and network analysis.",Douglas  Ferreira Sales-Medina; Ludmila Rodrigues Pinto Ferreira; Lavinia M. D. Romera; Karolina R Goncalves; Rafael V. C. Guido; Gilles Courtemanche; Marcos S. Buckeridge; Edison  Luiz Durigon; Carolina B. Moraes; Lucio Freitas Junior,"https://www.biorxiv.org/content/10.1101/2020.07.09.196337v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196337v1?rss=1,2020-07-10,2020-07-10,,False
519,"Inactivation analysis of SARS-CoV-2 by specimen transport media, nucleic acid extraction reagents, detergents and fixatives","The COVID-19 pandemic has necessitated a rapid multi-faceted response by the scientific community, bringing researchers, health officials and industry together to address the ongoing public health emergency. To meet this challenge, participants need an informed approach for working safely with the etiological agent, the novel human coronavirus SARS-CoV-2. Work with infectious SARS-CoV-2 is currently restricted to high-containment laboratories, but material can be handled at a lower containment level after inactivation. Given the wide array of inactivation reagents that are being used in laboratories during this pandemic, it is vital that their effectiveness is thoroughly investigated. Here, we evaluated a total of 23 commercial reagents designed for clinical sample transportation, nucleic acid extraction and virus inactivation for their ability to inactivate SARS-CoV-2, as well as seven other common chemicals including detergents and fixatives. As part of this study, we have also tested five filtration matrices for their effectiveness at removing the cytotoxic elements of each reagent, permitting accurate determination of levels of infectious virus remaining following treatment. In addition to providing critical data informing inactivation methods and risk assessments for diagnostic and research laboratories working with SARS-CoV-2, these data provide a framework for other laboratories to validate their inactivation processes and to guide similar studies for other pathogens.",Stephen Welch; Katherine Davies; Hubert Buczkowski; Nipunadi Hettiarachchi; Nicole Green; Ulrike Arnold; Matthew Jones; Matthew J Hannah; Reah Evans; Christopher Burton; Jane E Burton; Malcolm Guiver; Patricia A Cane; Neil Woodford; Christine B Bruce; Allen D.G Roberts; Marian J Killip,"https://www.biorxiv.org/content/10.1101/2020.07.08.194613v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.194613v1?rss=1,2020-07-10,2020-07-10,,False
520,A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified pathogen causing coronavirus disease 2019 (COVID-19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies. However, lung concentration (6.7 {micro}g/mL) to predict the in vivo antiviral efficacy might not be achievable with the currently proposed oral dosing regimen. Further, a high cumulative doses of HCQ may raise concerns of systemic toxicity, including cardiotoxicity. Here, we described a non-clinical study to investigate the pharmacokinetics of a novel formulation of liposomal HCQ administrated by intratracheal (IT) instillation in Sprague-Dawley (SD) rats which achieved 129.4 {micro}g/g (Cmax) in the lung. Compared to unformulated HCQ administered intravenous (IV), liposomal HCQ with normalized dose showed higher ([~]30-fold) lung exposure, longer ([~]2.5-fold) half-life in lung, but lower blood exposure with [~]20% of Cmax and 74% of AUC and lower heart exposure with 24% of Cmax and 58% of AUC. In conclusion, the pharmacokinetics results in an animal model demonstrate the proof of concept that inhalable liposomal HCQ may provide clinical benefit and serve as a potential treatment for COVID-19.",Tien-Tzu Tai; Tzung-Ju Wu; Huey-Dong Wu; Yi-Chen Tsai; Hui-Ting Wang; An-Min Wang; Sheue-Fang Shih; Yee-Chun Chen,"https://www.biorxiv.org/content/10.1101/2020.07.09.196618v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196618v1?rss=1,2020-07-10,2020-07-10,,False
521,Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of human infections and hundreds of thousands of deaths. Accordingly, an effective vaccine is of critical importance in mitigating coronavirus induced disease 2019 (COVID-19) and curtailing the pandemic. We developed a replication-competent vesicular stomatitis virus (VSV)-based vaccine by introducing a modified form of the SARS-CoV-2 spike gene in place of the native glycoprotein gene (VSV-eGFP-SARS-CoV-2). Immunization of mice with VSV-eGFP-SARS-CoV-2 elicits high titers of antibodies that neutralize SARS-CoV-2 infection and target the receptor binding domain that engages human angiotensin converting enzyme-2 (ACE2). Upon challenge with a human isolate of SARS-CoV-2, mice expressing human ACE2 and immunized with VSV-eGFP-SARS-CoV-2 show profoundly reduced viral infection and inflammation in the lung indicating protection against pneumonia. Finally, passive transfer of sera from VSV-eGFP-SARS-CoV-2-immunized animals protects naive mice from SARS-CoV-2 challenge. These data support development of VSV-eGFP-SARS-CoV-2 as an attenuated, replication-competent vaccine against SARS-CoV-2.",James Brett Case; Paul Rothlauf; Rita E. Chen; Natasha Kafai; Julie M. Fox; Swathi Shrihari; Broc T. McCune; Ian B. Harvey; Brittany Smith; Shamus Keeler; Louis-Marie Bloyet; Emma S Winkler; Michael J. Holtzman; Daved H. Fremont; Sean P. J. Whelan; Michael S. Diamond,"https://www.biorxiv.org/content/10.1101/2020.07.09.196386v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196386v1?rss=1,2020-07-10,2020-07-10,,False
522,Stabilizing the Closed SARS-CoV-2 Spike Trimer,"The trimeric spike (S) protein of SARS-CoV-2 is the primary focus of most vaccine design and development efforts. Due to intrinsic instability typical of class I fusion proteins, S tends to prematurely refold to the post-fusion conformation, compromising immunogenic properties and prefusion trimer yields. To support ongoing vaccine development efforts, we report the structure-based design of soluble S trimers, with increased yields and stabilities, based on introduction of single point mutations and disulfide-bridges. We identify two regions in the S-protein critical for the proteins stability: the heptad repeat region 1 of the S2 subunit and subunit domain 1 at the interface with S2. We combined a minimal selection of mostly interprotomeric mutations to create a stable S-closed variant with a 6.4-fold higher expression than the parental construct while no longer containing a heterologous trimerization domain. The cryo-EM structure reveals a correctly folded, predominantly closed pre-fusion conformation. Highly stable and well producing S protein and the increased understanding of S protein structure will support vaccine development and serological diagnostics.",Jarek Juraszek; Lucy Rutten; Sven Blokland; Pascale Bouchier; Richard Voorzaat; Tina Ritschel; Mark J.G. Bakkers; Ludovic L.R. Renault; Johannes P.M. Langedijk,"https://www.biorxiv.org/content/10.1101/2020.07.10.197814v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197814v1?rss=1,2020-07-10,2020-07-10,,False
523,A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.,"The SARS coronavirus type 2 (SARS-CoV-2) emerged in late 2019 as a zoonotic virus highly transmissible between humans that has caused the COVID-19 pandemic 1,2. This pandemic has the potential to disrupt healthcare globally and has already caused high levels of mortality, especially amongst the elderly. The overall case fatality rate for COVID-19 is estimated to be [~]2.3% overall 3 and 32.3% in hospitalized patients age 70-79 years 4. Therapeutic options for treating the underlying viremia in COVID-19 are presently limited by a lack of effective SARS-CoV-2 antiviral drugs, although steroidal anti-inflammatory treatment can be helpful. A variety of potential antiviral targets for SARS-CoV-2 have been considered including the spike protein and replicase. Based upon previous successful antiviral drug development for HIV-1 and hepatitis C, the SARS-CoV-2 main protease (Mpro) appears an attractive target for drug development. Here we show the existing pharmacopeia contains many drugs with potential for therapeutic repurposing as selective and potent inhibitors of SARS-CoV-2 Mpro. We screened a collection of [~]6,070 drugs with a previous history of use in humans for compounds that inhibit the activity of Mpro in vitro. In our primary screen we found [~]50 compounds with activity against Mpro (overall hit rate <0.75%). Subsequent dose validation studies demonstrated 8 dose responsive hits with an IC50 [&le;] 50 M. Hits from our screen are enriched with hepatitis C NS3/4A protease targeting drugs including Boceprevir (IC50=0.95 M), Ciluprevir (20.77M). Narlaprevir (IC50=1.10M), and Telaprevir (15.25M). These results demonstrate that some existing approved drugs can inhibit SARS-CoV-2 Mpro and that screen saturation of all approved drugs is both feasible and warranted. Taken together this work suggests previous large-scale commercial drug development initiatives targeting hepatitis C NS3/4A viral protease should be revisited because some previous lead compounds may be more potent against SARS-CoV-2 Mpro than Boceprevir and suitable for rapid repurposing.",Jeremy D Baker; Rikki L Uhrich; Gerald C Kraemer; Jason E Love; Brian C Kraemer,"https://www.biorxiv.org/content/10.1101/2020.07.10.197889v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.10.197889v1?rss=1,2020-07-10,2020-07-10,,False
524,Molecular analysis of binding region of an ACE2 as a receptor for SARS-CoV-2 between humans and mammals,"In June 2020, a second wave of coronavirus disease-2019 (COVID-19) infections raised concern in Beijing, where salmon sold a fresh fish wholesale market was suspected of being the source of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. It has raised questions in the press and elsewhere about the scientific basis of salmon as a source of infection. With the number of cases growing, the surface of a salmon chopping board in the market was examined for the presence of SARS-CoV-2 and a positive reaction was observed. Following these test results, there has been debate over whether salmon can be infected with SARS-CoV-2. To find assess this, we investigated the structural homology of angiotensin-converting enzyme 2 (ACE2), a host-side receptor for SARS-CoV-2, between humans and other species including salmon and mink. As a result, a high structural homology between ACE2 and mink, which has reportedly transmitted SARS-CoV-2 to humans, was confirmed. However, a non-high structural homology of ACE2 between salmon and humans was observed. Further experiments are needed to find the source of SARS-CoV-2 transmission to the salmon.",Takuma Hayashi; Kaoru Abiko; Masaki Mandai; Ikuo Konishi; Nobuo Yaegashi,"https://www.biorxiv.org/content/10.1101/2020.07.09.196378v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.196378v1?rss=1,2020-07-10,2020-07-10,,False
525,Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2,"During virus infection B cells are critical for the production of antibodies and protective immunity. Here we show that the human B cell compartment in patients with diagnostically confirmed SARS-CoV-2 and clinical COVID-19 is rapidly altered with the early recruitment of B cells expressing a limited subset of IGHV genes, progressing to a highly polyclonal response of B cells with broader IGHV gene usage and extensive class switching to IgG and IgA subclasses with limited somatic hypermutation in the initial weeks of infection. We identify extensive convergence of antibody sequences across SARS-CoV-2 patients, highlighting stereotyped naive responses to this virus. Notably, sequence-based detection in COVID-19 patients of convergent B cell clonotypes previously reported in SARS-CoV infection predicts the presence of SARS-CoV/SARS-CoV-2 cross-reactive antibody titers specific for the receptor-binding domain. These findings offer molecular insights into shared features of human B cell responses to SARS-CoV-2 and other zoonotic spillover coronaviruses.",Sandra C. A. Nielsen; Fan Yang; Katherine J. L. Jackson; Ramona A. Hoh; Katharina Rltgen; Bryan Stevens; Ji-Yeun Lee; Arjun Rustagi; Angela J. Rogers; Abigail E. Powell; Javaria Najeeb; Ana R. Otrelo-Cardoso; Kathryn E. Yost; Bence Daniel; Howard Y. Chang; Ansuman T. Satpathy; Theodore S. Jardetzky; Peter S. Kim; Taia T. Wang; Benjamin A. Pinsky; Catherine A. Blish; Scott D. Boyd,"https://www.biorxiv.org/content/10.1101/2020.07.08.194456v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.194456v1?rss=1,2020-07-09,2020-07-09,,False
526,Assessment of SARS-CoV-2 Specific CD4(+) and CD8 (+) T Cell Responses Using MHC Class I and II Tetramers,"The success of SARS-CoV-2 (CoV-2) vaccines is measured by their ability to mount immune memory responses that are long-lasting. To achieve this goal, it is important to identify surrogates of immune protection, namely, CoV-2 MHC Class I and II immunodominant pieces/epitopes and methodologies to measure them. Here, we present results of flow cytometry-based MHC Class I and II QuickSwitch platforms for assessing SARS-CoV-2 peptide binding affinities to various human alleles as well as the H-2 Kb mouse allele. Multiple SARS-CoV-2 potential MHC binders were screened and validated by QuickSwitch testing. While several predicted peptides with acceptable theoretical Kd showed poor MHC occupancies, fourteen MHC class II and a few MHC class I peptides showed promiscuity in that they bind with multiple MHC molecule types. With the peptide exchange generated MHC tetramers, scientists can assess CD4+ and CD8+ immune responses to these different MHC/peptide complexes. Results obtained with several SARS-CoV-2 MHC class I and II peptides are included and discussed.",Yuri Poluektov; Pirouz Daftarian; Marc C. Delcommenne,"https://www.biorxiv.org/content/10.1101/2020.07.08.194209v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.194209v1?rss=1,2020-07-09,2020-07-09,,False
527,Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals,"In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to COVID-19 patients. The therapy has been deemed safe and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of [&ge;]1:160 have been recommended in some convalescent plasma trials for inclusion. Here we performed repeated analyses at one-month interval on 31 convalescent individuals to evaluate how the humoral responses against the SARS-CoV-2 Spike, including neutralization, evolve over time. We observed that receptor-binding domain (RBD)-specific IgG slightly decreased between six and ten weeks after symptoms onset but RBD-specific IgM decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing SARS-CoV-2 S wild-type or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after symptoms resolution.",Guillaume Beaudoin-Bussires; Annemarie Laumaea; Sai Priya Anand; Jrmie Prvost; Romain Gasser; Guillaume Goyette; Halima Medjahed; Jose Perreault; Tony Tremblay; Antoine Lewin; Laurie Gokool; Chantal Morrisseau; Philippe Bgin; Ccile Tremblay; Valrie Martel-Laferrire; Daniel E. Kaufmann; Jonathan Richard; Rene Bazin; Andrs Finzi,"https://www.biorxiv.org/content/10.1101/2020.07.09.194639v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.194639v1?rss=1,2020-07-09,2020-07-09,,False
528,Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency,"Understanding the mechanism of neutralizing antibodies (NAbs) against SARS-CoV-2 is critical for effective vaccines and therapeutics development. We recently reported an exceptionally potent NAb, BD-368-2, and revealed the existence of VH3-53/VH3-66 convergent NAbs in COVID-19. Here we report the 3.5-[A] cryo-EM structure of BD-368-2s Fabs in complex with a mutation-induced prefusion-state-stabilized spike trimer. Unlike VH3-53/VH3-66 NAbs, BD-368-2 fully blocks ACE2 binding by occupying all three receptor-binding domains (RBDs) simultaneously, regardless of their ""up"" and ""down"" positions. BD-368-2 also triggers fusogenic-like structural rearrangements of the spike trimer, which could impede viral entry. Moreover, BD-368-2 completely avoids the common epitope of VH3-53/VH3-66 NAbs, evidenced by multiple crystal structures of their Fabs in tripartite complexes with RBD, suggesting a new way of pairing potent NAbs to prevent neutralization escape. Together, these results rationalize a unique epitope that leads to exceptional neutralization potency, and provide guidance for NAb therapeutics and vaccine designs against SARS-CoV-2.",Shuo Du; Yunlong Cao; Qinyu Zhu; Guopeng Wang; Xiaoxia Du; Runsheng He; Hua Xu; Yinghui Zheng; Bo Wang; Yali Bai; Chenggong Ji; Ayijiang Yisimayi; Qisheng Wang; Ning Gao; X. Sunney Xie; Xiao-dong Su; Junyu Xiao,"https://www.biorxiv.org/content/10.1101/2020.07.09.195263v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.195263v1?rss=1,2020-07-09,2020-07-09,,False
529,Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike,"Binding of the spike protein of SARS-CoV-2 to the human angiotensin converting enzyme 2 (ACE2) receptor triggers translocation of the virus into cells. Both the ACE2 receptor and the spike protein are heavily glycosylated, including at sites near their binding interface. We built fully glycosylated models of the ACE2 receptor bound to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Using atomistic molecular dynamics (MD) simulations, we found that the glycosylation of the human ACE2 receptor contributes substantially to the binding of the virus. Interestingly, the glycans at two glycosylation sites, N90 and N322, have opposite effects on spike protein binding. The glycan at the N90 site partly covers the binding interface of the spike RBD. Therefore, this glycan can interfere with the binding of the spike protein and protect against docking of the virus to the cell. By contrast, the glycan at the N322 site interacts tightly with the RBD of the ACE2-bound spike protein and strengthens the complex. Remarkably, the N322 glycan binds into a conserved region of the spike protein identified previously as a cryptic epitope for a neutralizing antibody. By mapping the glycan binding sites, our MD simulations aid in the targeted development of neutralizing antibodies and SARS-CoV-2 fusion inhibitors.",Ahmad Reza Mehdipour; Gerhard Hummer,"https://www.biorxiv.org/content/10.1101/2020.07.09.193680v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.193680v1?rss=1,2020-07-09,2020-07-09,,False
530,"Comprehensive variant and haplotype landscapes of 50,500 global SARS-CoV-2 isolates and accelerating accumulation of country-private variant profiles","Understanding the genetic etiology of COVID-19 requires a comprehensive understanding of the variant and haplotype landscape of all reported genomes of SARS-COV-2, the causative virus of the disease. Country-, state/region- and possibly even city-private variant profiles may contribute to varied disease exemplifications and fatality rates observed across the globe along with host factors such as age, ethnicity and comorbidity. The Childrens Hospital of Los Angeles (CHLA) COVID-19 Analysis Research Database (CARD) captures up-to-date fulllength SARS-CoV-2 sequences of ~50,500 isolates from GISAID, GenBank, CHLA Center for Personalized Medicine, and other sources (as of June 18, 2020). Among which, 49,637 isolates carry at least one variation from the reference genome NC_045512, a total of 6,070 variants and 2,513 haplotypes were detected in at least three isolates independently. Together, they constituted the most likely SARS-CoV-2 variant and haplotype landscapes world-wide currently.

Evidence supporting positive (orf3a, orf8, S genes) and purifying (M gene) selections were detected, which warrants further investigation. Most interestingly, we identified 1,583 countryprivate variants from 10,238 isolates (20.6% overall) reported in 48 countries. 807 countryprivate haplotypes, defined as a haplotype shared by at least 5 isolates all of which came from the same country, were identified in in 8,656 isolates from 39 countries. United Kingdom, USA, and Australia had 464, 166 and 32 private haplotypes respectively, comprising 22.4%, 16.6% and 16.4% of the isolates from each country. Together with their descendent and private haplotypes with fewer members, 22,171 (45.8%) isolates carried country-private haplotypes globally. The percentage were 28.2-29.6% in January to March, and rapidly increased to 46.4% and 59.6% in April and May, co-occurring with global travel restrictions. The localization of the variant profiles appeared to be similarly accelerating from 14.2% in March and 28.4% in April to over 40% isolates carrying the country-private variants around May.

In summary, a common pattern is seen world-wide in COVID-19 in which at the onset of disease there appeared to be a significant number of SARS-CoV-2 variants that accumulate quickly and then begin to rapidly coalesce into distinct haplotypes. This may be the result of localized outbreaks due to factors such as multiple points viral introduction, geographic separation and the introduction of policies such as travel restriction, social distancing and quarantine, resulting in the emergence of country-private haplotypes.",Lishuang Shen; Jennifer Dien Bard; Jaclyn A. Biegel; Alexander R. Judkins; Xiaowu Gai,"https://www.biorxiv.org/content/10.1101/2020.07.09.193722v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.193722v1?rss=1,2020-07-09,2020-07-09,,False
531,Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease,"ABSTRACTThe emergence of SARS-CoV-2 has created an international health crisis. Small animal models mirroring SARS-CoV-2 human disease are essential for medical countermeasure (MCM) development. Mice are refractory to SARS-CoV-2 infection due to low affinity binding to the murine angiotensin-converting enzyme 2 (ACE2) protein. Here we evaluated the pathogenesis of SARS-CoV-2 in male and female mice expressing the human ACE2 gene under the control of the keratin 18 promotor. In contrast to non-transgenic mice, intranasal exposure of K18-hACE2 animals to two different doses of SARS-CoV-2 resulted in acute disease including weight loss, lung injury, brain infection and lethality. Vasculitis was the most prominent finding in the lungs of infected mice. Transcriptomic analysis from lungs of infected animals revealed increases in transcripts involved in lung injury and inflammatory cytokines. In the lower dose challenge groups, there was a survival advantage in the female mice with 60% surviving infection whereas all male mice succumbed to disease. Male mice that succumbed to disease had higher levels of inflammatory transcripts compared to female mice. This is the first highly lethal murine infection model for SARS-CoV-2. The K18-hACE2 murine model will be valuable for the study of SARS-CoV-2 pathogenesis and the assessment of MCMs.Competing Interest StatementThe authors have declared no competing interest.View Full Text",Joseph W. Golden; Curtis R. Cline; Xiankun Zeng; Aura R. Garrison; Brian D. Carey; Eric M. Mucker; Lauren E. White; Joshua D. Shamblin; Rebecca L. Brocato; Jun Liu; April M. Babka; Hypaitia B. Rauch; Jeffrey M. Smith; Bradley S. Hollidge; Collin Fitzpatrick; Catherine V. Badger; Jay W. Hooper,"https://www.biorxiv.org/content/10.1101/2020.07.09.195230v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.195230v1?rss=1,2020-07-09,2020-07-09,,False
532,A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate,"The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.",Lorena Sanchez Felipe; Thomas Vercruysse; Sapna Sharma; Ji Ma; Viktor Lemmens; Dominique van Looveren; Mahadesh Prasad Arkalagud Javarappa; Robbert Boudewijns; Bert Malengier-Devlies; Suzanne F. Kaptein; Laurens Liesenborghs; Carolien De Keyzer; Lindsey Bervoets; Madina Rasulova; Laura Seldeslachts; Sander Jansen; Michael Bright Yakass; Osbourne Quaye; Li-Hsin Li; Xin Zhang; Sebastiaan ter Horst; Niraj Mishra; Lotte Coelmont; Christopher Cawthorne; Koen Van Laere; Ghislain Opdenakker; Greetje Van de Velde; Birgit Weynand; Dirk E. Teuwen; Patrick Matthys; Johan Neyts; Hendrik Jan Thibaut; Kai D,"https://www.biorxiv.org/content/10.1101/2020.07.08.193045v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.193045v1?rss=1,2020-07-09,2020-07-09,,False
533,Screening and testing for a suitable untransfected cell line for SARS-CoV-2 studies,"At present, the novel pandemic coronavirus SARS-CoV-2 is a major global threat to human health and hence demands united research activities at different levels. Finding appropriate cell systems for drug screening and testing molecular interactions of the virus with the host cell is mandatory for drug development and understanding the mechanisms of viral entry and replication. For this, we selected human cell lines represented in the Cancer Cell Line Encyclopedia (CCLE) based on RNA-seq data determined transcript levels of ACE2 and TMPRSS2, two membrane proteins that have been identified to aid SARS-CoV-2 entry into the host cell. mRNA and protein expression of these host factors were verified via RQ-PCR and western blot. We then tested permissiveness of these cell lines towards SARS-CoV-2 infection, cytopathic effect, and viral replication finding limited correlation between receptor expression and infectability. One of the candidate cancer cell lines, the human colon cancer cell line CL-14, tested positive for SARS-CoV-2 infection. Our data argue that SARS-CoV-2 in vitro infection models need careful selection and validation since ACE2/TMPRSS2 receptor expression on its own does not guarantee permissiveness to the virus.

Author summaryIn the midst of the pandemic outbreak of corona-virus SARS-CoV-2 therapeutics for disease treatment are still to be tested and the virus-host-interactions are to be elucidated. Drug testing and viral studies are commonly conducted with genetically manipulated cells. In order to find a cell model system without genetic modification we screened human cell lines for two proteins known to facilitate entry of SARS-CoV-2. We confirmed and quantified permissiveness of current cell line infection models, but dismissed a number of receptor-positive cell lines that did not support viral replication. Importantly, ACE2/TMPRSS2 co-expression seems to be necessary for viral entry but is not sufficient to predict permissiveness of various cancer cell lines. Moreover, the expression of specific splice variants and the absence of missense mutations of the host factors might hint on successful infection and virus replication of the cell lines.",Claudia Pommerenke; Ulfert Rand; Cord C. Uphoff; Stefan Nagel; Margarete Zaborski; Vivian Hauer; Maren Kaufmann; Corinna Meyer; Sabine A. Denkmann; Peggy Riese; Kathrin Eschke; Yeonsu Kim; Zeljka Macak Safranko; Ivan-Christian Kurolt; Alemka Markotic; Linda Brunotte; Stephan Ludwig; Luka Cicin-Sain; Laura Steenpa,"https://www.biorxiv.org/content/10.1101/2020.07.09.195040v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.195040v1?rss=1,2020-07-09,2020-07-09,,False
534,Air and surface contamination in non-health care settings among 641 environmental specimens of 39 COVID-19 cases,"BackgroundLittle is known about the SARS-CoV-2 contamination of environmental surfaces and air in non-health care settings among COVID-19 cases.

Methods and findingsWe explored the SARS-CoV-2 contamination of environmental surfaces and air by collecting air and swabbing environmental surfaces among 39 COVID-19 cases in Guangzhou, China. The specimens were tested by RT-PCR testing. The information collected for COVID-19 cases included basic demographic, clinical severity, onset of symptoms, radiological testing, laboratory testing and hospital admission. A total of 641 environmental surfaces and air specimens were collected among 39 COVID-19 cases before disinfection. Among them, 20 specimens (20/641, 3.1%) were tested positive from 9 COVID-19 cases (9/39, 23.1%), with 5 (5/101, 5.0%) positive specimens from 3 asymptomatic cases, 5 (5/220, 2.3%) from 3 mild cases, and 10 (10/374, 2.7%) from 3 moderate cases. All positive specimens were collected within 3 days after diagnosis, and 10 (10/42, 23.8%) were found in toilet (5 on toilet bowl, 4 on sink/faucet/shower, 1 on floor drain), 4 (4/21, 19.0%) in anteroom (2 on water dispenser/cup/bottle, 1 on chair/table, 1 on TV remote), 1 (1/8, 12.5%) in kitchen (1 on dining-table), 1 (1/18, 5.6%) in bedroom (1 on bed/sheet pillow/bedside table), 1 (1/5, 20.0%) in car (1 on steering wheel/seat/handlebar) and 3 (3/20, 21.4%) on door knobs. Air specimens in room (0/10, 0.0%) and car (0/1, 0.0%) were all negative.

ConclusionsSARS-CoV-2 was found on environmental surfaces especially in toilet, and could survive for several days. We provided evidence of potential for SARS-CoV-2 transmission through contamination of environmental surfaces.",Lei Luo [PhD]; Dan Liu [PhD]; Hao Zhang [MSc]; Zhihao Li [PhD]; Ruonan Zhen [MSc]; Xiru Zhang [PhD]; Huaping Xie [MSc]; Weiqi Song [MSc]; Jie Liu [MSc]; Qingmei Huang [MSc]; Jingwen Liu [MSc]; Xingfen Yang [PhD]; Zongqiu Chen [PhD]; Chen Mao [PhD],"https://www.biorxiv.org/content/10.1101/2020.07.09.195008v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.09.195008v1?rss=1,2020-07-09,2020-07-09,,False
535,Molecular architecture of the SARS-CoV-2 virus,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped virus responsible for the COVID-19 pandemic. Despite recent advances in the structural elucidation of SARS-CoV-2 proteins and the complexes of the spike (S) proteins with the cellular receptor ACE2 or neutralizing antibodies, detailed architecture of the intact virus remains to be unveiled. Here we report the molecular assembly of the authentic SARS-CoV-2 virus using cryo-electron tomography (cryo-ET) and subtomogram averaging (STA). Native structures of the S proteins in both pre- and postfusion conformations were determined to average resolutions of 9-11 . Compositions of the N-linked glycans from the native spikes were analyzed by mass spectrometry, which revealed highly similar overall processing states of the native glycans to that of the recombinant glycoprotein glycans. The in situ architecture of the ribonucleoproteins (RNP) and its higher-order assemblies were revealed. These characterizations have revealed the architecture of the SARS-CoV-2 virus to an unprecedented resolution, and shed lights on how the virus packs its ~30 Kb long single-segmented RNA in the ~80 nm diameter lumen. Overall, the results unveiled the molecular architecture and assembly of the SARS-CoV-2 in native context.Competing Interest StatementThe authors have declared no competing interest.View Full Text",Hangping Yao; Yutong Song; Yong Chen; Nanping Wu; Jialu Xu; Chujie Sun; Jiaxing Zhang; Tianhao Weng; Zheyuan Zhang; Zhigang Wu; Linfang Cheng; Danrong Shi; Xiangyun Lu; Jianlin Lei; Max Crispin; Yigong Shi; Lanjuan Li; Sai Li,"https://www.biorxiv.org/content/10.1101/2020.07.08.192104v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.192104v1?rss=1,2020-07-09,2020-07-09,,False
536,Genes associated with liver damage signalling pathways may impact the severity of COVID-19 symptoms in Spanish and Italian populations,"AimThe novel SARS-CoV-2 virus, which causes the COVID-19 disease, has infected more than 10 million people and caused 500K deaths worldwide. In Europe, over 2 million confirmed cases have been reported, while nearly 200K people have died from the disease. Despite strict containment measures in Spain and Italy after the first reported COVID-19 patient, these two countries have remained in the top five European nations with the highest mortality rate for over two months. We hypothesised that a genetic mechanism could partially explain the poor survival outcome observed in these two countries.

MethodsAn extensive literature search to identify human candidate genes linked to SARS-CoV infection, host immune evasion and disease aggressiveness was carried out. Pathway analysis (IPA) was performed to select the most significantly associated canonical signalling pathways with the genes of interest. The genetic variants at these genes with {+/-}1Mb flanking region was extracted (GRCh37/hg19 built). Over 80 million single nucleotide polymorphisms (SNPs) were analysed in genome-wide data of 2,504 individuals (1000 genomes, phase III, https://www.internationalgenome.org/). Principal component (PC) analysis was performed, ancestry by the whole genome was inferred and subsets of the regions of interest were extracted (PLINK v1.9b, http://pngu.mgh.harvard.edu/purcell/plink/). PC1 to PC20 values from five European ancestries, including the Spanish and Italian populations, were used for PC analysis. Gene function predictions were run with our genes of interest as a query to the GeneMANIA Cytoscape plugin (https://genemania.org/).

ResultsA total of 437 candidate genes associated with SARS were identified, including 21 correlated with COVID-19 aggressiveness. The two most significant pathways associated with all 437 genes (Caveolar-mediated Endocytosis and MSP-RON Signalling) did not show any segregation at the population level. However, the most significant canonical pathway associated with genes linked to COVID-19 aggressiveness, the Hepatic Fibrosis and Hepatic Stellate Cell Activation, showed population-specific segregation. Both the Spanish and Italian populations clustered together from the rest of Europe. This was also observed for the Finnish population but in the opposite direction. These results suggest some of the severe COVID-19 cases reported in Spain and Italy could be partially explained by a pre-existing liver condition (especially liver cancer) and/or may lead to further COVID-19 related liver complications.",Leire Moya; Samaneh Farashi; Prashanth N Suravajhala; Panchadsaram Janaththani; Jyotsna Batra,"https://www.biorxiv.org/content/10.1101/2020.07.03.179028v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.179028v1?rss=1,2020-07-08,2020-07-08,,False
537,Enhanced COVID-19 data for improved prediction of survival,"The current COVID-19 pandemic, caused by the rapid world-wide spread of the SARS-CoV-2 virus, is having severe consequences for human health and the world economy. The virus effects individuals quite differently, with many infected patients showing only mild symptoms, and others showing critical illness. To lessen the impact of the pandemic, one important question is which factors predict the death of a patient? Here, we construct an enhanced COVID-19 dataset by processing two existing databases (from Kaggle and WHO) and using natural language processing methods to enhance the data by adding local weather conditions and research sentiment.Author summary In this study, we contribute an enhanced COVID-19 dataset, which contains 183 samples and 43 features. Application of Extreme Gradient Boosting (XGBoost) on the enhanced dataset achieves 95% accuracy in predicting patients survival, with country-wise research sentiment, and then age and local weather, showing the most importance. All data and source code are available at http://ab.inf.uni-tuebingen.de/publications/papers/COVID-19.View Full Text",Wenhuan Zeng; Anupam Gautam; Daniel H Huson,"https://www.biorxiv.org/content/10.1101/2020.07.08.193144v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.193144v1?rss=1,2020-07-08,2020-07-08,,False
538,Towards the design of multiepitope-based peptide vaccine candidate against SARS-CoV-2,"Coronavirus disease 2019 is a current pandemic health threat especially for elderly patients with comorbidities. This respiratory disease is caused by a beta coronavirus known as severe acute respiratory syndrome coronavirus 2. The disease can progress into acute respiratory distress syndrome that can be fatal. Currently, no specific drug or vaccine are available to combat this pandemic outbreak. Social distancing and lockdown have been enforced in many places worldwide. The spike protein of coronavirus 2 is essential for viral entry into host target cells via interaction with angiotensin converting enzyme 2. This viral protein is considered a potential target for design and development of a drug or vaccine. Previously, we have reported several potential epitopes on coronavirus 2 spike protein with high antigenicity, low allergenicity and good stability against specified proteases. In the current study, we have constructed and evaluated a peptide vaccine from these potential epitopes by using in silico approach. This construct is predicted to have a protective immunogenicity, low allergenicity and good stability with minor structural flaws in model build. The population coverage of the used T-cells epitopes is believed to be high according to the employed restricted alleles. The vaccine construct can elicit efficient and long-lasting immune response as appeared through simulation analysis. This multiepitope-based peptide vaccine may represent a potential candidate against coronavirus 2. However, further in vitro and in vivo verification are required.",Hasanain Abdulhameed Odhar; Salam Waheed Ahjel; Suhad Sami Humadi,"https://www.biorxiv.org/content/10.1101/2020.07.07.186122v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.186122v1?rss=1,2020-07-08,2020-07-08,,False
539,Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus,"ABSTRACTSARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by TMPRRS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2-EVs are efficient decoys for SARS-CoV-2 S protein-containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is 500 to 1500 times more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.Competing Interest StatementThe authors have declared no competing interest.View Full Text",Federico Cocozza; Ester Piovesana; Nathalie Nvo; Xavier Lahaye; Julian Buchrieser; Olivier Schwartz; Nicolas Manel; Mercedes Tkach; Clotilde Thry; Lorena Martin-Jaular,"https://www.biorxiv.org/content/10.1101/2020.07.08.193672v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.193672v1?rss=1,2020-07-08,2020-07-08,,False
540,In vivo structural characterization of the whole SARS-CoV-2 RNA genome identifies host cell target proteins vulnerable to re-purposed drugs,"SUMMARYSARS-CoV-2 is an RNA virus of the Coronaviridae family that is the causal pathogen of the ongoing Coronavirus Disease 2019 pandemic. There are currently no antiviral drugs or vaccines to treat COVID-19, and the failure to identify effective interventions can be blamed on our incomplete understanding of the nature of this virus and its host cell infection process. Here, we experimentally determined structural maps of the SARS-CoV-2 RNA genome in infected human cells and also characterized in vitro refolded RNA structures for SARS-CoV-2 and 6 other coronaviruses. Our in vivo data confirms several structural elements predicted from theoretical analysis and goes much further in revealing many previously unknown structural features that functionally impact viral translation and discontinuous transcription in cells. Importantly, we harnessed our in vivo structure data alongside a deep-learning tool and accurately predicted several dozen functionally related host cell proteins that bind to the SARS-CoV-2 RNA genome, none of which were known previously. Thus, our in vivo structural study lays a foundation for coronavirus RNA biology and indicates promising directions for the rapid development of therapeutics to treat COVID-19.HIGHLIGHTSWe mapped the in vivo structure and built secondary structural models of the SARS-CoV-2 RNA genomeWe discovered functionally impactful structural features in the RNA genomes of multiple coronavirusesWe predicted and validated host cell proteins that bind to the SARS-CoV-2 RNA genome based on our in vivo RNA structural data using a deep-learning toolCompeting Interest StatementThe authors have declared no competing interest.View Full Text",Lei Sun; Pan Li; Xiaohui Ju; Jian Rao; Wenze Huang; Shaojun Zhang; Tuanlin Xiong; Kui Xu; Xiaolin Zhou; Lili Ren; Qiang Ding; Jianwei Wang; Qiangfeng Cliff Zhang,"https://www.biorxiv.org/content/10.1101/2020.07.07.192732v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.192732v1?rss=1,2020-07-08,2020-07-08,,False
541,SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques,"CD4 T follicular helper (Tfh) cells are important for the generation of long-lasting and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates Tfh cells and stimulates the germinal center response is an important question as we investigate vaccine options for the current pandemic. Here we report that, following infection with SARS-CoV-2, adult rhesus macaques exhibited transient accumulation of activated, proliferating Tfh cells in their peripheral blood on a transitory basis. The CD4 helper cell responses were skewed predominantly toward a Th1 response in blood, lung, and lymph nodes, reflective of the interferon-rich cytokine environment following infection. We also observed the generation of germinal center Tfh cells specific for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, and a corresponding early appearance of antiviral serum IgG antibodies but delayed or absent IgA antibodies. Our data suggest that a vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity.",Sonny R. Elizaldi; Yashavanth Shaan Lakshmanappa; Jamin W. Roh; Brian A. Schmidt; Timothy D. Carroll; Kourtney D. Weaver; Justin C. Smith; Jesse D. Deere; Joseph Dutra; Mars Stone; Rebecca Lee Sammak; Katherine J. Olstad; J. Rachel Reader; Zhong-Min Ma; Nancy K. Nguyen; Jennifer Watanabe; Jodie Usachaenko; Ramya Immareddy; JoAnn L. Yee; Daniela Weiskopf; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S. Iyer,"https://www.biorxiv.org/content/10.1101/2020.07.07.191007v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191007v1?rss=1,2020-07-08,2020-07-08,,False
542,Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex,"SARS-CoV-2 is the causative agent of the 2019-2020 pandemic. The SARS-CoV-2 genome is replicated-transcribed by the RNA-dependent RNA polymerase holoenzyme (subunits nsp7/nsp82/nsp12) along with a cast of accessory factors. One of these factors is the nsp13 helicase. Both the holo-RdRp and nsp13 are essential for viral replication and are targets for treating the disease COVID-19. Here we present cryo-electron microscopic structures of the SARS-CoV-2 holo-RdRp with an RNA template-product in complex with two molecules of the nsp13 helicase. The Nidovirus-order-specific N-terminal domains of each nsp13 interact with the N-terminal extension of each copy of nsp8. One nsp13 also contacts the nsp12-thumb. The structure places the nucleic acid-binding ATPase domains of the helicase directly in front of the replicating-transcribing holo-RdRp, constraining models for nsp13 function. We also observe ADP-Mg2+ bound in the nsp12 N-terminal nidovirus RdRp-associated nucleotidyltransferase domain, detailing a new pocket for anti-viral therapeutic development.",James Chen; Brandon Malone; Eliza Llewellyn; Michael Grasso; Patrick M. M. Shelton; Paul Dominic B. Olinares; Kashyap Maruthi; Ed Eng; Hasan Vatandaslar; Brian T. Chait; Tarun Kapoor; Seth A. Darst; Elizabeth A. Campbell,"https://www.biorxiv.org/content/10.1101/2020.07.08.194084v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.194084v1?rss=1,2020-07-08,2020-07-08,,False
543,Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures,"With the help of novel processing workflows and algorithms, we have obtained a better understanding of the flexibility and conformational dynamics of the SARS-CoV-2 spike in the prefusion state. We have re-analyzed previous cryo-EM data combining 3D clustering approaches with ways to explore a continuous flexibility space based on 3D Principal Component Analysis. These advanced analyses revealed a concerted motion involving the receptor-binding domain (RBD), N-terminal domain (NTD), and subdomain 1 and 2 (SD1 &amp; SD2) around the previously characterized 1-RBD-up state, which have been modeled as elastic deformations. We show that in this dataset there are not well-defined, stable, spike conformations, but virtually a continuum of states moving in a concerted fashion. We obtained an improved resolution ensemble map with minimum bias, from which we model by flexible fitting the extremes of the change along the direction of maximal variance. Moreover, a high-resolution structure of a recently described biochemically stabilized form of the spike is shown to greatly reduce the dynamics observed for the wild-type spike. Our results provide new detailed avenues to potentially restrain the spike dynamics for structure-based drug and vaccine design and at the same time give a warning of the potential image processing classification instability of these complicated datasets, having a direct impact on the interpretability of the results.Competing Interest StatementThe authors have declared no competing interest.View Full Text",Roberto Melero; Carlos Oscar S. Sorzano; Brent Foster; Jos-Luis Vilas; Marta Martnez; Roberto Marabini; Erney Ramrez-Aportela; Ruben Sanchez-Garcia; David Herreros; Laura del Cao; Patricia Losana; Yunior C. Fonseca-Reyna; Pablo Conesa; Daniel Wrapp; Pablo Chacon; Jason S. McLellan; Hemant D. Tagare; Jose-Maria Carazo,"https://www.biorxiv.org/content/10.1101/2020.07.08.191072v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.08.191072v1?rss=1,2020-07-08,2020-07-08,,False
544,Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model,"Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we used a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determine its pharmacokinetics. When treatment was initiated before or simultaneously to infection, favipiravir had a strong dose effect, leading to dramatic reduction of infectious titers in lungs and clinical alleviation of the disease. Antiviral effect of favipiravir correlated with incorporation of a large number of mutations into viral genomes and decrease of viral infectivity. The antiviral efficacy observed in this study was achieved with plasma drug exposure comparable with those previously found during human clinical trials and was associated with weight losses in animals. Thereby, pharmacokinetic and tolerance studies are required to determine whether similar effects can be safely achieved in humans.","Driouich, J.-S.; Cochin, M.; Lingas, G.; Moureau, G.; Touret, F.; Petit, P.-R.; Piorkowski, G.; Barthelemy, K.; Coutard, B.; Guedj, J.; de Lamballerie, X.; Solas, C.; Nougairede, A.","https://www.biorxiv.org/content/10.1101/2020.07.07.191775v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191775v1?rss=1,2020-07-07,2020-07-07,,False
545,Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic. In addition to the acute pulmonary symptoms of COVID-19 (the disease associated with SARS-CoV-2 infection), pulmonary and distal coagulopathies have caused morbidity and mortality in many patients. Currently, the molecular pathogenesis underlying COVID-19 associated coagulopathies are unknown. While there are many theories for the cause of this pathology, including hyper inflammation and excess tissue damage, the cellular and molecular underpinnings are not yet clear. By analyzing transcriptomic data sets from experimental and clinical research teams, we determined that changes in the gene expression of genes important in the extrinsic coagulation cascade in the lung epithelium may be important triggers for COVID-19 coagulopathy. This regulation of the extrinsic blood coagulation cascade is not seen with influenza A virus (IAV)-infected NHBEs suggesting that the lung epithelial derived coagulopathies are specific to SARS-Cov-2 infection. This study is the first to identify potential lung epithelial cell derived factors contributing to COVID-19 associated coagulopathy.

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC=""FIGDIR/small/182972v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (42K):
org.highwire.dtl.DTLVardef@b1dd85org.highwire.dtl.DTLVardef@1467c75org.highwire.dtl.DTLVardef@952179org.highwire.dtl.DTLVardef@c8c38c_HPS_FORMAT_FIGEXP  M_FIG C_FIG AUTHOR SUMMARYO_ST_ABSWhy was this study done?C_ST_ABSO_LISevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic.
C_LIO_LIIn addition to the acute pulmonary symptoms of COVID-19 (the disease associated with SARS-CoV-2 infection), pulmonary and distal coagulopathies have caused morbidity and mortality in many patients.
C_LIO_LICurrently, the molecular pathogenesis underlying COVID-19 associated coagulopathies are unknown. Understanding the molecular basis of dysregulated blood coagulation during SARS-CoV-2 infection may help promote new therapeutic strategies to mitigate these complications in COVID-19 patients.
C_LI

What did the researchers do and find?O_LIWe analyzed three publicly available RNA sequencing datasets to identify possible molecular etiologies of COVID-19 associated coagulopathies. These data sets include sequencing libraries from clinically isolated samples of bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2 positive patients and healthy controls. We also analyzed a publicly available RNA sequencing dataset derived from in vitro SARS-CoV-2 infected primary normal human bronchial epithelial (NHBE) cells and mock infected samples.
C_LIO_LIPathway analysis of both NHBE and BALF differential gene expression gene sets. We found that SARS-CoV-2 infection induces the activation of the extrinsic blood coagulation cascade and suppression of the plasminogen activation system in both NHBEs and cells isolated from the BALF. PBMCs did not differentially express genes regulating blood coagulation.
C_LIO_LIComparison with influenza A virus (IAV)-infected NHBEs revealed that the regulation of the extrinsic blood coagulation cascade is unique to SARS-CoV-2, and not seen with IAV infection.
C_LI

What do these findings mean?O_LIThe hyper-activation of the extrinsic blood coagulation cascade and the suppression of the plasminogen activation system in SARS-CoV-2 infected epithelial cells may drive diverse coagulopathies in the lung and distal organ systems.
C_LIO_LIThe gene transcription pattern in SARS-CoV-2 infected epithelial cells is distinct from IAV infected epithelial cells with regards to the regulation of blood coagulation.
C_LI","FitzGerald, E. S.; Jamieson, A. M.","https://www.biorxiv.org/content/10.1101/2020.07.06.182972v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.182972v1?rss=1,2020-07-07,2020-07-07,,False
546,The global and local distribution of RNA structure throughout the SARS-CoV-2 genome,"SARS-CoV-2 is the causative viral agent of COVID-19, the disease at the center of the current global pandemic. While knowledge of highly structured regions is integral for mechanistic insights into the viral infection cycle, very little is known about the location and folding stability of functional elements within the massive, ~30kb SARS-CoV-2 RNA genome. In this study, we analyze the folding stability of this RNA genome relative to the structural landscape of other well-known viral RNAs. We present an in-silico pipeline to locate regions of high base pair content across this long genome and also identify well-defined RNA structures, a method that allows for direct comparisons of RNA structural complexity within the several domains in SARS-CoV-2 genome. We report that the SARS-CoV-2 genomic propensity to stable RNA folding is exceptional among RNA viruses, superseding even that of HCV, one of the most highly structured viral RNAs in nature. Furthermore, our analysis reveals varying levels of RNA structure across genomic functional regions, with accessory and structural ORFs containing the highest structural density in the viral genome. Finally, we take a step further to examine how individual RNA structures formed by these ORFs are affected by the differences in genomic and subgenomic contexts. The conclusions reported in this study provide a foundation for structure-function hypotheses in SARS-CoV-2 biology, and in turn, may guide the 3D structural characterization of potential RNA drug targets for COVID-19 therapeutics.View Full Text","Tavares, R. d. C. A.; Mahadeshwar, G.; Pyle, A. M.","https://www.biorxiv.org/content/10.1101/2020.07.06.190660v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.190660v1?rss=1,2020-07-07,2020-07-07,,False
547,A Small interfering RNA lead targeting RNA-dependent RNA-polymerase effectively inhibit the SARS-CoV-2 infection in Golden Syrian hamster and Rhesus macaque,"A small interfering RNA (siRNA) inhibitors have demonstrated the novel modality for suppressing infectious diseases. Sixty-one siRNA molecules, predicted by the bioinformatics programs, were screened for the possibility of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an in vitro plaque assay. Among six siRNA leads with the efficacy of reducing plaque number, the siRNA targeting RNA-dependent RNA polymerase (RdRp) showed a reduction in SARS-CoV-2 infection-induced fever and virus titer in the Golden Syrian hamster and rhesus macaque. These results suggest the potential for RdRp targeting siRNA as a new treatment for the coronavirus disease 2019 (COVID-19).Competing Interest StatementThe authors have declared no competing interest.View Full Text","Gu, S. H.; Yu, C. H.; Song, Y.; Kim, N. Y.; Sim, E.; Choi, J. Y.; Song, D. H.; Hur, G. H.; Shin, Y. K.; Jeong, S. T.","https://www.biorxiv.org/content/10.1101/2020.07.07.190967v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.190967v1?rss=1,2020-07-07,2020-07-07,,False
548,SARS-CoV-2 Nsp1 binds ribosomal mRNA channel to inhibit translation,"The non-structural protein 1 (Nsp1), also referred to as the host shutoff factor, is the first viral protein that is synthesized in SARS-CoV-2 infected human cells to suppress host innate immune functions1,2. By combining cryo-electron microscopy and biochemical experiments, we show that SARS-CoV-2 Nsp1 binds to the human 40S subunit in ribosomal complexes including the 43S pre-initiation complex. The protein inserts its C-terminal domain at the entrance to the mRNA channel where it interferes with mRNA binding. We observe potent translation inhibition in the presence of Nsp1 in lysates from human cells. Based on the high-resolution structure of the 40S-Nsp1 complex, we identify residues of Nsp1 crucial for mediating translation inhibition. We further show that the full-length 5 untranslated region of the genomic viral mRNA stimulates translation in vitro, suggesting that SARS-CoV-2 combines inhibition of translation by Nsp1 with efficient translation of the viral mRNA to achieve expression of viral genes3.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Schubert, K.; Karousis, E. D.; Jomaa, A.; Scaiola, A.; Echeverria, B.; Gurzeler, L.-A.; Leibundgut, M.; Thiel, V.; Muehlemann, O.; Ban, N.","https://www.biorxiv.org/content/10.1101/2020.07.07.191676v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191676v1?rss=1,2020-07-07,2020-07-07,,False
549,A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex,"The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) emergence in 2003 introduced the first serious human coronavirus pathogen to an unprepared world. To control emerging viruses, existing successful anti(retro)viral therapies can inspire antiviral strategies, as conserved viral enzymes (eg., viral proteases and RNA-dependent RNA polymerases) represent targets of choice. Since 2003, much effort has been expended in the characterization of the SARS-CoV replication/transcription machinery. Until recently, a pure and highly active preparation of SARS-CoV recombinant RNA synthesis machinery was not available, impeding target-based high throughput screening of drug candidates against this viral family. The current Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic revealed a new pathogen whose RNA synthesis machinery is highly (>96% aa identity) homologous to SARS-CoV. This phylogenetic relatedness highlights the potential use of conserved replication enzymes to discover inhibitors against this significant pathogen, which in turn, contributes to scientific preparedness against emerging viruses. Here, we report the use of a purified and highly active SARS-CoV replication/transcription complex (RTC) to set-up a high-throughput screening of Coronavirus RNA synthesis inhibitors. The screening of a small (1,520 compounds) chemical library of FDA-approved drugs demonstrates the robustness of our assay and will allow to speed-up drug repositioning or novel drug discovery against the SARS-CoV-2.

Principle of SARS-CoV RNA synthesis detection by a fluorescence-based high throughput screening assay

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=81 SRC=""FIGDIR/small/192005v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (20K):
org.highwire.dtl.DTLVardef@e8122dorg.highwire.dtl.DTLVardef@18557org.highwire.dtl.DTLVardef@1d95362org.highwire.dtl.DTLVardef@f15222_HPS_FORMAT_FIGEXP  M_FIG C_FIG Highlights- A new SARS-CoV non radioactive RNA polymerase assay is described
- The robotized assay is suitable to identify RdRp inhibitors based on HTS","Eydoux, C.; Fattorini, V.; Shannon, A.; Le, T.-T.-N.; Didier, B.; Canard, B.; Guillemot, J.-C.","https://www.biorxiv.org/content/10.1101/2020.07.07.192005v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.192005v1?rss=1,2020-07-07,2020-07-07,,False
550,"Genes Encoding ACE2, TMPRSS2 and Related Proteins Mediating SARS-CoV-2 Viral Entry are Upregulated with Age in Human Cardiomyocytes","Age is an independent risk factor for adverse outcome in patients following COVID-19 infection. We hypothesised that differential expression of genes encoding proteins proposed to be required for entry of SARS-Cov-2 in aged compared to younger cardiomyocytes might contribute to the susceptibility of older individuals to COVID-19-associated cardiovascular complications.We generated strand-specific RNA-sequencing libraries from RNA isolated from flow-sorted cardiomyocyte nuclei from left ventricular tissue. RNASeq data were compared between five young (19-25yr) and five older (63-78yr) Caucasian males who had not been on medication or exhibited evidence of cardiovascular disease post-mortem.Expression of relevant genes encoding ACE2, TMPRSS2, TMPRS11D, TMPRS11E, FURIN, CTSL, CTSB and B0AT1/SLC6A19 were upregulated in aged cardiomyocytes and the combined relative cardiomyocyte expression of these genes correlated positively with age. Genes encoding proteins in the RAAS and interferon/interleukin pathways were also upregulated such as ACE, AGTR1, MAS1 and IL6R.Our results highlight SARS-CoV-2 related genes that have higher expression in aged compared with young adult cardiomyocytes. These data may inform studies using selective enzyme inhibitors/antagonists, available as experimental compounds or clinically approved drugs e.g. remdesivir that has recently been rapidly accepted for compassionate use, to further understand the contribution of these pathways in human cardiomyocytes to disease outcome in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Robinson, E. L.; Alkass, K.; Bergmann, O.; Maguire, J. J.; Roderick, L.; Davenport, A. P.","https://www.biorxiv.org/content/10.1101/2020.07.07.191429v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191429v1?rss=1,2020-07-07,2020-07-07,,False
551,Alignment of virus-host protein-protein interaction networks by integer linear programming: SARS-CoV-2,"Beside socio-economic issues, coronavirus pandemic COVID-19, the infectious disease caused by the newly discovered coronavirus SARS-CoV-2, has caused a deep impact in the scientific community, that has considerably increased its effort to discover the infection strategies of the new virus. Among the extensive and crucial research that has been carried out in the last few months, the analysis of the virus-host relationship plays an important role in drug discovery. Virus-host protein-protein interactions are the active agents in virus replication, and the analysis of virus-host protein-protein interaction networks is fundamental to the study of the virus-host relationship. We have adapted and implemented a recent integer linear programming model for protein-protein interaction network alignment to virus-host networks, and obtained a consensus alignment of the SARS-CoV-1 and SARS-CoV-2 virus-host protein-protein interaction networks. Despite the lack of shared human proteins in these virus-host networks and the low number of preserved virus-host interactions, the consensus alignment revealed aligned human proteins that share a function related to viral infection, as well as human proteins of high functional similarity that interact with SARS-CoV-1 and SARS-CoV-2 proteins, whose alignment would preserve these virus-host interactions.View Full Text","Llabres, M.; Valiente, G.","https://www.biorxiv.org/content/10.1101/2020.07.07.191247v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191247v1?rss=1,2020-07-07,2020-07-07,,False
552,Spike protein fusion loop controls SARS-CoV-2 fusogenicity and infectivity,"The Spike is a hallmark coronavirus protein that determines virus fusion, entry and spread in the host, and thus holds clues for the rapid spread of the SARS-CoV-2 pandemic. We have investigated the Spike from six -coronaviruses, including the SARS-CoV-2, and find that their surface-exposed fusion peptides constituting the fusion loop are spatially organized contiguous to each other to work synergistically for triggering the virus-host membrane fusion process. The SARS-CoV-2 fusion peptides have unique physicochemical properties, accrued in part from the presence of consecutive prolines that impart backbone rigidity which aids the virus fusogenicity. The specific contribution of these prolines has been inferred from comparative studies of their deletion mutant in a fellow murine -coronavirus MHV-A59 that show significantly diminished fusogenicity in vitro and associated pathogenesis in vivo. The Spike cleavage-linked priming and fusogenic conformational transition steered by the fusion loop may be critical for the SARS-CoV-2 spread.Summary The Spike protein on the SARS-CoV-2 surface is the prime mediator of COVID-191 because of its central role in virus-host attachment, virus-entry, and virus-spread2. The contagious nature of SARS-CoV-2 infection has been attributed to dense glycosylation of the Spike glycoprotein3, its high affinity of binding to human ACE2 receptor4, and cleavage5. While these may be imperative, it does not explain the uncontrolled infectivity. Here we show that properties of the fusion peptides constituting the fusion loop of SARS-CoV-2 Spike that triggers the virus fusion, distinguishes it from the other five -coronaviruses. The SARS-CoV-2 Spike trimer surface is relatively more hydrophobic, including the surface contributed by the fusion peptides. The fusion peptides are structurally rigid owing to its consecutive prolines, aromatic/hydrophobic clusters, a stretch of consecutive -branched amino acids, and the hydrogen bonds. The role of rigidity accrued from the presence of consecutive prolines contributing to virus fusogenicity can be deciphered from our previous murine -coronavirus, MHV-A59 studies6. The synergy brought about by the global location of the surface exposed fusion peptides, their physicochemical features, and the fusogenic conformational transition appears to drive the fusion process, which may explain the severity of the infection and widespread nature of the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Pal, D.","https://www.biorxiv.org/content/10.1101/2020.07.07.191973v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.191973v1?rss=1,2020-07-07,2020-07-07,,False
553,The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus,"SARS-CoV-1 and SARS-CoV-2 are not phylogenetically closely related; however, both use the ACE2 receptor in humans for cell entry. This is not a universal sarbecovirus trait; for example, many known sarbecoviruses related to SARS-CoV-1 have two deletions in the receptor binding domain of the spike protein that render them incapable of using human ACE2. Further, we report three novel sarbecoviruses from Rwanda and Uganda which are phylogenetically intermediate to SARS-CoV-1 and SARS-CoV-2 and demonstrate via in vitro studies that they are also unable to utilize human ACE2. Here, we show that recombination is most likely responsible for the observed patterns of ACE2 usage among sarbecoviruses. We show that the lineage that includes SARS-CoV-2 is most likely the ancestral ACE2-using lineage, and that recombination with at least one virus from this group conferred ACE2 usage to the progenitor of SARS-CoV-1 at some time in the past. We argue that alternative scenarios such as convergent evolution are much less parsimonious, show that biogeography and patterns of host tropism support the plausibility of a recombination scenario, and propose a competitive release hypothesis to explain how this recombination event could have been evolutionarily advantageous. The findings from this study provide important insights into the natural history of ACE2 usage for both SARS-CoV-1 and SARS-CoV-2, and a greater understanding of the evolutionary mechanisms that shape zoonotic potential of coronaviruses. This study also underscores the need for increased surveillance for sarbecoviruses in southwestern China, where ACE2-using viruses have been found to date, as well as other regions including Africa, where these viruses have only recently been discovered.","Wells, H. L.; Letko, M. C.; Lasso, G.; Ssebide, B.; Nziza, J.; Byarugaba, D. K.; Navarrete-Macias, I.; Liang, E.; Cranfield, M.; Han, B. A.; Tingley, M. W.; Diuk-Wasser, M.; Goldstein, T.; Kreuder Johnson, C.; Mazet, J.; Chandran, K.; Munster, V.; Gilardi, K.; Anthony, S. J.","https://www.biorxiv.org/content/10.1101/2020.07.07.190546v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.190546v1?rss=1,2020-07-07,2020-07-07,,False
554,A rapidly adaptable biomaterial vaccine for SARS-CoV-2,"ABSTRACTThe global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the adjuvant and SARS-CoV-2 spike proteins S1, S2, the nucleocapsid (N) protein, and receptor binding domain (RBD) as the target antigens. The dose of antigen and impact of pre-manufacturing of vaccines as versus loading antigen just-in-time was explored in these studies. Single shot MSR vaccines induced rapid and robust antibody titers to the presented antigens, even without the use of a boost, and sera from vaccinated animals demonstrated neutralizing activity against a SARS-CoV-2 pseudovirus. Overall, these results suggest the MSR vaccine system may provide potent protective immunity when utilized to present SARS-CoV-2 antigens.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Langellotto, F.; Seiler, B. T.; Yu, J.; Cartwright, M. J.; White, D.; Yeager, C.; Super, M.; Doherty, E. J.; Barouch, D. H.; Mooney, D. J.","https://www.biorxiv.org/content/10.1101/2020.07.07.192203v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.192203v1?rss=1,2020-07-07,2020-07-07,,False
555,Single source of pangolin CoVs with a near identical Spike RBD to SARS-CoV-2,"Multiple publications have independently described pangolin CoV genomes from the same batch of smuggled pangolins confiscated in Guangdong province in March, 2019. We analyzed the three metagenomic datasets that sampled this batch of pangolins and found that the two complete pangolin CoV genomes, GD_1 by Xiao et al. Nature and MP789 by Liu et al. PLoS Pathogens, were both built primarily using the 2019 dataset first described by Liu et al. Viruses. Other publications, such as Zhang et al. Current Biology and Lam et al. Nature, have also relied on this same dataset by Liu et al. Viruses for their assembly of pangolin CoV sequences and comparisons to SARS-CoV-2. To our knowledge, all of the published pangolin CoV genome sequences that share a nearly identical Spike receptor binding domain with SARS-CoV-2 originate from this single batch of smuggled pangolins. This raises the question of whether pangolins are truly reservoirs or hosts of SARS-CoV-2-related coronaviruses in the wild, or whether the pangolins may have contracted the CoV from another host species during trafficking. Our observations highlight the importance of requiring authors to publish their complete genome assembly pipeline and all contributing raw sequence data, particularly those supporting epidemiological investigations, in order to empower peer review and independent analysis of the sequence data.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Chan, Y. A.; Zhan, S. H.","https://www.biorxiv.org/content/10.1101/2020.07.07.184374v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.07.184374v1?rss=1,2020-07-07,2020-07-07,,False
556,Conserved Genomic Terminals of SARS-CoV-2 as Co-evolving Functional Elements and Potential Therapeutic Targets,"ABSTRACTTo identify features in the genome of the SARS-CoV-2 pathogen responsible for the COVID-19 pandemic that may contribute to its viral replication, host pathogenicity, and vulnerabilities, we investigated how and to what extent the SARS-CoV-2 genome sequence differs from other well-characterized human and animal coronavirus genomes. Our analyses suggest the presence of unique sequence signatures in the 3-untranslated region (UTR) of betacoronavirus lineage B, which phylogenetically encompasses SARS-CoV-2, SARS-CoV, as well as multiple groups of bat and animal coronaviruses. In addition, we identified genome-wide patterns of variation across different SARS-CoV-2 strains that likely reflect the effects of selection. Finally, we provide evidence for a possible host microRNA-mediated interaction between the 3-UTR and human microRNA hsa-miR-1307-3p based on predicted, yet extensive, complementary base-pairings and similar interactions involving the Influenza A H1N1 virus. This interaction also suggests a possible survival mechanism, whereby a mutation in the SARS-CoV-2 3-UTR leads to a weakened host immune response. The potential roles of host microRNAs in SARS-CoV-2 replication and infection, and the exploitation of conserved features in the 3-UTR as therapeutic targets warrant further investigation.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Chan, A. P.; Choi, Y.; Schork, N. J.","https://www.biorxiv.org/content/10.1101/2020.07.06.190207v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.190207v1?rss=1,2020-07-06,2020-07-06,,False
557,Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model,"COVID-19 presents herculean challenges to research and scientific communities for producing diagnostic and treatment solutions. Any return to normalcy requires rapid development of countermeasures, with animal models serving as a critical tool in testing vaccines and therapeutics. Animal disease status and potential COVID-19 exposure prior to study execution may severely bias efficacy testing. We developed a toolbox of immunological and molecular tests to monitor countermeasure impact on disease outcome and evaluate pre-challenge COVID-19 status. Assay application showed critical necessity for animal pre-screening. Specifically, real-time PCR results documented pre-exposure of an African Green Monkey prior to SARS-CoV-2 challenge with sequence confirmation as a community-acquired exposure. Longitudinal monitoring of nasopharyngeal swabs and serum showed pre-exposure impacted both viral disease course and resulting immunological response. This study demonstrates utility in a comprehensive pre-screening strategy for animal models, which captured the first documented case of community-acquired, non-human primate infection.

One Sentence SummaryPre-exposure to SARS-CoV-2 affects biomarker responses in animal models, highlighting a need for robust pre-screening protocols prior to medical countermeasure studies.","Ricks, K. M.; Herbert, A. S.; Koehler, J. W.; Kuehnert, P. A.; Clements, T. L.; Shoemaker, C. J.; Kuehne, A. I.; O'Brien, C. M.; Coyne, S. R.; Delp, K. L.; Akers, K. S.; Dye, J. M.; Hooper, J. W.; Smith, J. M.; Kugelman, J. R.; Beitzel, B. F.; Gibson, K. M.; Johnston, S. C.; Minogue, T. D.","https://www.biorxiv.org/content/10.1101/2020.07.06.189803v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.189803v1?rss=1,2020-07-06,2020-07-06,,False
558,Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3,"ABSTRACTThe Mac1 domain of the multifunctional SARS-CoV-2 non-structural protein 3 (nsp3) is a potential COVID-19 drug target because it is suspected to enhance the ability of the virus to evade the human immune system. The SARS-CoV-2 Mac1 domain binds ADP-ribose and proteins harboring this important post-translational modification. Small molecules that bind the Mac1 domain in place of ADP-ribose might therefore be useful as molecular probes or scaffolds for antiviral drug discovery. Two high throughput screens were used here to identify such ligands in small libraries of drugs and drug-like compounds. The first screen used differential scanning fluorimetry (DSF, aka the thermal shift or ThermoFluor assay) to examine the melting temperature of SARS-CoV-2 Mac1 domain in the presence of various compounds. In the second screen, various high-resolution SARS-CoV-2 Mac1 structures were used with Autodock VINA to identify potential ligands. Numerous hit compounds were either steroids (estradiol valerate &amp; flunisolide), beta-lactams (cefaclor &amp; cefatrizine), or benzimidazoles (telmisartan, rabeprazole, omeprazole, &amp; esomeprazole). Isothermal titration calorimetry was used to confirm that rabeprazole, omeprazole, and compounds in other chemical classes, such as irinotecan, nifedipine, trifluoperazine, bind SARS-CoV-2 Mac1 with an affinity similar to ADP-ribose.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Virdi, R. S.; Bavisotto, R. V.; Hopper, N. C.; Frick, D.","https://www.biorxiv.org/content/10.1101/2020.07.06.190413v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.190413v1?rss=1,2020-07-06,2020-07-06,,False
559,N and O glycosylation of the SARS-CoV-2 spike protein,"Covid-19 pandemic outbreak is the reason of the current world health crisis. The development of effective antiviral compounds and vaccines requires detailed descriptive studies of the SARS-CoV-2 proteins. The SARS-CoV-2 spike (S) protein mediates virion binding to the human cells through its interaction with the ACE2 cell surface receptor and is one of the prime immunization targets. A functional virion is composed of three S1 and three S2 subunits created by furin cleavage of the spike protein at R682, a polybasic cleavage sites that differs from the SARS-CoV spike protein of 2002. We observe that the spike protein is O-glycosylated on a threonine (T678) near the furin cleavage site occupied by core-1 and core-2 structures. In addition, we have identified eight additional O-glycopeptides on the spike glycoprotein and we confirmed that the spike protein is heavily N-glycosylated. Our recently developed LC-MS/MS methodology allowed us to identify LacdiNAc structural motives on all occupied N-glycopeptides and polyLacNAc structures on six glycopeptides of the spike protein. In conclusion, our study substantially expands the current knowledge of the spike proteins glycosylation and enables the investigation of the influence of the O-glycosylation on its proteolytic activation.","Sanda, M.; Morrison, L.; Goldman, R.","https://www.biorxiv.org/content/10.1101/2020.07.05.187344v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.05.187344v1?rss=1,2020-07-06,2020-07-06,,False
560,Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2,"COVID-19 pandemic has infected millions of people with mortality exceeding 300,000. There is an urgent need to find therapeutic agents that can help clear the virus to prevent the severe disease and death. Identifying effective and safer drugs can provide with more options to treat the COVID-19 infections either alone or in combination. Here we performed a high throughput screen of approximately 1700 US FDA approved compounds to identify novel therapeutic agents that can effectively inhibit replication of coronaviruses including SARS-CoV-2. Our two-step screen first used a human coronavirus strain OC43 to identify compounds with anti-coronaviral activities. The effective compounds were then screened for their effectiveness in inhibiting SARS-CoV-2. These screens have identified 24 anti-SARS-CoV-2 drugs including previously reported compounds such as hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride. Five of the newly identified drugs had a safety index (cytotoxic/effective concentration) of &gt;600, indicating wide therapeutic window compared to hydroxychloroquine which had safety index of 22 in similar experiments. Mechanistically, five of the effective compounds were found to block SARS-CoV-2 S protein-mediated cell fusion. These FDA approved compounds can provide much needed therapeutic options that we urgently need in the midst of the pandemic.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Xiao, X.; Wang, C.; Chang, D.; Wang, Y.; Dong, X.; Jiao, T.; Zhao, Z.; Ren, L.; Dela Cruz, C. S.; Sharma, L.; Lei, X.; Wang, J.","https://www.biorxiv.org/content/10.1101/2020.07.06.188953v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.188953v1?rss=1,2020-07-06,2020-07-06,,False
561,Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection,"Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is currently causing a worldwide pandemic with high morbidity and mortality. Development of animal models that recapitulate important aspects of coronavirus disease 2019 (COVID-19) is critical for the evaluation of vaccines and antivirals, and understanding disease pathogenesis. SARS-CoV-2 has been shown to use the same entry receptor as SARS-CoV-1, human angiotensin-converting enzyme 2 (hACE2)(1-3). Due to amino acid differences between murine and hACE2, inbred mouse strains fail to support high titer viral replication of SARS-CoV-2 virus. Therefore, a number of transgenic and knock-in mouse models, as well as viral vector-mediated hACE2 delivery systems have been developed. Here we compared the K18-hACE2 transgenic model to adenovirus-mediated delivery of hACE2 to the mouse lung. We show that K18-hACE2 mice replicate virus to high titers in both the lung and brain leading to lethality. In contrast, adenovirus-mediated delivery results in viral replication to lower titers limited to the lung, and no clinical signs of infection with a challenge dose of 104 plaque forming units. The K18-hACE2 model provides a stringent model for testing the ability of vaccines and antivirals to protect against disease, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Rathnasinghe, R.; Strohmeier, S.; Amanat, F.; Gillespie, V. L.; Krammer, F.; Garcia-Sastre, A.; Schotsaert, M.; Coughlan, L.; Uccellini, M. B.","https://www.biorxiv.org/content/10.1101/2020.07.06.190066v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.190066v1?rss=1,2020-07-06,2020-07-06,,False
562,Renal carcinoma is associated with increased risk of coronavirus infections,"The current pandemic COVID-19 has affected most severely to the people with old age, or with comorbidities such as hypertension, diabetes mellitus, chronic kidney disease, COPD, and cancers. Cancer patients are twice more likely to contract the disease because of the malignancy or treatment-related immunosuppression; hence identification of the vulnerable population among these patients is essential. It is speculated that along with ACE2, other auxiliary proteins (DPP4, ANPEP, ENPEP, TMPRSS2) might facilitate the entry of coronaviruses in the host cells. We took a bioinformatics approach to analyze the gene and protein expression data of these coronavirus receptors in human normal and cancer tissues of multiple organs. Here, we demonstrated an extensive RNA and protein expression profiling analysis of these receptors across solid tumors and normal tissues. We found that among all, renal tumor and normal tissues exhibited increased levels of ACE2, DPP4, ANPEP, and ENPEP. Our results revealed that TMPRSS2 may not be the co-receptor for coronavirus in renal carcinoma patients. The receptors expression levels were variable in different tumor stage, molecular and immune subtypes of renal carcinoma. In clear cell renal cell carcinomas, coronavirus receptors were associated with high immune infiltration, markers of immunosuppression, and T cell exhaustion. Our study indicates that CoV receptors may play an important role in modulating the immune infiltrate and hence cellular immunity in renal carcinoma. As our current knowledge of pathogenic mechanisms will improve, it may help us in designing focused therapeutic approaches.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Tripathi, S. C.; Deshmukh, V.; Creighton, C. J.; Patil, A.","https://www.biorxiv.org/content/10.1101/2020.07.02.184663v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.02.184663v1?rss=1,2020-07-06,2020-07-06,,False
563,Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity,"AbstractTo dissect the mechanisms underlying the observed inflation of variants in SARS-CoV-2 genome, we present the largest up-to-date analysis of intra-host genomic diversity, which reveals that the majority of samples present a complex sublineage architecture, due to the interplay between host-related mutational processes and transmission dynamics.Strikingly, the deconvolution of the entire set of intra-host variants reveals the existence of mutually exclusive viral mutational signatures, which prove that distinct hosts differently respond to SARS-CoV-2 infections. In particular, two signatures are likely ruled by APOBEC and Reactive Oxygen Species (ROS), which induce hypermutation in a significant number of samples, and appear to be affected by severe purifying selection.Conversely, several mutations linked to low-rate mutational processes appear to transit to clonality in the population, eventually leading to the definition of new viral genotypes and to an increase of overall genomic diversity. Finally, we demonstrate that a high number of variants are observed in samples associated to independent lineages, likely due to signature-related mutational hotspots or to positive selection.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Graudenzi, A.; Maspero, D.; Angaroni, F.; Piazza, R.; Ramazzotti, D.","https://www.biorxiv.org/content/10.1101/2020.07.06.189944v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.189944v1?rss=1,2020-07-06,2020-07-06,,False
564,Gene Expression Network Analysis Provides Potential Targets Against SARS-CoV-2,"ABSTRACTBACKGROUND Cell entry of SARS-CoV-2, the novel coronavirus causing COVID-19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). We aimed to identify and characterize genes that are co-expressed with ACE2 and TMPRSS2, and to further explore their biological functions and potential as druggable targets.METHODS Using the gene expression profiles of 1,038 lung tissue samples, we performed a weighted gene correlation network analysis (WGCNA) to identify modules of co-expressed genes. We explored the biology of co-expressed genes using bioinformatics databases, and identified known drug-gene interactions.RESULTS ACE2 was in a module of 681 co-expressed genes; 12 genes with moderate-high correlation with ACE2 (r&gt;0.3, FDR&lt;0.05) had known interactions with existing drug compounds. TMPRSS2 was in a module of 1,086 co-expressed genes; 15 of these genes were enriched in the gene ontology biologic process Entry into host cell, and 53 TMPRSS2-correlated genes had known interactions with drug compounds.CONCLUSION Dozens of genes are co-expressed with ACE2 and TMPRSS2, many of which have plausible links to COVID-19 pathophysiology. Many of the co-expressed genes are potentially targetable with existing drugs, which may help to fast-track the development of COVID-19 therapeutics.Competing Interest StatementS.M. reports personal fees from Novartis and Boehringer-Ingelheim, outside the submitted work. W.T. reports fees to Institution from Roche-Ventana, AbbVie, Merck-Sharp-Dohme and Bristol-Myers-Squibb, outside the submitted work. M.B. reports research grants paid to University from Astra Zeneca, Novartis, outside the submitted work. D.D.S. reports research funding from AstraZeneca and received honoraria for speaking engagements from Boehringer Ingelheim and AstraZeneca over the past 36 months, outside of the submitted work.View Full Text","Hernandez Cordero, A. I.; Li, X.; Yang, C. X.; Milne, S.; Bosse, Y. I.; Joubert, P.; Timens, W.; Berge, M. v. d.; Nickle, D.; Hao, K.; Sin, D. D.","https://www.biorxiv.org/content/10.1101/2020.07.06.182634v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.182634v1?rss=1,2020-07-06,2020-07-06,,False
565,SARS-CoV-2 contributes to altering the post-transcriptional regulatory networks across human tissues by sponging RNA binding proteins and micro-RNAs,"The outbreak of a novel coronavirus SARS-CoV2 responsible for COVID-19 pandemic has caused worldwide public health emergency. Due to the constantly evolving nature of the coronaviruses, SARS-CoV-2 mediated alteration on post-transcriptional gene regulation across human tissues remains elusive. In this study, we systematically dissected the crosstalk and dysregulation of human post-transcriptional regulatory networks governed by RNA binding proteins (RBPs) and micro-RNAs (miRs), due to SARS-CoV-2 infection. We uncovered that 13 out of 29 SARS-CoV-2 encoded proteins directly interact with 51 human RBPs of which majority of them were abundantly expressed in gonadal tissues and immune cells. We further performed functional analysis of differentially expressed genes in mock treated versus SARS-CoV-2 infected lung cells that revealed an enrichment for immune response, cytokine mediated signaling, and metabolism associated genes. This study also characterized the alternative splicing events in SARS-CoV-2 infected cells compared to control demonstrating that skipped exons and mutually exclusive exons were the most abundant events that potentially contributed to differential outcomes in response to viral infection. Motif enrichment analysis on the RNA genomic sequence of SARS-CoV-2 clearly revealed an enrichment for RBPs such as SRSFs, PCBPs, ELAVs and HNRNPs illustrating the sponging of RBPs by SARS-CoV-2 genome. Similar analysis to study the interactions of miRs with SARS-CoV-2 revealed the potential for several miRs to be sponged, suggesting that these interactions may contribute to altered pos-transcriptional regulation across human tissues. Given the need to understand the interactions of SARS-CoV-2 with key pos-transcriptional regulators in the human genome, this study provides a systematic analysis to dissect the role of dysregulated post-transcriptional regulatory networks controlled by RBPs and miRs, across tissues types during SARS-CoV2 infection.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Srivastava, R.; Daulatabad, S. V.; Srivastava, M.; Janga, S. C.","https://www.biorxiv.org/content/10.1101/2020.07.06.190348v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.190348v1?rss=1,2020-07-06,2020-07-06,,False
566,Comparison of three TaqMan Real-Time Reverse Transcription-PCR assays in detecting SARS-CoV-2,"Quick and accurate detection of SARS-CoV-2 is critical for COVID-19 control. Dozens of real-time reverse transcription PCR (qRT-PCR) assays have been developed to meet the urgent need of COVID-19 control. However, methodological comparisons among the developed qRT-PCR assays are limited. In the present study, we evaluated the sensitivity, specificity, amplification efficiency, and linear detection ranges of three qRT-PCR assays, including the assays developed by our group (IPBCAMS), and the assays recommended by WHO and China CDC (CCDC). The three qRT-PCR assays exhibited similar sensitivities, with the limit of detection (LOD) at about 10 copies per reaction (except the ORF 1b gene assay in CCDC assays with a LOD at about 100 copies per reaction). No cross reaction with other respiratory viruses were observed in all of the three qRT-PCR assays. Wide linear detection ranges from 106 to 101 copies per reaction and acceptable reproducibility were obtained. By using 25 clinical specimens, the N gene assay of IPBCAMS assays and CCDC assays performed better (with detection rates of 92% and 100%, respectively) than that of the WHO assays (with a detection rate of 60%), and the ORF 1b gene assay in IPBCAMS assays performed better (with a detection rate of 64%) than those of the WHO assays and the CCDC assays (with detection rates of 48% and 20%, respectively). In conclusion, the N gene assays of CCDC assays and IPBCAMS assays and the ORF 1b gene assay of IPBCAMS assays were recommended for qRT-PCR screening of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Xiao, Y.; Li, Z.; Wang, X.; Wang, Y.; Wang, Y.; Wang, G.; Ren, L.; Li, J.","https://www.biorxiv.org/content/10.1101/2020.07.06.189860v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.06.189860v1?rss=1,2020-07-06,2020-07-06,,False
567,Snapshot of the evolution and mutation patterns of SARS-CoV-2,"The COVID-19 pandemic is the most important public health threat in recent history. Here we study how its causal agent, SARS-CoV-2, has diversified genetically since its first emergence in December 2019. We have created a pipeline combining both phylogenetic and structural analysis to identify possible human-adaptation related mutations in a data set consisting of 4,894 SARS-CoV-2 complete genome sequences. Although the phylogenetic diversity of SARS-CoV-2 is low, the whole genome phylogenetic tree can be divided into five clusters/clades based on the tree topology and clustering of specific mutations, but its branches exhibit low genetic distance and bootstrap support values. We also identified 11 residues that are high-frequency substitutions, with four of them currently showing some signal for potential positive selection. These fast-evolving sites are in the non-structural proteins nsp2, nsp5 (3CL-protease), nsp6, nsp12 (polymerase) and nsp13 (helicase), in accessory proteins (ORF3a, ORF8) and in the structural proteins N and S. Temporal and spatial analysis of these potentially adaptive mutations revealed that the incidence of some of these sites was declining after having reached an (often local) peak, whereas the frequency of other sites is continually increasing and now exhibit a worldwide distribution. Structural analysis revealed that the mutations are located on the surface of the proteins that modulate biochemical properties. We speculate that this improves binding to cellular proteins and hence represents fine-tuning of adaptation to human cells. Our study has implications for the design of biochemical and clinical experiments to assess whether important properties of SARS-CoV-2 have changed during the epidemic.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Zhao, J.; zhai, x.; Zhou, J.","https://www.biorxiv.org/content/10.1101/2020.07.04.187435v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.04.187435v1?rss=1,2020-07-05,2020-07-05,,False
568,"Gender, race and parenthood impact academic productivity during the COVID-19 pandemic: from survey to action.","While the Coronavirus disease 2019 (COVID-19) pandemic is altering academia dynamics, those juggling remote work and domestic demands - including childcare - have already felt the impacts on productivity. Female authors are facing a decrease in papers submission rates since the beginning of the pandemic period. The reasons for this decline in women productivity need to be further investigated. Here we show the influence of gender, parenthood and race in academics productivity during the pandemic period, based on a survey answered by 3,345 Brazilian academics from various knowledge areas and research institutions. Findings revealed that male academics - especially childless ones - were the least affected group, whereas female academics, especially Black women and mothers, were the most impacted group. This scenario will leave long-term effects on the career progression of the most affected groups. The results presented here are crucial for the development of actions and policies that aim to avoid further deepening the gender gap in science. This particular situation we are facing during the pandemic demands institutional flexibility and academia should foster the discussion about actions to benefit Black scientists and academics with families in the post-pandemic scenario.","Staniscuaski, F.; Kmetzsch, L.; Zandona, E.; Reichert, F.; Soletti, R. C.; Ludwig, Z. M. C.; Lima, E. F.; Neumann, A.; Schwartz, I. V. D.; Mello-Carpes, P. B.; Tamajusuku, A. S. K.; Werneck, F. P.; Ricachenevsky, F. K.; Infanger, C.; Seixas, A.; Staats, C. C.; Oliveira, L.","https://www.biorxiv.org/content/10.1101/2020.07.04.187583v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.04.187583v1?rss=1,2020-07-04,2020-07-04,,False
569,The potential role of miR-21-3p in coronavirus-host interplay,ABSTRACTHost miRNAs are known as important regulators of virus replication and pathogenesis. They can interact with various viruses by several possible mechanisms including direct binding the viral RNA. Identification of human miRNAs involved in coronavirus-host interplay is becoming important due to the ongoing COVID-19 pandemic. In this work we performed computational prediction of high-confidence direct interactions between miRNAs and seven human coronavirus RNAs. In order to uncover the entire miRNA-virus interplay we further analyzed lungs miRNome of SARS-CoV infected mice using publicly available miRNA sequencing data. We found that miRNA miR-21-3p has the largest probability of binding the human coronavirus RNAs and being dramatically up-regulated in mouse lungs during infection induced by SARS-CoV. Further bioinformatic analysis of binding sites revealed high conservativity of miR-21-3p binding regions within RNAs of human coronaviruses and their strains.Competing Interest StatementThe authors have declared no competing interest.View Full Text,"Nersisyan, S.; Engibaryan, N.; Gorbonos, A.; Kirdey, K.; Makhonin, A.; Tonevitsky, A.","https://www.biorxiv.org/content/10.1101/2020.07.03.184846v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.184846v1?rss=1,2020-07-04,2020-07-04,,False
570,SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain,"The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral virus worldwide in a matter of months. Here we show that D614G was more infectious than the ancestral form on human lung cells, colon cells, and cells rendered permissive by ectopic expression of various mammalian ACE2 orthologs. Nonetheless, D614G affinity for ACE2 was reduced due to a faster dissociation rate. Assessment of the S protein trimer by cryo-electron microscopy showed that D614G disrupts a critical interprotomer contact and that this dramatically shifts the S protein trimer conformation toward an ACE2-binding and fusion-competent state. Consistent with the more open conformation, neutralization potency of antibodies targeting the S protein receptor-binding domain was not attenuated. These results indicate that D614G adopts conformations that make virion membrane fusion with the target cell membrane more probable but that D614G retains susceptibility to therapies that disrupt interaction of the SARS-CoV-2 S protein with the ACE2 receptor.","Yurkovetskiy, L.; Pascal, K. E.; Tompkins-Tinch, C.; Nyalile, T.; Wang, Y.; Baum, A.; Diehl, W. E.; Dauphin, A.; Carbone, C.; Veinotte, K.; Egri, S. B.; Schaffner, S. F.; Lemieux, J. E.; Munro, J.; Sabeti, P. C.; Kyratsous, C.; Shen, K.; Luban, J.","https://www.biorxiv.org/content/10.1101/2020.07.04.187757v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.04.187757v1?rss=1,2020-07-04,2020-07-04,,False
571,A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike,"The SARS-CoV-2 spike employs mobile receptor-binding domains (RBDs) to engage the ACE2 receptor and to facilitate virus entry. Antibodies can engage RBD but some, such as CR3022, fail to inhibit entry despite nanomolar spike affinity. Here we show the SARS-CoV-2 spike to have low unfolding enthalpy at serological pH and up to 10-times more unfolding enthalpy at endosomal pH, where we observe significantly reduced CR3022 affinity. Cryo-EM structures -at serological and endosomal pH- delineated spike recognition of up to three ACE2 molecules, revealing RBD to freely adopt the  up conformation. In the absence of ACE2, single-RBD-up conformations dominated at pH 5.5, resolving into a locked all-down conformation at lower pH. Notably, a pH-dependent refolding region (residues 824-858) at the spike-interdomain interface displayed dramatic structural rearrangements and mediated RBD positioning and spike shedding of antibodies like CR3022. An endosomal mechanism involving spike-conformational change can thus facilitate immune evasion from RBD- up-recognizing antibody.

HighlightsO_LIReveal spike at serological pH to have only ~10% the unfolding enthalpy of a typical globular protein, explaining how antibodies like CR3022 can bind with avidity
C_LIO_LIDefine an endosomal mechanism whereby spike binds ACE2, but sheds CR3022, enabling immune evasion from potentially neutralizing antibody
C_LIO_LIDetermine cryo-EM structures of the SARS-CoV-2 spike along its endosomal entry pathway-at pH 5.5, 4.5, and 4.0, and in complexes with ACE2 receptor at pH 7.4 and 5.5
C_LIO_LIShow spike to exclusively adopt an all RBD-down conformation at the low pH of the late endosome-early lysosome
C_LIO_LIReveal structural basis by which a switch domain mediates RBD position in response to pH
C_LI","Zhou, T.; Tsybovsky, Y.; Olia, A. S.; Gorman, J.; Rapp, M. A.; Cerutti, G.; Katsamba, P. S.; Nazzari, A.; Schon, A.; Wang, P. D.; Bimela, J.; Shi, W.; Teng, I.-T.; Zhang, B.; Boyington, J. C.; Chuang, G.-Y.; Sampson, J. M.; Sastry, M.; Stephens, T.; Stuckey, J.; Wang, S.; Friesner, R. A.; Ho, D. D.; Mascola, J. R.; Shapiro, L.; Kwong, P. D.","https://www.biorxiv.org/content/10.1101/2020.07.04.187989v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.04.187989v1?rss=1,2020-07-04,2020-07-04,,False
572,Robust and sensitive detection of SARS-CoV-2 using PCR based methods,"The World Health Organization (WHO) has declared the Coronavirus disease 2019 (COVID-19) as an international health emergency. Current diagnostic tests are based on the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) method, the gold standard test that involves the amplification of viral RNA. However, the RT-qPCR assay has limitations in terms of sensitivity and quantification. In this study, we tested both qPCR and droplet digital PCR (ddPCR) to detect low amounts of viral RNA. The cycle threshold (CT) of viral RNA by RT-PCR significantly varied according to the sequence of primer and probe sets with in vitro transcript (IVT) RNA or viral RNA as templates, whereas the copy number of viral RNA by ddPCR was effectively quantified with IVT RNA, cultured viral RNA, and RNA from clinical samples. Furthermore, the clinical samples were assayed via both methods, and the sensitivity of the ddPCR was determined to be significantly higher than RT-qPCR. These findings suggest that ddPCR could be used as a highly sensitive and compatible diagnostic method for viral RNA detection.","Park, C.; Lee, J.; Hassan, Z. U.; Ku, K. B.; Kim, S. J.; Kim, H. G.; Park, E. C.; Park, G.-S.; Park, D.; Baek, S.-H.; Park, D.; Lee, J.; Jeon, S.; Kim, S.; Lee, C.-S.; Yoo, H. M.; Kim, S.","https://www.biorxiv.org/content/10.1101/2020.07.03.186304v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.186304v1?rss=1,2020-07-03,2020-07-03,,False
573,The major genetic risk factor for severe COVID-19 is inherited from Neandertals,"A recent genetic association study (Ellinghaus et al. 2020) identified a gene cluster on chromosome 3 as a risk locus for respiratory failure in SARS-CoV-2. Recent data comprising 3,199 hospitalized COVID-19 patients and controls reproduce this and find that it is the major genetic risk factor for severe SARS-CoV-2 infection and hospitalization (COVID-19 Host Genetics Initiative). Here, we show that the risk is conferred by a genomic segment of ~50 kb that is inherited from Neandertals and occurs at a frequency of ~30% in south Asia and ~8% in Europe.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Zeberg, H.; Paabo, S.","https://www.biorxiv.org/content/10.1101/2020.07.03.186296v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.186296v1?rss=1,2020-07-03,2020-07-03,,False
574,A CRISPR-based SARS-CoV-2 diagnostic assay that is robust against viral evolution and RNA editing,"Extensive testing is essential to break the transmission of the new coronavirus SARS-CoV-2, which causes the ongoing COVID-19 pandemic. Recently, CRISPR-based diagnostics have emerged as attractive alternatives to quantitative real-time PCR due to their faster turnaround time and their potential to be used in point-of-care testing scenarios. However, existing CRISPR-based assays for COVID-19 have not considered viral genome mutations and RNA editing in human cells. Here, we present the VaNGuard (Variant Nucleotide Guard) test that is not only specific and sensitive for SARS-CoV-2, but can also detect the virus when its genome or transcriptome has evolved or has been edited by deaminases in infected human cells. We show that an engineered AsCas12a enzyme is more tolerant of mismatches than wildtype LbCas12a and that multiplexed Cas12a targeting can overcome the presence of single nucleotide variations. Our assay can be completed in 30 minutes with a dipstick for a rapid point-of-care test.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Ooi, K. H.; Tay, J. W. D.; Teo, S. Y.; Liu, M. M.; Kaewsapsak, P.; Jin, S.; Gao, Y.-G.; Tan, M. H.","https://www.biorxiv.org/content/10.1101/2020.07.03.185850v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.185850v1?rss=1,2020-07-03,2020-07-03,,False
575,Map of SARS-CoV-2 spike epitopes not shielded by glycans.,"The severity of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, calls for the urgent development of a vaccine. The primary immunological target is the SARS-CoV-2 spike (S) protein. S is exposed on the viral surface to mediate viral entry into the host cell. To identify possible antibody binding sites not shielded by glycans, we performed multi-microsecond molecular dynamics simulations of a 4.1 million atom system containing a patch of viral membrane with four full-length, fully glycosylated and palmitoylated S proteins. By mapping steric accessibility, structural rigidity, sequence conservation and generic antibody binding signatures, we recover known epitopes on S and reveal promising epitope candidates for vaccine development. We find that the extensive and inherently flexible glycan coat shields a surface area larger than expected from static structures, highlighting the importance of structural dynamics in epitope mapping.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Sikora, M.; von Bulow, S.; Blanc, F. E. C.; Gecht, M.; Covino, R.; Hummer, G.","https://www.biorxiv.org/content/10.1101/2020.07.03.186825v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.03.186825v1?rss=1,2020-07-03,2020-07-03,,False
576,6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities,"A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses.One Sentence Summary A repurposed drug that targets an essential enzymatic activity of SARS-CoV-2 represents a promising COVID-19 therapeutic.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Swaim, C. D.; Perng, Y.-C.; Zhao, X.; Canadeo, L. A.; Harastani, H. H.; Darling, T. L.; Boon, A. C. M.; Lenschow, D. J.; Huibregtse, J. M.","https://www.biorxiv.org/content/10.1101/2020.07.01.183020v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.183020v1?rss=1,2020-07-02,2020-07-02,,False
577,Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and correlation to tissue damage,"Clinical observations indicate that COVID-19 is a systemic disease. An investigation of the viral distribution within the human body in correlation to tissue damage can help understanding the pathophysiology of SARS-CoV-2 infection.We present a detailed mapping of viral RNA in 61 tissues and organs of 11 deceased patients with the diagnosis COVID-19. The autopsies were performed within the (very) early postmortem interval (mean: 5.6 hours) to avoid bias due to viral RNA and tissue degradation. Viral loads, blood levels of cytokines, prothrombotic factors as well as macro- and micro-morphology were correlated.Very high (&gt; 104 copies/ml) viral loads were detected in the lungs of most patients and then correlated to severe tissue damage. Intact viral particles could be verified in the lung tissue by transmission electron microscopy. Viral loads in the lymph nodes were associated with a loss of follicular architecture. Viral RNA was detected throughout further extra-pulmonary tissues and organs without visible tissue damage. Inflammatory cytokines as well as the prothrombotic factors were elevated in all patients.In conclusion, the dissemination of SARS-CoV-2-RNA throughout the body supports the hypothesis of a maladaptive host response with viremia and multi-organ dysfunction.View Full Text","Deinhardt-Emmer, S.; Wittschieber, D.; Sanft, J.; Kleemann, S.; Elschner, S.; Haupt, K. F.; Vau, V.; Haring, C.; Rodel, J.; Henke, A.; Ehrhardt, C.; Bauer, M.; Philipp, M.; Gassler, N.; Nietzsche, S.; Loffler, B.; Mall, G.","https://www.biorxiv.org/content/10.1101/2020.07.01.182550v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182550v1?rss=1,2020-07-02,2020-07-02,,False
578,Using iCn3D and the World Wide Web for structure-based collaborative research: Analyzing molecular interactions at the root of COVID-19,"ABSTRACTThe COVID-19 pandemic took us ill-prepared and tackling the many challenges it poses in a timely manner requires world-wide collaboration. Our ability to study the SARS-COV-2 virus and its interactions with its human host in molecular terms efficiently and collaboratively becomes indispensable and mission-critical in the race to develop vaccines, drugs, and neutralizing antibodies. There is already a significant corpus of 3D structures related to SARS and MERS coronaviruses, and the rapid generation of new structures demands the use of efficient tools to expedite the sharing of structural analyses and molecular designs and convey them in their native 3D context in sync with sequence data and annotations. We developed iCn3D (pronounced I see in 3D) 1 to take full advantage of web technologies and allow scientists of different backgrounds to perform and share sequence-structure analyses over the Internet and engage in collaborations through a simple mechanism of exchanging lifelong web links (URLs). This approach solves the very old problem of sharing of molecular scenes in a reliable and convenient manner. iCn3D links are sharable over the Internet and make data and entire analyses findable, accessible, and reproducible, with various levels of interoperability. Links and underlying data are FAIR 2 and can be embedded in preprints and papers, bringing a 3D live and interactive dimension to a world of text and static images used in current publications, eliminating at the same time the need for arcane supplemental materials. This paper exemplifies iCn3D capabilities in visualization, analysis, and sharing of COVID-19 related structures, sequence variability, and molecular interactions.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Youkharibache, P.; Cachau, R. E.; Wang, J.; Madej, T.","https://www.biorxiv.org/content/10.1101/2020.07.01.182964v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182964v1?rss=1,2020-07-02,2020-07-02,,False
579,Hidden genomic diversity of SARS-CoV-2: implications for qRT-PCR diagnostics and transmission,"The COVID-19 pandemic has sparked an urgent need to uncover the underlying biology of this devastating disease. Though RNA viruses mutate more rapidly than DNA viruses, there are a relatively small number of single nucleotide polymorphisms (SNPs) that differentiate the main SARS-CoV-2 clades that have spread throughout the world. In this study, we investigated over 7,000 SARS-CoV-2 datasets to unveil both intrahost and interhost diversity. Our intrahost and interhost diversity analyses yielded three major observations. First, the mutational profile of SARS-CoV-2 highlights iSNV and SNP similarity, albeit with high variability in C>T changes. Second, iSNV and SNP patterns in SARS-CoV-2 are more similar to MERS-CoV than SARS-CoV-1. Third, a significant fraction of small indels fuel the genetic diversity of SARS-CoV-2. Altogether, our findings provide insight into SARS-CoV-2 genomic diversity, inform the design of detection tests, and highlight the potential of iSNVs for tracking the transmission of SARS-CoV-2.","Sapoval, N.; Mahmoud, M.; Jochum, M. D.; Liu, Y.; Elworth, R. A. L.; Wang, Q.; Albin, D.; Ogilvie, H.; Lee, M. D.; Villapol, S.; Hernandez, K.; Maljkovic Berry, I.; Foox, J.; Beheshti, A.; Ternus, K.; Aagaard, K. M.; Posada, D.; Mason, C.; Sedlazeck, F. J.; Treangen, T. J.","https://www.biorxiv.org/content/10.1101/2020.07.02.184481v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.02.184481v1?rss=1,2020-07-02,2020-07-02,,False
580,Alpha-1 antitrypsin inhibits SARS-CoV-2 infection,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified 1-antitrypsin (1-AT) as specific inhibitor of SARS-CoV-2. 1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Our findings show that endogenous 1-AT restricts SARS-CoV-2 and repurposes 1-AT-based drugs for COVID-19 therapy.","Wettstein, L.; Conzelmann, C.; Mueller, J. A.; Weil, T.; Gross, R.; Hirschenberger, M.; Seidel, A.; Klute, S.; Prelli-Bozzo, c.; Zech, F.; Preising, N.; Fois, G.; Lochbaum, R.; Knaff, P.; Mailaender, V.; Staendker, L.; Thal, D.; Schumann, C.; Stenger, S.; Sparrer, K.; Kleger, A.; Lochnit, G.; Kirchhoff, F.; Frick, M.; Muench, J.","https://www.biorxiv.org/content/10.1101/2020.07.02.183764v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.02.183764v1?rss=1,2020-07-02,2020-07-02,,False
581,Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays,"Introduction Commercially available SARS-CoV-2 serological assays based on different viral antigens have been approved for the qualitative determination of anti-SARS-CoV-2 antibodies. However, there is limited published data associating the results from commercial assays with neutralizing antibodies.Methods 67 specimens from 48 patients with PCR-confirmed COVID-19 and a positive result by the Roche Elecsys SARS-CoV-2, Abbott SARS-CoV-2 IgG, or EUROIMMUN SARS-CoV-2 IgG assays and 5 control specimens were analyzed for the presence of neutralizing antibodies to SARS-CoV-2. Correlation, concordance, positive percent agreement (PPA), and negative percent agreement (NPA) were calculated at several cutoffs. Results were compared in patients categorized by clinical outcomes.Results The correlation between SARS-CoV-2 neutralizing titer (EC50) and the Roche, Abbott, and EUROIMMUN assays was 0.29, 0.47, and 0.46 respectively. At an EC50 of 1:32, the concordance kappa with Roche was 0.49 (95% CI; 0.23-0.75), with Abbott was 0.52 (0.28-0.77), and with EUROIMMUN was 0.61 (0.4-0.82). At the same neutralizing titer, the PPA and NPA for the Roche was 100% (94-100) &amp; 56% (30-80); Abbott was 96% (88-99) &amp; 69% (44-86); and EUROIMMUN was 91% (80-96) &amp; 81% (57-93) for distinguishing neutralizing antibodies. Patients who died, were intubated, or had a cardiac injury from COVID-19 infection had significantly higher neutralizing titers relative to those with mild symptoms.Conclusion COVID-19 patients generate an antibody response to multiple viral proteins such that the calibrator ratios on the Roche, Abbott, and EUROIMMUN assays are all associated with SARS-CoV-2 neutralization. Nevertheless, commercial serological assays have poor NPA for SARS-CoV-2 neutralization, making them imperfect proxies for neutralization.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Tang, M. S.; Case, J. B.; Franks, C. E.; Chen, R. E.; Anderson, N. W.; Henderson, J. P.; Diamond, M. S.; Gronowski, A. M.; Farnsworth, C. W.","https://www.biorxiv.org/content/10.1101/2020.07.01.182220v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182220v1?rss=1,2020-07-02,2020-07-02,,False
582,Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine,"Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Chiuppesi, F.; Werner, M. S.; Contreras, H.; Nguyen, H. V.; Martinez, J.; Park, S.; Nguyen, J.; Kha, M.; Iniguez, A.; Zhou, Q.; Kaltcheva, T.; Levytskyy, R.; Ebelt, N. D.; Kang, T. H.; Wu, X.; Rogers, T.; Manuel, E. R.; Shostak, Y.; Diamond, D. J.; Wussow, F.","https://www.biorxiv.org/content/10.1101/2020.07.01.183236v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.183236v1?rss=1,2020-07-02,2020-07-02,,False
583,Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. Here, we report that low plasma interleukin-3 (IL-3) levels were associated with increased severity and mortality during SARS-CoV-2 infections. IL-3 promoted the recruitment of antiviral circulating plasmacytoid dendritic cells (pDCs) into the airways by stimulating CXCL12 secretion from pulmonary CD123+ epithelial cells. This study identifies IL-3 as a predictive disease marker and potential therapeutic target for SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Benard, A.; Jacobsen, A.; Brunner, M.; Krautz, C.; Klosch, B.; Swierzy, I.; Naschberger, E.; Birkholz, T.; Castellanos, I.; Trufa, D.; Sirbu, H.; Vetter, M.; Kremer, A. E.; Hildner, K.; Hecker, A.; Edinger, F.; Tenbusch, M.; Richter, E.; Streeck, H.; Berger, M. M.; Brenner, T.; Weigand, M. A.; Swirski, F. K.; Schett, G.; Grutzmann, R.; Weber, G. F.","https://www.biorxiv.org/content/10.1101/2020.07.02.184093v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.02.184093v1?rss=1,2020-07-02,2020-07-02,,False
584,SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses,"The current pandemic is caused by the SARS-CoV-2 virus and large progress in understanding the pathology of the virus has been made since its emergence in late 2019. Several reports indicate short lasting immunity against endemic coronaviruses, which contrasts repeated reports that biobanked venous blood contains SARS-CoV-2 reactive T cells even before the outbreak in Wuhan. This suggests there exists a preformed T cell memory in individuals not exposed to the pandemic virus. Given the similarity of SARS-CoV-2 to other members of the Coronaviridae family, the endemic coronaviruses appear likely candidates to generate this T cell memory. However, given the apparent poor immunological memory created by the endemic coronaviruses, other immunity against other common pathogens might offer an alternative explanation. Here, we utilize a combination of epitope prediction and similarity to common human pathogens to identify potential sources of the SARS-CoV-2 T cell memory. We find that no common human virus, other than beta-coronaviruses, can explain the pre-existing SARS-CoV-2 reactive T cells in uninfected individuals. Our study suggests OC43 and HKU1 are the most likely pathogens giving rise to SARS-CoV-2 preformed immunity.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Stervbo, U.; Rahmann, S.; Roch, T.; Westhoff, T. H.; Babel, N.","https://www.biorxiv.org/content/10.1101/2020.07.01.182741v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182741v1?rss=1,2020-07-01,2020-07-01,,False
585,"A simple, safe and sensitive method for SARS-CoV-2 inactivation and RNA extraction for RT-qPCR","The SARS-CoV-2 pandemic has created an urgent need for large amounts of diagnostic tests to detect viral RNA, which commercial suppliers are increasingly unable to deliver. In addition to the lack of availability, the current methods do not always fully inactivate the virus. Together, this calls for the development of safer methods for extraction and detection of viral RNA from patient samples that utilise readily available reagents and equipment present in most standard laboratories. We present a rapid and straightforward RNA extraction protocol for inactivating the SARS-CoV-2 virus that uses standard lab reagents. This protocol expands analysis capacity as the inactivated samples can be used in RT-qPCR detection tests at laboratories not otherwise classified for viral work. The method circumvents the need for commercial RNA purification kits, takes about 30 minutes from swab to PCR-ready viral RNA, and enables downstream detection of SARS-CoV-2 by RT-qPCR with very high sensitivity (~4 viral RNA copies per RT-qPCR). In summary, we present a rapid, safe and sensitive method for high-throughput detection of SARS-CoV-2, that can be conducted in any laboratory equipped with a qPCR machine.","Kalnina, L.; Mateu-Regue, A.; Oerum, S.; Hald, A.; Gerstoft, J.; Oerum, H.; Cilius Nielsen, F.; Iversen, A. K. N.","https://www.biorxiv.org/content/10.1101/2020.06.29.179176v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.29.179176v1?rss=1,2020-07-01,2020-07-01,,False
586,Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2,"BackgroundRT-PCR testing is crucial in the diagnostic of SARS-CoV-2 infection. The use of reliable and comparable PCR assays is a cornerstone to allow use of different PCR assays depending on the local equipment. In this work, we provide a comparison of the Cobas(R) (Roche) and the RealStar(R) assay (Altona).

MethodsAssessment of the two assays was performed prospectively in three reference Parisians hospitals, using 170 clinical samples. They were tested with the Cobas(R) assay, selected to obtain a distribution of cycle threshold (Ct) as large as possible, and tested with the RealStar assay with three largely available extraction platforms: QIAsymphony (Qiagen), MagNAPure (Roche) and NucliSENS-easyMag (BioMerieux).

ResultsOverall, the agreement (positive for at least one gene) was 76%. This rate differed considerably depending on the Cobas Ct values for gene E: below 35 (n = 91), the concordance was 99%. Regarding the positive Ct values, linear regression analysis showed a determination correlation (R2) of 0.88 and the Deming regression line revealed a strong correlation with a slope of 1.023 and an intercept of -3.9. Bland-Altman analysis showed that the mean difference (Cobas(R) minus RealStar(R)) was + 3.3 Ct, with a SD of + 2.3 Ct.

ConclusionsIn this comparison, both RealStar(R) and Cobas(R) assays provided comparable qualitative results and a high correlation when both tests were positive. Discrepancies exist after 35 Ct and varied depending on the extraction system used for the RealStar(R) assay, probably due to a low viral load close to the detection limit of both assays.","Chaix, M.-L.; Wirden, M.; Feghoul, L.; Bertine, M.; Nere, M.-L.; Le Hingrat, Q.; Abdi, B.; Boutolleau, D.; Ferre, V. M.; Jary, A.; Delaugerre, C.; Marcelin, A.-G.; Descamps, D.; LeGoff, J.; Visseaux, B.","https://www.biorxiv.org/content/10.1101/2020.06.29.179184v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.29.179184v1?rss=1,2020-07-01,2020-07-01,,False
587,Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro,"COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.","Bobrowski, T.; Chen, L.; Eastman, R. T.; Itkin, Z.; Shinn, P.; Chen, C.; Guo, H.; Zheng, W.; Michael, S.; Simeonov, A.; Hall, M.; Zakharov, A. V.; Muratov, E. N.","https://www.biorxiv.org/content/10.1101/2020.06.29.178889v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.29.178889v1?rss=1,2020-07-01,2020-07-01,,False
588,periscope: sub-genomic RNA identification in SARS-CoV-2 ARTIC Network Nanopore Sequencing Data,"We have developed periscope, a tool for the detection and quantification of sub-genomic RNA in ARTIC network protocol generated Nanopore SARS-CoV-2 sequence data. We applied periscope to 1155 SARS-CoV-2 sequences from Sheffield, UK. Using a simple local alignment to detect reads which contain the leader sequence we were able to identify and quantify reads arising from canonical and non-canonical sub-genomic RNA. We were able to detect all canonical sub-genomic RNAs at expected abundances, with the exception of ORF10, suggesting that this is not a functional ORF. A number of recurrent non-canonical sub-genomic RNAs are detected. We show that the results are reproducible using technical replicates and determine the optimum number of reads for sub-genomic RNA analysis. Finally variants found in genomic RNA are transmitted to sub-genomic RNAs with high fidelity in most cases. This tool can be applied to tens of thousands of sequences worldwide to provide the most comprehensive analysis of SARS-CoV-2 sub-genomic RNA to date.","Parker, M. D.; Lindsey, B. B.; Leary, S.; Gaudieri, S.; Chopra, A.; Wyles, M.; Angyal, A.; Green, L. R.; Parsons, P.; Tucker, R. M.; Brown, R.; Groves, D.; Johnson, K.; Carrilero, L.; Heffer, J.; Partridge, D.; Evans, C.; Razza, M.; Keeley, A. J.; Smith, N.; Wang, D.; Mallal, S.; de Silva, T. I.","https://www.biorxiv.org/content/10.1101/2020.07.01.181867v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.181867v1?rss=1,2020-07-01,2020-07-01,,False
589,Assessment of Proton-Coupled Conformational Dynamics of SARS and MERS Coronavirus Papain-like Proteases: Implication for Designing Broad-Spectrum Antiviral Inhibitors,"Broad-spectrum antiviral drugs are urgently needed to stop the COVID-19 pandemic and prevent future ones. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is related to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which have caused the previous outbreaks. The papain-like protease (PLpro) is an attractive drug target due to its essential roles in the viral life cycle. As a cysteine protease, PLpro is rich in cysteines and histidines and their protonation/deprotonation modulates catalysis and conformational plasticity. Here we report the pKa calculations and assessment of the proton-coupled conformational dynamics of SARS-CoV-2 in comparison to SARS-CoV and MERS-CoV PLpros using a newly developed GPU-accelerated implicit-solvent continuous constant pH molecular dynamics method with an asynchronous replica-exchange scheme. The calculated pKas support the catalytic roles of the Cys-His-Asp triad. We also found that several residues can switch protonation states at physiological pH, among which is C270/271 located on the flexible blocking loop 2 (BL2) of SARS-CoV-2/CoV PLpro. Simulations revealed that the BL2 conformational dynamics is coupled to the titration of C271/270, in agreement with the crystal structures of SARS-CoV-2 PLpro. Simulations also revealed that BL2 in MERS-CoV PLpro is very flexible, sampling both open and closed states despite the lack of an analogous cysteine. Our work provides a starting point for more detailed mechanistic studies to assist structure-based design of broad-spectrum inhibitors against CoV PLpros.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Henderson, J. A.; Verma, N.; Shen, J.","https://www.biorxiv.org/content/10.1101/2020.06.30.181305v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.181305v1?rss=1,2020-07-01,2020-07-01,,False
590,Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis,"ABSTRACTThe novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we, therefore, designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of nucleocapsid protein that aid in viral replication. Promising antigenic B-cells and T cell epitopes were predicted using computational pipelines. The peptides RIRGGDGKMKDL and AFGRRGPEQTQGNFG were the B cell linear epitopes with good antigenic index and non-allergenic property. Two CD8+ and Three CD4+ T-cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and II alleles. With these selected epitopes, a non-allergenic chimeric peptide vaccine incapable of inducing a Type II hypersensitivity reaction was constructed. The molecular interaction between the toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally, in silico cloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Chukwudozie, O. S.; Chukwuanukwu, R. C.; Onyekachi, I. O.; Daniel, E. M.; Vincent, D. C.; Onaopemipo, D.-A. T.; David, K. B.; Taiwo, B. T.; Perpetua, O. C.; Elizabeth, O. U.","https://www.biorxiv.org/content/10.1101/2020.06.30.176537v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.176537v1?rss=1,2020-07-01,2020-07-01,,False
591,Genetic architecture of host proteins interacting with SARS-CoV-2,"Strategies to develop therapeutics for SARS-CoV-2 infection may be informed by experimental identification of viral-host protein interactions in cellular assays and measurement of host response proteins in COVID-19 patients. Identification of genetic variants that influence the level or activity of these proteins in the host could enable rapid  in silico assessment in human genetic studies of their causal relevance as molecular targets for new or repurposed drugs to treat COVID-19. We integrated large-scale genomic and aptamer-based plasma proteomic data from 10,708 individuals to characterize the genetic architecture of 179 host proteins reported to interact with SARS-CoV-2 proteins or to participate in the host response to COVID-19. We identified 220 host DNA sequence variants acting in cis (MAF 0.01-49.9%) and explaining 0.3-70.9% of the variance of 97 of these proteins, including 45 with no previously known protein quantitative trait loci (pQTL) and 38 encoding current drug targets. Systematic characterization of pQTLs across the phenome identified protein-drug-disease links, evidence that putative viral interaction partners such as MARK3 affect immune response, and establish the first link between a recently reported variant for respiratory failure of COVID-19 patients at the ABO locus and hypercoagulation, i.e. maladaptive host response. Our results accelerate the evaluation and prioritization of new drug development programmes and repurposing of trials to prevent, treat or reduce adverse outcomes. Rapid sharing and dynamic and detailed interrogation of results is facilitated through an interactive webserver (https://omicscience.org/apps/covidpgwas/).","Pietzner, M.; Wheeler, E.; Carrasco-Zanini, J.; Raffler, J.; Kerrison, N. D.; Oerton, E.; Auyeung, V. P. W.; Luan, J.; Finan, C.; Casas, J. P.; Ostroff, R.; Williams, S. A.; Kastenmuller, G.; Ralser, M.; Gamazon, E. G.; Wareham, N. J.; Hingorani, A. D.; Langenberg, C.","https://www.biorxiv.org/content/10.1101/2020.07.01.182709v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182709v1?rss=1,2020-07-01,2020-07-01,,False
592,Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow device compared to a nucleocapsid-only device,"Background There is a critical need for reliable antibody detection methods in order to study and evaluate the public health and clinical response to the ongoing COVID-19 pandemic. Lateral flow immunoassay (LFIA) devices offer the prospect of rapid point-of-care testing (POCT), but the performance of these devices must be evaluated for robustness before they can be adopted for routine clinical and public health use.Methods Plasma and serum specimens from SARS-CoV-2 RNA-positive (n = 131) and RNA-negative (n = 16) patients were taken from various time points with respect to the onset of symptoms. All 147 anonymised specimens were tested for IgM and IgG using the Hangzhou AllTest 2019-nCoV IgG/IgM Rapid Test Cassette and the Abbexa COVID-19 IgG/IgM Rapid Test Kit.Results IgM sensitivity ranged from 13% to 68%, depending on the date of symptom onset and the device. Regarding IgG, the Abbexa device outperformed the Hangzhou device at all cumulative timeline brackets, with sensitivity of 9787% (Abbexa) versus 6809% (Hangzhou) for samples beyond 21 days from symptom onset. Day 21 was therefore chosen as the cut-off for ascertaining test performance characteristics, beyond which the specificity was 100% for both devices and negative predictive value was 094 (Abbexa) versus 050 (Hangzhou).Discussion Based on this limited dataset, the performance characteristics of the Abbexa LFIA device were substantially better than those of the Hangzhou device. Applying a 21-day cut-off for the Abbexa device meets the minimum (98%) sensitivity and specificity thresholds set by the UK Medicine &amp; Healthcare products Regulatory Agency. The Abbexa device captures antibodies against both SARS-CoV-2 spike and nucleocapsid proteins, as opposed to Hangzhou that targets only the nucleocapsid protein. We therefore propose that spike glycoprotein antibodies be considered as part of the standard diagnostic approach towards SARS-CoV-2 antibody profiling to improve clinical sensitivity and potentially specificity, pending follow-up studies to confirm this approach.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Linares, C. A.; Ryan, F.; Moses, S. E.","https://www.biorxiv.org/content/10.1101/2020.07.01.182618v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182618v1?rss=1,2020-07-01,2020-07-01,,False
593,If the link missedCould inflammatory skin disorders with barrier dysfunction increase the risk of COVID-19?,"Since the end of 2019, COVID-19 pandemic caused by the SARS-CoV-2 emerged globally. The angiotensin-converting enzyme 2 (ACE2) on the cell surface is crucial for SARS-COV-2 entering into the cells. The expression of ACE2 in skin suggested that skin might be a way of transmitting SARS-CoV-2. We found the elevated ACE2 level of patients with psoriasis but downregulated after IL-17 antibody treatment. Further results showed that ACE2 expression increased either in psoriasis or in atopic dermatitis, which were typical inflammatory skin disorders with barrier dysfunction. And elevated ACE2 level was also detected in mouse models of dermatitis induced by imiquimod, calcipotriol, repeated tape-stripping or 1-Fluoro-2,4-dinitrobenzene (DNFB) respectively. Moreover, alleviation of cutaneous inflammation with skin recovery moisture also lowered expression of ACE2 in mouse models with barrier deteriorated inflammatory skin disorders. Furthermore, inflammatory skin disorders with barrier dysfunction increased the penetration of topical FITC conjugated spike protein into the skin. Conversely, improvement in skin permeability barrier could prevent this penetration. Thus, indicating the special link between inflammatory skin disorders with skin barrier dysfunction and increasing risk of COVID-19.","Xu, Q.; Chen, L.; Zhang, L.; Li, X.; Zheng, J.","https://www.biorxiv.org/content/10.1101/2020.06.30.181297v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.181297v1?rss=1,2020-07-01,2020-07-01,,False
594,Genetic analysis of SARS-CoV-2 strains collected from North Africa: viral origins and mutational spectrum,"In Morocco two waves of SARS-CoV-2 infections have been recorded. The first one occurred from March 02, 2020 with infections mostly imported from Europe and the second one dominated by local infections.

At the time of writing, the genetic diversity of Moroccan isolates of SARS-CoV-2 has not yet been reported. The present study aimed to analyze first the genomic variation of the twenty-eight Moroccan strains of SARS-CoV-2 isolated from March 03, 2020 to May 15, 2020, to compare their distributions with twelve other viral genomes from North Africa as well as to identify their possible sources.

Our finding revealed 61 mutations in the Moroccan genomes of SARS-CoV-2 compared to the reference sequence Wuhan-Hu-1/2019, of them 23 (37.7%) were present in two or more genomes. Focusing on non-synonymous mutations, 29 (47.54%) were distributed in five genes (ORF1ab, spike, membrane, nucleocapsid and ORF3a) with variable frequencies. The non-structural protein coding regions nsp3-Multi domain and nsp12-RdRp of the ORF1ab gene harbored more mutations, with six for each. The comparison of genetic variants of fourty North African strains revealed that two non-synonymous mutations D614G (in spike) and Q57H (in ORF3a) were common in four countries (Morocco, Tunisia, Algeria and Egypt), with a prevalence of 92.5% (n = 37) and 42.5% (n = 17), respectively, of the total genomes.

Phylogenetic analysis showed that the Moroccan and Tunisian SARS-CoV-2 strains were closely related to those from different origins (Asia, Europe, North and South America) and distributed in different distinct subclades. This could indicate different sources of infection with no specific strain dominating yet in in these countries. These results have the potential to lead to new comprehensive investigations combining genomic data, epidemiological information and the clinical characteristics of patients with SARS-CoV-2.","Laamarti, M.; Kartti, S.; Alouane, T.; Laamarti, R.; Allam, L.; Ouadghiri, M.; Chemao-Elfihri, M. W.; Smyej, I.; Rahoui, J.; Benrahma, H.; Diawara, I.; Essabbar, A.; Boumajdi, N.; Bendani, H.; Bouricha, E. M.; Aanniz, T.; El Attar, J.; El Hafidi, N.; El Jaoudi, R.; Sbabou, L.; Nejjari, C.; Amzazi, S.; Mentag, R.; Belyamani, L.; Ibrahimi, A.","https://www.biorxiv.org/content/10.1101/2020.06.30.181123v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.181123v1?rss=1,2020-07-01,2020-07-01,,False
595,Fourier spectral density of the coronavirus genome,"We present an analysis of the coronavirus RNA genome via a study of its Fourier spectral density based on a binary representation of the nucleotide sequence. We find that at low frequencies, the power spectrum presents a small and distinct departure from the behavior expected from an uncorrelated sequence. We provide a couple of simple models to characterize such deviations. Away from a small low-frequency domain, the spectrum presents largely stochastic fluctuations about fixed values and exhibits no other peaks apart from one associated with triplet codon usage. We uncover an interesting, new scaling law for the coronavirus genome: the complexity of the genome scales linearly with the power-law exponent that characterizes the low-frequency domain of the spectral density.","Tan, H. S.","https://www.biorxiv.org/content/10.1101/2020.06.30.180034v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.180034v1?rss=1,2020-07-01,2020-07-01,,False
596,Next-generation diagnostics: virus capture facilitates a sensitive viral diagnosis for epizootic and zoonotic pathogens including SARS-CoV-2,"BackgroundThe detection of pathogens in clinical and environmental samples using high-throughput sequencing (HTS) is often hampered by large amounts of background information, which is especially true for viruses with small genomes. Enormous sequencing depth can be necessary to compile sufficient information for identification of a certain pathogen. Generic HTS combining with in-solution capture enrichment can markedly increase the sensitivity for virus detection in complex diagnostic samples.

MethodsA virus panel based on the principle of biotinylated RNA-baits was developed for specific capture enrichment of epizootic and zoonotic viruses (VirBaits). The VirBaits set was supplemented by a SARS-CoV-2 predesigned bait set for testing recent SARS-CoV-2 positive samples. Libraries generated from complex samples were sequenced via generic HTS and afterwards enriched with the VirBaits set. For validation, an internal proficiency test for emerging epizootic and zoonotic viruses (African swine fever virus, Ebolavirus, Marburgvirus, Nipah henipavirus, Rift Valley fever virus) was conducted.

ResultsThe VirBaits set consists of 177,471 RNA-baits (80-mer) based on about 18,800 complete viral genomes targeting 35 epizootic and zoonotic viruses. In all tested samples, viruses with both DNA and RNA genomes were clearly enriched ranging from about 10-fold to 10,000-fold for viruses including distantly related viruses with at least 72% overall identity to viruses represented in the bait set. Viruses showing a lower overall identity (38% and 46%) to them were not enriched but could nonetheless be detected based on capturing conserved genome regions. The internal proficiency test supports the improved virus detection using the combination of HTS plus targeted enrichment but also point to the risk of carryover between samples.

ConclusionsThe VirBaits approach showed a high diagnostic performance, also for distantly related viruses. The bait set is modular and expandable according to the favored diagnostics, health sector or research question. The risk of carryover needs to be taken into consideration. The application of the RNA-baits principle turned out to be user-friendly, and even non-experts (without sophisticated bioinformatics skills) can easily use the VirBait workflow. The rapid extension of the established VirBaits set adapted to actual outbreak events is possible without any problems as shown for SARS-CoV-2.","Wylezich, C.; Calvelage, S.; Schlottau, K.; Ziegler, U.; Pohlmann, A.; Hoeper, D.; Beer, M.","https://www.biorxiv.org/content/10.1101/2020.06.30.181446v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.30.181446v1?rss=1,2020-07-01,2020-07-01,,False
597,Identification of peptide candidate against COVID-19 through reverse vaccinology: An immunoinformatics approach,"Novel corona virus disease 2019 (COVID-19) is emerging as a pandemic situation and declared as a global health emergency by WHO. Due to lack of specific medicine and vaccine, viral infection has gained a frightening rate and created a devastating state across the globe. Here the authors have attempted to design epitope based potential peptide as a vaccine candidate using immunoinformatics approach. As of evidence from literatures, SARS-CoV-2 Spike protein is a key protein to initiate the viral infection within a host cell thus used here as a reasonable vaccine target. We have predicted a 9-mer peptide as representative of both B-cell and T-cell epitopic region along with suitable properties such as antigenic and non-allergenic. To its support, strong molecular interaction of the predicted peptide was also observed with MHC molecules and Toll Like receptors. The present study may helpful to step forward in the development of vaccine candidates against COVID-19.

O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY","Das, R. P.; Jagadeb, M.; Rath, S. N.","https://www.biorxiv.org/content/10.1101/2020.07.01.150805v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.150805v1?rss=1,2020-07-01,2020-07-01,,False
598,High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity,"A novel coronavirus (SARS-CoV-2) has emerged to a global pandemic and caused significant damages to public health. Human angiotensin-converting enzyme 2(ACE2) was identified as the entry receptor for SARS-CoV-2. As a carboxypeptidase, ACE2 cleaves many biological substrates besides Ang II to control vasodilatation and permeability. Given the nanomolar high affinity between ACE2 and SARS-CoV-2 spike protein, we wonder how this interaction would affect the enzymatic activity of ACE2. Surprisingly, SARS-CoV-2 trimeric spike protein increased ACE2 proteolytic activity ~3-10 fold when fluorogenic caspase-1 substrate and Bradykinin-analog peptides were used to characterize ACE2 activity. In addition, the enhancement was mediated by ACE2 binding of RBD domain of SARS-CoV-2 spike. These results highlighted the altered activity of ACE2 during SARS-CoV-2 infection and would shed new lights on the pathogenesis of COVID-19 and its complications for better treatments.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Lu, J.; Sun, P. D.","https://www.biorxiv.org/content/10.1101/2020.07.01.182659v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.07.01.182659v1?rss=1,2020-07-01,2020-07-01,,False
599,Anti-frameshifting ligand active against SARS coronavirus-2 is resistant to natural mutations of the frameshift-stimulatory pseudoknot,"The coronavirus SARS-CoV-2 causing the COVID-19 pandemic uses 1 programmed ribosomal frameshifting (1 PRF) to control the expression levels of key viral proteins. Because modulating 1 PRF can attenuate viral propagation, ligands binding to the viral RNA pseudoknot that stimulates 1 PRF may prove useful as therapeutics. Mutations in the pseudoknot have been observed over the course of the pandemic, but how they affect 1 PRF and the activity of inhibitors is unknown. Cataloguing natural mutations in all parts of the SARS-CoV-2 pseudoknot, we studied a panel of 6 mutations in key structural regions. Most mutations left the 1 PRF efficiency unchanged, even when base-pairing was disrupted, but one led to a remarkable three-fold decrease, suggesting that SARS-CoV-2 propagation may be less sensitive to modulation of 1 PRF efficiency than some other viruses. Examining the effects of one of the few small-molecule ligands known to suppress 1 PRF significantly in SARS-CoV, we found that it did so by similar amounts in all SARS-CoV-2 mutants tested, regardless of the basal 1 PRF efficiency, indicating that the activity of anti-frameshifting ligands can be resistant to natural pseudoknot mutations. These results have important implications for therapeutic strategies targeting SARS-CoV-2 through modulation of 1 PRF.Competing Interest StatementThe authors have declared no competing interest.View Full Text","Neupane, K.; Munshi, S.; Zhao, M.; Ritchie, D. B.; Ileperuma, S. M.; Woodside, M. T.","https://www.biorxiv.org/content/10.1101/2020.06.29.178707v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.06.29.178707v1?rss=1,2020-06-30,2020-06-30,,False
